DrugMAP Full Data Download File Title - DrugMAP molecular interaction atlas of all drug in raw format Version 1.01 (2022.07.20) Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB) College of Pharmaceutical Sciences Zhejiang University https://idrblab.org/ Any question about data provided here, please contact with: Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn) DI: Drug ID DN: Drug Name MI: Molecule ID MN: Molecule Name MT: Molecule Type MA: Mode of Action RN: Reference Name RU: Reference URL DMMHNU2 DI DMMHNU2 DMMHNU2 DN (S)-(+)-Dimethindene maleate DMMHNU2 MI TTTIBOJ DMMHNU2 MN Histamine H1 receptor (H1R) DMMHNU2 MT DTT DMMHNU2 MA Antagonist DMMHNU2 RN Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93. DMMHNU2 RU https://pubmed.ncbi.nlm.nih.gov/19308787 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DTG3T6X DMIAHVU MN Glucose transporter type 1, erythrocyte/brain (SLC2A1) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN Glutamine 161 of Glut1 glucose transporter is critical for transport activity and exofacial ligand binding. J Biol Chem. 1994 Aug 12;269(32):20533-8. DMIAHVU RU http://www.jbc.org/content/269/32/20533.long DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DT3BI6S DMIAHVU MN Glucose transporter type 10 (SLC2A10) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN Sequence and functional analysis of GLUT10: a glucose transporter in the Type 2 diabetes-linked region of chromosome 20q12-13.1. Mol Genet Metab. 2001 Sep-Oct;74(1-2):186-99. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/11592815 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DTA5QI0 DMIAHVU MN Glucose transporter type 12 (SLC2A12) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN The human facilitative glucose transporter GLUT12: Expression and regulation in Caco-2 and 3T3-L1cells. DMIAHVU RU https://2017.febscongress.org/abstract_preview.aspx?idAbstractEnc=4424170093096096098098424170 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DT18YD9 DMIAHVU MN Glucose transporter type 14 (SLC2A14) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN The SLC2A14 gene, encoding the novel glucose/dehydroascorbate transporter GLUT14, is associated with inflammatory bowel disease. Am J Clin Nutr. 2017 Dec;106(6):1508-1513. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/28971850 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DTUJPOL DMIAHVU MN Glucose transporter type 2, liver (SLC2A2) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus. Mol Genet Metab. 2011 Dec;104(4):648-53. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/21920790 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DT9SQ3L DMIAHVU MN Glucose transporter type 3, brain (SLC2A3) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN Ascorbic acid-dependent GLUT3 inhibition is a critical step for switching neuronal metabolism. J Cell Physiol. 2011 Dec;226(12):3286-94. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/21321936 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DT4827A DMIAHVU MN Glucose transporter type 4, insulin-responsive (SLC2A4) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN Need for GLUT4 activation to reach maximum effect of insulin-mediated glucose uptake in brown adipocytes isolated from GLUT4myc-expressing mice. Diabetes. 2002 Sep;51(9):2719-26. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/12196464 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DTS4MKQ DMIAHVU MN Glucose transporter type 6 (SLC2A6) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/18660845 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DT8SQBG DMIAHVU MN Glucose transporter type 7 (SLC2A7) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/18660845 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DT2I7BM DMIAHVU MN Glucose transporter type 8 (SLC2A8) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN Functional Properties and Genomics of Glucose Transporters. Curr Genomics. 2007 Apr; 8(2): 113128. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/18660845 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DTMSNOU DMIAHVU MN Proton-associated sugar transporter A (SLC45A1) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN Dysfunction of the Cerebral Glucose Transporter SLC45A1 in Individuals with Intellectual Disability and Epilepsy. Am J Hum Genet. 2017 May 4;100(5):824-830. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/28434495 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DTOKC04 DMIAHVU MN Sodium/glucose cotransporter 1 (SLC5A1) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing. PLoS One. 2014 Feb 26;9(2):e89977. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/24587162 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DTO4FLB DMIAHVU MN Sodium/glucose cotransporter 3 (SLC5A4) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/12748858 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DT1CP40 DMIAHVU MN Sodium/glucose cotransporter 4 (SLC5A9) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci. 2005 Jan 14;76(9):1039-50. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/15607332 DMIAHVU DI DMIAHVU DMIAHVU DN 2-deoxyglucose DMIAHVU MI DTQNIG7 DMIAHVU MN Sodium/glucose cotransporter 5 (SLC5A10) DMIAHVU MT DTP DMIAHVU MA Substrate DMIAHVU RN The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8. DMIAHVU RU http://www.ncbi.nlm.nih.gov/pubmed/12748858 DMYFBMS DI DMYFBMS DMYFBMS DN 99mTc-fanolesomab DMYFBMS MI TTNV1KZ DMYFBMS MN Fucosyltransferase IV (CD15) DMYFBMS MT DTT DMYFBMS RN 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. DMYFBMS RU https://pubmed.ncbi.nlm.nih.gov/15756752 DMVZO01 DI DMVZO01 DMVZO01 DN 99mTc-sestamibi DMVZO01 MI DTSYQGK DMVZO01 MN Multidrug resistance-associated protein 1 (ABCC1) DMVZO01 MT DTP DMVZO01 MA Substrate DMVZO01 RN 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer. 1998;77(3):353-8. DMVZO01 RU https://doi.org/10.1038/bjc.1998.57 DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E MI DE017IC DMMN36E MN Alcohol dehydrogenase class-V (ADH6) DMMN36E MT DME DMMN36E MA Metabolism DMMN36E RN A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71. DMMN36E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18479171 DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E MI DTI7UX6 DMMN36E MN Breast cancer resistance protein (ABCG2) DMMN36E MT DTP DMMN36E MA Substrate DMMN36E RN QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev. 2009 Jan 31;61(1):34-46. DMMN36E RU https://doi.org/10.1016/j.addr.2008.10.004 DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E MI TT84ETX DMMN36E MN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMN36E MT DTT DMMN36E MA Inhibitor DMMN36E RN Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6. DMMN36E RU https://pubmed.ncbi.nlm.nih.gov/19442129 DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E MI DTCSGPB DMMN36E MN Multidrug resistance-associated protein 4 (ABCC4) DMMN36E MT DTP DMMN36E MA Substrate DMMN36E RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DMMN36E RU https://doi.org/10.1007/s11095-012-0935-x DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E MI DTUGYRD DMMN36E MN P-glycoprotein 1 (ABCB1) DMMN36E MT DTP DMMN36E MA Substrate DMMN36E RN The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109. DMMN36E RU https://doi.org/10.1016/j.antiviral.2008.12.013 DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E MI DEYGVN4 DMMN36E MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMMN36E MT DME DMMN36E MA Metabolism DMMN36E RN A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47(6):351-71. DMMN36E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18479171 DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E MI DEB3CV1 DMMN36E MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMMN36E MT DME DMMN36E MA Metabolism DMMN36E RN Product characteristics of Triumeq. DMMN36E RU https://www.ema.europa.eu/en/documents/product-information/triumeq-epar-product-information_en.pdf DMOERGM DI DMOERGM DMOERGM DN Abaloparatide DMOERGM MI TTFPD47 DMOERGM MN Parathyroid hormone 1 receptor (PTH1R) DMOERGM MT DTT DMOERGM MA Modulator DMOERGM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOERGM RU https://www.fda.gov/ DM2RX0I DI DM2RX0I DM2RX0I DN Abametapir DM2RX0I MI TT1GHVO DM2RX0I MN Matrix metalloproteinase (MMP) DM2RX0I MT DTT DM2RX0I MA Inhibitor DM2RX0I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM2RX0I RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf DM5WFNP DI DM5WFNP DM5WFNP DN Abarelix DM5WFNP MI TT8R70G DM5WFNP MN Gonadotropin-releasing hormone receptor (GNRHR) DM5WFNP MT DTT DM5WFNP MA Modulator DM5WFNP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5WFNP RU https://www.fda.gov/ DMSA8RU DI DMSA8RU DMSA8RU DN Abatacept DMSA8RU MI TTFZDNP DMSA8RU MN Activation B7-1 antigen (CD80) DMSA8RU MT DTT DMSA8RU MA Binder DMSA8RU RN Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. DMSA8RU RU https://pubmed.ncbi.nlm.nih.gov/19604448 DMSA8RU DI DMSA8RU DMSA8RU DN Abatacept DMSA8RU MI TTHGXBU DMSA8RU MN T-lymphocyte activation antigen CD86 (FUN1) DMSA8RU MT DTT DMSA8RU MA Binder DMSA8RU RN Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. DMSA8RU RU https://pubmed.ncbi.nlm.nih.gov/19604448 DMJO6GV DI DMJO6GV DMJO6GV DN Abciximab DMJO6GV MI TT38RM1 DMJO6GV MN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMJO6GV MT DTT DMJO6GV MA Modulator DMJO6GV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJO6GV RU https://www.fda.gov/ DM8V75C DI DM8V75C DM8V75C DN ABIRATERONE DM8V75C MI TTRA5BZ DM8V75C MN Steroid 17-alpha-monooxygenase (S17AH) DM8V75C MT DTT DM8V75C MA Modulator DM8V75C RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM8V75C RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMANBZI DI DMANBZI DMANBZI DN Abiraterone acetate DMANBZI MI DE4LYSA DMANBZI MN Cytochrome P450 3A4 (CYP3A4) DMANBZI MT DME DMANBZI MA Metabolism DMANBZI RN Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24. DMANBZI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22714819 DMANBZI DI DMANBZI DMANBZI DN Abiraterone acetate DMANBZI MI DTPFTEQ DMANBZI MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DMANBZI MT DTP DMANBZI MA Substrate DMANBZI RN The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. Prostate. 2017 May;77(13):1303-1311. DMANBZI RU http://www.ncbi.nlm.nih.gov/pubmed/28762529 DMANBZI DI DMANBZI DMANBZI DN Abiraterone acetate DMANBZI MI TTRA5BZ DMANBZI MN Steroid 17-alpha-monooxygenase (S17AH) DMANBZI MT DTT DMANBZI MA Modulator DMANBZI RN CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids.2015 Mar;95:80-7. DMANBZI RU https://www.ncbi.nlm.nih.gov/pubmed/25560485 DMANBZI DI DMANBZI DMANBZI DN Abiraterone acetate DMANBZI MI DE0P6LK DMANBZI MN Sulfotransferase 2A1 (SULT2A1) DMANBZI MT DME DMANBZI MA Metabolism DMANBZI RN Abiraterone for the treatment of metastatic castrate-resistant prostate cancer. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1016-24. DMANBZI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22714819 DMZT2P0 DI DMZT2P0 DMZT2P0 DN Abobotulinum toxin A DMZT2P0 MI TTZJD1B DMZT2P0 MN Acetylcholine release (Ach rele) DMZT2P0 MT DTT DMZT2P0 MA Modulator DMZT2P0 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMZT2P0 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM7GCVW DI DM7GCVW DM7GCVW DN Acalabrutinib DM7GCVW MI DE4LYSA DM7GCVW MN Cytochrome P450 3A4 (CYP3A4) DM7GCVW MT DME DM7GCVW MA Metabolism DM7GCVW RN FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration. DM7GCVW RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf DM7GCVW DI DM7GCVW DM7GCVW DN Acalabrutinib DM7GCVW MI DEIBDNY DM7GCVW MN Cytochrome P450 3A5 (CYP3A5) DM7GCVW MT DME DM7GCVW MA Metabolism DM7GCVW RN FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration. DM7GCVW RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210259s006s007lbl.pdf DM7GCVW DI DM7GCVW DM7GCVW DN Acalabrutinib DM7GCVW MI TTGM6VW DM7GCVW MN Tyrosine-protein kinase BTK (ATK) DM7GCVW MT DTT DM7GCVW MA Inhibitor DM7GCVW RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM7GCVW RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMO381I DI DMO381I DMO381I DN Acamprosate DMO381I MI TTAN6JD DMO381I MN Glutamate receptor AMPA (GRIA) DMO381I MT DTT DMO381I MA Agonist DMO381I RN Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37. DMO381I RU https://pubmed.ncbi.nlm.nih.gov/19523047 DMRM3AW DI DMRM3AW DMRM3AW DN Acarbose DMRM3AW MI TTXWASR DMRM3AW MN Intestinal maltase-glucoamylase (MGAM) DMRM3AW MT DTT DMRM3AW MA Modulator DMRM3AW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRM3AW RU https://www.fda.gov/ DM0TI4U DI DM0TI4U DM0TI4U DN Acebutolol DM0TI4U MI TTR6W5O DM0TI4U MN Adrenergic receptor beta-1 (ADRB1) DM0TI4U MT DTT DM0TI4U MA Antagonist DM0TI4U RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DM0TI4U RU https://pubmed.ncbi.nlm.nih.gov/16268148 DM0TI4U DI DM0TI4U DM0TI4U DN Acebutolol DM0TI4U MI DECB0K3 DM0TI4U MN Cytochrome P450 2D6 (CYP2D6) DM0TI4U MT DME DM0TI4U MA Metabolism DM0TI4U RN Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. DM0TI4U RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712 DM0TI4U DI DM0TI4U DM0TI4U DN Acebutolol DM0TI4U MI DTE2B1D DM0TI4U MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DM0TI4U MT DTP DM0TI4U MA Substrate DM0TI4U RN Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55. DM0TI4U RU http://www.ncbi.nlm.nih.gov/pubmed/21039758 DM0TI4U DI DM0TI4U DM0TI4U DN Acebutolol DM0TI4U MI DTT79CX DM0TI4U MN Organic cation transporter 1 (SLC22A1) DM0TI4U MT DTP DM0TI4U MA Substrate DM0TI4U RN Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33. DM0TI4U RU https://doi.org/10.1016/j.canlet.2005.06.051 DM0TI4U DI DM0TI4U DM0TI4U DN Acebutolol DM0TI4U MI DTUGYRD DM0TI4U MN P-glycoprotein 1 (ABCB1) DM0TI4U MT DTP DM0TI4U MA Substrate DM0TI4U RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DM0TI4U RU https://doi.org/10.1007/s11095-012-0935-x DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ MI TTZ9SOR DMOLNCZ MN Muscarinic acetylcholine receptor M1 (CHRM1) DMOLNCZ MT DTT DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ MI TTYEG6Q DMOLNCZ MN Muscarinic acetylcholine receptor M2 (CHRM2) DMOLNCZ MT DTT DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ MI TTQ13Z5 DMOLNCZ MN Muscarinic acetylcholine receptor M3 (CHRM3) DMOLNCZ MT DTT DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ MI TTQ3JTF DMOLNCZ MN Muscarinic acetylcholine receptor M4 (CHRM4) DMOLNCZ MT DTT DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ MI TTH18TF DMOLNCZ MN Muscarinic acetylcholine receptor M5 (CHRM5) DMOLNCZ MT DTT DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMZDF0B DI DMZDF0B DMZDF0B DN Aceclofenac DMZDF0B MI DE5IED8 DMZDF0B MN Cytochrome P450 2C9 (CYP2C9) DMZDF0B MT DME DMZDF0B MA Metabolism DMZDF0B RN Metabolism of aceclofenac in humans. Drug Metab Dispos. 1996 Aug;24(8):834-41. DMZDF0B RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8869816 DMZDF0B DI DMZDF0B DMZDF0B DN Aceclofenac DMZDF0B MI TTK0943 DMZDF0B MN Prostaglandin G/H synthase (COX) DMZDF0B MT DTT DMZDF0B MA Modulator DMZDF0B RN Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35. DMZDF0B RU https://pubmed.ncbi.nlm.nih.gov/12966366 DMH75KV DI DMH75KV DMH75KV DN Acenocoumarol DMH75KV MI DEJGDUW DMH75KV MN Cytochrome P450 1A2 (CYP1A2) DMH75KV MT DME DMH75KV MA Metabolism DMH75KV RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMH75KV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMH75KV DI DMH75KV DMH75KV DN Acenocoumarol DMH75KV MI DE5IED8 DMH75KV MN Cytochrome P450 2C9 (CYP2C9) DMH75KV MT DME DMH75KV MA Metabolism DMH75KV RN Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos. 2000 Feb;28(2):161-8. DMH75KV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10640513 DMH75KV DI DMH75KV DMH75KV DN Acenocoumarol DMH75KV MI DE4LYSA DMH75KV MN Cytochrome P450 3A4 (CYP3A4) DMH75KV MT DME DMH75KV MA Metabolism DMH75KV RN Possible interaction between topical terbinafine and acenocoumarol. Ann Pharmacother. 2009 Nov;43(11):1911-2. DMH75KV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19843835 DMH75KV DI DMH75KV DMH75KV DN Acenocoumarol DMH75KV MI DEGTFWK DMH75KV MN Mephenytoin 4-hydroxylase (CYP2C19) DMH75KV MT DME DMH75KV MA Metabolism DMH75KV RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMH75KV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMH75KV DI DMH75KV DMH75KV DN Acenocoumarol DMH75KV MI TTEUC8H DMH75KV MN Vitamin K epoxide reductase complex 1 (VKORC1) DMH75KV MT DTT DMH75KV MA Inhibitor DMH75KV RN Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep. 2010 Apr;37(4):1693-7. DMH75KV RU https://pubmed.ncbi.nlm.nih.gov/19562511 DM1SRQT DI DM1SRQT DM1SRQT DN Aceprometazine DM1SRQT MI TTTIBOJ DM1SRQT MN Histamine H1 receptor (H1R) DM1SRQT MT DTT DM1SRQT MA Antagonist DM1SRQT RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM1SRQT RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DE4OGUF DMUIE76 MN Cytochrome P450 102A1 (cyp102) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/17532492 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DE6OQ3W DMUIE76 MN Cytochrome P450 1A1 (CYP1A1) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8145237 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DEJGDUW DMUIE76 MN Cytochrome P450 1A2 (CYP1A2) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26049587 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DEJVYAZ DMUIE76 MN Cytochrome P450 2A6 (CYP2A6) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DE5IED8 DMUIE76 MN Cytochrome P450 2C9 (CYP2C9) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DECB0K3 DMUIE76 MN Cytochrome P450 2D6 (CYP2D6) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DEVDYN7 DMUIE76 MN Cytochrome P450 2E1 (CYP2E1) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20166895 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DE4LYSA DMUIE76 MN Cytochrome P450 3A4 (CYP3A4) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28872689 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DEIBDNY DMUIE76 MN Cytochrome P450 3A5 (CYP3A5) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17620348 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DE4ZHS1 DMUIE76 MN Glutathione S-transferase alpha-1 (GSTA1) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Retinoid X receptor alpha regulates the expression of glutathione s-transferase genes and modulates acetaminophen-glutathione conjugation in mouse liver. Mol Pharmacol. 2005 Dec;68(6):1590-6. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16157696 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DTFI42L DMUIE76 MN Multidrug resistance-associated protein 2 (ABCC2) DMUIE76 MT DTP DMUIE76 MA Substrate DMUIE76 RN Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8. DMUIE76 RU http://www.ncbi.nlm.nih.gov/pubmed/15276087 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI TTAWNKZ DMUIE76 MN Norepinephrine transporter (NET) DMUIE76 MT DTT DMUIE76 MA Inhibitor DMUIE76 RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI TTK0943 DMUIE76 MN Prostaglandin G/H synthase (COX) DMUIE76 MT DTT DMUIE76 MA Inhibitor DMUIE76 RN Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/15662292 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI TT3ROYC DMUIE76 MN Serotonin transporter (SERT) DMUIE76 MT DTT DMUIE76 MA Inhibitor DMUIE76 RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DEYWLRK DMUIE76 MN Sulfotransferase 1A1 (SULT1A1) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18232020 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DEYGVN4 DMUIE76 MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28932176 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DESD26P DMUIE76 MN UDP-glucuronosyltransferase 1A6 (UGT1A6) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21666065 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DE85D2P DMUIE76 MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29654492 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 MI DENZ6B1 DMUIE76 MN UDP-glucuronosyltransferase 2B15 (UGT2B15) DMUIE76 MT DME DMUIE76 MA Metabolism DMUIE76 RN Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab Dispos. 2011 Apr;39(4):644-52. DMUIE76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21245288 DM1AF5U DI DM1AF5U DM1AF5U DN Acetazolamide DM1AF5U MI TTHQPL7 DM1AF5U MN Carbonic anhydrase I (CA-I) DM1AF5U MT DTT DM1AF5U MA Modulator DM1AF5U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1AF5U RU https://www.fda.gov/ DM4SJ5Y DI DM4SJ5Y DM4SJ5Y DN Acetic Acid, Glacial DM4SJ5Y MI DEVDYN7 DM4SJ5Y MN Cytochrome P450 2E1 (CYP2E1) DM4SJ5Y MT DME DM4SJ5Y MA Metabolism DM4SJ5Y RN Kinetics of cytochrome P450 2E1-catalyzed oxidation of ethanol to acetic acid via acetaldehyde. J Biol Chem. 1999 Aug 20;274(34):23833-40. DM4SJ5Y RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10446146 DMR6N7H DI DMR6N7H DMR6N7H DN Acetohexamide DMR6N7H MI TTP835K DMR6N7H MN ATP-binding cassette transporter C8 (ABCC8) DMR6N7H MT DTT DMR6N7H MA Modulator DMR6N7H RN Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72. DMR6N7H RU https://www.ncbi.nlm.nih.gov/pubmed/16249427 DMR6N7H DI DMR6N7H DMR6N7H DN Acetohexamide DMR6N7H MI DE5IED8 DMR6N7H MN Cytochrome P450 2C9 (CYP2C9) DMR6N7H MT DME DMR6N7H MA Metabolism DMR6N7H RN Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab. 2016 Apr;7(2):69-83. DMR6N7H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27092232 DMR6N7H DI DMR6N7H DMR6N7H DN Acetohexamide DMR6N7H MI DEXPVUN DMR6N7H MN Short-chain dehydrogenase/reductase retSDR1 (DHRS3) DMR6N7H MT DME DMR6N7H MA Metabolism DMR6N7H RN Molecular and biochemical characterisation of human short-chain dehydrogenase/reductase member 3 (DHRS3). Chem Biol Interact. 2015 Jun 5;234:178-87. DMR6N7H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25451588 DMYX7NI DI DMYX7NI DMYX7NI DN Acetohydroxamic Acid DMYX7NI MI TTAS2UO DMYX7NI MN Bacterial Urease (Bact ureC) DMYX7NI MT DTT DMYX7NI MA Inhibitor DMYX7NI RN Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121. DMYX7NI RU https://pubmed.ncbi.nlm.nih.gov/18638408 DMZV2PJ DI DMZV2PJ DMZV2PJ DN Acetophenazine DMZV2PJ MI TTEX248 DMZV2PJ MN Dopamine D2 receptor (D2R) DMZV2PJ MT DTT DMZV2PJ MA Antagonist DMZV2PJ RN Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. DMZV2PJ RU https://pubmed.ncbi.nlm.nih.gov/11873706 DMDF79Z DI DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z MI DEQ2BAJ DMDF79Z MN Acetylcholinesterase (ACHE) DMDF79Z MT DME DMDF79Z MA Metabolism DMDF79Z RN How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDF79Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17139284 DMDF79Z DI DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z MI DT8KXR9 DMDF79Z MN Choline transporter-like protein 4 (SLC44A4) DMDF79Z MT DTP DMDF79Z MA Substrate DMDF79Z RN Choline transporter-like protein 4 (CTL4) links to non-neuronal acetylcholine synthesis. J Neurochem. 2013 Aug;126(4):451-61. DMDF79Z RU http://www.ncbi.nlm.nih.gov/pubmed/23651124 DMDF79Z DI DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z MI TTOXS3C DMDF79Z MN Muscarinic acetylcholine receptor (CHRM) DMDF79Z MT DTT DMDF79Z MA Agonist DMDF79Z RN Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66. DMDF79Z RU https://pubmed.ncbi.nlm.nih.gov/14722259 DMDF79Z DI DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z MI DTT79CX DMDF79Z MN Organic cation transporter 1 (SLC22A1) DMDF79Z MT DTP DMDF79Z MA Substrate DMDF79Z RN Role of acetylcholine and polyspecific cation transporters in serotonin-induced bronchoconstriction in the mouse. Respir Res. 2006 Apr 12;7:65. DMDF79Z RU http://www.ncbi.nlm.nih.gov/pubmed/16608531 DMDF79Z DI DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z MI DT6201N DMDF79Z MN Organic cation transporter 3 (SLC22A3) DMDF79Z MT DTP DMDF79Z MA Substrate DMDF79Z RN Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31. DMDF79Z RU http://www.ncbi.nlm.nih.gov/pubmed/19702534 DMDF79Z DI DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z MI DT3T2K0 DMDF79Z MN Vesicular acetylcholine transporter (SLC18A3) DMDF79Z MT DTP DMDF79Z MA Substrate DMDF79Z RN SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72. DMDF79Z RU http://www.ncbi.nlm.nih.gov/pubmed/23506877 DMHAUO0 DI DMHAUO0 DMHAUO0 DN Acetyldigitoxin DMHAUO0 MI TTWK8D0 DMHAUO0 MN Sodium pump subunit alpha-1 (ATP1A1) DMHAUO0 MT DTT DMHAUO0 MA Modulator DMHAUO0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHAUO0 RU https://www.fda.gov/ DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI DTW7AE3 DMYLOVR MN Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) DMYLOVR MT DTP DMYLOVR MA Substrate DMYLOVR RN Amino Acid Transporter ATB0,+ as a delivery system for drugs and prodrugs. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):357-64. DMYLOVR RU http://www.ncbi.nlm.nih.gov/pubmed/16375689 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI DTI7UX6 DMYLOVR MN Breast cancer resistance protein (ABCG2) DMYLOVR MT DTP DMYLOVR MA Substrate DMYLOVR RN Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity. Can J Physiol Pharmacol. 2011 Sep;89(9):675-80. DMYLOVR RU https://doi.org/10.1139/y11-045 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI TTIU7X1 DMYLOVR MN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMYLOVR MT DTT DMYLOVR MA Modulator DMYLOVR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYLOVR RU https://www.fda.gov/ DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI DTZGT0P DMYLOVR MN Multidrug and toxin extrusion protein 1 (SLC47A1) DMYLOVR MT DTP DMYLOVR MA Substrate DMYLOVR RN Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. DMYLOVR RU http://www.ncbi.nlm.nih.gov/pubmed/17509534 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI DT3TX4H DMYLOVR MN Multidrug and toxin extrusion protein 2 (SLC47A2) DMYLOVR MT DTP DMYLOVR MA Substrate DMYLOVR RN Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. DMYLOVR RU http://www.ncbi.nlm.nih.gov/pubmed/17509534 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI DTFI42L DMYLOVR MN Multidrug resistance-associated protein 2 (ABCC2) DMYLOVR MT DTP DMYLOVR MA Substrate DMYLOVR RN Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003 Aug;306(2):778-86. DMYLOVR RU http://www.ncbi.nlm.nih.gov/pubmed/12750437 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI DTQ23VB DMYLOVR MN Organic anion transporter 1 (SLC22A6) DMYLOVR MT DTP DMYLOVR MA Substrate DMYLOVR RN Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. DMYLOVR RU http://www.ncbi.nlm.nih.gov/pubmed/11861798 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI DT0OC1Q DMYLOVR MN Organic anion transporter 2 (SLC22A7) DMYLOVR MT DTP DMYLOVR MA Substrate DMYLOVR RN Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8. DMYLOVR RU http://www.ncbi.nlm.nih.gov/pubmed/18216183 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI DTVP67E DMYLOVR MN Organic anion transporter 3 (SLC22A8) DMYLOVR MT DTP DMYLOVR MA Substrate DMYLOVR RN Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metab Dispos. 2012 Mar;40(3):617-24. DMYLOVR RU http://www.ncbi.nlm.nih.gov/pubmed/22190696 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI DTT79CX DMYLOVR MN Organic cation transporter 1 (SLC22A1) DMYLOVR MT DTP DMYLOVR MA Substrate DMYLOVR RN Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24. DMYLOVR RU http://www.ncbi.nlm.nih.gov/pubmed/11861798 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR MI TTHPJTK DMYLOVR MN Varicella-zoster virus DNA polymerase (VZV ORF28) DMYLOVR MT DTT DMYLOVR MA Modulator DMYLOVR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYLOVR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8BKU9 DI DM8BKU9 DM8BKU9 DN Acitretin DM8BKU9 MI TTH8FZW DM8BKU9 MN Signal transducer and activator of transcription 3 (STAT3) DM8BKU9 MT DTT DM8BKU9 MA Inhibitor DM8BKU9 RN Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4. DM8BKU9 RU https://pubmed.ncbi.nlm.nih.gov/16737614 DMLFZHD DI DMLFZHD DMLFZHD DN Aclarubicin DMLFZHD MI TT0IHXV DMLFZHD MN DNA topoisomerase II (TOP2) DMLFZHD MT DTT DMLFZHD MA Inhibitor DMLFZHD RN Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15. DMLFZHD RU https://pubmed.ncbi.nlm.nih.gov/12375883 DM7JT24 DI DM7JT24 DM7JT24 DN Acocantherin DM7JT24 MI DTE2B1D DM7JT24 MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DM7JT24 MT DTP DM7JT24 MA Substrate DM7JT24 RN Molecular cloning and functional characterization of the mouse organic-anion-transporting polypeptide 1 (Oatp1) and mapping of the gene to chromosome X. Biochem J. 2000 Jan 1;345 Pt 1:115-20. DM7JT24 RU http://www.ncbi.nlm.nih.gov/pubmed/10600646 DM7JT24 DI DM7JT24 DM7JT24 DN Acocantherin DM7JT24 MI DT3D8F0 DM7JT24 MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DM7JT24 MT DTP DM7JT24 MA Substrate DM7JT24 RN Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. Int J Mol Sci. 2018 Mar 14;19(3). pii: E855. DM7JT24 RU http://www.ncbi.nlm.nih.gov/pubmed/29538325 DM7JT24 DI DM7JT24 DM7JT24 DN Acocantherin DM7JT24 MI DT9C1TS DM7JT24 MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DM7JT24 MT DTP DM7JT24 MA Substrate DM7JT24 RN Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. DM7JT24 RU http://www.ncbi.nlm.nih.gov/pubmed/11159893 DM7JT24 DI DM7JT24 DM7JT24 DN Acocantherin DM7JT24 MI DTY0QMU DM7JT24 MN Organic anion transporting polypeptide 4C1 (SLCO4C1) DM7JT24 MT DTP DM7JT24 MA Substrate DM7JT24 RN Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. DM7JT24 RU http://www.ncbi.nlm.nih.gov/pubmed/14993604 DM7JT24 DI DM7JT24 DM7JT24 DN Acocantherin DM7JT24 MI TTWK8D0 DM7JT24 MN Sodium pump subunit alpha-1 (ATP1A1) DM7JT24 MT DTT DM7JT24 MA Binder DM7JT24 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7JT24 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTIGA0 DI DMTIGA0 DMTIGA0 DN Acrivastine DMTIGA0 MI TTTIBOJ DMTIGA0 MN Histamine H1 receptor (H1R) DMTIGA0 MT DTT DMTIGA0 MA Antagonist DMTIGA0 RN Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999 May;36(5):329-52. DMTIGA0 RU https://pubmed.ncbi.nlm.nih.gov/10384858 DMTIGA0 DI DMTIGA0 DMTIGA0 DN Acrivastine DMTIGA0 MI DTUGYRD DMTIGA0 MN P-glycoprotein 1 (ABCB1) DMTIGA0 MT DTP DMTIGA0 MA Substrate DMTIGA0 RN Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. DMTIGA0 RU http://www.ncbi.nlm.nih.gov/pubmed/12438524 DMQMV1B DI DMQMV1B DMQMV1B DN Adalimumab DMQMV1B MI TTF8CQI DMQMV1B MN Tumor necrosis factor (TNF) DMQMV1B MT DTT DMQMV1B RN Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7. DMQMV1B RU https://pubmed.ncbi.nlm.nih.gov/19573024 DMX2358 DI DMX2358 DMX2358 DN Adapalene DMX2358 MI TTOD7B3 DMX2358 MN Retinoic acid receptor (RAR) DMX2358 MT DTT DMX2358 MA Binder DMX2358 RN A review of adapalene in the treatment of acne vulgaris. J Adolesc Health. 2008 Nov;43(5):421-4. DMX2358 RU https://pubmed.ncbi.nlm.nih.gov/18848668 DMM278X DI DMM278X DMM278X DN Adefovir DMM278X MI DTI7UX6 DMM278X MN Breast cancer resistance protein (ABCG2) DMM278X MT DTP DMM278X MA Substrate DMM278X RN ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem Pharmacol. 2012 Apr 15;83(8):1073-83. DMM278X RU https://doi.org/10.1016/j.bcp.2011.12.042 DMM278X DI DMM278X DMM278X DN Adefovir DMM278X MI DTSYQGK DMM278X MN Multidrug resistance-associated protein 1 (ABCC1) DMM278X MT DTP DMM278X MA Substrate DMM278X RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DMM278X RU https://doi.org/10.1007/s11095-012-0935-x DMM278X DI DMM278X DMM278X DN Adefovir DMM278X MI DTFI42L DMM278X MN Multidrug resistance-associated protein 2 (ABCC2) DMM278X MT DTP DMM278X MA Substrate DMM278X RN Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol. 2010 Feb;44(2):152-67. DMM278X RU https://doi.org/10.1007/s12033-009-9220-6 DMM278X DI DMM278X DMM278X DN Adefovir DMM278X MI DTCSGPB DMM278X MN Multidrug resistance-associated protein 4 (ABCC4) DMM278X MT DTP DMM278X MA Substrate DMM278X RN Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007 Feb;71(2):619-27. DMM278X RU http://www.ncbi.nlm.nih.gov/pubmed/17110501 DMM278X DI DMM278X DMM278X DN Adefovir DMM278X MI DTQ23VB DMM278X MN Organic anion transporter 1 (SLC22A6) DMM278X MT DTP DMM278X MA Substrate DMM278X RN Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000 Mar;11(3):383-93. DMM278X RU http://www.ncbi.nlm.nih.gov/pubmed/10703662 DMM278X DI DMM278X DMM278X DN Adefovir DMM278X MI DTVP67E DMM278X MN Organic anion transporter 3 (SLC22A8) DMM278X MT DTP DMM278X MA Substrate DMM278X RN FDA Drug Development and Drug Interactions DMM278X RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DMMAWY1 DI DMMAWY1 DMMAWY1 DN Adefovir dipivoxil DMMAWY1 MI DEY1FJO DMMAWY1 MN ATP-AMP transphosphorylase 2 (AK2) DMMAWY1 MT DME DMMAWY1 MA Metabolism DMMAWY1 RN Scientific discussion of Hepsera. DMMAWY1 RU https://www.ema.europa.eu/en/documents/scientific-discussion/hepsera-epar-scientific-discussion_en.pdf DMMAWY1 DI DMMAWY1 DMMAWY1 DN Adefovir dipivoxil DMMAWY1 MI TT84ETX DMMAWY1 MN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMAWY1 MT DTT DMMAWY1 MA Modulator DMMAWY1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMAWY1 RU https://www.fda.gov/ DMYQDBO DI DMYQDBO DMYQDBO DN Ademetionine DMYQDBO MI DEVDYN7 DMYQDBO MN Cytochrome P450 2E1 (CYP2E1) DMYQDBO MT DME DMYQDBO MA Metabolism DMYQDBO RN Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93. DMYQDBO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15763544 DMYQDBO DI DMYQDBO DMYQDBO DN Ademetionine DMYQDBO MI DEFQ8VO DMYQDBO MN Thiopurine methyltransferase (TPMT) DMYQDBO MT DME DMYQDBO MA Metabolism DMYQDBO RN Evolution of putrescine N-methyltransferase from spermidine synthase demanded alterations in substrate binding. FEBS Lett. 2009 Oct 20;583(20):3367-74. DMYQDBO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19796640 DMYQDBO DI DMYQDBO DMYQDBO DN Ademetionine DMYQDBO MI TTX2N1T DMYQDBO MN Transferase unspecific (TF) DMYQDBO MT DTT DMYQDBO MA Modulator DMYQDBO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2013 DMYQDBO RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf DMZLHKJ DI DMZLHKJ DMZLHKJ DN Adenine DMZLHKJ MI DTLMGFJ DMZLHKJ MN Adenine nucleotide translocator 3 (SLC25A6) DMZLHKJ MT DTP DMZLHKJ MA Substrate DMZLHKJ RN Adenine nucleotide (ADP/ATP) translocase 3 participates in the tumor necrosis factor induced apoptosis of MCF-7 cells. Mol Biol Cell. 2007 Nov;18(11):4681-9. DMZLHKJ RU http://www.ncbi.nlm.nih.gov/pubmed/17855512 DMZLHKJ DI DMZLHKJ DMZLHKJ DN Adenine DMZLHKJ MI TTUTN1I DMZLHKJ MN Human Deoxyribonucleic acid (hDNA) DMZLHKJ MT DTT DMZLHKJ MA Binder DMZLHKJ RN Escherichia coli DNA adenine methyltransferase: intrasite processivity and substrate-induced dimerization and activation. Biochemistry. 2009 Aug 11;48(31):7399-410. DMZLHKJ RU https://pubmed.ncbi.nlm.nih.gov/19580332 DMM2NSK DI DMM2NSK DMM2NSK DN Adenosine DMM2NSK MI TTNE7KG DMM2NSK MN Adenosine A2b receptor (ADORA2B) DMM2NSK MT DTT DMM2NSK MA Modulator DMM2NSK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM2NSK RU https://www.fda.gov/ DMM2NSK DI DMM2NSK DMM2NSK DN Adenosine DMM2NSK MI DEDQHBV DMM2NSK MN Adenosine aminohydrolase (ADA) DMM2NSK MT DME DMM2NSK MA Metabolism DMM2NSK RN A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15676-81. DMM2NSK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16221767 DMM2NSK DI DMM2NSK DMM2NSK DN Adenosine DMM2NSK MI DTXD1TQ DMM2NSK MN Equilibrative nucleoside transporter 1 (SLC29A1) DMM2NSK MT DTP DMM2NSK MA Substrate DMM2NSK RN Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol. 2006 Aug;208(2):451-60. DMM2NSK RU http://www.ncbi.nlm.nih.gov/pubmed/16688763 DMM2NSK DI DMM2NSK DMM2NSK DN Adenosine DMM2NSK MI DTYVM24 DMM2NSK MN Multidrug resistance-associated protein 5 (ABCC5) DMM2NSK MT DTP DMM2NSK MA Substrate DMM2NSK RN Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14. DMM2NSK RU http://www.ncbi.nlm.nih.gov/pubmed/12423063 DMM2NSK DI DMM2NSK DMM2NSK DN Adenosine DMM2NSK MI DEYWLRK DMM2NSK MN Sulfotransferase 1A1 (SULT1A1) DMM2NSK MT DME DMM2NSK MA Metabolism DMM2NSK RN Regulation of sulfate assimilation in plants: 7. Cysteine inactivation of adenosine 5'-phosphosulfate sulfotransferase in Lemna minor L. Plant Physiol. 1978 Mar;61(3):342-7. DMM2NSK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16660289 DMNIJT0 DI DMNIJT0 DMNIJT0 DN Adenosine monophosphate DMNIJT0 MI DE2MV1R DMNIJT0 MN Adenine phosphoribosyltransferase (APRT) DMNIJT0 MT DME DMNIJT0 MA Metabolism DMNIJT0 RN Configuration of a scintillation proximity assay for the activity assessment of recombinant human adenine phosphoribosyltransferase. Assay Drug Dev Technol. 2006 Dec;4(6):661-9. DMNIJT0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17199504 DMNIJT0 DI DMNIJT0 DMNIJT0 DN Adenosine monophosphate DMNIJT0 MI TTV1ZSQ DMNIJT0 MN Adenylate cyclase type 1 (ADCY1) DMNIJT0 MT DTT DMNIJT0 MA Binder DMNIJT0 RN Ecto- and cytosolic 5'-nucleotidases in normal and AMP deaminase-deficient human skeletal muscle. Biol Chem. 2006 Jan;387(1):53-8. DMNIJT0 RU https://pubmed.ncbi.nlm.nih.gov/16497164 DMNIJT0 DI DMNIJT0 DMNIJT0 DN Adenosine monophosphate DMNIJT0 MI DTYR5U7 DMNIJT0 MN Peroxisomal membrane protein PMP34 (SLC25A17) DMNIJT0 MT DTP DMNIJT0 MA Substrate DMNIJT0 RN The human gene SLC25A17 encodes a peroxisomal transporter of coenzyme A, FAD and NAD+. Biochem J. 2012 Apr 1;443(1):241-7. DMNIJT0 RU http://www.ncbi.nlm.nih.gov/pubmed/22185573 DM79F6G DI DM79F6G DM79F6G DN Adenosine triphosphate DM79F6G MI TT3PJMV DM79F6G MN Tyrosine-protein kinase ABL1 (ABL) DM79F6G MT DTT DM79F6G MA Inhibitor DM79F6G RN Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. DM79F6G RU https://pubmed.ncbi.nlm.nih.gov/18056932 DMBHO9Y DI DMBHO9Y DMBHO9Y DN Adinazolam DMBHO9Y MI DE4LYSA DMBHO9Y MN Cytochrome P450 3A4 (CYP3A4) DMBHO9Y MT DME DMBHO9Y MA Metabolism DMBHO9Y RN Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74. DMBHO9Y RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9600717 DMBHO9Y DI DMBHO9Y DMBHO9Y DN Adinazolam DMBHO9Y MI DEGTFWK DMBHO9Y MN Mephenytoin 4-hydroxylase (CYP2C19) DMBHO9Y MT DME DMBHO9Y MA Metabolism DMBHO9Y RN Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74. DMBHO9Y RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9600717 DMBHO9Y DI DMBHO9Y DMBHO9Y DN Adinazolam DMBHO9Y MI TTPTXIN DMBHO9Y MN Translocator protein (TSPO) DMBHO9Y MT DTT DMBHO9Y MA Agonist DMBHO9Y RN Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999 Apr 29;371(2-3):113-22. DMBHO9Y RU https://pubmed.ncbi.nlm.nih.gov/10357248 DMVWHTG DI DMVWHTG DMVWHTG DN Afamelanotide DMVWHTG MI TT0MV2T DMVWHTG MN Melanocortin receptor 1 (MC1R) DMVWHTG MT DTT DMVWHTG MA Modulator DMVWHTG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMVWHTG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I MI TT48I1Y DMT3D5I MN Placenta growth factor (PlGF) DMT3D5I MT DTT DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I MI TTOHSBA DMT3D5I MN Vascular endothelial growth factor A (VEGFA) DMT3D5I MT DTT DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I MI TTPJQHE DMT3D5I MN Vascular endothelial growth factor B (VEGFB) DMT3D5I MT DTT DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMPOD47 DI DMPOD47 DMPOD47 DN Ajmalicine DMPOD47 MI TTR6W5O DMPOD47 MN Adrenergic receptor beta-1 (ADRB1) DMPOD47 MT DTT DMPOD47 MA Modulator DMPOD47 RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMPOD47 RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMDJW5K DI DMDJW5K DMDJW5K DN Ajmaline DMDJW5K MI DECB0K3 DMDJW5K MN Cytochrome P450 2D6 (CYP2D6) DMDJW5K MT DME DMDJW5K MA Metabolism DMDJW5K RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMDJW5K RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMDJW5K DI DMDJW5K DMDJW5K DN Ajmaline DMDJW5K MI DTUGYRD DMDJW5K MN P-glycoprotein 1 (ABCB1) DMDJW5K MT DTP DMDJW5K MA Substrate DMDJW5K RN ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein. FEBS Lett. 1994 Apr 25;343(2):168-72. DMDJW5K RU http://www.ncbi.nlm.nih.gov/pubmed/7909523 DML6SRO DI DML6SRO DML6SRO DN Alacepril DML6SRO MI TTL69WB DML6SRO MN Angiotensin-converting enzyme (ACE) DML6SRO MT DTT DML6SRO MA Modulator DML6SRO RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DML6SRO RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMYZ57N DI DMYZ57N DMYZ57N DN Albendazole DMYZ57N MI DEJGDUW DMYZ57N MN Cytochrome P450 1A2 (CYP1A2) DMYZ57N MT DME DMYZ57N MA Metabolism DMYZ57N RN Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42. DMYZ57N RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12451431 DMYZ57N DI DMYZ57N DMYZ57N DN Albendazole DMYZ57N MI DE4LYSA DMYZ57N MN Cytochrome P450 3A4 (CYP3A4) DMYZ57N MT DME DMYZ57N MA Metabolism DMYZ57N RN Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. DMYZ57N RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490 DMYZ57N DI DMYZ57N DMYZ57N DN Albendazole DMYZ57N MI DEGTFWK DMYZ57N MN Mephenytoin 4-hydroxylase (CYP2C19) DMYZ57N MT DME DMYZ57N MA Metabolism DMYZ57N RN Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250-3. DMYZ57N RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26048912 DMYZ57N DI DMYZ57N DMYZ57N DN Albendazole DMYZ57N MI DTUGYRD DMYZ57N MN P-glycoprotein 1 (ABCB1) DMYZ57N MT DTP DMYZ57N MA Substrate DMYZ57N RN The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9. DMYZ57N RU http://www.ncbi.nlm.nih.gov/pubmed/11901088 DMYZ57N DI DMYZ57N DMYZ57N DN Albendazole DMYZ57N MI TTYFKSZ DMYZ57N MN Tubulin beta (TUBB) DMYZ57N MT DTT DMYZ57N MA Binder DMYZ57N RN Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. DMYZ57N RU https://pubmed.ncbi.nlm.nih.gov/19336257 DM1JEGF DI DM1JEGF DM1JEGF DN Albiglutide DM1JEGF MI TTVIMDE DM1JEGF MN Glucagon-like peptide 1 receptor (GLP1R) DM1JEGF MT DTT DM1JEGF MA Modulator DM1JEGF RN GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42. DM1JEGF RU https://www.ncbi.nlm.nih.gov/pubmed/22945360 DM5JTPU DI DM5JTPU DM5JTPU DN Albumin Human DM5JTPU MI TTFNGC9 DM5JTPU MN Serum albumin (ALB) DM5JTPU MT DTT DM5JTPU MA Modulator DM5JTPU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5JTPU RU https://www.fda.gov/ DM5J1NH DI DM5J1NH DM5J1NH DN Alcaftadine DM5J1NH MI TTTIBOJ DM5J1NH MN Histamine H1 receptor (H1R) DM5J1NH MT DTT DM5J1NH MA Antagonist DM5J1NH RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM5J1NH RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMAE84F DI DMAE84F DMAE84F DN Alclometasone DMAE84F MI TTJL8VG DMAE84F MN Corticosteroid-binding globulin (SERPINA6) DMAE84F MT DTT DMAE84F MA Binder DMAE84F RN The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2. DMAE84F RU https://pubmed.ncbi.nlm.nih.gov/2508442 DMAE84F DI DMAE84F DMAE84F DN Alclometasone DMAE84F MI DE4LYSA DMAE84F MN Cytochrome P450 3A4 (CYP3A4) DMAE84F MT DME DMAE84F MA Metabolism DMAE84F RN Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8. DMAE84F RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097 DM2U4XQ DI DM2U4XQ DM2U4XQ DN ALCURONIUM DM2U4XQ MI TTLA931 DM2U4XQ MN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM2U4XQ MT DTT DM2U4XQ MA Inhibitor DM2U4XQ RN Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29. DM2U4XQ RU https://pubmed.ncbi.nlm.nih.gov/17722904 DM4YMIS DI DM4YMIS DM4YMIS DN Aldesleukin DM4YMIS MI TTF89GD DM4YMIS MN Interleukin-2 (IL2) DM4YMIS MT DTT DM4YMIS MA Modulator DM4YMIS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4YMIS RU https://www.fda.gov/ DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW MI DE6TYUK DM9S2JW MN Aldosterone synthase (CYP11B2) DM9S2JW MT DME DM9S2JW MA Metabolism DM9S2JW RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem. 2005 Oct 20;48(21):6632-42. DM9S2JW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16220979 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW MI DE4LYSA DM9S2JW MN Cytochrome P450 3A4 (CYP3A4) DM9S2JW MT DME DM9S2JW MA Metabolism DM9S2JW RN Aldosterone receptor antagonists: effective but often forgotten. Circulation. 2010 Feb 23;121(7):934-9. DM9S2JW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20177008 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW MI DEIBDNY DM9S2JW MN Cytochrome P450 3A5 (CYP3A5) DM9S2JW MT DME DM9S2JW MA Metabolism DM9S2JW RN CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41. DM9S2JW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16141800 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW MI TT26PHO DM9S2JW MN Mineralocorticoid receptor (MR) DM9S2JW MT DTT DM9S2JW MA Agonist DM9S2JW RN Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42. DM9S2JW RU https://pubmed.ncbi.nlm.nih.gov/16188378 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW MI DTUGYRD DM9S2JW MN P-glycoprotein 1 (ABCB1) DM9S2JW MT DTP DM9S2JW MA Substrate DM9S2JW RN MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics. 2007 Feb;17(2):137-44. DM9S2JW RU http://www.ncbi.nlm.nih.gov/pubmed/17301693 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW MI TTS087L DM9S2JW MN Solute carrier family 12 member 1 (SLC12A1) DM9S2JW MT DTT DM9S2JW MA Blocker DM9S2JW RN Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78. DM9S2JW RU https://pubmed.ncbi.nlm.nih.gov/18769054 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW MI DEPE0RD DM9S2JW MN Steroid 11-beta-hydroxylase (CYP11B1) DM9S2JW MT DME DM9S2JW MA Metabolism DM9S2JW RN Quantitative assessment of CYP11B1 and CYP11B2 expression in aldosterone-producing adenomas. Eur J Endocrinol. 2002 Dec;147(6):795-802. DM9S2JW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12457455 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW MI DEB3CV1 DM9S2JW MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DM9S2JW MT DME DM9S2JW MA Metabolism DM9S2JW RN Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology. 2003 Jun;144(6):2659-68. DM9S2JW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12746330 DMP1I6Y DI DMP1I6Y DMP1I6Y DN Alectinib DMP1I6Y MI TTPMQSO DMP1I6Y MN ALK tyrosine kinase receptor (ALK) DMP1I6Y MT DTT DMP1I6Y MA Inhibitor DMP1I6Y RN CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90. DMP1I6Y RU https://pubmed.ncbi.nlm.nih.gov/21575866 DMP1I6Y DI DMP1I6Y DMP1I6Y DN Alectinib DMP1I6Y MI DE4LYSA DMP1I6Y MN Cytochrome P450 3A4 (CYP3A4) DMP1I6Y MT DME DMP1I6Y MA Metabolism DMP1I6Y RN In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes. Xenobiotica. 2018 Jun;48(6):546-554. DMP1I6Y RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28657423 DMMYPWO DI DMMYPWO DMMYPWO DN Alefacept DMMYPWO MI TT5KSBY DMMYPWO MN Surface glycoprotein LFA-3 (CD58) DMMYPWO MT DTT DMMYPWO MA Modulator DMMYPWO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMYPWO RU https://www.fda.gov/ DMZL3IV DI DMZL3IV DMZL3IV DN Alemtuzumab DMZL3IV MI TTQT5S9 DMZL3IV MN Cambridge pathology 1 antigen (CD52) DMZL3IV MT DTT DMZL3IV RN Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49. DMZL3IV RU https://pubmed.ncbi.nlm.nih.gov/19545375 DMY2KX9 DI DMY2KX9 DMY2KX9 DN Alendronate DMY2KX9 MI TTIKWV4 DMY2KX9 MN Geranyltranstransferase (FDPS) DMY2KX9 MT DTT DMY2KX9 MA Modulator DMY2KX9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMY2KX9 RU https://www.fda.gov/ DMCKPUR DI DMCKPUR DMCKPUR DN Alfaferone DMCKPUR MI TT95SOA DMCKPUR MN Interferon alpha (IFNA) DMCKPUR MT DTT DMCKPUR MA Modulator DMCKPUR RN Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7. DMCKPUR RU https://pubmed.ncbi.nlm.nih.gov/21739360 DMVO0UB DI DMVO0UB DMVO0UB DN Alfentanil DMVO0UB MI DE4LYSA DMVO0UB MN Cytochrome P450 3A4 (CYP3A4) DMVO0UB MT DME DMVO0UB MA Metabolism DMVO0UB RN Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology. 2005 Mar;102(3):550-6. DMVO0UB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15731592 DMVO0UB DI DMVO0UB DMVO0UB DN Alfentanil DMVO0UB MI DEIBDNY DMVO0UB MN Cytochrome P450 3A5 (CYP3A5) DMVO0UB MT DME DMVO0UB MA Metabolism DMVO0UB RN Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007 Oct;82(4):410-26. DMVO0UB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17554244 DMVO0UB DI DMVO0UB DMVO0UB DN Alfentanil DMVO0UB MI DERD86B DMVO0UB MN Cytochrome P450 3A7 (CYP3A7) DMVO0UB MT DME DMVO0UB MA Metabolism DMVO0UB RN Drug Interactions Flockhart Table DMVO0UB RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMVO0UB DI DMVO0UB DMVO0UB DN Alfentanil DMVO0UB MI TTKWM86 DMVO0UB MN Opioid receptor mu (MOP) DMVO0UB MT DTT DMVO0UB MA Agonist DMVO0UB RN Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87. DMVO0UB RU https://pubmed.ncbi.nlm.nih.gov/11240090 DMZVMKF DI DMZVMKF DMZVMKF DN Alfuzosin DMZVMKF MI TT34BHT DMZVMKF MN Adrenergic receptor alpha-1D (ADRA1D) DMZVMKF MT DTT DMZVMKF MA Antagonist DMZVMKF RN Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. DMZVMKF RU https://pubmed.ncbi.nlm.nih.gov/11893233 DMZVMKF DI DMZVMKF DMZVMKF DN Alfuzosin DMZVMKF MI DTI7UX6 DMZVMKF MN Breast cancer resistance protein (ABCG2) DMZVMKF MT DTP DMZVMKF MA Substrate DMZVMKF RN In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71. DMZVMKF RU https://doi.org/10.1007/978-3-642-14541-4_9 DM4LOD0 DI DM4LOD0 DM4LOD0 DN Alglucosidase alfa DM4LOD0 MI TT95ICL DM4LOD0 MN Mannose-6-phosphate receptor (M6PR) DM4LOD0 MT DTT DM4LOD0 MA Binder DM4LOD0 RN Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009 Sep;66(3):329-35. DM4LOD0 RU https://pubmed.ncbi.nlm.nih.gov/19542901 DM1BV7W DI DM1BV7W DM1BV7W DN Aliskiren DM1BV7W MI TTB2MXP DM1BV7W MN Angiotensinogenase renin (REN) DM1BV7W MT DTT DM1BV7W MA Inhibitor DM1BV7W RN Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patie... J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):157-67. DM1BV7W RU https://pubmed.ncbi.nlm.nih.gov/19617271 DM1BV7W DI DM1BV7W DM1BV7W DN Aliskiren DM1BV7W MI DE4LYSA DM1BV7W MN Cytochrome P450 3A4 (CYP3A4) DM1BV7W MT DME DM1BV7W MA Metabolism DM1BV7W RN Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47(8):515-31. DM1BV7W RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18611061 DM1BV7W DI DM1BV7W DM1BV7W DN Aliskiren DM1BV7W MI DTPFTEQ DM1BV7W MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DM1BV7W MT DTP DM1BV7W MA Substrate DM1BV7W RN Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol. 2011 May;71(5):718-26. DM1BV7W RU http://www.ncbi.nlm.nih.gov/pubmed/21204914 DM1BV7W DI DM1BV7W DM1BV7W DN Aliskiren DM1BV7W MI DTUGYRD DM1BV7W MN P-glycoprotein 1 (ABCB1) DM1BV7W MT DTP DM1BV7W MA Substrate DM1BV7W RN Effects of the inhibition of intestinal P-glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys. Biopharm Drug Dispos. 2015 Jan;36(1):15-33. DM1BV7W RU http://www.ncbi.nlm.nih.gov/pubmed/25264342 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH MI DE4LYSA DMME8LH MN Cytochrome P450 3A4 (CYP3A4) DMME8LH MT DME DMME8LH MA Metabolism DMME8LH RN Alitretinoin in dermatology-an update. Indian J Dermatol. 2015 Sep-Oct;60(5):520. DMME8LH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26538721 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH MI TTISP28 DMME8LH MN Retinoic acid receptor beta (RARB) DMME8LH MT DTT DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH MI TT1Q3IE DMME8LH MN Retinoic acid receptor gamma (RARG) DMME8LH MT DTT DMME8LH MA Modulator DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH MI TT6PEUO DMME8LH MN Retinoic acid receptor RXR-alpha (RXRA) DMME8LH MT DTT DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH MI TTKLV96 DMME8LH MN Retinoic acid receptor RXR-beta (RXRB) DMME8LH MT DTT DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH MI TTH029C DMME8LH MN Retinoic acid receptor RXR-gamma (RXRG) DMME8LH MT DTT DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMB4HFI DI DMB4HFI DMB4HFI DN Alkavervir DMB4HFI MI TTNZRI3 DMB4HFI MN Synaptic vesicle amine transporter (SLC18A2) DMB4HFI MT DTT DMB4HFI MA Modulator DMB4HFI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HFI RU https://www.fda.gov/ DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC MI DE7WS3H DMNLHAC MN Aldo-keto reductase 1B1 (AKR1B1) DMNLHAC MT DME DMNLHAC MA Metabolism DMNLHAC RN FDA Label of Brexanolone. The 2020 official website of the U.S. Food and Drug Administration. DMNLHAC RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211371lbl.pdf DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC MI TT1MPAY DMNLHAC MN GABA(A) receptor alpha-1 (GABRA1) DMNLHAC MT DTT DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC MI TTZA1NY DMNLHAC MN GABA(A) receptor beta-2 (GABRB2) DMNLHAC MT DTT DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC MI TTGXH6N DMNLHAC MN GABA(A) receptor delta (GABRD) DMNLHAC MT DTT DMNLHAC MA Inhibitor DMNLHAC RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC MI TT06RH5 DMNLHAC MN GABA(A) receptor gamma-2 (GABRG2) DMNLHAC MT DTT DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC MI TTEX6LM DMNLHAC MN GABA(A) receptor gamma-3 (GABRG3) DMNLHAC MT DTT DMNLHAC MA Modulator DMNLHAC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNLHAC RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC MI TTNJYV2 DMNLHAC MN Gamma-aminobutyric acid receptor (GAR) DMNLHAC MT DTT DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/16854065 DMLPAOB DI DMLPAOB DMLPAOB DN Allopurinol DMLPAOB MI DT0OC1Q DMLPAOB MN Organic anion transporter 2 (SLC22A7) DMLPAOB MT DTP DMLPAOB MA Substrate DMLPAOB RN Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14. DMLPAOB RU http://www.ncbi.nlm.nih.gov/pubmed/12065749 DMLPAOB DI DMLPAOB DMLPAOB DN Allopurinol DMLPAOB MI DTVP67E DMLPAOB MN Organic anion transporter 3 (SLC22A8) DMLPAOB MT DTP DMLPAOB MA Substrate DMLPAOB RN Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos. 2004 May;32(5):479-83. DMLPAOB RU http://www.ncbi.nlm.nih.gov/pubmed/15100168 DMLPAOB DI DMLPAOB DMLPAOB DN Allopurinol DMLPAOB MI DEZV4AP DMLPAOB MN RNA cytidine acetyltransferase (hALP) DMLPAOB MT DME DMLPAOB MA Metabolism DMLPAOB RN Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76. DMLPAOB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10027663 DMLPAOB DI DMLPAOB DMLPAOB DN Allopurinol DMLPAOB MI TT7RJY8 DMLPAOB MN Xanthine dehydrogenase/oxidase (XDH) DMLPAOB MT DTT DMLPAOB MA Inhibitor DMLPAOB RN Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1. DMLPAOB RU https://pubmed.ncbi.nlm.nih.gov/5324754 DM0SYAN DI DM0SYAN DM0SYAN DN Almitrine DM0SYAN MI TTWK8D0 DM0SYAN MN Sodium pump subunit alpha-1 (ATP1A1) DM0SYAN MT DTT DM0SYAN MA Binder DM0SYAN RN Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim Biophys Acta. 1989 Aug 3;975(3):325-9. DM0SYAN RU https://pubmed.ncbi.nlm.nih.gov/2527061 DM7I64Z DI DM7I64Z DM7I64Z DN Almogran DM7I64Z MI TT6MSOK DM7I64Z MN 5-HT 1D receptor (HTR1D) DM7I64Z MT DTT DM7I64Z MA Agonist DM7I64Z RN Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75. DM7I64Z RU https://pubmed.ncbi.nlm.nih.gov/11768838 DMFG5ST DI DMFG5ST DMFG5ST DN Almotriptan malate DMFG5ST MI DES5XRU DMFG5ST MN Cytochrome P450 2C8 (CYP2C8) DMFG5ST MT DME DMFG5ST MA Metabolism DMFG5ST RN Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. DMFG5ST RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466 DMFG5ST DI DMFG5ST DMFG5ST DN Almotriptan malate DMFG5ST MI DECB0K3 DMFG5ST MN Cytochrome P450 2D6 (CYP2D6) DMFG5ST MT DME DMFG5ST MA Metabolism DMFG5ST RN Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46. DMFG5ST RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767 DMFG5ST DI DMFG5ST DMFG5ST DN Almotriptan malate DMFG5ST MI DEVDYN7 DMFG5ST MN Cytochrome P450 2E1 (CYP2E1) DMFG5ST MT DME DMFG5ST MA Metabolism DMFG5ST RN Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. DMFG5ST RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466 DMFG5ST DI DMFG5ST DMFG5ST DN Almotriptan malate DMFG5ST MI DE4LYSA DMFG5ST MN Cytochrome P450 3A4 (CYP3A4) DMFG5ST MT DME DMFG5ST MA Metabolism DMFG5ST RN Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46. DMFG5ST RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767 DMFG5ST DI DMFG5ST DMFG5ST DN Almotriptan malate DMFG5ST MI DEP76YL DMFG5ST MN Dimethylaniline oxidase 3 (FMO3) DMFG5ST MT DME DMFG5ST MA Metabolism DMFG5ST RN Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. DMFG5ST RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466 DMFG5ST DI DMFG5ST DMFG5ST DN Almotriptan malate DMFG5ST MI DEGTFWK DMFG5ST MN Mephenytoin 4-hydroxylase (CYP2C19) DMFG5ST MT DME DMFG5ST MA Metabolism DMFG5ST RN Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11. DMFG5ST RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12642466 DMFG5ST DI DMFG5ST DMFG5ST DN Almotriptan malate DMFG5ST MI DERE4TU DMFG5ST MN Monoamine oxidase type A (MAO-A) DMFG5ST MT DME DMFG5ST MA Metabolism DMFG5ST RN Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46. DMFG5ST RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15762767 DM8WI3R DI DM8WI3R DM8WI3R DN Alogliptin DM8WI3R MI DECB0K3 DM8WI3R MN Cytochrome P450 2D6 (CYP2D6) DM8WI3R MT DME DM8WI3R MA Metabolism DM8WI3R RN An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38. DM8WI3R RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26218204 DM8WI3R DI DM8WI3R DM8WI3R DN Alogliptin DM8WI3R MI DE4LYSA DM8WI3R MN Cytochrome P450 3A4 (CYP3A4) DM8WI3R MT DME DM8WI3R MA Metabolism DM8WI3R RN An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus. Clin Exp Pharmacol Physiol. 2015 Dec;42(12):1225-38. DM8WI3R RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26218204 DM8WI3R DI DM8WI3R DM8WI3R DN Alogliptin DM8WI3R MI TTDIGC1 DM8WI3R MN Dipeptidyl peptidase 4 (DPP-4) DM8WI3R MT DTT DM8WI3R MA Inhibitor DM8WI3R RN Clinical pipeline report, company report or official report of Takeda (2009). DM8WI3R RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DML2A03 DI DML2A03 DML2A03 DN Alosetron DML2A03 MI TTPC4TU DML2A03 MN 5-HT 3A receptor (HTR3A) DML2A03 MT DTT DML2A03 MA Antagonist DML2A03 RN Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844. DML2A03 RU https://pubmed.ncbi.nlm.nih.gov/19471254 DML2A03 DI DML2A03 DML2A03 DN Alosetron DML2A03 MI DEJGDUW DML2A03 MN Cytochrome P450 1A2 (CYP1A2) DML2A03 MT DME DML2A03 MA Metabolism DML2A03 RN Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. Therap Adv Gastroenterol. 2010 May;3(3):165-72. DML2A03 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21180598 DML2A03 DI DML2A03 DML2A03 DN Alosetron DML2A03 MI DE5IED8 DML2A03 MN Cytochrome P450 2C9 (CYP2C9) DML2A03 MT DME DML2A03 MA Metabolism DML2A03 RN Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol. 2001 Apr;41(4):455-8. DML2A03 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11304903 DML2A03 DI DML2A03 DML2A03 DN Alosetron DML2A03 MI DE4LYSA DML2A03 MN Cytochrome P450 3A4 (CYP3A4) DML2A03 MT DME DML2A03 MA Metabolism DML2A03 RN Effect of alosetron on the pharmacokinetics of alprazolam. J Clin Pharmacol. 2001 Apr;41(4):452-4. DML2A03 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11304902 DMEXMYK DI DMEXMYK DMEXMYK DN Alpelisib DMEXMYK MI DE4LYSA DMEXMYK MN Cytochrome P450 3A4 (CYP3A4) DMEXMYK MT DME DMEXMYK MA Metabolism DMEXMYK RN Comparison of 19F NMR and 14C measurements for the assessment of ADME of BYL719 (Alpelisib) in humans. Drug Metab Dispos. 2017 Aug;45(8):900-907. DMEXMYK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28566285 DMEXMYK DI DMEXMYK DMEXMYK DN Alpelisib DMEXMYK MI TTEUNMR DMEXMYK MN PI3-kinase alpha (PIK3CA) DMEXMYK MT DTT DMEXMYK MA Inhibitor DMEXMYK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMEXMYK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf DMXC1K9 DI DMXC1K9 DMXC1K9 DN Alpha 1-PI DMXC1K9 MI TTN9D8E DMXC1K9 MN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMXC1K9 MT DTT DMXC1K9 MA Antagonist DMXC1K9 RN NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250. DMXC1K9 RU https://pubmed.ncbi.nlm.nih.gov/19381304 DMXC1K9 DI DMXC1K9 DMXC1K9 DN Alpha 1-PI DMXC1K9 MI TT3NKIB DMXC1K9 MN Pancreatic elastase 1 (CELA1) DMXC1K9 MT DTT DMXC1K9 MA Inhibitor DMXC1K9 RN Elastase inhibitors. J Soc Biol. 2001;195(2):143-50. DMXC1K9 RU https://pubmed.ncbi.nlm.nih.gov/11723826 DMAS02L DI DMAS02L DMAS02L DN Alpha-acetyldigoxin DMAS02L MI TTYHPRQ DMAS02L MN Sodium pump (NaP) DMAS02L MT DTT DMAS02L MA Modulator DMAS02L RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMAS02L RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMN7Y9K DI DMN7Y9K DMN7Y9K DN Alpidem DMN7Y9K MI TTNJYV2 DMN7Y9K MN Gamma-aminobutyric acid receptor (GAR) DMN7Y9K MT DTT DMN7Y9K MA Inhibitor DMN7Y9K RN Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18. DMN7Y9K RU https://pubmed.ncbi.nlm.nih.gov/9301675 DMN7Y9K DI DMN7Y9K DMN7Y9K DN Alpidem DMN7Y9K MI TTPTXIN DMN7Y9K MN Translocator protein (TSPO) DMN7Y9K MT DTT DMN7Y9K MA Inhibitor DMN7Y9K RN Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem. 2008 Sep 25;51(18):5798-806. DMN7Y9K RU https://pubmed.ncbi.nlm.nih.gov/18729350 DMC7XDN DI DMC7XDN DMC7XDN DN Alprazolam DMC7XDN MI DE5IED8 DMC7XDN MN Cytochrome P450 2C9 (CYP2C9) DMC7XDN MT DME DMC7XDN MA Metabolism DMC7XDN RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMC7XDN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMC7XDN DI DMC7XDN DMC7XDN DN Alprazolam DMC7XDN MI DE4LYSA DMC7XDN MN Cytochrome P450 3A4 (CYP3A4) DMC7XDN MT DME DMC7XDN MA Metabolism DMC7XDN RN No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. Planta Med. 2005 Apr;71(4):331-7. DMC7XDN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15856409 DMC7XDN DI DMC7XDN DMC7XDN DN Alprazolam DMC7XDN MI DEIBDNY DMC7XDN MN Cytochrome P450 3A5 (CYP3A5) DMC7XDN MT DME DMC7XDN MA Metabolism DMC7XDN RN Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther. 2005 Apr;77(4):259-70. DMC7XDN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15903124 DMC7XDN DI DMC7XDN DMC7XDN DN Alprazolam DMC7XDN MI DERD86B DMC7XDN MN Cytochrome P450 3A7 (CYP3A7) DMC7XDN MT DME DMC7XDN MA Metabolism DMC7XDN RN Drug Interactions Flockhart Table DMC7XDN RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMC7XDN DI DMC7XDN DMC7XDN DN Alprazolam DMC7XDN MI TTPTXIN DMC7XDN MN Translocator protein (TSPO) DMC7XDN MT DTT DMC7XDN MA Agonist DMC7XDN RN Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. DMC7XDN RU https://pubmed.ncbi.nlm.nih.gov/19443999 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ MI DTCSGPB DMWH7NQ MN Multidrug resistance-associated protein 4 (ABCC4) DMWH7NQ MT DTP DMWH7NQ MA Substrate DMWH7NQ RN The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. DMWH7NQ RU http://www.ncbi.nlm.nih.gov/pubmed/12835412 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ MI DTQ23VB DMWH7NQ MN Organic anion transporter 1 (SLC22A6) DMWH7NQ MT DTP DMWH7NQ MA Substrate DMWH7NQ RN Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. Prostaglandins Other Lipid Mediat. 2016 Jan;122:10-7. DMWH7NQ RU http://www.ncbi.nlm.nih.gov/pubmed/26692285 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ MI DT021JD DMWH7NQ MN Organic anion transporting polypeptide 2A1 (SLCO2A1) DMWH7NQ MT DTP DMWH7NQ MA Substrate DMWH7NQ RN Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. DMWH7NQ RU http://www.ncbi.nlm.nih.gov/pubmed/8787677 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ MI DTVNRXW DMWH7NQ MN Organic anion transporting polypeptide 3A1 (SLCO3A1) DMWH7NQ MT DTP DMWH7NQ MA Substrate DMWH7NQ RN Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. DMWH7NQ RU http://www.ncbi.nlm.nih.gov/pubmed/14631946 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ MI DEHKSC6 DMWH7NQ MN Prostaglandin dehydrogenase 1 (HPGD) DMWH7NQ MT DME DMWH7NQ MA Metabolism DMWH7NQ RN Effect of calcium ionophore A23187 on prostaglandin synthase type 2 and 15-hydroxy-prostaglandin dehydrogenase expression in human chorion trophoblast cells. Am J Obstet Gynecol. 2008 Nov;199(5):554.e1-8. DMWH7NQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18639206 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ MI TT1ZAVI DMWH7NQ MN Prostaglandin E2 receptor EP2 (PTGER2) DMWH7NQ MT DTT DMWH7NQ MA Agonist DMWH7NQ RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMWH7NQ RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ MI TT2O84V DMWH7NQ MN Thromboxane A2 receptor (TBXA2R) DMWH7NQ MT DTT DMWH7NQ MA Modulator DMWH7NQ RN Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6. DMWH7NQ RU https://pubmed.ncbi.nlm.nih.gov/10509658 DMB47TQ DI DMB47TQ DMB47TQ DN Alseroxylon DMB47TQ MI TTNZRI3 DMB47TQ MN Synaptic vesicle amine transporter (SLC18A2) DMB47TQ MT DTT DMB47TQ MA Blocker DMB47TQ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMB47TQ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMRJ3YX DI DMRJ3YX DMRJ3YX DN Alteplase DMRJ3YX MI TTP86E2 DMRJ3YX MN Plasminogen (PLG) DMRJ3YX MT DTT DMRJ3YX MA Activator DMRJ3YX RN Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32. DMRJ3YX RU https://pubmed.ncbi.nlm.nih.gov/15823070 DMKLAYG DI DMKLAYG DMKLAYG DN Altretamine DMKLAYG MI TTUTN1I DMKLAYG MN Human Deoxyribonucleic acid (hDNA) DMKLAYG MT DTT DMKLAYG MA Breaker DMKLAYG RN Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. DMKLAYG RU https://pubmed.ncbi.nlm.nih.gov/18305940 DMO9WDS DI DMO9WDS DMO9WDS DN Altropane DMO9WDS MI TTVBI8W DMO9WDS MN Dopamine transporter (DAT) DMO9WDS MT DTT DMO9WDS MA Inhibitor DMO9WDS RN Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41. DMO9WDS RU https://pubmed.ncbi.nlm.nih.gov/9593103 DM6ECN9 DI DM6ECN9 DM6ECN9 DN Aluminium DM6ECN9 MI TTWK8D0 DM6ECN9 MN Sodium pump subunit alpha-1 (ATP1A1) DM6ECN9 MT DTT DM6ECN9 MA Binder DM6ECN9 RN The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50. DM6ECN9 RU https://pubmed.ncbi.nlm.nih.gov/14507470 DMHR8KW DI DMHR8KW DMHR8KW DN Alvimopan DMHR8KW MI TTKWM86 DMHR8KW MN Opioid receptor mu (MOP) DMHR8KW MT DTT DMHR8KW MA Antagonist DMHR8KW RN Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77. DMHR8KW RU https://pubmed.ncbi.nlm.nih.gov/19574601 DMS3YE9 DI DMS3YE9 DMS3YE9 DN Amantadine DMS3YE9 MI TTXT3PU DMS3YE9 MN Influenza M2 protein (Influ M) DMS3YE9 MT DTT DMS3YE9 MA Inhibitor DMS3YE9 RN Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc. 2009 Jun 17;131(23):8066-76. DMS3YE9 RU https://pubmed.ncbi.nlm.nih.gov/19469531 DMS3YE9 DI DMS3YE9 DMS3YE9 DN Amantadine DMS3YE9 MI DT9IDPW DMS3YE9 MN Organic cation transporter 2 (SLC22A2) DMS3YE9 MT DTP DMS3YE9 MA Substrate DMS3YE9 RN Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52. DMS3YE9 RU http://www.ncbi.nlm.nih.gov/pubmed/9687576 DMOP0BL DI DMOP0BL DMOP0BL DN Ambenonium DMOP0BL MI TT1RS9F DMOP0BL MN Acetylcholinesterase (AChE) DMOP0BL MT DTT DMOP0BL MA Inhibitor DMOP0BL RN Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66. DMOP0BL RU https://pubmed.ncbi.nlm.nih.gov/18033235 DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW MI DE4LYSA DMD1QXW MN Cytochrome P450 3A4 (CYP3A4) DMD1QXW MT DME DMD1QXW MA Metabolism DMD1QXW RN Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805. DMD1QXW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719 DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW MI TTKRD0G DMD1QXW MN Endothelin A receptor (EDNRA) DMD1QXW MT DTT DMD1QXW MA Antagonist DMD1QXW RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMD1QXW RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW MI DEGTFWK DMD1QXW MN Mephenytoin 4-hydroxylase (CYP2C19) DMD1QXW MT DME DMD1QXW MA Metabolism DMD1QXW RN Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805. DMD1QXW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719 DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW MI DTUGYRD DMD1QXW MN P-glycoprotein 1 (ABCB1) DMD1QXW MT DTP DMD1QXW MA Substrate DMD1QXW RN Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20. DMD1QXW RU http://www.ncbi.nlm.nih.gov/pubmed/20811346 DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW MI DEF2WXN DMD1QXW MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMD1QXW MT DME DMD1QXW MA Metabolism DMD1QXW RN Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805. DMD1QXW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719 DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW MI DE85D2P DMD1QXW MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMD1QXW MT DME DMD1QXW MA Metabolism DMD1QXW RN Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805. DMD1QXW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719 DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW MI DEB3CV1 DMD1QXW MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMD1QXW MT DME DMD1QXW MA Metabolism DMD1QXW RN Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805. DMD1QXW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22205719 DMWJE9D DI DMWJE9D DMWJE9D DN Ambroxol DMWJE9D MI DE4LYSA DMWJE9D MN Cytochrome P450 3A4 (CYP3A4) DMWJE9D MT DME DMWJE9D MA Metabolism DMWJE9D RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMWJE9D RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMM1JL9 DI DMM1JL9 DMM1JL9 DN Amcinonide DMM1JL9 MI DE4LYSA DMM1JL9 MN Cytochrome P450 3A4 (CYP3A4) DMM1JL9 MT DME DMM1JL9 MA Metabolism DMM1JL9 RN Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. DMM1JL9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443 DMM1JL9 DI DMM1JL9 DMM1JL9 DN Amcinonide DMM1JL9 MI TTP3UTW DMM1JL9 MN Steroid hormone receptor ERR (ESRR) DMM1JL9 MT DTT DMM1JL9 MA Modulator DMM1JL9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM1JL9 RU https://www.fda.gov/ DMIG6FY DI DMIG6FY DMIG6FY DN Amdinocillin DMIG6FY MI TTHWB7G DMIG6FY MN Bacterial Penicillin binding protein 2 (Bact mrdA) DMIG6FY MT DTT DMIG6FY MA Inhibitor DMIG6FY RN Growth of Escherichia coli: significance of peptidoglycan degradation during elongation and septation. J Bacteriol. 2008 Jun;190(11):3914-22. DMIG6FY RU https://pubmed.ncbi.nlm.nih.gov/18390656 DM6I2WQ DI DM6I2WQ DM6I2WQ DN Amezinium DM6I2WQ MI TT2NUT5 DM6I2WQ MN Adrenergic receptor alpha-2C (ADRA2C) DM6I2WQ MT DTT DM6I2WQ MA Modulator DM6I2WQ RN Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65. DM6I2WQ RU https://pubmed.ncbi.nlm.nih.gov/7197970 DM9YSNQ DI DM9YSNQ DM9YSNQ DN Amfepramone DM9YSNQ MI TTAWNKZ DM9YSNQ MN Norepinephrine transporter (NET) DM9YSNQ MT DTT DM9YSNQ MA Inhibitor DM9YSNQ RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM9YSNQ RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM9YSNQ DI DM9YSNQ DM9YSNQ DN Amfepramone DM9YSNQ MI TT3ROYC DM9YSNQ MN Serotonin transporter (SERT) DM9YSNQ MT DTT DM9YSNQ MA Inhibitor DM9YSNQ RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM9YSNQ RU https://pubmed.ncbi.nlm.nih.gov/15977970 DMK08L3 DI DMK08L3 DMK08L3 DN Amifampridine DMK08L3 MI DE7OAB3 DMK08L3 MN N-acetyltransferase 1 (NAT1) DMK08L3 MT DME DMK08L3 MA Metabolism DMK08L3 RN Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099. DMK08L3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25692017 DMK08L3 DI DMK08L3 DMK08L3 DN Amifampridine DMK08L3 MI DER7TA0 DMK08L3 MN N-acetyltransferase 2 (NAT2) DMK08L3 MT DME DMK08L3 MA Metabolism DMK08L3 RN Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099. DMK08L3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25692017 DMK08L3 DI DMK08L3 DMK08L3 DN Amifampridine DMK08L3 MI TT1VOHK DMK08L3 MN Potassium channel unspecific (KC) DMK08L3 MT DTT DMK08L3 MA Blocker DMK08L3 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK08L3 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM5FL14 DI DM5FL14 DM5FL14 DN Amifostine DM5FL14 MI DEVEFKM DM5FL14 MN Alkaline phosphatase (ALPL) DM5FL14 MT DME DM5FL14 MA Metabolism DM5FL14 RN Pharmacokinetic profile of amifostine. Semin Oncol. 1996 Aug;23(4 Suppl 8):18-22. DM5FL14 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8783662 DM5FL14 DI DM5FL14 DM5FL14 DN Amifostine DM5FL14 MI TT0C9DV DM5FL14 MN Toxic reactive metabolite (TRM) DM5FL14 MT DTT DM5FL14 MA Modulator DM5FL14 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM5FL14 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM5PDRB DI DM5PDRB DM5PDRB DN Amikacin DM5PDRB MI DEWPAJD DM5PDRB MN Aminoglycoside O-phosphotransferase (aphA6) DM5PDRB MT DME DM5PDRB MA Metabolism DM5PDRB RN Relationship between antimicrobial resistance and aminoglycoside-modifying enzyme gene expressions in Acinetobacter baumannii. Chin Med J (Engl). 2005 Jan 20;118(2):141-5. DM5PDRB RU https://pubmed.ncbi.nlm.nih.gov/15667800 DM5PDRB DI DM5PDRB DM5PDRB DN Amikacin DM5PDRB MI DE1C8Q4 DM5PDRB MN Endoglucanase A (EGA) DM5PDRB MT DME DM5PDRB MA Metabolism DM5PDRB RN Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63. DM5PDRB RU https://pubmed.ncbi.nlm.nih.gov/10688695 DM5PDRB DI DM5PDRB DM5PDRB DN Amikacin DM5PDRB MI DE2AZTG DM5PDRB MN Endoglucanase Y (EGY) DM5PDRB MT DME DM5PDRB MA Metabolism DM5PDRB RN Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63. DM5PDRB RU https://pubmed.ncbi.nlm.nih.gov/10688695 DM5PDRB DI DM5PDRB DM5PDRB DN Amikacin DM5PDRB MI TTQ8KVI DM5PDRB MN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM5PDRB MT DTT DM5PDRB MA Binder DM5PDRB RN Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9. DM5PDRB RU https://pubmed.ncbi.nlm.nih.gov/10702385 DMRTSGP DI DMRTSGP DMRTSGP DN Amiloride DMRTSGP MI TTRJYB6 DMRTSGP MN Acid-sensing ion channel 1 (ASIC1) DMRTSGP MT DTT DMRTSGP MA Modulator DMRTSGP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRTSGP RU https://www.fda.gov/ DMRTSGP DI DMRTSGP DMRTSGP DN Amiloride DMRTSGP MI DTT79CX DMRTSGP MN Organic cation transporter 1 (SLC22A1) DMRTSGP MT DTP DMRTSGP MA Substrate DMRTSGP RN Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. DMRTSGP RU http://www.ncbi.nlm.nih.gov/pubmed/23984907 DMRTSGP DI DMRTSGP DMRTSGP DN Amiloride DMRTSGP MI DT9IDPW DMRTSGP MN Organic cation transporter 2 (SLC22A2) DMRTSGP MT DTP DMRTSGP MA Substrate DMRTSGP RN Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol. 2006 Jun;290(6):C1521-31. DMRTSGP RU http://www.ncbi.nlm.nih.gov/pubmed/16394027 DMFGND4 DI DMFGND4 DMFGND4 DN Aminocaproic acid DMFGND4 MI TTP86E2 DMFGND4 MN Plasminogen (PLG) DMFGND4 MT DTT DMFGND4 MA Inhibitor DMFGND4 RN The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92. DMFGND4 RU https://pubmed.ncbi.nlm.nih.gov/12007600 DMFGND4 DI DMFGND4 DMFGND4 DN Aminocaproic acid DMFGND4 MI TTXAGYU DMFGND4 MN Tissue-type plasminogen activator (PLAT) DMFGND4 MT DTT DMFGND4 MA Inhibitor DMFGND4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFGND4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWFHMZ DI DMWFHMZ DMWFHMZ DN Aminoglutethimide DMWFHMZ MI TTSZLWK DMWFHMZ MN Aromatase (CYP19A1) DMWFHMZ MT DTT DMWFHMZ MA Inhibitor DMWFHMZ RN Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45. DMWFHMZ RU https://pubmed.ncbi.nlm.nih.gov/17602675 DMWFHMZ DI DMWFHMZ DMWFHMZ DN Aminoglutethimide DMWFHMZ MI TTSYVO6 DMWFHMZ MN Cholesterol desmolase (CYP11A1) DMWFHMZ MT DTT DMWFHMZ MA Inhibitor DMWFHMZ RN Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma. Cell Immunol. 2000 Nov 25;206(1):7-15. DMWFHMZ RU https://pubmed.ncbi.nlm.nih.gov/11161433 DMS4BLQ DI DMS4BLQ DMS4BLQ DN Aminolevulinic acid hci DMS4BLQ MI TTJHKYD DMS4BLQ MN Delta-aminolevulinic acid dehydratase (ALAD) DMS4BLQ MT DTT DMS4BLQ MA Inhibitor DMS4BLQ RN Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. DMS4BLQ RU https://pubmed.ncbi.nlm.nih.gov/12665801 DMS4BLQ DI DMS4BLQ DMS4BLQ DN Aminolevulinic acid hci DMS4BLQ MI DT9G7XN DMS4BLQ MN Peptide transporter 1 (SLC15A1) DMS4BLQ MT DTP DMS4BLQ MA Substrate DMS4BLQ RN Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine. J Pharmacol Exp Ther. 2010 Jan;332(1):220-8. DMS4BLQ RU http://www.ncbi.nlm.nih.gov/pubmed/19789362 DMS4BLQ DI DMS4BLQ DMS4BLQ DN Aminolevulinic acid hci DMS4BLQ MI DT8QKNP DMS4BLQ MN Peptide transporter 2 (SLC15A2) DMS4BLQ MT DTP DMS4BLQ MA Substrate DMS4BLQ RN PEPT2-mediated transport of 5-aminolevulinic acid and carnosine in astrocytes. Brain Res. 2006 Nov 29;1122(1):18-23. DMS4BLQ RU http://www.ncbi.nlm.nih.gov/pubmed/17034769 DMS4BLQ DI DMS4BLQ DMS4BLQ DN Aminolevulinic acid hci DMS4BLQ MI DETBNY4 DMS4BLQ MN Porphobilinogen synthase (ALAD) DMS4BLQ MT DME DMS4BLQ MA Metabolism DMS4BLQ RN Modifying effects of delta-Aminolevulinate dehydratase polymorphism on blood lead levels and ALAD activity. Toxicol Lett. 2018 Oct 1;295:351-356. DMS4BLQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30025905 DMS4BLQ DI DMS4BLQ DMS4BLQ DN Aminolevulinic acid hci DMS4BLQ MI DT48WEM DMS4BLQ MN Proton-coupled amino acid transporter 1 (SLC36A1) DMS4BLQ MT DTP DMS4BLQ MA Substrate DMS4BLQ RN Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1). Br J Pharmacol. 2010 Mar;159(6):1339-53. DMS4BLQ RU http://www.ncbi.nlm.nih.gov/pubmed/20128809 DMWNHPC DI DMWNHPC DMWNHPC DN Aminolevulinic Acid Hydrochloride DMWNHPC MI TTNFMS9 DMWNHPC MN Protoporphyrinogen oxidase (PPOX) DMWNHPC MT DTT DMWNHPC MA Modulator DMWNHPC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWNHPC RU https://www.fda.gov/ DML2NIB DI DML2NIB DML2NIB DN Aminophylline DML2NIB MI DEJGDUW DML2NIB MN Cytochrome P450 1A2 (CYP1A2) DML2NIB MT DME DML2NIB MA Metabolism DML2NIB RN Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men. Pharmacotherapy. 1998 Nov-Dec;18(6):1237-48. DML2NIB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9855322 DML2NIB DI DML2NIB DML2NIB DN Aminophylline DML2NIB MI DEVDYN7 DML2NIB MN Cytochrome P450 2E1 (CYP2E1) DML2NIB MT DME DML2NIB MA Metabolism DML2NIB RN Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther. 1996 Mar;276(3):912-7. DML2NIB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8786569 DML2NIB DI DML2NIB DML2NIB DN Aminophylline DML2NIB MI TT06AWU DML2NIB MN Phosphodiesterase 3A (PDE3A) DML2NIB MT DTT DML2NIB MA Inhibitor DML2NIB RN Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3. DML2NIB RU https://pubmed.ncbi.nlm.nih.gov/17391155 DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 MI TTYZVDJ DMENSL5 MN Dihydrofolate reductase (DHFR) DMENSL5 MT DTT DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 MI DER7TA0 DMENSL5 MN N-acetyltransferase 2 (NAT2) DMENSL5 MT DME DMENSL5 MA Metabolism DMENSL5 RN Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis. Inflamm Bowel Dis. 2016 Aug;22(8):1793-802. DMENSL5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27416043 DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 MI TT8NGED DMENSL5 MN Prostaglandin G/H synthase 1 (COX-1) DMENSL5 MT DTT DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 MI TTVKILB DMENSL5 MN Prostaglandin G/H synthase 2 (COX-2) DMENSL5 MT DTT DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 MI DTKWJH3 DMENSL5 MN Sodium-coupled neutral amino acid transporter 3 (SLC38A3) DMENSL5 MT DTP DMENSL5 MA Substrate DMENSL5 RN Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2. Biochem J. 2000 May 15;348 Pt 1:159-66. DMENSL5 RU http://www.ncbi.nlm.nih.gov/pubmed/10794727 DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 MI DE6OQ3W DMUTEX3 MN Cytochrome P450 1A1 (CYP1A1) DMUTEX3 MT DME DMUTEX3 MA Metabolism DMUTEX3 RN A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. DMUTEX3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11038157 DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 MI DEJGDUW DMUTEX3 MN Cytochrome P450 1A2 (CYP1A2) DMUTEX3 MT DME DMUTEX3 MA Metabolism DMUTEX3 RN Role of desethylamiodarone in the anticoagulant effect of concurrent amiodarone and warfarin therapy. J Cardiovasc Pharmacol Ther. 2001 Oct;6(4):363-7. DMUTEX3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11907638 DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 MI DES5XRU DMUTEX3 MN Cytochrome P450 2C8 (CYP2C8) DMUTEX3 MT DME DMUTEX3 MA Metabolism DMUTEX3 RN Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos. 2005 May;33(5):630-6. DMUTEX3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15716363 DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 MI DE5IED8 DMUTEX3 MN Cytochrome P450 2C9 (CYP2C9) DMUTEX3 MT DME DMUTEX3 MA Metabolism DMUTEX3 RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMUTEX3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 MI DECB0K3 DMUTEX3 MN Cytochrome P450 2D6 (CYP2D6) DMUTEX3 MT DME DMUTEX3 MA Metabolism DMUTEX3 RN Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-38. DMUTEX3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12688833 DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 MI DE4LYSA DMUTEX3 MN Cytochrome P450 3A4 (CYP3A4) DMUTEX3 MT DME DMUTEX3 MA Metabolism DMUTEX3 RN The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci. 2008;11(1):147-59. DMUTEX3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18445370 DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 MI DEGTFWK DMUTEX3 MN Mephenytoin 4-hydroxylase (CYP2C19) DMUTEX3 MT DME DMUTEX3 MA Metabolism DMUTEX3 RN A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2000 Nov;28(11):1303-10. DMUTEX3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11038157 DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 MI DTUGYRD DMUTEX3 MN P-glycoprotein 1 (ABCB1) DMUTEX3 MT DTP DMUTEX3 MA Substrate DMUTEX3 RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMUTEX3 RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 MI TT1VOHK DMUTEX3 MN Potassium channel unspecific (KC) DMUTEX3 MT DTT DMUTEX3 MA Modulator DMUTEX3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUTEX3 RU https://www.fda.gov/ DMSJVAM DI DMSJVAM DMSJVAM DN Amisulpride DMSJVAM MI TTEX248 DMSJVAM MN Dopamine D2 receptor (D2R) DMSJVAM MT DTT DMSJVAM MA Antagonist DMSJVAM RN Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. DMSJVAM RU https://pubmed.ncbi.nlm.nih.gov/16696579 DMSJVAM DI DMSJVAM DMSJVAM DN Amisulpride DMSJVAM MI DTUGYRD DMSJVAM MN P-glycoprotein 1 (ABCB1) DMSJVAM MT DTP DMSJVAM MA Substrate DMSJVAM RN Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. DMSJVAM RU http://www.ncbi.nlm.nih.gov/pubmed/15285840 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DEJGDUW DMK7F9S MN Cytochrome P450 1A2 (CYP1A2) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN The genetic profiles of CYP1A1, CYP1A2 and CYP2E1 enzymes as susceptibility factor in xenobiotic toxicity in Turkish population. Saudi Pharm J. 2017 Feb;25(2):294-297. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28344482 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DEPKLMQ DMK7F9S MN Cytochrome P450 2B6 (CYP2B6) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11259560 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DES5XRU DMK7F9S MN Cytochrome P450 2C8 (CYP2C8) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol. 2000 Dec;50(6):573-80. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11136296 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DE5IED8 DMK7F9S MN Cytochrome P450 2C9 (CYP2C9) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997 Feb;43(2):137-44. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9131945 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DECB0K3 DMK7F9S MN Cytochrome P450 2D6 (CYP2D6) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DEVDYN7 DMK7F9S MN Cytochrome P450 2E1 (CYP2E1) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998 Feb;38(2):112-21. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9549641 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DE4LYSA DMK7F9S MN Cytochrome P450 3A4 (CYP3A4) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18359012 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DEIBDNY DMK7F9S MN Cytochrome P450 3A5 (CYP3A5) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol. 2003 Dec 15;66(12):2333-40. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14637191 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DEGTFWK DMK7F9S MN Mephenytoin 4-hydroxylase (CYP2C19) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci. 2017 Mar;10(2):93-101. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28296334 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI TTAWNKZ DMK7F9S MN Norepinephrine transporter (NET) DMK7F9S MT DTT DMK7F9S MA Inhibitor DMK7F9S RN Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. DMK7F9S RU https://pubmed.ncbi.nlm.nih.gov/18622371 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DTUGYRD DMK7F9S MN P-glycoprotein 1 (ABCB1) DMK7F9S MT DTP DMK7F9S MA Substrate DMK7F9S RN Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. DMK7F9S RU http://www.ncbi.nlm.nih.gov/pubmed/12954186 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI TT3ROYC DMK7F9S MN Serotonin transporter (SERT) DMK7F9S MT DTT DMK7F9S MA Inhibitor DMK7F9S RN Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. DMK7F9S RU https://pubmed.ncbi.nlm.nih.gov/18622371 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S MI DEYGVN4 DMK7F9S MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMK7F9S MT DME DMK7F9S MA Metabolism DMK7F9S RN Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition. J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71. DMK7F9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21497036 DM0DQM5 DI DM0DQM5 DM0DQM5 DN Amlexanox DM0DQM5 MI TT78R5H DM0DQM5 MN Heat shock protein 90 alpha (HSP90A) DM0DQM5 MT DTT DM0DQM5 MA Inhibitor DM0DQM5 RN Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. DM0DQM5 RU https://pubmed.ncbi.nlm.nih.gov/12803546 DMBDAZV DI DMBDAZV DMBDAZV DN Amlodipine DMBDAZV MI DE4LYSA DMBDAZV MN Cytochrome P450 3A4 (CYP3A4) DMBDAZV MT DME DMBDAZV MA Metabolism DMBDAZV RN Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9. DMBDAZV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24301608 DMBDAZV DI DMBDAZV DMBDAZV DN Amlodipine DMBDAZV MI TTFK1JQ DMBDAZV MN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMBDAZV MT DTT DMBDAZV MA Blocker DMBDAZV RN A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94. DMBDAZV RU https://pubmed.ncbi.nlm.nih.gov/18217647 DMOEVK6 DI DMOEVK6 DMOEVK6 DN Ammonia DMOEVK6 MI DTU6IF7 DMOEVK6 MN Ammonium transporter Rh type B (SLC42A2) DMOEVK6 MT DTP DMOEVK6 MA Substrate DMOEVK6 RN Functional analysis of human RhCG: comparison with E. coli ammonium transporter reveals similarities in the pore and differences in the vestibule. Am J Physiol Cell Physiol. 2009 Sep;297(3):C537-47. DMOEVK6 RU http://www.ncbi.nlm.nih.gov/pubmed/19553567 DMOEVK6 DI DMOEVK6 DMOEVK6 DN Ammonia DMOEVK6 MI DTF3LTV DMOEVK6 MN Ammonium transporter Rh type C (SLC42A3) DMOEVK6 MT DTP DMOEVK6 MA Substrate DMOEVK6 RN Functional analysis of human RhCG: comparison with E. coli ammonium transporter reveals similarities in the pore and differences in the vestibule. Am J Physiol Cell Physiol. 2009 Sep;297(3):C537-47. DMOEVK6 RU http://www.ncbi.nlm.nih.gov/pubmed/19553567 DMOEVK6 DI DMOEVK6 DMOEVK6 DN Ammonia DMOEVK6 MI DE5UC73 DMOEVK6 MN Glutamine synthetase (GLUL) DMOEVK6 MT DME DMOEVK6 MA Metabolism DMOEVK6 RN Ammonia metabolism capacity of HepG2 cells with high expression of human glutamine synthetase. Hepatobiliary Pancreat Dis Int. 2008 Dec;7(6):621-7. DMOEVK6 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19073408 DM0GQ8N DI DM0GQ8N DM0GQ8N DN Amobarbital DM0GQ8N MI TT1MPAY DM0GQ8N MN GABA(A) receptor alpha-1 (GABRA1) DM0GQ8N MT DTT DM0GQ8N MA Antagonist DM0GQ8N RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM0GQ8N RU https://pubmed.ncbi.nlm.nih.gov/18048412 DME4RA8 DI DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 MI DE4OGUF DME4RA8 MN Cytochrome P450 102A1 (cyp102) DME4RA8 MT DME DME4RA8 MA Metabolism DME4RA8 RN The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98. DME4RA8 RU https://pubmed.ncbi.nlm.nih.gov/17532492 DME4RA8 DI DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 MI DE6OQ3W DME4RA8 MN Cytochrome P450 1A1 (CYP1A1) DME4RA8 MT DME DME4RA8 MA Metabolism DME4RA8 RN Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407. DME4RA8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11805197 DME4RA8 DI DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 MI DE9QHP6 DME4RA8 MN Cytochrome P450 1B1 (CYP1B1) DME4RA8 MT DME DME4RA8 MA Metabolism DME4RA8 RN Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407. DME4RA8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11805197 DME4RA8 DI DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 MI DES5XRU DME4RA8 MN Cytochrome P450 2C8 (CYP2C8) DME4RA8 MT DME DME4RA8 MA Metabolism DME4RA8 RN Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007 Aug;82(2):197-203. DME4RA8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17361129 DME4RA8 DI DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 MI DERQ52Z DME4RA8 MN Glutathione S-transferase mu-4 (GSTM4) DME4RA8 MT DME DME4RA8 MA Metabolism DME4RA8 RN Human glutathione S-transferases- and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: possible implications for susceptibility to amodiaquine-induced liver toxicity. Toxicol Lett. 2017 Jun 5;275:83-91. DME4RA8 RU https://pubmed.ncbi.nlm.nih.gov/28478157 DME4RA8 DI DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 MI TT2B6EV DME4RA8 MN Histamine N-methyltransferase (HNMT) DME4RA8 MT DTT DME4RA8 MA Inhibitor DME4RA8 RN Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84. DME4RA8 RU https://pubmed.ncbi.nlm.nih.gov/17222819 DML8QSZ DI DML8QSZ DML8QSZ DN Amosulalol DML8QSZ MI TT2NUT5 DML8QSZ MN Adrenergic receptor alpha-2C (ADRA2C) DML8QSZ MT DTT DML8QSZ MA Modulator DML8QSZ RN Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. DML8QSZ RU https://pubmed.ncbi.nlm.nih.gov/8095542 DML8QSZ DI DML8QSZ DML8QSZ DN Amosulalol DML8QSZ MI TTMXGCW DML8QSZ MN Adrenergic receptor beta-3 (ADRB3) DML8QSZ MT DTT DML8QSZ MA Modulator DML8QSZ RN Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. DML8QSZ RU https://pubmed.ncbi.nlm.nih.gov/8095542 DMKITQE DI DMKITQE DMKITQE DN Amoxapine DMKITQE MI DECB0K3 DMKITQE MN Cytochrome P450 2D6 (CYP2D6) DMKITQE MT DME DMKITQE MA Metabolism DMKITQE RN Addition of amoxapine improves positive and negative symptoms in a patient with schizophrenia. Ther Adv Psychopharmacol. 2013 Dec;3(6):340-2. DMKITQE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24294487 DMKITQE DI DMKITQE DMKITQE DN Amoxapine DMKITQE MI TTAWNKZ DMKITQE MN Norepinephrine transporter (NET) DMKITQE MT DTT DMKITQE MA Inhibitor DMKITQE RN Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25. DMKITQE RU https://pubmed.ncbi.nlm.nih.gov/7845548 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI TTXT4D5 DMUYNEI MN Bacterial Cell membrane (Bact CM) DMUYNEI MT DTT DMUYNEI MA Modulator DMUYNEI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUYNEI RU https://www.fda.gov/ DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DED0TBR DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Major phenylpropanoid-derived metabolites in the human gut can arise from microbial fermentation of protein. Mol Nutr Food Res. 2013 Mar;57(3):523-35. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/23349065 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEX8KJO DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN The prevalence of beta-lactamase producing bacteria in subgingival plaque and their sensitivity to Augmentin. Br J Oral Maxillofac Surg. 1990 Jun;28(3):180-4. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/1983762 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEAYSTX DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN ACI-1 beta-lactamase is widespread across human gut microbiomes in Negativicutes due to transposons harboured by tailed prophages. Environ Microbiol. 2018 Jun;20(6):2288-2300. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30014616 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DERGEVU DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/2221864 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEV0KWQ DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/15621454 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEQMISO DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/2221864 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEHFJ4G DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/2221864 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEHPJRC DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/2221864 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEITMS0 DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci. Antimicrob Agents Chemother. 2000 Nov;44(11):3144-9. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/11036038 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DET9I1W DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DE7IH52 DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/15621454 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DENJ2SQ DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DE5HV8P DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DE47ARF DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEG2PK9 DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEWHJ7A DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEU1RXB DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DETDS7E DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/15621454 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DE37FJH DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother. 1990 Aug;34(8):1546-50. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/2221864 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEC7JEF DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/15621454 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEP7MN1 DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/29737548 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEAILCM DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/29737548 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DET4XFN DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/15621454 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEACNTL DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN IncU plasmid harbouring bla CTX-M-8 in multidrug-resistant Shigella sonnei in Brazil. J Glob Antimicrob Resist. 2018 Sep;14:99-100. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/29964206 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEE8742 DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/24013195 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEY09SU DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/15621454 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEQLVCA DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevotella strains and lactamic resistance gene distribution in different oral environments of children with pulp necrosis. Int Endod J. 2018 Nov;51(11):1196-1204. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/29737548 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DE2IL34 DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/24013195 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DE1NJIW DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Yersinia enterocolitica and Photorhabdus asymbiotica beta-lactamases BlaA are exported by the twin-arginine translocation pathway. Int J Med Microbiol. 2013 Jan;303(1):16-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/23276548 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEDIMN9 DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEJ8X2W DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEFEVNH DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/24013195 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEAPGXV DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/15621454 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DE0PDVC DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/24013195 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEQL32N DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN High prevalence of beta-lactam and macrolide resistance genes in human oral Capnocytophaga species. J Antimicrob Chemother. 2014 Feb;69(2):381-4. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/24013195 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DE9HF0I DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DESHI6O DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEZS3N4 DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/15621454 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DE5NSUX DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Detection and characterization of beta-lactamase genes in subgingival bacteria from patients with refractory periodontitis. FEMS Microbiol Lett. 2005 Jan 15;242(2):319-24. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/15621454 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEW193R DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/27381397 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEQ1CTE DMUYNEI MN Beta-lactamase (blaB) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN High prevalence of cfxA beta-lactamase in aminopenicillin-resistant Prevotella strains isolated from periodontal pockets. Oral Microbiol Immunol. 2002 Apr;17(2):85-8. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/11929554 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEGTFWK DMUYNEI MN Mephenytoin 4-hydroxylase (CYP2C19) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8. DMUYNEI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14696516 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEPCQ12 DMUYNEI MN Metallo-beta-lactamase (blaM) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/27381397 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEK9VG2 DMUYNEI MN Metallo-beta-lactamase (blaM) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Interspecies dissemination of a mobilizable plasmid harboring blaIMP-19 and the possibility of horizontal gene transfer in a single patient. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5412-9. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/27381397 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEIU0XN DMUYNEI MN N-acylhomoserine lactone acylase (lacA) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/28455333 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DEBGCYQ DMUYNEI MN New delhi metallo-beta-lactamase NDM-1 (blaNDM) DMUYNEI MT DME DMUYNEI MA Metabolism DMUYNEI RN Genomic characterization of an extensively-drug resistance Salmonella enterica serotype Indiana strain harboring bla NDM-1 gene isolated from a chicken carcass in China. Microbiol Res. 2017 Nov;204:48-54. DMUYNEI RU https://pubmed.ncbi.nlm.nih.gov/28870291 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DTQ23VB DMUYNEI MN Organic anion transporter 1 (SLC22A6) DMUYNEI MT DTP DMUYNEI MA Substrate DMUYNEI RN The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9. DMUYNEI RU http://www.ncbi.nlm.nih.gov/pubmed/11744606 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DT9G7XN DMUYNEI MN Peptide transporter 1 (SLC15A1) DMUYNEI MT DTP DMUYNEI MA Substrate DMUYNEI RN Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. DMUYNEI RU http://www.ncbi.nlm.nih.gov/pubmed/16434549 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DT8QKNP DMUYNEI MN Peptide transporter 2 (SLC15A2) DMUYNEI MT DTP DMUYNEI MA Substrate DMUYNEI RN Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. DMUYNEI RU http://www.ncbi.nlm.nih.gov/pubmed/16434549 DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI MI DTUGYRD DMUYNEI MN P-glycoprotein 1 (ABCB1) DMUYNEI MT DTP DMUYNEI MA Substrate DMUYNEI RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DMUYNEI RU https://doi.org/10.1007/s11095-012-0935-x DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK MI DECB0K3 DMSZQAK MN Cytochrome P450 2D6 (CYP2D6) DMSZQAK MT DME DMSZQAK MA Metabolism DMSZQAK RN Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32. DMSZQAK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690 DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK MI DT6201N DMSZQAK MN Organic cation transporter 3 (SLC22A3) DMSZQAK MT DTP DMSZQAK MA Substrate DMSZQAK RN Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9. DMSZQAK RU http://www.ncbi.nlm.nih.gov/pubmed/20402963 DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK MI DT3HUVD DMSZQAK MN Organic cation/carnitine transporter 2 (SLC22A5) DMSZQAK MT DTP DMSZQAK MA Substrate DMSZQAK RN Novel organic cation transporter 2-mediated carnitine uptake in placental choriocarcinoma (BeWo) cells. J Pharmacol Exp Ther. 2005 Jan;312(1):192-8. DMSZQAK RU http://www.ncbi.nlm.nih.gov/pubmed/15316089 DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK MI DT3BA8L DMSZQAK MN Sodium-dependent dopamine transporter (SLC6A3) DMSZQAK MT DTP DMSZQAK MA Substrate DMSZQAK RN Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50. DMSZQAK RU http://www.ncbi.nlm.nih.gov/pubmed/25542076 DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK MI DT9JBVI DMSZQAK MN Sodium-dependent noradrenaline transporter (SLC6A2) DMSZQAK MT DTP DMSZQAK MA Substrate DMSZQAK RN Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50. DMSZQAK RU http://www.ncbi.nlm.nih.gov/pubmed/25542076 DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK MI TTIU98M DMSZQAK MN Trace amine-associated receptor-1 (TAAR1) DMSZQAK MT DTT DMSZQAK MA Modulator DMSZQAK RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMSZQAK RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK MI DEB3TNR DMSZQAK MN Tyramine oxidase (tynA) DMSZQAK MT DME DMSZQAK MA Metabolism DMSZQAK RN Mechanistic elucidation of amphetamine metabolism by tyramine oxidase from human gut microbiota using molecular dynamics simulations. J Cell Biochem. 2019 Jan 30. DMSZQAK RU https://pubmed.ncbi.nlm.nih.gov/30701587 DMTAJQE DI DMTAJQE DMTAJQE DN Amphotericin B DMTAJQE MI TTQKWA4 DMTAJQE MN Fungal Cell membrane ergosterol (Fung CME) DMTAJQE MT DTT DMTAJQE MA Modulator DMTAJQE RN Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim Biophys Acta. 2002 Dec 23;1567(1-2):63-78. DMTAJQE RU https://pubmed.ncbi.nlm.nih.gov/12488039 DMTAJQE DI DMTAJQE DMTAJQE DN Amphotericin B DMTAJQE MI DTUGYRD DMTAJQE MN P-glycoprotein 1 (ABCB1) DMTAJQE MT DTP DMTAJQE MA Substrate DMTAJQE RN Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87. DMTAJQE RU https://doi.org/10.1016/j.phymed.2012.05.010 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DERI7LO DMHWE7P MN AmpC beta-lactamase (ampC) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/30012762 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI TTJP4SM DMHWE7P MN Bacterial Penicillin binding protein (Bact PBP) DMHWE7P MT DTT DMHWE7P MA Binder DMHWE7P RN Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/11959556 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DET9I1W DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/7492085 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DE3FVRW DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/15327642 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DETDS7E DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/15327642 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DEQX0DG DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/15327642 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DEC7JEF DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/15327642 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DEXB2A9 DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/10837443 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DEBKS91 DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/21034630 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DEWMGC3 DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/15327642 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DEWYT5M DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/15327642 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DE52KD0 DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/15327642 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DEG5Y4W DMHWE7P MN Beta-lactamase (blaB) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN Beta-lactamase production and antimicrobial susceptibility of subgingival bacteria from refractory periodontitis. Oral Microbiol Immunol. 2004 Oct;19(5):303-8. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/15327642 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DTFI42L DMHWE7P MN Multidrug resistance-associated protein 2 (ABCC2) DMHWE7P MT DTP DMHWE7P MA Substrate DMHWE7P RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMHWE7P RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DEIU0XN DMHWE7P MN N-acylhomoserine lactone acylase (lacA) DMHWE7P MT DME DMHWE7P MA Metabolism DMHWE7P RN A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/28455333 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DT9G7XN DMHWE7P MN Peptide transporter 1 (SLC15A1) DMHWE7P MT DTP DMHWE7P MA Substrate DMHWE7P RN Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449. DMHWE7P RU http://www.ncbi.nlm.nih.gov/pubmed/28214542 DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P MI DT8QKNP DMHWE7P MN Peptide transporter 2 (SLC15A2) DMHWE7P MT DTP DMHWE7P MA Substrate DMHWE7P RN Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. DMHWE7P RU http://www.ncbi.nlm.nih.gov/pubmed/16597710 DM5BS98 DI DM5BS98 DM5BS98 DN Ampiroxicam DM5BS98 MI TTK0943 DM5BS98 MN Prostaglandin G/H synthase (COX) DM5BS98 MT DTT DM5BS98 MA Modulator DM5BS98 RN Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7. DM5BS98 RU https://pubmed.ncbi.nlm.nih.gov/16540287 DMLMXE0 DI DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 MI DE5IED8 DMLMXE0 MN Cytochrome P450 2C9 (CYP2C9) DMLMXE0 MT DME DMLMXE0 MA Metabolism DMLMXE0 RN Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72. DMLMXE0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10868554 DMLMXE0 DI DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 MI DECB0K3 DMLMXE0 MN Cytochrome P450 2D6 (CYP2D6) DMLMXE0 MT DME DMLMXE0 MA Metabolism DMLMXE0 RN Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor. Clin Ther. 2000 May;22(5):549-72. DMLMXE0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10868554 DMLMXE0 DI DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 MI DE4LYSA DMLMXE0 MN Cytochrome P450 3A4 (CYP3A4) DMLMXE0 MT DME DMLMXE0 MA Metabolism DMLMXE0 RN Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85. DMLMXE0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16433896 DMLMXE0 DI DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 MI DEIBDNY DMLMXE0 MN Cytochrome P450 3A5 (CYP3A5) DMLMXE0 MT DME DMLMXE0 MA Metabolism DMLMXE0 RN Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003 Mar;31(3):275-81. DMLMXE0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12584153 DMLMXE0 DI DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 MI TT5FNQT DMLMXE0 MN Human immunodeficiency virus Protease (HIV PR) DMLMXE0 MT DTT DMLMXE0 MA Inhibitor DMLMXE0 RN Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503. DMLMXE0 RU https://pubmed.ncbi.nlm.nih.gov/19323590 DMLMXE0 DI DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 MI DTUGYRD DMLMXE0 MN P-glycoprotein 1 (ABCB1) DMLMXE0 MT DTP DMLMXE0 MA Substrate DMLMXE0 RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMLMXE0 RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMZKYIV DI DMZKYIV DMZKYIV DN Amsacrine DMZKYIV MI DECB0K3 DMZKYIV MN Cytochrome P450 2D6 (CYP2D6) DMZKYIV MT DME DMZKYIV MA Metabolism DMZKYIV RN Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res. 2000 Aug;6(8):3088-94. DMZKYIV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10955788 DMZKYIV DI DMZKYIV DMZKYIV DN Amsacrine DMZKYIV MI TT0IHXV DMZKYIV MN DNA topoisomerase II (TOP2) DMZKYIV MT DTT DMZKYIV MA Inhibitor DMZKYIV RN Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21. DMZKYIV RU https://pubmed.ncbi.nlm.nih.gov/11716434 DMAWU35 DI DMAWU35 DMAWU35 DN Amtolmetin guacil DMAWU35 MI TTK0943 DMAWU35 MN Prostaglandin G/H synthase (COX) DMAWU35 MT DTT DMAWU35 MA Modulator DMAWU35 RN Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):809-18. DMAWU35 RU https://pubmed.ncbi.nlm.nih.gov/16396699 DMJKO05 DI DMJKO05 DMJKO05 DN Amyl nitrite DMJKO05 MI DEWYTJB DMJKO05 MN Aldehyde dehydrogenase 2 (ALDH2) DMJKO05 MT DME DMJKO05 MA Metabolism DMJKO05 RN Mitochondrial aldehyde dehydrogenase mediates vasodilator responses of glyceryl trinitrate and sodium nitrite in the pulmonary vascular bed of the rat. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H819-26. DMJKO05 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20543077 DMJKO05 DI DMJKO05 DMJKO05 DN Amyl nitrite DMJKO05 MI DE4ZHS1 DMJKO05 MN Glutathione S-transferase alpha-1 (GSTA1) DMJKO05 MT DME DMJKO05 MA Metabolism DMJKO05 RN Subunit specificity and organ distribution of glutathione transferase-catalysed S-nitrosoglutathione formation from alkyl nitrites in the rat. Biochem Pharmacol. 1997 Jan 10;53(1):117-20. DMJKO05 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8960071 DMJXIC9 DI DMJXIC9 DMJXIC9 DN Anagliptin DMJXIC9 MI TTDIGC1 DMJXIC9 MN Dipeptidyl peptidase 4 (DPP-4) DMJXIC9 MT DTT DMJXIC9 MA Modulator DMJXIC9 RN Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30. DMJXIC9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646042/ DMSQ8MD DI DMSQ8MD DMSQ8MD DN Anagrelide DMSQ8MD MI DEJGDUW DMSQ8MD MN Cytochrome P450 1A2 (CYP1A2) DMSQ8MD MT DME DMSQ8MD MA Metabolism DMSQ8MD RN Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-nae Japanese patients with essential thrombocythemia. Int J Hematol. 2013 Mar;97(3):360-8. DMSQ8MD RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23378182 DMSQ8MD DI DMSQ8MD DMSQ8MD DN Anagrelide DMSQ8MD MI TT06AWU DMSQ8MD MN Phosphodiesterase 3A (PDE3A) DMSQ8MD MT DTT DMSQ8MD MA Inhibitor DMSQ8MD RN Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. DMSQ8MD RU https://pubmed.ncbi.nlm.nih.gov/16000354 DMU8KOD DI DMU8KOD DMU8KOD DN Anakinra DMU8KOD MI TTWOTEA DMU8KOD MN Interleukin 1 receptor type 1 (IL1R1) DMU8KOD MT DTT DMU8KOD MA Antagonist DMU8KOD RN IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur Cytokine Netw. 2009 Jun 1;20(2):81-87. DMU8KOD RU https://pubmed.ncbi.nlm.nih.gov/19541594 DMV96ZH DI DMV96ZH DMV96ZH DN Anapsos DMV96ZH MI TTXL3MF DMV96ZH MN Lymphoid cell adhesion molecule expression (LCDME) DMV96ZH MT DTT DMV96ZH MA Modulator DMV96ZH RN Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion molecules. Pharmacol Res. 2002 Aug;46(2):185-90. DMV96ZH RU https://pubmed.ncbi.nlm.nih.gov/12220959 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F MI TTSZLWK DMNP60F MN Aromatase (CYP19A1) DMNP60F MT DTT DMNP60F MA Inhibitor DMNP60F RN Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8. DMNP60F RU https://pubmed.ncbi.nlm.nih.gov/12199354 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F MI DES5XRU DMNP60F MN Cytochrome P450 2C8 (CYP2C8) DMNP60F MT DME DMNP60F MA Metabolism DMNP60F RN In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69. DMNP60F RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F MI DE4LYSA DMNP60F MN Cytochrome P450 3A4 (CYP3A4) DMNP60F MT DME DMNP60F MA Metabolism DMNP60F RN In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69. DMNP60F RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F MI DEIBDNY DMNP60F MN Cytochrome P450 3A5 (CYP3A5) DMNP60F MT DME DMNP60F MA Metabolism DMNP60F RN In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69. DMNP60F RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F MI DT2EGUN DMNP60F MN Putative sodium-coupled neutral amino acid transporter 7 (SLC38A7) DMNP60F MT DTP DMNP60F MA Substrate DMNP60F RN Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. Clin Pharmacol Ther. 2019 Jan 16. DMNP60F RU http://www.ncbi.nlm.nih.gov/pubmed/30648747 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F MI DEYGVN4 DMNP60F MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMNP60F MT DME DMNP60F MA Metabolism DMNP60F RN In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69. DMNP60F RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F MI DEF2WXN DMNP60F MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMNP60F MT DME DMNP60F MA Metabolism DMNP60F RN In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69. DMNP60F RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F MI DEB3CV1 DMNP60F MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMNP60F MT DME DMNP60F MA Metabolism DMNP60F RN In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69. DMNP60F RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21175441 DMLWQ27 DI DMLWQ27 DMLWQ27 DN Angiotensin Ii DMLWQ27 MI TT8DBY3 DMLWQ27 MN Angiotensin II receptor type-1 (AGTR1) DMLWQ27 MT DTT DMLWQ27 MA Inhibitor DMLWQ27 RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMLWQ27 RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMLWQ27 DI DMLWQ27 DMLWQ27 DN Angiotensin Ii DMLWQ27 MI TTQVOEI DMLWQ27 MN Angiotensin II receptor type-2 (AGTR2) DMLWQ27 MT DTT DMLWQ27 MA Inhibitor DMLWQ27 RN The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993). DMLWQ27 RU http://www.sciencedirect.com/science/article/pii/S0960894X00806885 DM8QM5U DI DM8QM5U DM8QM5U DN Anidulafungin DM8QM5U MI TT0SFXH DM8QM5U MN Fungal 1,3-beta-glucan synthase (Fung GSC2) DM8QM5U MT DTT DM8QM5U MA Modulator DM8QM5U RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM8QM5U RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMBAUED DI DMBAUED DMBAUED DN Anileridine DMBAUED MI TTKWM86 DMBAUED MN Opioid receptor mu (MOP) DMBAUED MT DTT DMBAUED MA Agonist DMBAUED RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMBAUED RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMC128O DI DMC128O DMC128O DN Anileridine Hydrochloride DMC128O MI TTKWM86 DMC128O MN Opioid receptor mu (MOP) DMC128O MT DTT DMC128O MA Modulator DMC128O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC128O RU https://www.fda.gov/ DMOIFW0 DI DMOIFW0 DMOIFW0 DN Aniracetam DMOIFW0 MI TTJQOD7 DMOIFW0 MN 5-HT 2A receptor (HTR2A) DMOIFW0 MT DTT DMOIFW0 MA Inhibitor DMOIFW0 RN Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. DMOIFW0 RU https://pubmed.ncbi.nlm.nih.gov/11412837 DMOIFW0 DI DMOIFW0 DMOIFW0 DN Aniracetam DMOIFW0 MI TTEX248 DMOIFW0 MN Dopamine D2 receptor (D2R) DMOIFW0 MT DTT DMOIFW0 MA Inhibitor DMOIFW0 RN Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. DMOIFW0 RU https://pubmed.ncbi.nlm.nih.gov/11412837 DM2C48U DI DM2C48U DM2C48U DN Anisindione DM2C48U MI TT6L509 DM2C48U MN Coagulation factor IIa (F2) DM2C48U MT DTT DM2C48U MA Modulator DM2C48U RN Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6. DM2C48U RU https://pubmed.ncbi.nlm.nih.gov/12680483 DMW51AX DI DMW51AX DMW51AX DN Anisodamine DMW51AX MI TTR6W5O DMW51AX MN Adrenergic receptor beta-1 (ADRB1) DMW51AX MT DTT DMW51AX MA Modulator DMW51AX RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMW51AX RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMW51AX DI DMW51AX DMW51AX DN Anisodamine DMW51AX MI DECB0K3 DMW51AX MN Cytochrome P450 2D6 (CYP2D6) DMW51AX MT DME DMW51AX MA Metabolism DMW51AX RN Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. DMW51AX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712 DMNOSWU DI DMNOSWU DMNOSWU DN Anisodine DMNOSWU MI TTR6W5O DMNOSWU MN Adrenergic receptor beta-1 (ADRB1) DMNOSWU MT DTT DMNOSWU MA Modulator DMNOSWU RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNOSWU RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNOSWU DI DMNOSWU DMNOSWU DN Anisodine DMNOSWU MI TTH18TF DMNOSWU MN Muscarinic acetylcholine receptor M5 (CHRM5) DMNOSWU MT DTT DMNOSWU MA Modulator DMNOSWU RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNOSWU RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMIJRF0 DI DMIJRF0 DMIJRF0 DN Anisotropine Methylbromide DMIJRF0 MI TTH18TF DMIJRF0 MN Muscarinic acetylcholine receptor M5 (CHRM5) DMIJRF0 MT DTT DMIJRF0 MA Binder DMIJRF0 RN Anisotropine methylbromide: a new antispasmodic for gastrointestinal disorders. Curr Ther Res Clin Exp. 1963 May;5:213-8. DMIJRF0 RU https://pubmed.ncbi.nlm.nih.gov/13966843 DM6Q4B0 DI DM6Q4B0 DM6Q4B0 DN Anistreplase DM6Q4B0 MI TTP86E2 DM6Q4B0 MN Plasminogen (PLG) DM6Q4B0 MT DTT DM6Q4B0 MA Activator DM6Q4B0 RN Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7. DM6Q4B0 RU https://pubmed.ncbi.nlm.nih.gov/9360848 DMUMOEV DI DMUMOEV DMUMOEV DN Ansuvimab DMUMOEV MI TT2F0AU DMUMOEV MN Ebola virus Envelope glycoprotein (EV GP) DMUMOEV MT DTT DMUMOEV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMUMOEV RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf DMA04JS DI DMA04JS DMA04JS DN Antazoline DMA04JS MI TTTIBOJ DMA04JS MN Histamine H1 receptor (H1R) DMA04JS MT DTT DMA04JS MA Antagonist DMA04JS RN Histamine and the convulsive threshold or effectiveness of antiepileptic drugs. Przegl Lek. 2008;65(11):803-6. DMA04JS RU https://pubmed.ncbi.nlm.nih.gov/19205365 DMNC64R DI DMNC64R DMNC64R DN Antegren DMNC64R MI TT4BT06 DMNC64R MN Integrin alpha-4 (ITGA4) DMNC64R MT DTT DMNC64R RN Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7. DMNC64R RU https://pubmed.ncbi.nlm.nih.gov/9736917 DMH4CFE DI DMH4CFE DMH4CFE DN Antithymocyte globulin DMH4CFE MI TTBGTFN DMH4CFE MN T-cell surface glycoprotein CD1a (CD1A) DMH4CFE MT DTT DMH4CFE MA Binder DMH4CFE RN Acute sensory neuropathy associated with rabbit antithymocyte globulin. Am J Transplant. 2007 Feb;7(2):484-6. DMH4CFE RU https://pubmed.ncbi.nlm.nih.gov/17283492 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN MI DTI7UX6 DM89JLN MN Breast cancer resistance protein (ABCG2) DM89JLN MT DTP DM89JLN MA Substrate DM89JLN RN Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013 Apr;41(4):827-35. DM89JLN RU http://www.ncbi.nlm.nih.gov/pubmed/23382458 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN MI TTCIHJA DM89JLN MN Coagulation factor Xa (F10) DM89JLN MT DTT DM89JLN MA Inhibitor DM89JLN RN Pfizer. Product Development Pipeline. March 31 2009. DM89JLN RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN MI DEJGDUW DM89JLN MN Cytochrome P450 1A2 (CYP1A2) DM89JLN MT DME DM89JLN MA Metabolism DM89JLN RN Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509. DM89JLN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN MI DES5XRU DM89JLN MN Cytochrome P450 2C8 (CYP2C8) DM89JLN MT DME DM89JLN MA Metabolism DM89JLN RN Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509. DM89JLN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN MI DE5IED8 DM89JLN MN Cytochrome P450 2C9 (CYP2C9) DM89JLN MT DME DM89JLN MA Metabolism DM89JLN RN Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509. DM89JLN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN MI DE4LYSA DM89JLN MN Cytochrome P450 3A4 (CYP3A4) DM89JLN MT DME DM89JLN MA Metabolism DM89JLN RN In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010 Mar;38(3):448-58. DM89JLN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19940026 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN MI DEIBDNY DM89JLN MN Cytochrome P450 3A5 (CYP3A5) DM89JLN MT DME DM89JLN MA Metabolism DM89JLN RN Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire Int. 2012 Sep;21(130):201-2, 204. DM89JLN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23016247 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN MI DEGTFWK DM89JLN MN Mephenytoin 4-hydroxylase (CYP2C19) DM89JLN MT DME DM89JLN MA Metabolism DM89JLN RN Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509. DM89JLN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24421512 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN MI DTUGYRD DM89JLN MN P-glycoprotein 1 (ABCB1) DM89JLN MT DTP DM89JLN MA Substrate DM89JLN RN Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J Cardiovasc Drugs. 2016 Apr;16(2):119-27. DM89JLN RU http://www.ncbi.nlm.nih.gov/pubmed/26749408 DMX38HQ DI DMX38HQ DMX38HQ DN Apomorphine DMX38HQ MI TTEX248 DMX38HQ MN Dopamine D2 receptor (D2R) DMX38HQ MT DTT DMX38HQ MA Agonist DMX38HQ RN Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse. 2009 May;63(5):378-89. DMX38HQ RU https://pubmed.ncbi.nlm.nih.gov/19173265 DMX38HQ DI DMX38HQ DMX38HQ DN Apomorphine DMX38HQ MI DEYWLRK DMX38HQ MN Sulfotransferase 1A1 (SULT1A1) DMX38HQ MT DME DMX38HQ MA Metabolism DMX38HQ RN Sulfation of apomorphine by human sulfotransferases: evidence of a major role for the polymorphic phenol sulfotransferase, SULT1A1. Xenobiotica. 2003 Nov;33(11):1139-48. DMX38HQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14660177 DMO4PVE DI DMO4PVE DMO4PVE DN Apraclonidine DMO4PVE MI TTQ8AFT DMO4PVE MN Adrenergic receptor Alpha-2 (ADRA2) DMO4PVE MT DTT DMO4PVE MA Agonist DMO4PVE RN Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation. Anesth Analg. 2002 Mar;94(3):701-5; table of contents. DMO4PVE RU https://pubmed.ncbi.nlm.nih.gov/11867401 DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E MI TT0PG8F DMTWS9E MN Cyclin-dependent kinase 4 (CDK4) DMTWS9E MT DTT DMTWS9E MA Inhibitor DMTWS9E RN Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. DMTWS9E RU http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E MI TTO0FDJ DMTWS9E MN Cyclin-dependent kinase 6 (CDK6) DMTWS9E MT DTT DMTWS9E MA Inhibitor DMTWS9E RN Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. DMTWS9E RU http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E MI DEJGDUW DMTWS9E MN Cytochrome P450 1A2 (CYP1A2) DMTWS9E MT DME DMTWS9E MA Metabolism DMTWS9E RN Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500. DMTWS9E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26236137 DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E MI DEJVYAZ DMTWS9E MN Cytochrome P450 2A6 (CYP2A6) DMTWS9E MT DME DMTWS9E MA Metabolism DMTWS9E RN Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015 Aug;40(8):495-500. DMTWS9E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26236137 DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E MI DE4LYSA DMTWS9E MN Cytochrome P450 3A4 (CYP3A4) DMTWS9E MT DME DMTWS9E MA Metabolism DMTWS9E RN Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: a novel treatment option for nurse practitioners treating patients with psoriatic disease. J Am Assoc Nurse Pract. 2016 Dec;28(12):683-695. DMTWS9E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27869356 DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E MI DTUGYRD DMTWS9E MN P-glycoprotein 1 (ABCB1) DMTWS9E MT DTP DMTWS9E MA Substrate DMTWS9E RN Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. DMTWS9E RU https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E MI TTV5CGO DMTWS9E MN Phosphodiesterase 4 (PDE4) DMTWS9E MT DTT DMTWS9E MA Inhibitor DMTWS9E RN Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26. DMTWS9E RU https://pubmed.ncbi.nlm.nih.gov/17352685 DM053KT DI DM053KT DM053KT DN Aprepitant DM053KT MI DEJGDUW DM053KT MN Cytochrome P450 1A2 (CYP1A2) DM053KT MT DME DM053KT MA Metabolism DM053KT RN Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92. DM053KT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15304427 DM053KT DI DM053KT DM053KT DN Aprepitant DM053KT MI DE4LYSA DM053KT MN Cytochrome P450 3A4 (CYP3A4) DM053KT MT DME DM053KT MA Metabolism DM053KT RN Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005 Jun;55(6):609-16. DM053KT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15723220 DM053KT DI DM053KT DM053KT DN Aprepitant DM053KT MI DEGTFWK DM053KT MN Mephenytoin 4-hydroxylase (CYP2C19) DM053KT MT DME DM053KT MA Metabolism DM053KT RN Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92. DM053KT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15304427 DM053KT DI DM053KT DM053KT DN Aprepitant DM053KT MI DTUGYRD DM053KT MN P-glycoprotein 1 (ABCB1) DM053KT MT DTP DM053KT MA Substrate DM053KT RN Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. DM053KT RU https://doi.org/10.1016/j.addr.2011.12.008 DM053KT DI DM053KT DM053KT DN Aprepitant DM053KT MI TTZPO1L DM053KT MN Substance-P receptor (TACR1) DM053KT MT DTT DM053KT MA Antagonist DM053KT RN Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46. DM053KT RU https://pubmed.ncbi.nlm.nih.gov/19354254 DMBXWU8 DI DMBXWU8 DMBXWU8 DN Aprindine DMBXWU8 MI TTV3NH6 DMBXWU8 MN Calmodulin (CALM) DMBXWU8 MT DTT DMBXWU8 MA Inhibitor DMBXWU8 RN Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6. DMBXWU8 RU https://pubmed.ncbi.nlm.nih.gov/6186851 DMBXWU8 DI DMBXWU8 DMBXWU8 DN Aprindine DMBXWU8 MI DECB0K3 DMBXWU8 MN Cytochrome P450 2D6 (CYP2D6) DMBXWU8 MT DME DMBXWU8 MA Metabolism DMBXWU8 RN Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. Biol Pharm Bull. 2006 Mar;29(3):517-21. DMBXWU8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16508157 DMOWK6B DI DMOWK6B DMOWK6B DN Aprobarbital DMOWK6B MI TTAN6JD DMOWK6B MN Glutamate receptor AMPA (GRIA) DMOWK6B MT DTT DMOWK6B MA Binder DMOWK6B RN Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2002 Jun 1;28(5):903-8. DMOWK6B RU https://pubmed.ncbi.nlm.nih.gov/12039632 DM0QD4W DI DM0QD4W DM0QD4W DN Aprotinin DM0QD4W MI TTEMV5X DM0QD4W MN Serine protease unspecific (SP) DM0QD4W MT DTT DM0QD4W MA Modulator DM0QD4W RN Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding Clin Trials. 2005;2(3):218-29; discussion 229-32. DM0QD4W RU https://pubmed.ncbi.nlm.nih.gov/16279145 DMHTXSL DI DMHTXSL DMHTXSL DN Arbekacin DMHTXSL MI TTA4FIU DMHTXSL MN Ribosome A (hRA) DMHTXSL MT DTT DMHTXSL MA Modulator DMHTXSL RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMHTXSL RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMHTXSL DI DMHTXSL DMHTXSL DN Arbekacin DMHTXSL MI DEZV4AP DMHTXSL MN RNA cytidine acetyltransferase (hALP) DMHTXSL MT DME DMHTXSL MA Metabolism DMHTXSL RN The novel enzymatic 3''-N-acetylation of arbekacin by an aminoglycoside 3-N-acetyltransferase of Streptomyces origin and the resulting activity. J Antibiot (Tokyo). 1998 Aug;51(8):735-42. DMHTXSL RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9766465 DMOQK8Z DI DMOQK8Z DMOQK8Z DN Arbidol DMOQK8Z MI TTF4CAM DMOQK8Z MN Influenza Hemagglutinin (Influ HA) DMOQK8Z MT DTT DMOQK8Z MA Inhibitor DMOQK8Z RN Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92. DMOQK8Z RU https://pubmed.ncbi.nlm.nih.gov/19446151 DMCY8AF DI DMCY8AF DMCY8AF DN Arbutamine DMCY8AF MI TTR6W5O DMCY8AF MN Adrenergic receptor beta-1 (ADRB1) DMCY8AF MT DTT DMCY8AF MA Stimulator DMCY8AF RN Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. Cardiovasc Drugs Ther. 1996 Mar;10(1):39-47. DMCY8AF RU https://pubmed.ncbi.nlm.nih.gov/8723169 DM9GH25 DI DM9GH25 DM9GH25 DN Arcitumomab DM9GH25 MI TTPX7I5 DM9GH25 MN Carcinoembryonic antigen CGM1 (CD66d) DM9GH25 MT DTT DM9GH25 RN In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing tumor cells in mice. Radiology. 2008 Jun;247(3):779-87. DM9GH25 RU https://pubmed.ncbi.nlm.nih.gov/18413884 DMYRX8B DI DMYRX8B DMYRX8B DN Ardeparin DMYRX8B MI TT4QPUL DMYRX8B MN Antithrombin-III (ATIII) DMYRX8B MT DTT DMYRX8B MA Modulator DMYRX8B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYRX8B RU https://www.fda.gov/ DMVMY7K DI DMVMY7K DMVMY7K DN Arepanrix DMVMY7K MI TT3J5ZI DMVMY7K MN Cell mediated immunity response (CMIR) DMVMY7K MT DTT DMVMY7K RN Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44-57. DMVMY7K RU https://pubmed.ncbi.nlm.nih.gov/25452148 DMYM974 DI DMYM974 DMYM974 DN Arformoterol DMYM974 MI TT2CJVK DMYM974 MN Adrenergic receptor beta-2 (ADRB2) DMYM974 MT DTT DMYM974 MA Agonist DMYM974 RN Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9. DMYM974 RU https://pubmed.ncbi.nlm.nih.gov/19271027 DMYM974 DI DMYM974 DMYM974 DN Arformoterol DMYM974 MI DEJVYAZ DMYM974 MN Cytochrome P450 2A6 (CYP2A6) DMYM974 MT DME DMYM974 MA Metabolism DMYM974 RN A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805. DMYM974 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976 DMYM974 DI DMYM974 DMYM974 DN Arformoterol DMYM974 MI DECB0K3 DMYM974 MN Cytochrome P450 2D6 (CYP2D6) DMYM974 MT DME DMYM974 MA Metabolism DMYM974 RN A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805. DMYM974 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976 DMYM974 DI DMYM974 DMYM974 DN Arformoterol DMYM974 MI DEGTFWK DMYM974 MN Mephenytoin 4-hydroxylase (CYP2C19) DMYM974 MT DME DMYM974 MA Metabolism DMYM974 RN A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. Drug Metab Dispos. 2007 Oct;35(10):1797-805. DMYM974 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17627976 DMFI46A DI DMFI46A DMFI46A DN Argatroban DMFI46A MI TT6L509 DMFI46A MN Coagulation factor IIa (F2) DMFI46A MT DTT DMFI46A MA Inhibitor DMFI46A RN Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44. DMFI46A RU https://pubmed.ncbi.nlm.nih.gov/12496240 DMFI46A DI DMFI46A DMFI46A DN Argatroban DMFI46A MI DE4LYSA DMFI46A MN Cytochrome P450 3A4 (CYP3A4) DMFI46A MT DME DMFI46A MA Metabolism DMFI46A RN Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9. DMFI46A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10234600 DMFI46A DI DMFI46A DMFI46A DN Argatroban DMFI46A MI DEIBDNY DMFI46A MN Cytochrome P450 3A5 (CYP3A5) DMFI46A MT DME DMFI46A MA Metabolism DMFI46A RN Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9. DMFI46A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10234600 DMRE4FC DI DMRE4FC DMRE4FC DN Arginine DMRE4FC MI DTDPJ3F DMRE4FC MN Mitochondrial ornithine transporter 2 (SLC25A2) DMRE4FC MT DTP DMRE4FC MA Substrate DMRE4FC RN Asymmetric dimethylarginine is transported by the mitochondrial carrier SLC25A2. Amino Acids. 2016 Feb;48(2):427-36. DMRE4FC RU http://www.ncbi.nlm.nih.gov/pubmed/26403849 DMRE4FC DI DMRE4FC DMRE4FC DN Arginine DMRE4FC MI DT96BT4 DMRE4FC MN Mitochondrial ornithine transporter 3 (SLC25A29) DMRE4FC MT DTP DMRE4FC MA Substrate DMRE4FC RN The human gene SLC25A29, of solute carrier family 25, encodes a mitochondrial transporter of basic amino acids. J Biol Chem. 2014 May 9;289(19):13374-84. DMRE4FC RU http://www.ncbi.nlm.nih.gov/pubmed/24652292 DMRE4FC DI DMRE4FC DMRE4FC DN Arginine DMRE4FC MI DTF7MYK DMRE4FC MN Sodium-coupled neutral amino acid transporter 9 (SLC38A9) DMRE4FC MT DTP DMRE4FC MA Substrate DMRE4FC RN Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science. 2015 Jan 9;347(6218):188-94. DMRE4FC RU http://www.ncbi.nlm.nih.gov/pubmed/25567906 DM3NUMH DI DM3NUMH DM3NUMH DN Aripiprazole DM3NUMH MI DECB0K3 DM3NUMH MN Cytochrome P450 2D6 (CYP2D6) DM3NUMH MT DME DM3NUMH MA Metabolism DM3NUMH RN Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36. DM3NUMH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15257633 DM3NUMH DI DM3NUMH DM3NUMH DN Aripiprazole DM3NUMH MI DE4LYSA DM3NUMH MN Cytochrome P450 3A4 (CYP3A4) DM3NUMH MT DME DM3NUMH MA Metabolism DM3NUMH RN Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36. DM3NUMH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15257633 DM3NUMH DI DM3NUMH DM3NUMH DN Aripiprazole DM3NUMH MI DEIBDNY DM3NUMH MN Cytochrome P450 3A5 (CYP3A5) DM3NUMH MT DME DM3NUMH MA Metabolism DM3NUMH RN Drug Interactions Flockhart Table DM3NUMH RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM3NUMH DI DM3NUMH DM3NUMH DN Aripiprazole DM3NUMH MI DERD86B DM3NUMH MN Cytochrome P450 3A7 (CYP3A7) DM3NUMH MT DME DM3NUMH MA Metabolism DM3NUMH RN Drug Interactions Flockhart Table DM3NUMH RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM3NUMH DI DM3NUMH DM3NUMH DN Aripiprazole DM3NUMH MI TTEX248 DM3NUMH MN Dopamine D2 receptor (D2R) DM3NUMH MT DTT DM3NUMH MA Agonist DM3NUMH RN Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. DM3NUMH RU https://pubmed.ncbi.nlm.nih.gov/17501690 DMGB035 DI DMGB035 DMGB035 DN Armodafinil DMGB035 MI TT34BHT DMGB035 MN Adrenergic receptor alpha-1D (ADRA1D) DMGB035 MT DTT DMGB035 MA Agonist DMGB035 RN Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364. DMGB035 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654794/ DMGB035 DI DMGB035 DMGB035 DN Armodafinil DMGB035 MI DE4LYSA DMGB035 MN Cytochrome P450 3A4 (CYP3A4) DMGB035 MT DME DMGB035 MA Metabolism DMGB035 RN Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet. 2008;47(1):61-74. DMGB035 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18076219 DMGB035 DI DMGB035 DMGB035 DN Armodafinil DMGB035 MI DEIBDNY DMGB035 MN Cytochrome P450 3A5 (CYP3A5) DMGB035 MT DME DMGB035 MA Metabolism DMGB035 RN Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37. DMGB035 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12537513 DMT81LZ DI DMT81LZ DMT81LZ DN Arn-509 DMT81LZ MI TTS64P2 DMT81LZ MN Androgen receptor (AR) DMT81LZ MT DTT DMT81LZ MA Inhibitor DMT81LZ RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMT81LZ RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMT81LZ DI DMT81LZ DMT81LZ DN Arn-509 DMT81LZ MI DES5XRU DMT81LZ MN Cytochrome P450 2C8 (CYP2C8) DMT81LZ MT DME DMT81LZ MA Metabolism DMT81LZ RN Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705. DMT81LZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29626324 DMT81LZ DI DMT81LZ DMT81LZ DN Arn-509 DMT81LZ MI DE4LYSA DMT81LZ MN Cytochrome P450 3A4 (CYP3A4) DMT81LZ MT DME DMT81LZ MA Metabolism DMT81LZ RN Apalutamide: first global approval. Drugs. 2018 Apr;78(6):699-705. DMT81LZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29626324 DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR MI DTI7UX6 DM1P6FR MN Breast cancer resistance protein (ABCG2) DM1P6FR MT DTP DM1P6FR MA Substrate DM1P6FR RN The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391. DM1P6FR RU http://www.ncbi.nlm.nih.gov/pubmed/28921565 DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR MI DEJGDUW DM1P6FR MN Cytochrome P450 1A2 (CYP1A2) DM1P6FR MT DME DM1P6FR MA Metabolism DM1P6FR RN FDA Label of Binimetinib. The 2020 official website of the U.S. Food and Drug Administration. DM1P6FR RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR MI TTZCRP3 DM1P6FR MN ERK activator kinase (MEK) DM1P6FR MT DTT DM1P6FR MA Inhibitor DM1P6FR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1P6FR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR MI TTROQ37 DM1P6FR MN MAPK/ERK kinase kinase (MAP3K) DM1P6FR MT DTT DM1P6FR MA Modulator DM1P6FR RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DM1P6FR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR MI DTUGYRD DM1P6FR MN P-glycoprotein 1 (ABCB1) DM1P6FR MT DTP DM1P6FR MA Substrate DM1P6FR RN The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer. 2018 Jan 15;142(2):381-391. DM1P6FR RU http://www.ncbi.nlm.nih.gov/pubmed/28921565 DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR MI DEYGVN4 DM1P6FR MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM1P6FR MT DME DM1P6FR MA Metabolism DM1P6FR RN Binimetinib - European Medicines Agency - European Union DM1P6FR RU https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-balimek-binimetinib_en.pdf DMTL2Y1 DI DMTL2Y1 DMTL2Y1 DN Arsenic DMTL2Y1 MI DE9KJP3 DMTL2Y1 MN Arsenite methyltransferase (AS3MT) DMTL2Y1 MT DME DMTL2Y1 MA Metabolism DMTL2Y1 RN Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ Health Perspect. 2011 Feb;119(2):182-8. DMTL2Y1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21247820 DMTL2Y1 DI DMTL2Y1 DMTL2Y1 DN Arsenic DMTL2Y1 MI DEOT0QC DMTL2Y1 MN Methylarsonite methyltransferase N6AMT1 (N6AMT1) DMTL2Y1 MT DME DMTL2Y1 MA Metabolism DMTL2Y1 RN Interactive influence of N6AMT1 and As3MT genetic variations on arsenic metabolism in the population of Inner Mongolia, China. Toxicol Sci. 2017 Jan;155(1):124-134. DMTL2Y1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27637898 DMTL2Y1 DI DMTL2Y1 DMTL2Y1 DN Arsenic DMTL2Y1 MI DEYLWI6 DMTL2Y1 MN Serine sulfhydrase (CBS) DMTL2Y1 MT DME DMTL2Y1 MA Metabolism DMTL2Y1 RN Association of genetic variation in cystathionine-beta-synthase and arsenic metabolism. Environ Res. 2010 Aug;110(6):580-7. DMTL2Y1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20670920 DM61TA4 DI DM61TA4 DM61TA4 DN Arsenic trioxide DM61TA4 MI TTJ3E9X DM61TA4 MN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DM61TA4 MT DTT DM61TA4 MA Inhibitor DM61TA4 RN How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13. DM61TA4 RU https://pubmed.ncbi.nlm.nih.gov/12209159 DM61TA4 DI DM61TA4 DM61TA4 DN Arsenic trioxide DM61TA4 MI DTFI42L DM61TA4 MN Multidrug resistance-associated protein 2 (ABCC2) DM61TA4 MT DTP DM61TA4 MA Substrate DM61TA4 RN MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10. DM61TA4 RU http://www.ncbi.nlm.nih.gov/pubmed/17324950 DM61TA4 DI DM61TA4 DM61TA4 DN Arsenic trioxide DM61TA4 MI DTUGYRD DM61TA4 MN P-glycoprotein 1 (ABCB1) DM61TA4 MT DTP DM61TA4 MA Substrate DM61TA4 RN Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26. DM61TA4 RU http://www.ncbi.nlm.nih.gov/pubmed/12647012 DMQLX7O DI DMQLX7O DMQLX7O DN Arteether DMQLX7O MI TT9X7H4 DMQLX7O MN Beta-hematin formation (BHF) DMQLX7O MT DTT DMQLX7O MA Modulator DMQLX7O RN Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob Agents Chemother. 2012 May;56(5):2546-52. DMQLX7O RU https://pubmed.ncbi.nlm.nih.gov/22354307 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT MI DEPKLMQ DM48QOT MN Cytochrome P450 2B6 (CYP2B6) DM48QOT MT DME DM48QOT MA Metabolism DM48QOT RN Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425. DM48QOT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27709010 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT MI DE5IED8 DM48QOT MN Cytochrome P450 2C9 (CYP2C9) DM48QOT MT DME DM48QOT MA Metabolism DM48QOT RN Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial. HIV Med. 2013 Aug;14(7):421-9. DM48QOT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23441978 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT MI DECB0K3 DM48QOT MN Cytochrome P450 2D6 (CYP2D6) DM48QOT MT DME DM48QOT MA Metabolism DM48QOT RN The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36. DM48QOT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9842988 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT MI DE4LYSA DM48QOT MN Cytochrome P450 3A4 (CYP3A4) DM48QOT MT DME DM48QOT MA Metabolism DM48QOT RN The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther. 1999 Oct;66(4):408-14. DM48QOT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10546925 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT MI DEIBDNY DM48QOT MN Cytochrome P450 3A5 (CYP3A5) DM48QOT MT DME DM48QOT MA Metabolism DM48QOT RN Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017 Jul 3;16(1):267. DM48QOT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28673292 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT MI DEGTFWK DM48QOT MN Mephenytoin 4-hydroxylase (CYP2C19) DM48QOT MT DME DM48QOT MA Metabolism DM48QOT RN The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur J Drug Metab Pharmacokinet. 1998 Jul-Sep;23(3):429-36. DM48QOT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9842988 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT MI TTWK8D0 DM48QOT MN Sodium pump subunit alpha-1 (ATP1A1) DM48QOT MT DTT DM48QOT MA Binder DM48QOT RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM48QOT RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 MI DEJVYAZ DMOY7W3 MN Cytochrome P450 2A6 (CYP2A6) DMOY7W3 MT DME DMOY7W3 MA Metabolism DMOY7W3 RN Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999 Oct;48(4):528-35. DMOY7W3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10583023 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 MI DEPKLMQ DMOY7W3 MN Cytochrome P450 2B6 (CYP2B6) DMOY7W3 MT DME DMOY7W3 MA Metabolism DMOY7W3 RN Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65. DMOY7W3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15761118 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 MI DE4LYSA DMOY7W3 MN Cytochrome P450 3A4 (CYP3A4) DMOY7W3 MT DME DMOY7W3 MA Metabolism DMOY7W3 RN Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005 Jun;67(6):1954-65. DMOY7W3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15761118 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 MI DE4ZHS1 DMOY7W3 MN Glutathione S-transferase alpha-1 (GSTA1) DMOY7W3 MT DME DMOY7W3 MA Metabolism DMOY7W3 RN Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. Int J Cancer. 2002 Feb 10;97(5):700-5. DMOY7W3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11807801 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 MI TT3PQ2Y DMOY7W3 MN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMOY7W3 MT DTT DMOY7W3 MA Inhibitor DMOY7W3 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMOY7W3 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 MI TTZVSJ2 DMOY7W3 MN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMOY7W3 MT DTT DMOY7W3 MA Inhibitor DMOY7W3 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMOY7W3 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMFETDK DI DMFETDK DMFETDK DN Artemisinin SP DMFETDK MI TTAN6JD DMFETDK MN Glutamate receptor AMPA (GRIA) DMFETDK MT DTT DMFETDK MA Agonist DMFETDK RN GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32. DMFETDK RU https://pubmed.ncbi.nlm.nih.gov/12171573 DMFETDK DI DMFETDK DMFETDK DN Artemisinin SP DMFETDK MI TTZVSJ2 DMFETDK MN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMFETDK MT DTT DMFETDK MA Inhibitor DMFETDK RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMFETDK RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMR27C8 DI DMR27C8 DMR27C8 DN Artesunate DMR27C8 MI DEJVYAZ DMR27C8 MN Cytochrome P450 2A6 (CYP2A6) DMR27C8 MT DME DMR27C8 MA Metabolism DMR27C8 RN Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. DMR27C8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12920490 DMR27C8 DI DMR27C8 DMR27C8 DN Artesunate DMR27C8 MI TTZVSJ2 DMR27C8 MN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMR27C8 MT DTT DMR27C8 MA Inhibitor DMR27C8 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMR27C8 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMOKCVI DI DMOKCVI DMOKCVI DN ARZOXIFENE DMOKCVI MI TTZAYWL DMOKCVI MN Estrogen receptor (ESR) DMOKCVI MT DTT DMOKCVI MA Inhibitor DMOKCVI RN Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. DMOKCVI RU https://pubmed.ncbi.nlm.nih.gov/17489582 DMOKCVI DI DMOKCVI DMOKCVI DN ARZOXIFENE DMOKCVI MI TTOM3J0 DMOKCVI MN Estrogen receptor beta (ESR2) DMOKCVI MT DTT DMOKCVI MA Inhibitor DMOKCVI RN Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. DMOKCVI RU https://pubmed.ncbi.nlm.nih.gov/17489582 DMV05SW DI DMV05SW DMV05SW DN As-1670542 DMV05SW MI TTIHYA4 DMV05SW MN Thrombopoietin receptor (MPL) DMV05SW MT DTT DMV05SW MA Agonist DMV05SW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DMV05SW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DMCZIHT DI DMCZIHT DMCZIHT DN Asasantin DMCZIHT MI TTK0943 DMCZIHT MN Prostaglandin G/H synthase (COX) DMCZIHT MT DTT DMCZIHT MA Inhibitor DMCZIHT RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMCZIHT RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMSQZE2 DI DMSQZE2 DMSQZE2 DN Asenapine DMSQZE2 MI DEJGDUW DMSQZE2 MN Cytochrome P450 1A2 (CYP1A2) DMSQZE2 MT DME DMSQZE2 MA Metabolism DMSQZE2 RN Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903. DMSQZE2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24793403 DMSQZE2 DI DMSQZE2 DMSQZE2 DN Asenapine DMSQZE2 MI DECB0K3 DMSQZE2 MN Cytochrome P450 2D6 (CYP2D6) DMSQZE2 MT DME DMSQZE2 MA Metabolism DMSQZE2 RN Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):893-903. DMSQZE2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24793403 DMSQZE2 DI DMSQZE2 DMSQZE2 DN Asenapine DMSQZE2 MI DE4LYSA DMSQZE2 MN Cytochrome P450 3A4 (CYP3A4) DMSQZE2 MT DME DMSQZE2 MA Metabolism DMSQZE2 RN Asenapine for the treatment of manic and mixed episodes associated with bipolar I disorder: from clinical research to clinical practice. Expert Opin Pharmacother. 2013 Mar;14(4):489-504. DMSQZE2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23356509 DMSQZE2 DI DMSQZE2 DMSQZE2 DN Asenapine DMSQZE2 MI TTXFI1K DMSQZE2 MN Hyaluronidase (HYAL) DMSQZE2 MT DTT DMSQZE2 MA Modulator DMSQZE2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSQZE2 RU https://www.fda.gov/ DMM4FXA DI DMM4FXA DMM4FXA DN Asfotase alfa DMM4FXA MI TTMR5UV DMM4FXA MN Alkaline phosphatase tissue-nonspecific (ALPL) DMM4FXA MT DTT DMM4FXA MA Modulator DMM4FXA RN Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012 Mar 8;366(10):904-13. DMM4FXA RU https://pubmed.ncbi.nlm.nih.gov/22397652 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DE5IED8 DM672AH MN Cytochrome P450 2C9 (CYP2C9) DM672AH MT DME DM672AH MA Metabolism DM672AH RN Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6. DM672AH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI TTPADOQ DM672AH MN HMG-CoA reductase (HMGCR) DM672AH MT DTT DM672AH MA Inhibitor DM672AH RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DM672AH RU https://pubmed.ncbi.nlm.nih.gov/16503827 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DEGTFWK DM672AH MN Mephenytoin 4-hydroxylase (CYP2C19) DM672AH MT DME DM672AH MA Metabolism DM672AH RN Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264-71. DM672AH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12621391 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DER7TA0 DM672AH MN N-acetyltransferase 2 (NAT2) DM672AH MT DME DM672AH MA Metabolism DM672AH RN Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6. DM672AH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DT0OC1Q DM672AH MN Organic anion transporter 2 (SLC22A7) DM672AH MT DTP DM672AH MA Substrate DM672AH RN Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82. DM672AH RU http://www.ncbi.nlm.nih.gov/pubmed/9650585 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DTUGYRD DM672AH MN P-glycoprotein 1 (ABCB1) DM672AH MT DTP DM672AH MA Substrate DM672AH RN Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. DM672AH RU http://www.ncbi.nlm.nih.gov/pubmed/12954186 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DTHE530 DM672AH MN Probable small intestine urate exporter (SLC17A4) DM672AH MT DTP DM672AH MA Substrate DM672AH RN A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60. DM672AH RU http://www.ncbi.nlm.nih.gov/pubmed/22460716 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI TTK0943 DM672AH MN Prostaglandin G/H synthase (COX) DM672AH MT DTT DM672AH MA Inhibitor DM672AH RN Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77. DM672AH RU https://pubmed.ncbi.nlm.nih.gov/19075637 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DT8ARWJ DM672AH MN Sodium-dependent phosphate transport protein 1 (SLC17A1) DM672AH MT DTP DM672AH MA Substrate DM672AH RN Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13. DM672AH RU http://www.ncbi.nlm.nih.gov/pubmed/20566650 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DEYWLRK DM672AH MN Sulfotransferase 1A1 (SULT1A1) DM672AH MT DME DM672AH MA Metabolism DM672AH RN Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53. DM672AH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17073578 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DEYGVN4 DM672AH MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM672AH MT DME DM672AH MA Metabolism DM672AH RN Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009 Nov;10(9):998-1008. DM672AH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20214591 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH MI DESD26P DM672AH MN UDP-glucuronosyltransferase 1A6 (UGT1A6) DM672AH MT DME DM672AH MA Metabolism DM672AH RN Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6. DM672AH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21966608 DMSYRBX DI DMSYRBX DMSYRBX DN Atazanavir DMSYRBX MI DE5IED8 DMSYRBX MN Cytochrome P450 2C9 (CYP2C9) DMSYRBX MT DME DMSYRBX MA Metabolism DMSYRBX RN Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. DMSYRBX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441 DMSYRBX DI DMSYRBX DMSYRBX DN Atazanavir DMSYRBX MI DE4LYSA DMSYRBX MN Cytochrome P450 3A4 (CYP3A4) DMSYRBX MT DME DMSYRBX MA Metabolism DMSYRBX RN Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70. DMSYRBX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714 DMSYRBX DI DMSYRBX DMSYRBX DN Atazanavir DMSYRBX MI DEIBDNY DMSYRBX MN Cytochrome P450 3A5 (CYP3A5) DMSYRBX MT DME DMSYRBX MA Metabolism DMSYRBX RN Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70. DMSYRBX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714 DMSYRBX DI DMSYRBX DMSYRBX DN Atazanavir DMSYRBX MI DERD86B DMSYRBX MN Cytochrome P450 3A7 (CYP3A7) DMSYRBX MT DME DMSYRBX MA Metabolism DMSYRBX RN Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70. DMSYRBX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15764714 DMSYRBX DI DMSYRBX DMSYRBX DN Atazanavir DMSYRBX MI TT5FNQT DMSYRBX MN Human immunodeficiency virus Protease (HIV PR) DMSYRBX MT DTT DMSYRBX MA Modulator DMSYRBX RN Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9. DMSYRBX RU https://pubmed.ncbi.nlm.nih.gov/11237841 DMSYRBX DI DMSYRBX DMSYRBX DN Atazanavir DMSYRBX MI DEYGVN4 DMSYRBX MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMSYRBX MT DME DMSYRBX MA Metabolism DMSYRBX RN In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos. 2005 Nov;33(11):1729-39. DMSYRBX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16118329 DMNKG1Z DI DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z MI TTR6W5O DMNKG1Z MN Adrenergic receptor beta-1 (ADRB1) DMNKG1Z MT DTT DMNKG1Z MA Antagonist DMNKG1Z RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DMNKG1Z RU https://pubmed.ncbi.nlm.nih.gov/16268148 DMNKG1Z DI DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z MI DECB0K3 DMNKG1Z MN Cytochrome P450 2D6 (CYP2D6) DMNKG1Z MT DME DMNKG1Z MA Metabolism DMNKG1Z RN Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. DMNKG1Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712 DMNKG1Z DI DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z MI DE4LYSA DMNKG1Z MN Cytochrome P450 3A4 (CYP3A4) DMNKG1Z MT DME DMNKG1Z MA Metabolism DMNKG1Z RN Metabolism of atenolol in man. Xenobiotica. 1978 May;8(5):313-20. DMNKG1Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27019 DMNKG1Z DI DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z MI DTE2B1D DMNKG1Z MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DMNKG1Z MT DTP DMNKG1Z MA Substrate DMNKG1Z RN Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55. DMNKG1Z RU http://www.ncbi.nlm.nih.gov/pubmed/21039758 DMNKG1Z DI DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z MI DTT79CX DMNKG1Z MN Organic cation transporter 1 (SLC22A1) DMNKG1Z MT DTP DMNKG1Z MA Substrate DMNKG1Z RN Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. DMNKG1Z RU http://www.ncbi.nlm.nih.gov/pubmed/23984907 DMNKG1Z DI DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z MI DTUGYRD DMNKG1Z MN P-glycoprotein 1 (ABCB1) DMNKG1Z MT DTP DMNKG1Z MA Substrate DMNKG1Z RN Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. DMNKG1Z RU http://www.ncbi.nlm.nih.gov/pubmed/11895100 DMMF8U0 DI DMMF8U0 DMMF8U0 DN Atezolizumab DMMF8U0 MI TT8ZLTI DMMF8U0 MN Programmed cell death 1 ligand 1 (PD-L1) DMMF8U0 MT DTT DMMF8U0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMF8U0 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s018lbl.pdf DM5L6HI DI DM5L6HI DM5L6HI DN Atomoxetine DM5L6HI MI DECB0K3 DM5L6HI MN Cytochrome P450 2D6 (CYP2D6) DM5L6HI MT DME DM5L6HI MA Metabolism DM5L6HI RN Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26. DM5L6HI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26859445 DM5L6HI DI DM5L6HI DM5L6HI DN Atomoxetine DM5L6HI MI DEGTFWK DM5L6HI MN Mephenytoin 4-hydroxylase (CYP2C19) DM5L6HI MT DME DM5L6HI MA Metabolism DM5L6HI RN Atomoxetine: a review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016 May;26(4):314-26. DM5L6HI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26859445 DM5L6HI DI DM5L6HI DM5L6HI DN Atomoxetine DM5L6HI MI TTAWNKZ DM5L6HI MN Norepinephrine transporter (NET) DM5L6HI MT DTT DM5L6HI MA Inhibitor DM5L6HI RN Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50. DM5L6HI RU https://pubmed.ncbi.nlm.nih.gov/18568443 DM5L6HI DI DM5L6HI DM5L6HI DN Atomoxetine DM5L6HI MI DTUGYRD DM5L6HI MN P-glycoprotein 1 (ABCB1) DM5L6HI MT DTP DM5L6HI MA Substrate DM5L6HI RN Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. DM5L6HI RU https://doi.org/10.1016/j.addr.2011.12.008 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DES5XRU DMF28YC MN Cytochrome P450 2C8 (CYP2C8) DMF28YC MT DME DMF28YC MA Metabolism DMF28YC RN Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. DMF28YC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DE4LYSA DMF28YC MN Cytochrome P450 3A4 (CYP3A4) DMF28YC MT DME DMF28YC MA Metabolism DMF28YC RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMF28YC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DEIBDNY DMF28YC MN Cytochrome P450 3A5 (CYP3A5) DMF28YC MT DME DMF28YC MA Metabolism DMF28YC RN Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12. DMF28YC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16388406 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DERD86B DMF28YC MN Cytochrome P450 3A7 (CYP3A7) DMF28YC MT DME DMF28YC MA Metabolism DMF28YC RN Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. DMF28YC RU https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI TTPADOQ DMF28YC MN HMG-CoA reductase (HMGCR) DMF28YC MT DTT DMF28YC MA Inhibitor DMF28YC RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DMF28YC RU https://pubmed.ncbi.nlm.nih.gov/11523064 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DT342ZG DMF28YC MN Monocarboxylate transporter 1 (SLC16A1) DMF28YC MT DTP DMF28YC MA Substrate DMF28YC RN H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19. DMF28YC RU https://doi.org/10.1113/expphysiol.2005.029959 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DTLT3UG DMF28YC MN Monocarboxylate transporter 2 (SLC16A7) DMF28YC MT DTP DMF28YC MA Substrate DMF28YC RN Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB. DMF28YC RU https://www.njacs.org/wp-content/docs/2010-Spring-DrugMet-Marilyn_Morris.pdf DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DTE2B1D DMF28YC MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DMF28YC MT DTP DMF28YC MA Substrate DMF28YC RN Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53. DMF28YC RU http://www.ncbi.nlm.nih.gov/pubmed/20797388 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DT3D8F0 DMF28YC MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMF28YC MT DTP DMF28YC MA Substrate DMF28YC RN Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52. DMF28YC RU http://www.ncbi.nlm.nih.gov/pubmed/19374892 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DT9C1TS DMF28YC MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMF28YC MT DTP DMF28YC MA Substrate DMF28YC RN FDA Drug Development and Drug Interactions DMF28YC RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DTPFTEQ DMF28YC MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DMF28YC MT DTP DMF28YC MA Substrate DMF28YC RN Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37. DMF28YC RU http://www.ncbi.nlm.nih.gov/pubmed/19237515 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DTUGYRD DMF28YC MN P-glycoprotein 1 (ABCB1) DMF28YC MT DTP DMF28YC MA Substrate DMF28YC RN Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. DMF28YC RU https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DEYGVN4 DMF28YC MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMF28YC MT DME DMF28YC MA Metabolism DMF28YC RN Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24. DMF28YC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17470524 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC MI DEF2WXN DMF28YC MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMF28YC MT DME DMF28YC MA Metabolism DMF28YC RN UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7. DMF28YC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23580084 DMY4UMW DI DMY4UMW DMY4UMW DN Atovaquone DMY4UMW MI DE4LYSA DMY4UMW MN Cytochrome P450 3A4 (CYP3A4) DMY4UMW MT DME DMY4UMW MA Metabolism DMY4UMW RN Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol. 2002 Apr;58(1):19-27. DMY4UMW RU https://www.ncbi.nlm.nih.gov/pubmed/11956669 DMY4UMW DI DMY4UMW DMY4UMW DN Atovaquone DMY4UMW MI TT3PQ2Y DMY4UMW MN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMY4UMW MT DTT DMY4UMW MA Inhibitor DMY4UMW RN Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42. DMY4UMW RU https://pubmed.ncbi.nlm.nih.gov/15044733 DM42HXN DI DM42HXN DM42HXN DN Atracurium DM42HXN MI TTJSZTB DM42HXN MN Nicotinic acetylcholine receptor (nAChR) DM42HXN MT DTT DM42HXN MA Antagonist DM42HXN RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DM42HXN RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMEN6X7 DI DMEN6X7 DMEN6X7 DN Atropine DMEN6X7 MI TTH18TF DMEN6X7 MN Muscarinic acetylcholine receptor M5 (CHRM5) DMEN6X7 MT DTT DMEN6X7 MA Antagonist DMEN6X7 RN Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204. DMEN6X7 RU https://pubmed.ncbi.nlm.nih.gov/19526284 DMEN6X7 DI DMEN6X7 DMEN6X7 DN Atropine DMEN6X7 MI DTT79CX DMEN6X7 MN Organic cation transporter 1 (SLC22A1) DMEN6X7 MT DTP DMEN6X7 MA Substrate DMEN6X7 RN Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. DMEN6X7 RU http://www.ncbi.nlm.nih.gov/pubmed/23984907 DM79Y2T DI DM79Y2T DM79Y2T DN ATryn antithrombin DM79Y2T MI TT6L509 DM79Y2T MN Coagulation factor IIa (F2) DM79Y2T MT DTT DM79Y2T MA Modulator DM79Y2T RN Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779. DM79Y2T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875262/ DMWE2N4 DI DMWE2N4 DMWE2N4 DN Auranofin DMWE2N4 MI DTZGT0P DMWE2N4 MN Multidrug and toxin extrusion protein 1 (SLC47A1) DMWE2N4 MT DTP DMWE2N4 MA Substrate DMWE2N4 RN Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078. DMWE2N4 RU http://www.ncbi.nlm.nih.gov/pubmed/29221187 DMWE2N4 DI DMWE2N4 DMWE2N4 DN Auranofin DMWE2N4 MI DTT79CX DMWE2N4 MN Organic cation transporter 1 (SLC22A1) DMWE2N4 MT DTP DMWE2N4 MA Substrate DMWE2N4 RN Selection and characterization of a human ovarian cancer cell line resistant to auranofin. Oncotarget. 2017 Oct 9;8(56):96062-96078. DMWE2N4 RU http://www.ncbi.nlm.nih.gov/pubmed/29221187 DMWE2N4 DI DMWE2N4 DMWE2N4 DN Auranofin DMWE2N4 MI TTP3UTW DMWE2N4 MN Steroid hormone receptor ERR (ESRR) DMWE2N4 MT DTT DMWE2N4 MA Modulator DMWE2N4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWE2N4 RU https://www.fda.gov/ DM75CXN DI DM75CXN DM75CXN DN Avanafil DM75CXN MI DE4LYSA DM75CXN MN Cytochrome P450 3A4 (CYP3A4) DM75CXN MT DME DM75CXN MA Metabolism DM75CXN RN An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother. 2013 Jul;14(10):1333-44. DM75CXN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23675780 DM75CXN DI DM75CXN DM75CXN DN Avanafil DM75CXN MI TTJ0IQB DM75CXN MN Phosphodiesterase 5A (PDE5A) DM75CXN MT DTT DM75CXN MA Modulator DM75CXN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM75CXN RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMK2GZX DI DMK2GZX DMK2GZX DN Avapritinib DMK2GZX MI TT8FYO9 DMK2GZX MN Platelet-derived growth factor receptor alpha (PDGFRA) DMK2GZX MT DTT DMK2GZX MA Inhibitor DMK2GZX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMK2GZX RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf DMSZLJR DI DMSZLJR DMSZLJR DN Avelumab DMSZLJR MI TT8ZLTI DMSZLJR MN Programmed cell death 1 ligand 1 (PD-L1) DMSZLJR MT DTT DMSZLJR RN Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57. DMSZLJR RU https://pubmed.ncbi.nlm.nih.gov/26014098 DM1AEH4 DI DM1AEH4 DM1AEH4 DN Avibactam DM1AEH4 MI DE7IH52 DM1AEH4 MN Beta-lactamase (blaB) DM1AEH4 MT DME DM1AEH4 MA Metabolism DM1AEH4 RN nan DM1AEH4 RU nan DMYHN59 DI DMYHN59 DMYHN59 DN Axicabtagene ciloleucel DMYHN59 MI TTW640A DMYHN59 MN B-lymphocyte surface antigen B4 (CD19) DMYHN59 MT DTT DMYHN59 MA CAR-T-Cell-Therapy DMYHN59 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMYHN59 RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N MI DEJGDUW DMGVH6N MN Cytochrome P450 1A2 (CYP1A2) DMGVH6N MT DME DMGVH6N MA Metabolism DMGVH6N RN Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25. DMGVH6N RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N MI DE4LYSA DMGVH6N MN Cytochrome P450 3A4 (CYP3A4) DMGVH6N MT DME DMGVH6N MA Metabolism DMGVH6N RN Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25. DMGVH6N RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N MI DEIBDNY DMGVH6N MN Cytochrome P450 3A5 (CYP3A5) DMGVH6N MT DME DMGVH6N MA Metabolism DMGVH6N RN Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25. DMGVH6N RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N MI DEGTFWK DMGVH6N MN Mephenytoin 4-hydroxylase (CYP2C19) DMGVH6N MT DME DMGVH6N MA Metabolism DMGVH6N RN Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25. DMGVH6N RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N MI DT3D8F0 DMGVH6N MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMGVH6N MT DTP DMGVH6N MA Substrate DMGVH6N RN Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55. DMGVH6N RU http://www.ncbi.nlm.nih.gov/pubmed/22170007 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N MI DTUGYRD DMGVH6N MN P-glycoprotein 1 (ABCB1) DMGVH6N MT DTP DMGVH6N MA Substrate DMGVH6N RN Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012 May;68(5):645-55. DMGVH6N RU http://www.ncbi.nlm.nih.gov/pubmed/22170007 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N MI DEYGVN4 DMGVH6N MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMGVH6N MT DME DMGVH6N MA Metabolism DMGVH6N RN Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25. DMGVH6N RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23677771 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N MI TTUTJGQ DMGVH6N MN Vascular endothelial growth factor receptor 2 (KDR) DMGVH6N MT DTT DMGVH6N MA Modulator DMGVH6N RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMGVH6N RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMTA5OE DI DMTA5OE DMTA5OE DN Azacitidine DMTA5OE MI DEKEDRC DMTA5OE MN Cytidine aminohydrolase (CDA) DMTA5OE MT DME DMTA5OE MA Metabolism DMTA5OE RN A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4. DMTA5OE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18548103 DMTA5OE DI DMTA5OE DMTA5OE DN Azacitidine DMTA5OE MI DEYILK4 DMTA5OE MN Cytidine deaminase (cdd) DMTA5OE MT DME DMTA5OE MA Metabolism DMTA5OE RN Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9. DMTA5OE RU https://pubmed.ncbi.nlm.nih.gov/26322268 DMTA5OE DI DMTA5OE DMTA5OE DN Azacitidine DMTA5OE MI TTHVCUP DMTA5OE MN DNA [cytosine-5]-methyltransferase (DNMT) DMTA5OE MT DTT DMTA5OE MA Inhibitor DMTA5OE RN The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28. DMTA5OE RU https://pubmed.ncbi.nlm.nih.gov/19194470 DMZ80SB DI DMZ80SB DMZ80SB DN Azatadine DMZ80SB MI TTTIBOJ DMZ80SB MN Histamine H1 receptor (H1R) DMZ80SB MT DTT DMZ80SB MA Antagonist DMZ80SB RN Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7. DMZ80SB RU https://pubmed.ncbi.nlm.nih.gov/1982614 DMMZSXQ DI DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ MI TTZFTY4 DMMZSXQ MN Amidophosphoribosyltransferase (PPAT) DMMZSXQ MT DTT DMMZSXQ MA Inhibitor DMMZSXQ RN IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008 Jan;65(1):69-77. DMMZSXQ RU https://pubmed.ncbi.nlm.nih.gov/17662091 DMMZSXQ DI DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ MI DEJGDUW DMMZSXQ MN Cytochrome P450 1A2 (CYP1A2) DMMZSXQ MT DME DMMZSXQ MA Metabolism DMMZSXQ RN Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis. 2000 Jun;21(6):1157-62. DMMZSXQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10837004 DMMZSXQ DI DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ MI DEH49YS DMMZSXQ MN Glutathione S-transferase alpha-2 (GSTA2) DMMZSXQ MT DME DMMZSXQ MA Metabolism DMMZSXQ RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040) DMMZSXQ RU https://www.pharmgkb.org/pathway/PA2040 DMMZSXQ DI DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ MI DEYZEJA DMMZSXQ MN Glutathione S-transferase mu-1 (GSTM1) DMMZSXQ MT DME DMMZSXQ MA Metabolism DMMZSXQ RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040) DMMZSXQ RU https://www.pharmgkb.org/pathway/PA2040 DMMZSXQ DI DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ MI DTUGYRD DMMZSXQ MN P-glycoprotein 1 (ABCB1) DMMZSXQ MT DTP DMMZSXQ MA Substrate DMMZSXQ RN Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. DMMZSXQ RU http://www.ncbi.nlm.nih.gov/pubmed/12954186 DMMZSXQ DI DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ MI DEFQ8VO DMMZSXQ MN Thiopurine methyltransferase (TPMT) DMMZSXQ MT DME DMMZSXQ MA Metabolism DMMZSXQ RN Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402. DMMZSXQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20726808 DMHVL0J DI DMHVL0J DMHVL0J DN Azelaic Acid DMHVL0J MI TT2A0DR DMHVL0J MN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMHVL0J MT DTT DMHVL0J MA Inhibitor DMHVL0J RN Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32. DMHVL0J RU https://pubmed.ncbi.nlm.nih.gov/3207614 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ MI DEJGDUW DMXTMBJ MN Cytochrome P450 1A2 (CYP1A2) DMXTMBJ MT DME DMXTMBJ MA Metabolism DMXTMBJ RN In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6. DMXTMBJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ MI DEJVYAZ DMXTMBJ MN Cytochrome P450 2A6 (CYP2A6) DMXTMBJ MT DME DMXTMBJ MA Metabolism DMXTMBJ RN Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91. DMXTMBJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ MI DES5XRU DMXTMBJ MN Cytochrome P450 2C8 (CYP2C8) DMXTMBJ MT DME DMXTMBJ MA Metabolism DMXTMBJ RN Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91. DMXTMBJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ MI DE5IED8 DMXTMBJ MN Cytochrome P450 2C9 (CYP2C9) DMXTMBJ MT DME DMXTMBJ MA Metabolism DMXTMBJ RN Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91. DMXTMBJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ MI DECB0K3 DMXTMBJ MN Cytochrome P450 2D6 (CYP2D6) DMXTMBJ MT DME DMXTMBJ MA Metabolism DMXTMBJ RN Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Jul;27(7):792-7. DMXTMBJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10383922 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ MI DE4LYSA DMXTMBJ MN Cytochrome P450 3A4 (CYP3A4) DMXTMBJ MT DME DMXTMBJ MA Metabolism DMXTMBJ RN In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6. DMXTMBJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ MI DEIBDNY DMXTMBJ MN Cytochrome P450 3A5 (CYP3A5) DMXTMBJ MT DME DMXTMBJ MA Metabolism DMXTMBJ RN Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91. DMXTMBJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10570018 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ MI TTTIBOJ DMXTMBJ MN Histamine H1 receptor (H1R) DMXTMBJ MT DTT DMXTMBJ MA Antagonist DMXTMBJ RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMXTMBJ RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ MI DEGTFWK DMXTMBJ MN Mephenytoin 4-hydroxylase (CYP2C19) DMXTMBJ MT DME DMXTMBJ MA Metabolism DMXTMBJ RN In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos. 1999 Aug;27(8):942-6. DMXTMBJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10421623 DMOIX5S DI DMOIX5S DMOIX5S DN Azilsartan DMOIX5S MI TT8DBY3 DMOIX5S MN Angiotensin II receptor type-1 (AGTR1) DMOIX5S MT DTT DMOIX5S MA Modulator DMOIX5S RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMOIX5S RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMIR5QP DI DMIR5QP DMIR5QP DN Azlocillin DMIR5QP MI TTJP4SM DMIR5QP MN Bacterial Penicillin binding protein (Bact PBP) DMIR5QP MT DTT DMIR5QP MA Binder DMIR5QP RN Reactivation of peptidoglycan synthesis in ether-permeabilized Escherichia coli after inhibition by beta-lactam antibiotics. Antimicrob Agents Chemother. 1989 Dec;33(12):2101-8. DMIR5QP RU https://pubmed.ncbi.nlm.nih.gov/2515794 DMDNJHG DI DMDNJHG DMDNJHG DN Aztreonam DMDNJHG MI TT85JMW DMDNJHG MN Bacterial Penicillin binding protein 3 (Bact mrcA) DMDNJHG MT DTT DMDNJHG MA Binder DMDNJHG RN Penicillin-binding protein PBP2 of Escherichia coli localizes preferentially in the lateral wall and at mid-cell in comparison with the old cell pole. Mol Microbiol. 2003 Jan;47(2):539-47. DMDNJHG RU https://pubmed.ncbi.nlm.nih.gov/12519203 DMDNJHG DI DMDNJHG DMDNJHG DN Aztreonam DMDNJHG MI DEP0IWS DMDNJHG MN Beta-lactamase (blaB) DMDNJHG MT DME DMDNJHG MA Metabolism DMDNJHG RN Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8. DMDNJHG RU https://pubmed.ncbi.nlm.nih.gov/26505351 DMDNJHG DI DMDNJHG DMDNJHG DN Aztreonam DMDNJHG MI DEEAL81 DMDNJHG MN Beta-lactamase (blaB) DMDNJHG MT DME DMDNJHG MA Metabolism DMDNJHG RN Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 1996 Sep;38(3):409-24. DMDNJHG RU https://pubmed.ncbi.nlm.nih.gov/8889716 DMDNJHG DI DMDNJHG DMDNJHG DN Aztreonam DMDNJHG MI DE4LYSA DMDNJHG MN Cytochrome P450 3A4 (CYP3A4) DMDNJHG MT DME DMDNJHG MA Metabolism DMDNJHG RN Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42. DMDNJHG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141 DMDNJHG DI DMDNJHG DMDNJHG DN Aztreonam DMDNJHG MI DEIBDNY DMDNJHG MN Cytochrome P450 3A5 (CYP3A5) DMDNJHG MT DME DMDNJHG MA Metabolism DMDNJHG RN Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42. DMDNJHG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141 DMDNJHG DI DMDNJHG DMDNJHG DN Aztreonam DMDNJHG MI DERD86B DMDNJHG MN Cytochrome P450 3A7 (CYP3A7) DMDNJHG MT DME DMDNJHG MA Metabolism DMDNJHG RN Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42. DMDNJHG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8153141 DMP54C7 DI DMP54C7 DMP54C7 DN Bacampicillin DMP54C7 MI TTJP4SM DMP54C7 MN Bacterial Penicillin binding protein (Bact PBP) DMP54C7 MT DTT DMP54C7 MA Binder DMP54C7 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMP54C7 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMD2871 DI DMD2871 DMD2871 DN Bacitracin DMD2871 MI DEK9LVM DMD2871 MN Endoglucanase A (EGA) DMD2871 MT DME DMD2871 MA Metabolism DMD2871 RN Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63. DMD2871 RU https://pubmed.ncbi.nlm.nih.gov/10688695 DMD2871 DI DMD2871 DMD2871 DN Bacitracin DMD2871 MI DE2M583 DMD2871 MN Endoglucanase Y (EGY) DMD2871 MT DME DMD2871 MA Metabolism DMD2871 RN Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63. DMD2871 RU https://pubmed.ncbi.nlm.nih.gov/10688695 DM5OHYE DI DM5OHYE DM5OHYE DN Bacitracin DM5OHYE MI TT2EDHU DM5OHYE MN Insulin-degrading enzyme (IDE) DM5OHYE MT DTT DM5OHYE MA Inhibitor DM5OHYE RN Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004 Oct 27;24(43):9632-7. DM5OHYE RU https://pubmed.ncbi.nlm.nih.gov/15509750 DM0QV1J DI DM0QV1J DM0QV1J DN Baclofen DM0QV1J MI TTDCVZW DM0QV1J MN Gamma-aminobutyric acid B receptor (GABBR) DM0QV1J MT DTT DM0QV1J MA Modulator DM0QV1J RN Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9. DM0QV1J RU https://pubmed.ncbi.nlm.nih.gov/10354414 DMPWNDB DI DMPWNDB DMPWNDB DN Balofloxacin DMPWNDB MI TTJP4SM DMPWNDB MN Bacterial Penicillin binding protein (Bact PBP) DMPWNDB MT DTT DMPWNDB MA Inhibitor DMPWNDB RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMPWNDB RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM1UV7F DI DM1UV7F DM1UV7F DN Baloxavir marboxil DM1UV7F MI DE4LYSA DM1UV7F MN Cytochrome P450 3A4 (CYP3A4) DM1UV7F MT DME DM1UV7F MA Metabolism DM1UV7F RN FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration. DM1UV7F RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf DM1UV7F DI DM1UV7F DM1UV7F DN Baloxavir marboxil DM1UV7F MI TTWORX6 DM1UV7F MN Influenza Polymerase acidic endonuclease (Influ PA) DM1UV7F MT DTT DM1UV7F MA Inhibitor DM1UV7F RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1UV7F RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMRJ9EN DI DMRJ9EN DMRJ9EN DN Baloxavir marboxil DMRJ9EN MI DTUGYRD DMRJ9EN MN P-glycoprotein 1 (ABCB1) DMRJ9EN MT DTP DMRJ9EN MA Substrate DMRJ9EN RN Baloxavir Marboxil FDA label DMRJ9EN RU https://s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/002/078/original/Baloxavir_Marboxil_FDA_label.pdf?1543255968 DM1UV7F DI DM1UV7F DM1UV7F DN Baloxavir marboxil DM1UV7F MI DEF2WXN DM1UV7F MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DM1UV7F MT DME DM1UV7F MA Metabolism DM1UV7F RN FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration. DM1UV7F RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210854s000lbl.pdf DM7I1T9 DI DM7I1T9 DM7I1T9 DN Balsalazide DM7I1T9 MI DEEHWOG DM7I1T9 MN Azoreductase (azoR) DM7I1T9 MT DME DM7I1T9 MA Metabolism DM7I1T9 RN Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci. 1983 Jul;28(7):609-15. DM7I1T9 RU https://pubmed.ncbi.nlm.nih.gov/6345112 DM7I1T9 DI DM7I1T9 DM7I1T9 DN Balsalazide DM7I1T9 MI DETQAEP DM7I1T9 MN FMN-dependent NADH-azoreductase (azoR1) DM7I1T9 MT DME DM7I1T9 MA Metabolism DM7I1T9 RN nan DM7I1T9 RU nan DMO091F DI DMO091F DMO091F DN Balsalazide DMO091F MI TT8NGED DMO091F MN Prostaglandin G/H synthase 1 (COX-1) DMO091F MT DTT DMO091F MA Inhibitor DMO091F RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMO091F RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMKLSHF DI DMKLSHF DMKLSHF DN Bambuterol DMKLSHF MI TT2CJVK DMKLSHF MN Adrenergic receptor beta-2 (ADRB2) DMKLSHF MT DTT DMKLSHF MA Agonist DMKLSHF RN Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. Pharmazie. 2007 Nov;62(11):836-40. DMKLSHF RU https://pubmed.ncbi.nlm.nih.gov/18065099 DMXLHYN DI DMXLHYN DMXLHYN DN Bamifylline DMXLHYN MI DEJGDUW DMXLHYN MN Cytochrome P450 1A2 (CYP1A2) DMXLHYN MT DME DMXLHYN MA Metabolism DMXLHYN RN PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95. DMXLHYN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536 DME1DJX DI DME1DJX DME1DJX DN Baquting DME1DJX MI TTWODQF DME1DJX MN Fibrin (FG) DME1DJX MT DTT DME1DJX MA Modulator DME1DJX RN Baquting, enable our sales and marketing team to effectively promote our principal products and help to stimulate the sales of our other pharmaceuticals. DME1DJX RU http://www.sec.gov/Archives/edgar/data/1474952/000119312509239183/df1.htm DMJ8NMC DI DMJ8NMC DMJ8NMC DN Barbital DMJ8NMC MI TT1MPAY DMJ8NMC MN GABA(A) receptor alpha-1 (GABRA1) DMJ8NMC MT DTT DMJ8NMC MA Antagonist DMJ8NMC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMJ8NMC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMJ8NMC DI DMJ8NMC DMJ8NMC DN Barbital DMJ8NMC MI DEGTFWK DMJ8NMC MN Mephenytoin 4-hydroxylase (CYP2C19) DMJ8NMC MT DME DMJ8NMC MA Metabolism DMJ8NMC RN Effects of cytochrome P450 (CYP)2C19 polymorphisms on pharmacokinetics of phenobarbital in neonates and infants with seizures. Arch Dis Child. 2012 Jun;97(6):569-72. DMJ8NMC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22331680 DMJIA6T DI DMJIA6T DMJIA6T DN Barbiturate DMJIA6T MI TT1MPAY DMJIA6T MN GABA(A) receptor alpha-1 (GABRA1) DMJIA6T MT DTT DMJIA6T MA Antagonist DMJIA6T RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMJIA6T RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMJIA6T DI DMJIA6T DMJIA6T DN Barbiturate DMJIA6T MI TTAN6JD DMJIA6T MN Glutamate receptor AMPA (GRIA) DMJIA6T MT DTT DMJIA6T MA Agonist DMJIA6T RN Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. DMJIA6T RU https://pubmed.ncbi.nlm.nih.gov/17073666 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 MI DTI7UX6 DM4ONW5 MN Breast cancer resistance protein (ABCG2) DM4ONW5 MT DTP DM4ONW5 MA Substrate DM4ONW5 RN Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran. Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17. DM4ONW5 RU http://www.ncbi.nlm.nih.gov/pubmed/28848011 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 MI DE4LYSA DM4ONW5 MN Cytochrome P450 3A4 (CYP3A4) DM4ONW5 MT DME DM4ONW5 MA Metabolism DM4ONW5 RN FDA label of Baricitinib. The 2020 official website of the U.S. Food and Drug Administration. DM4ONW5 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 MI TT6DM01 DM4ONW5 MN Janus kinase 1 (JAK-1) DM4ONW5 MT DTT DM4ONW5 MA Modulator DM4ONW5 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 MI TTRMX3V DM4ONW5 MN Janus kinase 2 (JAK-2) DM4ONW5 MT DTT DM4ONW5 MA Modulator DM4ONW5 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 MI DTUGYRD DM4ONW5 MN P-glycoprotein 1 (ABCB1) DM4ONW5 MT DTP DM4ONW5 MA Substrate DM4ONW5 RN Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib. Clin Transl Sci. 2017 Nov;10(6):509-519. DM4ONW5 RU http://www.ncbi.nlm.nih.gov/pubmed/28749581 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 MI TTJSQEF DM4ONW5 MN Tyrosine-protein kinase (PTK) DM4ONW5 MT DTT DM4ONW5 MA Inhibitor DM4ONW5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMWNRZT DI DMWNRZT DMWNRZT DN Basiliximab DMWNRZT MI TT10Y9E DMWNRZT MN Interleukin 2 receptor alpha (IL2RA) DMWNRZT MT DTT DMWNRZT MA Modulator DMWNRZT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWNRZT RU https://www.fda.gov/ DMU9C8F DI DMU9C8F DMU9C8F DN Bavencio DMU9C8F MI TT8ZLTI DMU9C8F MN Programmed cell death 1 ligand 1 (PD-L1) DMU9C8F MT DTT DMU9C8F MA Inhibitor DMU9C8F RN ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health. DMU9C8F RU https://clinicaltrials.gov/ct2/show/NCT03403777 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R MI DE6OQ3W DMLOS5R MN Cytochrome P450 1A1 (CYP1A1) DMLOS5R MT DME DMLOS5R MA Metabolism DMLOS5R RN FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration. DMLOS5R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R MI DE4LYSA DMLOS5R MN Cytochrome P450 3A4 (CYP3A4) DMLOS5R MT DME DMLOS5R MA Metabolism DMLOS5R RN FDA label of Copanlisib. The 2020 official website of the U.S. Food and Drug Administration. DMLOS5R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R MI TTEUNMR DMLOS5R MN PI3-kinase alpha (PIK3CA) DMLOS5R MT DTT DMLOS5R MA Inhibitor DMLOS5R RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMLOS5R RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R MI TTGBPJE DMLOS5R MN PI3-kinase delta (PIK3CD) DMLOS5R MT DTT DMLOS5R MA Inhibitor DMLOS5R RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMLOS5R RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R MI TTHBTOP DMLOS5R MN PI3-kinase gamma (PIK3CG) DMLOS5R MT DTT DMLOS5R MA Modulator DMLOS5R RN BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30. DMLOS5R RU https://www.ncbi.nlm.nih.gov/pubmed/24170767 DMY85QW DI DMY85QW DMY85QW DN Bazedoxifene DMY85QW MI DEWTCUK DMY85QW MN Beta-glucuronidase (uidA) DMY85QW MT DME DMY85QW MA Metabolism DMY85QW RN Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal beta-glucuronidase activity without impacting overall microbiome community. Sci Rep. 2018 May 25;8(1):8166. DMY85QW RU https://pubmed.ncbi.nlm.nih.gov/29802368 DMY85QW DI DMY85QW DMY85QW DN Bazedoxifene DMY85QW MI TTZAYWL DMY85QW MN Estrogen receptor (ESR) DMY85QW MT DTT DMY85QW MA Modulator DMY85QW RN Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009 Nov-Dec;16(6):1109-15. DMY85QW RU https://pubmed.ncbi.nlm.nih.gov/19543129 DMY85QW DI DMY85QW DMY85QW DN Bazedoxifene DMY85QW MI DEYGVN4 DMY85QW MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMY85QW MT DME DMY85QW MA Metabolism DMY85QW RN UGT1A1*28 polymorphism influences glucuronidation of bazedoxifene. Pharmazie. 2015 Feb;70(2):94-6. DMY85QW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25997248 DMY85QW DI DMY85QW DMY85QW DN Bazedoxifene DMY85QW MI DEL5N6Y DMY85QW MN UDP-glucuronosyltransferase 1A10 (UGT1A10) DMY85QW MT DME DMY85QW MA Metabolism DMY85QW RN In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9. DMY85QW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20516255 DM1R5X4 DI DM1R5X4 DM1R5X4 DN Becaplermin DM1R5X4 MI TTI7421 DM1R5X4 MN Platelet-derived growth factor receptor beta (PDGFRB) DM1R5X4 MT DTT DM1R5X4 MA Modulator DM1R5X4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1R5X4 RU https://www.fda.gov/ DMZPHIK DI DMZPHIK DMZPHIK DN Beclomethasone DMZPHIK MI DEDH7FP DMZPHIK MN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DMZPHIK MT DME DMZPHIK MA Metabolism DMZPHIK RN Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46. DMZPHIK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16549198 DMZPHIK DI DMZPHIK DMZPHIK DN Beclomethasone DMZPHIK MI DE4LYSA DMZPHIK MN Cytochrome P450 3A4 (CYP3A4) DMZPHIK MT DME DMZPHIK MA Metabolism DMZPHIK RN Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther. 2013 May;345(2):308-16. DMZPHIK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23512537 DMZPHIK DI DMZPHIK DMZPHIK DN Beclomethasone DMZPHIK MI DTUGYRD DMZPHIK MN P-glycoprotein 1 (ABCB1) DMZPHIK MT DTP DMZPHIK MA Substrate DMZPHIK RN Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302. DMZPHIK RU https://doi.org/10.1016/j.taap.2012.03.008 DMZPHIK DI DMZPHIK DMZPHIK DN Beclomethasone DMZPHIK MI TTP3UTW DMZPHIK MN Steroid hormone receptor ERR (ESRR) DMZPHIK MT DTT DMZPHIK MA Modulator DMZPHIK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZPHIK RU https://www.fda.gov/ DM3906J DI DM3906J DM3906J DN Bedaquiline DM3906J MI DE4LYSA DM3906J MN Cytochrome P450 3A4 (CYP3A4) DM3906J MT DME DM3906J MA Metabolism DM3906J RN Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos. 2014 May;42(5):863-6. DM3906J RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24513655 DM3906J DI DM3906J DM3906J DN Bedaquiline DM3906J MI TT19K0L DM3906J MN Mycobacterium Proton pump (MycB Prop) DM3906J MT DTT DM3906J MA Modulator DM3906J RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM3906J RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM8WCXM DI DM8WCXM DM8WCXM DN Befunolol hci DM8WCXM MI TTVIREA DM8WCXM MN Adrenergic receptor (ADR) DM8WCXM MT DTT DM8WCXM MA Modulator DM8WCXM RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM8WCXM RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMBT3AI DI DMBT3AI DMBT3AI DN Belantamab mafodotin DMBT3AI MI TTZ3P4W DMBT3AI MN B-cell maturation protein (TNFRSF17) DMBT3AI MT DTT DMBT3AI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBT3AI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf DMXLYQF DI DMXLYQF DMXLYQF DN Belatacept DMXLYQF MI TTQ13FT DMXLYQF MN T-cell-specific surface glycoprotein CD28 (CD28) DMXLYQF MT DTT DMXLYQF MA Inhibitor DMXLYQF RN New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. DMXLYQF RU https://pubmed.ncbi.nlm.nih.gov/19265486 DM3OBQF DI DM3OBQF DM3OBQF DN Belimumab DM3OBQF MI TTWMIDN DM3OBQF MN B-cell-activating factor (TNFSF13B) DM3OBQF MT DTT DM3OBQF RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM3OBQF RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM2RBWK DI DM2RBWK DM2RBWK DN Belladonna DM2RBWK MI TTH18TF DM2RBWK MN Muscarinic acetylcholine receptor M5 (CHRM5) DM2RBWK MT DTT DM2RBWK MA Modulator DM2RBWK RN Plasma level of atropine after accidental ingestion of Atropa belladonna. Clin Toxicol (Phila). 2009 Jul;47(6):602-4. DM2RBWK RU https://pubmed.ncbi.nlm.nih.gov/19586361 DM3SRJZ DI DM3SRJZ DM3SRJZ DN Belotecan hydrocholoride DM3SRJZ MI TTGTQHC DM3SRJZ MN DNA topoisomerase I (TOP1) DM3SRJZ MT DTT DM3SRJZ MA Modulator DM3SRJZ RN Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43. DM3SRJZ RU https://pubmed.ncbi.nlm.nih.gov/19422222 DM1CI9R DI DM1CI9R DM1CI9R DN Bempedoic acid DM1CI9R MI TT0Z6Y2 DM1CI9R MN ATP-citrate synthase (ACLY) DM1CI9R MT DTT DM1CI9R MA Inhibitor DM1CI9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1CI9R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf DM1CI9R DI DM1CI9R DM1CI9R DN Bempedoic acid DM1CI9R MI TTRA79S DM1CI9R MN Cholesterol synthesis (Chole synth) DM1CI9R MT DTT DM1CI9R MA Inhibitor DM1CI9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1CI9R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf DMH1M9B DI DMH1M9B DMH1M9B DN Benazepril DMH1M9B MI TTL69WB DMH1M9B MN Angiotensin-converting enzyme (ACE) DMH1M9B MT DTT DMH1M9B MA Inhibitor DMH1M9B RN Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83. DMH1M9B RU https://pubmed.ncbi.nlm.nih.gov/19572914 DMH1M9B DI DMH1M9B DMH1M9B DN Benazepril DMH1M9B MI DEOXTPZ DMH1M9B MN Methylenetetrahydrofolate reductase (MTHFR) DMH1M9B MT DME DMH1M9B MA Metabolism DMH1M9B RN Effects of MTHFR and MS gene polymorphisms on baseline blood pressure and Benazepril effectiveness in Chinese hypertensive patients. J Hum Hypertens. 2011 Mar;25(3):172-7. DMH1M9B RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20445573 DMH1M9B DI DMH1M9B DMH1M9B DN Benazepril DMH1M9B MI DT9G7XN DMH1M9B MN Peptide transporter 1 (SLC15A1) DMH1M9B MT DTP DMH1M9B MA Substrate DMH1M9B RN Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. DMH1M9B RU http://www.ncbi.nlm.nih.gov/pubmed/18713951 DMH1M9B DI DMH1M9B DMH1M9B DN Benazepril DMH1M9B MI DT8QKNP DMH1M9B MN Peptide transporter 2 (SLC15A2) DMH1M9B MT DTP DMH1M9B MA Substrate DMH1M9B RN Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. DMH1M9B RU http://www.ncbi.nlm.nih.gov/pubmed/18713951 DMFH15Z DI DMFH15Z DMFH15Z DN Bendamustine hydrochloride DMFH15Z MI DEJGDUW DMFH15Z MN Cytochrome P450 1A2 (CYP1A2) DMFH15Z MT DME DMFH15Z MA Metabolism DMFH15Z RN Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54. DMFH15Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25829094 DMFH15Z DI DMFH15Z DMFH15Z DN Bendamustine hydrochloride DMFH15Z MI TTUTN1I DMFH15Z MN Human Deoxyribonucleic acid (hDNA) DMFH15Z MT DTT DMFH15Z MA Modulator DMFH15Z RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMFH15Z RU https://pubmed.ncbi.nlm.nih.gov/19180096 DM7EVLC DI DM7EVLC DM7EVLC DN Bendroflumethiazide DM7EVLC MI TTS087L DM7EVLC MN Solute carrier family 12 member 1 (SLC12A1) DM7EVLC MT DTT DM7EVLC MA Blocker DM7EVLC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7EVLC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7EVLC DI DM7EVLC DM7EVLC DN Bendroflumethiazide DM7EVLC MI TTP362L DM7EVLC MN Solute carrier family 12 member 3 (SLC12A3) DM7EVLC MT DTT DM7EVLC MA Blocker DM7EVLC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7EVLC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7P1J4 DI DM7P1J4 DM7P1J4 DN Benralizumab DM7P1J4 MI TTXH9AD DM7P1J4 MN Interleukin 5 receptor alpha (IL5RA) DM7P1J4 MT DTT DM7P1J4 MA Modulator DM7P1J4 RN Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. DM7P1J4 RU https://www.ncbi.nlm.nih.gov/pubmed/22136436 DM7P1J4 DI DM7P1J4 DM7P1J4 DN Benralizumab DM7P1J4 MI TTPREZD DM7P1J4 MN Interleukin-5 (IL5) DM7P1J4 MT DTT DM7P1J4 MA Modulator DM7P1J4 RN Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma DM7P1J4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587289 DMRVBWU DI DMRVBWU DMRVBWU DN Bentazepam DMRVBWU MI TTEX6LM DMRVBWU MN GABA(A) receptor gamma-3 (GABRG3) DMRVBWU MT DTT DMRVBWU MA Modulator DMRVBWU RN Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011Jan;25(1):87-96. DMRVBWU RU https://pubmed.ncbi.nlm.nih.gov/20530587 DMF7EXL DI DMF7EXL DMF7EXL DN Benzatropine DMF7EXL MI DECB0K3 DMF7EXL MN Cytochrome P450 2D6 (CYP2D6) DMF7EXL MT DME DMF7EXL MA Metabolism DMF7EXL RN Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53. DMF7EXL RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230 DMF7EXL DI DMF7EXL DMF7EXL DN Benzatropine DMF7EXL MI DEGTFWK DMF7EXL MN Mephenytoin 4-hydroxylase (CYP2C19) DMF7EXL MT DME DMF7EXL MA Metabolism DMF7EXL RN Transport, metabolism, and in vivo population pharmacokinetics of the chloro benztropine analogs, a class of compounds extensively evaluated in animal models of drug abuse. J Pharmacol Exp Ther. 2007 Jan;320(1):344-53. DMF7EXL RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17003230 DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA MI TTOJI4S DMC3YUA MN Calcium-dependent chloride channel anoctamin (ANO) DMC3YUA MT DTT DMC3YUA MA Antagonist DMC3YUA RN Anoctamin Channels in Human Myometrium: A Novel Target for Tocolysis.Reprod Sci. 2018 Nov;25(11):1589-1600. DMC3YUA RU https://pubmed.ncbi.nlm.nih.gov/29471754 DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA MI DE5IED8 DMC3YUA MN Cytochrome P450 2C9 (CYP2C9) DMC3YUA MT DME DMC3YUA MA Metabolism DMC3YUA RN Quantitative binding models for CYP2C9 based on benzbromarone analogues. Biochemistry. 2004 Jun 8;43(22):6948-58. DMC3YUA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15170332 DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA MI TTOI92F DMC3YUA MN Multidrug resistance-associated protein 1 (ABCC1) DMC3YUA MT DTT DMC3YUA MA Stimulator DMC3YUA RN Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transpo... Drug Metab Dispos. 2009 Jan;37(1):129-36. DMC3YUA RU https://pubmed.ncbi.nlm.nih.gov/18845662 DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA MI DT582KR DMC3YUA MN Multidrug resistance-associated protein 6 (ABCC6) DMC3YUA MT DTP DMC3YUA MA Substrate DMC3YUA RN The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 3.A.1.208.10) DMC3YUA RU http://www.tcdb.org/search/result.php?tc=3.A.1.208.10 DMI18HW DI DMI18HW DMI18HW DN Benzocaine DMI18HW MI TTRK8B9 DMI18HW MN Sodium channel unspecific (NaC) DMI18HW MT DTT DMI18HW MA Blocker DMI18HW RN Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008 Jan 4;102(1):86-94. DMI18HW RU https://pubmed.ncbi.nlm.nih.gov/17967784 DMKB9FI DI DMKB9FI DMKB9FI DN Benzoic acid DMKB9FI MI TT958S6 DMKB9FI MN Ras-related protein Rab-9A (RAB9A) DMKB9FI MT DTT DMKB9FI MA Inhibitor DMKB9FI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKB9FI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKB9FI DI DMKB9FI DMKB9FI DN Benzoic acid DMKB9FI MI DTM301H DMKB9FI MN Sodium-coupled monocarboxylate transporter 2 (SLC5A12) DMKB9FI MT DTP DMKB9FI MA Substrate DMKB9FI RN Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. AAPS J. 2008;10(1):193-9. DMKB9FI RU http://www.ncbi.nlm.nih.gov/pubmed/18446519 DM9U4FO DI DM9U4FO DM9U4FO DN Benzonatate DM9U4FO MI TTZOVE0 DM9U4FO MN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM9U4FO MT DTT DM9U4FO MA Blocker DM9U4FO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9U4FO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIJATC DI DMIJATC DMIJATC DN Benzphetamine DMIJATC MI DEPKLMQ DMIJATC MN Cytochrome P450 2B6 (CYP2B6) DMIJATC MT DME DMIJATC MA Metabolism DMIJATC RN Mechanistic analysis of the inactivation of cytochrome P450 2B6 by phencyclidine: effects on substrate binding, electron transfer, and uncoupling. Drug Metab Dispos. 2009 Apr;37(4):745-52. DMIJATC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19144770 DMIJATC DI DMIJATC DMIJATC DN Benzphetamine DMIJATC MI DE4LYSA DMIJATC MN Cytochrome P450 3A4 (CYP3A4) DMIJATC MT DME DMIJATC MA Metabolism DMIJATC RN Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75. DMIJATC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8486332 DMIJATC DI DMIJATC DMIJATC DN Benzphetamine DMIJATC MI DEIZLTN DMIJATC MN Docosahexaenoic acid omega-hydroxylase (CYP4F11) DMIJATC MT DME DMIJATC MA Metabolism DMIJATC RN Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304. DMIJATC RU https://pubmed.ncbi.nlm.nih.gov/15364545 DMIJATC DI DMIJATC DMIJATC DN Benzphetamine DMIJATC MI DE3N2FM DMIJATC MN NADPH-cytochrome P450 reductase (CPR) DMIJATC MT DME DMIJATC MA Metabolism DMIJATC RN On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403. DMIJATC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=3924914 DMIJATC DI DMIJATC DMIJATC DN Benzphetamine DMIJATC MI TT9IK2Z DMIJATC MN N-methyl-D-aspartate receptor (NMDAR) DMIJATC MT DTT DMIJATC MA Antagonist DMIJATC RN Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16. DMIJATC RU https://pubmed.ncbi.nlm.nih.gov/11861810 DMU4D5Y DI DMU4D5Y DMU4D5Y DN Benzquinamide DMU4D5Y MI TT0JLSD DMU4D5Y MN Multidrug resistance protein (MDR) DMU4D5Y MT DTT DMU4D5Y MA Inhibitor DMU4D5Y RN Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res. 1992;4(8-9):359-65. DMU4D5Y RU https://pubmed.ncbi.nlm.nih.gov/1362504 DMQWZ0H DI DMQWZ0H DMQWZ0H DN Benzthiazide DMQWZ0H MI TTANPDJ DMQWZ0H MN Carbonic anhydrase II (CA-II) DMQWZ0H MT DTT DMQWZ0H MA Inhibitor DMQWZ0H RN Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4. DMQWZ0H RU https://pubmed.ncbi.nlm.nih.gov/13760527 DMGZOVN DI DMGZOVN DMGZOVN DN Benztropine DMGZOVN MI TTZ9SOR DMGZOVN MN Muscarinic acetylcholine receptor M1 (CHRM1) DMGZOVN MT DTT DMGZOVN MA Antagonist DMGZOVN RN Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60. DMGZOVN RU https://pubmed.ncbi.nlm.nih.gov/18417307 DMGZOVN DI DMGZOVN DMGZOVN DN Benztropine DMGZOVN MI DT3BA8L DMGZOVN MN Sodium-dependent dopamine transporter (SLC6A3) DMGZOVN MT DTP DMGZOVN MA Substrate DMGZOVN RN Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist. J Pharmacol Exp Ther. 2014 Jan;348(1):106-15. DMGZOVN RU http://www.ncbi.nlm.nih.gov/pubmed/24194528 DMBVYDI DI DMBVYDI DMBVYDI DN Benzyl alcohol DMBVYDI MI DEWYTJB DMBVYDI MN Aldehyde dehydrogenase 2 (ALDH2) DMBVYDI MT DME DMBVYDI MA Metabolism DMBVYDI RN Effects of ALDH2, CYP1A1, and CYP2E1 genetic polymorphisms and smoking and drinking habits on toluene metabolism in humans. Toxicol Appl Pharmacol. 1995 Aug;133(2):295-304. DMBVYDI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=7645026 DMBVYDI DI DMBVYDI DMBVYDI DN Benzyl alcohol DMBVYDI MI DEJGDUW DMBVYDI MN Cytochrome P450 1A2 (CYP1A2) DMBVYDI MT DME DMBVYDI MA Metabolism DMBVYDI RN Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65. DMBVYDI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9253143 DMBVYDI DI DMBVYDI DMBVYDI DN Benzyl alcohol DMBVYDI MI DES5XRU DMBVYDI MN Cytochrome P450 2C8 (CYP2C8) DMBVYDI MT DME DMBVYDI MA Metabolism DMBVYDI RN Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica. 1997 Jul;27(7):657-65. DMBVYDI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9253143 DMBVYDI DI DMBVYDI DMBVYDI DN Benzyl alcohol DMBVYDI MI DECB0K3 DMBVYDI MN Cytochrome P450 2D6 (CYP2D6) DMBVYDI MT DME DMBVYDI MA Metabolism DMBVYDI RN Mechanism of cytochrome P4503A4- and 2D6-catalyzed dehydrogenation of ezlopitant as probed with isotope effects using five deuterated analogs. Drug Metab Dispos. 2001 Dec;29(12):1599-607. DMBVYDI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11717179 DMBVYDI DI DMBVYDI DMBVYDI DN Benzyl alcohol DMBVYDI MI DEVDYN7 DMBVYDI MN Cytochrome P450 2E1 (CYP2E1) DMBVYDI MT DME DMBVYDI MA Metabolism DMBVYDI RN The metabolic rate constants and specific activity of human and rat hepatic cytochrome P-450 2E1 toward toluene and chloroform. J Toxicol Environ Health A. 2004 Apr 9;67(7):537-53. DMBVYDI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15129551 DMBVYDI DI DMBVYDI DMBVYDI DN Benzyl alcohol DMBVYDI MI DEYWLRK DMBVYDI MN Sulfotransferase 1A1 (SULT1A1) DMBVYDI MT DME DMBVYDI MA Metabolism DMBVYDI RN Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4. DMBVYDI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444 DMBVYDI DI DMBVYDI DMBVYDI DN Benzyl alcohol DMBVYDI MI DERUZL7 DMBVYDI MN Sulfotransferase 1A2 (SULT1A2) DMBVYDI MT DME DMBVYDI MA Metabolism DMBVYDI RN Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4. DMBVYDI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444 DMBVYDI DI DMBVYDI DMBVYDI DN Benzyl alcohol DMBVYDI MI DED5UR3 DMBVYDI MN Sulfotransferase 1B1 (SULT1B1) DMBVYDI MT DME DMBVYDI MA Metabolism DMBVYDI RN Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4. DMBVYDI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26663444 DMDPYI5 DI DMDPYI5 DMDPYI5 DN Benzyl benzoate DMDPYI5 MI TTLUQ8E DMDPYI5 MN Hormone sensitive lipase (LIPE) DMDPYI5 MT DTT DMDPYI5 MA Modulator DMDPYI5 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMDPYI5 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMDPYI5 DI DMDPYI5 DMDPYI5 DN Benzyl benzoate DMDPYI5 MI DE4IY8S DMDPYI5 MN Peroxidase (katG) DMDPYI5 MT DME DMDPYI5 MA Metabolism DMDPYI5 RN Peroxidase activity in the sulfate-reducing bacterium Desulfotomaculum acetoxidans DSM 771. Pol J Microbiol. 2010;59(4):249-55. DMDPYI5 RU https://pubmed.ncbi.nlm.nih.gov/21466042 DMQHM2D DI DMQHM2D DMQHM2D DN Benzylpenicilloyl Polylysine DMQHM2D MI TTDGEC0 DMQHM2D MN Immunoglobulin epsilon Fc receptor gamma (FCERG) DMQHM2D MT DTT DMQHM2D MA Binder DMQHM2D RN Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60. DMQHM2D RU https://pubmed.ncbi.nlm.nih.gov/7436456 DMXDZAQ DI DMXDZAQ DMXDZAQ DN Bepotastine DMXDZAQ MI TTTIBOJ DMXDZAQ MN Histamine H1 receptor (H1R) DMXDZAQ MT DTT DMXDZAQ MA Antagonist DMXDZAQ RN Mast cells play a critical role in the pathogenesis of viral myocarditis. Circulation. 2008 Jul 22;118(4):363-72. DMXDZAQ RU https://pubmed.ncbi.nlm.nih.gov/18606918 DM0RKS4 DI DM0RKS4 DM0RKS4 DN Bepridil DM0RKS4 MI TT5HONZ DM0RKS4 MN Calcium channel unspecific (CaC) DM0RKS4 MT DTT DM0RKS4 MA Modulator DM0RKS4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0RKS4 RU https://www.fda.gov/ DM0RKS4 DI DM0RKS4 DM0RKS4 DN Bepridil DM0RKS4 MI DECB0K3 DM0RKS4 MN Cytochrome P450 2D6 (CYP2D6) DM0RKS4 MT DME DM0RKS4 MA Metabolism DM0RKS4 RN Serum flecainide S/R ratio reflects the CYP2D6 genotype and changes in CYP2D6 activity. Drug Metab Pharmacokinet. 2015 Aug;30(4):257-62. DM0RKS4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26195225 DM0RKS4 DI DM0RKS4 DM0RKS4 DN Bepridil DM0RKS4 MI DE4LYSA DM0RKS4 MN Cytochrome P450 3A4 (CYP3A4) DM0RKS4 MT DME DM0RKS4 MA Metabolism DM0RKS4 RN Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. DM0RKS4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822 DM0RKS4 DI DM0RKS4 DM0RKS4 DN Bepridil DM0RKS4 MI DTUGYRD DM0RKS4 MN P-glycoprotein 1 (ABCB1) DM0RKS4 MT DTP DM0RKS4 MA Substrate DM0RKS4 RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DM0RKS4 RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMEBY2D DI DMEBY2D DMEBY2D DN Beriplast-P DMEBY2D MI TTWODQF DMEBY2D MN Fibrin (FG) DMEBY2D MT DTT DMEBY2D MA Modulator DMEBY2D RN Wound healing and degradation of the fibrin sealant Beriplast P following partial liver resection in rabbits. Wound Repair Regen. 2005 May-Jun;13(3):318-23. DMEBY2D RU https://pubmed.ncbi.nlm.nih.gov/15953052 DMWA2DZ DI DMWA2DZ DMWA2DZ DN Berotralstat DMWA2DZ MI TTMF8H9 DMWA2DZ MN Plasma kallikrein (KLKB1) DMWA2DZ MT DTT DMWA2DZ MA Inhibitor DMWA2DZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWA2DZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf DMPHXMI DI DMPHXMI DMPHXMI DN Besifloxacin DMPHXMI MI TTN6J5F DMPHXMI MN Bacterial DNA gyrase (Bact gyrase) DMPHXMI MT DTT DMPHXMI MA Modulator DMPHXMI RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMPHXMI RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMPHXMI DI DMPHXMI DMPHXMI DN Besifloxacin DMPHXMI MI TTIXTO3 DMPHXMI MN Staphylococcus Topoisomerase IV (Stap-coc parC) DMPHXMI MT DTT DMPHXMI MA Modulator DMPHXMI RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMPHXMI RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM8L9D4 DI DM8L9D4 DM8L9D4 DN Bestatin DM8L9D4 MI TTXZEAJ DM8L9D4 MN Leukotriene A-4 hydrolase (LTA4H) DM8L9D4 MT DTT DM8L9D4 MA Inhibitor DM8L9D4 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM8L9D4 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM8L9D4 DI DM8L9D4 DM8L9D4 DN Bestatin DM8L9D4 MI DT9G7XN DM8L9D4 MN Peptide transporter 1 (SLC15A1) DM8L9D4 MT DTP DM8L9D4 MA Substrate DM8L9D4 RN Dipeptide transporters in apical and basolateral membranes of the human intestinal cell line Caco-2. Am J Physiol. 1993 Aug;265(2 Pt 1):G289-94. DM8L9D4 RU http://www.ncbi.nlm.nih.gov/pubmed/8396335 DM8L9D4 DI DM8L9D4 DM8L9D4 DN Bestatin DM8L9D4 MI DT8QKNP DM8L9D4 MN Peptide transporter 2 (SLC15A2) DM8L9D4 MT DTP DM8L9D4 MA Substrate DM8L9D4 RN Molecular mechanism of dipeptide and drug transport by the human renal H+/oligopeptide cotransporter hPEPT2. Am J Physiol Renal Physiol. 2008 Jun;294(6):F1422-32. DM8L9D4 RU http://www.ncbi.nlm.nih.gov/pubmed/18367661 DMI6GKT DI DMI6GKT DMI6GKT DN Beta-acetyldigoxin DMI6GKT MI DTUGYRD DMI6GKT MN P-glycoprotein 1 (ABCB1) DMI6GKT MT DTP DMI6GKT MA Substrate DMI6GKT RN P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43. DMI6GKT RU https://doi.org/10.1007/s002100000354 DMI6GKT DI DMI6GKT DMI6GKT DN Beta-acetyldigoxin DMI6GKT MI TTYHPRQ DMI6GKT MN Sodium pump (NaP) DMI6GKT MT DTT DMI6GKT MA Modulator DMI6GKT RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMI6GKT RU https://pubmed.ncbi.nlm.nih.gov/3879679 DM0RXBT DI DM0RXBT DM0RXBT DN Beta-carotene DM0RXBT MI DE6BOK3 DM0RXBT MN Beta,beta-carotene 15,15'-dioxygenase (BCO1) DM0RXBT MT DME DM0RXBT MA Metabolism DM0RXBT RN Substrate specificity of purified recombinant human beta-carotene 15,15'-oxygenase (BCO1). J Biol Chem. 2013 Dec 27;288(52):37094-103. DM0RXBT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24187135 DM0RXBT DI DM0RXBT DM0RXBT DN Beta-carotene DM0RXBT MI DTUGYRD DM0RXBT MN P-glycoprotein 1 (ABCB1) DM0RXBT MT DTP DM0RXBT MA Substrate DM0RXBT RN Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. Phytomedicine. 2012 Aug 15;19(11):977-87. DM0RXBT RU https://doi.org/10.1016/j.phymed.2012.05.010 DMGRZW2 DI DMGRZW2 DMGRZW2 DN Betaine DMGRZW2 MI DTBPTJF DMGRZW2 MN Na(+)/Cl(-) betaine/GABA transporter (SLC6A12) DMGRZW2 MT DTP DMGRZW2 MA Substrate DMGRZW2 RN Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Res. 2011 Jun;95(1-2):70-81. DMGRZW2 RU http://www.ncbi.nlm.nih.gov/pubmed/21459558 DMAHJEF DI DMAHJEF DMAHJEF DN Betamethasone DMAHJEF MI TTYRL6O DMAHJEF MN Glucocorticoid receptor (NR3C1) DMAHJEF MT DTT DMAHJEF MA Agonist DMAHJEF RN The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83. DMAHJEF RU https://pubmed.ncbi.nlm.nih.gov/16824511 DMAHJEF DI DMAHJEF DMAHJEF DN Betamethasone DMAHJEF MI DTUGYRD DMAHJEF MN P-glycoprotein 1 (ABCB1) DMAHJEF MT DTP DMAHJEF MA Substrate DMAHJEF RN Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. DMAHJEF RU http://www.ncbi.nlm.nih.gov/pubmed/14661924 DMRMS1A DI DMRMS1A DMRMS1A DN Betamethasone Benzoate DMRMS1A MI TTYRL6O DMRMS1A MN Glucocorticoid receptor (NR3C1) DMRMS1A MT DTT DMRMS1A MA Modulator DMRMS1A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRMS1A RU https://www.fda.gov/ DMMIAXO DI DMMIAXO DMMIAXO DN Betamethasone valerate DMMIAXO MI DEDH7FP DMMIAXO MN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DMMIAXO MT DME DMMIAXO MA Metabolism DMMIAXO RN Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46. DMMIAXO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16549198 DMMIAXO DI DMMIAXO DMMIAXO DN Betamethasone valerate DMMIAXO MI DE4LYSA DMMIAXO MN Cytochrome P450 3A4 (CYP3A4) DMMIAXO MT DME DMMIAXO MA Metabolism DMMIAXO RN Studies on Drug Interactions between CYP3A4 Inhibitors and Glucocorticoids. DMMIAXO RU https://pdfs.semanticscholar.org/dc99/4682bd504ab29f1c7075b9d769eb4ac4a9ce.pdf DMMIAXO DI DMMIAXO DMMIAXO DN Betamethasone valerate DMMIAXO MI TTYRL6O DMMIAXO MN Glucocorticoid receptor (NR3C1) DMMIAXO MT DTT DMMIAXO MA Modulator DMMIAXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMIAXO RU https://www.fda.gov/ DM6EUL5 DI DM6EUL5 DM6EUL5 DN Betaxolol DM6EUL5 MI TTR6W5O DM6EUL5 MN Adrenergic receptor beta-1 (ADRB1) DM6EUL5 MT DTT DM6EUL5 MA Antagonist DM6EUL5 RN beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29. DM6EUL5 RU https://pubmed.ncbi.nlm.nih.gov/19439240 DM6EUL5 DI DM6EUL5 DM6EUL5 DN Betaxolol DM6EUL5 MI DEJGDUW DM6EUL5 MN Cytochrome P450 1A2 (CYP1A2) DM6EUL5 MT DME DM6EUL5 MA Metabolism DM6EUL5 RN Drugs that may have potential CYP1A2 interactions. DM6EUL5 RU https://drug-interactions.medicine.iu.edu/MainTable.aspx DM6EUL5 DI DM6EUL5 DM6EUL5 DN Betaxolol DM6EUL5 MI DECB0K3 DM6EUL5 MN Cytochrome P450 2D6 (CYP2D6) DM6EUL5 MT DME DM6EUL5 MA Metabolism DM6EUL5 RN Association of CYP2D6 and ADRB1 genes with hypotensive and antichronotropic action of betaxolol in patients with arterial hypertension. Fundam Clin Pharmacol. 2007 Aug;21(4):437-43. DM6EUL5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17635183 DMUFGAY DI DMUFGAY DMUFGAY DN Betazole DMUFGAY MI TTQHJ1K DMUFGAY MN Histamine H2 receptor (H2R) DMUFGAY MT DTT DMUFGAY MA Antagonist DMUFGAY RN Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6. DMUFGAY RU https://pubmed.ncbi.nlm.nih.gov/2892392 DMCLHO0 DI DMCLHO0 DMCLHO0 DN Bethanechol DMCLHO0 MI TTH18TF DMCLHO0 MN Muscarinic acetylcholine receptor M5 (CHRM5) DMCLHO0 MT DTT DMCLHO0 MA Agonist DMCLHO0 RN Loss of Ca-mediated ion transport during colitis correlates with reduced ion transport responses to a Ca-activated K channel opener. Br J Pharmacol. 2009 Apr;156(7):1085-97. DMCLHO0 RU https://pubmed.ncbi.nlm.nih.gov/19298254 DM2C4RF DI DM2C4RF DM2C4RF DN Betrixaban DM2C4RF MI TTCIHJA DM2C4RF MN Coagulation factor Xa (F10) DM2C4RF MT DTT DM2C4RF MA Modulator DM2C4RF RN Company report (Portola) DM2C4RF RU https://www.portola.com/clinical-development/betrixaban-fxa-inhibitor/ DM2C4RF DI DM2C4RF DM2C4RF DN Betrixaban DM2C4RF MI DTUGYRD DM2C4RF MN P-glycoprotein 1 (ABCB1) DM2C4RF MT DTP DM2C4RF MA Substrate DM2C4RF RN Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015 Jun 26;11:343-51. DM2C4RF RU http://www.ncbi.nlm.nih.gov/pubmed/26170684 DMSD1UN DI DMSD1UN DMSD1UN DN Bevacizumab DMSD1UN MI TTOHSBA DMSD1UN MN Vascular endothelial growth factor A (VEGFA) DMSD1UN MT DTT DMSD1UN MA Inhibitor DMSD1UN RN FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085. DMSD1UN RU https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085 DMZFICR DI DMZFICR DMZFICR DN Bevantolol DMZFICR MI DECB0K3 DMZFICR MN Cytochrome P450 2D6 (CYP2D6) DMZFICR MT DME DMZFICR MA Metabolism DMZFICR RN Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. DMZFICR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712 DMZFICR DI DMZFICR DMZFICR DN Bevantolol DMZFICR MI TTEX248 DMZFICR MN Dopamine D2 receptor (D2R) DMZFICR MT DTT DMZFICR MA Antagonist DMZFICR RN Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique. Arch Pharm Res. 2007 Jul;30(7):890-7. DMZFICR RU https://pubmed.ncbi.nlm.nih.gov/17703743 DMOBIKY DI DMOBIKY DMOBIKY DN Bexarotene DMOBIKY MI DE5IED8 DMOBIKY MN Cytochrome P450 2C9 (CYP2C9) DMOBIKY MT DME DMOBIKY MA Metabolism DMOBIKY RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMOBIKY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMOBIKY DI DMOBIKY DMOBIKY DN Bexarotene DMOBIKY MI DE4LYSA DMOBIKY MN Cytochrome P450 3A4 (CYP3A4) DMOBIKY MT DME DMOBIKY MA Metabolism DMOBIKY RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMOBIKY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMOBIKY DI DMOBIKY DMOBIKY DN Bexarotene DMOBIKY MI TT6PEUO DMOBIKY MN Retinoic acid receptor RXR-alpha (RXRA) DMOBIKY MT DTT DMOBIKY MA Modulator DMOBIKY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOBIKY RU https://www.fda.gov/ DMZDCS0 DI DMZDCS0 DMZDCS0 DN Bezafibrate DMZDCS0 MI DE4LYSA DMZDCS0 MN Cytochrome P450 3A4 (CYP3A4) DMZDCS0 MT DME DMZDCS0 MA Metabolism DMZDCS0 RN Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62. DMZDCS0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185 DMZDCS0 DI DMZDCS0 DMZDCS0 DN Bezafibrate DMZDCS0 MI TTJ584C DMZDCS0 MN Peroxisome proliferator-activated receptor alpha (PPARA) DMZDCS0 MT DTT DMZDCS0 MA Agonist DMZDCS0 RN Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92. DMZDCS0 RU https://pubmed.ncbi.nlm.nih.gov/19124612 DMTZC5G DI DMTZC5G DMTZC5G DN Bezlotoxumab DMTZC5G MI TTQH65V DMTZC5G MN Clostridium difficile Toxin B (CD toxB) DMTZC5G MT DTT DMTZC5G MA Modulator DMTZC5G RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMTZC5G RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q MI DTI7UX6 DMTKD7Q MN Breast cancer resistance protein (ABCG2) DMTKD7Q MT DTP DMTKD7Q MA Substrate DMTKD7Q RN Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50. DMTKD7Q RU http://www.ncbi.nlm.nih.gov/pubmed/28288939 DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q MI TTGKNB4 DMTKD7Q MN Epidermal growth factor receptor (EGFR) DMTKD7Q MT DTT DMTKD7Q MA Inhibitor DMTKD7Q RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMTKD7Q RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q MI TT6EO5L DMTKD7Q MN Erbb2 tyrosine kinase receptor (HER2) DMTKD7Q MT DTT DMTKD7Q MA Inhibitor DMTKD7Q RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMTKD7Q RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q MI DTUGYRD DMTKD7Q MN P-glycoprotein 1 (ABCB1) DMTKD7Q MT DTP DMTKD7Q MA Substrate DMTKD7Q RN Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacol Res. 2017 Jun;120:43-50. DMTKD7Q RU http://www.ncbi.nlm.nih.gov/pubmed/28288939 DMZMSPF DI DMZMSPF DMZMSPF DN Bicalutamide DMZMSPF MI TTS64P2 DMZMSPF MN Androgen receptor (AR) DMZMSPF MT DTT DMZMSPF MA Antagonist DMZMSPF RN Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11. DMZMSPF RU https://pubmed.ncbi.nlm.nih.gov/19533338 DMZMSPF DI DMZMSPF DMZMSPF DN Bicalutamide DMZMSPF MI DTI7UX6 DMZMSPF MN Breast cancer resistance protein (ABCG2) DMZMSPF MT DTP DMZMSPF MA Substrate DMZMSPF RN Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11. DMZMSPF RU http://www.ncbi.nlm.nih.gov/pubmed/25124867 DMZMSPF DI DMZMSPF DMZMSPF DN Bicalutamide DMZMSPF MI DE4LYSA DMZMSPF MN Cytochrome P450 3A4 (CYP3A4) DMZMSPF MT DME DMZMSPF MA Metabolism DMZMSPF RN Bicalutamide: clinical pharmacokinetics and metabolism. Clin Pharmacokinet. 2004;43(13):855-78. DMZMSPF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15509184 DMZMSPF DI DMZMSPF DMZMSPF DN Bicalutamide DMZMSPF MI DTUGYRD DMZMSPF MN P-glycoprotein 1 (ABCB1) DMZMSPF MT DTP DMZMSPF MA Substrate DMZMSPF RN Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans. Clin Chim Acta. 2015 Jan 1;438:7-11. DMZMSPF RU http://www.ncbi.nlm.nih.gov/pubmed/25124867 DMG0H8K DI DMG0H8K DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K MI TT5FH9Y DMG0H8K MN Human immunodeficiency virus Integrase (HIV IN) DMG0H8K MT DTT DMG0H8K MA Inhibitor DMG0H8K RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMG0H8K RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMG0H8K DI DMG0H8K DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K MI TT84ETX DMG0H8K MN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMG0H8K MT DTT DMG0H8K MA Inhibitor DMG0H8K RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMG0H8K RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM3KN7V DI DM3KN7V DM3KN7V DN Bifonazole DM3KN7V MI TTTSOUD DM3KN7V MN Candida Cytochrome P450 51 (Candi ERG11) DM3KN7V MT DTT DM3KN7V MA Inhibitor DM3KN7V RN Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7. DM3KN7V RU https://pubmed.ncbi.nlm.nih.gov/17027909 DMX0E5B DI DMX0E5B DMX0E5B DN Bimatoprost DMX0E5B MI DE4LYSA DMX0E5B MN Cytochrome P450 3A4 (CYP3A4) DMX0E5B MT DME DMX0E5B MA Metabolism DMX0E5B RN Product monograph: LUMIGAN RC (Bimatoprost). DMX0E5B RU https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf DMX0E5B DI DMX0E5B DMX0E5B DN Bimatoprost DMX0E5B MI DEIBDNY DMX0E5B MN Cytochrome P450 3A5 (CYP3A5) DMX0E5B MT DME DMX0E5B MA Metabolism DMX0E5B RN Product monograph: LUMIGAN RC (Bimatoprost). DMX0E5B RU https://allergan-web-cdn-prod.azureedge.net/allergancanadaspecialty/allergancanadaspecialty/media/actavis-canada-specialty/en/products/pms/lumigan-rc-pm-2016-05-11_e.pdf DMX0E5B DI DMX0E5B DMX0E5B DN Bimatoprost DMX0E5B MI TT9B4N3 DMX0E5B MN Prostaglandin receptor (PTGR) DMX0E5B MT DTT DMX0E5B MA Modulator DMX0E5B RN Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95. DMX0E5B RU https://pubmed.ncbi.nlm.nih.gov/19274525 DME78OA DI DME78OA DME78OA DN Biperiden DME78OA MI TTZ9SOR DME78OA MN Muscarinic acetylcholine receptor M1 (CHRM1) DME78OA MT DTT DME78OA MA Antagonist DME78OA RN Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm. 1999;106(7-8):583-92. DME78OA RU https://pubmed.ncbi.nlm.nih.gov/10907719 DMTKU46 DI DMTKU46 DMTKU46 DN Bismuth DMTKU46 MI TTFNGC9 DMTKU46 MN Serum albumin (ALB) DMTKU46 MT DTT DMTKU46 MA Binder DMTKU46 RN Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35. DMTKU46 RU https://pubmed.ncbi.nlm.nih.gov/11110794 DM3UZ95 DI DM3UZ95 DM3UZ95 DN Bisoprolol DM3UZ95 MI TTR6W5O DM3UZ95 MN Adrenergic receptor beta-1 (ADRB1) DM3UZ95 MT DTT DM3UZ95 MA Antagonist DM3UZ95 RN Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J. 2008 May;49(3):281-93. DM3UZ95 RU https://pubmed.ncbi.nlm.nih.gov/18612186 DM3UZ95 DI DM3UZ95 DM3UZ95 DN Bisoprolol DM3UZ95 MI DECB0K3 DM3UZ95 MN Cytochrome P450 2D6 (CYP2D6) DM3UZ95 MT DME DM3UZ95 MA Metabolism DM3UZ95 RN Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. DM3UZ95 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14732961 DM3UZ95 DI DM3UZ95 DM3UZ95 DN Bisoprolol DM3UZ95 MI DE4LYSA DM3UZ95 MN Cytochrome P450 3A4 (CYP3A4) DM3UZ95 MT DME DM3UZ95 MA Metabolism DM3UZ95 RN Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108. DM3UZ95 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9763205 DMK6XAV DI DMK6XAV DMK6XAV DN Bitolterol DMK6XAV MI TTMXGCW DMK6XAV MN Adrenergic receptor beta-3 (ADRB3) DMK6XAV MT DTT DMK6XAV MA Modulator DMK6XAV RN Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37. DMK6XAV RU https://pubmed.ncbi.nlm.nih.gov/3895171 DMECRX1 DI DMECRX1 DMECRX1 DN Bivalirudin DMECRX1 MI TT6L509 DMECRX1 MN Coagulation factor IIa (F2) DMECRX1 MT DTT DMECRX1 MA Inhibitor DMECRX1 RN New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8. DMECRX1 RU https://pubmed.ncbi.nlm.nih.gov/11479484 DMECRX1 DI DMECRX1 DMECRX1 DN Bivalirudin DMECRX1 MI TTRTKPV DMECRX1 MN Trypanosoma Trypanothione reductase (Trypano TPR) DMECRX1 MT DTT DMECRX1 MA Inhibitor DMECRX1 RN 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8. DMECRX1 RU https://pubmed.ncbi.nlm.nih.gov/12937775 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 MI TTPOI4B DMR8YD6 MN Acetyl-CoA:lyso-PAF acetyltransferase (PCAT) DMR8YD6 MT DTT DMR8YD6 MA Inhibitor DMR8YD6 RN Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res. 1996 Nov;45(11):546-9. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/8951505 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 MI TTLP6GN DMR8YD6 MN Bacterial DD-carboxypeptidase (Bact vanYB) DMR8YD6 MT DTT DMR8YD6 MA Inhibitor DMR8YD6 RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/18804175 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 MI TTGTQHC DMR8YD6 MN DNA topoisomerase I (TOP1) DMR8YD6 MT DTT DMR8YD6 MA Inhibitor DMR8YD6 RN Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/12027807 DMNER5S DI DMNER5S DMNER5S DN Bleomycin DMNER5S MI DECH1VP DMNER5S MN Bleomycin hydrolase (BLMH) DMNER5S MT DME DMNER5S MA Metabolism DMNER5S RN The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosomal damage. Mutat Res. 1998 Oct 12;421(1):1-7. DMNER5S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9748474 DMNER5S DI DMNER5S DMNER5S DN Bleomycin DMNER5S MI TTUTN1I DMNER5S MN Human Deoxyribonucleic acid (hDNA) DMNER5S MT DTT DMNER5S MA Breaker DMNER5S RN Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85. DMNER5S RU https://pubmed.ncbi.nlm.nih.gov/6177398 DMGECIJ DI DMGECIJ DMGECIJ DN Blinatumomab DMGECIJ MI TTW640A DMGECIJ MN B-lymphocyte surface antigen B4 (CD19) DMGECIJ MT DTT DMGECIJ MA Modulator DMGECIJ RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGECIJ RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGECIJ DI DMGECIJ DMGECIJ DN Blinatumomab DMGECIJ MI TTUN7MC DMGECIJ MN T-cell surface glycoprotein CD3 (CD3) DMGECIJ MT DTT DMGECIJ MA Modulator DMGECIJ RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGECIJ RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMQTAGO DI DMQTAGO DMQTAGO DN BMS-201038 DMQTAGO MI TTUS1RD DMQTAGO MN Microsomal triglyceride transfer protein (MTTP) DMQTAGO MT DTT DMQTAGO MA Inhibitor DMQTAGO RN Dyslipidemia and cardiovascular diseases. Curr Opin Lipidol. 2009 Apr;20(2):157-8. DMQTAGO RU https://pubmed.ncbi.nlm.nih.gov/19276898 DMBSHMF DI DMBSHMF DMBSHMF DN Boceprevir DMBSHMF MI DE4LYSA DMBSHMF MN Cytochrome P450 3A4 (CYP3A4) DMBSHMF MT DME DMBSHMF MA Metabolism DMBSHMF RN Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8. DMBSHMF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23529734 DMBSHMF DI DMBSHMF DMBSHMF DN Boceprevir DMBSHMF MI DEIBDNY DMBSHMF MN Cytochrome P450 3A5 (CYP3A5) DMBSHMF MT DME DMBSHMF MA Metabolism DMBSHMF RN Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. DMBSHMF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23140245 DMBSHMF DI DMBSHMF DMBSHMF DN Boceprevir DMBSHMF MI TTHC7JD DMBSHMF MN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMBSHMF MT DTT DMBSHMF MA Modulator DMBSHMF RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMBSHMF RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMBSHMF DI DMBSHMF DMBSHMF DN Boceprevir DMBSHMF MI DTUGYRD DMBSHMF MN P-glycoprotein 1 (ABCB1) DMBSHMF MT DTP DMBSHMF MA Substrate DMBSHMF RN Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89. DMBSHMF RU http://www.ncbi.nlm.nih.gov/pubmed/24817413 DM2EXC5 DI DM2EXC5 DM2EXC5 DN BOL-303259-X DM2EXC5 MI DTPFTEQ DM2EXC5 MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DM2EXC5 MT DTP DM2EXC5 MA Substrate DM2EXC5 RN The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11. DM2EXC5 RU http://www.ncbi.nlm.nih.gov/pubmed/20019365 DM2EXC5 DI DM2EXC5 DM2EXC5 DN BOL-303259-X DM2EXC5 MI TTT2ZAR DM2EXC5 MN Prostaglandin F2-alpha receptor (PTGFR) DM2EXC5 MT DTT DM2EXC5 MA Agonist DM2EXC5 RN Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5. DM2EXC5 RU https://pubmed.ncbi.nlm.nih.gov/21396362 DMIFYLX DI DMIFYLX DMIFYLX DN Bopindolol DMIFYLX MI TTMXGCW DMIFYLX MN Adrenergic receptor beta-3 (ADRB3) DMIFYLX MT DTT DMIFYLX MA Modulator DMIFYLX RN Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3. DMIFYLX RU https://pubmed.ncbi.nlm.nih.gov/2439825 DMIFYLX DI DMIFYLX DMIFYLX DN Bopindolol DMIFYLX MI DECB0K3 DMIFYLX MN Cytochrome P450 2D6 (CYP2D6) DMIFYLX MT DME DMIFYLX MA Metabolism DMIFYLX RN Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. DMIFYLX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U MI TT2WR1T DMNO38U MN Cationic trypsinogen (PRSS1) DMNO38U MT DTT DMNO38U MA Inhibitor DMNO38U RN Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22. DMNO38U RU https://pubmed.ncbi.nlm.nih.gov/7739010 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U MI DEJGDUW DMNO38U MN Cytochrome P450 1A2 (CYP1A2) DMNO38U MT DME DMNO38U MA Metabolism DMNO38U RN Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos. 2005 Jun;33(6):771-7. DMNO38U RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15764713 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U MI DE5IED8 DMNO38U MN Cytochrome P450 2C9 (CYP2C9) DMNO38U MT DME DMNO38U MA Metabolism DMNO38U RN Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes. Drug Metab Dispos. 2006 Apr;34(4):702-8. DMNO38U RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16443666 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U MI DECB0K3 DMNO38U MN Cytochrome P450 2D6 (CYP2D6) DMNO38U MT DME DMNO38U MA Metabolism DMNO38U RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMNO38U RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U MI DE4LYSA DMNO38U MN Cytochrome P450 3A4 (CYP3A4) DMNO38U MT DME DMNO38U MA Metabolism DMNO38U RN Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 2005 Nov;33(11):1723-8. DMNO38U RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16103134 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U MI TT5L2VC DMNO38U MN Kallikrein-related peptidase (KLK) DMNO38U MT DTT DMNO38U MA Inhibitor DMNO38U RN Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22. DMNO38U RU https://pubmed.ncbi.nlm.nih.gov/7739010 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U MI DEGTFWK DMNO38U MN Mephenytoin 4-hydroxylase (CYP2C19) DMNO38U MT DME DMNO38U MA Metabolism DMNO38U RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMNO38U RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U MI DTUGYRD DMNO38U MN P-glycoprotein 1 (ABCB1) DMNO38U MT DTP DMNO38U MA Substrate DMNO38U RN CNS uptake of bortezomib is enhanced by P-glycoprotein inhibition: implications for spinal muscular atrophy. Neurobiol Dis. 2016 Apr;88:118-24. DMNO38U RU http://www.ncbi.nlm.nih.gov/pubmed/26792401 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U MI TTU7ZMG DMNO38U MN Proteasome (PS) DMNO38U MT DTT DMNO38U MA Modulator DMNO38U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNO38U RU https://www.fda.gov/ DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU MI DE5IED8 DMIOGBU MN Cytochrome P450 2C9 (CYP2C9) DMIOGBU MT DME DMIOGBU MA Metabolism DMIOGBU RN Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42(3):293-301. DMIOGBU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12603176 DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU MI DE4LYSA DMIOGBU MN Cytochrome P450 3A4 (CYP3A4) DMIOGBU MT DME DMIOGBU MA Metabolism DMIOGBU RN Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7. DMIOGBU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17496208 DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU MI TTKRD0G DMIOGBU MN Endothelin A receptor (EDNRA) DMIOGBU MT DTT DMIOGBU MA Modulator DMIOGBU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIOGBU RU https://www.fda.gov/ DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU MI TT3ZTGU DMIOGBU MN Endothelin B receptor (EDNRB) DMIOGBU MT DTT DMIOGBU MA Modulator DMIOGBU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIOGBU RU https://www.fda.gov/ DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU MI DT3D8F0 DMIOGBU MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMIOGBU MT DTP DMIOGBU MA Substrate DMIOGBU RN Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7. DMIOGBU RU http://www.ncbi.nlm.nih.gov/pubmed/17496208 DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU MI DT9C1TS DMIOGBU MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMIOGBU MT DTP DMIOGBU MA Substrate DMIOGBU RN Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7. DMIOGBU RU http://www.ncbi.nlm.nih.gov/pubmed/17496208 DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU MI DTPFTEQ DMIOGBU MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DMIOGBU MT DTP DMIOGBU MA Substrate DMIOGBU RN Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos. 2007 Aug;35(8):1400-7. DMIOGBU RU http://www.ncbi.nlm.nih.gov/pubmed/17496208 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE MI DE4LYSA DMTI8YE MN Cytochrome P450 3A4 (CYP3A4) DMTI8YE MT DME DMTI8YE MA Metabolism DMTI8YE RN In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9. DMTI8YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE MI DTUGYRD DMTI8YE MN P-glycoprotein 1 (ABCB1) DMTI8YE MT DTP DMTI8YE MA Substrate DMTI8YE RN In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. J Hematol Oncol. 2015 Jul 7;8:81. DMTI8YE RU http://www.ncbi.nlm.nih.gov/pubmed/26149173 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE MI TT6PKBN DMTI8YE MN Proto-oncogene c-Src (SRC) DMTI8YE MT DTT DMTI8YE MA Inhibitor DMTI8YE RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMTI8YE RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE MI TT3PJMV DMTI8YE MN Tyrosine-protein kinase ABL1 (ABL) DMTI8YE MT DTT DMTI8YE MA Inhibitor DMTI8YE RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMTI8YE RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMW67MU DI DMW67MU DMW67MU DN Botulinum Toxin Type A DMW67MU MI TTYQWA0 DMW67MU MN Synaptosomal-associated protein 25 (SNAP25) DMW67MU MT DTT DMW67MU MA Inhibitor DMW67MU RN Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct duration... J Biol Chem. 2003 Jan 10;278(2):1363-71. DMW67MU RU https://pubmed.ncbi.nlm.nih.gov/12381720 DM58QS1 DI DM58QS1 DM58QS1 DN Botulinum Toxin Type B DM58QS1 MI TTG25NJ DM58QS1 MN Vesicle-associated membrane protein (VAMP) DM58QS1 MT DTT DM58QS1 MA Binder DM58QS1 RN Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009 Apr;256(4):563-7. DM58QS1 RU https://pubmed.ncbi.nlm.nih.gov/19401804 DM20LIM DI DM20LIM DM20LIM DN Bremelanotide DM20LIM MI TT0MV2T DM20LIM MN Melanocortin receptor 1 (MC1R) DM20LIM MT DTT DM20LIM MA Agonist DM20LIM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20LIM RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf DM20LIM DI DM20LIM DM20LIM DN Bremelanotide DM20LIM MI TTD0CIQ DM20LIM MN Melanocortin receptor 4 (MC4R) DM20LIM MT DTT DM20LIM MA Agonist DM20LIM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20LIM RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf DMWLC57 DI DMWLC57 DMWLC57 DN Brentuximab vedotin DMWLC57 MI DE4LYSA DMWLC57 MN Cytochrome P450 3A4 (CYP3A4) DMWLC57 MT DME DMWLC57 MA Metabolism DMWLC57 RN Brentuximab vedotin. DMWLC57 RU https://www.cancercareontario.ca/sites/ccocancercare/files/brentuximab%20vedotin.pdf DMWLC57 DI DMWLC57 DMWLC57 DN Brentuximab vedotin DMWLC57 MI TT2GM5R DMWLC57 MN Lymphocyte activation antigen CD30 (TNFRSF8) DMWLC57 MT DTT DMWLC57 MA Modulator DMWLC57 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMWLC57 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM1FX74 DI DM1FX74 DM1FX74 DN Bretylium DM1FX74 MI TTR6W5O DM1FX74 MN Adrenergic receptor beta-1 (ADRB1) DM1FX74 MT DTT DM1FX74 MA Antagonist DM1FX74 RN Components of functional sympathetic control of heart rate in neonatal rats. Am J Physiol. 1985 May;248(5 Pt 2):R601-10. DM1FX74 RU https://pubmed.ncbi.nlm.nih.gov/2859811 DM1FX74 DI DM1FX74 DM1FX74 DN Bretylium DM1FX74 MI DT3BA8L DM1FX74 MN Sodium-dependent dopamine transporter (SLC6A3) DM1FX74 MT DTP DM1FX74 MA Substrate DM1FX74 RN Which form of dopamine is the substrate for the human dopamine transporter: the cationic or the uncharged species? J Biol Chem. 1999 Feb 19;274(8):4876-82. DM1FX74 RU http://www.ncbi.nlm.nih.gov/pubmed/9988729 DM7W94S DI DM7W94S DM7W94S DN Brigatinib DM7W94S MI TTPMQSO DM7W94S MN ALK tyrosine kinase receptor (ALK) DM7W94S MT DTT DM7W94S MA Inhibitor DM7W94S RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM7W94S RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM7W94S DI DM7W94S DM7W94S DN Brigatinib DM7W94S MI DTKVEXO DM7W94S MN ATP-binding cassette sub-family B member 5 (ABCB5) DM7W94S MT DTP DM7W94S MA Substrate DM7W94S RN NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA. DM7W94S RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf DM7W94S DI DM7W94S DM7W94S DN Brigatinib DM7W94S MI DTI7UX6 DM7W94S MN Breast cancer resistance protein (ABCG2) DM7W94S MT DTP DM7W94S MA Substrate DM7W94S RN NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA. DM7W94S RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208772Orig1s000MultidisciplineR.pdf DM7W94S DI DM7W94S DM7W94S DN Brigatinib DM7W94S MI DES5XRU DM7W94S MN Cytochrome P450 2C8 (CYP2C8) DM7W94S MT DME DM7W94S MA Metabolism DM7W94S RN Brigatinib: first global approval. Drugs. 2017 Jul;77(10):1131-1135. DM7W94S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28597393 DMBR01X DI DMBR01X DMBR01X DN Brilinta DMBR01X MI DE4LYSA DMBR01X MN Cytochrome P450 3A4 (CYP3A4) DMBR01X MT DME DMBR01X MA Metabolism DMBR01X RN Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21. DMBR01X RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20551239 DMBR01X DI DMBR01X DMBR01X DN Brilinta DMBR01X MI TTZ1DT0 DMBR01X MN P2Y purinoceptor 12 (P2RY12) DMBR01X MT DTT DMBR01X MA Antagonist DMBR01X RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMBR01X RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMBR01X DI DMBR01X DMBR01X DN Brilinta DMBR01X MI DTUGYRD DMBR01X MN P-glycoprotein 1 (ABCB1) DMBR01X MT DTP DMBR01X MA Substrate DMBR01X RN KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) DMBR01X RU https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665 DMQLT4N DI DMQLT4N DMQLT4N DN Brimonidine DMQLT4N MI TTQ8AFT DMQLT4N MN Adrenergic receptor Alpha-2 (ADRA2) DMQLT4N MT DTT DMQLT4N MA Agonist DMQLT4N RN Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90. DMQLT4N RU https://pubmed.ncbi.nlm.nih.gov/10943881 DMQLT4N DI DMQLT4N DMQLT4N DN Brimonidine DMQLT4N MI TT2NUT5 DMQLT4N MN Adrenergic receptor alpha-2C (ADRA2C) DMQLT4N MT DTT DMQLT4N MA Modulator DMQLT4N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520). DMQLT4N RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520 DMBAPFG DI DMBAPFG DMBAPFG DN Brinzolamide DMBAPFG MI TTZHA0O DMBAPFG MN Carbonic anhydrase IV (CA-IV) DMBAPFG MT DTT DMBAPFG MA Modulator DMBAPFG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBAPFG RU https://www.fda.gov/ DMBAPFG DI DMBAPFG DMBAPFG DN Brinzolamide DMBAPFG MI DE4LYSA DMBAPFG MN Cytochrome P450 3A4 (CYP3A4) DMBAPFG MT DME DMBAPFG MA Metabolism DMBAPFG RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMBAPFG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMSEPK8 DI DMSEPK8 DMSEPK8 DN Brivaracetam DMSEPK8 MI DEPKLMQ DMSEPK8 MN Cytochrome P450 2B6 (CYP2B6) DMSEPK8 MT DME DMSEPK8 MA Metabolism DMSEPK8 RN Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45. DMSEPK8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17908923 DMSEPK8 DI DMSEPK8 DMSEPK8 DN Brivaracetam DMSEPK8 MI DE5IED8 DMSEPK8 MN Cytochrome P450 2C9 (CYP2C9) DMSEPK8 MT DME DMSEPK8 MA Metabolism DMSEPK8 RN Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012 Aug;40(8):1466-72. DMSEPK8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22538270 DMSEPK8 DI DMSEPK8 DMSEPK8 DN Brivaracetam DMSEPK8 MI DEGTFWK DMSEPK8 MN Mephenytoin 4-hydroxylase (CYP2C19) DMSEPK8 MT DME DMSEPK8 MA Metabolism DMSEPK8 RN Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008 Jan;36(1):36-45. DMSEPK8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17908923 DMSEPK8 DI DMSEPK8 DMSEPK8 DN Brivaracetam DMSEPK8 MI TTT3P91 DMSEPK8 MN Synaptic vesicle glycoprotein 2A (SV2A) DMSEPK8 MT DTT DMSEPK8 MA Inhibitor DMSEPK8 RN Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39. DMSEPK8 RU https://pubmed.ncbi.nlm.nih.gov/18778117 DMASDQ6 DI DMASDQ6 DMASDQ6 DN Brodalumab DMASDQ6 MI TT69OHW DMASDQ6 MN Interleukin 17 receptor (IL17R) DMASDQ6 MT DTT DMASDQ6 MA Antagonist DMASDQ6 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMASDQ6 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMASDQ6 DI DMASDQ6 DMASDQ6 DN Brodalumab DMASDQ6 MI TTG0MT6 DMASDQ6 MN Interleukin-17 (IL17) DMASDQ6 MT DTT DMASDQ6 MA Modulator DMASDQ6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMASDQ6 RU https://www.fda.gov/ DMW8QNG DI DMW8QNG DMW8QNG DN Brolucizumab DMW8QNG MI TT9HKJA DMW8QNG MN Vascular endothelial growth factor (VEGF) DMW8QNG MT DTT DMW8QNG MA Inhibitor DMW8QNG RN Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000. DMW8QNG RU https://pubmed.ncbi.nlm.nih.gov/31768932 DMW8QNG DI DMW8QNG DMW8QNG DN Brolucizumab DMW8QNG MI TTOHSBA DMW8QNG MN Vascular endothelial growth factor A (VEGFA) DMW8QNG MT DTT DMW8QNG MA Inhibitor DMW8QNG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMW8QNG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf DMY9TCW DI DMY9TCW DMY9TCW DN Bromazepam DMY9TCW MI DEJGDUW DMY9TCW MN Cytochrome P450 1A2 (CYP1A2) DMY9TCW MT DME DMY9TCW MA Metabolism DMY9TCW RN Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71. DMY9TCW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9435993 DMY9TCW DI DMY9TCW DMY9TCW DN Bromazepam DMY9TCW MI TTAN6JD DMY9TCW MN Glutamate receptor AMPA (GRIA) DMY9TCW MT DTT DMY9TCW MA Binder DMY9TCW RN Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71. DMY9TCW RU https://pubmed.ncbi.nlm.nih.gov/19099296 DMY9TCW DI DMY9TCW DMY9TCW DN Bromazepam DMY9TCW MI DEGTFWK DMY9TCW MN Mephenytoin 4-hydroxylase (CYP2C19) DMY9TCW MT DME DMY9TCW MA Metabolism DMY9TCW RN Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. Clin Pharmacokinet. 1997 Dec;33(6):454-71. DMY9TCW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9435993 DMKB79O DI DMKB79O DMKB79O DN Bromfenac DMKB79O MI DES5XRU DMKB79O MN Cytochrome P450 2C8 (CYP2C8) DMKB79O MT DME DMKB79O MA Metabolism DMKB79O RN Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257. DMKB79O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452 DMKB79O DI DMKB79O DMKB79O DN Bromfenac DMKB79O MI DE5IED8 DMKB79O MN Cytochrome P450 2C9 (CYP2C9) DMKB79O MT DME DMKB79O MA Metabolism DMKB79O RN Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257. DMKB79O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452 DMKB79O DI DMKB79O DMKB79O DN Bromfenac DMKB79O MI DEGTFWK DMKB79O MN Mephenytoin 4-hydroxylase (CYP2C19) DMKB79O MT DME DMKB79O MA Metabolism DMKB79O RN Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257. DMKB79O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452 DMKB79O DI DMKB79O DMKB79O DN Bromfenac DMKB79O MI DT3D8F0 DMKB79O MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMKB79O MT DTP DMKB79O MA Substrate DMKB79O RN Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. DMKB79O RU http://www.ncbi.nlm.nih.gov/pubmed/30135178 DMKB79O DI DMKB79O DMKB79O DN Bromfenac DMKB79O MI TT8NGED DMKB79O MN Prostaglandin G/H synthase 1 (COX-1) DMKB79O MT DTT DMKB79O MA Inhibitor DMKB79O RN Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. DMKB79O RU https://pubmed.ncbi.nlm.nih.gov/16846546 DMKB79O DI DMKB79O DMKB79O DN Bromfenac DMKB79O MI DEB3CV1 DMKB79O MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMKB79O MT DME DMKB79O MA Metabolism DMKB79O RN Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257. DMKB79O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31815452 DMVE3TK DI DMVE3TK DMVE3TK DN Bromocriptine DMVE3TK MI DE4LYSA DMVE3TK MN Cytochrome P450 3A4 (CYP3A4) DMVE3TK MT DME DMVE3TK MA Metabolism DMVE3TK RN Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry. 2005 Oct 25;44(42):13902-13. DMVE3TK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16229479 DMVE3TK DI DMVE3TK DMVE3TK DN Bromocriptine DMVE3TK MI TTEX248 DMVE3TK MN Dopamine D2 receptor (D2R) DMVE3TK MT DTT DMVE3TK MA Agonist DMVE3TK RN Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine. 2009 Sep;16(9):839-44. DMVE3TK RU https://pubmed.ncbi.nlm.nih.gov/19303749 DMVE3TK DI DMVE3TK DMVE3TK DN Bromocriptine DMVE3TK MI DTUGYRD DMVE3TK MN P-glycoprotein 1 (ABCB1) DMVE3TK MT DTP DMVE3TK MA Substrate DMVE3TK RN Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. DMVE3TK RU https://doi.org/10.1016/j.addr.2011.12.008 DMNDJT5 DI DMNDJT5 DMNDJT5 DN Bromodiphenhydramine DMNDJT5 MI TTTIBOJ DMNDJT5 MN Histamine H1 receptor (H1R) DMNDJT5 MT DTT DMNDJT5 MA Antagonist DMNDJT5 RN Studies on synergism between penicillins and ambodryl (bromodiphenhydramine HCl), an antihistamine with antimicrobial property. Indian J Exp Biol. 1990 Mar;28(3):253-8. DMNDJT5 RU https://pubmed.ncbi.nlm.nih.gov/1973150 DM24XYQ DI DM24XYQ DM24XYQ DN Bromperidol DM24XYQ MI DE4LYSA DM24XYQ MN Cytochrome P450 3A4 (CYP3A4) DM24XYQ MT DME DM24XYQ MA Metabolism DM24XYQ RN CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000 Nov 3;67(24):2913-20. DM24XYQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11133003 DMFOVSD DI DMFOVSD DMFOVSD DN Brompheniramine DMFOVSD MI TTTIBOJ DMFOVSD MN Histamine H1 receptor (H1R) DMFOVSD MT DTT DMFOVSD MA Antagonist DMFOVSD RN Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol. 1994 Mar;93(3):606-14. DMFOVSD RU https://pubmed.ncbi.nlm.nih.gov/8151062 DMXKZT3 DI DMXKZT3 DMXKZT3 DN Buclizine DMXKZT3 MI TTTIBOJ DMXKZT3 MN Histamine H1 receptor (H1R) DMXKZT3 MT DTT DMXKZT3 MA Antagonist DMXKZT3 RN Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J Allergy. 1956 Jan;27(1):63-7. DMXKZT3 RU https://pubmed.ncbi.nlm.nih.gov/13294975 DMJIBAW DI DMJIBAW DMJIBAW DN Budesonide DMJIBAW MI DE4LYSA DMJIBAW MN Cytochrome P450 3A4 (CYP3A4) DMJIBAW MT DME DMJIBAW MA Metabolism DMJIBAW RN No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 Mar;41(3):595-602. DMJIBAW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15726657 DMJIBAW DI DMJIBAW DMJIBAW DN Budesonide DMJIBAW MI TTYRL6O DMJIBAW MN Glucocorticoid receptor (NR3C1) DMJIBAW MT DTT DMJIBAW MA Antagonist DMJIBAW RN PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71. DMJIBAW RU https://pubmed.ncbi.nlm.nih.gov/19138736 DMJIBAW DI DMJIBAW DMJIBAW DN Budesonide DMJIBAW MI DEYWLRK DMJIBAW MN Sulfotransferase 1A1 (SULT1A1) DMJIBAW MT DME DMJIBAW MA Metabolism DMJIBAW RN Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab Dispos. 2002 May;30(5):582-5. DMJIBAW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11950791 DMODHQI DI DMODHQI DMODHQI DN Budipine DMODHQI MI TTGP7BY DMODHQI MN Monoamine oxidase type B (MAO-B) DMODHQI MT DTT DMODHQI MA Modulator DMODHQI RN Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105. DMODHQI RU https://pubmed.ncbi.nlm.nih.gov/10370904 DMG1OPF DI DMG1OPF DMG1OPF DN Buflomedil DMG1OPF MI DECB0K3 DMG1OPF MN Cytochrome P450 2D6 (CYP2D6) DMG1OPF MT DME DMG1OPF MA Metabolism DMG1OPF RN DMW/ISSX 2000 Meeting. The Drug Metabolism Workshop/International Society for the Study of Xenobiotics. St. Andrews, Scotland, June 11-16, 2000. Abstracts. Drug Metab Rev. 2000;32 Suppl 1:1-136. DMG1OPF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10909680 DMG1OPF DI DMG1OPF DMG1OPF DN Buflomedil DMG1OPF MI DEGTFWK DMG1OPF MN Mephenytoin 4-hydroxylase (CYP2C19) DMG1OPF MT DME DMG1OPF MA Metabolism DMG1OPF RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMG1OPF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMX82DO DI DMX82DO DMX82DO DN Buformin DMX82DO MI DTT79CX DMX82DO MN Organic cation transporter 1 (SLC22A1) DMX82DO MT DTP DMX82DO MA Substrate DMX82DO RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DMX82DO RU https://doi.org/10.1007/s11095-012-0935-x DMJUVE6 DI DMJUVE6 DMJUVE6 DN Bulevirtide DMJUVE6 MI TTWZRY5 DMJUVE6 MN Sodium/bile acid cotransporter (SLC10A1) DMJUVE6 MT DTT DMJUVE6 MA Inhibitor DMJUVE6 RN Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605. DMJUVE6 RU https://pubmed.ncbi.nlm.nih.gov/32926353 DMRV7H0 DI DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 MI DT3I124 DMRV7H0 MN Monocarboxylate transporter 6 (SLC16A5) DMRV7H0 MT DTP DMRV7H0 MA Substrate DMRV7H0 RN Quercetin, Morin, Luteolin, and Phloretin Are Dietary Flavonoid Inhibitors of Monocarboxylate Transporter 6. Mol Pharm. 2017 Sep 5;14(9):2930-2936. DMRV7H0 RU http://www.ncbi.nlm.nih.gov/pubmed/28513167 DMRV7H0 DI DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 MI DT0OC1Q DMRV7H0 MN Organic anion transporter 2 (SLC22A7) DMRV7H0 MT DTP DMRV7H0 MA Substrate DMRV7H0 RN Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8. DMRV7H0 RU http://www.ncbi.nlm.nih.gov/pubmed/15901346 DMRV7H0 DI DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 MI DTVP67E DMRV7H0 MN Organic anion transporter 3 (SLC22A8) DMRV7H0 MT DTP DMRV7H0 MA Substrate DMRV7H0 RN Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9. DMRV7H0 RU http://www.ncbi.nlm.nih.gov/pubmed/14610216 DMRV7H0 DI DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 MI DT06JWZ DMRV7H0 MN Organic anion transporter 4 (SLC22A11) DMRV7H0 MT DTP DMRV7H0 MA Substrate DMRV7H0 RN Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9. DMRV7H0 RU http://www.ncbi.nlm.nih.gov/pubmed/14610216 DMRV7H0 DI DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 MI TTS087L DMRV7H0 MN Solute carrier family 12 member 1 (SLC12A1) DMRV7H0 MT DTT DMRV7H0 MA Blocker DMRV7H0 RN Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. DMRV7H0 RU https://pubmed.ncbi.nlm.nih.gov/19141616 DMRV7H0 DI DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 MI DT6MDC9 DMRV7H0 MN Thiazide-sensitive sodium-chloride cotransporter (SLC12A3) DMRV7H0 MT DTP DMRV7H0 MA Substrate DMRV7H0 RN Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. DMRV7H0 RU http://www.ncbi.nlm.nih.gov/pubmed/17460608 DM4I8O7 DI DM4I8O7 DM4I8O7 DN Bunazosin DM4I8O7 MI TT34BHT DM4I8O7 MN Adrenergic receptor alpha-1D (ADRA1D) DM4I8O7 MT DTT DM4I8O7 MA Modulator DM4I8O7 RN Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56. DM4I8O7 RU https://pubmed.ncbi.nlm.nih.gov/15867947 DM4PRFC DI DM4PRFC DM4PRFC DN Bupivacaine DM4PRFC MI DECB0K3 DM4PRFC MN Cytochrome P450 2D6 (CYP2D6) DM4PRFC MT DME DM4PRFC MA Metabolism DM4PRFC RN Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5. DM4PRFC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304 DM4PRFC DI DM4PRFC DM4PRFC DN Bupivacaine DM4PRFC MI DE4LYSA DM4PRFC MN Cytochrome P450 3A4 (CYP3A4) DM4PRFC MT DME DM4PRFC MA Metabolism DM4PRFC RN Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5. DM4PRFC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304 DM4PRFC DI DM4PRFC DM4PRFC DN Bupivacaine DM4PRFC MI DEGTFWK DM4PRFC MN Mephenytoin 4-hydroxylase (CYP2C19) DM4PRFC MT DME DM4PRFC MA Metabolism DM4PRFC RN Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5. DM4PRFC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10725304 DM4PRFC DI DM4PRFC DM4PRFC DN Bupivacaine DM4PRFC MI TT90XZ8 DM4PRFC MN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM4PRFC MT DTT DM4PRFC MA Modulator DM4PRFC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PRFC RU https://www.fda.gov/ DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G MI DEZMWRE DMPRI8G MN Cytochrome P450 2C18 (CYP2C18) DMPRI8G MT DME DMPRI8G MA Metabolism DMPRI8G RN In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95. DMPRI8G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15743975 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G MI DES5XRU DMPRI8G MN Cytochrome P450 2C8 (CYP2C8) DMPRI8G MT DME DMPRI8G MA Metabolism DMPRI8G RN Buprenorphine in cancer pain. Support Care Cancer. 2005 Nov;13(11):878-87. DMPRI8G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16010532 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G MI DE5IED8 DMPRI8G MN Cytochrome P450 2C9 (CYP2C9) DMPRI8G MT DME DMPRI8G MA Metabolism DMPRI8G RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMPRI8G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G MI DECB0K3 DMPRI8G MN Cytochrome P450 2D6 (CYP2D6) DMPRI8G MT DME DMPRI8G MA Metabolism DMPRI8G RN Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull. 2005 Feb;28(2):212-6. DMPRI8G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15684471 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G MI DE4LYSA DMPRI8G MN Cytochrome P450 3A4 (CYP3A4) DMPRI8G MT DME DMPRI8G MA Metabolism DMPRI8G RN Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010 Jan-Feb;19(1):4-16. DMPRI8G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20132117 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G MI DEIBDNY DMPRI8G MN Cytochrome P450 3A5 (CYP3A5) DMPRI8G MT DME DMPRI8G MA Metabolism DMPRI8G RN Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019 Mar/Apr;13(2):93-103. DMPRI8G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30531584 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G MI DERD86B DMPRI8G MN Cytochrome P450 3A7 (CYP3A7) DMPRI8G MT DME DMPRI8G MA Metabolism DMPRI8G RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMPRI8G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G MI TTKWM86 DMPRI8G MN Opioid receptor mu (MOP) DMPRI8G MT DTT DMPRI8G MA Agonist DMPRI8G RN Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8. DMPRI8G RU https://pubmed.ncbi.nlm.nih.gov/19494155 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G MI DEYGVN4 DMPRI8G MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMPRI8G MT DME DMPRI8G MA Metabolism DMPRI8G RN Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos. 2010 Jan;38(1):40-5. DMPRI8G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19841060 DMBQEGT DI DMBQEGT DMBQEGT DN Buprenorphine + naloxone DMBQEGT MI TTKWM86 DMBQEGT MN Opioid receptor mu (MOP) DMBQEGT MT DTT DMBQEGT MA Agonist DMBQEGT RN Abstracts of Poster Presentations: CNS Summit 2013: November 14-17, 2013 Boca Raton, Florida. Innov Clin Neurosci. 2013 Nov-Dec; 10(11-12 Suppl B): 1-18. DMBQEGT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051412/ DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 MI DTI7UX6 DM5PCS7 MN Breast cancer resistance protein (ABCG2) DM5PCS7 MT DTP DM5PCS7 MA Substrate DM5PCS7 RN Role of transporter-mediated efflux in the placental biodisposition of bupropion and its metabolite, OH-bupropion. Biochem Pharmacol. 2010 Oct 1;80(7):1080-6. DM5PCS7 RU http://www.ncbi.nlm.nih.gov/pubmed/20599802 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 MI DEPKLMQ DM5PCS7 MN Cytochrome P450 2B6 (CYP2B6) DM5PCS7 MT DME DM5PCS7 MA Metabolism DM5PCS7 RN Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates. Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):123-132. DM5PCS7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30916845 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 MI DE5IED8 DM5PCS7 MN Cytochrome P450 2C9 (CYP2C9) DM5PCS7 MT DME DM5PCS7 MA Metabolism DM5PCS7 RN Product Monograph of Wellbutrin SR(Bupropion Hydrochloride). DM5PCS7 RU https://pdf.hres.ca/dpd_pm/00038603.PDF DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 MI DECB0K3 DM5PCS7 MN Cytochrome P450 2D6 (CYP2D6) DM5PCS7 MT DME DM5PCS7 MA Metabolism DM5PCS7 RN In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017 Jan 1;123:85-96. DM5PCS7 RU https://www.ncbi.nlm.nih.gov/pubmed/27836670 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 MI DEVDYN7 DM5PCS7 MN Cytochrome P450 2E1 (CYP2E1) DM5PCS7 MT DME DM5PCS7 MA Metabolism DM5PCS7 RN Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos. 2000 Oct;28(10):1222-30. DM5PCS7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10997944 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 MI TTAWNKZ DM5PCS7 MN Norepinephrine transporter (NET) DM5PCS7 MT DTT DM5PCS7 MA Inhibitor DM5PCS7 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DM5PCS7 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 MI DTUGYRD DM5PCS7 MN P-glycoprotein 1 (ABCB1) DM5PCS7 MT DTP DM5PCS7 MA Substrate DM5PCS7 RN Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231-4. DM5PCS7 RU https://doi.org/10.1248/bpb.31.231 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 MI TT3ROYC DM5PCS7 MN Serotonin transporter (SERT) DM5PCS7 MT DTT DM5PCS7 MA Inhibitor DM5PCS7 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DM5PCS7 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DMKUOQV DI DMKUOQV DMKUOQV DN Burosumab DMKUOQV MI TT2IZ4K DMKUOQV MN Fibroblast growth factor-23 (FGF23) DMKUOQV MT DTT DMKUOQV MA Modulator DMKUOQV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMKUOQV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMBS632 DI DMBS632 DMBS632 DN Buspirone DMBS632 MI TTSQIFT DMBS632 MN 5-HT 1A receptor (HTR1A) DMBS632 MT DTT DMBS632 MA Agonist DMBS632 RN Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204. DMBS632 RU https://pubmed.ncbi.nlm.nih.gov/16594259 DMBS632 DI DMBS632 DMBS632 DN Buspirone DMBS632 MI DE4OGUF DMBS632 MN Cytochrome P450 102A1 (cyp102) DMBS632 MT DME DMBS632 MA Metabolism DMBS632 RN The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98. DMBS632 RU https://pubmed.ncbi.nlm.nih.gov/17532492 DMBS632 DI DMBS632 DMBS632 DN Buspirone DMBS632 MI DECB0K3 DMBS632 MN Cytochrome P450 2D6 (CYP2D6) DMBS632 MT DME DMBS632 MA Metabolism DMBS632 RN Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. DMBS632 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15640381 DMBS632 DI DMBS632 DMBS632 DN Buspirone DMBS632 MI DE4LYSA DMBS632 MN Cytochrome P450 3A4 (CYP3A4) DMBS632 MT DME DMBS632 MA Metabolism DMBS632 RN Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):926-31. DMBS632 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17376576 DMBS632 DI DMBS632 DMBS632 DN Buspirone DMBS632 MI DEIBDNY DMBS632 MN Cytochrome P450 3A5 (CYP3A5) DMBS632 MT DME DMBS632 MA Metabolism DMBS632 RN Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7. DMBS632 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15640381 DMBS632 DI DMBS632 DMBS632 DN Buspirone DMBS632 MI DERD86B DMBS632 MN Cytochrome P450 3A7 (CYP3A7) DMBS632 MT DME DMBS632 MA Metabolism DMBS632 RN Drug Interactions Flockhart Table DMBS632 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C MI DE4LYSA DMXYJ9C MN Cytochrome P450 3A4 (CYP3A4) DMXYJ9C MT DME DMXYJ9C MA Metabolism DMXYJ9C RN Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998 Jan-Feb;18(1):84-112. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9469685 DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C MI DE4ZHS1 DMXYJ9C MN Glutathione S-transferase alpha-1 (GSTA1) DMXYJ9C MT DME DMXYJ9C MA Metabolism DMXYJ9C RN Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood. 2004 Sep 1;104(5):1574-7. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15142875 DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C MI DEH49YS DMXYJ9C MN Glutathione S-transferase alpha-2 (GSTA2) DMXYJ9C MT DME DMXYJ9C MA Metabolism DMXYJ9C RN Endothelial cells do not express GSTA1: potential relevance to busulfan-mediated endothelial damage during haematopoietic stem cell transplantation. Eur J Haematol. 2008 Apr;80(4):299-302. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18194479 DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C MI DEYZEJA DMXYJ9C MN Glutathione S-transferase mu-1 (GSTM1) DMXYJ9C MT DME DMXYJ9C MA Metabolism DMXYJ9C RN Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8886613 DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C MI DEK6079 DMXYJ9C MN Glutathione S-transferase pi (GSTP1) DMXYJ9C MT DME DMXYJ9C MA Metabolism DMXYJ9C RN Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8886613 DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C MI TTUTN1I DMXYJ9C MN Human Deoxyribonucleic acid (hDNA) DMXYJ9C MT DTT DMXYJ9C MA Modulator DMXYJ9C RN DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/15132775 DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C MI DE31KMQ DMXYJ9C MN Microsomal glutathione S-transferase 2 (MGST2) DMXYJ9C MT DME DMXYJ9C MA Metabolism DMXYJ9C RN Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest. 2005;23(1):19-25. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15779864 DMC5AST DI DMC5AST DMC5AST DN Butabarbital DMC5AST MI TT1MPAY DMC5AST MN GABA(A) receptor alpha-1 (GABRA1) DMC5AST MT DTT DMC5AST MA Antagonist DMC5AST RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMC5AST RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM584TM DI DM584TM DM584TM DN Butacaine DM584TM MI TTRK8B9 DM584TM MN Sodium channel unspecific (NaC) DM584TM MT DTT DM584TM MA Modulator DM584TM RN WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers. DM584TM RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080717&CC=WO&NR=2008085711A1&KC=A1 DM9J04X DI DM9J04X DM9J04X DN Butalbital DM9J04X MI TT1MPAY DM9J04X MN GABA(A) receptor alpha-1 (GABRA1) DM9J04X MT DTT DM9J04X MA Antagonist DM9J04X RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM9J04X RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMOJ4ZI DI DMOJ4ZI DMOJ4ZI DN Butenafine DMOJ4ZI MI TTM9XSU DMOJ4ZI MN Candida Squalene epoxidase (Candi ERG1) DMOJ4ZI MT DTT DMOJ4ZI MA Modulator DMOJ4ZI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOJ4ZI RU https://www.fda.gov/ DM7JHX0 DI DM7JHX0 DM7JHX0 DN Butethal DM7JHX0 MI TT1MPAY DM7JHX0 MN GABA(A) receptor alpha-1 (GABRA1) DM7JHX0 MT DTT DM7JHX0 MA Antagonist DM7JHX0 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7JHX0 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM8SY60 DI DM8SY60 DM8SY60 DN Butoconazole DM8SY60 MI TTTSOUD DM8SY60 MN Candida Cytochrome P450 51 (Candi ERG11) DM8SY60 MT DTT DM8SY60 MA Inhibitor DM8SY60 RN Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans. Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):31-5. DM8SY60 RU https://pubmed.ncbi.nlm.nih.gov/2184984 DM5KYPJ DI DM5KYPJ DM5KYPJ DN Butorphanol DM5KYPJ MI TT27RFC DM5KYPJ MN Opioid receptor delta (OPRD1) DM5KYPJ MT DTT DM5KYPJ MA Agonist DM5KYPJ RN Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. DM5KYPJ RU https://pubmed.ncbi.nlm.nih.gov/15942128 DMZKXB7 DI DMZKXB7 DMZKXB7 DN Butylscopolamine DMZKXB7 MI TTH18TF DMZKXB7 MN Muscarinic acetylcholine receptor M5 (CHRM5) DMZKXB7 MT DTT DMZKXB7 MA Modulator DMZKXB7 RN Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7. DMZKXB7 RU https://pubmed.ncbi.nlm.nih.gov/8036897 DMPAZHC DI DMPAZHC DMPAZHC DN Cabazitaxel DMPAZHC MI DES5XRU DMPAZHC MN Cytochrome P450 2C8 (CYP2C8) DMPAZHC MT DME DMPAZHC MA Metabolism DMPAZHC RN DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit. DMPAZHC RU https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa DMPAZHC DI DMPAZHC DMPAZHC DN Cabazitaxel DMPAZHC MI DE4LYSA DMPAZHC MN Cytochrome P450 3A4 (CYP3A4) DMPAZHC MT DME DMPAZHC MA Metabolism DMPAZHC RN DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit. DMPAZHC RU https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa DMPAZHC DI DMPAZHC DMPAZHC DN Cabazitaxel DMPAZHC MI DEIBDNY DMPAZHC MN Cytochrome P450 3A5 (CYP3A5) DMPAZHC MT DME DMPAZHC MA Metabolism DMPAZHC RN DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit. DMPAZHC RU https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa DMPAZHC DI DMPAZHC DMPAZHC DN Cabazitaxel DMPAZHC MI TTML2WA DMPAZHC MN Tubulin (TUB) DMPAZHC MT DTT DMPAZHC MA Inhibitor DMPAZHC RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMPAZHC RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMQ4HIN DI DMQ4HIN DMQ4HIN DN Cabergoline DMQ4HIN MI DE4LYSA DMQ4HIN MN Cytochrome P450 3A4 (CYP3A4) DMQ4HIN MT DME DMQ4HIN MA Metabolism DMQ4HIN RN Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. DMQ4HIN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18691132 DMQ4HIN DI DMQ4HIN DMQ4HIN DN Cabergoline DMQ4HIN MI TTEX248 DMQ4HIN MN Dopamine D2 receptor (D2R) DMQ4HIN MT DTT DMQ4HIN MA Agonist DMQ4HIN RN Role of D1 and D2 receptors in the regulation of voluntary movements. Bull Exp Biol Med. 2008 Jul;146(1):14-7. DMQ4HIN RU https://pubmed.ncbi.nlm.nih.gov/19145338 DMQ4HIN DI DMQ4HIN DMQ4HIN DN Cabergoline DMQ4HIN MI DTUGYRD DMQ4HIN MN P-glycoprotein 1 (ABCB1) DMQ4HIN MT DTP DMQ4HIN MA Substrate DMQ4HIN RN Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012 Sep;167(3):327-35. DMQ4HIN RU http://www.ncbi.nlm.nih.gov/pubmed/22672924 DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 MI DE5IED8 DMIYDT4 MN Cytochrome P450 2C9 (CYP2C9) DMIYDT4 MT DME DMIYDT4 MA Metabolism DMIYDT4 RN FDA Label of Cabozantinib. The 2020 official website of the U.S. Food and Drug Administration. DMIYDT4 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 MI DE4LYSA DMIYDT4 MN Cytochrome P450 3A4 (CYP3A4) DMIYDT4 MT DME DMIYDT4 MA Metabolism DMIYDT4 RN Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma. Onco Targets Ther. 2017 Oct 19;10:5053-5064. DMIYDT4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29089775 DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 MI TTNDSF4 DMIYDT4 MN Proto-oncogene c-Met (MET) DMIYDT4 MT DTT DMIYDT4 MA Inhibitor DMIYDT4 RN Clinical pipeline report, company report or official report of Exelixis (2011). DMIYDT4 RU http://www.exelixis.com/pipeline DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 MI TTUTJGQ DMIYDT4 MN Vascular endothelial growth factor receptor 2 (KDR) DMIYDT4 MT DTT DMIYDT4 MA Inhibitor DMIYDT4 RN Clinical pipeline report, company report or official report of Exelixis (2011). DMIYDT4 RU http://www.exelixis.com/pipeline DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI TTK25J1 DMKBJWP MN Adenosine A1 receptor (ADORA1) DMKBJWP MT DTT DMKBJWP MA Antagonist DMKBJWP RN Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. DMKBJWP RU https://pubmed.ncbi.nlm.nih.gov/15095008 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI TTM2AOE DMKBJWP MN Adenosine A2a receptor (ADORA2A) DMKBJWP MT DTT DMKBJWP MA Antagonist DMKBJWP RN Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. DMKBJWP RU https://pubmed.ncbi.nlm.nih.gov/15095008 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI DEJGDUW DMKBJWP MN Cytochrome P450 1A2 (CYP1A2) DMKBJWP MT DME DMKBJWP MA Metabolism DMKBJWP RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMKBJWP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI DE9QHP6 DMKBJWP MN Cytochrome P450 1B1 (CYP1B1) DMKBJWP MT DME DMKBJWP MA Metabolism DMKBJWP RN Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22. DMKBJWP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9152602 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI DES5XRU DMKBJWP MN Cytochrome P450 2C8 (CYP2C8) DMKBJWP MT DME DMKBJWP MA Metabolism DMKBJWP RN PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95. DMKBJWP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI DE5IED8 DMKBJWP MN Cytochrome P450 2C9 (CYP2C9) DMKBJWP MT DME DMKBJWP MA Metabolism DMKBJWP RN Monkey liver cytochrome P450 2C9 is involved in caffeine 7-N-demethylation to form theophylline. Xenobiotica. 2013 Dec;43(12):1037-42. DMKBJWP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23679834 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI DECB0K3 DMKBJWP MN Cytochrome P450 2D6 (CYP2D6) DMKBJWP MT DME DMKBJWP MA Metabolism DMKBJWP RN Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol. 1998 Jun;18(3):198-207. DMKBJWP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9617978 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI DEVDYN7 DMKBJWP MN Cytochrome P450 2E1 (CYP2E1) DMKBJWP MT DME DMKBJWP MA Metabolism DMKBJWP RN CYP2E1 active site residues in substrate recognition sequence 5 identified by photoaffinity labeling and homology modeling. Arch Biochem Biophys. 2007 Mar 1;459(1):59-69. DMKBJWP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17222385 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI DE4LYSA DMKBJWP MN Cytochrome P450 3A4 (CYP3A4) DMKBJWP MT DME DMKBJWP MA Metabolism DMKBJWP RN Effect of cytochrome P450 (CYP) inducers on caffeine metabolism in the rat. Pharmacol Rep. 2007 May-Jun;59(3):296-305. DMKBJWP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17652830 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP MI DEZV4AP DMKBJWP MN RNA cytidine acetyltransferase (hALP) DMKBJWP MT DME DMKBJWP MA Metabolism DMKBJWP RN A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41. DMKBJWP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8354022 DMQZBXI DI DMQZBXI DMQZBXI DN Calaspargase pegol DMQZBXI MI TT4WT91 DMQZBXI MN Asparaginase (ASRGL1) DMQZBXI MT DTT DMQZBXI MA Inhibitor DMQZBXI RN Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014 Dec 1;32(34):3874-82. DMQZBXI RU https://pubmed.ncbi.nlm.nih.gov/25348002 DMN4CV5 DI DMN4CV5 DMN4CV5 DN Calcidiol DMN4CV5 MI DE3FYEM DMN4CV5 MN Calcidiol 1-monooxygenase (CYP27B1) DMN4CV5 MT DME DMN4CV5 MA Metabolism DMN4CV5 RN Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta. 2011 Jan;1814(1):186-99. DMN4CV5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20619365 DMN4CV5 DI DMN4CV5 DMN4CV5 DN Calcidiol DMN4CV5 MI DEFI12S DMN4CV5 MN Vitamin D(3) 24-hydroxylase (CYP24A1) DMN4CV5 MT DME DMN4CV5 MA Metabolism DMN4CV5 RN Asthma families show transmission disequilibrium of gene variants in the vitamin D metabolism and signalling pathway. Respir Res. 2006 Apr 6;7:60. DMN4CV5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16600026 DMN4CV5 DI DMN4CV5 DMN4CV5 DN Calcidiol DMN4CV5 MI TTK59TV DMN4CV5 MN Vitamin D3 receptor (VDR) DMN4CV5 MT DTT DMN4CV5 MA Antagonist DMN4CV5 RN Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41. DMN4CV5 RU https://pubmed.ncbi.nlm.nih.gov/18525006 DM03CP7 DI DM03CP7 DM03CP7 DN Calcipotriol DM03CP7 MI TTK59TV DM03CP7 MN Vitamin D3 receptor (VDR) DM03CP7 MT DTT DM03CP7 MA Antagonist DM03CP7 RN Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59. DM03CP7 RU https://pubmed.ncbi.nlm.nih.gov/18393827 DM0N9WA DI DM0N9WA DM0N9WA DN Calcitonin Human DM0N9WA MI TTLWS2O DM0N9WA MN Calcitonin receptor (CALCR) DM0N9WA MT DTT DM0N9WA MA Modulator DM0N9WA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N9WA RU https://www.fda.gov/ DM8ZVJ7 DI DM8ZVJ7 DM8ZVJ7 DN Calcitriol DM8ZVJ7 MI DE4LYSA DM8ZVJ7 MN Cytochrome P450 3A4 (CYP3A4) DM8ZVJ7 MT DME DM8ZVJ7 MA Metabolism DM8ZVJ7 RN Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol. 2006 Jan;69(1):56-65. DM8ZVJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16207822 DM8ZVJ7 DI DM8ZVJ7 DM8ZVJ7 DN Calcitriol DM8ZVJ7 MI DELOY3P DM8ZVJ7 MN UDP-glucuronosyltransferase 1A4 (UGT1A4) DM8ZVJ7 MT DME DM8ZVJ7 MA Metabolism DM8ZVJ7 RN Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol. 2008 Mar 1;75(5):1240-50. DM8ZVJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18177842 DM8ZVJ7 DI DM8ZVJ7 DM8ZVJ7 DN Calcitriol DM8ZVJ7 MI DEFI12S DM8ZVJ7 MN Vitamin D(3) 24-hydroxylase (CYP24A1) DM8ZVJ7 MT DME DM8ZVJ7 MA Metabolism DM8ZVJ7 RN The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014 May;14(5):342-57. DM8ZVJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24705652 DM8ZVJ7 DI DM8ZVJ7 DM8ZVJ7 DN Calcitriol DM8ZVJ7 MI TTK59TV DM8ZVJ7 MN Vitamin D3 receptor (VDR) DM8ZVJ7 MT DTT DM8ZVJ7 MA Agonist DM8ZVJ7 RN Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94. DM8ZVJ7 RU https://pubmed.ncbi.nlm.nih.gov/11050002 DM3W15N DI DM3W15N DM3W15N DN Calcium carbimide DM3W15N MI TTCTAOJ DM3W15N MN Acetaldehyde dehydrogenase (ALDH) DM3W15N MT DTT DM3W15N MA Inhibitor DM3W15N RN Disulfiram and calcium carbimide. Mode of action, adverse effects and clinical use. Tidsskr Nor Laegeforen. 1990 Apr 10;110(10):1224-8. DM3W15N RU https://pubmed.ncbi.nlm.nih.gov/2185581 DM3W15N DI DM3W15N DM3W15N DN Calcium carbimide DM3W15N MI DE1XPGH DM3W15N MN Catalase (CAT) DM3W15N MT DME DM3W15N MA Metabolism DM3W15N RN Vasiliou V. and Petersen D. (2010). Comprehensive toxicology (2nd ed.). Elsevier. DM3W15N RU https://www.elsevier.com/books/comprehensive-toxicology/mcqueen/978-0-08-100601-6 DMJ3CFY DI DMJ3CFY DMJ3CFY DN Calcium phosphate dihydrate DMJ3CFY MI DTKS517 DMJ3CFY MN Sodium-dependent phosphate transport protein 2C (SLC34A3) DMJ3CFY MT DTP DMJ3CFY MA Substrate DMJ3CFY RN Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. DMJ3CFY RU http://www.ncbi.nlm.nih.gov/pubmed/23398154 DMWIO46 DI DMWIO46 DMWIO46 DN Camphor DMWIO46 MI DE9JBQK DMWIO46 MN Cytochrome P450 101D1 (cyp101) DMWIO46 MT DME DMWIO46 MA Metabolism DMWIO46 RN Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003 Nov;38(5):1250-7. DMWIO46 RU https://pubmed.ncbi.nlm.nih.gov/14578864 DMWIO46 DI DMWIO46 DMWIO46 DN Camphor DMWIO46 MI DE7HL3C DMWIO46 MN Cytochrome P450 101D2 (cyp101) DMWIO46 MT DME DMWIO46 MA Metabolism DMWIO46 RN Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology. 2003 Nov;38(5):1250-7. DMWIO46 RU https://pubmed.ncbi.nlm.nih.gov/14578864 DMWIO46 DI DMWIO46 DMWIO46 DN Camphor DMWIO46 MI DEJVYAZ DMWIO46 MN Cytochrome P450 2A6 (CYP2A6) DMWIO46 MT DME DMWIO46 MA Metabolism DMWIO46 RN In vitro metabolism of (-)-camphor using human liver microsomes and CYP2A6. Biol Pharm Bull. 2007 Feb;30(2):230-3. DMWIO46 RU https://pubmed.ncbi.nlm.nih.gov/17268056 DMFRM1I DI DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I MI DTI7UX6 DMFRM1I MN Breast cancer resistance protein (ABCG2) DMFRM1I MT DTP DMFRM1I MA Substrate DMFRM1I RN In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096. DMFRM1I RU http://www.ncbi.nlm.nih.gov/pubmed/27862160 DMFRM1I DI DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I MI DE4LYSA DMFRM1I MN Cytochrome P450 3A4 (CYP3A4) DMFRM1I MT DME DMFRM1I MA Metabolism DMFRM1I RN Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview. P T. 2015 Jul;40(7):451-62. DMFRM1I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26185406 DMFRM1I DI DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I MI DTUGYRD DMFRM1I MN P-glycoprotein 1 (ABCB1) DMFRM1I MT DTP DMFRM1I MA Substrate DMFRM1I RN In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2017 May;83(5):1082-1096. DMFRM1I RU http://www.ncbi.nlm.nih.gov/pubmed/27862160 DMFRM1I DI DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I MI TTLWPVF DMFRM1I MN Sodium/glucose cotransporter 2 (SGLT2) DMFRM1I MT DTT DMFRM1I MA Modulator DMFRM1I RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMFRM1I RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMFRM1I DI DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I MI DE85D2P DMFRM1I MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMFRM1I MT DME DMFRM1I MA Metabolism DMFRM1I RN Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28. DMFRM1I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25407255 DMFRM1I DI DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I MI DENUPDX DMFRM1I MN UDP-glucuronosyltransferase 2B4 (UGT2B4) DMFRM1I MT DME DMFRM1I MA Metabolism DMFRM1I RN Effects of rifampin, cyclosporine A, and probenecid on the pharmacokinetic profile of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Int J Clin Pharmacol Ther. 2015 Feb;53(2):115-28. DMFRM1I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25407255 DM8HLO5 DI DM8HLO5 DM8HLO5 DN Canakinumab DM8HLO5 MI TTRYK0X DM8HLO5 MN Interleukin-1 beta (IL1B) DM8HLO5 MT DTT DM8HLO5 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM8HLO5 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMRK8OT DI DMRK8OT DMRK8OT DN Candesartan DMRK8OT MI TT8DBY3 DMRK8OT MN Angiotensin II receptor type-1 (AGTR1) DMRK8OT MT DTT DMRK8OT MA Antagonist DMRK8OT RN Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. DMRK8OT RU https://pubmed.ncbi.nlm.nih.gov/19563275 DMRK8OT DI DMRK8OT DMRK8OT DN Candesartan DMRK8OT MI DEB30C5 DMRK8OT MN Carboxylesterase 1 (CES1) DMRK8OT MT DME DMRK8OT MA Metabolism DMRK8OT RN Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Drug Metab Dispos. 2013 Nov;41(11):1888-95. DMRK8OT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23946449 DMRK8OT DI DMRK8OT DMRK8OT DN Candesartan DMRK8OT MI DE5IED8 DMRK8OT MN Cytochrome P450 2C9 (CYP2C9) DMRK8OT MT DME DMRK8OT MA Metabolism DMRK8OT RN Product Monograph of Atacand. DMRK8OT RU https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/ATACAND%20-%20Product-Monograph_001.pdf DMRK8OT DI DMRK8OT DMRK8OT DN Candesartan DMRK8OT MI DE073H6 DMRK8OT MN Prostaglandin G/H synthase 1 (COX-1) DMRK8OT MT DME DMRK8OT MA Metabolism DMRK8OT RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMRK8OT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMRK8OT DI DMRK8OT DMRK8OT DN Candesartan DMRK8OT MI DEYGVN4 DMRK8OT MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMRK8OT MT DME DMRK8OT MA Metabolism DMRK8OT RN The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72. DMRK8OT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18674515 DMRK8OT DI DMRK8OT DMRK8OT DN Candesartan DMRK8OT MI DEF2WXN DMRK8OT MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMRK8OT MT DME DMRK8OT MA Metabolism DMRK8OT RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMRK8OT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMNZSC1 DI DMNZSC1 DMNZSC1 DN Candicidin DMNZSC1 MI TTQKWA4 DMNZSC1 MN Fungal Cell membrane ergosterol (Fung CME) DMNZSC1 MT DTT DMNZSC1 MA Modulator DMNZSC1 RN Mode of Action of the Polyene Antibiotic Candicidin: Binding Factors in the Wall of Candida albicans DMNZSC1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC429577 DM8JRH0 DI DM8JRH0 DM8JRH0 DN Cangrelor DM8JRH0 MI TTZ1DT0 DM8JRH0 MN P2Y purinoceptor 12 (P2RY12) DM8JRH0 MT DTT DM8JRH0 MA Antagonist DM8JRH0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328). DM8JRH0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E MI TT94IAG DM0659E MN Cannabinoid receptor (CB) DM0659E MT DTT DM0659E MA Binder DM0659E RN (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106. DM0659E RU https://pubmed.ncbi.nlm.nih.gov/12450575 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E MI DE5IED8 DM0659E MN Cytochrome P450 2C9 (CYP2C9) DM0659E MT DME DM0659E MA Metabolism DM0659E RN Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. DM0659E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E MI DECB0K3 DM0659E MN Cytochrome P450 2D6 (CYP2D6) DM0659E MT DME DM0659E MA Metabolism DM0659E RN Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95. DM0659E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E MI DE4LYSA DM0659E MN Cytochrome P450 3A4 (CYP3A4) DM0659E MT DME DM0659E MA Metabolism DM0659E RN Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. DM0659E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E MI DEIBDNY DM0659E MN Cytochrome P450 3A5 (CYP3A5) DM0659E MT DME DM0659E MA Metabolism DM0659E RN Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95. DM0659E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24160757 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E MI DEGTFWK DM0659E MN Mephenytoin 4-hydroxylase (CYP2C19) DM0659E MT DME DM0659E MA Metabolism DM0659E RN Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015 Oct;12(4):699-730. DM0659E RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26264914 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E MI DTUGYRD DM0659E MN P-glycoprotein 1 (ABCB1) DM0659E MT DTP DM0659E MA Substrate DM0659E RN KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) DM0659E RU https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665 DMBP5N3 DI DMBP5N3 DMBP5N3 DN Cantharidin DMBP5N3 MI TTFLH0E DMBP5N3 MN Serine/threonine PP1-alpha (PPP1CA) DMBP5N3 MT DTT DMBP5N3 MA Inhibitor DMBP5N3 RN Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75. DMBP5N3 RU https://pubmed.ncbi.nlm.nih.gov/11881984 DMTS85L DI DMTS85L DMTS85L DN Capecitabine DMTS85L MI TTU6BFZ DMTS85L MN Candida Thymidylate synthase (Candi TMP1) DMTS85L MT DTT DMTS85L MA Inhibitor DMTS85L RN UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. DMTS85L RU https://pubmed.ncbi.nlm.nih.gov/15709193 DMTS85L DI DMTS85L DMTS85L DN Capecitabine DMTS85L MI DEKEDRC DMTS85L MN Cytidine aminohydrolase (CDA) DMTS85L MT DME DMTS85L MA Metabolism DMTS85L RN Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. Int J Cancer. 2003 Sep 20;106(5):799-805. DMTS85L RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12866042 DMTS85L DI DMTS85L DMTS85L DN Capecitabine DMTS85L MI DE4HCYL DMTS85L MN Thymidine phosphorylase (TYMP) DMTS85L MT DME DMTS85L MA Metabolism DMTS85L RN Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45. DMTS85L RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12481438 DMPUKA7 DI DMPUKA7 DMPUKA7 DN Caplacizumab DMPUKA7 MI TT3SZBT DMPUKA7 MN von Willebrand factor (VWF) DMPUKA7 MT DTT DMPUKA7 MA Inhibitor DMPUKA7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMPUKA7 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761112s000lbl.pdf DMYCXKL DI DMYCXKL DMYCXKL DN Capmatinib DMYCXKL MI TTNDSF4 DMYCXKL MN Proto-oncogene c-Met (MET) DMYCXKL MT DTT DMYCXKL MA Modulator DMYCXKL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMYCXKL RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf DMNZBRY DI DMNZBRY DMNZBRY DN Capreomycin DMNZBRY MI TTIA0J5 DMNZBRY MN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DMNZBRY MT DTT DMNZBRY MA Binder DMNZBRY RN Interaction between the ribosomal subunits: 16S rRNA suppressors of the lethal DeltaA1916 mutation in the 23S rRNA of Escherichia coli. Mol Genet Genomics. 2007 Sep;278(3):307-15. DMNZBRY RU https://pubmed.ncbi.nlm.nih.gov/17564727 DM346QI DI DM346QI DM346QI DN Capreomycin Sulfate DM346QI MI TTIA0J5 DM346QI MN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DM346QI MT DTT DM346QI MA Modulator DM346QI RN The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome.Nat Struct Mol Biol.2010 Mar;17(3):289-93. DM346QI RU https://www.ncbi.nlm.nih.gov/pubmed/20154709 DMHERIJ DI DMHERIJ DMHERIJ DN Capromab DMHERIJ MI TT9G4N0 DMHERIJ MN Glutamate carboxypeptidase II (GCPII) DMHERIJ MT DTT DMHERIJ RN Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28. DMHERIJ RU https://pubmed.ncbi.nlm.nih.gov/17161036 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI DE6OQ3W DMGMF6V MN Cytochrome P450 1A1 (CYP1A1) DMGMF6V MT DME DMGMF6V MA Metabolism DMGMF6V RN Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49. DMGMF6V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI DEJGDUW DMGMF6V MN Cytochrome P450 1A2 (CYP1A2) DMGMF6V MT DME DMGMF6V MA Metabolism DMGMF6V RN Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49. DMGMF6V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI DEPKLMQ DMGMF6V MN Cytochrome P450 2B6 (CYP2B6) DMGMF6V MT DME DMGMF6V MA Metabolism DMGMF6V RN Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49. DMGMF6V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI DES5XRU DMGMF6V MN Cytochrome P450 2C8 (CYP2C8) DMGMF6V MT DME DMGMF6V MA Metabolism DMGMF6V RN Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49. DMGMF6V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI DE5IED8 DMGMF6V MN Cytochrome P450 2C9 (CYP2C9) DMGMF6V MT DME DMGMF6V MA Metabolism DMGMF6V RN Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49. DMGMF6V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI DECB0K3 DMGMF6V MN Cytochrome P450 2D6 (CYP2D6) DMGMF6V MT DME DMGMF6V MA Metabolism DMGMF6V RN Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49. DMGMF6V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI DEVDYN7 DMGMF6V MN Cytochrome P450 2E1 (CYP2E1) DMGMF6V MT DME DMGMF6V MA Metabolism DMGMF6V RN Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49. DMGMF6V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI DE4LYSA DMGMF6V MN Cytochrome P450 3A4 (CYP3A4) DMGMF6V MT DME DMGMF6V MA Metabolism DMGMF6V RN Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49. DMGMF6V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI DEGTFWK DMGMF6V MN Mephenytoin 4-hydroxylase (CYP2C19) DMGMF6V MT DME DMGMF6V MA Metabolism DMGMF6V RN Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells. Chem Res Toxicol. 2003 Mar;16(3):336-49. DMGMF6V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12641434 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V MI TTMI6F5 DMGMF6V MN Transient receptor potential cation channel V1 (TRPV1) DMGMF6V MT DTT DMGMF6V MA Agonist DMGMF6V RN Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71. DMGMF6V RU https://pubmed.ncbi.nlm.nih.gov/17217056 DM458UM DI DM458UM DM458UM DN Captopril DM458UM MI TTL69WB DM458UM MN Angiotensin-converting enzyme (ACE) DM458UM MT DTT DM458UM MA Inhibitor DM458UM RN Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8. DM458UM RU https://pubmed.ncbi.nlm.nih.gov/12182524 DM458UM DI DM458UM DM458UM DN Captopril DM458UM MI DECB0K3 DM458UM MN Cytochrome P450 2D6 (CYP2D6) DM458UM MT DME DM458UM MA Metabolism DM458UM RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DM458UM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DM458UM DI DM458UM DM458UM DN Captopril DM458UM MI DT9G7XN DM458UM MN Peptide transporter 1 (SLC15A1) DM458UM MT DTP DM458UM MA Substrate DM458UM RN Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36. DM458UM RU https://doi.org/10.1038/nrd3028 DM458UM DI DM458UM DM458UM DN Captopril DM458UM MI DEFQ8VO DM458UM MN Thiopurine methyltransferase (TPMT) DM458UM MT DME DM458UM MA Metabolism DM458UM RN S-methylation of captopril. Demonstration of captopril thiol methyltransferase activity in human erythrocytes and enzyme distribution in rat tissues. Biochem Pharmacol. 1983 May 15;32(10):1557-62. DM458UM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=6344869 DMX9K8F DI DMX9K8F DMX9K8F DN Carbachol DMX9K8F MI TTF4E0J DMX9K8F MN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMX9K8F MT DTT DMX9K8F MA Antagonist DMX9K8F RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DMX9K8F RU https://pubmed.ncbi.nlm.nih.gov/18633030 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI DEJGDUW DMZOLBI MN Cytochrome P450 1A2 (CYP1A2) DMZOLBI MT DME DMZOLBI MA Metabolism DMZOLBI RN Interactions between antiepileptics and second-generation antipsychotics. Expert Opin Drug Metab Toxicol. 2012 Mar;8(3):311-34. DMZOLBI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22332980 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI DEPKLMQ DMZOLBI MN Cytochrome P450 2B6 (CYP2B6) DMZOLBI MT DME DMZOLBI MA Metabolism DMZOLBI RN Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab Dispos. 2004 Mar;32(3):348-58. DMZOLBI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14977870 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI DES5XRU DMZOLBI MN Cytochrome P450 2C8 (CYP2C8) DMZOLBI MT DME DMZOLBI MA Metabolism DMZOLBI RN Potential interaction between ritonavir and carbamazepine. Pharmacotherapy. 2000 Jul;20(7):851-4. DMZOLBI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10907977 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI DE4LYSA DMZOLBI MN Cytochrome P450 3A4 (CYP3A4) DMZOLBI MT DME DMZOLBI MA Metabolism DMZOLBI RN Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11. DMZOLBI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15519127 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI DEIBDNY DMZOLBI MN Cytochrome P450 3A5 (CYP3A5) DMZOLBI MT DME DMZOLBI MA Metabolism DMZOLBI RN Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7. DMZOLBI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12673034 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI DERD86B DMZOLBI MN Cytochrome P450 3A7 (CYP3A7) DMZOLBI MT DME DMZOLBI MA Metabolism DMZOLBI RN CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids. Drug Metab Dispos. 2003 Apr;31(4):432-8. DMZOLBI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12642469 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI DELB4KP DMZOLBI MN Epoxide hydrolase 1 (EPHX1) DMZOLBI MT DME DMZOLBI MA Metabolism DMZOLBI RN Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients. Eur J Clin Pharmacol. 2005 Mar;61(1):25-34. DMZOLBI RU https://pubmed.ncbi.nlm.nih.gov/15692831 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI DTFI42L DMZOLBI MN Multidrug resistance-associated protein 2 (ABCC2) DMZOLBI MT DTP DMZOLBI MA Substrate DMZOLBI RN A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet Genomics. 2010 Apr;20(4):249-56. DMZOLBI RU http://www.ncbi.nlm.nih.gov/pubmed/20216337 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI TTRK8B9 DMZOLBI MN Sodium channel unspecific (NaC) DMZOLBI MT DTT DMZOLBI MA Modulator DMZOLBI RN Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7. DMZOLBI RU https://pubmed.ncbi.nlm.nih.gov/24319110 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI MI DEB3CV1 DMZOLBI MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMZOLBI MT DME DMZOLBI MA Metabolism DMZOLBI RN Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics. 2013 Jan;14(1):35-45. DMZOLBI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23252947 DMLEDNK DI DMLEDNK DMLEDNK DN Carbenicillin DMLEDNK MI TTJP4SM DMLEDNK MN Bacterial Penicillin binding protein (Bact PBP) DMLEDNK MT DTT DMLEDNK MA Binder DMLEDNK RN Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23. DMLEDNK RU https://pubmed.ncbi.nlm.nih.gov/2112536 DMLEDNK DI DMLEDNK DMLEDNK DN Carbenicillin DMLEDNK MI DEXB2A9 DMLEDNK MN Beta-lactamase (blaB) DMLEDNK MT DME DMLEDNK MA Metabolism DMLEDNK RN Beta-lactamase expression in Plesiomonas shigelloides. J Antimicrob Chemother. 2000 Jun;45(6):877-80. DMLEDNK RU https://pubmed.ncbi.nlm.nih.gov/10837443 DMLEDNK DI DMLEDNK DMLEDNK DN Carbenicillin DMLEDNK MI DEF01WC DMLEDNK MN Beta-lactamase (blaB) DMLEDNK MT DME DMLEDNK MA Metabolism DMLEDNK RN Beta-lactamase activity in Chromobacterium violaceum. J Infect Dis. 1976 Sep;134(3):290-3. DMLEDNK RU https://pubmed.ncbi.nlm.nih.gov/977998 DMLEDNK DI DMLEDNK DMLEDNK DN Carbenicillin DMLEDNK MI DEIU0XN DMLEDNK MN N-acylhomoserine lactone acylase (lacA) DMLEDNK MT DME DMLEDNK MA Metabolism DMLEDNK RN A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17. DMLEDNK RU https://pubmed.ncbi.nlm.nih.gov/28455333 DMLEDNK DI DMLEDNK DMLEDNK DN Carbenicillin DMLEDNK MI DE2ARDZ DMLEDNK MN PenA beta-lactamase (penA1) DMLEDNK MT DME DMLEDNK MA Metabolism DMLEDNK RN Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405. DMLEDNK RU https://pubmed.ncbi.nlm.nih.gov/9371340 DME2XG3 DI DME2XG3 DME2XG3 DN Carbenicillin Indanyl Sodium DME2XG3 MI TTJP4SM DME2XG3 MN Bacterial Penicillin binding protein (Bact PBP) DME2XG3 MT DTT DME2XG3 MA Modulator DME2XG3 RN Carbenicillin resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):255-61. DME2XG3 RU https://www.ncbi.nlm.nih.gov/pubmed/6821456 DMUSLW3 DI DMUSLW3 DMUSLW3 DN Carbetocin DMUSLW3 MI TTSCIUP DMUSLW3 MN Oxytocin receptor (OTR) DMUSLW3 MT DTT DMUSLW3 MA Agonist DMUSLW3 RN Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. DMUSLW3 RU https://pubmed.ncbi.nlm.nih.gov/18655903 DMHRG8Q DI DMHRG8Q DMHRG8Q DN Carbidopa DMHRG8Q MI TTN451K DMHRG8Q MN Aromatic-L-amino-acid decarboxylase (DDC) DMHRG8Q MT DTT DMHRG8Q MA Inhibitor DMHRG8Q RN Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. DMHRG8Q RU https://pubmed.ncbi.nlm.nih.gov/11346021 DMULAI4 DI DMULAI4 DMULAI4 DN Carbimazole DMULAI4 MI TT52XDZ DMULAI4 MN Thyroid peroxidase (TPO) DMULAI4 MT DTT DMULAI4 MA Inhibitor DMULAI4 RN Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73. DMULAI4 RU https://pubmed.ncbi.nlm.nih.gov/7952157 DMCT31R DI DMCT31R DMCT31R DN Carbinoxamine DMCT31R MI TTTIBOJ DMCT31R MN Histamine H1 receptor (H1R) DMCT31R MT DTT DMCT31R MA Antagonist DMCT31R RN Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. DMCT31R RU https://pubmed.ncbi.nlm.nih.gov/7513381 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S MI DEYZEJA DMG281S MN Glutathione S-transferase mu-1 (GSTM1) DMG281S MT DME DMG281S MA Metabolism DMG281S RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) DMG281S RU https://www.pharmgkb.org/pathway/PA150642262 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S MI DEK6079 DMG281S MN Glutathione S-transferase pi (GSTP1) DMG281S MT DME DMG281S MA Metabolism DMG281S RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) DMG281S RU https://www.pharmgkb.org/pathway/PA150642262 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S MI DE3PKUG DMG281S MN Glutathione S-transferase theta-1 (GSTT1) DMG281S MT DME DMG281S MA Metabolism DMG281S RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) DMG281S RU https://www.pharmgkb.org/pathway/PA150642262 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S MI DTP8L4F DMG281S MN High affinity copper uptake protein 1 (SLC31A1) DMG281S MT DTP DMG281S MA Substrate DMG281S RN Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61. DMG281S RU http://www.ncbi.nlm.nih.gov/pubmed/24122978 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S MI TTUTN1I DMG281S MN Human Deoxyribonucleic acid (hDNA) DMG281S MT DTT DMG281S MA Modulator DMG281S RN Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905. DMG281S RU https://www.ncbi.nlm.nih.gov/pubmed/20719935 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S MI DE5ME8A DMG281S MN Metallothionein-1A (MT1A) DMG281S MT DME DMG281S MA Metabolism DMG281S RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) DMG281S RU https://www.pharmgkb.org/pathway/PA150642262 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S MI DEFKGT7 DMG281S MN Metallothionein-2A (MT2A) DMG281S MT DME DMG281S MA Metabolism DMG281S RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) DMG281S RU https://www.pharmgkb.org/pathway/PA150642262 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S MI DEA3U9Y DMG281S MN Myeloperoxidase (MPO) DMG281S MT DME DMG281S MA Metabolism DMG281S RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) DMG281S RU https://www.pharmgkb.org/pathway/PA150642262 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S MI DENP5RY DMG281S MN Quinone reductase 1 (NQO1) DMG281S MT DME DMG281S MA Metabolism DMG281S RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) DMG281S RU https://www.pharmgkb.org/pathway/PA150642262 DMS3508 DI DMS3508 DMS3508 DN Carboprost tromethamine DMS3508 MI TTT2ZAR DMS3508 MN Prostaglandin F2-alpha receptor (PTGFR) DMS3508 MT DTT DMS3508 MA Modulator DMS3508 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS3508 RU https://www.fda.gov/ DM48K0X DI DM48K0X DM48K0X DN Carfilzomib DM48K0X MI DTUGYRD DM48K0X MN P-glycoprotein 1 (ABCB1) DM48K0X MT DTP DM48K0X MA Substrate DM48K0X RN Identification of an ABCB1 (P-glycoprotein)-positive carfilzomib-resistant myeloma subpopulation by the pluripotent stem cell fluorescent dye CDy1. Am J Hematol. 2013 Apr;88(4):265-72. DM48K0X RU http://www.ncbi.nlm.nih.gov/pubmed/23475625 DM48K0X DI DM48K0X DM48K0X DN Carfilzomib DM48K0X MI TTU7ZMG DM48K0X MN Proteasome (PS) DM48K0X MT DTT DM48K0X MA Modulator DM48K0X RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM48K0X RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMCY0TI DI DMCY0TI DMCY0TI DN Carglumic acid DMCY0TI MI TT42M75 DMCY0TI MN Carbamoyl-phosphate synthetase I (CPS1) DMCY0TI MT DTT DMCY0TI MA Activator DMCY0TI RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCY0TI RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK MI DECB0K3 DMJYDVK MN Cytochrome P450 2D6 (CYP2D6) DMJYDVK MT DME DMJYDVK MA Metabolism DMJYDVK RN Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206. DMJYDVK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23320989 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK MI DE4LYSA DMJYDVK MN Cytochrome P450 3A4 (CYP3A4) DMJYDVK MT DME DMJYDVK MA Metabolism DMJYDVK RN Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):193-206. DMJYDVK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23320989 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK MI TTEX248 DMJYDVK MN Dopamine D2 receptor (D2R) DMJYDVK MT DTT DMJYDVK MA Modulator DMJYDVK RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMJYDVK RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK MI TT4C8EA DMJYDVK MN Dopamine D3 receptor (D3R) DMJYDVK MT DTT DMJYDVK MA Modulator DMJYDVK RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMJYDVK RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMWR1JC DI DMWR1JC DMWR1JC DN Carisoprodol DMWR1JC MI DEGTFWK DMWR1JC MN Mephenytoin 4-hydroxylase (CYP2C19) DMWR1JC MT DME DMWR1JC MA Metabolism DMWR1JC RN Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003 Jul;13(7):383-8. DMWR1JC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12835613 DMHTB31 DI DMHTB31 DMHTB31 DN Carphenazine DMHTB31 MI TTEX248 DMHTB31 MN Dopamine D2 receptor (D2R) DMHTB31 MT DTT DMHTB31 MA Antagonist DMHTB31 RN Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. DMHTB31 RU https://pubmed.ncbi.nlm.nih.gov/11873706 DMHMP05 DI DMHMP05 DMHMP05 DN Carprofen DMHMP05 MI TTVKILB DMHMP05 MN Prostaglandin G/H synthase 2 (COX-2) DMHMP05 MT DTT DMHMP05 MA Inhibitor DMHMP05 RN Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91. DMHMP05 RU https://pubmed.ncbi.nlm.nih.gov/17181139 DMHMP05 DI DMHMP05 DMHMP05 DN Carprofen DMHMP05 MI DEB3CV1 DMHMP05 MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMHMP05 MT DME DMHMP05 MA Metabolism DMHMP05 RN Enantioselective inhibition of carprofen towards UDP-glucuronosyltransferase (UGT) 2B7. Chirality. 2015 Mar;27(3):189-93. DMHMP05 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25502512 DMFMDOB DI DMFMDOB DMFMDOB DN Carteolol DMFMDOB MI TTR6W5O DMFMDOB MN Adrenergic receptor beta-1 (ADRB1) DMFMDOB MT DTT DMFMDOB MA Agonist DMFMDOB RN Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92. DMFMDOB RU https://pubmed.ncbi.nlm.nih.gov/11138729 DMFMDOB DI DMFMDOB DMFMDOB DN Carteolol DMFMDOB MI DECB0K3 DMFMDOB MN Cytochrome P450 2D6 (CYP2D6) DMFMDOB MT DME DMFMDOB MA Metabolism DMFMDOB RN Involvement of CYP2D1 in the metabolism of carteolol by male rat liver microsomes. Xenobiotica. 1997 Nov;27(11):1121-9. DMFMDOB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9413916 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO MI TTG28O6 DMHTEAO MN Adrenergic receptor Alpha-1 (ADRA1) DMHTEAO MT DTT DMHTEAO MA Antagonist DMHTEAO RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DMHTEAO RU https://pubmed.ncbi.nlm.nih.gov/19491545 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO MI DEJGDUW DMHTEAO MN Cytochrome P450 1A2 (CYP1A2) DMHTEAO MT DME DMHTEAO MA Metabolism DMHTEAO RN Pharmacokinetic interactions study between carvedilol and some antidepressants in rat liver microsomes - a comparative study. Med Pharm Rep. 2019 Apr;92(2):158-164. DMHTEAO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31086844 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO MI DE5IED8 DMHTEAO MN Cytochrome P450 2C9 (CYP2C9) DMHTEAO MT DME DMHTEAO MA Metabolism DMHTEAO RN The role of CYP2C9 genetic polymorphism in carvedilol O-desmethylation in vitro. Eur J Drug Metab Pharmacokinet. 2016 Feb;41(1):79-86. DMHTEAO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25476996 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO MI DECB0K3 DMHTEAO MN Cytochrome P450 2D6 (CYP2D6) DMHTEAO MT DME DMHTEAO MA Metabolism DMHTEAO RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMHTEAO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO MI DEVDYN7 DMHTEAO MN Cytochrome P450 2E1 (CYP2E1) DMHTEAO MT DME DMHTEAO MA Metabolism DMHTEAO RN In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab Dispos. 1997 Aug;25(8):970-7. DMHTEAO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9280405 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO MI DE4LYSA DMHTEAO MN Cytochrome P450 3A4 (CYP3A4) DMHTEAO MT DME DMHTEAO MA Metabolism DMHTEAO RN Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro. Drug Des Devel Ther. 2016 Jun 8;10:1909-16. DMHTEAO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27354764 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO MI DTUGYRD DMHTEAO MN P-glycoprotein 1 (ABCB1) DMHTEAO MT DTP DMHTEAO MA Substrate DMHTEAO RN Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. DMHTEAO RU https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO MI DEYGVN4 DMHTEAO MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMHTEAO MT DME DMHTEAO MA Metabolism DMHTEAO RN Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. DMHTEAO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO MI DEB3CV1 DMHTEAO MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMHTEAO MT DME DMHTEAO MA Metabolism DMHTEAO RN Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. DMHTEAO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429 DMZPXRC DI DMZPXRC DMZPXRC DN Carzinophilin DMZPXRC MI TTY1GPO DMZPXRC MN Human Deoxyribonucleic acid major groove (hDNA maj) DMZPXRC MT DTT DMZPXRC MA Modulator DMZPXRC RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMZPXRC RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMGQIPT DI DMGQIPT DMGQIPT DN Caspofungin DMGQIPT MI TT0SFXH DMGQIPT MN Fungal 1,3-beta-glucan synthase (Fung GSC2) DMGQIPT MT DTT DMGQIPT MA Modulator DMGQIPT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQIPT RU https://www.fda.gov/ DMGQIPT DI DMGQIPT DMGQIPT DN Caspofungin DMGQIPT MI DT3D8F0 DMGQIPT MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMGQIPT MT DTP DMGQIPT MA Substrate DMGQIPT RN Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. DMGQIPT RU http://www.ncbi.nlm.nih.gov/pubmed/21245207 DMRSZA5 DI DMRSZA5 DMRSZA5 DN Cefacetrile DMRSZA5 MI TTJP4SM DMRSZA5 MN Bacterial Penicillin binding protein (Bact PBP) DMRSZA5 MT DTT DMRSZA5 MA Binder DMRSZA5 RN Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol. 2008 Sep;15(9):837-42. DMRSZA5 RU https://pubmed.ncbi.nlm.nih.gov/18665871 DMJXDGC DI DMJXDGC DMJXDGC DN Cefaclor DMJXDGC MI TTJP4SM DMJXDGC MN Bacterial Penicillin binding protein (Bact PBP) DMJXDGC MT DTT DMJXDGC MA Binder DMJXDGC RN Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. Jpn J Antibiot. 2004 Dec;57(6):465-74. DMJXDGC RU https://pubmed.ncbi.nlm.nih.gov/15747584 DMJXDGC DI DMJXDGC DMJXDGC DN Cefaclor DMJXDGC MI DTQ23VB DMJXDGC MN Organic anion transporter 1 (SLC22A6) DMJXDGC MT DTP DMJXDGC MA Substrate DMJXDGC RN FDA Drug Development and Drug Interactions DMJXDGC RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DMJXDGC DI DMJXDGC DMJXDGC DN Cefaclor DMJXDGC MI DTVP67E DMJXDGC MN Organic anion transporter 3 (SLC22A8) DMJXDGC MT DTP DMJXDGC MA Substrate DMJXDGC RN Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13. DMJXDGC RU http://www.ncbi.nlm.nih.gov/pubmed/16098483 DMJXDGC DI DMJXDGC DMJXDGC DN Cefaclor DMJXDGC MI DT9G7XN DMJXDGC MN Peptide transporter 1 (SLC15A1) DMJXDGC MT DTP DMJXDGC MA Substrate DMJXDGC RN Protein hydrolysate-induced cholecystokinin secretion from enteroendocrine cells is indirectly mediated by the intestinal oligopeptide transporter PepT1. Am J Physiol Gastrointest Liver Physiol. 2011 May;300(5):G895-902. DMJXDGC RU http://www.ncbi.nlm.nih.gov/pubmed/21311026 DMJXDGC DI DMJXDGC DMJXDGC DN Cefaclor DMJXDGC MI DT8QKNP DMJXDGC MN Peptide transporter 2 (SLC15A2) DMJXDGC MT DTP DMJXDGC MA Substrate DMJXDGC RN Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55. DMJXDGC RU http://www.ncbi.nlm.nih.gov/pubmed/16434549 DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 MI TTJP4SM DMMC345 MN Bacterial Penicillin binding protein (Bact PBP) DMMC345 MT DTT DMMC345 MA Binder DMMC345 RN Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32. DMMC345 RU https://pubmed.ncbi.nlm.nih.gov/9352657 DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 MI DTSYQGK DMMC345 MN Multidrug resistance-associated protein 1 (ABCC1) DMMC345 MT DTP DMMC345 MA Substrate DMMC345 RN Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21. DMMC345 RU http://www.ncbi.nlm.nih.gov/pubmed/22166395 DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 MI DTFI42L DMMC345 MN Multidrug resistance-associated protein 2 (ABCC2) DMMC345 MT DTP DMMC345 MA Substrate DMMC345 RN Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21. DMMC345 RU http://www.ncbi.nlm.nih.gov/pubmed/22166395 DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 MI DTQ3ZHF DMMC345 MN Multidrug resistance-associated protein 3 (ABCC3) DMMC345 MT DTP DMMC345 MA Substrate DMMC345 RN Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21. DMMC345 RU http://www.ncbi.nlm.nih.gov/pubmed/22166395 DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 MI DTCSGPB DMMC345 MN Multidrug resistance-associated protein 4 (ABCC4) DMMC345 MT DTP DMMC345 MA Substrate DMMC345 RN Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21. DMMC345 RU http://www.ncbi.nlm.nih.gov/pubmed/22166395 DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 MI DEIU0XN DMMC345 MN N-acylhomoserine lactone acylase (lacA) DMMC345 MT DME DMMC345 MA Metabolism DMMC345 RN A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17. DMMC345 RU https://pubmed.ncbi.nlm.nih.gov/28455333 DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 MI DT9G7XN DMMC345 MN Peptide transporter 1 (SLC15A1) DMMC345 MT DTP DMMC345 MA Substrate DMMC345 RN High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9. DMMC345 RU http://www.ncbi.nlm.nih.gov/pubmed/18824524 DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 MI DT8QKNP DMMC345 MN Peptide transporter 2 (SLC15A2) DMMC345 MT DTP DMMC345 MA Substrate DMMC345 RN Species Differences in Human and Rodent PEPT2-Mediated Transport of Glycylsarcosine and Cefadroxil in Pichia Pastoris Transformants. Drug Metab Dispos. 2017 Feb;45(2):130-136. DMMC345 RU http://www.ncbi.nlm.nih.gov/pubmed/27836942 DMVYSLE DI DMVYSLE DMVYSLE DN Cefalotin DMVYSLE MI DERI7LO DMVYSLE MN AmpC beta-lactamase (ampC) DMVYSLE MT DME DMVYSLE MA Metabolism DMVYSLE RN Characterization of the AmpC beta-Lactamase from Burkholderia multivorans. Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01140-18. DMVYSLE RU https://pubmed.ncbi.nlm.nih.gov/30012762 DMVYSLE DI DMVYSLE DMVYSLE DN Cefalotin DMVYSLE MI TTLP6GN DMVYSLE MN Bacterial DD-carboxypeptidase (Bact vanYB) DMVYSLE MT DTT DMVYSLE MA Inhibitor DMVYSLE RN Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40. DMVYSLE RU https://pubmed.ncbi.nlm.nih.gov/7626623 DMVYSLE DI DMVYSLE DMVYSLE DN Cefalotin DMVYSLE MI DET9I1W DMVYSLE MN Beta-lactamase (blaB) DMVYSLE MT DME DMVYSLE MA Metabolism DMVYSLE RN Purification and characterization of a new beta-lactamase from Bacteroides uniformis. Antimicrob Agents Chemother. 1995 Jul;39(7):1458-61. DMVYSLE RU https://pubmed.ncbi.nlm.nih.gov/7492085 DMVYSLE DI DMVYSLE DMVYSLE DN Cefalotin DMVYSLE MI DENJ2SQ DMVYSLE MN Beta-lactamase (blaB) DMVYSLE MT DME DMVYSLE MA Metabolism DMVYSLE RN Antibacterial activity of cefoperazone against anaerobic bacteria (author's transl). Jpn J Antibiot. 1980 Nov;33(11):1171-82. DMVYSLE RU https://pubmed.ncbi.nlm.nih.gov/6454011 DMNEXZF DI DMNEXZF DMNEXZF DN Cefamandole DMNEXZF MI TTJP4SM DMNEXZF MN Bacterial Penicillin binding protein (Bact PBP) DMNEXZF MT DTT DMNEXZF MA Binder DMNEXZF RN The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis. 1998 Jan;177(1):146-54. DMNEXZF RU https://pubmed.ncbi.nlm.nih.gov/9419181 DMNEXZF DI DMNEXZF DMNEXZF DN Cefamandole DMNEXZF MI DT9G7XN DMNEXZF MN Peptide transporter 1 (SLC15A1) DMNEXZF MT DTP DMNEXZF MA Substrate DMNEXZF RN Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61. DMNEXZF RU https://doi.org/10.1023/A:1018814627484 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI TTJP4SM DMPDYFR MN Bacterial Penicillin binding protein (Bact PBP) DMPDYFR MT DTT DMPDYFR MA Binder DMPDYFR RN Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9. DMPDYFR RU https://pubmed.ncbi.nlm.nih.gov/18218742 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI DEP0IWS DMPDYFR MN Beta-lactamase (blaB) DMPDYFR MT DME DMPDYFR MA Metabolism DMPDYFR RN Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8. DMPDYFR RU https://pubmed.ncbi.nlm.nih.gov/26505351 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI DE7IH52 DMPDYFR MN Beta-lactamase (blaB) DMPDYFR MT DME DMPDYFR MA Metabolism DMPDYFR RN Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018 Aug;51(4):565-572. DMPDYFR RU https://pubmed.ncbi.nlm.nih.gov/28711438 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI DENJ2SQ DMPDYFR MN Beta-lactamase (blaB) DMPDYFR MT DME DMPDYFR MA Metabolism DMPDYFR RN Prevalence of antimicrobial resistance genes in Bacteroides spp. and Prevotella spp. Dutch clinical isolates. Clin Microbiol Infect. 2019 Sep;25(9):1156.e9-1156.e13. DMPDYFR RU https://pubmed.ncbi.nlm.nih.gov/30802650 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI DTCSGPB DMPDYFR MN Multidrug resistance-associated protein 4 (ABCC4) DMPDYFR MT DTP DMPDYFR MA Substrate DMPDYFR RN Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21. DMPDYFR RU http://www.ncbi.nlm.nih.gov/pubmed/22166395 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI DTQ23VB DMPDYFR MN Organic anion transporter 1 (SLC22A6) DMPDYFR MT DTP DMPDYFR MA Substrate DMPDYFR RN Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7. DMPDYFR RU http://www.ncbi.nlm.nih.gov/pubmed/14984259 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI DTVP67E DMPDYFR MN Organic anion transporter 3 (SLC22A8) DMPDYFR MT DTP DMPDYFR MA Substrate DMPDYFR RN Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7. DMPDYFR RU http://www.ncbi.nlm.nih.gov/pubmed/14984259 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI DT3D8F0 DMPDYFR MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMPDYFR MT DTP DMPDYFR MA Substrate DMPDYFR RN Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. DMPDYFR RU http://www.ncbi.nlm.nih.gov/pubmed/21245207 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI DT9G7XN DMPDYFR MN Peptide transporter 1 (SLC15A1) DMPDYFR MT DTP DMPDYFR MA Substrate DMPDYFR RN Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9. DMPDYFR RU http://www.ncbi.nlm.nih.gov/pubmed/15974593 DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR MI DEFQ8VO DMPDYFR MN Thiopurine methyltransferase (TPMT) DMPDYFR MT DME DMPDYFR MA Metabolism DMPDYFR RN Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8. DMPDYFR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12228189 DMJ7A0H DI DMJ7A0H DMJ7A0H DN Cefdinir DMJ7A0H MI TTJP4SM DMJ7A0H MN Bacterial Penicillin binding protein (Bact PBP) DMJ7A0H MT DTT DMJ7A0H MA Binder DMJ7A0H RN Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60. DMJ7A0H RU https://pubmed.ncbi.nlm.nih.gov/17540669 DMJ7A0H DI DMJ7A0H DMJ7A0H DN Cefdinir DMJ7A0H MI DTVP67E DMJ7A0H MN Organic anion transporter 3 (SLC22A8) DMJ7A0H MT DTP DMJ7A0H MA Substrate DMJ7A0H RN Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13. DMJ7A0H RU http://www.ncbi.nlm.nih.gov/pubmed/16098483 DMJ7A0H DI DMJ7A0H DMJ7A0H DN Cefdinir DMJ7A0H MI DT9G7XN DMJ7A0H MN Peptide transporter 1 (SLC15A1) DMJ7A0H MT DTP DMJ7A0H MA Substrate DMJ7A0H RN Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov Today. 2004 Aug 15;9(16):712-20. DMJ7A0H RU https://doi.org/10.1016/S1359-6446(04)03198-8 DMSUVM1 DI DMSUVM1 DMSUVM1 DN Cefditoren DMSUVM1 MI TTJP4SM DMSUVM1 MN Bacterial Penicillin binding protein (Bact PBP) DMSUVM1 MT DTT DMSUVM1 MA Binder DMSUVM1 RN Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial ... Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7. DMSUVM1 RU https://pubmed.ncbi.nlm.nih.gov/17724158 DMSUVM1 DI DMSUVM1 DMSUVM1 DN Cefditoren DMSUVM1 MI DT3D8F0 DMSUVM1 MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMSUVM1 MT DTP DMSUVM1 MA Substrate DMSUVM1 RN Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. DMSUVM1 RU http://www.ncbi.nlm.nih.gov/pubmed/21245207 DMHVWIK DI DMHVWIK DMHVWIK DN Cefepime DMHVWIK MI TTHWB7G DMHVWIK MN Bacterial Penicillin binding protein 2 (Bact mrdA) DMHVWIK MT DTT DMHVWIK MA Modulator DMHVWIK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHVWIK RU https://www.fda.gov/ DMY60I8 DI DMY60I8 DMY60I8 DN Cefixime DMY60I8 MI TTJP4SM DMY60I8 MN Bacterial Penicillin binding protein (Bact PBP) DMY60I8 MT DTT DMY60I8 MA Binder DMY60I8 RN Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51. DMY60I8 RU https://pubmed.ncbi.nlm.nih.gov/19528266 DMY60I8 DI DMY60I8 DMY60I8 DN Cefixime DMY60I8 MI DT9G7XN DMY60I8 MN Peptide transporter 1 (SLC15A1) DMY60I8 MT DTP DMY60I8 MA Substrate DMY60I8 RN Flavonoids with epidermal growth factor-receptor tyrosine kinase inhibitory activity stimulate PEPT1-mediated cefixime uptake into human intestinal epithelial cells. J Pharmacol Exp Ther. 2001 Oct;299(1):351-7. DMY60I8 RU http://www.ncbi.nlm.nih.gov/pubmed/11561098 DMY60I8 DI DMY60I8 DMY60I8 DN Cefixime DMY60I8 MI DT8QKNP DMY60I8 MN Peptide transporter 2 (SLC15A2) DMY60I8 MT DTP DMY60I8 MA Substrate DMY60I8 RN Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. DMY60I8 RU http://www.ncbi.nlm.nih.gov/pubmed/16597710 DMPLY7B DI DMPLY7B DMPLY7B DN Cefmenoxime DMPLY7B MI TT85JMW DMPLY7B MN Bacterial Penicillin binding protein 3 (Bact mrcA) DMPLY7B MT DTT DMPLY7B MA Binder DMPLY7B RN In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701. DMPLY7B RU https://pubmed.ncbi.nlm.nih.gov/3134847 DM42W1B DI DM42W1B DM42W1B DN Cefmetazole DM42W1B MI TT85JMW DM42W1B MN Bacterial Penicillin binding protein 3 (Bact mrcA) DM42W1B MT DTT DM42W1B MA Binder DM42W1B RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DM42W1B RU https://pubmed.ncbi.nlm.nih.gov/9841767 DM42W1B DI DM42W1B DM42W1B DN Cefmetazole DM42W1B MI DT9C1TS DM42W1B MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DM42W1B MT DTP DM42W1B MA Substrate DM42W1B RN Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95. DM42W1B RU http://www.ncbi.nlm.nih.gov/pubmed/21372390 DM42W1B DI DM42W1B DM42W1B DN Cefmetazole DM42W1B MI DT9G7XN DM42W1B MN Peptide transporter 1 (SLC15A1) DM42W1B MT DTP DM42W1B MA Substrate DM42W1B RN Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61. DM42W1B RU https://doi.org/10.1023/A:1018814627484 DMORSGU DI DMORSGU DMORSGU DN Cefodizime DMORSGU MI DTFI42L DMORSGU MN Multidrug resistance-associated protein 2 (ABCC2) DMORSGU MT DTP DMORSGU MA Substrate DMORSGU RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMORSGU RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMTX2BH DI DMTX2BH DMTX2BH DN Cefonicid DMTX2BH MI TTJP4SM DMTX2BH MN Bacterial Penicillin binding protein (Bact PBP) DMTX2BH MT DTT DMTX2BH MA Binder DMTX2BH RN Affinity of cefonicid, a long-acting cephalosporin, for the penicillin-binding proteins of Escherichia coli K-12. J Antibiot (Tokyo). 1984 May;37(5):572-6. DMTX2BH RU https://pubmed.ncbi.nlm.nih.gov/6376452 DM53PV8 DI DM53PV8 DM53PV8 DN Cefoperazone DM53PV8 MI TTJP4SM DM53PV8 MN Bacterial Penicillin binding protein (Bact PBP) DM53PV8 MT DTT DM53PV8 MA Binder DM53PV8 RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DM53PV8 RU https://pubmed.ncbi.nlm.nih.gov/9841767 DM53PV8 DI DM53PV8 DM53PV8 DN Cefoperazone DM53PV8 MI DT3D8F0 DM53PV8 MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DM53PV8 MT DTP DM53PV8 MA Substrate DM53PV8 RN Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. DM53PV8 RU http://www.ncbi.nlm.nih.gov/pubmed/21245207 DM53PV8 DI DM53PV8 DM53PV8 DN Cefoperazone DM53PV8 MI DT9C1TS DM53PV8 MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DM53PV8 MT DTP DM53PV8 MA Substrate DM53PV8 RN Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95. DM53PV8 RU http://www.ncbi.nlm.nih.gov/pubmed/21372390 DM53PV8 DI DM53PV8 DM53PV8 DN Cefoperazone DM53PV8 MI DTUGYRD DM53PV8 MN P-glycoprotein 1 (ABCB1) DM53PV8 MT DTP DM53PV8 MA Substrate DM53PV8 RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DM53PV8 RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMSQVD6 DI DMSQVD6 DMSQVD6 DN Ceforanide DMSQVD6 MI TTJP4SM DMSQVD6 MN Bacterial Penicillin binding protein (Bact PBP) DMSQVD6 MT DTT DMSQVD6 MA Binder DMSQVD6 RN The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003 Jul 30;3:3. DMSQVD6 RU https://pubmed.ncbi.nlm.nih.gov/12890292 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DE0TCN3 DMEB837 MN Ampc beta-lactamase (ampC) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Cell wall recycling-linked coregulation of AmpC and PenB beta-lactamases through ampD mutations in Burkholderia cenocepacia. Antimicrob Agents Chemother. 2015 Dec;59(12):7602-10. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/26416862 DMMKHBJ DI DMMKHBJ DMMKHBJ DN Cefotaxime DMMKHBJ MI TTLP6GN DMMKHBJ MN Bacterial DD-carboxypeptidase (Bact vanYB) DMMKHBJ MT DTT DMMKHBJ MA Inhibitor DMMKHBJ RN Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307. DMMKHBJ RU https://pubmed.ncbi.nlm.nih.gov/17661704 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEAYSTX DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN ACI-1 beta-lactamase is widespread across human gut microbiomes in Negativicutes due to transposons harboured by tailed prophages. Environ Microbiol. 2018 Jun;20(6):2288-2300. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/30014616 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEITMS0 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN ACI-1 from Acidaminococcus fermentans: characterization of the first beta-lactamase in Anaerobic cocci. Antimicrob Agents Chemother. 2000 Nov;44(11):3144-9. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/11036038 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEP0IWS DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/26505351 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEEAL81 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN nan DMEB837 RU nan DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DE7IH52 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN nan DMEB837 RU nan DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DE5HV8P DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DE47ARF DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEHJVX4 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEG2PK9 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEWHJ7A DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN nan DMEB837 RU nan DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEU1RXB DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEMIUB2 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/17438917 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEYIEO5 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/30666031 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEVHXAU DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against beta-lactam antibiotics. J Antimicrob Chemother. 2015 Mar;70(3):701-9. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/25433011 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEZLFV5 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Cell wall recycling-linked coregulation of AmpC and PenB beta-lactamases through ampD mutations in Burkholderia cenocepacia. Antimicrob Agents Chemother. 2015 Dec;59(12):7602-10. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/26416862 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DE5AHG6 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Novel TEM-type extended-spectrum beta-lactamase, TEM-134, in a Citrobacter koseri clinical isolate. Antimicrob Agents Chemother. 2005 Apr;49(4):1564-6. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/15793140 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DEKGVS4 DMEB837 MN Beta-lactamase (blaB) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Overcoming an extremely drug resistant (XDR) pathogen: avibactam restores susceptibility to ceftazidime for Burkholderia cepacia complex isolates from cystic fibrosis patients. ACS Infect Dis. 2017 Jul 14;3(7):502-511. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/28264560 DMEB837 DI DMEB837 DMEB837 DN Cefotaxime DMEB837 MI DE2ARDZ DMEB837 MN PenA beta-lactamase (penA1) DMEB837 MT DME DMEB837 MA Metabolism DMEB837 RN Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. Antimicrob Agents Chemother. 1997 Nov;41(11):2399-405. DMEB837 RU https://pubmed.ncbi.nlm.nih.gov/9371340 DM07TX3 DI DM07TX3 DM07TX3 DN Cefotetan DM07TX3 MI TTJP4SM DM07TX3 MN Bacterial Penicillin binding protein (Bact PBP) DM07TX3 MT DTT DM07TX3 MA Binder DM07TX3 RN In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. DM07TX3 RU https://pubmed.ncbi.nlm.nih.gov/17488372 DM07TX3 DI DM07TX3 DM07TX3 DN Cefotetan DM07TX3 MI DTUGYRD DM07TX3 MN P-glycoprotein 1 (ABCB1) DM07TX3 MT DTP DM07TX3 MA Substrate DM07TX3 RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DM07TX3 RU https://doi.org/10.1007/s11095-012-0935-x DMF5HU6 DI DMF5HU6 DMF5HU6 DN Cefotiam DMF5HU6 MI TT85JMW DMF5HU6 MN Bacterial Penicillin binding protein 3 (Bact mrcA) DMF5HU6 MT DTT DMF5HU6 MA Binder DMF5HU6 RN Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis. 2006 Feb;59(1):36-41. DMF5HU6 RU https://pubmed.ncbi.nlm.nih.gov/16495632 DMF5HU6 DI DMF5HU6 DMF5HU6 DN Cefotiam DMF5HU6 MI DTVP67E DMF5HU6 MN Organic anion transporter 3 (SLC22A8) DMF5HU6 MT DTP DMF5HU6 MA Substrate DMF5HU6 RN Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. Am J Physiol Renal Physiol. 2008 Jul;295(1):F247-52. DMF5HU6 RU http://www.ncbi.nlm.nih.gov/pubmed/18480179 DMYTXVR DI DMYTXVR DMYTXVR DN Cefoxitin DMYTXVR MI TTJP4SM DMYTXVR MN Bacterial Penicillin binding protein (Bact PBP) DMYTXVR MT DTT DMYTXVR MA Binder DMYTXVR RN Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66. DMYTXVR RU https://pubmed.ncbi.nlm.nih.gov/18725435 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DEP0IWS DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Analysis of the drug-resistant characteristics of Klebsiella pneumoniae isolated from the respiratory tract and CTX-M ESBL genes. Genet Mol Res. 2015 Oct 5;14(4):12043-8. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/26505351 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DEEAL81 DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN nan DMY8NC4 RU nan DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DE7IH52 DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Citrobacter freundii bacteremia: Risk factors of mortality and prevalence of resistance genes. J Microbiol Immunol Infect. 2018 Aug;51(4):565-572. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/28711438 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DE5HV8P DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DE47ARF DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DEHJVX4 DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DEG2PK9 DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DEWHJ7A DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DEU1RXB DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Presence of the cfxA gene in Bacteroides distasonis. Res Microbiol. 2003 Jun;154(5):369-74. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/12837513 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DEMIUB2 DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Oral streptococcal strains isolated from odontogenic infections and their susceptibility to antibiotics. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):1012-5. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/17438917 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DEQAG48 DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology. J Antimicrob Chemother. 2004 Jun;53(6):1076-80. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/15128725 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DEF01WC DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Beta-lactamase activity in Chromobacterium violaceum. J Infect Dis. 1976 Sep;134(3):290-3. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/977998 DMY8NC4 DI DMY8NC4 DMY8NC4 DN Cefoxitin DMY8NC4 MI DE5AHG6 DMY8NC4 MN Beta-lactamase (blaB) DMY8NC4 MT DME DMY8NC4 MA Metabolism DMY8NC4 RN Citrobacter koseri and Citrobacter amalonaticus isolates carry highly divergent beta-lactamase genes despite having high levels of biochemical similarity and 16S rRNA sequence homology. J Antimicrob Chemother. 2004 Jun;53(6):1076-80. DMY8NC4 RU https://pubmed.ncbi.nlm.nih.gov/15128725 DMYTXVR DI DMYTXVR DMYTXVR DN Cefoxitin DMYTXVR MI DT9G7XN DMYTXVR MN Peptide transporter 1 (SLC15A1) DMYTXVR MT DTP DMYTXVR MA Substrate DMYTXVR RN Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9. DMYTXVR RU http://www.ncbi.nlm.nih.gov/pubmed/15974593 DMKBTFG DI DMKBTFG DMKBTFG DN Cefozopran DMKBTFG MI TT4ILYC DMKBTFG MN Bacterial Dihydropteroate synthetase (Bact folP) DMKBTFG MT DTT DMKBTFG MA Inhibitor DMKBTFG RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMKBTFG RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMZ2WL4 DI DMZ2WL4 DMZ2WL4 DN Cefpiramide DMZ2WL4 MI TTJP4SM DMZ2WL4 MN Bacterial Penicillin binding protein (Bact PBP) DMZ2WL4 MT DTT DMZ2WL4 MA Binder DMZ2WL4 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMZ2WL4 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMJUNY5 DI DMJUNY5 DMJUNY5 DN Cefpodoxime DMJUNY5 MI TTJP4SM DMJUNY5 MN Bacterial Penicillin binding protein (Bact PBP) DMJUNY5 MT DTT DMJUNY5 MA Binder DMJUNY5 RN Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. DMJUNY5 RU https://pubmed.ncbi.nlm.nih.gov/16940068 DMJUNY5 DI DMJUNY5 DMJUNY5 DN Cefpodoxime DMJUNY5 MI DEQAG48 DMJUNY5 MN Beta-lactamase (blaB) DMJUNY5 MT DME DMJUNY5 MA Metabolism DMJUNY5 RN Low-virulence Citrobacter species encode resistance to multiple antimicrobials. Antimicrob Agents Chemother. 2002 Nov;46(11):3555-60. DMJUNY5 RU https://pubmed.ncbi.nlm.nih.gov/12384364 DMJUNY5 DI DMJUNY5 DMJUNY5 DN Cefpodoxime DMJUNY5 MI DEEQ3RW DMJUNY5 MN Beta-lactamase (blaB) DMJUNY5 MT DME DMJUNY5 MA Metabolism DMJUNY5 RN Low-virulence Citrobacter species encode resistance to multiple antimicrobials. Antimicrob Agents Chemother. 2002 Nov;46(11):3555-60. DMJUNY5 RU https://pubmed.ncbi.nlm.nih.gov/12384364 DMJUNY5 DI DMJUNY5 DMJUNY5 DN Cefpodoxime DMJUNY5 MI DT9G7XN DMJUNY5 MN Peptide transporter 1 (SLC15A1) DMJUNY5 MT DTP DMJUNY5 MA Substrate DMJUNY5 RN Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9. DMJUNY5 RU http://www.ncbi.nlm.nih.gov/pubmed/15974593 DM7DSYP DI DM7DSYP DM7DSYP DN Cefprozil DM7DSYP MI TTJP4SM DM7DSYP MN Bacterial Penicillin binding protein (Bact PBP) DM7DSYP MT DTT DM7DSYP MA Binder DM7DSYP RN Microbiology and antimicrobial management of sinusitis. J Laryngol Otol. 2005 Apr;119(4):251-8. DM7DSYP RU https://pubmed.ncbi.nlm.nih.gov/15949076 DMUNSWV DI DMUNSWV DMUNSWV DN Cefradine DMUNSWV MI TTJP4SM DMUNSWV MN Bacterial Penicillin binding protein (Bact PBP) DMUNSWV MT DTT DMUNSWV MA Binder DMUNSWV RN Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66. DMUNSWV RU https://pubmed.ncbi.nlm.nih.gov/18725435 DMUNSWV DI DMUNSWV DMUNSWV DN Cefradine DMUNSWV MI DT9G7XN DMUNSWV MN Peptide transporter 1 (SLC15A1) DMUNSWV MT DTP DMUNSWV MA Substrate DMUNSWV RN Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol. 1997 Nov;273(5 Pt 2):F706-11. DMUNSWV RU http://www.ncbi.nlm.nih.gov/pubmed/9374833 DMUNSWV DI DMUNSWV DMUNSWV DN Cefradine DMUNSWV MI DT8QKNP DMUNSWV MN Peptide transporter 2 (SLC15A2) DMUNSWV MT DTP DMUNSWV MA Substrate DMUNSWV RN Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. DMUNSWV RU http://www.ncbi.nlm.nih.gov/pubmed/16597710 DMQXLF3 DI DMQXLF3 DMQXLF3 DN Cefsulodin DMQXLF3 MI DT9G7XN DMQXLF3 MN Peptide transporter 1 (SLC15A1) DMQXLF3 MT DTP DMQXLF3 MA Substrate DMQXLF3 RN Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61. DMQXLF3 RU https://doi.org/10.1023/A:1018814627484 DM41GRA DI DM41GRA DM41GRA DN Ceftazidime DM41GRA MI TTJP4SM DM41GRA MN Bacterial Penicillin binding protein (Bact PBP) DM41GRA MT DTT DM41GRA MA Binder DM41GRA RN New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41. DM41GRA RU https://pubmed.ncbi.nlm.nih.gov/18318877 DMWV2AG DI DMWV2AG DMWV2AG DN Ceftibuten DMWV2AG MI TTJP4SM DMWV2AG MN Bacterial Penicillin binding protein (Bact PBP) DMWV2AG MT DTT DMWV2AG MA Binder DMWV2AG RN Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91. DMWV2AG RU https://pubmed.ncbi.nlm.nih.gov/19532086 DMWV2AG DI DMWV2AG DMWV2AG DN Ceftibuten DMWV2AG MI DT9G7XN DMWV2AG MN Peptide transporter 1 (SLC15A1) DMWV2AG MT DTP DMWV2AG MA Substrate DMWV2AG RN Increased protein level of PEPT1 intestinal H+-peptide cotransporter upregulates absorption of glycylsarcosine and ceftibuten in 5/6 nephrectomized rats. Am J Physiol Gastrointest Liver Physiol. 2005 Apr;288(4):G664-70. DMWV2AG RU http://www.ncbi.nlm.nih.gov/pubmed/15528259 DMWV2AG DI DMWV2AG DMWV2AG DN Ceftibuten DMWV2AG MI DT8QKNP DMWV2AG MN Peptide transporter 2 (SLC15A2) DMWV2AG MT DTP DMWV2AG MA Substrate DMWV2AG RN Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. DMWV2AG RU http://www.ncbi.nlm.nih.gov/pubmed/16597710 DMR2SOZ DI DMR2SOZ DMR2SOZ DN Ceftiofur DMR2SOZ MI DE3FVRW DMR2SOZ MN Beta-lactamase (blaB) DMR2SOZ MT DME DMR2SOZ MA Metabolism DMR2SOZ RN The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60. DMR2SOZ RU https://pubmed.ncbi.nlm.nih.gov/4165044 DMR2SOZ DI DMR2SOZ DMR2SOZ DN Ceftiofur DMR2SOZ MI DEYM2D3 DMR2SOZ MN Beta-lactamase (blaB) DMR2SOZ MT DME DMR2SOZ MA Metabolism DMR2SOZ RN Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8. DMR2SOZ RU https://pubmed.ncbi.nlm.nih.gov/21876048 DMR2SOZ DI DMR2SOZ DMR2SOZ DN Ceftiofur DMR2SOZ MI DE9ZQ3L DMR2SOZ MN Beta-lactamase (blaB) DMR2SOZ MT DME DMR2SOZ MA Metabolism DMR2SOZ RN Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8. DMR2SOZ RU https://pubmed.ncbi.nlm.nih.gov/21876048 DMR2SOZ DI DMR2SOZ DMR2SOZ DN Ceftiofur DMR2SOZ MI DE69OXF DMR2SOZ MN Beta-lactamase (blaB) DMR2SOZ MT DME DMR2SOZ MA Metabolism DMR2SOZ RN Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8. DMR2SOZ RU https://pubmed.ncbi.nlm.nih.gov/21876048 DMR2SOZ DI DMR2SOZ DMR2SOZ DN Ceftiofur DMR2SOZ MI DEPYGS9 DMR2SOZ MN Beta-lactamase (blaB) DMR2SOZ MT DME DMR2SOZ MA Metabolism DMR2SOZ RN Bovine intestinal bacteria inactivate and degrade ceftiofur and ceftriaxone with multiple beta-lactamases. Antimicrob Agents Chemother. 2011 Nov;55(11):4990-8. DMR2SOZ RU https://pubmed.ncbi.nlm.nih.gov/21876048 DMR2SOZ DI DMR2SOZ DMR2SOZ DN Ceftiofur DMR2SOZ MI DEPGFHV DMR2SOZ MN Beta-lactamase (blaB) DMR2SOZ MT DME DMR2SOZ MA Metabolism DMR2SOZ RN Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol. 2009 Oct 20;139(1-2):89-96. DMR2SOZ RU https://pubmed.ncbi.nlm.nih.gov/19428193 DMR2SOZ DI DMR2SOZ DMR2SOZ DN Ceftiofur DMR2SOZ MI DENZLGX DMR2SOZ MN Beta-lactamase (blaB) DMR2SOZ MT DME DMR2SOZ MA Metabolism DMR2SOZ RN Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol. 2009 Oct 20;139(1-2):89-96. DMR2SOZ RU https://pubmed.ncbi.nlm.nih.gov/19428193 DMR2SOZ DI DMR2SOZ DMR2SOZ DN Ceftiofur DMR2SOZ MI DEZAQPD DMR2SOZ MN Beta-lactamase (blaB) DMR2SOZ MT DME DMR2SOZ MA Metabolism DMR2SOZ RN Isolation of bacterial strains from bovine fecal microflora capable of degradation of ceftiofur. Vet Microbiol. 2009 Oct 20;139(1-2):89-96. DMR2SOZ RU https://pubmed.ncbi.nlm.nih.gov/19428193 DM3VOGS DI DM3VOGS DM3VOGS DN Ceftizoxime DM3VOGS MI TTJP4SM DM3VOGS MN Bacterial Penicillin binding protein (Bact PBP) DM3VOGS MT DTT DM3VOGS MA Binder DM3VOGS RN Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24. DM3VOGS RU https://pubmed.ncbi.nlm.nih.gov/15716453 DM3VOGS DI DM3VOGS DM3VOGS DN Ceftizoxime DM3VOGS MI DTCSGPB DM3VOGS MN Multidrug resistance-associated protein 4 (ABCC4) DM3VOGS MT DTP DM3VOGS MA Substrate DM3VOGS RN Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos. 2012 Mar;40(3):515-21. DM3VOGS RU http://www.ncbi.nlm.nih.gov/pubmed/22166395 DM3VOGS DI DM3VOGS DM3VOGS DN Ceftizoxime DM3VOGS MI DTQ23VB DM3VOGS MN Organic anion transporter 1 (SLC22A6) DM3VOGS MT DTP DM3VOGS MA Substrate DM3VOGS RN FDA Drug Development and Drug Interactions DM3VOGS RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DM3VOGS DI DM3VOGS DM3VOGS DN Ceftizoxime DM3VOGS MI DTVP67E DM3VOGS MN Organic anion transporter 3 (SLC22A8) DM3VOGS MT DTP DM3VOGS MA Substrate DM3VOGS RN Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13. DM3VOGS RU http://www.ncbi.nlm.nih.gov/pubmed/16098483 DM9QWAH DI DM9QWAH DM9QWAH DN Ceftolozane/tazobactam DM9QWAH MI TTHI19T DM9QWAH MN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM9QWAH MT DTT DM9QWAH MA Modulator DM9QWAH RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM9QWAH RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 MI TTJP4SM DMCEW64 MN Bacterial Penicillin binding protein (Bact PBP) DMCEW64 MT DTT DMCEW64 MA Modulator DMCEW64 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMCEW64 RU https://www.fda.gov/ DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 MI DEEAL81 DMCEW64 MN Beta-lactamase (blaB) DMCEW64 MT DME DMCEW64 MA Metabolism DMCEW64 RN Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother. 1996 Sep;38(3):409-24. DMCEW64 RU https://pubmed.ncbi.nlm.nih.gov/8889716 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 MI DEYIEO5 DMCEW64 MN Beta-lactamase (blaB) DMCEW64 MT DME DMCEW64 MA Metabolism DMCEW64 RN Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130. DMCEW64 RU https://pubmed.ncbi.nlm.nih.gov/30666031 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 MI DEBKS91 DMCEW64 MN Beta-lactamase (blaB) DMCEW64 MT DME DMCEW64 MA Metabolism DMCEW64 RN Drug-resistant genes carried by Acinetobacter baumanii isolated from patients with lower respiratory tract infection. Chin Med J (Engl). 2010 Sep;123(18):2571-5. DMCEW64 RU https://pubmed.ncbi.nlm.nih.gov/21034630 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 MI DTFI42L DMCEW64 MN Multidrug resistance-associated protein 2 (ABCC2) DMCEW64 MT DTP DMCEW64 MA Substrate DMCEW64 RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMCEW64 RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 MI DT9C1TS DMCEW64 MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMCEW64 MT DTP DMCEW64 MA Substrate DMCEW64 RN Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95. DMCEW64 RU http://www.ncbi.nlm.nih.gov/pubmed/21372390 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 MI DT9G7XN DMCEW64 MN Peptide transporter 1 (SLC15A1) DMCEW64 MT DTP DMCEW64 MA Substrate DMCEW64 RN Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61. DMCEW64 RU https://doi.org/10.1023/A:1018814627484 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 MI DTUGYRD DMCEW64 MN P-glycoprotein 1 (ABCB1) DMCEW64 MT DTP DMCEW64 MA Substrate DMCEW64 RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMCEW64 RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMSIMD8 DI DMSIMD8 DMSIMD8 DN Cefuroxime DMSIMD8 MI TTJP4SM DMSIMD8 MN Bacterial Penicillin binding protein (Bact PBP) DMSIMD8 MT DTT DMSIMD8 MA Binder DMSIMD8 RN Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30. DMSIMD8 RU https://pubmed.ncbi.nlm.nih.gov/12615852 DM4CHN0 DI DM4CHN0 DM4CHN0 DN Cefuroxime axetil DM4CHN0 MI DT9G7XN DM4CHN0 MN Peptide transporter 1 (SLC15A1) DM4CHN0 MT DTP DM4CHN0 MA Substrate DM4CHN0 RN Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61. DM4CHN0 RU https://doi.org/10.1023/A:1018814627484 DM6LOQU DI DM6LOQU DM6LOQU DN Celecoxib DM6LOQU MI DES5XRU DM6LOQU MN Cytochrome P450 2C8 (CYP2C8) DM6LOQU MT DME DM6LOQU MA Metabolism DM6LOQU RN Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510. DM6LOQU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19761371 DM6LOQU DI DM6LOQU DM6LOQU DN Celecoxib DM6LOQU MI DE5IED8 DM6LOQU MN Cytochrome P450 2C9 (CYP2C9) DM6LOQU MT DME DM6LOQU MA Metabolism DM6LOQU RN Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311. DM6LOQU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15058617 DM6LOQU DI DM6LOQU DM6LOQU DN Celecoxib DM6LOQU MI DECB0K3 DM6LOQU MN Cytochrome P450 2D6 (CYP2D6) DM6LOQU MT DME DM6LOQU MA Metabolism DM6LOQU RN Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227. DM6LOQU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30219715 DM6LOQU DI DM6LOQU DM6LOQU DN Celecoxib DM6LOQU MI DE4LYSA DM6LOQU MN Cytochrome P450 3A4 (CYP3A4) DM6LOQU MT DME DM6LOQU MA Metabolism DM6LOQU RN Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9. DM6LOQU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10773015 DM6LOQU DI DM6LOQU DM6LOQU DN Celecoxib DM6LOQU MI TTVKILB DM6LOQU MN Prostaglandin G/H synthase 2 (COX-2) DM6LOQU MT DTT DM6LOQU MA Inhibitor DM6LOQU RN Pfizer. Product Development Pipeline. March 31 2009. DM6LOQU RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM6LOQU DI DM6LOQU DM6LOQU DN Celecoxib DM6LOQU MI DEYWLRK DM6LOQU MN Sulfotransferase 1A1 (SULT1A1) DM6LOQU MT DME DM6LOQU MA Metabolism DM6LOQU RN Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92. DM6LOQU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17239972 DMD5LBX DI DMD5LBX DMD5LBX DN Celiprolol HCL DMD5LBX MI TTVIREA DMD5LBX MN Adrenergic receptor (ADR) DMD5LBX MT DTT DMD5LBX MA Modulator DMD5LBX RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMD5LBX RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMD5LBX DI DMD5LBX DMD5LBX DN Celiprolol HCL DMD5LBX MI DTE2B1D DMD5LBX MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DMD5LBX MT DTP DMD5LBX MA Substrate DMD5LBX RN Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci. 2009 Jul;98(7):2529-39. DMD5LBX RU http://www.ncbi.nlm.nih.gov/pubmed/19067419 DMD5LBX DI DMD5LBX DMD5LBX DN Celiprolol HCL DMD5LBX MI DTUGYRD DMD5LBX MN P-glycoprotein 1 (ABCB1) DMD5LBX MT DTP DMD5LBX MA Substrate DMD5LBX RN Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig. 2010 Oct 19;1(5):208-11. DMD5LBX RU https://doi.org/10.1111/j.2042-7158.1996.tb05904.x DMYT2FP DI DMYT2FP DMYT2FP DN Cellulose Sodium Phosphate DMYT2FP MI TT8X5NO DMYT2FP MN Calcium (Ca) DMYT2FP MT DTT DMYT2FP MA Modulator DMYT2FP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYT2FP RU https://www.fda.gov/ DMTIUFA DI DMTIUFA DMTIUFA DN Celtura DMTIUFA MI TT3J5ZI DMTIUFA MN Cell mediated immunity response (CMIR) DMTIUFA MT DTT DMTIUFA RN A prospective observational safety study on MF59( ) adjuvanted cell culture-derived vaccine, Celtura( ) during the A/H1N1 (2009) influenza pandemic. Vaccine. 2012 Oct 5;30(45):6436-43. DMTIUFA RU https://pubmed.ncbi.nlm.nih.gov/22902681 DMKMJHE DI DMKMJHE DMKMJHE DN Cemiplimab DMKMJHE MI TTNBFWK DMKMJHE MN Programmed cell death protein 1 (PD-1) DMKMJHE MT DTT DMKMJHE MA Modulator DMKMJHE RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMKMJHE RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM8Y2RU DI DM8Y2RU DM8Y2RU DN Cenegermin DM8Y2RU MI TTEDJN4 DM8Y2RU MN Low-affinity nerve growth factor receptor (NGFR) DM8Y2RU MT DTT DM8Y2RU MA Agonist DM8Y2RU RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM8Y2RU RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMXQS7K DI DMXQS7K DMXQS7K DN Cenestin DMXQS7K MI TTZAYWL DMXQS7K MN Estrogen receptor (ESR) DMXQS7K MT DTT DMXQS7K MA Agonist DMXQS7K RN Estrogen replacement therapy and cardioprotection: mechanisms and controversies. Braz J Med Biol Res. 2002 Mar;35(3):271-6. DMXQS7K RU https://pubmed.ncbi.nlm.nih.gov/11887204 DM8KLU9 DI DM8KLU9 DM8KLU9 DN Cenobamate DM8KLU9 MI DEJVYAZ DM8KLU9 MN Cytochrome P450 2A6 (CYP2A6) DM8KLU9 MT DME DM8KLU9 MA Metabolism DM8KLU9 RN FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration. DM8KLU9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf DM8KLU9 DI DM8KLU9 DM8KLU9 DN Cenobamate DM8KLU9 MI DEPKLMQ DM8KLU9 MN Cytochrome P450 2B6 (CYP2B6) DM8KLU9 MT DME DM8KLU9 MA Metabolism DM8KLU9 RN FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration. DM8KLU9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf DM8KLU9 DI DM8KLU9 DM8KLU9 DN Cenobamate DM8KLU9 MI DEVDYN7 DM8KLU9 MN Cytochrome P450 2E1 (CYP2E1) DM8KLU9 MT DME DM8KLU9 MA Metabolism DM8KLU9 RN FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration. DM8KLU9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf DM8KLU9 DI DM8KLU9 DM8KLU9 DN Cenobamate DM8KLU9 MI DE4LYSA DM8KLU9 MN Cytochrome P450 3A4 (CYP3A4) DM8KLU9 MT DME DM8KLU9 MA Metabolism DM8KLU9 RN FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration. DM8KLU9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf DM8KLU9 DI DM8KLU9 DM8KLU9 DN Cenobamate DM8KLU9 MI DEIBDNY DM8KLU9 MN Cytochrome P450 3A5 (CYP3A5) DM8KLU9 MT DME DM8KLU9 MA Metabolism DM8KLU9 RN FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration. DM8KLU9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf DM8KLU9 DI DM8KLU9 DM8KLU9 DN Cenobamate DM8KLU9 MI DEGTFWK DM8KLU9 MN Mephenytoin 4-hydroxylase (CYP2C19) DM8KLU9 MT DME DM8KLU9 MA Metabolism DM8KLU9 RN FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration. DM8KLU9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf DM8KLU9 DI DM8KLU9 DM8KLU9 DN Cenobamate DM8KLU9 MI DEB3CV1 DM8KLU9 MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DM8KLU9 MT DME DM8KLU9 MA Metabolism DM8KLU9 RN FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration. DM8KLU9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212839s000lbl.pdf DMGOVHA DI DMGOVHA DMGOVHA DN Cenobamate DMGOVHA MI TTIG65Q DMGOVHA MN Voltage-gated sodium channel (Nav) DMGOVHA MT DTT DMGOVHA MA Inhibitor DMGOVHA RN Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182. DMGOVHA RU https://pubmed.ncbi.nlm.nih.gov/31063770 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 MI TTJP4SM DMD5JU8 MN Bacterial Penicillin binding protein (Bact PBP) DMD5JU8 MT DTT DMD5JU8 MA Binder DMD5JU8 RN Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21. DMD5JU8 RU https://pubmed.ncbi.nlm.nih.gov/14970246 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 MI DECB0K3 DMD5JU8 MN Cytochrome P450 2D6 (CYP2D6) DMD5JU8 MT DME DMD5JU8 MA Metabolism DMD5JU8 RN Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol. 2004 Sep;60(7):473-80. DMD5JU8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15289959 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 MI DE4LYSA DMD5JU8 MN Cytochrome P450 3A4 (CYP3A4) DMD5JU8 MT DME DMD5JU8 MA Metabolism DMD5JU8 RN Transport and metabolic characterization of Caco-2 cells expressing CYP3A4 and CYP3A4 plus oxidoreductase. Pharm Res. 1999 Sep;16(9):1352-9. DMD5JU8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10496649 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 MI DTZGT0P DMD5JU8 MN Multidrug and toxin extrusion protein 1 (SLC47A1) DMD5JU8 MT DTP DMD5JU8 MA Substrate DMD5JU8 RN Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6. DMD5JU8 RU http://www.ncbi.nlm.nih.gov/pubmed/20484555 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 MI DEIU0XN DMD5JU8 MN N-acylhomoserine lactone acylase (lacA) DMD5JU8 MT DME DMD5JU8 MA Metabolism DMD5JU8 RN A novel quorum-quenching N-acylhomoserine lactone acylase from Acidovorax sp. strain MR-S7 mediates antibiotic resistance. Appl Environ Microbiol. 2017 Jun 16;83(13). pii: e00080-17. DMD5JU8 RU https://pubmed.ncbi.nlm.nih.gov/28455333 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 MI DT9G7XN DMD5JU8 MN Peptide transporter 1 (SLC15A1) DMD5JU8 MT DTP DMD5JU8 MA Substrate DMD5JU8 RN Direct evidence for efficient transport and minimal metabolism of L-cephalexin by oligopeptide transporter 1 in budded baculovirus fraction. Biol Pharm Bull. 2009 Aug;32(8):1459-61. DMD5JU8 RU http://www.ncbi.nlm.nih.gov/pubmed/19652390 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 MI DT8QKNP DMD5JU8 MN Peptide transporter 2 (SLC15A2) DMD5JU8 MT DTP DMD5JU8 MA Substrate DMD5JU8 RN Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. DMD5JU8 RU http://www.ncbi.nlm.nih.gov/pubmed/16597710 DMYZITL DI DMYZITL DMYZITL DN Cephaloglycin DMYZITL MI TTJP4SM DMYZITL MN Bacterial Penicillin binding protein (Bact PBP) DMYZITL MT DTT DMYZITL MA Modulator DMYZITL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYZITL RU https://www.fda.gov/ DMYZITL DI DMYZITL DMYZITL DN Cephaloglycin DMYZITL MI DT9G7XN DMYZITL MN Peptide transporter 1 (SLC15A1) DMYZITL MT DTP DMYZITL MA Substrate DMYZITL RN Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol. 2008 May;60(5):543-85. DMYZITL RU https://doi.org/10.1211/jpp.60.5.0002 DM79XDW DI DM79XDW DM79XDW DN Cephalosporin DM79XDW MI TTLP6GN DM79XDW MN Bacterial DD-carboxypeptidase (Bact vanYB) DM79XDW MT DTT DM79XDW MA Binder DM79XDW RN A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1427-31. DM79XDW RU https://pubmed.ncbi.nlm.nih.gov/11171967 DM79XDW DI DM79XDW DM79XDW DN Cephalosporin DM79XDW MI DESIWFO DM79XDW MN Beta-lactamase (blaB) DM79XDW MT DME DM79XDW MA Metabolism DM79XDW RN EBR-1, a novel Ambler subclass B1 beta-lactamase from Empedobacter brevis. Antimicrob Agents Chemother. 2002 Oct;46(10):3223-7. DM79XDW RU https://pubmed.ncbi.nlm.nih.gov/12234848 DM51Z9E DI DM51Z9E DM51Z9E DN Cephalothin sodium DM51Z9E MI TTJP4SM DM51Z9E MN Bacterial Penicillin binding protein (Bact PBP) DM51Z9E MT DTT DM51Z9E MA Modulator DM51Z9E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM51Z9E RU https://www.fda.gov/ DM51Z9E DI DM51Z9E DM51Z9E DN Cephalothin sodium DM51Z9E MI DTI7UX6 DM51Z9E MN Breast cancer resistance protein (ABCG2) DM51Z9E MT DTP DM51Z9E MA Substrate DM51Z9E RN Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26. DM51Z9E RU https://doi.org/10.1042/BJ20040791 DMV2JNY DI DMV2JNY DMV2JNY DN Cephapirin DMV2JNY MI TTJP4SM DMV2JNY MN Bacterial Penicillin binding protein (Bact PBP) DMV2JNY MT DTT DMV2JNY MA Binder DMV2JNY RN The formation of functional penicillin-binding proteins. J Biol Chem. 1975 Aug 25;250(16):6578-85. DMV2JNY RU https://pubmed.ncbi.nlm.nih.gov/808545 DM9Y5JB DI DM9Y5JB DM9Y5JB DN Cepharanthine DM9Y5JB MI DTUGYRD DM9Y5JB MN P-glycoprotein 1 (ABCB1) DM9Y5JB MT DTP DM9Y5JB MA Substrate DM9Y5JB RN Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein. J Pharmacol Exp Ther. 1995 Oct;275(1):73-8. DM9Y5JB RU http://jpet.aspetjournals.org/content/275/1/73.long DMB920Z DI DMB920Z DMB920Z DN Ceritinib DMB920Z MI TTPMQSO DMB920Z MN ALK tyrosine kinase receptor (ALK) DMB920Z MT DTT DMB920Z MA Modulator DMB920Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397). DMB920Z RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397 DMB920Z DI DMB920Z DMB920Z DN Ceritinib DMB920Z MI DTUGYRD DMB920Z MN P-glycoprotein 1 (ABCB1) DMB920Z MT DTP DMB920Z MA Substrate DMB920Z RN P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine. 2015 Dec 12;3:54-66. DMB920Z RU http://www.ncbi.nlm.nih.gov/pubmed/26870817 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DTI7UX6 DMXCM7H MN Breast cancer resistance protein (ABCG2) DMXCM7H MT DTP DMXCM7H MA Substrate DMXCM7H RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMXCM7H RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DES5XRU DMXCM7H MN Cytochrome P450 2C8 (CYP2C8) DMXCM7H MT DME DMXCM7H MA Metabolism DMXCM7H RN Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. DMXCM7H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DE4LYSA DMXCM7H MN Cytochrome P450 3A4 (CYP3A4) DMXCM7H MT DME DMXCM7H MA Metabolism DMXCM7H RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMXCM7H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DEIBDNY DMXCM7H MN Cytochrome P450 3A5 (CYP3A5) DMXCM7H MT DME DMXCM7H MA Metabolism DMXCM7H RN Drug Interactions Flockhart Table DMXCM7H RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DERD86B DMXCM7H MN Cytochrome P450 3A7 (CYP3A7) DMXCM7H MT DME DMXCM7H MA Metabolism DMXCM7H RN Drug Interactions Flockhart Table DMXCM7H RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI TTPADOQ DMXCM7H MN HMG-CoA reductase (HMGCR) DMXCM7H MT DTT DMXCM7H MA Inhibitor DMXCM7H RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMXCM7H RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DTFI42L DMXCM7H MN Multidrug resistance-associated protein 2 (ABCC2) DMXCM7H MT DTP DMXCM7H MA Substrate DMXCM7H RN Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. DMXCM7H RU https://doi.org/10.1124/jpet.105.085589 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DT3D8F0 DMXCM7H MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMXCM7H MT DTP DMXCM7H MA Substrate DMXCM7H RN FDA Drug Development and Drug Interactions DMXCM7H RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DT9C1TS DMXCM7H MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMXCM7H MT DTP DMXCM7H MA Substrate DMXCM7H RN FDA Drug Development and Drug Interactions DMXCM7H RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DTPFTEQ DMXCM7H MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DMXCM7H MT DTP DMXCM7H MA Substrate DMXCM7H RN pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm. 2011 Aug 1;8(4):1303-13. DMXCM7H RU https://doi.org/10.1021/mp200103h DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DTUGYRD DMXCM7H MN P-glycoprotein 1 (ABCB1) DMXCM7H MT DTP DMXCM7H MA Substrate DMXCM7H RN Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. DMXCM7H RU https://doi.org/10.1124/jpet.105.085589 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DT56EKP DMXCM7H MN Sodium/taurocholate cotransporting polypeptide (SLC10A1) DMXCM7H MT DTP DMXCM7H MA Substrate DMXCM7H RN Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica. 2011 Jan;41(1):24-34. DMXCM7H RU http://www.ncbi.nlm.nih.gov/pubmed/20946088 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DEYGVN4 DMXCM7H MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMXCM7H MT DME DMXCM7H MA Metabolism DMXCM7H RN Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8. DMXCM7H RU https://www.ncbi.nlm.nih.gov/pubmed/21386754 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H MI DEF2WXN DMXCM7H MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMXCM7H MT DME DMXCM7H MA Metabolism DMXCM7H RN Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8. DMXCM7H RU https://www.ncbi.nlm.nih.gov/pubmed/21386754 DM0HAC8 DI DM0HAC8 DM0HAC8 DN Cerliponase Alfa DM0HAC8 MI TTOVYPT DM0HAC8 MN Tripeptidyl-peptidase I (TPP1) DM0HAC8 MT DTT DM0HAC8 MA Modulator DM0HAC8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0HAC8 RU https://www.fda.gov/ DM5CL9Z DI DM5CL9Z DM5CL9Z DN Certolizumab DM5CL9Z MI TTF8CQI DM5CL9Z MN Tumor necrosis factor (TNF) DM5CL9Z MT DTT DM5CL9Z MA Inhibitor DM5CL9Z RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DM5CL9Z RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMUR94J DI DMUR94J DMUR94J DN Certoparin sodium DMUR94J MI TTCIHJA DMUR94J MN Coagulation factor Xa (F10) DMUR94J MT DTT DMUR94J MA Modulator DMUR94J RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUR94J RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM6N4PR DI DM6N4PR DM6N4PR DN Cerulenin DM6N4PR MI TT7AOUD DM6N4PR MN Fatty acid synthase (FASN) DM6N4PR MT DTT DM6N4PR MA Inhibitor DM6N4PR RN Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91. DM6N4PR RU https://pubmed.ncbi.nlm.nih.gov/19382912 DM2WE5K DI DM2WE5K DM2WE5K DN Ceruletide DM2WE5K MI TTVFO0U DM2WE5K MN Gastrin/cholecystokinin type B receptor (CCKBR) DM2WE5K MT DTT DM2WE5K MA Agonist DM2WE5K RN Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8. DM2WE5K RU https://pubmed.ncbi.nlm.nih.gov/18537882 DMOMP9U DI DMOMP9U DMOMP9U DN Cetirizine DMOMP9U MI TTTIBOJ DMOMP9U MN Histamine H1 receptor (H1R) DMOMP9U MT DTT DMOMP9U MA Antagonist DMOMP9U RN Design, synthesis and histamine H1-receptor antagonistic activity of some novel 4-amino-2-(substituted)-5-(substituted) aryl-6-[(substituted aryl) amino] pyrimidines. Arzneimittelforschung. 2009;59(5):243-7. DMOMP9U RU https://pubmed.ncbi.nlm.nih.gov/19537525 DMOMP9U DI DMOMP9U DMOMP9U DN Cetirizine DMOMP9U MI DTUGYRD DMOMP9U MN P-glycoprotein 1 (ABCB1) DMOMP9U MT DTP DMOMP9U MA Substrate DMOMP9U RN Stereoselective and multiple carrier-mediated transport of cetirizine across Caco-2 cell monolayers with potential drug interaction. Chirality. 2010 Jul;22(7):684-92. DMOMP9U RU http://www.ncbi.nlm.nih.gov/pubmed/20014242 DMSP4JX DI DMSP4JX DMSP4JX DN Cetraxate DMSP4JX MI TT5L2VC DMSP4JX MN Kallikrein-related peptidase (KLK) DMSP4JX MT DTT DMSP4JX MA Modulator DMSP4JX RN A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48. DMSP4JX RU https://pubmed.ncbi.nlm.nih.gov/4261023 DMFD9Q6 DI DMFD9Q6 DMFD9Q6 DN Cetrorelix DMFD9Q6 MI TT8R70G DMFD9Q6 MN Gonadotropin-releasing hormone receptor (GNRHR) DMFD9Q6 MT DTT DMFD9Q6 MA Antagonist DMFD9Q6 RN Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33. DMFD9Q6 RU https://pubmed.ncbi.nlm.nih.gov/19301301 DMLNCE0 DI DMLNCE0 DMLNCE0 DN Cetuximab DMLNCE0 MI TTGKNB4 DMLNCE0 MN Epidermal growth factor receptor (EGFR) DMLNCE0 MT DTT DMLNCE0 RN Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14. DMLNCE0 RU https://pubmed.ncbi.nlm.nih.gov/12479268 DMWSMND DI DMWSMND DMWSMND DN Cevimeline DMWSMND MI DECB0K3 DMWSMND MN Cytochrome P450 2D6 (CYP2D6) DMWSMND MT DME DMWSMND MA Metabolism DMWSMND RN Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33. DMWSMND RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12608011 DMWSMND DI DMWSMND DMWSMND DN Cevimeline DMWSMND MI DE4LYSA DMWSMND MN Cytochrome P450 3A4 (CYP3A4) DMWSMND MT DME DMWSMND MA Metabolism DMWSMND RN Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33. DMWSMND RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12608011 DMWSMND DI DMWSMND DMWSMND DN Cevimeline DMWSMND MI TTQ13Z5 DMWSMND MN Muscarinic acetylcholine receptor M3 (CHRM3) DMWSMND MT DTT DMWSMND MA Agonist DMWSMND RN Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123. DMWSMND RU https://pubmed.ncbi.nlm.nih.gov/18450949 DMKN345 DI DMKN345 DMKN345 DN Charybdotoxin DMKN345 MI TTMNI76 DMKN345 MN Calcium-activated potassium channel (KCN) DMKN345 MT DTT DMKN345 MA Blocker DMKN345 RN Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8. DMKN345 RU https://pubmed.ncbi.nlm.nih.gov/16741254 DMQ8JIK DI DMQ8JIK DMQ8JIK DN Chenodiol DMQ8JIK MI DE4LYSA DMQ8JIK MN Cytochrome P450 3A4 (CYP3A4) DMQ8JIK MT DME DMQ8JIK MA Metabolism DMQ8JIK RN Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos. 2008 Oct;36(10):1983-91. DMQ8JIK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18583509 DMQ8JIK DI DMQ8JIK DMQ8JIK DN Chenodiol DMQ8JIK MI DETL4WB DMQ8JIK MN Cytochrome P450 8B1 (CYP8B1) DMQ8JIK MT DME DMQ8JIK MA Metabolism DMQ8JIK RN Conversion of chenodeoxycholic acid to cholic acid by human CYP8B1. Biol Chem. 2019 Apr 24;400(5):625-628. DMQ8JIK RU https://pubmed.ncbi.nlm.nih.gov/30465713 DMQ8JIK DI DMQ8JIK DMQ8JIK DN Chenodiol DMQ8JIK MI TTS4UGC DMQ8JIK MN Farnesoid X-activated receptor (FXR) DMQ8JIK MT DTT DMQ8JIK MA Modulator DMQ8JIK RN Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. DMQ8JIK RU https://pubmed.ncbi.nlm.nih.gov/12052824 DMQ8JIK DI DMQ8JIK DMQ8JIK DN Chenodiol DMQ8JIK MI DEYGVN4 DMQ8JIK MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMQ8JIK MT DME DMQ8JIK MA Metabolism DMQ8JIK RN Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology. 2006 Nov;44(5):1158-70. DMQ8JIK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17058234 DMXGJEI DI DMXGJEI DMXGJEI DN Chlophedianol DMXGJEI MI TTTIBOJ DMXGJEI MN Histamine H1 receptor (H1R) DMXGJEI MT DTT DMXGJEI MA Antagonist DMXGJEI RN Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41. DMXGJEI RU https://pubmed.ncbi.nlm.nih.gov/2905706 DMRKE63 DI DMRKE63 DMRKE63 DN Chlorambucil DMRKE63 MI TTABD5E DMRKE63 MN DNA replication (DNA repli) DMRKE63 MT DTT DMRKE63 MA Intercalator DMRKE63 RN Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23. DMRKE63 RU https://pubmed.ncbi.nlm.nih.gov/19509245 DMRKE63 DI DMRKE63 DMRKE63 DN Chlorambucil DMRKE63 MI DEK6079 DMRKE63 MN Glutathione S-transferase pi (GSTP1) DMRKE63 MT DME DMRKE63 MA Metabolism DMRKE63 RN The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol. 2008 Jun 27;380(1):131-44. DMRKE63 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18511072 DMRKE63 DI DMRKE63 DMRKE63 DN Chlorambucil DMRKE63 MI DTE2B1D DMRKE63 MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DMRKE63 MT DTP DMRKE63 MA Substrate DMRKE63 RN Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-66. DMRKE63 RU https://doi.org/10.1146/annurev.pharmtox.44.101802.121856 DMRKE63 DI DMRKE63 DMRKE63 DN Chlorambucil DMRKE63 MI DTUGYRD DMRKE63 MN P-glycoprotein 1 (ABCB1) DMRKE63 MT DTP DMRKE63 MA Substrate DMRKE63 RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMRKE63 RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT MI TTLFGBV DMFXEWT MN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMFXEWT MT DTT DMFXEWT MA Binder DMFXEWT RN Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94. DMFXEWT RU https://pubmed.ncbi.nlm.nih.gov/15554968 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT MI DE26V9J DMFXEWT MN Chloramphenicolase (chlR) DMFXEWT MT DME DMFXEWT MA Metabolism DMFXEWT RN The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60. DMFXEWT RU https://pubmed.ncbi.nlm.nih.gov/4165044 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT MI DEMUBWL DMFXEWT MN Chloramphenicolase (chlR) DMFXEWT MT DME DMFXEWT MA Metabolism DMFXEWT RN The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60. DMFXEWT RU https://pubmed.ncbi.nlm.nih.gov/4165044 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT MI DECMT89 DMFXEWT MN Chloramphenicolase (chlR) DMFXEWT MT DME DMFXEWT MA Metabolism DMFXEWT RN The bacterial degradation of chloramphenico. Lancet. 1967 Jun 10;1(7502):1259-60. DMFXEWT RU https://pubmed.ncbi.nlm.nih.gov/4165044 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT MI DEFVHQU DMFXEWT MN Glycerol-3-phosphate dehydrogenase (gpsA) DMFXEWT MT DME DMFXEWT MA Metabolism DMFXEWT RN Porcine beta-defensin 2 displays broad antimicrobial activity against pathogenic intestinal bacteria. Mol Immunol. 2008 Jan;45(2):386-94. DMFXEWT RU http://www.ncbi.nlm.nih.gov/pubmed/17658606 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT MI DEGTFWK DMFXEWT MN Mephenytoin 4-hydroxylase (CYP2C19) DMFXEWT MT DME DMFXEWT MA Metabolism DMFXEWT RN Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother. 2003 Nov;47(11):3464-9. DMFXEWT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14576103 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT MI DTUGYRD DMFXEWT MN P-glycoprotein 1 (ABCB1) DMFXEWT MT DTP DMFXEWT MA Substrate DMFXEWT RN Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. J Pharm Sci. 2018 Apr;107(4):1178-1184. DMFXEWT RU http://www.ncbi.nlm.nih.gov/pubmed/29221992 DMTN5XI DI DMTN5XI DMTN5XI DN Chlordiazepoxide DMTN5XI MI TTPTXIN DMTN5XI MN Translocator protein (TSPO) DMTN5XI MT DTT DMTN5XI MA Modulator DMTN5XI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTN5XI RU https://www.fda.gov/ DMQ9MVG DI DMQ9MVG DMQ9MVG DN Chlorhexidine DMQ9MVG MI TT4ILYC DMQ9MVG MN Bacterial Dihydropteroate synthetase (Bact folP) DMQ9MVG MT DTT DMQ9MVG MA Breaker DMQ9MVG RN The mechanism of action of chlorhexidine. FEMS Microbiol Lett. 1992 Dec 15;79(1-3):211-5. DMQ9MVG RU https://pubmed.ncbi.nlm.nih.gov/1335944 DMSF4PR DI DMSF4PR DMSF4PR DN Chlormerodrin DMSF4PR MI TTJUWVB DMSF4PR MN Succinate-semialdehyde dehydrogenase (ALDH5A1) DMSF4PR MT DTT DMSF4PR MA Modulator DMSF4PR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSF4PR RU https://www.fda.gov/ DMTWUXR DI DMTWUXR DMTWUXR DN Chlormezanone DMTWUXR MI TTPTXIN DMTWUXR MN Translocator protein (TSPO) DMTWUXR MT DTT DMTWUXR MA Agonist DMTWUXR RN Successful treatment of anxiety with a single night-time dose of chlormezanone: double-blind comparison with diazepam. Curr Med Res Opin. 1982;8(1):33-8. DMTWUXR RU https://pubmed.ncbi.nlm.nih.gov/7105820 DMSOQK1 DI DMSOQK1 DMSOQK1 DN Chloroprocaine DMSOQK1 MI TTWK8D0 DMSOQK1 MN Sodium pump subunit alpha-1 (ATP1A1) DMSOQK1 MT DTT DMSOQK1 MA Blocker DMSOQK1 RN Inhibition of the Na,K-ATPase of canine renal medulla by several local anesthetics. Pharmacol Res. 2001 Apr;43(4):399-403. DMSOQK1 RU https://pubmed.ncbi.nlm.nih.gov/11352545 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB MI DE6OQ3W DMSI5CB MN Cytochrome P450 1A1 (CYP1A1) DMSI5CB MT DME DMSI5CB MA Metabolism DMSI5CB RN In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003 Jun;31(6):748-54. DMSI5CB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12756207 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB MI DES5XRU DMSI5CB MN Cytochrome P450 2C8 (CYP2C8) DMSI5CB MT DME DMSI5CB MA Metabolism DMSI5CB RN Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health. 2005 Dec;10(12):1271-3. DMSI5CB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16359408 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB MI DECB0K3 DMSI5CB MN Cytochrome P450 2D6 (CYP2D6) DMSI5CB MT DME DMSI5CB MA Metabolism DMSI5CB RN Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br J Clin Pharmacol. 1998 Mar;45(3):315-7. DMSI5CB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10896408 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB MI DE4LYSA DMSI5CB MN Cytochrome P450 3A4 (CYP3A4) DMSI5CB MT DME DMSI5CB MA Metabolism DMSI5CB RN Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7. DMSI5CB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12967198 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB MI DEIBDNY DMSI5CB MN Cytochrome P450 3A5 (CYP3A5) DMSI5CB MT DME DMSI5CB MA Metabolism DMSI5CB RN Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7. DMSI5CB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12967198 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB MI TTKY2NS DMSI5CB MN Duffy antigen chemokine receptor (ACKR1) DMSI5CB MT DTT DMSI5CB MA Modulator DMSI5CB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSI5CB RU https://www.fda.gov/ DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB MI DTZGT0P DMSI5CB MN Multidrug and toxin extrusion protein 1 (SLC47A1) DMSI5CB MT DTP DMSI5CB MA Substrate DMSI5CB RN Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8. DMSI5CB RU http://www.ncbi.nlm.nih.gov/pubmed/21518836 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB MI DTUGYRD DMSI5CB MN P-glycoprotein 1 (ABCB1) DMSI5CB MT DTP DMSI5CB MA Substrate DMSI5CB RN Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. DMSI5CB RU https://doi.org/10.1016/j.addr.2011.12.008 DMLHESP DI DMLHESP DMLHESP DN Chlorothiazide DMLHESP MI DTI7UX6 DMLHESP MN Breast cancer resistance protein (ABCG2) DMLHESP MT DTP DMLHESP MA Substrate DMLHESP RN ABCG2 modulates chlorothiazide permeability--in vitro-characterization of its interactions. Drug Metab Pharmacokinet. 2012;27(3):349-53. DMLHESP RU https://doi.org/10.2133/dmpk.DMPK-11-NT-068 DMLHESP DI DMLHESP DMLHESP DN Chlorothiazide DMLHESP MI TTANPDJ DMLHESP MN Carbonic anhydrase II (CA-II) DMLHESP MT DTT DMLHESP MA Inhibitor DMLHESP RN Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8. DMLHESP RU https://pubmed.ncbi.nlm.nih.gov/10731484 DMLHESP DI DMLHESP DMLHESP DN Chlorothiazide DMLHESP MI DTVP67E DMLHESP MN Organic anion transporter 3 (SLC22A8) DMLHESP MT DTP DMLHESP MA Substrate DMLHESP RN Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol. 2008 Apr;294(4):F867-73. DMLHESP RU http://www.ncbi.nlm.nih.gov/pubmed/18216144 DMFZBMQ DI DMFZBMQ DMFZBMQ DN Chloroxine DMFZBMQ MI TTQW87Y DMFZBMQ MN Opioid receptor kappa (OPRK1) DMFZBMQ MT DTT DMFZBMQ MA Inhibitor DMFZBMQ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMFZBMQ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM5URA2 DI DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 MI DECB0K3 DM5URA2 MN Cytochrome P450 2D6 (CYP2D6) DM5URA2 MT DME DM5URA2 MA Metabolism DM5URA2 RN The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25. DM5URA2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058 DM5URA2 DI DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 MI DE4LYSA DM5URA2 MN Cytochrome P450 3A4 (CYP3A4) DM5URA2 MT DME DM5URA2 MA Metabolism DM5URA2 RN Drug Interactions Flockhart Table DM5URA2 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM5URA2 DI DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 MI DEIBDNY DM5URA2 MN Cytochrome P450 3A5 (CYP3A5) DM5URA2 MT DME DM5URA2 MA Metabolism DM5URA2 RN Drug Interactions Flockhart Table DM5URA2 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM5URA2 DI DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 MI DERD86B DM5URA2 MN Cytochrome P450 3A7 (CYP3A7) DM5URA2 MT DME DM5URA2 MA Metabolism DM5URA2 RN Drug Interactions Flockhart Table DM5URA2 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM5URA2 DI DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 MI TTTIBOJ DM5URA2 MN Histamine H1 receptor (H1R) DM5URA2 MT DTT DM5URA2 MA Antagonist DM5URA2 RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM5URA2 RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM5URA2 DI DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 MI DTSYQGK DM5URA2 MN Multidrug resistance-associated protein 1 (ABCC1) DM5URA2 MT DTP DM5URA2 MA Substrate DM5URA2 RN Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci. 2005 Mar;94(3):613-24. DM5URA2 RU http://www.ncbi.nlm.nih.gov/pubmed/15666293 DMQRPOS DI DMQRPOS DMQRPOS DN Chlorphentermine hydrochloride DMQRPOS MI TT3ROYC DMQRPOS MN Serotonin transporter (SERT) DMQRPOS MT DTT DMQRPOS MA Modulator DMQRPOS RN Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates.Implications for primary pulmonary hypertension.Circulation.1999 Aug 24;100(8):869-75. DMQRPOS RU https://www.ncbi.nlm.nih.gov/pubmed/10458725 DM1IFGT DI DM1IFGT DM1IFGT DN Chlorproguanil DM1IFGT MI TT9SL3Q DM1IFGT MN Polypeptide deformylase (PDF) DM1IFGT MT DTT DM1IFGT MA Inhibitor DM1IFGT RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM1IFGT RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMBGZI3 DI DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 MI DEJGDUW DMBGZI3 MN Cytochrome P450 1A2 (CYP1A2) DMBGZI3 MT DME DMBGZI3 MA Metabolism DMBGZI3 RN Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1297-302. DMBGZI3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17611010 DMBGZI3 DI DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 MI DECB0K3 DMBGZI3 MN Cytochrome P450 2D6 (CYP2D6) DMBGZI3 MT DME DMBGZI3 MA Metabolism DMBGZI3 RN Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. DMBGZI3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16910628 DMBGZI3 DI DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 MI DE4LYSA DMBGZI3 MN Cytochrome P450 3A4 (CYP3A4) DMBGZI3 MT DME DMBGZI3 MA Metabolism DMBGZI3 RN Effect of classic and atypical neuroleptics on cytochrome P450 3A (CYP3A) in rat liver. Pharmacol Rep. 2012;64(6):1411-8. DMBGZI3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23406751 DMBGZI3 DI DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 MI DEIZLTN DMBGZI3 MN Docosahexaenoic acid omega-hydroxylase (CYP4F11) DMBGZI3 MT DME DMBGZI3 MA Metabolism DMBGZI3 RN Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304. DMBGZI3 RU https://pubmed.ncbi.nlm.nih.gov/15364545 DMBGZI3 DI DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 MI TTEX248 DMBGZI3 MN Dopamine D2 receptor (D2R) DMBGZI3 MT DTT DMBGZI3 MA Antagonist DMBGZI3 RN Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3. DMBGZI3 RU https://pubmed.ncbi.nlm.nih.gov/19374860 DMBGZI3 DI DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 MI DTUGYRD DMBGZI3 MN P-glycoprotein 1 (ABCB1) DMBGZI3 MT DTP DMBGZI3 MA Substrate DMBGZI3 RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMBGZI3 RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMPHZQE DI DMPHZQE DMPHZQE DN Chlorpropamide DMPHZQE MI DE5IED8 DMPHZQE MN Cytochrome P450 2C9 (CYP2C9) DMPHZQE MT DME DMPHZQE MA Metabolism DMPHZQE RN Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63. DMPHZQE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15842554 DMPHZQE DI DMPHZQE DMPHZQE DN Chlorpropamide DMPHZQE MI TTG140O DMPHZQE MN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMPHZQE MT DTT DMPHZQE MA Blocker DMPHZQE RN Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53. DMPHZQE RU https://pubmed.ncbi.nlm.nih.gov/14998554 DMPHZQE DI DMPHZQE DMPHZQE DN Chlorpropamide DMPHZQE MI DEGTFWK DMPHZQE MN Mephenytoin 4-hydroxylase (CYP2C19) DMPHZQE MT DME DMPHZQE MA Metabolism DMPHZQE RN Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol. 2005 May;59(5):552-63. DMPHZQE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15842554 DMY0KGJ DI DMY0KGJ DMY0KGJ DN Chlorprothixene DMY0KGJ MI TTEX248 DMY0KGJ MN Dopamine D2 receptor (D2R) DMY0KGJ MT DTT DMY0KGJ MA Antagonist DMY0KGJ RN Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42. DMY0KGJ RU https://pubmed.ncbi.nlm.nih.gov/19091563 DM4DMBT DI DM4DMBT DM4DMBT DN Chlorthalidone DM4DMBT MI TTS087L DM4DMBT MN Solute carrier family 12 member 1 (SLC12A1) DM4DMBT MT DTT DM4DMBT MA Blocker DM4DMBT RN The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52. DM4DMBT RU https://pubmed.ncbi.nlm.nih.gov/15134800 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT MI TTMNI76 DMCYVDT MN Calcium-activated potassium channel (KCN) DMCYVDT MT DTT DMCYVDT MA Activator DMCYVDT RN Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. DMCYVDT RU https://pubmed.ncbi.nlm.nih.gov/16859676 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT MI DE4OGUF DMCYVDT MN Cytochrome P450 102A1 (cyp102) DMCYVDT MT DME DMCYVDT MA Metabolism DMCYVDT RN Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23. DMCYVDT RU https://pubmed.ncbi.nlm.nih.gov/17235582 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT MI DEJGDUW DMCYVDT MN Cytochrome P450 1A2 (CYP1A2) DMCYVDT MT DME DMCYVDT MA Metabolism DMCYVDT RN Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver. Pharmacogenetics. 1998 Oct;8(5):375-82. DMCYVDT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9825829 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT MI DEJVYAZ DMCYVDT MN Cytochrome P450 2A6 (CYP2A6) DMCYVDT MT DME DMCYVDT MA Metabolism DMCYVDT RN Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80. DMCYVDT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10534312 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT MI DECB0K3 DMCYVDT MN Cytochrome P450 2D6 (CYP2D6) DMCYVDT MT DME DMCYVDT MA Metabolism DMCYVDT RN Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80. DMCYVDT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10534312 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT MI DEVDYN7 DMCYVDT MN Cytochrome P450 2E1 (CYP2E1) DMCYVDT MT DME DMCYVDT MA Metabolism DMCYVDT RN Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7. DMCYVDT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9879636 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT MI DE4LYSA DMCYVDT MN Cytochrome P450 3A4 (CYP3A4) DMCYVDT MT DME DMCYVDT MA Metabolism DMCYVDT RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMCYVDT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMGU74E DI DMGU74E DMGU74E DN Cholecalciferol DMGU74E MI TTK59TV DMGU74E MN Vitamin D3 receptor (VDR) DMGU74E MT DTT DMGU74E MA Binder DMGU74E RN [Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20. DMGU74E RU https://pubmed.ncbi.nlm.nih.gov/18406498 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI DT7JELC DM7OKQV MN Apical sodium-dependent bile acid transporter (SLC10A2) DM7OKQV MT DTP DM7OKQV MA Substrate DM7OKQV RN Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1):G157-69. DM7OKQV RU http://ajpgi.physiology.org/content/274/1/G157.long DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI DTI7UX6 DM7OKQV MN Breast cancer resistance protein (ABCG2) DM7OKQV MT DTP DM7OKQV MA Substrate DM7OKQV RN Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol. 2012 Feb;81(2):273-83. DM7OKQV RU https://doi.org/10.1124/mol.111.075143 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI TTQ6VF4 DM7OKQV MN Ferrochelatase (FECH) DM7OKQV MT DTT DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI TTMF541 DM7OKQV MN Liver carboxylesterase (CES1) DM7OKQV MT DTT DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI DTFI42L DM7OKQV MN Multidrug resistance-associated protein 2 (ABCC2) DM7OKQV MT DTP DM7OKQV MA Substrate DM7OKQV RN Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells. Br J Pharmacol. 2002 Mar;135(5):1263-75. DM7OKQV RU https://doi.org/10.1038/sj.bjp.0704560 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI DTCSGPB DM7OKQV MN Multidrug resistance-associated protein 4 (ABCC4) DM7OKQV MT DTP DM7OKQV MA Substrate DM7OKQV RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DM7OKQV RU https://doi.org/10.1007/s11095-012-0935-x DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI DTE2B1D DM7OKQV MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DM7OKQV MT DTP DM7OKQV MA Substrate DM7OKQV RN Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82. DM7OKQV RU http://www.ncbi.nlm.nih.gov/pubmed/7557095 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI DT3D8F0 DM7OKQV MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DM7OKQV MT DTP DM7OKQV MA Substrate DM7OKQV RN Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. DM7OKQV RU http://www.ncbi.nlm.nih.gov/pubmed/21245207 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI TT9V5JH DM7OKQV MN Phospholipase A2 (PLA2G1B) DM7OKQV MT DTT DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV MI DEYWLRK DM7OKQV MN Sulfotransferase 1A1 (SULT1A1) DM7OKQV MT DME DM7OKQV MA Metabolism DM7OKQV RN Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94. DM7OKQV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20102295 DMOI1ZF DI DMOI1ZF DMOI1ZF DN Choline alfoscerate DMOI1ZF MI TTH18TF DMOI1ZF MN Muscarinic acetylcholine receptor M5 (CHRM5) DMOI1ZF MT DTT DMOI1ZF MA Modulator DMOI1ZF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMOI1ZF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DM8P137 DI DM8P137 DM8P137 DN Choline salicylate DM8P137 MI DEAHED0 DM8P137 MN Choline dehydrogenase (CHDH) DM8P137 MT DME DM8P137 MA Metabolism DM8P137 RN Usual choline and betaine dietary intake and incident coronary heart disease: the atherosclerosis risk in communities (ARIC) study. BMC Cardiovasc Disord. 2007 Jul 13;7:20. DM8P137 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17629908 DM8P137 DI DM8P137 DM8P137 DN Choline salicylate DM8P137 MI DE5NGOW DM8P137 MN Choline O-acetyltransferase (CHAT) DM8P137 MT DME DM8P137 MA Metabolism DM8P137 RN The effect of trichlorfon and methylazoxymethanol on the development of guinea pig cerebellum. Toxicol Appl Pharmacol. 2007 Mar;219(2-3):128-35. DM8P137 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17150236 DM8P137 DI DM8P137 DM8P137 DN Choline salicylate DM8P137 MI DEL87ZT DM8P137 MN Choline/ethanolaminephosphotransferase 1 (CEPT1) DM8P137 MT DME DM8P137 MA Metabolism DM8P137 RN PC and PE synthesis: mixed micellar analysis of the cholinephosphotransferase and ethanolaminephosphotransferase activities of human choline/ethanolamine phosphotransferase 1 (CEPT1). Lipids. 2002 Jul;37(7):663-72. DM8P137 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12216837 DMFMZ3G DI DMFMZ3G DMFMZ3G DN Choriogonadotropin alfa DMFMZ3G MI TT2O4W9 DMFMZ3G MN Luteinizing hormone receptor (LHCGR) DMFMZ3G MT DTT DMFMZ3G MA Modulator DMFMZ3G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFMZ3G RU https://www.fda.gov/ DMFT73E DI DMFT73E DMFT73E DN Chorionic Gonadotropin DMFT73E MI TT2O4W9 DMFT73E MN Luteinizing hormone receptor (LHCGR) DMFT73E MT DTT DMFT73E MA Modulator DMFT73E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFT73E RU https://www.fda.gov/ DM2NA4K DI DM2NA4K DM2NA4K DN Ciclesonide DM2NA4K MI TTJL8VG DM2NA4K MN Corticosteroid-binding globulin (SERPINA6) DM2NA4K MT DTT DM2NA4K MA Binder DM2NA4K RN Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. DM2NA4K RU https://pubmed.ncbi.nlm.nih.gov/10634411 DM2NA4K DI DM2NA4K DM2NA4K DN Ciclesonide DM2NA4K MI DECB0K3 DM2NA4K MN Cytochrome P450 2D6 (CYP2D6) DM2NA4K MT DME DM2NA4K MA Metabolism DM2NA4K RN Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86. DM2NA4K RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16435573 DM2NA4K DI DM2NA4K DM2NA4K DN Ciclesonide DM2NA4K MI DE4LYSA DM2NA4K MN Cytochrome P450 3A4 (CYP3A4) DM2NA4K MT DME DM2NA4K MA Metabolism DM2NA4K RN Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet. 2005 Oct-Dec;30(4):275-86. DM2NA4K RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16435573 DM2NA4K DI DM2NA4K DM2NA4K DN Ciclesonide DM2NA4K MI DTUGYRD DM2NA4K MN P-glycoprotein 1 (ABCB1) DM2NA4K MT DTP DM2NA4K MA Substrate DM2NA4K RN Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302. DM2NA4K RU https://doi.org/10.1016/j.taap.2012.03.008 DMN5T2A DI DMN5T2A DMN5T2A DN Ciclopirox DMN5T2A MI TTJQFBG DMN5T2A MN HIF-prolyl hydroxylase (HPH) DMN5T2A MT DTT DMN5T2A MA Modulator DMN5T2A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMN5T2A RU https://www.fda.gov/ DMT2KRV DI DMT2KRV DMT2KRV DN Ciclosporin DMT2KRV MI DTI7UX6 DMT2KRV MN Breast cancer resistance protein (ABCG2) DMT2KRV MT DTP DMT2KRV MA Substrate DMT2KRV RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMT2KRV RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMT2KRV DI DMT2KRV DMT2KRV DN Ciclosporin DMT2KRV MI TTA4LDE DMT2KRV MN Calcineurin (PPP3CA) DMT2KRV MT DTT DMT2KRV MA Inhibitor DMT2KRV RN Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45. DMT2KRV RU https://pubmed.ncbi.nlm.nih.gov/17414949 DMAZJFX DI DMAZJFX DMAZJFX DN Ciclosporin DMAZJFX MI DE4LYSA DMAZJFX MN Cytochrome P450 3A4 (CYP3A4) DMAZJFX MT DME DMAZJFX MA Metabolism DMAZJFX RN Dasatinib significantly reduced in vivo exposure to cyclosporine in a rat model: The possible involvement of CYP3A induction. Pharmacol Rep. 2019 Apr;71(2):201-205. DMAZJFX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30785057 DMAZJFX DI DMAZJFX DMAZJFX DN Ciclosporin DMAZJFX MI DEIBDNY DMAZJFX MN Cytochrome P450 3A5 (CYP3A5) DMAZJFX MT DME DMAZJFX MA Metabolism DMAZJFX RN CYP3A4*18B and CYP3A5*3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. Eur J Pharm Sci. 2015 Aug 30;76:238-44. DMAZJFX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25976223 DMAZJFX DI DMAZJFX DMAZJFX DN Ciclosporin DMAZJFX MI DERD86B DMAZJFX MN Cytochrome P450 3A7 (CYP3A7) DMAZJFX MT DME DMAZJFX MA Metabolism DMAZJFX RN CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit. 2008 Dec;30(6):689-99. DMAZJFX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18978522 DMT2KRV DI DMT2KRV DMT2KRV DN Ciclosporin DMT2KRV MI DTFI42L DMT2KRV MN Multidrug resistance-associated protein 2 (ABCC2) DMT2KRV MT DTP DMT2KRV MA Substrate DMT2KRV RN Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol. 2010 Feb;66(2):153-8. DMT2KRV RU https://doi.org/10.1007/s00228-009-0740-6 DMT2KRV DI DMT2KRV DMT2KRV DN Ciclosporin DMT2KRV MI DTUGYRD DMT2KRV MN P-glycoprotein 1 (ABCB1) DMT2KRV MT DTP DMT2KRV MA Substrate DMT2KRV RN Contribution of down-regulation of intestinal and hepatic cytochrome P450 3A to increased absorption of cyclosporine A in a rat nephrosis model. J Pharmacol Exp Ther. 2008 Nov;327(2):592-9. DMT2KRV RU http://www.ncbi.nlm.nih.gov/pubmed/18725544 DMA13GD DI DMA13GD DMA13GD DN Cidofovir DMA13GD MI TTIU7X1 DMA13GD MN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMA13GD MT DTT DMA13GD MA Modulator DMA13GD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA13GD RU https://www.fda.gov/ DMA13GD DI DMA13GD DMA13GD DN Cidofovir DMA13GD MI DTFI42L DMA13GD MN Multidrug resistance-associated protein 2 (ABCC2) DMA13GD MT DTP DMA13GD MA Substrate DMA13GD RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMA13GD RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMA13GD DI DMA13GD DMA13GD DN Cidofovir DMA13GD MI DTQ23VB DMA13GD MN Organic anion transporter 1 (SLC22A6) DMA13GD MT DTP DMA13GD MA Substrate DMA13GD RN Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007 Apr;24(4):811-5. DMA13GD RU http://www.ncbi.nlm.nih.gov/pubmed/17372702 DMA13GD DI DMA13GD DMA13GD DN Cidofovir DMA13GD MI DTVP67E DMA13GD MN Organic anion transporter 3 (SLC22A8) DMA13GD MT DTP DMA13GD MA Substrate DMA13GD RN Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007 Apr;24(4):811-5. DMA13GD RU http://www.ncbi.nlm.nih.gov/pubmed/17372702 DME2H5T DI DME2H5T DME2H5T DN Cilastatin DME2H5T MI TTYUENF DME2H5T MN Dehydropeptidase I (DPEP1) DME2H5T MT DTT DME2H5T MA Inhibitor DME2H5T RN Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Respir Med. 2006 Feb;100(2):324-31. DME2H5T RU https://pubmed.ncbi.nlm.nih.gov/16493791 DM4V6JA DI DM4V6JA DM4V6JA DN Cilazapril DM4V6JA MI TTL69WB DM4V6JA MN Angiotensin-converting enzyme (ACE) DM4V6JA MT DTT DM4V6JA MA Inhibitor DM4V6JA RN Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93. DM4V6JA RU https://pubmed.ncbi.nlm.nih.gov/18423812 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI DEJGDUW DMZMSCT MN Cytochrome P450 1A2 (CYP1A2) DMZMSCT MT DME DMZMSCT MA Metabolism DMZMSCT RN Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. DMZMSCT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI DECB0K3 DMZMSCT MN Cytochrome P450 2D6 (CYP2D6) DMZMSCT MT DME DMZMSCT MA Metabolism DMZMSCT RN Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. DMZMSCT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI DE4LYSA DMZMSCT MN Cytochrome P450 3A4 (CYP3A4) DMZMSCT MT DME DMZMSCT MA Metabolism DMZMSCT RN Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. DMZMSCT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI DEIBDNY DMZMSCT MN Cytochrome P450 3A5 (CYP3A5) DMZMSCT MT DME DMZMSCT MA Metabolism DMZMSCT RN Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. DMZMSCT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI DERD86B DMZMSCT MN Cytochrome P450 3A7 (CYP3A7) DMZMSCT MT DME DMZMSCT MA Metabolism DMZMSCT RN Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. DMZMSCT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI DEGTFWK DMZMSCT MN Mephenytoin 4-hydroxylase (CYP2C19) DMZMSCT MT DME DMZMSCT MA Metabolism DMZMSCT RN Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. DMZMSCT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI DTVP67E DMZMSCT MN Organic anion transporter 3 (SLC22A8) DMZMSCT MT DTP DMZMSCT MA Substrate DMZMSCT RN Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007. DMZMSCT RU http://www.ncbi.nlm.nih.gov/pubmed/24692216 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI DT3D8F0 DMZMSCT MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMZMSCT MT DTP DMZMSCT MA Substrate DMZMSCT RN Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523. DMZMSCT RU http://www.ncbi.nlm.nih.gov/pubmed/28535976 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI DT9C1TS DMZMSCT MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMZMSCT MT DTP DMZMSCT MA Substrate DMZMSCT RN Organic Anion-Transporting Polypeptide and Efflux Transporter-Mediated Hepatic Uptake and Biliary Excretion of Cilostazol and Its Metabolites in Rats and Humans. J Pharm Sci. 2017 Sep;106(9):2515-2523. DMZMSCT RU http://www.ncbi.nlm.nih.gov/pubmed/28535976 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI TTZCG4L DMZMSCT MN Phosphodiesterase 3 (PDE3) DMZMSCT MT DTT DMZMSCT MA Modulator DMZMSCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZMSCT RU https://www.fda.gov/ DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT MI TT06AWU DMZMSCT MN Phosphodiesterase 3A (PDE3A) DMZMSCT MT DTT DMZMSCT MA Inhibitor DMZMSCT RN A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. DMZMSCT RU https://pubmed.ncbi.nlm.nih.gov/2985781 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB MI DTI7UX6 DMH61ZB MN Breast cancer resistance protein (ABCG2) DMH61ZB MT DTP DMH61ZB MA Substrate DMH61ZB RN Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Mol Pharmacol. 2008 Mar;73(3):613-5. DMH61ZB RU http://www.ncbi.nlm.nih.gov/pubmed/18086804 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB MI TTQHJ1K DMH61ZB MN Histamine H2 receptor (H2R) DMH61ZB MT DTT DMH61ZB MA Antagonist DMH61ZB RN Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. DMH61ZB RU https://pubmed.ncbi.nlm.nih.gov/11180002 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB MI DTZGT0P DMH61ZB MN Multidrug and toxin extrusion protein 1 (SLC47A1) DMH61ZB MT DTP DMH61ZB MA Substrate DMH61ZB RN Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. DMH61ZB RU http://www.ncbi.nlm.nih.gov/pubmed/17509534 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB MI DT3TX4H DMH61ZB MN Multidrug and toxin extrusion protein 2 (SLC47A2) DMH61ZB MT DTP DMH61ZB MA Substrate DMH61ZB RN Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. DMH61ZB RU http://www.ncbi.nlm.nih.gov/pubmed/17509534 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB MI DTVP67E DMH61ZB MN Organic anion transporter 3 (SLC22A8) DMH61ZB MT DTP DMH61ZB MA Substrate DMH61ZB RN Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83. DMH61ZB RU http://www.ncbi.nlm.nih.gov/pubmed/17314201 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB MI DTT79CX DMH61ZB MN Organic cation transporter 1 (SLC22A1) DMH61ZB MT DTP DMH61ZB MA Substrate DMH61ZB RN Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. DMH61ZB RU http://www.ncbi.nlm.nih.gov/pubmed/23984907 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB MI DT9IDPW DMH61ZB MN Organic cation transporter 2 (SLC22A2) DMH61ZB MT DTP DMH61ZB MA Substrate DMH61ZB RN Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34. DMH61ZB RU http://www.ncbi.nlm.nih.gov/pubmed/20814153 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB MI DTUGYRD DMH61ZB MN P-glycoprotein 1 (ABCB1) DMH61ZB MT DTP DMH61ZB MA Substrate DMH61ZB RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMH61ZB RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMZHPNE DI DMZHPNE DMZHPNE DN Cimetropium bromide DMZHPNE MI TTH18TF DMZHPNE MN Muscarinic acetylcholine receptor M5 (CHRM5) DMZHPNE MT DTT DMZHPNE MA Modulator DMZHPNE RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMZHPNE RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMCX0K3 DI DMCX0K3 DMCX0K3 DN Cinacalcet DMCX0K3 MI DEJGDUW DMCX0K3 MN Cytochrome P450 1A2 (CYP1A2) DMCX0K3 MT DME DMCX0K3 MA Metabolism DMCX0K3 RN Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8. DMCX0K3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10702888 DMCX0K3 DI DMCX0K3 DMCX0K3 DN Cinacalcet DMCX0K3 MI DECB0K3 DMCX0K3 MN Cytochrome P450 2D6 (CYP2D6) DMCX0K3 MT DME DMCX0K3 MA Metabolism DMCX0K3 RN Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11. DMCX0K3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19566113 DMCX0K3 DI DMCX0K3 DMCX0K3 DN Cinacalcet DMCX0K3 MI DE4LYSA DMCX0K3 MN Cytochrome P450 3A4 (CYP3A4) DMCX0K3 MT DME DMCX0K3 MA Metabolism DMCX0K3 RN Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Clin Pharmacokinet. 2009;48(5):303-11. DMCX0K3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19566113 DMCX0K3 DI DMCX0K3 DMCX0K3 DN Cinacalcet DMCX0K3 MI TTBUYHA DMCX0K3 MN Extracellular calcium-sensing receptor (CASR) DMCX0K3 MT DTT DMCX0K3 MA Agonist DMCX0K3 RN Clinical pipeline report, company report or official report of Amgen (2009). DMCX0K3 RU http://www.amgen.com/science/pipe.jsp DMFIC0M DI DMFIC0M DMFIC0M DN Cinalukast DMFIC0M MI TTGKOY9 DMFIC0M MN Leukotriene CysLT1 receptor (CYSLTR1) DMFIC0M MT DTT DMFIC0M MA Antagonist DMFIC0M RN Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5. DMFIC0M RU https://pubmed.ncbi.nlm.nih.gov/9042047 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ MI DEJGDUW DM7U5QJ MN Cytochrome P450 1A2 (CYP1A2) DM7U5QJ MT DME DM7U5QJ MA Metabolism DM7U5QJ RN Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009 Sep;11(3):481-94. DM7U5QJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19590965 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ MI DEJVYAZ DM7U5QJ MN Cytochrome P450 2A6 (CYP2A6) DM7U5QJ MT DME DM7U5QJ MA Metabolism DM7U5QJ RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM7U5QJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ MI DEPKLMQ DM7U5QJ MN Cytochrome P450 2B6 (CYP2B6) DM7U5QJ MT DME DM7U5QJ MA Metabolism DM7U5QJ RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM7U5QJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ MI DE5IED8 DM7U5QJ MN Cytochrome P450 2C9 (CYP2C9) DM7U5QJ MT DME DM7U5QJ MA Metabolism DM7U5QJ RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM7U5QJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ MI DECB0K3 DM7U5QJ MN Cytochrome P450 2D6 (CYP2D6) DM7U5QJ MT DME DM7U5QJ MA Metabolism DM7U5QJ RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM7U5QJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ MI DE4LYSA DM7U5QJ MN Cytochrome P450 3A4 (CYP3A4) DM7U5QJ MT DME DM7U5QJ MA Metabolism DM7U5QJ RN Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. DM7U5QJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ MI TTTIBOJ DM7U5QJ MN Histamine H1 receptor (H1R) DM7U5QJ MT DTT DM7U5QJ MA Antagonist DM7U5QJ RN Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4. DM7U5QJ RU https://pubmed.ncbi.nlm.nih.gov/12056673 DMDX1ZC DI DMDX1ZC DMDX1ZC DN Cinolazepam DMDX1ZC MI TTPTXIN DMDX1ZC MN Translocator protein (TSPO) DMDX1ZC MT DTT DMDX1ZC MA Binder DMDX1ZC RN Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise. Int J Clin Pharmacol Res. 1987;7(5):407-18. DMDX1ZC RU https://pubmed.ncbi.nlm.nih.gov/2889679 DM4EWNS DI DM4EWNS DM4EWNS DN Cinoxacin DM4EWNS MI TT0IHXV DM4EWNS MN DNA topoisomerase II (TOP2) DM4EWNS MT DTT DM4EWNS MA Inhibitor DM4EWNS RN The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. DM4EWNS RU https://pubmed.ncbi.nlm.nih.gov/10411577 DMVIKJZ DI DMVIKJZ DMVIKJZ DN Cinryze DMVIKJZ MI TTVQ6R9 DMVIKJZ MN C1 esterase inhibitor (SERPING1) DMVIKJZ MT DTT DMVIKJZ MA Modulator DMVIKJZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVIKJZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVIKJZ DI DMVIKJZ DMVIKJZ DN Cinryze DMVIKJZ MI TT7LRQH DMVIKJZ MN Complement C1s component (C1S) DMVIKJZ MT DTT DMVIKJZ MA Modulator DMVIKJZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVIKJZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMGC5DB DI DMGC5DB DMGC5DB DN Ciprofibrate DMGC5DB MI DE4LYSA DMGC5DB MN Cytochrome P450 3A4 (CYP3A4) DMGC5DB MT DME DMGC5DB MA Metabolism DMGC5DB RN Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62. DMGC5DB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185 DMGC5DB DI DMGC5DB DMGC5DB DN Ciprofibrate DMGC5DB MI TTJ584C DMGC5DB MN Peroxisome proliferator-activated receptor alpha (PPARA) DMGC5DB MT DTT DMGC5DB MA Agonist DMGC5DB RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMGC5DB RU https://pubmed.ncbi.nlm.nih.gov/10828060 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 MI TTN6J5F DM2NLS9 MN Bacterial DNA gyrase (Bact gyrase) DM2NLS9 MT DTT DM2NLS9 MA Modulator DM2NLS9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2NLS9 RU https://www.fda.gov/ DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 MI TTJP4SM DM2NLS9 MN Bacterial Penicillin binding protein (Bact PBP) DM2NLS9 MT DTT DM2NLS9 MA Inhibitor DM2NLS9 RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM2NLS9 RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 MI DTI7UX6 DM2NLS9 MN Breast cancer resistance protein (ABCG2) DM2NLS9 MT DTP DM2NLS9 MA Substrate DM2NLS9 RN Fluoroquinolone efflux mediated by ABC transporters. J Pharm Sci. 2008 Sep;97(9):3483-93. DM2NLS9 RU http://www.ncbi.nlm.nih.gov/pubmed/18200507 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 MI TTU6BFZ DM2NLS9 MN Candida Thymidylate synthase (Candi TMP1) DM2NLS9 MT DTT DM2NLS9 MA Inhibitor DM2NLS9 RN Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99. DM2NLS9 RU https://pubmed.ncbi.nlm.nih.gov/12494465 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 MI DTCSGPB DM2NLS9 MN Multidrug resistance-associated protein 4 (ABCC4) DM2NLS9 MT DTP DM2NLS9 MA Substrate DM2NLS9 RN Identification of the efflux transporter of the fluoroquinolone antibiotic ciprofloxacin in murine macrophages: studies with ciprofloxacin-resistant cells. Antimicrob Agents Chemother. 2009 Jun;53(6):2410-6. DM2NLS9 RU http://www.ncbi.nlm.nih.gov/pubmed/19307362 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 MI DTVP67E DM2NLS9 MN Organic anion transporter 3 (SLC22A8) DM2NLS9 MT DTP DM2NLS9 MA Substrate DM2NLS9 RN Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin. Mol Pharmacol. 2008 Jul;74(1):122-31. DM2NLS9 RU http://www.ncbi.nlm.nih.gov/pubmed/18381565 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 MI DTE2B1D DM2NLS9 MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DM2NLS9 MT DTP DM2NLS9 MA Substrate DM2NLS9 RN Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55. DM2NLS9 RU http://www.ncbi.nlm.nih.gov/pubmed/21039758 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 MI TTIXTO3 DM2NLS9 MN Staphylococcus Topoisomerase IV (Stap-coc parC) DM2NLS9 MT DTT DM2NLS9 MA Modulator DM2NLS9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2NLS9 RU https://www.fda.gov/ DMZR26N DI DMZR26N DMZR26N DN Ciprofloxacin+dexamethasone DMZR26N MI TT0IHXV DMZR26N MN DNA topoisomerase II (TOP2) DMZR26N MT DTT DMZR26N MA Binder DMZR26N RN Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64. DMZR26N RU https://pubmed.ncbi.nlm.nih.gov/16634700 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED MI TT07C3Y DMY7PED MN 5-HT 4 receptor (HTR4) DMY7PED MT DTT DMY7PED MA Agonist DMY7PED RN Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90. DMY7PED RU https://pubmed.ncbi.nlm.nih.gov/18948374 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED MI DEJVYAZ DMY7PED MN Cytochrome P450 2A6 (CYP2A6) DMY7PED MT DME DMY7PED MA Metabolism DMY7PED RN Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67. DMY7PED RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10780971 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED MI DEPKLMQ DMY7PED MN Cytochrome P450 2B6 (CYP2B6) DMY7PED MT DME DMY7PED MA Metabolism DMY7PED RN Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800. DMY7PED RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED MI DES5XRU DMY7PED MN Cytochrome P450 2C8 (CYP2C8) DMY7PED MT DME DMY7PED MA Metabolism DMY7PED RN Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800. DMY7PED RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED MI DE5IED8 DMY7PED MN Cytochrome P450 2C9 (CYP2C9) DMY7PED MT DME DMY7PED MA Metabolism DMY7PED RN Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co-medication interactions. Br J Pharmacol. 2000 Apr;129(8):1655-67. DMY7PED RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10780971 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED MI DE4LYSA DMY7PED MN Cytochrome P450 3A4 (CYP3A4) DMY7PED MT DME DMY7PED MA Metabolism DMY7PED RN Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther. 2003 Mar;73(3):209-22. DMY7PED RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12621386 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED MI DEIBDNY DMY7PED MN Cytochrome P450 3A5 (CYP3A5) DMY7PED MT DME DMY7PED MA Metabolism DMY7PED RN Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800. DMY7PED RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED MI DERD86B DMY7PED MN Cytochrome P450 3A7 (CYP3A7) DMY7PED MT DME DMY7PED MA Metabolism DMY7PED RN Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800. DMY7PED RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED MI DEGTFWK DMY7PED MN Mephenytoin 4-hydroxylase (CYP2C19) DMY7PED MT DME DMY7PED MA Metabolism DMY7PED RN Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800. DMY7PED RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10859153 DMUZPJ5 DI DMUZPJ5 DMUZPJ5 DN Cisatracurium DMUZPJ5 MI TTUPDWN DMUZPJ5 MN Cholinergic receptor unspecific (CHR) DMUZPJ5 MT DTT DMUZPJ5 MA Antagonist DMUZPJ5 RN Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92. DMUZPJ5 RU https://pubmed.ncbi.nlm.nih.gov/9429048 DMUZPJ5 DI DMUZPJ5 DMUZPJ5 DN Cisatracurium DMUZPJ5 MI TTF4E0J DMUZPJ5 MN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMUZPJ5 MT DTT DMUZPJ5 MA Antagonist DMUZPJ5 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMUZPJ5 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DTI7UX6 DMRHGI9 MN Breast cancer resistance protein (ABCG2) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93. DMRHGI9 RU https://doi.org/10.1016/j.bcp.2008.11.007 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DT206GF DMRHGI9 MN Copper-transporting ATPase 2 (ATP7B) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Effect of cisplatin on the transport activity of PII-type ATPases. Metallomics. 2017 Jul 19;9(7):960-968. DMRHGI9 RU http://www.ncbi.nlm.nih.gov/pubmed/28636017 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DEVDYN7 DMRHGI9 MN Cytochrome P450 2E1 (CYP2E1) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12675844 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DE4ZHS1 DMRHGI9 MN Glutathione S-transferase alpha-1 (GSTA1) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Mol Cancer Ther. 2008 Oct;7(10):3247-55. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18852128 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DEH7XYP DMRHGI9 MN Glutathione S-transferase alpha-4 (GSTA4) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN GSTA4 mediates reduction of cisplatin ototoxicity in female mice. Nat Commun. 2019 Sep 12;10(1):4150. DMRHGI9 RU https://pubmed.ncbi.nlm.nih.gov/31515474 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DEYZEJA DMRHGI9 MN Glutathione S-transferase mu-1 (GSTM1) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11081456 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DEK6079 DMRHGI9 MN Glutathione S-transferase pi (GSTP1) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11081456 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DE3PKUG DMRHGI9 MN Glutathione S-transferase theta-1 (GSTT1) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11081456 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DTP8L4F DMRHGI9 MN High affinity copper uptake protein 1 (SLC31A1) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61. DMRHGI9 RU http://www.ncbi.nlm.nih.gov/pubmed/24122978 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI TTUTN1I DMRHGI9 MN Human Deoxyribonucleic acid (hDNA) DMRHGI9 MT DTT DMRHGI9 MA Modulator DMRHGI9 RN Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/8533159 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DE5ME8A DMRHGI9 MN Metallothionein-1A (MT1A) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10709094 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DEFKGT7 DMRHGI9 MN Metallothionein-2A (MT2A) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10709094 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DTSYQGK DMRHGI9 MN Multidrug resistance-associated protein 1 (ABCC1) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14. DMRHGI9 RU http://www.ncbi.nlm.nih.gov/pubmed/11687904 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DTFI42L DMRHGI9 MN Multidrug resistance-associated protein 2 (ABCC2) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55. DMRHGI9 RU http://www.ncbi.nlm.nih.gov/pubmed/18834541 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DT582KR DMRHGI9 MN Multidrug resistance-associated protein 6 (ABCC6) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. DMRHGI9 RU http://www.ncbi.nlm.nih.gov/pubmed/12414644 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DEA3U9Y DMRHGI9 MN Myeloperoxidase (MPO) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19818462 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DTT79CX DMRHGI9 MN Organic cation transporter 1 (SLC22A1) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86. DMRHGI9 RU http://www.ncbi.nlm.nih.gov/pubmed/16914559 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DT9IDPW DMRHGI9 MN Organic cation transporter 2 (SLC22A2) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84. DMRHGI9 RU http://www.ncbi.nlm.nih.gov/pubmed/16314463 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DTUGYRD DMRHGI9 MN P-glycoprotein 1 (ABCB1) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMRHGI9 RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DT8Q56F DMRHGI9 MN Probable low affinity copper uptake protein 2 (SLC31A2) DMRHGI9 MT DTP DMRHGI9 MA Substrate DMRHGI9 RN Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol. 2011 Jan;79(1):157-66. DMRHGI9 RU http://www.ncbi.nlm.nih.gov/pubmed/20930109 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DENP5RY DMRHGI9 MN Quinone reductase 1 (NQO1) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) DMRHGI9 RU https://www.pharmgkb.org/pathway/PA150642262 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 MI DEUTDON DMRHGI9 MN Superoxide dismutase 1 (SOD1) DMRHGI9 MT DME DMRHGI9 MA Metabolism DMRHGI9 RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262) DMRHGI9 RU https://www.pharmgkb.org/pathway/PA150642262 DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE MI DECB0K3 DM2G9AE MN Cytochrome P450 2D6 (CYP2D6) DM2G9AE MT DME DM2G9AE MA Metabolism DM2G9AE RN Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. DM2G9AE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8968657 DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE MI DEVDYN7 DM2G9AE MN Cytochrome P450 2E1 (CYP2E1) DM2G9AE MT DME DM2G9AE MA Metabolism DM2G9AE RN Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80. DM2G9AE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778 DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE MI DE4LYSA DM2G9AE MN Cytochrome P450 3A4 (CYP3A4) DM2G9AE MT DME DM2G9AE MA Metabolism DM2G9AE RN PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72. DM2G9AE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21546862 DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE MI DEGTFWK DM2G9AE MN Mephenytoin 4-hydroxylase (CYP2C19) DM2G9AE MT DME DM2G9AE MA Metabolism DM2G9AE RN Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999 Sep 15;46(6):839-49. DM2G9AE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10494454 DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE MI DTSYQGK DM2G9AE MN Multidrug resistance-associated protein 1 (ABCC1) DM2G9AE MT DTP DM2G9AE MA Substrate DM2G9AE RN MRP1 polymorphisms associated with citalopram response in patients with major depression. J Clin Psychopharmacol. 2010 Apr;30(2):116-25. DM2G9AE RU http://www.ncbi.nlm.nih.gov/pubmed/20520284 DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE MI DTT79CX DM2G9AE MN Organic cation transporter 1 (SLC22A1) DM2G9AE MT DTP DM2G9AE MA Substrate DM2G9AE RN Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53. DM2G9AE RU https://doi.org/10.2133/dmpk.23.243 DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE MI DTUGYRD DM2G9AE MN P-glycoprotein 1 (ABCB1) DM2G9AE MT DTP DM2G9AE MA Substrate DM2G9AE RN ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. Int J Legal Med. 2013 May;127(3):579-86. DM2G9AE RU http://www.ncbi.nlm.nih.gov/pubmed/23515680 DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE MI TT3ROYC DM2G9AE MN Serotonin transporter (SERT) DM2G9AE MT DTT DM2G9AE MA Modulator DM2G9AE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2G9AE RU https://www.fda.gov/ DMI4XBM DI DMI4XBM DMI4XBM DN Citicoline DMI4XBM MI DEQJ8N3 DMI4XBM MN ASM-like phosphodiesterase 3a (SMPDL3A) DMI4XBM MT DME DMI4XBM MA Metabolism DMI4XBM RN The structure and catalytic mechanism of human sphingomyelin phosphodiesterase like 3a--an acid sphingomyelinase homologue with a novel nucleotide hydrolase activity. FEBS J. 2016 Mar;283(6):1107-23. DMI4XBM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26783088 DMI4XBM DI DMI4XBM DMI4XBM DN Citicoline DMI4XBM MI DEH6S1Q DMI4XBM MN CDP-choline phosphohydrolase (ADPRM) DMI4XBM MT DME DMI4XBM MA Metabolism DMI4XBM RN Molecular bases of catalysis and ADP-ribose preference of human Mn2+-dependent ADP-ribose/CDP-alcohol diphosphatase and conversion by mutagenesis to a preferential cyclic ADP-ribose phosphohydrolase. PLoS One. 2015 Feb 18;10(2):e0118680. DMI4XBM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25692488 DMMEBWR DI DMMEBWR DMMEBWR DN Citric acid, magnesium oxide, sodium picosulfate DMMEBWR MI DEHYDG9 DMMEBWR MN Arylsulfate sulfotransferase (astA) DMMEBWR MT DME DMMEBWR MA Metabolism DMMEBWR RN The role of intestinal bacteria in the transformation of sodium picosulfate. Jpn J Pharmacol. 1992 May;59(1):1-5. DMMEBWR RU https://pubmed.ncbi.nlm.nih.gov/1507649 DM3JDRP DI DM3JDRP DM3JDRP DN Cladribine DM3JDRP MI TTLP57V DM3JDRP MN Adenosine deaminase (ADA) DM3JDRP MT DTT DM3JDRP MA Inhibitor DM3JDRP RN Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57. DM3JDRP RU https://pubmed.ncbi.nlm.nih.gov/15485311 DM3JDRP DI DM3JDRP DM3JDRP DN Cladribine DM3JDRP MI DTI7UX6 DM3JDRP MN Breast cancer resistance protein (ABCG2) DM3JDRP MT DTP DM3JDRP MA Substrate DM3JDRP RN Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102. DM3JDRP RU http://www.ncbi.nlm.nih.gov/pubmed/18765824 DM3JDRP DI DM3JDRP DM3JDRP DN Cladribine DM3JDRP MI DE9FGNK DM3JDRP MN Deoxycytidine kinase (DCK) DM3JDRP MT DME DM3JDRP MA Metabolism DM3JDRP RN Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019 May;30:176-186. DM3JDRP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30785074 DM3JDRP DI DM3JDRP DM3JDRP DN Cladribine DM3JDRP MI DTZAWTH DM3JDRP MN Equilibrative nucleoside transporter 3 (SLC29A3) DM3JDRP MT DTP DM3JDRP MA Substrate DM3JDRP RN Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem. 2005 Apr 22;280(16):15880-7. DM3JDRP RU http://www.ncbi.nlm.nih.gov/pubmed/15701636 DM3JDRP DI DM3JDRP DM3JDRP DN Cladribine DM3JDRP MI DTCSGPB DM3JDRP MN Multidrug resistance-associated protein 4 (ABCC4) DM3JDRP MT DTP DM3JDRP MA Substrate DM3JDRP RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DM3JDRP RU https://doi.org/10.1007/s11095-012-0935-x DM3JDRP DI DM3JDRP DM3JDRP DN Cladribine DM3JDRP MI DTT79CX DM3JDRP MN Organic cation transporter 1 (SLC22A1) DM3JDRP MT DTP DM3JDRP MA Substrate DM3JDRP RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DM3JDRP RU https://doi.org/10.1007/s11095-012-0935-x DM4M1SG DI DM4M1SG DM4M1SG DN Clarithromycin DM4M1SG MI TTUWYEA DM4M1SG MN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4M1SG MT DTT DM4M1SG MA Binder DM4M1SG RN Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. DM4M1SG RU https://pubmed.ncbi.nlm.nih.gov/11677599 DM4M1SG DI DM4M1SG DM4M1SG DN Clarithromycin DM4M1SG MI DE4LYSA DM4M1SG MN Cytochrome P450 3A4 (CYP3A4) DM4M1SG MT DME DM4M1SG MA Metabolism DM4M1SG RN Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. J Cyst Fibros. 2014 Mar;13(2):179-85. DM4M1SG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24035278 DM4M1SG DI DM4M1SG DM4M1SG DN Clarithromycin DM4M1SG MI DEIBDNY DM4M1SG MN Cytochrome P450 3A5 (CYP3A5) DM4M1SG MT DME DM4M1SG MA Metabolism DM4M1SG RN Drug Interactions Flockhart Table DM4M1SG RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM4M1SG DI DM4M1SG DM4M1SG DN Clarithromycin DM4M1SG MI DEGTFWK DM4M1SG MN Mephenytoin 4-hydroxylase (CYP2C19) DM4M1SG MT DME DM4M1SG MA Metabolism DM4M1SG RN Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73. DM4M1SG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15952098 DM4M1SG DI DM4M1SG DM4M1SG DN Clarithromycin DM4M1SG MI DTUGYRD DM4M1SG MN P-glycoprotein 1 (ABCB1) DM4M1SG MT DTP DM4M1SG MA Substrate DM4M1SG RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DM4M1SG RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMPGR1E DI DMPGR1E DMPGR1E DN Clascoterone DMPGR1E MI TTS64P2 DMPGR1E MN Androgen receptor (AR) DMPGR1E MT DTT DMPGR1E MA Antagonist DMPGR1E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMPGR1E RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf DM2FGRT DI DM2FGRT DM2FGRT DN Clavulanate DM2FGRT MI TTHI19T DM2FGRT MN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM2FGRT MT DTT DM2FGRT MA Inhibitor DM2FGRT RN A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9. DM2FGRT RU https://pubmed.ncbi.nlm.nih.gov/19505232 DMBZWQL DI DMBZWQL DMBZWQL DN Clemastine DMBZWQL MI TTTIBOJ DMBZWQL MN Histamine H1 receptor (H1R) DMBZWQL MT DTT DMBZWQL MA Antagonist DMBZWQL RN Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91. DMBZWQL RU https://pubmed.ncbi.nlm.nih.gov/18548114 DMCKYZ5 DI DMCKYZ5 DMCKYZ5 DN Clenbuterol DMCKYZ5 MI TT2CJVK DMCKYZ5 MN Adrenergic receptor beta-2 (ADRB2) DMCKYZ5 MT DTT DMCKYZ5 MA Agonist DMCKYZ5 RN Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7. DMCKYZ5 RU https://pubmed.ncbi.nlm.nih.gov/19095863 DMCKYZ5 DI DMCKYZ5 DMCKYZ5 DN Clenbuterol DMCKYZ5 MI DE6OQ3W DMCKYZ5 MN Cytochrome P450 1A1 (CYP1A1) DMCKYZ5 MT DME DMCKYZ5 MA Metabolism DMCKYZ5 RN Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50. DMCKYZ5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15710352 DMCKYZ5 DI DMCKYZ5 DMCKYZ5 DN Clenbuterol DMCKYZ5 MI DEJGDUW DMCKYZ5 MN Cytochrome P450 1A2 (CYP1A2) DMCKYZ5 MT DME DMCKYZ5 MA Metabolism DMCKYZ5 RN Beta-adrenergic receptor modulation of the LPS-mediated depression in CYP1A activity in astrocytes. Biochem Pharmacol. 2005 Mar 1;69(5):741-50. DMCKYZ5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15710352 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 MI TT5HONZ DMW4M97 MN Calcium channel unspecific (CaC) DMW4M97 MT DTT DMW4M97 MA Modulator DMW4M97 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMW4M97 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 MI DECB0K3 DMW4M97 MN Cytochrome P450 2D6 (CYP2D6) DMW4M97 MT DME DMW4M97 MA Metabolism DMW4M97 RN Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. DMW4M97 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 MI DEVDYN7 DMW4M97 MN Cytochrome P450 2E1 (CYP2E1) DMW4M97 MT DME DMW4M97 MA Metabolism DMW4M97 RN Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. DMW4M97 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16501008 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 MI DE4LYSA DMW4M97 MN Cytochrome P450 3A4 (CYP3A4) DMW4M97 MT DME DMW4M97 MA Metabolism DMW4M97 RN Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. DMW4M97 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 MI TTXHYV6 DMW4M97 MN Voltage-gated L-type calcium channel (L-CaC) DMW4M97 MT DTT DMW4M97 MA Inhibitor DMW4M97 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMW4M97 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUMQZ0 DI DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 MI TTOXS3C DMUMQZ0 MN Muscarinic acetylcholine receptor (CHRM) DMUMQZ0 MT DTT DMUMQZ0 MA Antagonist DMUMQZ0 RN Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7. DMUMQZ0 RU https://pubmed.ncbi.nlm.nih.gov/9454790 DMUMQZ0 DI DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 MI TTZ9SOR DMUMQZ0 MN Muscarinic acetylcholine receptor M1 (CHRM1) DMUMQZ0 MT DTT DMUMQZ0 MA Antagonist DMUMQZ0 RN Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460. DMUMQZ0 RU https://pubmed.ncbi.nlm.nih.gov/19465630 DMUMQZ0 DI DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 MI DTT79CX DMUMQZ0 MN Organic cation transporter 1 (SLC22A1) DMUMQZ0 MT DTP DMUMQZ0 MA Substrate DMUMQZ0 RN Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. DMUMQZ0 RU http://www.ncbi.nlm.nih.gov/pubmed/23984907 DM15HL8 DI DM15HL8 DM15HL8 DN Clindamycin DM15HL8 MI TTUWYEA DM15HL8 MN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM15HL8 MT DTT DM15HL8 MA Binder DM15HL8 RN Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. DM15HL8 RU https://pubmed.ncbi.nlm.nih.gov/11677599 DM15HL8 DI DM15HL8 DM15HL8 DN Clindamycin DM15HL8 MI DEMSNER DM15HL8 MN Beta-lactamase (blaB) DM15HL8 MT DME DM15HL8 MA Metabolism DM15HL8 RN Comparison of antimicrobial susceptibility, beta-lactamase production, plasmid analysis and serum bactericidal activity in Edwardsiella tarda, E. ictaluri and E. hoshinae. J Med Microbiol. 1993 Oct;39(4):273-81. DM15HL8 RU https://pubmed.ncbi.nlm.nih.gov/8411088 DM15HL8 DI DM15HL8 DM15HL8 DN Clindamycin DM15HL8 MI DE4LYSA DM15HL8 MN Cytochrome P450 3A4 (CYP3A4) DM15HL8 MT DME DM15HL8 MA Metabolism DM15HL8 RN In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos. 2003 Jul;31(7):878-87. DM15HL8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12814964 DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 MI DEPKLMQ DMW1OQ0 MN Cytochrome P450 2B6 (CYP2B6) DMW1OQ0 MT DME DMW1OQ0 MA Metabolism DMW1OQ0 RN In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86. DMW1OQ0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195 DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 MI DEZMWRE DMW1OQ0 MN Cytochrome P450 2C18 (CYP2C18) DMW1OQ0 MT DME DMW1OQ0 MA Metabolism DMW1OQ0 RN In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86. DMW1OQ0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195 DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 MI DE4LYSA DMW1OQ0 MN Cytochrome P450 3A4 (CYP3A4) DMW1OQ0 MT DME DMW1OQ0 MA Metabolism DMW1OQ0 RN In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos. 2004 Nov;32(11):1279-86. DMW1OQ0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15483195 DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 MI TT1MPAY DMW1OQ0 MN GABA(A) receptor alpha-1 (GABRA1) DMW1OQ0 MT DTT DMW1OQ0 MA Antagonist DMW1OQ0 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMW1OQ0 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 MI TTEX6LM DMW1OQ0 MN GABA(A) receptor gamma-3 (GABRG3) DMW1OQ0 MT DTT DMW1OQ0 MA Modulator DMW1OQ0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW1OQ0 RU https://www.fda.gov/ DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 MI DEGTFWK DMW1OQ0 MN Mephenytoin 4-hydroxylase (CYP2C19) DMW1OQ0 MT DME DMW1OQ0 MA Metabolism DMW1OQ0 RN A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev. 2004 Dec;26(8):530-4. DMW1OQ0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15533655 DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 MI DTUGYRD DMW1OQ0 MN P-glycoprotein 1 (ABCB1) DMW1OQ0 MT DTP DMW1OQ0 MA Substrate DMW1OQ0 RN Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. DMW1OQ0 RU https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false DMUXP52 DI DMUXP52 DMUXP52 DN Clobetasol DMUXP52 MI TT9V5JH DMUXP52 MN Phospholipase A2 (PLA2G1B) DMUXP52 MT DTT DMUXP52 MA Inhibitor DMUXP52 RN Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203. DMUXP52 RU https://pubmed.ncbi.nlm.nih.gov/6743552 DM9ZMQH DI DM9ZMQH DM9ZMQH DN Clocortolone DM9ZMQH MI TT9V5JH DM9ZMQH MN Phospholipase A2 (PLA2G1B) DM9ZMQH MT DTT DM9ZMQH MA Inducer DM9ZMQH RN Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8. DM9ZMQH RU https://pubmed.ncbi.nlm.nih.gov/6986236 DM9Y6X7 DI DM9Y6X7 DM9Y6X7 DN Clodronate DM9Y6X7 MI TTU5A6Q DM9Y6X7 MN Adenine nucleotide translocator 1 (SLC25A4) DM9Y6X7 MT DTT DM9Y6X7 MA Inhibitor DM9Y6X7 RN Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62. DM9Y6X7 RU https://pubmed.ncbi.nlm.nih.gov/11961144 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 MI TTJP4SM DMCVJ86 MN Bacterial Penicillin binding protein (Bact PBP) DMCVJ86 MT DTT DMCVJ86 MA Binder DMCVJ86 RN Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. DMCVJ86 RU https://pubmed.ncbi.nlm.nih.gov/17852710 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 MI DTI7UX6 DMCVJ86 MN Breast cancer resistance protein (ABCG2) DMCVJ86 MT DTP DMCVJ86 MA Substrate DMCVJ86 RN Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102. DMCVJ86 RU http://www.ncbi.nlm.nih.gov/pubmed/18765824 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 MI DT4YL5R DMCVJ86 MN Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3) DMCVJ86 MT DTP DMCVJ86 MA Substrate DMCVJ86 RN Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62. DMCVJ86 RU http://www.ncbi.nlm.nih.gov/pubmed/24692694 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 MI DE9FGNK DMCVJ86 MN Deoxycytidine kinase (DCK) DMCVJ86 MT DME DMCVJ86 MA Metabolism DMCVJ86 RN FDA label of Belinostat. The 2020 official website of the U.S. Food and Drug Administration. DMCVJ86 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021673s024lbl.pdf DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 MI DTXD1TQ DMCVJ86 MN Equilibrative nucleoside transporter 1 (SLC29A1) DMCVJ86 MT DTP DMCVJ86 MA Substrate DMCVJ86 RN Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62. DMCVJ86 RU http://www.ncbi.nlm.nih.gov/pubmed/24692694 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 MI DTW78DQ DMCVJ86 MN Equilibrative nucleoside transporter 2 (SLC29A2) DMCVJ86 MT DTP DMCVJ86 MA Substrate DMCVJ86 RN Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62. DMCVJ86 RU http://www.ncbi.nlm.nih.gov/pubmed/24692694 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 MI TTX09M4 DMCVJ86 MN Ribonucleotide reductase (RIR) DMCVJ86 MT DTT DMCVJ86 MA Inhibitor DMCVJ86 RN Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. DMCVJ86 RU https://pubmed.ncbi.nlm.nih.gov/17852710 DMEBOFW DI DMEBOFW DMEBOFW DN Clofazimine DMEBOFW MI TTS1W4A DMEBOFW MN Bacterial Deoxyribonucleic acid (Bact DNA) DMEBOFW MT DTT DMEBOFW MA Modulator DMEBOFW RN The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4. DMEBOFW RU https://www.ncbi.nlm.nih.gov/pubmed/945233 DMEBOFW DI DMEBOFW DMEBOFW DN Clofazimine DMEBOFW MI DE4LYSA DMEBOFW MN Cytochrome P450 3A4 (CYP3A4) DMEBOFW MT DME DMEBOFW MA Metabolism DMEBOFW RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMEBOFW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMEBOFW DI DMEBOFW DMEBOFW DN Clofazimine DMEBOFW MI DTUGYRD DMEBOFW MN P-glycoprotein 1 (ABCB1) DMEBOFW MT DTP DMEBOFW MA Substrate DMEBOFW RN Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26. DMEBOFW RU http://www.ncbi.nlm.nih.gov/pubmed/26472768 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI DE6OQ3W DMPC1J7 MN Cytochrome P450 1A1 (CYP1A1) DMPC1J7 MT DME DMPC1J7 MA Metabolism DMPC1J7 RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMPC1J7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI DEJGDUW DMPC1J7 MN Cytochrome P450 1A2 (CYP1A2) DMPC1J7 MT DME DMPC1J7 MA Metabolism DMPC1J7 RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMPC1J7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI DEJVYAZ DMPC1J7 MN Cytochrome P450 2A6 (CYP2A6) DMPC1J7 MT DME DMPC1J7 MA Metabolism DMPC1J7 RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMPC1J7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI DEPKLMQ DMPC1J7 MN Cytochrome P450 2B6 (CYP2B6) DMPC1J7 MT DME DMPC1J7 MA Metabolism DMPC1J7 RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMPC1J7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI DE5IED8 DMPC1J7 MN Cytochrome P450 2C9 (CYP2C9) DMPC1J7 MT DME DMPC1J7 MA Metabolism DMPC1J7 RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMPC1J7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI DECB0K3 DMPC1J7 MN Cytochrome P450 2D6 (CYP2D6) DMPC1J7 MT DME DMPC1J7 MA Metabolism DMPC1J7 RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMPC1J7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI DE4LYSA DMPC1J7 MN Cytochrome P450 3A4 (CYP3A4) DMPC1J7 MT DME DMPC1J7 MA Metabolism DMPC1J7 RN Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62. DMPC1J7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI DE4ZHS1 DMPC1J7 MN Glutathione S-transferase alpha-1 (GSTA1) DMPC1J7 MT DME DMPC1J7 MA Metabolism DMPC1J7 RN Characterization and formation of the glutathione conjugate of clofibric acid. Drug Metab Dispos. 1995 Jan;23(1):119-23. DMPC1J7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=7720514 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI DE2XQGW DMPC1J7 MN Lauric acid omega-hydroxylase (CYP4A11) DMPC1J7 MT DME DMPC1J7 MA Metabolism DMPC1J7 RN Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol Sci. 2004 Jun;79(2):233-41. DMPC1J7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15056802 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 MI TTOF3WZ DMPC1J7 MN Lipoprotein lipase (LPL) DMPC1J7 MT DTT DMPC1J7 MA Activator DMPC1J7 RN Effects of clofibrate treatment in laying hens. Poult Sci. 2007 Jun;86(6):1187-95. DMPC1J7 RU https://pubmed.ncbi.nlm.nih.gov/17495091 DMKI7RB DI DMKI7RB DMKI7RB DN Clomifene DMKI7RB MI DECB0K3 DMKI7RB MN Cytochrome P450 2D6 (CYP2D6) DMKI7RB MT DME DMKI7RB MA Metabolism DMKI7RB RN CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet. 2008;23(2):101-5. DMKI7RB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18445989 DMKI7RB DI DMKI7RB DMKI7RB DN Clomifene DMKI7RB MI TTZAYWL DMKI7RB MN Estrogen receptor (ESR) DMKI7RB MT DTT DMKI7RB MA Modulator DMKI7RB RN The future of the new selective estrogen receptor modulators. Menopause Int. 2007 Mar;13(1):27-34. DMKI7RB RU https://pubmed.ncbi.nlm.nih.gov/17448265 DMKI7RB DI DMKI7RB DMKI7RB DN Clomifene DMKI7RB MI DTUGYRD DMKI7RB MN P-glycoprotein 1 (ABCB1) DMKI7RB MT DTP DMKI7RB MA Substrate DMKI7RB RN Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92. DMKI7RB RU http://www.ncbi.nlm.nih.gov/pubmed/7914405 DMS51VC DI DMS51VC DMS51VC DN Clomiphene citrate DMS51VC MI TTZAYWL DMS51VC MN Estrogen receptor (ESR) DMS51VC MT DTT DMS51VC MA Modulator DMS51VC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS51VC RU https://www.fda.gov/ DMS51VC DI DMS51VC DMS51VC DN Clomiphene citrate DMS51VC MI DTUGYRD DMS51VC MN P-glycoprotein 1 (ABCB1) DMS51VC MT DTP DMS51VC MA Substrate DMS51VC RN Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92. DMS51VC RU http://www.ncbi.nlm.nih.gov/pubmed/7914405 DMINRKW DI DMINRKW DMINRKW DN Clomipramine DMINRKW MI DTUGYRD DMINRKW MN P-glycoprotein 1 (ABCB1) DMINRKW MT DTP DMINRKW MA Substrate DMINRKW RN Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. DMINRKW RU https://doi.org/10.1016/j.addr.2011.12.008 DMINRKW DI DMINRKW DMINRKW DN Clomipramine DMINRKW MI TT3ROYC DMINRKW MN Serotonin transporter (SERT) DMINRKW MT DTT DMINRKW MA Inhibitor DMINRKW RN Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009 Apr;21(4):207-13. DMINRKW RU https://pubmed.ncbi.nlm.nih.gov/19366379 DM0ZRMQ DI DM0ZRMQ DM0ZRMQ DN Clomocycline DM0ZRMQ MI TTQ8KVI DM0ZRMQ MN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM0ZRMQ MT DTT DM0ZRMQ MA Binder DM0ZRMQ RN Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5. DM0ZRMQ RU https://pubmed.ncbi.nlm.nih.gov/18219717 DMTO13J DI DMTO13J DMTO13J DN Clonazepam DMTO13J MI DE4LYSA DMTO13J MN Cytochrome P450 3A4 (CYP3A4) DMTO13J MT DME DMTO13J MA Metabolism DMTO13J RN Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75. DMTO13J RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8486332 DMTO13J DI DMTO13J DMTO13J DN Clonazepam DMTO13J MI TTNJYV2 DMTO13J MN Gamma-aminobutyric acid receptor (GAR) DMTO13J MT DTT DMTO13J MA Agonist DMTO13J RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMTO13J RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMTO13J DI DMTO13J DMTO13J DN Clonazepam DMTO13J MI DE0QLUZ DMTO13J MN Oxygen-insensitive NADPH nitroreductase B (nfsB) DMTO13J MT DME DMTO13J MA Metabolism DMTO13J RN Characterization of Escherichia coli nitroreductase NfsB in the metabolism of nitrobenzodiazepines. Biochem Pharmacol. 2009 Jul 1;78(1):96-103. DMTO13J RU https://pubmed.ncbi.nlm.nih.gov/19447228 DMTO13J DI DMTO13J DMTO13J DN Clonazepam DMTO13J MI DEZV4AP DMTO13J MN RNA cytidine acetyltransferase (hALP) DMTO13J MT DME DMTO13J MA Metabolism DMTO13J RN Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5. DMTO13J RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19356010 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI TTQ8AFT DM6RZ9Q MN Adrenergic receptor Alpha-2 (ADRA2) DM6RZ9Q MT DTT DM6RZ9Q MA Agonist DM6RZ9Q RN Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. DM6RZ9Q RU https://pubmed.ncbi.nlm.nih.gov/11164065 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI DEJGDUW DM6RZ9Q MN Cytochrome P450 1A2 (CYP1A2) DM6RZ9Q MT DME DM6RZ9Q MA Metabolism DM6RZ9Q RN CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. DM6RZ9Q RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI DECB0K3 DM6RZ9Q MN Cytochrome P450 2D6 (CYP2D6) DM6RZ9Q MT DME DM6RZ9Q MA Metabolism DM6RZ9Q RN CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. DM6RZ9Q RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI DE4LYSA DM6RZ9Q MN Cytochrome P450 3A4 (CYP3A4) DM6RZ9Q MT DME DM6RZ9Q MA Metabolism DM6RZ9Q RN CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. DM6RZ9Q RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI DEIBDNY DM6RZ9Q MN Cytochrome P450 3A5 (CYP3A5) DM6RZ9Q MT DME DM6RZ9Q MA Metabolism DM6RZ9Q RN CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6. DM6RZ9Q RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20570945 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI TT7HC21 DM6RZ9Q MN Membrane copper amine oxidase (AOC3) DM6RZ9Q MT DTT DM6RZ9Q MA Inhibitor DM6RZ9Q RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM6RZ9Q RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI DTT79CX DM6RZ9Q MN Organic cation transporter 1 (SLC22A1) DM6RZ9Q MT DTP DM6RZ9Q MA Substrate DM6RZ9Q RN Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145. DM6RZ9Q RU http://www.ncbi.nlm.nih.gov/pubmed/28768994 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI DT9IDPW DM6RZ9Q MN Organic cation transporter 2 (SLC22A2) DM6RZ9Q MT DTP DM6RZ9Q MA Substrate DM6RZ9Q RN Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145. DM6RZ9Q RU http://www.ncbi.nlm.nih.gov/pubmed/28768994 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI DT6201N DM6RZ9Q MN Organic cation transporter 3 (SLC22A3) DM6RZ9Q MT DTP DM6RZ9Q MA Substrate DM6RZ9Q RN Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145. DM6RZ9Q RU http://www.ncbi.nlm.nih.gov/pubmed/28768994 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q MI DTUGYRD DM6RZ9Q MN P-glycoprotein 1 (ABCB1) DM6RZ9Q MT DTP DM6RZ9Q MA Substrate DM6RZ9Q RN Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. DM6RZ9Q RU http://www.ncbi.nlm.nih.gov/pubmed/12954186 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H MI DEJGDUW DMOL54H MN Cytochrome P450 1A2 (CYP1A2) DMOL54H MT DME DMOL54H MA Metabolism DMOL54H RN Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet. 2015 Feb;54(2):147-66. DMOL54H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25559342 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H MI DEPKLMQ DMOL54H MN Cytochrome P450 2B6 (CYP2B6) DMOL54H MT DME DMOL54H MA Metabolism DMOL54H RN Clopidogrel pathway. Pharmacogenet Genomics. 2010 Jul;20(7):463-5. DMOL54H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20440227 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H MI DE5IED8 DMOL54H MN Cytochrome P450 2C9 (CYP2C9) DMOL54H MT DME DMOL54H MA Metabolism DMOL54H RN Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41. DMOL54H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17361128 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H MI DE4LYSA DMOL54H MN Cytochrome P450 3A4 (CYP3A4) DMOL54H MT DME DMOL54H MA Metabolism DMOL54H RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMOL54H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H MI DEIBDNY DMOL54H MN Cytochrome P450 3A5 (CYP3A5) DMOL54H MT DME DMOL54H MA Metabolism DMOL54H RN Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41. DMOL54H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17361128 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H MI DEGTFWK DMOL54H MN Mephenytoin 4-hydroxylase (CYP2C19) DMOL54H MT DME DMOL54H MA Metabolism DMOL54H RN Impact of the CYP2C19 gene polymorphism on clopidogrel personalized drug regimen and the clinical outcomes. Clin Lab. 2016 Sep 1;62(9):1773-1780. DMOL54H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28164572 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H MI TTZ1DT0 DMOL54H MN P2Y purinoceptor 12 (P2RY12) DMOL54H MT DTT DMOL54H MA Antagonist DMOL54H RN P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. DMOL54H RU https://pubmed.ncbi.nlm.nih.gov/15199474 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H MI DTUGYRD DMOL54H MN P-glycoprotein 1 (ABCB1) DMOL54H MT DTP DMOL54H MA Substrate DMOL54H RN Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006 Nov;80(5):486-501. DMOL54H RU http://www.ncbi.nlm.nih.gov/pubmed/17112805 DMC3JST DI DMC3JST DMC3JST DN Clorazepate DMC3JST MI DE4LYSA DMC3JST MN Cytochrome P450 3A4 (CYP3A4) DMC3JST MT DME DMC3JST MA Metabolism DMC3JST RN In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20. DMC3JST RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11251565 DMC3JST DI DMC3JST DMC3JST DN Clorazepate DMC3JST MI TTPTXIN DMC3JST MN Translocator protein (TSPO) DMC3JST MT DTT DMC3JST MA Modulator DMC3JST RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC3JST RU https://www.fda.gov/ DMCEUJD DI DMCEUJD DMCEUJD DN Clorgyline DMCEUJD MI TT32XQJ DMCEUJD MN Monoamine oxidase (MAO) DMCEUJD MT DTT DMCEUJD MA Inhibitor DMCEUJD RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCEUJD RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCEUJD DI DMCEUJD DMCEUJD DN Clorgyline DMCEUJD MI TT3WG5C DMCEUJD MN Monoamine oxidase type A (MAO-A) DMCEUJD MT DTT DMCEUJD MA Inhibitor DMCEUJD RN Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6. DMCEUJD RU https://pubmed.ncbi.nlm.nih.gov/19423952 DM6K1OA DI DM6K1OA DM6K1OA DN Clothiapine DM6K1OA MI DERD86B DM6K1OA MN Cytochrome P450 3A7 (CYP3A7) DM6K1OA MT DME DM6K1OA MA Metabolism DM6K1OA RN Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000 May;38(5):393-414. DM6K1OA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10843459 DM59AZT DI DM59AZT DM59AZT DN Clotiazepam DM59AZT MI DEPKLMQ DM59AZT MN Cytochrome P450 2B6 (CYP2B6) DM59AZT MT DME DM59AZT MA Metabolism DM59AZT RN Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6. DM59AZT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545 DM59AZT DI DM59AZT DM59AZT DN Clotiazepam DM59AZT MI DEZMWRE DM59AZT MN Cytochrome P450 2C18 (CYP2C18) DM59AZT MT DME DM59AZT MA Metabolism DM59AZT RN Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6. DM59AZT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545 DM59AZT DI DM59AZT DM59AZT DN Clotiazepam DM59AZT MI DE4LYSA DM59AZT MN Cytochrome P450 3A4 (CYP3A4) DM59AZT MT DME DM59AZT MA Metabolism DM59AZT RN Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6. DM59AZT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545 DM59AZT DI DM59AZT DM59AZT DN Clotiazepam DM59AZT MI DEGTFWK DM59AZT MN Mephenytoin 4-hydroxylase (CYP2C19) DM59AZT MT DME DM59AZT MA Metabolism DM59AZT RN Contribution of human hepatic cytochrome p450 isoforms to the metabolism of psychotropic drugs. Biol Pharm Bull. 2005 Sep;28(9):1711-6. DM59AZT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16141545 DM59AZT DI DM59AZT DM59AZT DN Clotiazepam DM59AZT MI TTPTXIN DM59AZT MN Translocator protein (TSPO) DM59AZT MT DTT DM59AZT MA Agonist DM59AZT RN Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40. DM59AZT RU https://pubmed.ncbi.nlm.nih.gov/2574062 DMMFCIH DI DMMFCIH DMMFCIH DN Clotrimazole DMMFCIH MI TT30C9G DMMFCIH MN C-X-C chemokine receptor type 2 (CXCR2) DMMFCIH MT DTT DMMFCIH MA Modulator DMMFCIH RN Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44. DMMFCIH RU https://www.ncbi.nlm.nih.gov/pubmed/3895959 DMMFCIH DI DMMFCIH DMMFCIH DN Clotrimazole DMMFCIH MI DE4LYSA DMMFCIH MN Cytochrome P450 3A4 (CYP3A4) DMMFCIH MT DME DMMFCIH MA Metabolism DMMFCIH RN Tacrolimus interaction with clotrimazole: a concise case report and literature review. P T. 2010 Oct;35(10):568-9. DMMFCIH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21037909 DMUTL7O DI DMUTL7O DMUTL7O DN Cloxacillin DMUTL7O MI TTJP4SM DMUTL7O MN Bacterial Penicillin binding protein (Bact PBP) DMUTL7O MT DTT DMUTL7O MA Binder DMUTL7O RN Development of a receptor-based microplate assay for the detection of beta-lactam antibiotics in different food matrices. Anal Chim Acta. 2007 Mar 14;586(1-2):296-303. DMUTL7O RU https://pubmed.ncbi.nlm.nih.gov/17386727 DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L MI DEJGDUW DMFC71L MN Cytochrome P450 1A2 (CYP1A2) DMFC71L MT DME DMFC71L MA Metabolism DMFC71L RN Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22. DMFC71L RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17214606 DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L MI DEJVYAZ DMFC71L MN Cytochrome P450 2A6 (CYP2A6) DMFC71L MT DME DMFC71L MA Metabolism DMFC71L RN Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metab Dispos. 2013 Mar;41(3):651-8. DMFC71L RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23297297 DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L MI DES5XRU DMFC71L MN Cytochrome P450 2C8 (CYP2C8) DMFC71L MT DME DMFC71L MA Metabolism DMFC71L RN Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9. DMFC71L RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9840430 DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L MI DE5IED8 DMFC71L MN Cytochrome P450 2C9 (CYP2C9) DMFC71L MT DME DMFC71L MA Metabolism DMFC71L RN Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):592-9. DMFC71L RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9840430 DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L MI DECB0K3 DMFC71L MN Cytochrome P450 2D6 (CYP2D6) DMFC71L MT DME DMFC71L MA Metabolism DMFC71L RN Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84. DMFC71L RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810 DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L MI DE4LYSA DMFC71L MN Cytochrome P450 3A4 (CYP3A4) DMFC71L MT DME DMFC71L MA Metabolism DMFC71L RN Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9. DMFC71L RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10422890 DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L MI TTE0A2F DMFC71L MN Dopamine D4 receptor (D4R) DMFC71L MT DTT DMFC71L MA Modulator DMFC71L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFC71L RU https://www.fda.gov/ DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L MI DEGTFWK DMFC71L MN Mephenytoin 4-hydroxylase (CYP2C19) DMFC71L MT DME DMFC71L MA Metabolism DMFC71L RN Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999 Jun;9(4):301-9. DMFC71L RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10422890 DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L MI DTUGYRD DMFC71L MN P-glycoprotein 1 (ABCB1) DMFC71L MT DTP DMFC71L MA Substrate DMFC71L RN Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. DMFC71L RU http://www.ncbi.nlm.nih.gov/pubmed/15285840 DMPC2QY DI DMPC2QY DMPC2QY DN CNTO-1959 DMPC2QY MI TTC1GLB DMPC2QY MN Interleukin-23 (IL23) DMPC2QY MT DTT DMPC2QY RN Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4. DMPC2QY RU https://pubmed.ncbi.nlm.nih.gov/25807335 DM8HBJI DI DM8HBJI DM8HBJI DN Coagulation Factor IX DM8HBJI MI TTCIHJA DM8HBJI MN Coagulation factor Xa (F10) DM8HBJI MT DTT DM8HBJI MA Activator DM8HBJI RN Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24. DM8HBJI RU https://pubmed.ncbi.nlm.nih.gov/16086639 DM6L4H2 DI DM6L4H2 DM6L4H2 DN Cobicistat DM6L4H2 MI DECB0K3 DM6L4H2 MN Cytochrome P450 2D6 (CYP2D6) DM6L4H2 MT DME DM6L4H2 MA Metabolism DM6L4H2 RN Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Jul;71(7):1755-8. DM6L4H2 RU https://academic.oup.com/jac/article/71/7/1755/1750409 DM6L4H2 DI DM6L4H2 DM6L4H2 DN Cobicistat DM6L4H2 MI TTIJQ3O DM6L4H2 MN Cytochrome P450 3A (CYP3A) DM6L4H2 MT DTT DM6L4H2 MA Modulator DM6L4H2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7535). DM6L4H2 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535 DM6L4H2 DI DM6L4H2 DM6L4H2 DN Cobicistat DM6L4H2 MI DE4LYSA DM6L4H2 MN Cytochrome P450 3A4 (CYP3A4) DM6L4H2 MT DME DM6L4H2 MA Metabolism DM6L4H2 RN Drug interactions between hormonal contraceptives and antiretrovirals. AIDS. 2017 Apr 24;31(7):917-952. DM6L4H2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28060009 DM6L4H2 DI DM6L4H2 DM6L4H2 DN Cobicistat DM6L4H2 MI DEIBDNY DM6L4H2 MN Cytochrome P450 3A5 (CYP3A5) DM6L4H2 MT DME DM6L4H2 MA Metabolism DM6L4H2 RN Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9. DM6L4H2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20043009 DM6L4H2 DI DM6L4H2 DM6L4H2 DN Cobicistat DM6L4H2 MI DERD86B DM6L4H2 MN Cytochrome P450 3A7 (CYP3A7) DM6L4H2 MT DME DM6L4H2 MA Metabolism DM6L4H2 RN Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9. DM6L4H2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20043009 DMDKXTO DI DMDKXTO DMDKXTO DN Cobicistat/darunavir DMDKXTO MI TTIJQ3O DMDKXTO MN Cytochrome P450 3A (CYP3A) DMDKXTO MT DTT DMDKXTO MA Modulator DMDKXTO RN Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb;74(2):195-206. DMDKXTO RU https://pubmed.ncbi.nlm.nih.gov/24343782 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I MI DEIHSMD DMSOX7I MN Butyrylcholine esterase (BCHE) DMSOX7I MT DME DMSOX7I MA Metabolism DMSOX7I RN An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties. Chem Biol Interact. 2008 Sep 25;175(1-3):83-7. DMSOX7I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18514640 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I MI DECB0K3 DMSOX7I MN Cytochrome P450 2D6 (CYP2D6) DMSOX7I MT DME DMSOX7I MA Metabolism DMSOX7I RN Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol. 1991 Jul;40(1):63-8. DMSOX7I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=1857341 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I MI DE4LYSA DMSOX7I MN Cytochrome P450 3A4 (CYP3A4) DMSOX7I MT DME DMSOX7I MA Metabolism DMSOX7I RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMSOX7I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I MI DEIBDNY DMSOX7I MN Cytochrome P450 3A5 (CYP3A5) DMSOX7I MT DME DMSOX7I MA Metabolism DMSOX7I RN Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996 Mar;23(3):515-23. DMSOX7I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8617431 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I MI DERD86B DMSOX7I MN Cytochrome P450 3A7 (CYP3A7) DMSOX7I MT DME DMSOX7I MA Metabolism DMSOX7I RN Drug Interactions Flockhart Table DMSOX7I RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I MI TTVBI8W DMSOX7I MN Dopamine transporter (DAT) DMSOX7I MT DTT DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I MI TTAWNKZ DMSOX7I MN Norepinephrine transporter (NET) DMSOX7I MT DTT DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I MI TT3ROYC DMSOX7I MN Serotonin transporter (SERT) DMSOX7I MT DTT DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG MI DECB0K3 DMJX6ZG MN Cytochrome P450 2D6 (CYP2D6) DMJX6ZG MT DME DMJX6ZG MA Metabolism DMJX6ZG RN Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. DMJX6ZG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19817501 DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG MI DE4LYSA DMJX6ZG MN Cytochrome P450 3A4 (CYP3A4) DMJX6ZG MT DME DMJX6ZG MA Metabolism DMJX6ZG RN Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. DMJX6ZG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429 DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG MI DERD86B DMJX6ZG MN Cytochrome P450 3A7 (CYP3A7) DMJX6ZG MT DME DMJX6ZG MA Metabolism DMJX6ZG RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMJX6ZG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG MI TT27RFC DMJX6ZG MN Opioid receptor delta (OPRD1) DMJX6ZG MT DTT DMJX6ZG MA Agonist DMJX6ZG RN Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. DMJX6ZG RU https://pubmed.ncbi.nlm.nih.gov/15942128 DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG MI DTT79CX DMJX6ZG MN Organic cation transporter 1 (SLC22A1) DMJX6ZG MT DTP DMJX6ZG MA Substrate DMJX6ZG RN Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes. 2015 May;64(5):1786-93. DMJX6ZG RU http://www.ncbi.nlm.nih.gov/pubmed/25510240 DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG MI DEYGVN4 DMJX6ZG MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMJX6ZG MT DME DMJX6ZG MA Metabolism DMJX6ZG RN Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 Sep;31(9):1125-33. DMJX6ZG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12920168 DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG MI DENUPDX DMJX6ZG MN UDP-glucuronosyltransferase 2B4 (UGT2B4) DMJX6ZG MT DME DMJX6ZG MA Metabolism DMJX6ZG RN Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. Br J Clin Pharmacol. 2012 May;73(5):786-94. DMJX6ZG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22092298 DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG MI DEB3CV1 DMJX6ZG MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMJX6ZG MT DME DMJX6ZG MA Metabolism DMJX6ZG RN Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997 Jan;25(1):1-4. DMJX6ZG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9010622 DM2POTE DI DM2POTE DM2POTE DN Colchicine DM2POTE MI DE4LYSA DM2POTE MN Cytochrome P450 3A4 (CYP3A4) DM2POTE MT DME DM2POTE MA Metabolism DM2POTE RN Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9. DM2POTE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12815172 DM2POTE DI DM2POTE DM2POTE DN Colchicine DM2POTE MI DTSYQGK DM2POTE MN Multidrug resistance-associated protein 1 (ABCC1) DM2POTE MT DTP DM2POTE MA Substrate DM2POTE RN Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53. DM2POTE RU http://molpharm.aspetjournals.org/content/52/3/344 DM2POTE DI DM2POTE DM2POTE DN Colchicine DM2POTE MI DTUGYRD DM2POTE MN P-glycoprotein 1 (ABCB1) DM2POTE MT DTP DM2POTE MA Substrate DM2POTE RN Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. DM2POTE RU http://www.ncbi.nlm.nih.gov/pubmed/19427995 DM2POTE DI DM2POTE DM2POTE DN Colchicine DM2POTE MI TTML2WA DM2POTE MN Tubulin (TUB) DM2POTE MT DTT DM2POTE MA Binder DM2POTE RN Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74. DM2POTE RU https://pubmed.ncbi.nlm.nih.gov/19527023 DMJ01D8 DI DMJ01D8 DMJ01D8 DN Colforsin daropate hci DMJ01D8 MI TTULOB6 DMJ01D8 MN Cathelicidin antimicrobial peptide (CAMP) DMJ01D8 MT DTT DMJ01D8 MA Modulator DMJ01D8 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJ01D8 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMZ9BMU DI DMZ9BMU DMZ9BMU DN Colistimethate DMZ9BMU MI TT4ILYC DMZ9BMU MN Bacterial Dihydropteroate synthetase (Bact folP) DMZ9BMU MT DTT DMZ9BMU MA Binder DMZ9BMU RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMZ9BMU RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMMD9QE DI DMMD9QE DMMD9QE DN Colistin DMMD9QE MI TT4ILYC DMMD9QE MN Bacterial Dihydropteroate synthetase (Bact folP) DMMD9QE MT DTT DMMD9QE MA Binder DMMD9QE RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMMD9QE RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMMD9QE DI DMMD9QE DMMD9QE DN Colistin DMMD9QE MI DE2M583 DMMD9QE MN Endoglucanase Y (EGY) DMMD9QE MT DME DMMD9QE MA Metabolism DMMD9QE RN Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63. DMMD9QE RU https://pubmed.ncbi.nlm.nih.gov/10688695 DMMD9QE DI DMMD9QE DMMD9QE DN Colistin DMMD9QE MI DE2AZTG DMMD9QE MN Endoglucanase Y (EGY) DMMD9QE MT DME DMMD9QE MA Metabolism DMMD9QE RN Expression of Clostridium thermocellum endoglucanase gene in Lactobacillus gasseri and Lactobacillus johnsonii and characterization of the genetically modified probiotic lactobacilli. Curr Microbiol. 2000 Apr;40(4):257-63. DMMD9QE RU https://pubmed.ncbi.nlm.nih.gov/10688695 DMFJ2OG DI DMFJ2OG DMFJ2OG DN Collagenase DMFJ2OG MI TTK982E DMFJ2OG MN Collagen (CO) DMFJ2OG MT DTT DMFJ2OG MA Breaker DMFJ2OG RN Contact dermatitis with clostridiopeptidase A contained in Noruxol ointment. Contact Dermatitis. 2007 Jun;56(6):361-2. DMFJ2OG RU https://pubmed.ncbi.nlm.nih.gov/17577383 DM1V329 DI DM1V329 DM1V329 DN Conivaptan DM1V329 MI DE4LYSA DM1V329 MN Cytochrome P450 3A4 (CYP3A4) DM1V329 MT DME DM1V329 MA Metabolism DM1V329 RN Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. DM1V329 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17919259 DM1V329 DI DM1V329 DM1V329 DN Conivaptan DM1V329 MI TT4TFGN DM1V329 MN Vasopressin V1a receptor (V1AR) DM1V329 MT DTT DM1V329 MA Modulator DM1V329 RN Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23. DM1V329 RU https://pubmed.ncbi.nlm.nih.gov/11705818 DM1V329 DI DM1V329 DM1V329 DN Conivaptan DM1V329 MI TTK8R02 DM1V329 MN Vasopressin V2 receptor (V2R) DM1V329 MT DTT DM1V329 MA Modulator DM1V329 RN Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23. DM1V329 RU https://pubmed.ncbi.nlm.nih.gov/11705818 DMLT0E1 DI DMLT0E1 DMLT0E1 DN Conjugated estrogens DMLT0E1 MI DE9RA0I DMLT0E1 MN Beta-glucuronidase (uidA) DMLT0E1 MT DME DMLT0E1 MA Metabolism DMLT0E1 RN Long-term administration of conjugated estrogen and bazedoxifene decreased murine fecal beta-glucuronidase activity without impacting overall microbiome community. Sci Rep. 2018 May 25;8(1):8166. DMLT0E1 RU https://pubmed.ncbi.nlm.nih.gov/29802368 DMLT0E1 DI DMLT0E1 DMLT0E1 DN Conjugated estrogens DMLT0E1 MI DEJGDUW DMLT0E1 MN Cytochrome P450 1A2 (CYP1A2) DMLT0E1 MT DME DMLT0E1 MA Metabolism DMLT0E1 RN Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. J Clin Pharmacol. 2006 Nov;46(11):1299-307. DMLT0E1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17050794 DMLT0E1 DI DMLT0E1 DMLT0E1 DN Conjugated estrogens DMLT0E1 MI DE4LYSA DMLT0E1 MN Cytochrome P450 3A4 (CYP3A4) DMLT0E1 MT DME DMLT0E1 MA Metabolism DMLT0E1 RN Conjugated oestrogens/bazedoxifene. Aust Prescr. 2017 Jun;40(3):114-115. DMLT0E1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28798519 DMLT0E1 DI DMLT0E1 DMLT0E1 DN Conjugated estrogens DMLT0E1 MI TTOM3J0 DMLT0E1 MN Estrogen receptor beta (ESR2) DMLT0E1 MT DTT DMLT0E1 MA Antagonist DMLT0E1 RN Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85. DMLT0E1 RU https://pubmed.ncbi.nlm.nih.gov/19036900 DMTPIZC DI DMTPIZC DMTPIZC DN Conjugated estrogens a DMTPIZC MI TTZAYWL DMTPIZC MN Estrogen receptor (ESR) DMTPIZC MT DTT DMTPIZC MA Modulator DMTPIZC RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMTPIZC RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMU7SF8 DI DMU7SF8 DMU7SF8 DN Conjugated estrogens b DMU7SF8 MI TTZAYWL DMU7SF8 MN Estrogen receptor (ESR) DMU7SF8 MT DTT DMU7SF8 MA Modulator DMU7SF8 RN Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid. No To Shinkei. 1977 Feb;29(2):205-13. DMU7SF8 RU https://pubmed.ncbi.nlm.nih.gov/326277 DMF29Q5 DI DMF29Q5 DMF29Q5 DN Connexyn DMF29Q5 MI TTWG9A4 DMF29Q5 MN Adrenergic receptor alpha-2A (ADRA2A) DMF29Q5 MT DTT DMF29Q5 MA Agonist DMF29Q5 RN alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51. DMF29Q5 RU https://pubmed.ncbi.nlm.nih.gov/19527774 DMF29Q5 DI DMF29Q5 DMF29Q5 DN Connexyn DMF29Q5 MI DE4LYSA DMF29Q5 MN Cytochrome P450 3A4 (CYP3A4) DMF29Q5 MT DME DMF29Q5 MA Metabolism DMF29Q5 RN Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6. DMF29Q5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9396389 DM26KR1 DI DM26KR1 DM26KR1 DN Copper dotatate Cu-64 DM26KR1 MI TTZ6T9E DM26KR1 MN Somatostatin receptor type 2 (SSTR2) DM26KR1 MT DTT DM26KR1 MA Binder DM26KR1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM26KR1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf DMP9TWZ DI DMP9TWZ DMP9TWZ DN Corticotropin DMP9TWZ MI DE4LYSA DMP9TWZ MN Cytochrome P450 3A4 (CYP3A4) DMP9TWZ MT DME DMP9TWZ MA Metabolism DMP9TWZ RN Troglitazone induces CYP3A4 activity leading to falsely abnormal dexamethasone suppression test. J Clin Endocrinol Metab. 2003 Jul;88(7):3113-6. DMP9TWZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12843151 DMU5QZX DI DMU5QZX DMU5QZX DN Cortisone DMU5QZX MI DTUGYRD DMU5QZX MN P-glycoprotein 1 (ABCB1) DMU5QZX MT DTP DMU5QZX MA Substrate DMU5QZX RN Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. DMU5QZX RU http://www.ncbi.nlm.nih.gov/pubmed/14661924 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 MI DEZDRQO DMG8K57 MN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMG8K57 MT DME DMG8K57 MA Metabolism DMG8K57 RN Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101. DMG8K57 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16087724 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 MI DEDH7FP DMG8K57 MN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DMG8K57 MT DME DMG8K57 MA Metabolism DMG8K57 RN Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101. DMG8K57 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16087724 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 MI DE4LYSA DMG8K57 MN Cytochrome P450 3A4 (CYP3A4) DMG8K57 MT DME DMG8K57 MA Metabolism DMG8K57 RN Prediction of tacrolimus metabolism and dosage requirements based on CYP3A4 phenotype and CYP3A5(*)3 genotype in Chinese renal transplant recipients. Acta Pharmacol Sin. 2016 Apr;37(4):555-60. DMG8K57 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26924289 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 MI DEIBDNY DMG8K57 MN Cytochrome P450 3A5 (CYP3A5) DMG8K57 MT DME DMG8K57 MA Metabolism DMG8K57 RN Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63. DMG8K57 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21198436 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 MI DERD86B DMG8K57 MN Cytochrome P450 3A7 (CYP3A7) DMG8K57 MT DME DMG8K57 MA Metabolism DMG8K57 RN Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63. DMG8K57 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21198436 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 MI DEEXSKI DMG8K57 MN Short-chain dehydrogenase/reductase retSDR4 (DHRS7) DMG8K57 MT DME DMG8K57 MA Metabolism DMG8K57 RN Human DHRS7, promising enzyme in metabolism of steroids and retinoids? J Steroid Biochem Mol Biol. 2016 Jan;155(Pt A):112-9. DMG8K57 RU https://pubmed.ncbi.nlm.nih.gov/26466768 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 MI TTP3UTW DMG8K57 MN Steroid hormone receptor ERR (ESRR) DMG8K57 MT DTT DMG8K57 MA Modulator DMG8K57 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMG8K57 RU https://www.fda.gov/ DMUIASK DI DMUIASK DMUIASK DN Cosyntropin DMUIASK MI TTPWFDX DMUIASK MN Melanocortin receptor 2 (MC2R) DMUIASK MT DTT DMUIASK MA Antagonist DMUIASK RN Hypothalamic-pituitary-adrenal axis dysfunction in hospitalized neonatal foals. J Vet Intern Med. 2009 Jul-Aug;23(4):901-12. DMUIASK RU https://pubmed.ncbi.nlm.nih.gov/19496914 DMCEZ1B DI DMCEZ1B DMCEZ1B DN Cotinine DMCEZ1B MI TTJSZTB DMCEZ1B MN Nicotinic acetylcholine receptor (nAChR) DMCEZ1B MT DTT DMCEZ1B MA Modulator DMCEZ1B RN Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31. DMCEZ1B RU https://pubmed.ncbi.nlm.nih.gov/12008000 DMCEZ1B DI DMCEZ1B DMCEZ1B DN Cotinine DMCEZ1B MI DEI8NGH DMCEZ1B MN UDP-glucuronosyltransferase 2B10 (UGT2B10) DMCEZ1B MT DME DMCEZ1B MA Metabolism DMCEZ1B RN Human UDP-glucuronosyltransferase (UGT) 2B10: validation of cotinine as a selective probe substrate, inhibition by UGT enzyme-selective inhibitors and antidepressant and antipsychotic drugs, and structural determinants of enzyme inhibition. Drug Metab Dispos. 2016 Mar;44(3):378-88. DMCEZ1B RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26669329 DMJ7IQX DI DMJ7IQX DMJ7IQX DN Crestor/TriLipix DMJ7IQX MI TTPADOQ DMJ7IQX MN HMG-CoA reductase (HMGCR) DMJ7IQX MT DTT DMJ7IQX MA Inhibitor DMJ7IQX RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMJ7IQX RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMNVKU6 DI DMNVKU6 DMNVKU6 DN Crisaborole DMNVKU6 MI TTV5CGO DMNVKU6 MN Phosphodiesterase 4 (PDE4) DMNVKU6 MT DTT DMNVKU6 MA Modulator DMNVKU6 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMNVKU6 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMAHOVJ DI DMAHOVJ DMAHOVJ DN Crizanlizumab DMAHOVJ MI TTE5VG0 DMAHOVJ MN P-selectin (SELP) DMAHOVJ MT DTT DMAHOVJ MA Inhibitor DMAHOVJ RN Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84. DMAHOVJ RU https://pubmed.ncbi.nlm.nih.gov/31933169 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C MI TTPMQSO DM4F29C MN ALK tyrosine kinase receptor (ALK) DM4F29C MT DTT DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C MI DE4LYSA DM4F29C MN Cytochrome P450 3A4 (CYP3A4) DM4F29C MT DME DM4F29C MA Metabolism DM4F29C RN Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. DM4F29C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23686600 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C MI DEIBDNY DM4F29C MN Cytochrome P450 3A5 (CYP3A5) DM4F29C MT DME DM4F29C MA Metabolism DM4F29C RN Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. DM4F29C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23686600 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C MI TTKA5LP DM4F29C MN HGF/Met signaling pathway (HGF/Met pathway) DM4F29C MT DTT DM4F29C MA Inhibitor DM4F29C RN Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907. DM4F29C RU https://pubmed.ncbi.nlm.nih.gov/26345996 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C MI DT3D8F0 DM4F29C MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DM4F29C MT DTP DM4F29C MA Substrate DM4F29C RN Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66. DM4F29C RU http://www.ncbi.nlm.nih.gov/pubmed/23340295 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C MI DT9C1TS DM4F29C MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DM4F29C MT DTP DM4F29C MA Substrate DM4F29C RN Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66. DM4F29C RU http://www.ncbi.nlm.nih.gov/pubmed/23340295 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C MI DTUGYRD DM4F29C MN P-glycoprotein 1 (ABCB1) DM4F29C MT DTP DM4F29C MA Substrate DM4F29C RN Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94. DM4F29C RU http://www.ncbi.nlm.nih.gov/pubmed/24037730 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C MI TTNDSF4 DM4F29C MN Proto-oncogene c-Met (MET) DM4F29C MT DTT DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C MI TTSZ6Y3 DM4F29C MN Proto-oncogene c-Ros (ROS1) DM4F29C MT DTT DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4AMQZ DI DM4AMQZ DM4AMQZ DN Crofelemer DM4AMQZ MI TTOJI4S DM4AMQZ MN Calcium-dependent chloride channel anoctamin (ANO) DM4AMQZ MT DTT DM4AMQZ MA Modulator DM4AMQZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM4AMQZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM4AMQZ DI DM4AMQZ DM4AMQZ DN Crofelemer DM4AMQZ MI TTRLZHP DM4AMQZ MN cAMP-dependent chloride channel (CFTR) DM4AMQZ MT DTT DM4AMQZ MA Modulator DM4AMQZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM4AMQZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM74LZK DI DM74LZK DM74LZK DN Cromoglicate DM74LZK MI TT78R5H DM74LZK MN Heat shock protein 90 alpha (HSP90A) DM74LZK MT DTT DM74LZK MA Inhibitor DM74LZK RN Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. DM74LZK RU https://pubmed.ncbi.nlm.nih.gov/12803546 DMHCTAL DI DMHCTAL DMHCTAL DN Cryptenamine Acetates DMHCTAL MI TTH18TF DMHCTAL MN Muscarinic acetylcholine receptor M5 (CHRM5) DMHCTAL MT DTT DMHCTAL MA Modulator DMHCTAL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHCTAL RU https://www.fda.gov/ DMB8PF3 DI DMB8PF3 DMB8PF3 DN CT-102 DMB8PF3 MI TTI2WET DMB8PF3 MN Platelet-derived growth factor receptor (PDGFR) DMB8PF3 MT DTT DMB8PF3 MA Activator DMB8PF3 RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMB8PF3 RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMP0NFQ DI DMP0NFQ DMP0NFQ DN Cupric Sulfate DMP0NFQ MI DTP8L4F DMP0NFQ MN High affinity copper uptake protein 1 (SLC31A1) DMP0NFQ MT DTP DMP0NFQ MA Substrate DMP0NFQ RN Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010 Jul 14;30(28):9500-9. DMP0NFQ RU http://www.ncbi.nlm.nih.gov/pubmed/20631178 DMHSJB4 DI DMHSJB4 DMHSJB4 DN Cyclacillin DMHSJB4 MI TTJP4SM DMHSJB4 MN Bacterial Penicillin binding protein (Bact PBP) DMHSJB4 MT DTT DMHSJB4 MA Binder DMHSJB4 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMHSJB4 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMHSJB4 DI DMHSJB4 DMHSJB4 DN Cyclacillin DMHSJB4 MI DT9G7XN DMHSJB4 MN Peptide transporter 1 (SLC15A1) DMHSJB4 MT DTP DMHSJB4 MA Substrate DMHSJB4 RN Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. DMHSJB4 RU http://www.ncbi.nlm.nih.gov/pubmed/16597710 DMHSJB4 DI DMHSJB4 DMHSJB4 DN Cyclacillin DMHSJB4 MI DT8QKNP DMHSJB4 MN Peptide transporter 2 (SLC15A2) DMHSJB4 MT DTP DMHSJB4 MA Substrate DMHSJB4 RN Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. DMHSJB4 RU http://www.ncbi.nlm.nih.gov/pubmed/16597710 DMO0R76 DI DMO0R76 DMO0R76 DN Cyclandelate DMO0R76 MI DE4LYSA DMO0R76 MN Cytochrome P450 3A4 (CYP3A4) DMO0R76 MT DME DMO0R76 MA Metabolism DMO0R76 RN Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. DMO0R76 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822 DM9G7BS DI DM9G7BS DM9G7BS DN Cyclizine DM9G7BS MI TTTIBOJ DM9G7BS MN Histamine H1 receptor (H1R) DM9G7BS MT DTT DM9G7BS MA Antagonist DM9G7BS RN Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6. DM9G7BS RU https://pubmed.ncbi.nlm.nih.gov/12657913 DM1YBRM DI DM1YBRM DM1YBRM DN Cyclobenzaprine DM1YBRM MI TTYSN63 DM1YBRM MN 5-HT 2 receptor (5HT2R) DM1YBRM MT DTT DM1YBRM MA Antagonist DM1YBRM RN Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92. DM1YBRM RU https://pubmed.ncbi.nlm.nih.gov/19590258 DM1YBRM DI DM1YBRM DM1YBRM DN Cyclobenzaprine DM1YBRM MI DEJGDUW DM1YBRM MN Cytochrome P450 1A2 (CYP1A2) DM1YBRM MT DME DM1YBRM MA Metabolism DM1YBRM RN Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. DM1YBRM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577 DM1YBRM DI DM1YBRM DM1YBRM DN Cyclobenzaprine DM1YBRM MI DECB0K3 DM1YBRM MN Cytochrome P450 2D6 (CYP2D6) DM1YBRM MT DME DM1YBRM MA Metabolism DM1YBRM RN Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. DM1YBRM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577 DM1YBRM DI DM1YBRM DM1YBRM DN Cyclobenzaprine DM1YBRM MI DE4LYSA DM1YBRM MN Cytochrome P450 3A4 (CYP3A4) DM1YBRM MT DME DM1YBRM MA Metabolism DM1YBRM RN Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. DM1YBRM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8818577 DMT5RMB DI DMT5RMB DMT5RMB DN Cyclofenil DMT5RMB MI TTZAYWL DMT5RMB MN Estrogen receptor (ESR) DMT5RMB MT DTT DMT5RMB MA Modulator DMT5RMB RN Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem. 2006 Apr 20;49(8):2496-511. DMT5RMB RU https://pubmed.ncbi.nlm.nih.gov/16610793 DMA8LM5 DI DMA8LM5 DMA8LM5 DN Cyclopentolate DMA8LM5 MI TTH18TF DMA8LM5 MN Muscarinic acetylcholine receptor M5 (CHRM5) DMA8LM5 MT DTT DMA8LM5 MA Antagonist DMA8LM5 RN High spatial resolution studies of muscarinic neuroeffector junctions in mouse isolated vas deferens. Neuroscience. 2009 Sep 15;162(4):1366-76. DMA8LM5 RU https://pubmed.ncbi.nlm.nih.gov/19486927 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI DEJVYAZ DM4O2Z7 MN Cytochrome P450 2A6 (CYP2A6) DM4O2Z7 MT DME DM4O2Z7 MA Metabolism DM4O2Z7 RN Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI DEPKLMQ DM4O2Z7 MN Cytochrome P450 2B6 (CYP2B6) DM4O2Z7 MT DME DM4O2Z7 MA Metabolism DM4O2Z7 RN The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12065440 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI DEZMWRE DM4O2Z7 MN Cytochrome P450 2C18 (CYP2C18) DM4O2Z7 MT DME DM4O2Z7 MA Metabolism DM4O2Z7 RN Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10348794 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI DES5XRU DM4O2Z7 MN Cytochrome P450 2C8 (CYP2C8) DM4O2Z7 MT DME DM4O2Z7 MA Metabolism DM4O2Z7 RN Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9157990 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI DE5IED8 DM4O2Z7 MN Cytochrome P450 2C9 (CYP2C9) DM4O2Z7 MT DME DM4O2Z7 MA Metabolism DM4O2Z7 RN CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16475710 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI DE4LYSA DM4O2Z7 MN Cytochrome P450 3A4 (CYP3A4) DM4O2Z7 MT DME DM4O2Z7 MA Metabolism DM4O2Z7 RN Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29129847 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI DERD86B DM4O2Z7 MN Cytochrome P450 3A7 (CYP3A7) DM4O2Z7 MT DME DM4O2Z7 MA Metabolism DM4O2Z7 RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI TTUTN1I DM4O2Z7 MN Human Deoxyribonucleic acid (hDNA) DM4O2Z7 MT DTT DM4O2Z7 MA Modulator DM4O2Z7 RN O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/9714064 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI DEGTFWK DM4O2Z7 MN Mephenytoin 4-hydroxylase (CYP2C19) DM4O2Z7 MT DME DM4O2Z7 MA Metabolism DM4O2Z7 RN Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16550168 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 MI DTCSGPB DM4O2Z7 MN Multidrug resistance-associated protein 4 (ABCC4) DM4O2Z7 MT DTP DM4O2Z7 MA Substrate DM4O2Z7 RN Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8. DM4O2Z7 RU http://www.ncbi.nlm.nih.gov/pubmed/20405259 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 MI TTLD29N DMT1I52 MN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMT1I52 MT DTT DMT1I52 MA Inhibitor DMT1I52 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 MI TT6TMZU DMT1I52 MN Mycobacterium Biosynthetic alanine racemase (MycB alr) DMT1I52 MT DTT DMT1I52 MA Inhibitor DMT1I52 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 MI TTCS3P1 DMT1I52 MN Mycobacterium D-alanine-D-alanine ligase A (MycB ddl) DMT1I52 MT DTT DMT1I52 MA Inhibitor DMT1I52 RN Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase ... J Biol Chem. 2004 Oct 29;279(44):46143-52. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/15302885 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 MI TT9IK2Z DMT1I52 MN N-methyl-D-aspartate receptor (NMDAR) DMT1I52 MT DTT DMT1I52 MA Agonist DMT1I52 RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 MI DT48WEM DMT1I52 MN Proton-coupled amino acid transporter 1 (SLC36A1) DMT1I52 MT DTP DMT1I52 MA Substrate DMT1I52 RN Indirect regulation of the intestinal H+-coupled amino acid transporter hPAT1 (SLC36A1). J Cell Physiol. 2005 Aug;204(2):604-13. DMT1I52 RU http://www.ncbi.nlm.nih.gov/pubmed/15754324 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 MI DTAOPTV DMT1I52 MN Proton-coupled amino acid transporter 2 (SLC36A2) DMT1I52 MT DTP DMT1I52 MA Substrate DMT1I52 RN Substrate specificity and functional characterisation of the H+/amino acid transporter rat PAT2 (Slc36a2). Br J Pharmacol. 2005 Jan;144(1):28-41. DMT1I52 RU http://www.ncbi.nlm.nih.gov/pubmed/15644866 DMJ4AWC DI DMJ4AWC DMJ4AWC DN Cyclothiazide DMJ4AWC MI TTANPDJ DMJ4AWC MN Carbonic anhydrase II (CA-II) DMJ4AWC MT DTT DMJ4AWC MA Inhibitor DMJ4AWC RN Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82. DMJ4AWC RU https://pubmed.ncbi.nlm.nih.gov/8914012 DM8C43Q DI DM8C43Q DM8C43Q DN Cycrimine DM8C43Q MI TTZ9SOR DM8C43Q MN Muscarinic acetylcholine receptor M1 (CHRM1) DM8C43Q MT DTT DM8C43Q MA Binder DM8C43Q RN Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42. DM8C43Q RU https://pubmed.ncbi.nlm.nih.gov/2573609 DMUY2OR DI DMUY2OR DMUY2OR DN Cynarin DMUY2OR MI TTLOQ79 DMUY2OR MN Taste receptor (TASR) DMUY2OR MT DTT DMUY2OR MA Modulator DMUY2OR RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMUY2OR RU https://pubmed.ncbi.nlm.nih.gov/3879679 DM92AH3 DI DM92AH3 DM92AH3 DN Cyproheptadine DM92AH3 MI TTTIBOJ DM92AH3 MN Histamine H1 receptor (H1R) DM92AH3 MT DTT DM92AH3 MA Antagonist DM92AH3 RN Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1;112(3):760-9. DM92AH3 RU https://pubmed.ncbi.nlm.nih.gov/18502826 DM92AH3 DI DM92AH3 DM92AH3 DN Cyproheptadine DM92AH3 MI DEYGVN4 DM92AH3 MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM92AH3 MT DME DM92AH3 MA Metabolism DM92AH3 RN Effect of common exon variant (p.P364L) on drug glucuronidation by the human UDP-glucuronosyltransferase 1 family. Basic Clin Pharmacol Toxicol. 2011 Dec;109(6):486-93. DM92AH3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21726413 DM92AH3 DI DM92AH3 DM92AH3 DN Cyproheptadine DM92AH3 MI DEF2WXN DM92AH3 MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DM92AH3 MT DME DM92AH3 MA Metabolism DM92AH3 RN Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12. DM92AH3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9616184 DMQXLD2 DI DMQXLD2 DMQXLD2 DN Cyproterone DMQXLD2 MI TTS64P2 DMQXLD2 MN Androgen receptor (AR) DMQXLD2 MT DTT DMQXLD2 MA Antagonist DMQXLD2 RN Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74. DMQXLD2 RU https://pubmed.ncbi.nlm.nih.gov/19463689 DMSYFM8 DI DMSYFM8 DMSYFM8 DN Cysteamine DMSYFM8 MI DEA3U9Y DMSYFM8 MN Myeloperoxidase (MPO) DMSYFM8 MT DME DMSYFM8 MA Metabolism DMSYFM8 RN Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75. DMSYFM8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8381104 DMSYFM8 DI DMSYFM8 DMSYFM8 DN Cysteamine DMSYFM8 MI TTWF7UG DMSYFM8 MN Somatostatin (SST) DMSYFM8 MT DTT DMSYFM8 MA Binder DMSYFM8 RN Somatostatin, Alzheimer's disease and cognition: an old story coming of age Prog Neurobiol. 2009 Oct;89(2):153-61. DMSYFM8 RU https://pubmed.ncbi.nlm.nih.gov/19595735 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DT0EQPW DMZD5QR MN Concentrative nucleoside transporter 1 (SLC28A1) DMZD5QR MT DTP DMZD5QR MA Substrate DMZD5QR RN FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799. DMZD5QR RU http://www.ncbi.nlm.nih.gov/pubmed/27391351 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DEKEDRC DMZD5QR MN Cytidine aminohydrolase (CDA) DMZD5QR MT DME DMZD5QR MA Metabolism DMZD5QR RN Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74. DMZD5QR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19842938 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DEYILK4 DMZD5QR MN Cytidine deaminase (cdd) DMZD5QR MT DME DMZD5QR MA Metabolism DMZD5QR RN Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9. DMZD5QR RU https://pubmed.ncbi.nlm.nih.gov/26322268 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DE4LYSA DMZD5QR MN Cytochrome P450 3A4 (CYP3A4) DMZD5QR MT DME DMZD5QR MA Metabolism DMZD5QR RN Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma. J Med Chem. 2006 Dec 28;49(26):7711-20. DMZD5QR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17181153 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DEXL3P2 DMZD5QR MN Deoxycytidylate deaminase (DCTD) DMZD5QR MT DME DMZD5QR MA Metabolism DMZD5QR RN Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74. DMZD5QR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19842938 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DE3Z9HM DMZD5QR MN Ecto-5'-nucleotidase (NT5E) DMZD5QR MT DME DMZD5QR MA Metabolism DMZD5QR RN Genetic factors influencing cytarabine therapy. Pharmacogenomics. 2009 Oct;10(10):1657-74. DMZD5QR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19842938 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DTXD1TQ DMZD5QR MN Equilibrative nucleoside transporter 1 (SLC29A1) DMZD5QR MT DTP DMZD5QR MA Substrate DMZD5QR RN FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799. DMZD5QR RU http://www.ncbi.nlm.nih.gov/pubmed/27391351 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DTW78DQ DMZD5QR MN Equilibrative nucleoside transporter 2 (SLC29A2) DMZD5QR MT DTP DMZD5QR MA Substrate DMZD5QR RN FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799. DMZD5QR RU http://www.ncbi.nlm.nih.gov/pubmed/27391351 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI TTIU7X1 DMZD5QR MN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMZD5QR MT DTT DMZD5QR MA Inhibitor DMZD5QR RN Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72. DMZD5QR RU https://pubmed.ncbi.nlm.nih.gov/19372559 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DTT79CX DMZD5QR MN Organic cation transporter 1 (SLC22A1) DMZD5QR MT DTP DMZD5QR MA Substrate DMZD5QR RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DMZD5QR RU https://doi.org/10.1007/s11095-012-0935-x DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DT2EG60 DMZD5QR MN Organic cation/carnitine transporter 1 (SLC22A4) DMZD5QR MT DTP DMZD5QR MA Substrate DMZD5QR RN OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111. DMZD5QR RU http://www.ncbi.nlm.nih.gov/pubmed/28209616 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR MI DTUGYRD DMZD5QR MN P-glycoprotein 1 (ABCB1) DMZD5QR MT DTP DMZD5QR MA Substrate DMZD5QR RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMZD5QR RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMDI6R4 DI DMDI6R4 DMDI6R4 DN Dabigatran DMDI6R4 MI TT6L509 DMDI6R4 MN Coagulation factor IIa (F2) DMDI6R4 MT DTT DMDI6R4 MA Inhibitor DMDI6R4 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMDI6R4 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMDI6R4 DI DMDI6R4 DMDI6R4 DN Dabigatran DMDI6R4 MI DTUGYRD DMDI6R4 MN P-glycoprotein 1 (ABCB1) DMDI6R4 MT DTP DMDI6R4 MA Substrate DMDI6R4 RN Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849. DMDI6R4 RU http://www.ncbi.nlm.nih.gov/pubmed/29091211 DMX6OE3 DI DMX6OE3 DMX6OE3 DN Dabrafenib DMX6OE3 MI DTI7UX6 DMX6OE3 MN Breast cancer resistance protein (ABCG2) DMX6OE3 MT DTP DMX6OE3 MA Substrate DMX6OE3 RN Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64. DMX6OE3 RU http://www.ncbi.nlm.nih.gov/pubmed/23249624 DMX6OE3 DI DMX6OE3 DMX6OE3 DN Dabrafenib DMX6OE3 MI DES5XRU DMX6OE3 MN Cytochrome P450 2C8 (CYP2C8) DMX6OE3 MT DME DMX6OE3 MA Metabolism DMX6OE3 RN Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. DMX6OE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703 DMX6OE3 DI DMX6OE3 DMX6OE3 DN Dabrafenib DMX6OE3 MI DE4LYSA DMX6OE3 MN Cytochrome P450 3A4 (CYP3A4) DMX6OE3 MT DME DMX6OE3 MA Metabolism DMX6OE3 RN Physiologically based pharmacokinetic modeling to identify physiological and molecular characteristics driving variability in drug exposure. Clin Pharmacol Ther. 2018 Dec;104(6):1219-1228. DMX6OE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29574693 DMX6OE3 DI DMX6OE3 DMX6OE3 DN Dabrafenib DMX6OE3 MI DTUGYRD DMX6OE3 MN P-glycoprotein 1 (ABCB1) DMX6OE3 MT DTP DMX6OE3 MA Substrate DMX6OE3 RN Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther. 2013 Mar;344(3):655-64. DMX6OE3 RU http://www.ncbi.nlm.nih.gov/pubmed/23249624 DMX6OE3 DI DMX6OE3 DMX6OE3 DN Dabrafenib DMX6OE3 MI TTWCGQT DMX6OE3 MN Serine/threonine-protein kinase B-raf (BRAF) DMX6OE3 MT DTT DMX6OE3 MA Inhibitor DMX6OE3 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2011). DMX6OE3 RU http://www.gsk.com/ DMNPZL4 DI DMNPZL4 DMNPZL4 DN Dacarbazine DMNPZL4 MI DE6OQ3W DMNPZL4 MN Cytochrome P450 1A1 (CYP1A1) DMNPZL4 MT DME DMNPZL4 MA Metabolism DMNPZL4 RN Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999 Aug;5(8):2192-7. DMNPZL4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10473105 DMNPZL4 DI DMNPZL4 DMNPZL4 DN Dacarbazine DMNPZL4 MI DEJGDUW DMNPZL4 MN Cytochrome P450 1A2 (CYP1A2) DMNPZL4 MT DME DMNPZL4 MA Metabolism DMNPZL4 RN Study on mesenchymal stem cells mediated enzyme-prodrug gene CYP1A2 targeting anti-tumor effect. Zhonghua Xue Ye Xue Za Zhi. 2009 Oct;30(10):667-71. DMNPZL4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19954661 DMNPZL4 DI DMNPZL4 DMNPZL4 DN Dacarbazine DMNPZL4 MI DEVDYN7 DMNPZL4 MN Cytochrome P450 2E1 (CYP2E1) DMNPZL4 MT DME DMNPZL4 MA Metabolism DMNPZL4 RN Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec;7(12):4239-44. DMNPZL4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11751525 DMNPZL4 DI DMNPZL4 DMNPZL4 DN Dacarbazine DMNPZL4 MI TTUTN1I DMNPZL4 MN Human Deoxyribonucleic acid (hDNA) DMNPZL4 MT DTT DMNPZL4 MA Breaker DMNPZL4 RN Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8. DMNPZL4 RU https://pubmed.ncbi.nlm.nih.gov/19561552 DMSFK9V DI DMSFK9V DMSFK9V DN Daclatasvir DMSFK9V MI DE4LYSA DMSFK9V MN Cytochrome P450 3A4 (CYP3A4) DMSFK9V MT DME DMSFK9V MA Metabolism DMSFK9V RN Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46. DMSFK9V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762 DMSFK9V DI DMSFK9V DMSFK9V DN Daclatasvir DMSFK9V MI DEIBDNY DMSFK9V MN Cytochrome P450 3A5 (CYP3A5) DMSFK9V MT DME DMSFK9V MA Metabolism DMSFK9V RN Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46. DMSFK9V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762 DMSFK9V DI DMSFK9V DMSFK9V DN Daclatasvir DMSFK9V MI DERD86B DMSFK9V MN Cytochrome P450 3A7 (CYP3A7) DMSFK9V MT DME DMSFK9V MA Metabolism DMSFK9V RN Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46. DMSFK9V RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26486762 DMSFK9V DI DMSFK9V DMSFK9V DN Daclatasvir DMSFK9V MI TTCJ2X8 DMSFK9V MN Hepatitis C virus Non-structural 5A (HCV NS5A) DMSFK9V MT DTT DMSFK9V MA Inhibitor DMSFK9V RN 2011 Pipeline of Bristol-Myers Squibb. DMSFK9V RU http://www.bms.com/pages/default.aspx DMSFK9V DI DMSFK9V DMSFK9V DN Daclatasvir DMSFK9V MI DTUGYRD DMSFK9V MN P-glycoprotein 1 (ABCB1) DMSFK9V MT DTP DMSFK9V MA Substrate DMSFK9V RN Influence of ABCB11 and HNF4 genes on daclatasvir plasma concentration: preliminary pharmacogenetic data from the Kineti-C study. J Antimicrob Chemother. 2017 Oct 1;72(10):2846-2849. DMSFK9V RU http://www.ncbi.nlm.nih.gov/pubmed/29091211 DM6OZQV DI DM6OZQV DM6OZQV DN Daclizumab DM6OZQV MI TTF89GD DM6OZQV MN Interleukin-2 (IL2) DM6OZQV MT DTT DM6OZQV MA Modulator DM6OZQV RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM6OZQV RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY MI DE5IED8 DMOH8VY MN Cytochrome P450 2C9 (CYP2C9) DMOH8VY MT DME DMOH8VY MA Metabolism DMOH8VY RN Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466. DMOH8VY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY MI DECB0K3 DMOH8VY MN Cytochrome P450 2D6 (CYP2D6) DMOH8VY MT DME DMOH8VY MA Metabolism DMOH8VY RN Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466. DMOH8VY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY MI DE4LYSA DMOH8VY MN Cytochrome P450 3A4 (CYP3A4) DMOH8VY MT DME DMOH8VY MA Metabolism DMOH8VY RN Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6. Xenobiotica. 2018 May;48(5):459-466. DMOH8VY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28648122 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY MI TTGKNB4 DMOH8VY MN Epidermal growth factor receptor (EGFR) DMOH8VY MT DTT DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY MI TT6EO5L DMOH8VY MN Erbb2 tyrosine kinase receptor (HER2) DMOH8VY MT DTT DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY MI TT0JESD DMOH8VY MN Erbb4 tyrosine kinase receptor (Erbb-4) DMOH8VY MT DTT DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422 DM2YGNW DI DM2YGNW DM2YGNW DN Dactinomycin DM2YGNW MI DTI7UX6 DM2YGNW MN Breast cancer resistance protein (ABCG2) DM2YGNW MT DTP DM2YGNW MA Substrate DM2YGNW RN Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72. DM2YGNW RU https://doi.org/10.1124/mol.63.1.65 DM2YGNW DI DM2YGNW DM2YGNW DN Dactinomycin DM2YGNW MI TTUTN1I DM2YGNW MN Human Deoxyribonucleic acid (hDNA) DM2YGNW MT DTT DM2YGNW MA Breaker DM2YGNW RN Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215. DM2YGNW RU https://pubmed.ncbi.nlm.nih.gov/10576292 DM2YGNW DI DM2YGNW DM2YGNW DN Dactinomycin DM2YGNW MI DTSYQGK DM2YGNW MN Multidrug resistance-associated protein 1 (ABCC1) DM2YGNW MT DTP DM2YGNW MA Substrate DM2YGNW RN Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 1995 Nov 15;55(22):5342-7. DM2YGNW RU http://cancerres.aacrjournals.org/content/55/22/5342 DM2YGNW DI DM2YGNW DM2YGNW DN Dactinomycin DM2YGNW MI DTUGYRD DM2YGNW MN P-glycoprotein 1 (ABCB1) DM2YGNW MT DTP DM2YGNW MA Substrate DM2YGNW RN Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35. DM2YGNW RU https://doi.org/10.1111/j.0013-9580.2005.31904.x DMGMNH3 DI DMGMNH3 DMGMNH3 DN Dalbavancin DMGMNH3 MI TTXMY0J DMGMNH3 MN Pancreatic triacylglycerol lipase (PNLIP) DMGMNH3 MT DTT DMGMNH3 MA Inhibitor DMGMNH3 RN Pfizer. Product Development Pipeline. March 31 2009. DMGMNH3 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMM0PDO DI DMM0PDO DMM0PDO DN Dalfampridine DMM0PDO MI DEVDYN7 DMM0PDO MN Cytochrome P450 2E1 (CYP2E1) DMM0PDO MT DME DMM0PDO MA Metabolism DMM0PDO RN Dalfampridine: a medication to improve walking in patients with multiple sclerosis. Ann Pharmacother. 2012 Jul-Aug;46(7-8):1010-5. DMM0PDO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22764324 DMM0PDO DI DMM0PDO DMM0PDO DN Dalfampridine DMM0PDO MI TT1VOHK DMM0PDO MN Potassium channel unspecific (KC) DMM0PDO MT DTT DMM0PDO MA Modulator DMM0PDO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMM0PDO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM4LTKV DI DM4LTKV DM4LTKV DN Dalfopristin DM4LTKV MI TTUWYEA DM4LTKV MN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4LTKV MT DTT DM4LTKV MA Binder DM4LTKV RN The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9. DM4LTKV RU https://pubmed.ncbi.nlm.nih.gov/15991995 DM6CLBN DI DM6CLBN DM6CLBN DN Danaparoid DM6CLBN MI TTCIHJA DM6CLBN MN Coagulation factor Xa (F10) DM6CLBN MT DTT DM6CLBN MA Inhibitor DM6CLBN RN Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6. DM6CLBN RU https://pubmed.ncbi.nlm.nih.gov/12402196 DML8KTN DI DML8KTN DML8KTN DN Danazol DML8KTN MI TTZAYWL DML8KTN MN Estrogen receptor (ESR) DML8KTN MT DTT DML8KTN MA Antagonist DML8KTN RN Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors. Proc Soc Exp Biol Med. 1990 May;194(1):54-7. DML8KTN RU https://pubmed.ncbi.nlm.nih.gov/2326286 DM1D8XY DI DM1D8XY DM1D8XY DN Dantrolene DM1D8XY MI DE4LYSA DM1D8XY MN Cytochrome P450 3A4 (CYP3A4) DM1D8XY MT DME DM1D8XY MA Metabolism DM1D8XY RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DM1D8XY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DM1D8XY DI DM1D8XY DM1D8XY DN Dantrolene DM1D8XY MI TT9YXM1 DM1D8XY MN Ryanodine receptor (RYR) DM1D8XY MT DTT DM1D8XY MA Modulator DM1D8XY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1D8XY RU https://www.fda.gov/ DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG MI DEJGDUW DM28UJG MN Cytochrome P450 1A2 (CYP1A2) DM28UJG MT DME DM28UJG MA Metabolism DM28UJG RN Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. DM28UJG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG MI DEJVYAZ DM28UJG MN Cytochrome P450 2A6 (CYP2A6) DM28UJG MT DME DM28UJG MA Metabolism DM28UJG RN Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. DM28UJG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG MI DE5IED8 DM28UJG MN Cytochrome P450 2C9 (CYP2C9) DM28UJG MT DME DM28UJG MA Metabolism DM28UJG RN Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. DM28UJG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG MI DECB0K3 DM28UJG MN Cytochrome P450 2D6 (CYP2D6) DM28UJG MT DME DM28UJG MA Metabolism DM28UJG RN Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. DM28UJG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG MI DE4LYSA DM28UJG MN Cytochrome P450 3A4 (CYP3A4) DM28UJG MT DME DM28UJG MA Metabolism DM28UJG RN Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. DM28UJG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG MI TTLWPVF DM28UJG MN Sodium/glucose cotransporter 2 (SGLT2) DM28UJG MT DTT DM28UJG MA Modulator DM28UJG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM28UJG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG MI DE85D2P DM28UJG MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DM28UJG MT DME DM28UJG MA Metabolism DM28UJG RN Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. DM28UJG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG MI DEB3CV1 DM28UJG MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DM28UJG MT DME DM28UJG MA Metabolism DM28UJG RN Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. DM28UJG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24105299 DM34TXO DI DM34TXO DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO MI TTDIGC1 DM34TXO MN Dipeptidyl peptidase 4 (DPP-4) DM34TXO MT DTT DM34TXO MA Modulator DM34TXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM34TXO RU https://www.fda.gov/ DM34TXO DI DM34TXO DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO MI TTLWPVF DM34TXO MN Sodium/glucose cotransporter 2 (SGLT2) DM34TXO MT DTT DM34TXO MA Modulator DM34TXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM34TXO RU https://www.fda.gov/ DMOXJKF DI DMOXJKF DMOXJKF DN Dapiprazole DMOXJKF MI TTEX248 DMOXJKF MN Dopamine D2 receptor (D2R) DMOXJKF MT DTT DMOXJKF MA Antagonist DMOXJKF RN Effect of ibopamine on aqueous humor production in normotensive humans. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4853-8. DMOXJKF RU https://pubmed.ncbi.nlm.nih.gov/14578408 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DEZMWRE DM4LT8A MN Cytochrome P450 2C18 (CYP2C18) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8. DM4LT8A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DES5XRU DM4LT8A MN Cytochrome P450 2C8 (CYP2C8) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8. DM4LT8A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DE5IED8 DM4LT8A MN Cytochrome P450 2C9 (CYP2C9) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41. DM4LT8A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15130760 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DEVDYN7 DM4LT8A MN Cytochrome P450 2E1 (CYP2E1) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8. DM4LT8A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DE4LYSA DM4LT8A MN Cytochrome P450 3A4 (CYP3A4) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):164-171. DM4LT8A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8742227 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DEIBDNY DM4LT8A MN Cytochrome P450 3A5 (CYP3A5) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN Drug Interactions Flockhart Table DM4LT8A RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DERD86B DM4LT8A MN Cytochrome P450 3A7 (CYP3A7) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN Drug Interactions Flockhart Table DM4LT8A RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DEGTFWK DM4LT8A MN Mephenytoin 4-hydroxylase (CYP2C19) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8. DM4LT8A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10901692 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DEA3U9Y DM4LT8A MN Myeloperoxidase (MPO) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM4LT8A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI TT6NHYC DM4LT8A MN Pneumocystis carinii Dihydropteroate synthase (PC DHPS) DM4LT8A MT DTT DM4LT8A MA Modulator DM4LT8A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4LT8A RU https://www.fda.gov/ DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DE073H6 DM4LT8A MN Prostaglandin G/H synthase 1 (COX-1) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM4LT8A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A MI DE492CE DM4LT8A MN Prostaglandin G/H synthase 2 (COX-2) DM4LT8A MT DME DM4LT8A MA Metabolism DM4LT8A RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM4LT8A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMKDU16 DI DMKDU16 DMKDU16 DN Daptomycin DMKDU16 MI TT4ILYC DMKDU16 MN Bacterial Dihydropteroate synthetase (Bact folP) DMKDU16 MT DTT DMKDU16 MA Binder DMKDU16 RN Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57. DMKDU16 RU https://pubmed.ncbi.nlm.nih.gov/15271353 DMFDQ3I DI DMFDQ3I DMFDQ3I DN Daptomycin DMFDQ3I MI DE49HWX DMFDQ3I MN CDP-alcohol phosphatidyltransferase (pgsA) DMFDQ3I MT DME DMFDQ3I MA Metabolism DMFDQ3I RN Mutations in cdsA and pgsA correlate with daptomycin resistance in Streptococcus mitis and S. oralis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01531-18. DMFDQ3I RU https://pubmed.ncbi.nlm.nih.gov/30509945 DMFDQ3I DI DMFDQ3I DMFDQ3I DN Daptomycin DMFDQ3I MI DETMA7Z DMFDQ3I MN CDP-alcohol phosphatidyltransferase (pgsA) DMFDQ3I MT DME DMFDQ3I MA Metabolism DMFDQ3I RN Mutations in cdsA and pgsA correlate with daptomycin resistance in Streptococcus mitis and S. oralis. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01531-18. DMFDQ3I RU https://pubmed.ncbi.nlm.nih.gov/30509945 DMKCIUZ DI DMKCIUZ DMKCIUZ DN Daratumumab DMKCIUZ MI TTPURFN DMKCIUZ MN Cyclic ADP-ribose hydrolase 1 (CD38) DMKCIUZ MT DTT DMKCIUZ RN Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. DMKCIUZ RU https://pubmed.ncbi.nlm.nih.gov/26308596 DMMJTYW DI DMMJTYW DMMJTYW DN Darbepoetin alfa DMMJTYW MI TTAUX24 DMMJTYW MN Erythropoietin Receptor (EPOR) DMMJTYW MT DTT DMMJTYW MA Agonist DMMJTYW RN A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9. DMMJTYW RU https://pubmed.ncbi.nlm.nih.gov/10406949 DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ MI DECB0K3 DMWXLYZ MN Cytochrome P450 2D6 (CYP2D6) DMWXLYZ MT DME DMWXLYZ MA Metabolism DMWXLYZ RN The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. DMWXLYZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16584282 DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ MI DE4LYSA DMWXLYZ MN Cytochrome P450 3A4 (CYP3A4) DMWXLYZ MT DME DMWXLYZ MA Metabolism DMWXLYZ RN The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet. 2006;45(4):325-50. DMWXLYZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16584282 DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ MI TTOXS3C DMWXLYZ MN Muscarinic acetylcholine receptor (CHRM) DMWXLYZ MT DTT DMWXLYZ MA Antagonist DMWXLYZ RN Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84. DMWXLYZ RU https://pubmed.ncbi.nlm.nih.gov/9029489 DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ MI TTQ13Z5 DMWXLYZ MN Muscarinic acetylcholine receptor M3 (CHRM3) DMWXLYZ MT DTT DMWXLYZ MA Antagonist DMWXLYZ RN M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. DMWXLYZ RU https://pubmed.ncbi.nlm.nih.gov/19416629 DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT MI TTS64P2 DMV7YFT MN Androgen receptor (AR) DMV7YFT MT DTT DMV7YFT MA Antagonist DMV7YFT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMV7YFT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT MI DE4LYSA DMV7YFT MN Cytochrome P450 3A4 (CYP3A4) DMV7YFT MT DME DMV7YFT MA Metabolism DMV7YFT RN Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. DMV7YFT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146 DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT MI DEYGVN4 DMV7YFT MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMV7YFT MT DME DMV7YFT MA Metabolism DMV7YFT RN Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. DMV7YFT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146 DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT MI DEF2WXN DMV7YFT MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMV7YFT MT DME DMV7YFT MA Metabolism DMV7YFT RN Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. DMV7YFT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146 DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT MI DE2GB8N DMV7YFT MN UDP-glucuronosyltransferase 1A8 (UGT1A8) DMV7YFT MT DME DMV7YFT MA Metabolism DMV7YFT RN Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. DMV7YFT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146 DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT MI DE85D2P DMV7YFT MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMV7YFT MT DME DMV7YFT MA Metabolism DMV7YFT RN Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. DMV7YFT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146 DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT MI DEAZDL8 DMV7YFT MN UDP-glucuronosyltransferase 2B17 (UGT2B17) DMV7YFT MT DME DMV7YFT MA Metabolism DMV7YFT RN Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. DMV7YFT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31571146 DMN3GCH DI DMN3GCH DMN3GCH DN Darunavir DMN3GCH MI DE4LYSA DMN3GCH MN Cytochrome P450 3A4 (CYP3A4) DMN3GCH MT DME DMN3GCH MA Metabolism DMN3GCH RN Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48(4):211-41. DMN3GCH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19492868 DMN3GCH DI DMN3GCH DMN3GCH DN Darunavir DMN3GCH MI TT5FNQT DMN3GCH MN Human immunodeficiency virus Protease (HIV PR) DMN3GCH MT DTT DMN3GCH MA Modulator DMN3GCH RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMN3GCH RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMN3GCH DI DMN3GCH DMN3GCH DN Darunavir DMN3GCH MI DTE2B1D DMN3GCH MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DMN3GCH MT DTP DMN3GCH MA Substrate DMN3GCH RN P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull. 2009 Sep;32(9):1588-93. DMN3GCH RU https://doi.org/10.1248/bpb.32.1588 DMN3GCH DI DMN3GCH DMN3GCH DN Darunavir DMN3GCH MI DT3D8F0 DMN3GCH MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMN3GCH MT DTP DMN3GCH MA Substrate DMN3GCH RN Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. DMN3GCH RU http://www.ncbi.nlm.nih.gov/pubmed/21245207 DMN3GCH DI DMN3GCH DMN3GCH DN Darunavir DMN3GCH MI DTUGYRD DMN3GCH MN P-glycoprotein 1 (ABCB1) DMN3GCH MT DTP DMN3GCH MA Substrate DMN3GCH RN Impact of drug transporters on cellular resistance towards saquinavir and darunavir. J Antimicrob Chemother. 2010 Nov;65(11):2319-28. DMN3GCH RU https://doi.org/10.1093/jac/dkq324 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI DTI7UX6 DMJV2EK MN Breast cancer resistance protein (ABCG2) DMJV2EK MT DTP DMJV2EK MA Substrate DMJV2EK RN Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. DMJV2EK RU http://www.ncbi.nlm.nih.gov/pubmed/19785662 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI DEJGDUW DMJV2EK MN Cytochrome P450 1A2 (CYP1A2) DMJV2EK MT DME DMJV2EK MA Metabolism DMJV2EK RN Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. DMJV2EK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI DE4LYSA DMJV2EK MN Cytochrome P450 3A4 (CYP3A4) DMJV2EK MT DME DMJV2EK MA Metabolism DMJV2EK RN Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. DMJV2EK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI DEIBDNY DMJV2EK MN Cytochrome P450 3A5 (CYP3A5) DMJV2EK MT DME DMJV2EK MA Metabolism DMJV2EK RN Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. DMJV2EK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI DEP76YL DMJV2EK MN Dimethylaniline oxidase 3 (FMO3) DMJV2EK MT DME DMJV2EK MA Metabolism DMJV2EK RN Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. DMJV2EK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18556438 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI TTS7G69 DMJV2EK MN Fusion protein Bcr-Abl (Bcr-Abl) DMJV2EK MT DTT DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI TT2B9KF DMJV2EK MN Fyn tyrosine protein kinase (FYN) DMJV2EK MT DTT DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI TT860QF DMJV2EK MN LCK tyrosine protein kinase (LCK) DMJV2EK MT DTT DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI DT3D8F0 DMJV2EK MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMJV2EK MT DTP DMJV2EK MA Substrate DMJV2EK RN Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66. DMJV2EK RU http://www.ncbi.nlm.nih.gov/pubmed/23340295 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI DT9C1TS DMJV2EK MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMJV2EK MT DTP DMJV2EK MA Substrate DMJV2EK RN Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66. DMJV2EK RU http://www.ncbi.nlm.nih.gov/pubmed/23340295 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI DTUGYRD DMJV2EK MN P-glycoprotein 1 (ABCB1) DMJV2EK MT DTP DMJV2EK MA Substrate DMJV2EK RN Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. DMJV2EK RU http://www.ncbi.nlm.nih.gov/pubmed/20423956 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK MI TT6PKBN DMJV2EK MN Proto-oncogene c-Src (SRC) DMJV2EK MT DTT DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM74SVE DI DM74SVE DM74SVE DN Dasiglucagon DM74SVE MI TT9O6WS DM74SVE MN Glucagon receptor (GCGR) DM74SVE MT DTT DM74SVE MA Agonist DM74SVE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DM74SVE RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV MI TTVBI8W DMLDQFV MN Dopamine transporter (DAT) DMLDQFV MT DTT DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV MI TTAWNKZ DMLDQFV MN Norepinephrine transporter (NET) DMLDQFV MT DTT DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV MI TT3ROYC DMLDQFV MN Serotonin transporter (SERT) DMLDQFV MT DTT DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV MI TT8G3Z7 DMLDQFV MN Serotoninnorepinephrinedopamine reuptake (SNDR) DMLDQFV MT DTT DMLDQFV MA Inhibitor DMLDQFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLDQFV RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DTI7UX6 DMQUSBT MN Breast cancer resistance protein (ABCG2) DMQUSBT MT DTP DMQUSBT MA Substrate DMQUSBT RN Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7. DMQUSBT RU http://www.ncbi.nlm.nih.gov/pubmed/11437380 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DE6OQ3W DMQUSBT MN Cytochrome P450 1A1 (CYP1A1) DMQUSBT MT DME DMQUSBT MA Metabolism DMQUSBT RN The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91. DMQUSBT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DEJGDUW DMQUSBT MN Cytochrome P450 1A2 (CYP1A2) DMQUSBT MT DME DMQUSBT MA Metabolism DMQUSBT RN The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91. DMQUSBT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DE4LYSA DMQUSBT MN Cytochrome P450 3A4 (CYP3A4) DMQUSBT MT DME DMQUSBT MA Metabolism DMQUSBT RN The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro. Physiol Res. 2004;53(6):683-91. DMQUSBT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15588138 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI TTABD5E DMQUSBT MN DNA replication (DNA repli) DMQUSBT MT DTT DMQUSBT MA Modulator DMQUSBT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQUSBT RU https://www.fda.gov/ DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI TTUTN1I DMQUSBT MN Human Deoxyribonucleic acid (hDNA) DMQUSBT MT DTT DMQUSBT MA Intercalator DMQUSBT RN 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12. DMQUSBT RU https://pubmed.ncbi.nlm.nih.gov/2472832 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DTSYQGK DMQUSBT MN Multidrug resistance-associated protein 1 (ABCC1) DMQUSBT MT DTP DMQUSBT MA Substrate DMQUSBT RN Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83. DMQUSBT RU http://www.ncbi.nlm.nih.gov/pubmed/10917554 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DT582KR DMQUSBT MN Multidrug resistance-associated protein 6 (ABCC6) DMQUSBT MT DTP DMQUSBT MA Substrate DMQUSBT RN Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. DMQUSBT RU http://www.ncbi.nlm.nih.gov/pubmed/12414644 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DE3N2FM DMQUSBT MN NADPH-cytochrome P450 reductase (CPR) DMQUSBT MT DME DMQUSBT MA Metabolism DMQUSBT RN Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97. DMQUSBT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10543722 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DE9JFMC DMQUSBT MN NADPH-dependent carbonyl reductase 1 (CBR1) DMQUSBT MT DME DMQUSBT MA Metabolism DMQUSBT RN Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact. 2008 Jul 30;174(2):98-108. DMQUSBT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18579125 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DEIVKZ8 DMQUSBT MN NADPH-dependent carbonyl reductase 3 (CBR3) DMQUSBT MT DME DMQUSBT MA Metabolism DMQUSBT RN Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63. DMQUSBT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20007405 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT MI DTUGYRD DMQUSBT MN P-glycoprotein 1 (ABCB1) DMQUSBT MT DTP DMQUSBT MA Substrate DMQUSBT RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMQUSBT RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMC50ME DI DMC50ME DMC50ME DN Debrisoquin DMC50ME MI TTT04VN DMC50ME MN Adrenergic neuron (AD neuro) DMC50ME MT DTT DMC50ME MA Blocker DMC50ME RN Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596-604. DMC50ME RU https://pubmed.ncbi.nlm.nih.gov/5431666 DMC50ME DI DMC50ME DMC50ME DN Debrisoquin DMC50ME MI DE6OQ3W DMC50ME MN Cytochrome P450 1A1 (CYP1A1) DMC50ME MT DME DMC50ME MA Metabolism DMC50ME RN 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine. J Pharmacol Exp Ther. 2002 Jun;301(3):1025-32. DMC50ME RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12023534 DMC50ME DI DMC50ME DMC50ME DN Debrisoquin DMC50ME MI DECB0K3 DMC50ME MN Cytochrome P450 2D6 (CYP2D6) DMC50ME MT DME DMC50ME MA Metabolism DMC50ME RN Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution. Proteins. 2005 May 1;59(2):339-46. DMC50ME RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15726636 DMC50ME DI DMC50ME DMC50ME DN Debrisoquin DMC50ME MI DTT79CX DMC50ME MN Organic cation transporter 1 (SLC22A1) DMC50ME MT DTP DMC50ME MA Substrate DMC50ME RN The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol. 2012 May 15;83(10):1427-34. DMC50ME RU https://doi.org/10.1016/j.bcp.2012.01.032 DMC50ME DI DMC50ME DMC50ME DN Debrisoquin DMC50ME MI DTUGYRD DMC50ME MN P-glycoprotein 1 (ABCB1) DMC50ME MT DTP DMC50ME MA Substrate DMC50ME RN Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. DMC50ME RU http://www.ncbi.nlm.nih.gov/pubmed/10213372 DMSBRUW DI DMSBRUW DMSBRUW DN Decamethonium DMSBRUW MI TT54JVQ DMSBRUW MN Neuronal acetylcholine receptor alpha-1 (CHRNA1) DMSBRUW MT DTT DMSBRUW MA Modulator DMSBRUW RN Potency of nondepolarizing muscle relaxants on muscle-type acetylcholine receptors in denervated mouse skeletal muscle.Acta Pharmacol Sin.2010 Dec;31(12):1541-6. DMSBRUW RU https://www.ncbi.nlm.nih.gov/pubmed/21102480 DMQL8XJ DI DMQL8XJ DMQL8XJ DN Decitabine DMQL8XJ MI DEKEDRC DMQL8XJ MN Cytidine aminohydrolase (CDA) DMQL8XJ MT DME DMQL8XJ MA Metabolism DMQL8XJ RN Tracking decitabine incorporation into malignant myeloid cell DNA in vitro and in vivo by LC-MS/MS with enzymatic digestion. Sci Rep. 2019 Mar 14;9(1):4558. DMQL8XJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30872721 DMQL8XJ DI DMQL8XJ DMQL8XJ DN Decitabine DMQL8XJ MI DEYILK4 DMQL8XJ MN Cytidine deaminase (cdd) DMQL8XJ MT DME DMQL8XJ MA Metabolism DMQL8XJ RN Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9. DMQL8XJ RU https://pubmed.ncbi.nlm.nih.gov/26322268 DMQL8XJ DI DMQL8XJ DMQL8XJ DN Decitabine DMQL8XJ MI TTUTN1I DMQL8XJ MN Human Deoxyribonucleic acid (hDNA) DMQL8XJ MT DTT DMQL8XJ MA Modulator DMQL8XJ RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMQL8XJ RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM6ETS0 DI DM6ETS0 DM6ETS0 DN Deferasirox DM6ETS0 MI DEYGVN4 DM6ETS0 MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM6ETS0 MT DME DM6ETS0 MA Metabolism DM6ETS0 RN Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554. DM6ETS0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28346059 DM6ETS0 DI DM6ETS0 DM6ETS0 DN Deferasirox DM6ETS0 MI DEF2WXN DM6ETS0 MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DM6ETS0 MT DME DM6ETS0 MA Metabolism DM6ETS0 RN Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554. DM6ETS0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28346059 DMS2M7O DI DMS2M7O DMS2M7O DN Deferiprone DMS2M7O MI TTUDR0C DMS2M7O MN Iron (Fe) DMS2M7O MT DTT DMS2M7O MA Modulator DMS2M7O RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMS2M7O RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMS2M7O DI DMS2M7O DMS2M7O DN Deferiprone DMS2M7O MI DESD26P DMS2M7O MN UDP-glucuronosyltransferase 1A6 (UGT1A6) DMS2M7O MT DME DMS2M7O MA Metabolism DMS2M7O RN Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9. DMS2M7O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18971318 DMTUKZH DI DMTUKZH DMTUKZH DN Deferoxamine mesylate DMTUKZH MI TTUDR0C DMTUKZH MN Iron (Fe) DMTUKZH MT DTT DMTUKZH MA Modulator DMTUKZH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTUKZH RU https://www.fda.gov/ DMV0RNS DI DMV0RNS DMV0RNS DN Deflazacort DMV0RNS MI DE4LYSA DMV0RNS MN Cytochrome P450 3A4 (CYP3A4) DMV0RNS MT DME DMV0RNS MA Metabolism DMV0RNS RN Mechanisms and clinical significance of pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017. Drug Metab Dispos. 2019 Feb;47(2):135-144. DMV0RNS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30442649 DMV0RNS DI DMV0RNS DMV0RNS DN Deflazacort DMV0RNS MI TTYRL6O DMV0RNS MN Glucocorticoid receptor (NR3C1) DMV0RNS MT DTT DMV0RNS MA Modulator DMV0RNS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMV0RNS RU https://www.fda.gov/ DMV0RNS DI DMV0RNS DMV0RNS DN Deflazacort DMV0RNS MI DTUGYRD DMV0RNS MN P-glycoprotein 1 (ABCB1) DMV0RNS MT DTP DMV0RNS MA Substrate DMV0RNS RN KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) DMV0RNS RU https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665 DM3O8QY DI DM3O8QY DM3O8QY DN Degarelix DM3O8QY MI TT8R70G DM3O8QY MN Gonadotropin-releasing hormone receptor (GNRHR) DM3O8QY MT DTT DM3O8QY MA Inhibitor DM3O8QY RN Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60. DM3O8QY RU https://pubmed.ncbi.nlm.nih.gov/16033265 DM4Q80H DI DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H MI DTI7UX6 DM4Q80H MN Breast cancer resistance protein (ABCG2) DM4Q80H MT DTP DM4Q80H MA Substrate DM4Q80H RN A prediction model of substrates and non-substrates of breast cancer resistance protein (BCRP) developed by GA-CG-SVM method. Comput Biol Med. 2011 Nov;41(11):1006-13. DM4Q80H RU https://doi.org/10.1016/j.compbiomed.2011.08.009 DM4Q80H DI DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H MI DTSYQGK DM4Q80H MN Multidrug resistance-associated protein 1 (ABCC1) DM4Q80H MT DTP DM4Q80H MA Substrate DM4Q80H RN Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7. DM4Q80H RU http://www.ncbi.nlm.nih.gov/pubmed/12523936 DM4Q80H DI DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H MI DTFI42L DM4Q80H MN Multidrug resistance-associated protein 2 (ABCC2) DM4Q80H MT DTP DM4Q80H MA Substrate DM4Q80H RN Directional trans-epithelial transport of organic anions in porcine LLC-PK1 cells that co-express human OATP1B1 (OATP-C) and MRP2. Biochem Pharmacol. 2005 Feb 1;69(3):415-23. DM4Q80H RU http://www.ncbi.nlm.nih.gov/pubmed/15652233 DM4Q80H DI DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H MI DTQ3ZHF DM4Q80H MN Multidrug resistance-associated protein 3 (ABCC3) DM4Q80H MT DTP DM4Q80H MA Substrate DM4Q80H RN Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur J Pharm Sci. 2006 Apr;27(5):447-86. DM4Q80H RU https://doi.org/10.1016/j.ejps.2005.12.007 DM4Q80H DI DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H MI DTCSGPB DM4Q80H MN Multidrug resistance-associated protein 4 (ABCC4) DM4Q80H MT DTP DM4Q80H MA Substrate DM4Q80H RN Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J. 2003 Apr 15;371(Pt 2):361-7. DM4Q80H RU http://www.ncbi.nlm.nih.gov/pubmed/12523936 DM4Q80H DI DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H MI DTE2B1D DM4Q80H MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DM4Q80H MT DTP DM4Q80H MA Substrate DM4Q80H RN Membrane transporters in drug development. Nat Rev Drug Discov. 2010 Mar;9(3):215-36. DM4Q80H RU https://doi.org/10.1038/nrd3028 DM4Q80H DI DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H MI DT3D8F0 DM4Q80H MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DM4Q80H MT DTP DM4Q80H MA Substrate DM4Q80H RN Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. DM4Q80H RU http://www.ncbi.nlm.nih.gov/pubmed/21245207 DM4Q80H DI DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H MI DT9C1TS DM4Q80H MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DM4Q80H MT DTP DM4Q80H MA Substrate DM4Q80H RN LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99. DM4Q80H RU http://www.ncbi.nlm.nih.gov/pubmed/11375950 DM4Q80H DI DM4Q80H DM4Q80H DN Dehydroepiandrosterone sulfate DM4Q80H MI DTPFTEQ DM4Q80H MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DM4Q80H MT DTP DM4Q80H MA Substrate DM4Q80H RN Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One. 2011;6(5):e20372. DM4Q80H RU https://doi.org/10.1371/journal.pone.0020372 DMVTU5Q DI DMVTU5Q DMVTU5Q DN Delafloxacin Meglumine DMVTU5Q MI TTZ82MR DMVTU5Q MN Plasmodium DNA gyrase (Malaria gyrase) DMVTU5Q MT DTT DMVTU5Q MA Inhibitor DMVTU5Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMVTU5Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMVTU5Q DI DMVTU5Q DMVTU5Q DN Delafloxacin Meglumine DMVTU5Q MI TTIXTO3 DMVTU5Q MN Staphylococcus Topoisomerase IV (Stap-coc parC) DMVTU5Q MT DTT DMVTU5Q MA Inhibitor DMVTU5Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMVTU5Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMXE76K DI DMXE76K DMXE76K DN Delamanid DMXE76K MI TTXT4D5 DMXE76K MN Bacterial Cell membrane (Bact CM) DMXE76K MT DTT DMXE76K MA Inhibitor DMXE76K RN Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483. DMXE76K RU https://pubmed.ncbi.nlm.nih.gov/33243846 DMXE76K DI DMXE76K DMXE76K DN Delamanid DMXE76K MI DE4LYSA DMXE76K MN Cytochrome P450 3A4 (CYP3A4) DMXE76K MT DME DMXE76K MA Metabolism DMXE76K RN Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans: importance of albumin metabolism in vivo. Drug Metab Dispos. 2015 Aug;43(8):1267-76. DMXE76K RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26055620 DM7EUK3 DI DM7EUK3 DM7EUK3 DN Delapril DM7EUK3 MI TTL69WB DM7EUK3 MN Angiotensin-converting enzyme (ACE) DM7EUK3 MT DTT DM7EUK3 MA Modulator DM7EUK3 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM7EUK3 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G MI DTI7UX6 DM3NF5G MN Breast cancer resistance protein (ABCG2) DM3NF5G MT DTP DM3NF5G MA Substrate DM3NF5G RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DM3NF5G RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G MI DECB0K3 DM3NF5G MN Cytochrome P450 2D6 (CYP2D6) DM3NF5G MT DME DM3NF5G MA Metabolism DM3NF5G RN Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol. 2001 Jan;41(1):85-91. DM3NF5G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11225565 DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G MI DE4LYSA DM3NF5G MN Cytochrome P450 3A4 (CYP3A4) DM3NF5G MT DME DM3NF5G MA Metabolism DM3NF5G RN Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2001;40(3):207-26. DM3NF5G RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11327199 DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G MI DEIBDNY DM3NF5G MN Cytochrome P450 3A5 (CYP3A5) DM3NF5G MT DME DM3NF5G MA Metabolism DM3NF5G RN Drug Interactions Flockhart Table DM3NF5G RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G MI DERD86B DM3NF5G MN Cytochrome P450 3A7 (CYP3A7) DM3NF5G MT DME DM3NF5G MA Metabolism DM3NF5G RN Drug Interactions Flockhart Table DM3NF5G RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G MI TT84ETX DM3NF5G MN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM3NF5G MT DTT DM3NF5G MA Modulator DM3NF5G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3NF5G RU https://www.fda.gov/ DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G MI DTUGYRD DM3NF5G MN P-glycoprotein 1 (ABCB1) DM3NF5G MT DTP DM3NF5G MA Substrate DM3NF5G RN The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 2009 May;82(2):A99-109. DM3NF5G RU https://doi.org/10.1016/j.antiviral.2008.12.013 DMAYEU1 DI DMAYEU1 DMAYEU1 DN Demecarium bromide DMAYEU1 MI TT1RS9F DMAYEU1 MN Acetylcholinesterase (AChE) DMAYEU1 MT DTT DMAYEU1 MA Inhibitor DMAYEU1 RN The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5. DMAYEU1 RU https://pubmed.ncbi.nlm.nih.gov/12641839 DMZEPFJ DI DMZEPFJ DMZEPFJ DN Demeclocycline DMZEPFJ MI TTQ8KVI DMZEPFJ MN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMZEPFJ MT DTT DMZEPFJ MA Binder DMZEPFJ RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMZEPFJ RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMCZQGK DI DMCZQGK DMCZQGK DN Demecolcine DMCZQGK MI TT1EDJZ DMCZQGK MN Microtubule-associated protein (MAP) DMCZQGK MT DTT DMCZQGK MA Modulator DMCZQGK RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMCZQGK RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMMHR1U DI DMMHR1U DMMHR1U DN Denileukin diftitox DMMHR1U MI TTAJU0S DMMHR1U MN Interleukin 2 receptor (IL2R) DMMHR1U MT DTT DMMHR1U MA Binder DMMHR1U RN Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. DMMHR1U RU https://pubmed.ncbi.nlm.nih.gov/18684057 DM8C3GN DI DM8C3GN DM8C3GN DN Denopamine DM8C3GN MI TTEX248 DM8C3GN MN Dopamine D2 receptor (D2R) DM8C3GN MT DTT DM8C3GN MA Modulator DM8C3GN RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM8C3GN RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM8C3GN DI DM8C3GN DM8C3GN DN Denopamine DM8C3GN MI DEAZDL8 DM8C3GN MN UDP-glucuronosyltransferase 2B17 (UGT2B17) DM8C3GN MT DME DM8C3GN MA Metabolism DM8C3GN RN Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform. Drug Metab Dispos. 2005 Mar;33(3):403-12. DM8C3GN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15608137 DMNI0KO DI DMNI0KO DMNI0KO DN Denosumab DMNI0KO MI TT9E8HR DMNI0KO MN Osteoclast differentiation factor (ODF) DMNI0KO MT DTT DMNI0KO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMNI0KO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM3GYAL DI DM3GYAL DM3GYAL DN Deoxycholic acid DM3GYAL MI DT7JELC DM3GYAL MN Apical sodium-dependent bile acid transporter (SLC10A2) DM3GYAL MT DTP DM3GYAL MA Substrate DM3GYAL RN Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery. Biomaterials. 2018 Jan;151:13-23. DM3GYAL RU http://www.ncbi.nlm.nih.gov/pubmed/29055774 DM3GYAL DI DM3GYAL DM3GYAL DN Deoxycholic acid DM3GYAL MI DTI7UX6 DM3GYAL MN Breast cancer resistance protein (ABCG2) DM3GYAL MT DTP DM3GYAL MA Substrate DM3GYAL RN Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26. DM3GYAL RU https://doi.org/10.1042/BJ20040791 DMYE5LJ DI DMYE5LJ DMYE5LJ DN DEOXYCYTIDINE DMYE5LJ MI TTP3QRF DMYE5LJ MN Thymidine kinase 1 (TK1) DMYE5LJ MT DTT DMYE5LJ MA Inhibitor DMYE5LJ RN Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9. DMYE5LJ RU https://pubmed.ncbi.nlm.nih.gov/7097717 DMRH7CV DI DMRH7CV DMRH7CV DN Deserpidine DMRH7CV MI TTL69WB DMRH7CV MN Angiotensin-converting enzyme (ACE) DMRH7CV MT DTT DMRH7CV MA Inhibitor DMRH7CV RN Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. J Physiol. 2003 May 1;548(Pt 3):893-906. DMRH7CV RU https://pubmed.ncbi.nlm.nih.gov/12651915 DM2TO9R DI DM2TO9R DM2TO9R DN Desflurane DM2TO9R MI TTAN6JD DM2TO9R MN Glutamate receptor AMPA (GRIA) DM2TO9R MT DTT DM2TO9R MA Antagonist DM2TO9R RN Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics. Anesth Analg. 2001 May;92(5):1182-91. DM2TO9R RU https://pubmed.ncbi.nlm.nih.gov/11323344 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC MI DEJGDUW DMT2FDC MN Cytochrome P450 1A2 (CYP1A2) DMT2FDC MT DME DMT2FDC MA Metabolism DMT2FDC RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMT2FDC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC MI DEPKLMQ DMT2FDC MN Cytochrome P450 2B6 (CYP2B6) DMT2FDC MT DME DMT2FDC MA Metabolism DMT2FDC RN Drugs that may have potential CYP2B6 interactions. DMT2FDC RU https://drug-interactions.medicine.iu.edu/MainTable.aspx DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC MI DECB0K3 DMT2FDC MN Cytochrome P450 2D6 (CYP2D6) DMT2FDC MT DME DMT2FDC MA Metabolism DMT2FDC RN Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73-8. DMT2FDC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8880055 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC MI DE4LYSA DMT2FDC MN Cytochrome P450 3A4 (CYP3A4) DMT2FDC MT DME DMT2FDC MA Metabolism DMT2FDC RN Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol. 2014 Jul-Aug;38(6):368-74. DMT2FDC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24782142 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC MI DEGTFWK DMT2FDC MN Mephenytoin 4-hydroxylase (CYP2C19) DMT2FDC MT DME DMT2FDC MA Metabolism DMT2FDC RN Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9. DMT2FDC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9884317 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC MI TTAWNKZ DMT2FDC MN Norepinephrine transporter (NET) DMT2FDC MT DTT DMT2FDC MA Inhibitor DMT2FDC RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMT2FDC RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC MI DTT79CX DMT2FDC MN Organic cation transporter 1 (SLC22A1) DMT2FDC MT DTP DMT2FDC MA Substrate DMT2FDC RN Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33. DMT2FDC RU https://doi.org/10.1016/j.canlet.2005.06.051 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC MI DTUGYRD DMT2FDC MN P-glycoprotein 1 (ABCB1) DMT2FDC MT DTP DMT2FDC MA Substrate DMT2FDC RN A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. DMT2FDC RU https://doi.org/10.1007/s00210-008-0345-0 DM2BTFN DI DM2BTFN DM2BTFN DN Desirudin Recombinant DM2BTFN MI TT6L509 DM2BTFN MN Coagulation factor IIa (F2) DM2BTFN MT DTT DM2BTFN MA Modulator DM2BTFN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2BTFN RU https://www.fda.gov/ DMB3ZSK DI DMB3ZSK DMB3ZSK DN Deslanoside DMB3ZSK MI TTWK8D0 DMB3ZSK MN Sodium pump subunit alpha-1 (ATP1A1) DMB3ZSK MT DTT DMB3ZSK MA Binder DMB3ZSK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB3ZSK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM56YN7 DI DM56YN7 DM56YN7 DN Desloratadine DM56YN7 MI DES5XRU DM56YN7 MN Cytochrome P450 2C8 (CYP2C8) DM56YN7 MT DME DM56YN7 MA Metabolism DM56YN7 RN Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015 Sep;43(9):1294-302. DM56YN7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26135009 DM56YN7 DI DM56YN7 DM56YN7 DN Desloratadine DM56YN7 MI TTTIBOJ DM56YN7 MN Histamine H1 receptor (H1R) DM56YN7 MT DTT DM56YN7 MA Antagonist DM56YN7 RN Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79. DM56YN7 RU https://pubmed.ncbi.nlm.nih.gov/19236123 DM56YN7 DI DM56YN7 DM56YN7 DN Desloratadine DM56YN7 MI DTUGYRD DM56YN7 MN P-glycoprotein 1 (ABCB1) DM56YN7 MT DTP DM56YN7 MA Substrate DM56YN7 RN P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8. DM56YN7 RU http://www.ncbi.nlm.nih.gov/pubmed/12584158 DM56YN7 DI DM56YN7 DM56YN7 DN Desloratadine DM56YN7 MI DEI8NGH DM56YN7 MN UDP-glucuronosyltransferase 2B10 (UGT2B10) DM56YN7 MT DME DM56YN7 MA Metabolism DM56YN7 RN Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab Dispos. 2015 Sep;43(9):1294-302. DM56YN7 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26135009 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE MI TTSCIUP DMS3GVE MN Oxytocin receptor (OTR) DMS3GVE MT DTT DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE MI TTYCILE DMS3GVE MN Vasopressin receptor (VR) DMS3GVE MT DTT DMS3GVE MA Modulator DMS3GVE RN Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/10594321 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE MI TT4TFGN DMS3GVE MN Vasopressin V1a receptor (V1AR) DMS3GVE MT DTT DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE MI TTL9MHW DMS3GVE MN Vasopressin V1b receptor (V1BR) DMS3GVE MT DTT DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE MI TTK8R02 DMS3GVE MN Vasopressin V2 receptor (V2R) DMS3GVE MT DTT DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DM27U4Y DI DM27U4Y DM27U4Y DN Desogestrel DM27U4Y MI DE5IED8 DM27U4Y MN Cytochrome P450 2C9 (CYP2C9) DM27U4Y MT DME DM27U4Y MA Metabolism DM27U4Y RN The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82. DM27U4Y RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9864282 DM27U4Y DI DM27U4Y DM27U4Y DN Desogestrel DM27U4Y MI DE4LYSA DM27U4Y MN Cytochrome P450 3A4 (CYP3A4) DM27U4Y MT DME DM27U4Y MA Metabolism DM27U4Y RN The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75. DM27U4Y RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15963096 DM27U4Y DI DM27U4Y DM27U4Y DN Desogestrel DM27U4Y MI DEGTFWK DM27U4Y MN Mephenytoin 4-hydroxylase (CYP2C19) DM27U4Y MT DME DM27U4Y MA Metabolism DM27U4Y RN The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel. J Pharmacol Exp Ther. 1998 Dec;287(3):975-82. DM27U4Y RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9864282 DM27U4Y DI DM27U4Y DM27U4Y DN Desogestrel DM27U4Y MI TTUV8G9 DM27U4Y MN Progesterone receptor (PGR) DM27U4Y MT DTT DM27U4Y MA Modulator DM27U4Y RN Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40. DM27U4Y RU https://pubmed.ncbi.nlm.nih.gov/11108884 DMTP2NJ DI DMTP2NJ DMTP2NJ DN Desonide DMTP2NJ MI DE4LYSA DMTP2NJ MN Cytochrome P450 3A4 (CYP3A4) DMTP2NJ MT DME DMTP2NJ MA Metabolism DMTP2NJ RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMTP2NJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMTP2NJ DI DMTP2NJ DMTP2NJ DN Desonide DMTP2NJ MI TTP3UTW DMTP2NJ MN Steroid hormone receptor ERR (ESRR) DMTP2NJ MT DTT DMTP2NJ MA Modulator DMTP2NJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTP2NJ RU https://www.fda.gov/ DM4PXF6 DI DM4PXF6 DM4PXF6 DN Desoximetasone DM4PXF6 MI TTP3UTW DM4PXF6 MN Steroid hormone receptor ERR (ESRR) DM4PXF6 MT DTT DM4PXF6 MA Modulator DM4PXF6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PXF6 RU https://www.fda.gov/ DMS0AFE DI DMS0AFE DMS0AFE DN Desoxycorticosterone acetate DMS0AFE MI DE4LYSA DMS0AFE MN Cytochrome P450 3A4 (CYP3A4) DMS0AFE MT DME DMS0AFE MA Metabolism DMS0AFE RN Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207. DMS0AFE RU https://www.sciencedirect.com/science/article/pii/S0079612308810114 DMS0AFE DI DMS0AFE DMS0AFE DN Desoxycorticosterone acetate DMS0AFE MI TT26PHO DMS0AFE MN Mineralocorticoid receptor (MR) DMS0AFE MT DTT DMS0AFE MA Modulator DMS0AFE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS0AFE RU https://www.fda.gov/ DMSA4B3 DI DMSA4B3 DMSA4B3 DN Desoxycorticosterone pivalate DMSA4B3 MI DE4LYSA DMSA4B3 MN Cytochrome P450 3A4 (CYP3A4) DMSA4B3 MT DME DMSA4B3 MA Metabolism DMSA4B3 RN Progress in Brain Research. Chapter 11 - Steroidogenic Enzymes in the Brain: Morphological Aspects. 2010, 181:193-207. DMSA4B3 RU https://www.sciencedirect.com/science/article/pii/S0079612308810114 DMSA4B3 DI DMSA4B3 DMSA4B3 DN Desoxycorticosterone pivalate DMSA4B3 MI TT26PHO DMSA4B3 MN Mineralocorticoid receptor (MR) DMSA4B3 MT DTT DMSA4B3 MA Binder DMSA4B3 RN Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. DMSA4B3 RU https://pubmed.ncbi.nlm.nih.gov/6227474 DMEZFXR DI DMEZFXR DMEZFXR DN Desoxyribonuclease DMEZFXR MI TT3C1VN DMEZFXR MN Enzyme unspecific (Enz) DMEZFXR MT DTT DMEZFXR MA Modulator DMEZFXR RN Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52. DMEZFXR RU https://pubmed.ncbi.nlm.nih.gov/486431 DMJE6KO DI DMJE6KO DMJE6KO DN Desvenalfaxine succinate DMJE6KO MI DECB0K3 DMJE6KO MN Cytochrome P450 2D6 (CYP2D6) DMJE6KO MT DME DMJE6KO MA Metabolism DMJE6KO RN Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol. 1999 Apr;47(4):450-3. DMJE6KO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10233212 DMJE6KO DI DMJE6KO DMJE6KO DN Desvenalfaxine succinate DMJE6KO MI DE4LYSA DMJE6KO MN Cytochrome P450 3A4 (CYP3A4) DMJE6KO MT DME DMJE6KO MA Metabolism DMJE6KO RN Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother. 2011 Dec;12(18):2923-8. DMJE6KO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22098230 DMJE6KO DI DMJE6KO DMJE6KO DN Desvenalfaxine succinate DMJE6KO MI TTAWNKZ DMJE6KO MN Norepinephrine transporter (NET) DMJE6KO MT DTT DMJE6KO MA Inhibitor DMJE6KO RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMJE6KO RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMHD4PE DI DMHD4PE DMHD4PE DN Desvenlafaxine DMHD4PE MI TT3ROYC DMHD4PE MN Serotonin transporter (SERT) DMHD4PE MT DTT DMHD4PE MA Modulator DMHD4PE RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMHD4PE RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMUPFLI DI DMUPFLI DMUPFLI DN Deutetrabenazine DMUPFLI MI DEJGDUW DMUPFLI MN Cytochrome P450 1A2 (CYP1A2) DMUPFLI MT DME DMUPFLI MA Metabolism DMUPFLI RN FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration. DMUPFLI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf DMUPFLI DI DMUPFLI DMUPFLI DN Deutetrabenazine DMUPFLI MI DECB0K3 DMUPFLI MN Cytochrome P450 2D6 (CYP2D6) DMUPFLI MT DME DMUPFLI MA Metabolism DMUPFLI RN FDA Label of Deutetrabenazine. The 2020 official website of the U.S. Food and Drug Administration. DMUPFLI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208082s000lbl.pdf DMUPFLI DI DMUPFLI DMUPFLI DN Deutetrabenazine DMUPFLI MI TTNZRI3 DMUPFLI MN Synaptic vesicle amine transporter (SLC18A2) DMUPFLI MT DTT DMUPFLI MA Modulator DMUPFLI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUPFLI RU https://www.fda.gov/ DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET MI DETHCPD DMMWZET MN Carboxylesterase 2 (CES2) DMMWZET MT DME DMMWZET MA Metabolism DMMWZET RN In vitro metabolism of dexamethasone cipecilate, a novel synthetic corticosteroid, in human liver and nasal mucosa. Xenobiotica. 2011 Oct;41(10):874-84. DMMWZET RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21657966 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET MI DEDH7FP DMMWZET MN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DMMWZET MT DME DMMWZET MA Metabolism DMMWZET RN Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46. DMMWZET RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16549198 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET MI DE4LYSA DMMWZET MN Cytochrome P450 3A4 (CYP3A4) DMMWZET MT DME DMMWZET MA Metabolism DMMWZET RN Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90. DMMWZET RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8866917 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET MI DEIBDNY DMMWZET MN Cytochrome P450 3A5 (CYP3A5) DMMWZET MT DME DMMWZET MA Metabolism DMMWZET RN Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52. DMMWZET RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12538830 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET MI DERD86B DMMWZET MN Cytochrome P450 3A7 (CYP3A7) DMMWZET MT DME DMMWZET MA Metabolism DMMWZET RN Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7. DMMWZET RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17207564 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET MI TTYRL6O DMMWZET MN Glucocorticoid receptor (NR3C1) DMMWZET MT DTT DMMWZET MA Agonist DMMWZET RN Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72. DMMWZET RU https://pubmed.ncbi.nlm.nih.gov/19375647 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET MI DT9G7XN DMMWZET MN Peptide transporter 1 (SLC15A1) DMMWZET MT DTP DMMWZET MA Substrate DMMWZET RN Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18. DMMWZET RU https://doi.org/10.1007/BF02980227 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET MI DTUGYRD DMMWZET MN P-glycoprotein 1 (ABCB1) DMMWZET MT DTP DMMWZET MA Substrate DMMWZET RN Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605. DMMWZET RU http://www.ncbi.nlm.nih.gov/pubmed/17029589 DMIG8DW DI DMIG8DW DMIG8DW DN Dexamethasone sodium phosphate DMIG8DW MI DE4LYSA DMIG8DW MN Cytochrome P450 3A4 (CYP3A4) DMIG8DW MT DME DMIG8DW MA Metabolism DMIG8DW RN Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90. DMIG8DW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8866917 DMIG8DW DI DMIG8DW DMIG8DW DN Dexamethasone sodium phosphate DMIG8DW MI TTYRL6O DMIG8DW MN Glucocorticoid receptor (NR3C1) DMIG8DW MT DTT DMIG8DW MA Agonist DMIG8DW RN Dexamethasone rapidly increases GABA release in the dorsal motor nucleus of the vagus via retrograde messenger-mediated enhancement of TRPV1 activity. PLoS One. 2013 Jul 30;8(7):e70505. DMIG8DW RU https://pubmed.ncbi.nlm.nih.gov/23936221 DMKVWGE DI DMKVWGE DMKVWGE DN Dexbrompheniramine DMKVWGE MI TTTIBOJ DMKVWGE MN Histamine H1 receptor (H1R) DMKVWGE MT DTT DMKVWGE MA Antagonist DMKVWGE RN H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol Behav. 1998 Aug;65(1):105-13. DMKVWGE RU https://pubmed.ncbi.nlm.nih.gov/9811372 DMA8DPN DI DMA8DPN DMA8DPN DN Dexchlorpheniramine maleate DMA8DPN MI DECB0K3 DMA8DPN MN Cytochrome P450 2D6 (CYP2D6) DMA8DPN MT DME DMA8DPN MA Metabolism DMA8DPN RN The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol. 2002 May;53(5):519-25. DMA8DPN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11994058 DMA8DPN DI DMA8DPN DMA8DPN DN Dexchlorpheniramine maleate DMA8DPN MI TTTIBOJ DMA8DPN MN Histamine H1 receptor (H1R) DMA8DPN MT DTT DMA8DPN MA Modulator DMA8DPN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA8DPN RU https://www.fda.gov/ DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 MI DEGKWJB DMFYBD0 MN Alpha-methylacyl-CoA racemase (AMACR) DMFYBD0 MT DME DMFYBD0 MA Metabolism DMFYBD0 RN Alpha-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. Prog Lipid Res. 2013 Apr;52(2):220-30. DMFYBD0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23376124 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 MI DES5XRU DMFYBD0 MN Cytochrome P450 2C8 (CYP2C8) DMFYBD0 MT DME DMFYBD0 MA Metabolism DMFYBD0 RN Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. Biopharm Drug Dispos. 2013 Jul;34(5):278-87. DMFYBD0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23536207 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 MI DE5IED8 DMFYBD0 MN Cytochrome P450 2C9 (CYP2C9) DMFYBD0 MT DME DMFYBD0 MA Metabolism DMFYBD0 RN New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. DMFYBD0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 MI DEGTFWK DMFYBD0 MN Mephenytoin 4-hydroxylase (CYP2C19) DMFYBD0 MT DME DMFYBD0 MA Metabolism DMFYBD0 RN PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015 Feb;25(2):96-106. DMFYBD0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25502615 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 MI TTK0943 DMFYBD0 MN Prostaglandin G/H synthase (COX) DMFYBD0 MT DTT DMFYBD0 MA Modulator DMFYBD0 RN Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64. DMFYBD0 RU https://pubmed.ncbi.nlm.nih.gov/12708604 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 MI DEYGVN4 DMFYBD0 MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMFYBD0 MT DME DMFYBD0 MA Metabolism DMFYBD0 RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMFYBD0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 MI DEF2WXN DMFYBD0 MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMFYBD0 MT DME DMFYBD0 MA Metabolism DMFYBD0 RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMFYBD0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 MI DE85D2P DMFYBD0 MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMFYBD0 MT DME DMFYBD0 MA Metabolism DMFYBD0 RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMFYBD0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 MI DEB3CV1 DMFYBD0 MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMFYBD0 MT DME DMFYBD0 MA Metabolism DMFYBD0 RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMFYBD0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 MI DE4LYSA DM1DBV5 MN Cytochrome P450 3A4 (CYP3A4) DM1DBV5 MT DME DM1DBV5 MA Metabolism DM1DBV5 RN Absorption, distribution, metabolism and excretion of [14C]dexlansoprazole in healthy male subjects. Clin Drug Investig. 2012 May 1;32(5):319-32. DM1DBV5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22455762 DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 MI TTLOKXP DM1DBV5 MN Gastric H(+)/K(+) ATPase (Proton pump) DM1DBV5 MT DTT DM1DBV5 MA Modulator DM1DBV5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1DBV5 RU https://www.fda.gov/ DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 MI TTF1QVM DM1DBV5 MN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM1DBV5 MT DTT DM1DBV5 MA Inhibitor DM1DBV5 RN Clinical pipeline report, company report or official report of Takeda (2009). DM1DBV5 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 MI DEGTFWK DM1DBV5 MN Mephenytoin 4-hydroxylase (CYP2C19) DM1DBV5 MT DME DM1DBV5 MA Metabolism DM1DBV5 RN Pharmacological and safety profile of dexlansoprazole: a new proton pump inhibitor - implications for treatment of gastroesophageal reflux disease in the Asia Pacific region. J Neurogastroenterol Motil. 2016 Jul 30;22(3):355-66. DM1DBV5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26932927 DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 MI DTUGYRD DM1DBV5 MN P-glycoprotein 1 (ABCB1) DM1DBV5 MT DTP DM1DBV5 MA Substrate DM1DBV5 RN A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):11-26. DM1DBV5 RU https://doi.org/10.1007/s00210-008-0345-0 DM93L4X DI DM93L4X DM93L4X DN Dexmedetomidine DM93L4X MI TTQ8AFT DM93L4X MN Adrenergic receptor Alpha-2 (ADRA2) DM93L4X MT DTT DM93L4X MA Agonist DM93L4X RN Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95. DM93L4X RU https://pubmed.ncbi.nlm.nih.gov/12503262 DM93L4X DI DM93L4X DM93L4X DN Dexmedetomidine DM93L4X MI DEJGDUW DM93L4X MN Cytochrome P450 1A2 (CYP1A2) DM93L4X MT DME DM93L4X MA Metabolism DM93L4X RN Predominant role of peripheral catecholamines in the stress-induced modulation of CYP1A2 inducibility by benzo(alpha)pyrene. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):35-44. DM93L4X RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17973897 DM93L4X DI DM93L4X DM93L4X DN Dexmedetomidine DM93L4X MI DEJVYAZ DM93L4X MN Cytochrome P450 2A6 (CYP2A6) DM93L4X MT DME DM93L4X MA Metabolism DM93L4X RN Impact of CYP2A6 gene polymorphism on the pharmacokinetics of dexmedetomidine for premedication. Expert Rev Clin Pharmacol. 2018 Sep;11(9):917-922. DM93L4X RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30092666 DM93L4X DI DM93L4X DM93L4X DN Dexmedetomidine DM93L4X MI DEVDYN7 DM93L4X MN Cytochrome P450 2E1 (CYP2E1) DM93L4X MT DME DM93L4X MA Metabolism DM93L4X RN Metabolic stability and determination of cytochrome P450 isoenzymes' contribution to the metabolism of medetomidine in dog liver microsomes. Biomed Chromatogr. 2010 Aug;24(8):868-77. DM93L4X RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20020418 DMUQE2A DI DMUQE2A DMUQE2A DN Dexmethylphenidate DMUQE2A MI DEB30C5 DMUQE2A MN Carboxylesterase 1 (CES1) DMUQE2A MT DME DMUQE2A MA Metabolism DMUQE2A RN Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder. Neuropsychiatr Dis Treat. 2006 Dec;2(4):467-73. DMUQE2A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19412495 DM8WBAH DI DM8WBAH DM8WBAH DN Dexmethylphenidate hydrochloride DM8WBAH MI TTVBI8W DM8WBAH MN Dopamine transporter (DAT) DM8WBAH MT DTT DM8WBAH MA Inhibitor DM8WBAH RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM8WBAH RU https://pubmed.ncbi.nlm.nih.gov/17489581 DMD7X1O DI DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O MI DE0EUXB DMD7X1O MN Dihydropyrimidinase-related protein 1 (DRP1) DMD7X1O MT DME DMD7X1O MA Metabolism DMD7X1O RN Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. Drug Metab Dispos. 2005 Jun;33(6):719-25. DMD7X1O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15764716 DMD7X1O DI DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O MI TT0IHXV DMD7X1O MN DNA topoisomerase II (TOP2) DMD7X1O MT DTT DMD7X1O MA Modulator DMD7X1O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMD7X1O RU https://www.fda.gov/ DMD7X1O DI DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O MI TT4NVEM DMD7X1O MN DNA topoisomerase II beta (TOP2B) DMD7X1O MT DTT DMD7X1O MA Inhibitor DMD7X1O RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD7X1O RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMIHVP DI DMMIHVP DMMIHVP DN Dextroamphetamine DMMIHVP MI DECB0K3 DMMIHVP MN Cytochrome P450 2D6 (CYP2D6) DMMIHVP MT DME DMMIHVP MA Metabolism DMMIHVP RN Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica. 1999 Jul;29(7):719-32. DMMIHVP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10456690 DMMIHVP DI DMMIHVP DMMIHVP DN Dextroamphetamine DMMIHVP MI TTIU98M DMMIHVP MN Trace amine-associated receptor-1 (TAAR1) DMMIHVP MT DTT DMMIHVP MA Modulator DMMIHVP RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMMIHVP RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DEKP5HX DMUDJZM MN Cholesterol 24-hydroxylase (CYP46A1) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92. DMUDJZM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DE4OGUF DMUDJZM MN Cytochrome P450 102A1 (cyp102) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98. DMUDJZM RU https://pubmed.ncbi.nlm.nih.gov/17532492 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DE6CQ0I DMUDJZM MN Cytochrome P450 130A1 (cyp130) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets? Appl Microbiol Biotechnol. 2019 May;103(9):3597-3614. DMUDJZM RU https://pubmed.ncbi.nlm.nih.gov/30810776 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DEPKLMQ DMUDJZM MN Cytochrome P450 2B6 (CYP2B6) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6. DMUDJZM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10760842 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DE5IED8 DMUDJZM MN Cytochrome P450 2C9 (CYP2C9) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004. DMUDJZM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9811160 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DECB0K3 DMUDJZM MN Cytochrome P450 2D6 (CYP2D6) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. DMUDJZM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19817501 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DE4LYSA DMUDJZM MN Cytochrome P450 3A4 (CYP3A4) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities? Drug Metab Dispos. 2001 Nov;29(11):1514-20. DMUDJZM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11602530 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DEIBDNY DMUDJZM MN Cytochrome P450 3A5 (CYP3A5) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMUDJZM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DERD86B DMUDJZM MN Cytochrome P450 3A7 (CYP3A7) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994 Jul 5;48(1):173-82. DMUDJZM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8043020 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI DEGTFWK DMUDJZM MN Mephenytoin 4-hydroxylase (CYP2C19) DMUDJZM MT DME DMUDJZM MA Metabolism DMUDJZM RN Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol. 1998 Sep;50(9):997-1004. DMUDJZM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9811160 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM MI TT5TPI6 DMUDJZM MN Opioid receptor sigma 1 (OPRS1) DMUDJZM MT DTT DMUDJZM MA Agonist DMUDJZM RN Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7. DMUDJZM RU https://pubmed.ncbi.nlm.nih.gov/15869321 DMEHCY5 DI DMEHCY5 DMEHCY5 DN Dextromethorphan polistirex DMEHCY5 MI TT5TPI6 DMEHCY5 MN Opioid receptor sigma 1 (OPRS1) DMEHCY5 MT DTT DMEHCY5 MA Modulator DMEHCY5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEHCY5 RU https://www.fda.gov/ DMEHCY5 DI DMEHCY5 DMEHCY5 DN Dextromethorphan polistirex DMEHCY5 MI TT3ROYC DMEHCY5 MN Serotonin transporter (SERT) DMEHCY5 MT DTT DMEHCY5 MA Modulator DMEHCY5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEHCY5 RU https://www.fda.gov/ DM23HCX DI DM23HCX DM23HCX DN Dextropropoxyphene DM23HCX MI DECB0K3 DM23HCX MN Cytochrome P450 2D6 (CYP2D6) DM23HCX MT DME DM23HCX MA Metabolism DM23HCX RN Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol. 1997;52(1):41-7. DM23HCX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9143866 DM23HCX DI DM23HCX DM23HCX DN Dextropropoxyphene DM23HCX MI DE4LYSA DM23HCX MN Cytochrome P450 3A4 (CYP3A4) DM23HCX MT DME DM23HCX MA Metabolism DM23HCX RN CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica. 2004 Oct;34(10):875-87. DM23HCX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15764408 DM23HCX DI DM23HCX DM23HCX DN Dextropropoxyphene DM23HCX MI TTN4QDT DM23HCX MN Opioid receptor (OPR) DM23HCX MT DTT DM23HCX MA Agonist DM23HCX RN Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9. DM23HCX RU https://pubmed.ncbi.nlm.nih.gov/19021937 DMBVEC7 DI DMBVEC7 DMBVEC7 DN Dextrothyroxine Sodium DMBVEC7 MI TTTSEPU DMBVEC7 MN Thyroid hormone receptor alpha (THRA) DMBVEC7 MT DTT DMBVEC7 MA Modulator DMBVEC7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBVEC7 RU https://www.fda.gov/ DMBVEC7 DI DMBVEC7 DMBVEC7 DN Dextrothyroxine Sodium DMBVEC7 MI TTGER3L DMBVEC7 MN Thyroid hormone receptor beta (THRB) DMBVEC7 MT DTT DMBVEC7 MA Modulator DMBVEC7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBVEC7 RU https://www.fda.gov/ DMJDB0Y DI DMJDB0Y DMJDB0Y DN Dezocine DMJDB0Y MI TTQW87Y DMJDB0Y MN Opioid receptor kappa (OPRK1) DMJDB0Y MT DTT DMJDB0Y MA Antagonist DMJDB0Y RN Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. DMJDB0Y RU https://pubmed.ncbi.nlm.nih.gov/16433932 DMU3FGB DI DMU3FGB DMU3FGB DN Dhaq diacetate DMU3FGB MI TT0IHXV DMU3FGB MN DNA topoisomerase II (TOP2) DMU3FGB MT DTT DMU3FGB MA Inhibitor DMU3FGB RN The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7. DMU3FGB RU https://pubmed.ncbi.nlm.nih.gov/19176397 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DEJGDUW DM08E9O MN Cytochrome P450 1A2 (CYP1A2) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003 Dec 15;146(3):263-72. DM08E9O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14642738 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DEPKLMQ DM08E9O MN Cytochrome P450 2B6 (CYP2B6) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 1998 May 15;55(10):1633-40. DM08E9O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9633999 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DEZMWRE DM08E9O MN Cytochrome P450 2C18 (CYP2C18) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64. DM08E9O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9028867 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DES5XRU DM08E9O MN Cytochrome P450 2C8 (CYP2C8) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol. 2000 Apr 14;394(2-3):199-209. DM08E9O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10771285 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DE5IED8 DM08E9O MN Cytochrome P450 2C9 (CYP2C9) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN Phenytoin-diazepam interaction. Ann Pharmacother. 2003 May;37(5):659-63. DM08E9O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12708941 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DE4LYSA DM08E9O MN Cytochrome P450 3A4 (CYP3A4) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica. 2002 Nov;32(11):937-47. DM08E9O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12487724 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DEIBDNY DM08E9O MN Cytochrome P450 3A5 (CYP3A5) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9. DM08E9O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9884317 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DERD86B DM08E9O MN Cytochrome P450 3A7 (CYP3A7) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN Drug Interactions Flockhart Table DM08E9O RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DEGTFWK DM08E9O MN Mephenytoin 4-hydroxylase (CYP2C19) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DM08E9O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DTUGYRD DM08E9O MN P-glycoprotein 1 (ABCB1) DM08E9O MT DTP DM08E9O MA Substrate DM08E9O RN Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. DM08E9O RU http://www.ncbi.nlm.nih.gov/pubmed/11785684 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI DE073H6 DM08E9O MN Prostaglandin G/H synthase 1 (COX-1) DM08E9O MT DME DM08E9O MA Metabolism DM08E9O RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM08E9O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O MI TTPTXIN DM08E9O MN Translocator protein (TSPO) DM08E9O MT DTT DM08E9O MA Agonist DM08E9O RN Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8. DM08E9O RU https://pubmed.ncbi.nlm.nih.gov/19782064 DML1538 DI DML1538 DML1538 DN Diazoxide DML1538 MI TT1VOHK DML1538 MN Potassium channel unspecific (KC) DML1538 MT DTT DML1538 MA Modulator DML1538 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DML1538 RU https://www.fda.gov/ DMF9G7L DI DMF9G7L DMF9G7L DN Dibucaine DMF9G7L MI TTZOVE0 DMF9G7L MN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMF9G7L MT DTT DMF9G7L MA Blocker DMF9G7L RN Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81. DMF9G7L RU https://pubmed.ncbi.nlm.nih.gov/12354567 DMH7IDQ DI DMH7IDQ DMH7IDQ DN Dichlorphenamide DMH7IDQ MI TTHQPL7 DMH7IDQ MN Carbonic anhydrase I (CA-I) DMH7IDQ MT DTT DMH7IDQ MA Modulator DMH7IDQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMH7IDQ RU https://www.fda.gov/ DMH7IDQ DI DMH7IDQ DMH7IDQ DN Dichlorphenamide DMH7IDQ MI TTANPDJ DMH7IDQ MN Carbonic anhydrase II (CA-II) DMH7IDQ MT DTT DMH7IDQ MA Inhibitor DMH7IDQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMH7IDQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DTI7UX6 DMPIHLS MN Breast cancer resistance protein (ABCG2) DMPIHLS MT DTP DMPIHLS MA Substrate DMPIHLS RN Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36. DMPIHLS RU http://www.ncbi.nlm.nih.gov/pubmed/18845662 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DEKP5HX DMPIHLS MN Cholesterol 24-hydroxylase (CYP46A1) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. Biochemistry. 2003 Dec 9;42(48):14284-92. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14640697 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DE4OGUF DMPIHLS MN Cytochrome P450 102A1 (cyp102) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Both reactivity and accessibility are important in cytochrome P450 metabolism: a combined DFT and MD study of fenamic acids in BM3 mutants. J Chem Inf Model. 2019 Feb 25;59(2):743-753. DMPIHLS RU https://pubmed.ncbi.nlm.nih.gov/30758202 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DECV2ME DMPIHLS MN Cytochrome P450 105D7 (cyp105) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN The metagenome of Caracolus marginella gut microbiome using culture independent approaches and shotgun sequencing. Data Brief. 2017 Nov 22;16:501-505. DMPIHLS RU https://pubmed.ncbi.nlm.nih.gov/29270447 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DE6OQ3W DMPIHLS MN Cytochrome P450 1A1 (CYP1A1) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DEJGDUW DMPIHLS MN Cytochrome P450 1A2 (CYP1A2) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27034690 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DEPKLMQ DMPIHLS MN Cytochrome P450 2B6 (CYP2B6) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10449188 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DEZMWRE DMPIHLS MN Cytochrome P450 2C18 (CYP2C18) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DES5XRU DMPIHLS MN Cytochrome P450 2C8 (CYP2C8) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15581350 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DE5IED8 DMPIHLS MN Cytochrome P450 2C9 (CYP2C9) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20167001 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DE4LYSA DMPIHLS MN Cytochrome P450 3A4 (CYP3A4) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10950847 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DEGTFWK DMPIHLS MN Mephenytoin 4-hydroxylase (CYP2C19) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10572000 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DT9C1TS DMPIHLS MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMPIHLS MT DTP DMPIHLS MA Substrate DMPIHLS RN Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53. DMPIHLS RU http://www.ncbi.nlm.nih.gov/pubmed/21389119 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI TTK0943 DMPIHLS MN Prostaglandin G/H synthase (COX) DMPIHLS MT DTT DMPIHLS MA Modulator DMPIHLS RN Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82. DMPIHLS RU https://pubmed.ncbi.nlm.nih.gov/11221916 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DEF2WXN DMPIHLS MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15843492 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DE85D2P DMPIHLS MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15843492 DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS MI DEB3CV1 DMPIHLS MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMPIHLS MT DME DMPIHLS MA Metabolism DMPIHLS RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMPIHLS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM8EU0Z DI DM8EU0Z DM8EU0Z DN Dicloxacillin DM8EU0Z MI TTJP4SM DM8EU0Z MN Bacterial Penicillin binding protein (Bact PBP) DM8EU0Z MT DTT DM8EU0Z MA Binder DM8EU0Z RN Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71. DM8EU0Z RU https://pubmed.ncbi.nlm.nih.gov/6335600 DM8EU0Z DI DM8EU0Z DM8EU0Z DN Dicloxacillin DM8EU0Z MI DT9G7XN DM8EU0Z MN Peptide transporter 1 (SLC15A1) DM8EU0Z MT DTP DM8EU0Z MA Substrate DM8EU0Z RN Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. DM8EU0Z RU http://www.ncbi.nlm.nih.gov/pubmed/16597710 DM8EU0Z DI DM8EU0Z DM8EU0Z DN Dicloxacillin DM8EU0Z MI DT8QKNP DM8EU0Z MN Peptide transporter 2 (SLC15A2) DM8EU0Z MT DTP DM8EU0Z MA Substrate DM8EU0Z RN Transport characteristics of a novel peptide transporter 1 substrate, antihypotensive drug midodrine, and its amino acid derivatives. J Pharmacol Exp Ther. 2006 Jul;318(1):455-60. DM8EU0Z RU http://www.ncbi.nlm.nih.gov/pubmed/16597710 DM8EU0Z DI DM8EU0Z DM8EU0Z DN Dicloxacillin DM8EU0Z MI DTUGYRD DM8EU0Z MN P-glycoprotein 1 (ABCB1) DM8EU0Z MT DTP DM8EU0Z MA Substrate DM8EU0Z RN Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res. 2002 Apr;19(4):457-62. DM8EU0Z RU http://www.ncbi.nlm.nih.gov/pubmed/12033380 DMFQCB1 DI DMFQCB1 DMFQCB1 DN Dicumarol DMFQCB1 MI DE5IED8 DMFQCB1 MN Cytochrome P450 2C9 (CYP2C9) DMFQCB1 MT DME DMFQCB1 MA Metabolism DMFQCB1 RN Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life. 2015 Apr-Jun;8(2):171-5. DMFQCB1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25866574 DMFQCB1 DI DMFQCB1 DMFQCB1 DN Dicumarol DMFQCB1 MI TTEUC8H DMFQCB1 MN Vitamin K epoxide reductase complex 1 (VKORC1) DMFQCB1 MT DTT DMFQCB1 MA Inhibitor DMFQCB1 RN Vitamin K antagonism of coumarin intoxication in the rat. Thromb Haemost. 1986 Apr 30;55(2):235-9. DMFQCB1 RU https://pubmed.ncbi.nlm.nih.gov/2424118 DMZSDGX DI DMZSDGX DMZSDGX DN Dicyclomine DMZSDGX MI TTZ9SOR DMZSDGX MN Muscarinic acetylcholine receptor M1 (CHRM1) DMZSDGX MT DTT DMZSDGX MA Antagonist DMZSDGX RN [Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. Endocrinol Nutr. 2009 Mar;56(3):106-11. DMZSDGX RU https://pubmed.ncbi.nlm.nih.gov/19627722 DMI2QPE DI DMI2QPE DMI2QPE DN Didanosine DMI2QPE MI DT82KPY DMI2QPE MN Concentrative nucleoside transporter 2 (SLC28A2) DMI2QPE MT DTP DMI2QPE MA Substrate DMI2QPE RN Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals. DMI2QPE RU https://books.google.co.jp/books?id=cYBGAAAAQBAJ&pg=PA59&lpg=PA59&dq=SLC15A1%09Didanosine&source=bl&ots=CeeUnMnW6Z&sig=ACfU3U10UhN6m18-AuKuLOfFeDKtUo5VYw&hl=zh-CN&sa=X&ved=2ahUKEwjh_IyK9KHiAhVIzbwKHZKiDoMQ6AEwAXoECAgQAQ#v=onepage&q=SLC15A1%09Didanosine&f=false DMI2QPE DI DMI2QPE DMI2QPE DN Didanosine DMI2QPE MI TT84ETX DMI2QPE MN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMI2QPE MT DTT DMI2QPE MA Inhibitor DMI2QPE RN The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304. DMI2QPE RU https://pubmed.ncbi.nlm.nih.gov/19412117 DMBSXI0 DI DMBSXI0 DMBSXI0 DN Dienestrol DMBSXI0 MI TTZAYWL DMBSXI0 MN Estrogen receptor (ESR) DMBSXI0 MT DTT DMBSXI0 MA Agonist DMBSXI0 RN Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone. 2009 Jan;44(1):102-12. DMBSXI0 RU https://pubmed.ncbi.nlm.nih.gov/18976723 DM1TJ8F DI DM1TJ8F DM1TJ8F DN Diethylcarbamazine DM1TJ8F MI TT2J34L DM1TJ8F MN Arachidonate 5-lipoxygenase (5-LOX) DM1TJ8F MT DTT DM1TJ8F MA Inhibitor DM1TJ8F RN Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7. DM1TJ8F RU https://pubmed.ncbi.nlm.nih.gov/10518442 DMN3UXQ DI DMN3UXQ DMN3UXQ DN Diethylstilbestrol DMN3UXQ MI DES5XRU DMN3UXQ MN Cytochrome P450 2C8 (CYP2C8) DMN3UXQ MT DME DMN3UXQ MA Metabolism DMN3UXQ RN Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21. DMN3UXQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21553654 DMN3UXQ DI DMN3UXQ DMN3UXQ DN Diethylstilbestrol DMN3UXQ MI DE4LYSA DMN3UXQ MN Cytochrome P450 3A4 (CYP3A4) DMN3UXQ MT DME DMN3UXQ MA Metabolism DMN3UXQ RN Comparative analysis of human CYP3A4 and rat CYP3A1 induction and relevant gene expression by bisphenol A and diethylstilbestrol: implications for toxicity testing paradigms. Reprod Toxicol. 2013 Jun;37:24-30. DMN3UXQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23384967 DMN3UXQ DI DMN3UXQ DMN3UXQ DN Diethylstilbestrol DMN3UXQ MI TTZAYWL DMN3UXQ MN Estrogen receptor (ESR) DMN3UXQ MT DTT DMN3UXQ MA Agonist DMN3UXQ RN Effects of diethylstilbestrol on programmed oocyte death and induction of polyovular follicles in neonatal mouse ovaries. Biol Reprod. 2009 Nov;81(5):1002-9. DMN3UXQ RU https://pubmed.ncbi.nlm.nih.gov/19553606 DMN3UXQ DI DMN3UXQ DMN3UXQ DN Diethylstilbestrol DMN3UXQ MI DTUGYRD DMN3UXQ MN P-glycoprotein 1 (ABCB1) DMN3UXQ MT DTP DMN3UXQ MA Substrate DMN3UXQ RN Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92. DMN3UXQ RU http://www.ncbi.nlm.nih.gov/pubmed/7914405 DMI9PRJ DI DMI9PRJ DMI9PRJ DN Diflorasone DMI9PRJ MI TT9V5JH DMI9PRJ MN Phospholipase A2 (PLA2G1B) DMI9PRJ MT DTT DMI9PRJ MA Inhibitor DMI9PRJ RN Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11. DMI9PRJ RU https://pubmed.ncbi.nlm.nih.gov/19013475 DM7EN8I DI DM7EN8I DM7EN8I DN Diflunisal DM7EN8I MI TTVKILB DM7EN8I MN Prostaglandin G/H synthase 2 (COX-2) DM7EN8I MT DTT DM7EN8I MA Inhibitor DM7EN8I RN Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. DM7EN8I RU https://pubmed.ncbi.nlm.nih.gov/11315375 DM7EN8I DI DM7EN8I DM7EN8I DN Diflunisal DM7EN8I MI DEYGVN4 DM7EN8I MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM7EN8I MT DME DM7EN8I MA Metabolism DM7EN8I RN Differential effects of phenobarbital on ester and ether glucuronidation of diflunisal in rats. J Pharmacol Exp Ther. 1987 Sep;242(3):1013-8. DM7EN8I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=3656106 DMMFVB3 DI DMMFVB3 DMMFVB3 DN Difluprednate DMMFVB3 MI DE4LYSA DMMFVB3 MN Cytochrome P450 3A4 (CYP3A4) DMMFVB3 MT DME DMMFVB3 MA Metabolism DMMFVB3 RN Prevalence of non-cytochrome P450-mediated metabolism in food and drug administration-approved oral and intravenous drugs: 2006-2015. Drug Metab Dispos. 2016 Aug;44(8):1246-52. DMMFVB3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27084892 DMMFVB3 DI DMMFVB3 DMMFVB3 DN Difluprednate DMMFVB3 MI TTUCK4B DMMFVB3 MN Phospholipase A2 inhibitory protein (PA2IP) DMMFVB3 MT DTT DMMFVB3 MA Agonist DMMFVB3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMMFVB3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMWVIGP DI DMWVIGP DMWVIGP DN Digitoxin DMWVIGP MI DE4LYSA DMWVIGP MN Cytochrome P450 3A4 (CYP3A4) DMWVIGP MT DME DMWVIGP MA Metabolism DMWVIGP RN Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol Pharmacol. 1991 Nov;40(5):859-67. DMWVIGP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=1944247 DMWVIGP DI DMWVIGP DMWVIGP DN Digitoxin DMWVIGP MI DTUGYRD DMWVIGP MN P-glycoprotein 1 (ABCB1) DMWVIGP MT DTP DMWVIGP MA Substrate DMWVIGP RN The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients. Eur J Clin Pharmacol. 2008 Apr;64(4):367-72. DMWVIGP RU http://www.ncbi.nlm.nih.gov/pubmed/18080812 DMWVIGP DI DMWVIGP DMWVIGP DN Digitoxin DMWVIGP MI TTQ38E9 DMWVIGP MN Sodium/potassium-transporting ATPase (SPT ATPase) DMWVIGP MT DTT DMWVIGP MA Inhibitor DMWVIGP RN Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7. DMWVIGP RU https://pubmed.ncbi.nlm.nih.gov/11525233 DMWVIGP DI DMWVIGP DMWVIGP DN Digitoxin DMWVIGP MI DEYWLRK DMWVIGP MN Sulfotransferase 1A1 (SULT1A1) DMWVIGP MT DME DMWVIGP MA Metabolism DMWVIGP RN Hydroxysteroid sulfotransferase and a specific UDP-glucuronosyltransferase are involved in the metabolism of digitoxin in man. Naunyn Schmiedebergs Arch Pharmacol. 1992 Aug;346(2):226-33. DMWVIGP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=1448185 DMWVIGP DI DMWVIGP DMWVIGP DN Digitoxin DMWVIGP MI DEYGVN4 DMWVIGP MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMWVIGP MT DME DMWVIGP MA Metabolism DMWVIGP RN Use of a human liver microsome bank in drug glucuronidation studies. Toxicol In Vitro. 1991;5(5-6):559-62. DMWVIGP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20732077 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DE84PFW DMQCTIH MN Cardiac glycoside reductase 1 (cgr1) DMQCTIH MT DME DMQCTIH MA Metabolism DMQCTIH RN Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 2014 Mar-Apr;5(2):233-8. DMQCTIH RU https://pubmed.ncbi.nlm.nih.gov/24637603 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DE9VSLW DMQCTIH MN Cardiac glycoside reductase 2 (cgr2) DMQCTIH MT DME DMQCTIH MA Metabolism DMQCTIH RN Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes. 2014 Mar-Apr;5(2):233-8. DMQCTIH RU https://pubmed.ncbi.nlm.nih.gov/24637603 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DE4LYSA DMQCTIH MN Cytochrome P450 3A4 (CYP3A4) DMQCTIH MT DME DMQCTIH MA Metabolism DMQCTIH RN Omeprazole-associated digoxin toxicity. South Med J. 2007 Apr;100(4):400-2. DMQCTIH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17458401 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DTZRMK5 DMQCTIH MN Multidrug resistance protein 3 (ABCB4) DMQCTIH MT DTP DMQCTIH MA Substrate DMQCTIH RN MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J Biol Chem. 2000 Aug 4;275(31):23530-9. DMQCTIH RU http://www.ncbi.nlm.nih.gov/pubmed/10918072 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI TTACFNR DMQCTIH MN Organic anion transporter M1 (SLCO4C1) DMQCTIH MT DTT DMQCTIH MA Modulator DMQCTIH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1227). DMQCTIH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1227 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DT9C1TS DMQCTIH MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMQCTIH MT DTP DMQCTIH MA Substrate DMQCTIH RN Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33. DMQCTIH RU http://www.ncbi.nlm.nih.gov/pubmed/11159893 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DTPFTEQ DMQCTIH MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DMQCTIH MT DTP DMQCTIH MA Substrate DMQCTIH RN Drug Interactions in Infectious Diseases. DMQCTIH RU http://www.springer.com/medicine/internal/book/978-1-61779-212-0 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DTY0QMU DMQCTIH MN Organic anion transporting polypeptide 4C1 (SLCO4C1) DMQCTIH MT DTP DMQCTIH MA Substrate DMQCTIH RN Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3569-74. DMQCTIH RU http://www.ncbi.nlm.nih.gov/pubmed/14993604 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DTMEQ32 DMQCTIH MN Organic solute transporter subunit alpha (SLC51A) DMQCTIH MT DTP DMQCTIH MA Substrate DMQCTIH RN Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. DMQCTIH RU http://www.ncbi.nlm.nih.gov/pubmed/12719432 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DT1V9AJ DMQCTIH MN Organic solute transporter subunit beta (SLC51B) DMQCTIH MT DTP DMQCTIH MA Substrate DMQCTIH RN Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. DMQCTIH RU http://www.ncbi.nlm.nih.gov/pubmed/12719432 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI DTUGYRD DMQCTIH MN P-glycoprotein 1 (ABCB1) DMQCTIH MT DTP DMQCTIH MA Substrate DMQCTIH RN MDR1 function is sensitive to the phosphorylation state of myosin regulatory light chain. Biochem Biophys Res Commun. 2010 Jul 16;398(1):7-12. DMQCTIH RU http://www.ncbi.nlm.nih.gov/pubmed/20510202 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH MI TTQ38E9 DMQCTIH MN Sodium/potassium-transporting ATPase (SPT ATPase) DMQCTIH MT DTT DMQCTIH MA Inhibitor DMQCTIH RN Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33. DMQCTIH RU https://pubmed.ncbi.nlm.nih.gov/15554746 DMZIXU9 DI DMZIXU9 DMZIXU9 DN Dihydralazine DMZIXU9 MI DEJGDUW DMZIXU9 MN Cytochrome P450 1A2 (CYP1A2) DMZIXU9 MT DME DMZIXU9 MA Metabolism DMZIXU9 RN Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem Res Toxicol. 1999 Oct;12(10):1028-32. DMZIXU9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10525281 DMZIXU9 DI DMZIXU9 DMZIXU9 DN Dihydralazine DMZIXU9 MI DE4LYSA DMZIXU9 MN Cytochrome P450 3A4 (CYP3A4) DMZIXU9 MT DME DMZIXU9 MA Metabolism DMZIXU9 RN Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 2005;44(3):279-304. DMZIXU9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15762770 DMZIXU9 DI DMZIXU9 DMZIXU9 DN Dihydralazine DMZIXU9 MI DEZV4AP DMZIXU9 MN RNA cytidine acetyltransferase (hALP) DMZIXU9 MT DME DMZIXU9 MA Metabolism DMZIXU9 RN The influence of the acetylator phenotype for the clinical use of dihydralazine. Int J Clin Pharmacol Ther Toxicol. 1985 Apr;23 Suppl 1:S74-8. DMZIXU9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=3842694 DMBXVMZ DI DMBXVMZ DMBXVMZ DN Dihydroartemisinin DMBXVMZ MI TTZVSJ2 DMBXVMZ MN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMBXVMZ MT DTT DMBXVMZ MA Inhibitor DMBXVMZ RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMBXVMZ RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMBXVMZ DI DMBXVMZ DMBXVMZ DN Dihydroartemisinin DMBXVMZ MI DE85D2P DMBXVMZ MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMBXVMZ MT DME DMBXVMZ MA Metabolism DMBXVMZ RN Eurartesim - European Medicines Agency DMBXVMZ RU http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf DMBXVMZ DI DMBXVMZ DMBXVMZ DN Dihydroartemisinin DMBXVMZ MI DEB3CV1 DMBXVMZ MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMBXVMZ MT DME DMBXVMZ MA Metabolism DMBXVMZ RN Eurartesim - European Medicines Agency DMBXVMZ RU http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001199/WC500118116.pdf DM5SQ1G DI DM5SQ1G DM5SQ1G DN Dihydroergocristine DM5SQ1G MI TT2NUT5 DM5SQ1G MN Adrenergic receptor alpha-2C (ADRA2C) DM5SQ1G MT DTT DM5SQ1G MA Modulator DM5SQ1G RN Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7. DM5SQ1G RU https://pubmed.ncbi.nlm.nih.gov/6321209 DM5SQ1G DI DM5SQ1G DM5SQ1G DN Dihydroergocristine DM5SQ1G MI DTUGYRD DM5SQ1G MN P-glycoprotein 1 (ABCB1) DM5SQ1G MT DTP DM5SQ1G MA Substrate DM5SQ1G RN Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. DM5SQ1G RU https://doi.org/10.1124/jpet.102.037549 DM5IKUF DI DM5IKUF DM5IKUF DN Dihydroergotamine DM5IKUF MI DE4LYSA DM5IKUF MN Cytochrome P450 3A4 (CYP3A4) DM5IKUF MT DME DM5IKUF MA Metabolism DM5IKUF RN CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97. DM5IKUF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14998425 DM5IKUF DI DM5IKUF DM5IKUF DN Dihydroergotamine DM5IKUF MI TTEX248 DM5IKUF MN Dopamine D2 receptor (D2R) DM5IKUF MT DTT DM5IKUF MA Agonist DM5IKUF RN Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. DM5IKUF RU https://pubmed.ncbi.nlm.nih.gov/18626630 DM5D6WZ DI DM5D6WZ DM5D6WZ DN Dihydroergotoxine DM5D6WZ MI TTEX248 DM5D6WZ MN Dopamine D2 receptor (D2R) DM5D6WZ MT DTT DM5D6WZ MA Agonist DM5D6WZ RN Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. DM5D6WZ RU https://pubmed.ncbi.nlm.nih.gov/10084415 DM5D6WZ DI DM5D6WZ DM5D6WZ DN Dihydroergotoxine DM5D6WZ MI TTAN6JD DM5D6WZ MN Glutamate receptor AMPA (GRIA) DM5D6WZ MT DTT DM5D6WZ MA Agonist DM5D6WZ RN Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. DM5D6WZ RU https://pubmed.ncbi.nlm.nih.gov/10084415 DMFB97P DI DMFB97P DMFB97P DN Dihydrotachysterol DMFB97P MI TTK59TV DMFB97P MN Vitamin D3 receptor (VDR) DMFB97P MT DTT DMFB97P MA Antagonist DMFB97P RN In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92. DMFB97P RU https://pubmed.ncbi.nlm.nih.gov/8380156 DMM1LG2 DI DMM1LG2 DMM1LG2 DN Dihydroxyacetone DMM1LG2 MI DEX9ZJQ DMM1LG2 MN Triokinase/FMN cyclase (TKFC) DMM1LG2 MT DME DMM1LG2 MA Metabolism DMM1LG2 RN Bifunctional homodimeric triokinase/FMN cyclase: contribution of protein domains to the activities of the human enzyme and molecular dynamics simulation of domain movements. J Biol Chem. 2014 Apr 11;289(15):10620-36. DMM1LG2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24569995 DM8YXKW DI DM8YXKW DM8YXKW DN Dihydroxyaluminium DM8YXKW MI TT8RDXP DM8YXKW MN Troponin C (TN-C) DM8YXKW MT DTT DM8YXKW MA Stimulator DM8YXKW RN A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med. 2009 Dec;9(4):303-12. DM8YXKW RU https://pubmed.ncbi.nlm.nih.gov/19350363 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV MI DES5XRU DMAI7ZV MN Cytochrome P450 2C8 (CYP2C8) DMAI7ZV MT DME DMAI7ZV MA Metabolism DMAI7ZV RN Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther. 1997 Jul;282(1):294-300. DMAI7ZV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9223567 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV MI DE5IED8 DMAI7ZV MN Cytochrome P450 2C9 (CYP2C9) DMAI7ZV MT DME DMAI7ZV MA Metabolism DMAI7ZV RN Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30. DMAI7ZV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV MI DECB0K3 DMAI7ZV MN Cytochrome P450 2D6 (CYP2D6) DMAI7ZV MT DME DMAI7ZV MA Metabolism DMAI7ZV RN Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30. DMAI7ZV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV MI DE4LYSA DMAI7ZV MN Cytochrome P450 3A4 (CYP3A4) DMAI7ZV MT DME DMAI7ZV MA Metabolism DMAI7ZV RN Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002 Aug;30(8):883-91. DMAI7ZV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12124305 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV MI DEIBDNY DMAI7ZV MN Cytochrome P450 3A5 (CYP3A5) DMAI7ZV MT DME DMAI7ZV MA Metabolism DMAI7ZV RN Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. J Clin Pharm Ther. 2016 Jun;41(3):341-7. DMAI7ZV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27149910 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV MI DERD86B DMAI7ZV MN Cytochrome P450 3A7 (CYP3A7) DMAI7ZV MT DME DMAI7ZV MA Metabolism DMAI7ZV RN FDA Drug Development and Drug Interactions DMAI7ZV RU https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table3-2 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV MI DEGTFWK DMAI7ZV MN Mephenytoin 4-hydroxylase (CYP2C19) DMAI7ZV MT DME DMAI7ZV MA Metabolism DMAI7ZV RN Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos. 2001 Oct;29(10):1284-9. DMAI7ZV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11560871 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV MI DTUGYRD DMAI7ZV MN P-glycoprotein 1 (ABCB1) DMAI7ZV MT DTP DMAI7ZV MA Substrate DMAI7ZV RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMAI7ZV RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV MI TTFK1JQ DMAI7ZV MN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMAI7ZV MT DTT DMAI7ZV MA Blocker DMAI7ZV RN Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24. DMAI7ZV RU https://pubmed.ncbi.nlm.nih.gov/19590189 DM264B3 DI DM264B3 DM264B3 DN Dimenhydrinate DM264B3 MI TTTIBOJ DM264B3 MN Histamine H1 receptor (H1R) DM264B3 MT DTT DM264B3 MA Antagonist DM264B3 RN Histamine 1 receptor antagonist in symptomatic treatment of renal colic accompanied by nausea: two birds with one stone Urology. 2009 Jan;73(1):32-6. DM264B3 RU https://pubmed.ncbi.nlm.nih.gov/18849063 DM32YAI DI DM32YAI DM32YAI DN Dimethindene DM32YAI MI TTTIBOJ DM32YAI MN Histamine H1 receptor (H1R) DM32YAI MT DTT DM32YAI MA Antagonist DM32YAI RN Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93. DM32YAI RU https://pubmed.ncbi.nlm.nih.gov/19308787 DMXQKSL DI DMXQKSL DMXQKSL DN Dinoprost Tromethamine DMXQKSL MI TTOFYT1 DMXQKSL MN Prostacyclin receptor (PTGIR) DMXQKSL MT DTT DMXQKSL MA Antagonist DMXQKSL RN Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. DMXQKSL RU https://pubmed.ncbi.nlm.nih.gov/12488443 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DEJGDUW DMTYOPD MN Cytochrome P450 1A2 (CYP1A2) DMTYOPD MT DME DMTYOPD MA Metabolism DMTYOPD RN Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15224350 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DE3GT9C DMTYOPD MN Cytochrome P450 4F2 (CYP4F2) DMTYOPD MT DME DMTYOPD MA Metabolism DMTYOPD RN Cloning and characterization of CYP4F21: a prostaglandin E2 20-hydroxylase of ram seminal vesicles. Arch Biochem Biophys. 2001 May 1;389(1):123-9. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11370662 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTFI42L DMTYOPD MN Multidrug resistance-associated protein 2 (ABCC2) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8. DMTYOPD RU https://doi.org/10.1111/j.1478-3231.2005.01234.x DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTCSGPB DMTYOPD MN Multidrug resistance-associated protein 4 (ABCC4) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/12835412 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTQ23VB DMTYOPD MN Organic anion transporter 1 (SLC22A6) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/11907186 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DT0OC1Q DMTYOPD MN Organic anion transporter 2 (SLC22A7) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/11907186 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTVP67E DMTYOPD MN Organic anion transporter 3 (SLC22A8) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/11907186 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DT06JWZ DMTYOPD MN Organic anion transporter 4 (SLC22A11) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/11907186 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTE2B1D DMTYOPD MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/11713643 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DT3D8F0 DMTYOPD MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/21245207 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTPYCQ4 DMTYOPD MN Organic anion transporting polypeptide 1C1 (SLCO1C1) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/12351693 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DT021JD DMTYOPD MN Organic anion transporting polypeptide 2A1 (SLCO2A1) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/10873595 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTPFTEQ DMTYOPD MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/10873595 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTVNRXW DMTYOPD MN Organic anion transporting polypeptide 3A1 (SLCO3A1) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/14631946 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DT8H2IC DMTYOPD MN Organic anion transporting polypeptide 4A1 (SLCO4A1) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/10873595 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTYVQ5M DMTYOPD MN Organic anion transporting polypeptide 5A1 (SLCO5A1) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Expression and regulation of prostaglandin transporters, ATP-binding cassette, subfamily C, member 1 and 9, and solute carrier organic anion transporter family, member 2A1 and 5A1 in the uterine endometrium during the estrous cycle and pregnancy in pigs. Asian-Australas J Anim Sci. 2017 May;30(5):643-652. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/27764917 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTT79CX DMTYOPD MN Organic cation transporter 1 (SLC22A1) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/16211406 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DT9IDPW DMTYOPD MN Organic cation transporter 2 (SLC22A2) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/16211406 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DTMEQ32 DMTYOPD MN Organic solute transporter subunit alpha (SLC51A) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/12719432 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI DT1V9AJ DMTYOPD MN Organic solute transporter subunit beta (SLC51B) DMTYOPD MT DTP DMTYOPD MA Substrate DMTYOPD RN Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. DMTYOPD RU http://www.ncbi.nlm.nih.gov/pubmed/12719432 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI TT1ZAVI DMTYOPD MN Prostaglandin E2 receptor EP2 (PTGER2) DMTYOPD MT DTT DMTYOPD MA Antagonist DMTYOPD RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD MI TTT2ZAR DMTYOPD MN Prostaglandin F2-alpha receptor (PTGFR) DMTYOPD MT DTT DMTYOPD MA Antagonist DMTYOPD RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMXVU6D DI DMXVU6D DMXVU6D DN Diphemanil Methylsulfate DMXVU6D MI TTZ9SOR DMXVU6D MN Muscarinic acetylcholine receptor M1 (CHRM1) DMXVU6D MT DTT DMXVU6D MA Modulator DMXVU6D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMXVU6D RU https://www.fda.gov/ DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA MI DE5IED8 DMKQTBA MN Cytochrome P450 2C9 (CYP2C9) DMKQTBA MT DME DMKQTBA MA Metabolism DMKQTBA RN Pharmacogenomics in psychiatry: implications for practice. Recent Pat Biotechnol. 2014;8(2):152-9. DMKQTBA RU https://www.ncbi.nlm.nih.gov/pubmed/25185985 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA MI DECB0K3 DMKQTBA MN Cytochrome P450 2D6 (CYP2D6) DMKQTBA MT DME DMKQTBA MA Metabolism DMKQTBA RN Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos. 2007 Jan;35(1):72-8. DMKQTBA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17020955 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA MI TTTIBOJ DMKQTBA MN Histamine H1 receptor (H1R) DMKQTBA MT DTT DMKQTBA MA Antagonist DMKQTBA RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMKQTBA RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA MI TT2B6EV DMKQTBA MN Histamine N-methyltransferase (HNMT) DMKQTBA MT DTT DMKQTBA MA Inhibitor DMKQTBA RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKQTBA RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA MI DEGTFWK DMKQTBA MN Mephenytoin 4-hydroxylase (CYP2C19) DMKQTBA MT DME DMKQTBA MA Metabolism DMKQTBA RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMKQTBA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA MI DE073H6 DMKQTBA MN Prostaglandin G/H synthase 1 (COX-1) DMKQTBA MT DME DMKQTBA MA Metabolism DMKQTBA RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMKQTBA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMHPWOM DI DMHPWOM DMHPWOM DN Diphenidol DMHPWOM MI TTQ3JTF DMHPWOM MN Muscarinic acetylcholine receptor M4 (CHRM4) DMHPWOM MT DTT DMHPWOM MA Antagonist DMHPWOM RN Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2972-6. DMHPWOM RU https://pubmed.ncbi.nlm.nih.gov/18395442 DMO5SZX DI DMO5SZX DMO5SZX DN Diphenoxylate DMO5SZX MI TTKWM86 DMO5SZX MN Opioid receptor mu (MOP) DMO5SZX MT DTT DMO5SZX MA Agonist DMO5SZX RN Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8. DMO5SZX RU https://pubmed.ncbi.nlm.nih.gov/18192961 DMW4X37 DI DMW4X37 DMW4X37 DN Diphenylpyraline DMW4X37 MI TTTIBOJ DMW4X37 MN Histamine H1 receptor (H1R) DMW4X37 MT DTT DMW4X37 MA Antagonist DMW4X37 RN Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. Biol Pharm Bull. 1994 May;17(5):676-9. DMW4X37 RU https://pubmed.ncbi.nlm.nih.gov/7920432 DM0FSIM DI DM0FSIM DM0FSIM DN Diphtheria-tetanus vaccine DM0FSIM MI TTXT4D5 DM0FSIM MN Bacterial Cell membrane (Bact CM) DM0FSIM MT DTT DM0FSIM RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM0FSIM RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMH5W0G DI DMH5W0G DMH5W0G DN Dipivefrin DMH5W0G MI TTR6W5O DMH5W0G MN Adrenergic receptor beta-1 (ADRB1) DMH5W0G MT DTT DMH5W0G MA Antagonist DMH5W0G RN Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol. 1996 May;5(3):146-53. DMH5W0G RU https://pubmed.ncbi.nlm.nih.gov/8803576 DMXY30O DI DMXY30O DMXY30O DN Dipyridamole DMXY30O MI DTI7UX6 DMXY30O MN Breast cancer resistance protein (ABCG2) DMXY30O MT DTP DMXY30O MA Substrate DMXY30O RN ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13. DMXY30O RU https://doi.org/10.1016/j.addr.2008.11.003 DMXY30O DI DMXY30O DMXY30O DN Dipyridamole DMXY30O MI DTUGYRD DMXY30O MN P-glycoprotein 1 (ABCB1) DMXY30O MT DTP DMXY30O MA Substrate DMXY30O RN Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. DMXY30O RU https://doi.org/10.1016/j.addr.2011.12.008 DMXY30O DI DMXY30O DMXY30O DN Dipyridamole DMXY30O MI TTJ0IQB DMXY30O MN Phosphodiesterase 5A (PDE5A) DMXY30O MT DTT DMXY30O MA Modulator DMXY30O RN Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46. DMXY30O RU https://www.ncbi.nlm.nih.gov/pubmed/21649691 DM0D9YJ DI DM0D9YJ DM0D9YJ DN Dirithromycin DM0D9YJ MI TTUWYEA DM0D9YJ MN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM0D9YJ MT DTT DM0D9YJ MA Binder DM0D9YJ RN Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98. DM0D9YJ RU https://pubmed.ncbi.nlm.nih.gov/11324679 DM0D9YJ DI DM0D9YJ DM0D9YJ DN Dirithromycin DM0D9YJ MI DTI7UX6 DM0D9YJ MN Breast cancer resistance protein (ABCG2) DM0D9YJ MT DTP DM0D9YJ MA Substrate DM0D9YJ RN Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26. DM0D9YJ RU https://doi.org/10.1042/BJ20040791 DM0D9YJ DI DM0D9YJ DM0D9YJ DN Dirithromycin DM0D9YJ MI DE4LYSA DM0D9YJ MN Cytochrome P450 3A4 (CYP3A4) DM0D9YJ MT DME DM0D9YJ MA Metabolism DM0D9YJ RN Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. DM0D9YJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11020135 DM5SYZP DI DM5SYZP DM5SYZP DN Disopyramide DM5SYZP MI DEJGDUW DM5SYZP MN Cytochrome P450 1A2 (CYP1A2) DM5SYZP MT DME DM5SYZP MA Metabolism DM5SYZP RN Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83. DM5SYZP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11407536 DM5SYZP DI DM5SYZP DM5SYZP DN Disopyramide DM5SYZP MI DE4LYSA DM5SYZP MN Cytochrome P450 3A4 (CYP3A4) DM5SYZP MT DME DM5SYZP MA Metabolism DM5SYZP RN Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83. DM5SYZP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11407536 DM5SYZP DI DM5SYZP DM5SYZP DN Disopyramide DM5SYZP MI DTT79CX DM5SYZP MN Organic cation transporter 1 (SLC22A1) DM5SYZP MT DTP DM5SYZP MA Substrate DM5SYZP RN Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. DM5SYZP RU http://www.ncbi.nlm.nih.gov/pubmed/23984907 DM5SYZP DI DM5SYZP DM5SYZP DN Disopyramide DM5SYZP MI TTZOVE0 DM5SYZP MN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM5SYZP MT DTT DM5SYZP MA Blocker DM5SYZP RN Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. DM5SYZP RU https://pubmed.ncbi.nlm.nih.gov/11196553 DMCL2OK DI DMCL2OK DMCL2OK DN Disulfiram DMCL2OK MI DEVDYN7 DMCL2OK MN Cytochrome P450 2E1 (CYP2E1) DMCL2OK MT DME DMCL2OK MA Metabolism DMCL2OK RN Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans. J Pharmacol Exp Ther. 1999 Oct;291(1):213-9. DMCL2OK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10490907 DMCL2OK DI DMCL2OK DMCL2OK DN Disulfiram DMCL2OK MI DE4LYSA DMCL2OK MN Cytochrome P450 3A4 (CYP3A4) DMCL2OK MT DME DMCL2OK MA Metabolism DMCL2OK RN Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism. Am J Addict. 2014 Mar-Apr;23(2):137-44. DMCL2OK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24118434 DMCL2OK DI DMCL2OK DMCL2OK DN Disulfiram DMCL2OK MI DEIBDNY DMCL2OK MN Cytochrome P450 3A5 (CYP3A5) DMCL2OK MT DME DMCL2OK MA Metabolism DMCL2OK RN Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res. 1998 Sep;22(6):1212-9. DMCL2OK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9756035 DMCL2OK DI DMCL2OK DMCL2OK DN Disulfiram DMCL2OK MI TTB6UM0 DMCL2OK MN Fatty aldehyde dehydrogenase (ALDH3A2) DMCL2OK MT DTT DMCL2OK MA Inhibitor DMCL2OK RN Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76. DMCL2OK RU https://pubmed.ncbi.nlm.nih.gov/16545872 DM4RK0G DI DM4RK0G DM4RK0G DN Divalproex sodium DM4RK0G MI TTT2LD9 DM4RK0G MN GABA transaminase (ABAT) DM4RK0G MT DTT DM4RK0G MA Inhibitor DM4RK0G RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM4RK0G RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMD1B8Z DI DMD1B8Z DMD1B8Z DN Dobutamine DMD1B8Z MI TTR6W5O DMD1B8Z MN Adrenergic receptor beta-1 (ADRB1) DMD1B8Z MT DTT DMD1B8Z MA Agonist DMD1B8Z RN Beta-adrenoceptor alterations coupled with secretory response and experimental periodontitis in rat submandibular glands. Arch Oral Biol. 2008 Jun;53(6):509-16. DMD1B8Z RU https://pubmed.ncbi.nlm.nih.gov/18275933 DMD1B8Z DI DMD1B8Z DMD1B8Z DN Dobutamine DMD1B8Z MI DEV3T4A DMD1B8Z MN Catechol O-methyltransferase (COMT) DMD1B8Z MT DME DMD1B8Z MA Metabolism DMD1B8Z RN Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents. Xenobiotica. 1986 Jan;16(1):47-52. DMD1B8Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=2868577 DMS5IEB DI DMS5IEB DMS5IEB DN Docarpamine DMS5IEB MI TTEX248 DMS5IEB MN Dopamine D2 receptor (D2R) DMS5IEB MT DTT DMS5IEB MA Modulator DMS5IEB RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMS5IEB RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DTI7UX6 DMDI269 MN Breast cancer resistance protein (ABCG2) DMDI269 MT DTP DMDI269 MA Substrate DMDI269 RN Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32. DMDI269 RU http://www.ncbi.nlm.nih.gov/pubmed/21262849 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DE4LYSA DMDI269 MN Cytochrome P450 3A4 (CYP3A4) DMDI269 MT DME DMDI269 MA Metabolism DMDI269 RN Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9. DMDI269 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15657405 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DEIBDNY DMDI269 MN Cytochrome P450 3A5 (CYP3A5) DMDI269 MT DME DMDI269 MA Metabolism DMDI269 RN Drug Interactions Flockhart Table DMDI269 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DERD86B DMDI269 MN Cytochrome P450 3A7 (CYP3A7) DMDI269 MT DME DMDI269 MA Metabolism DMDI269 RN Drug Interactions Flockhart Table DMDI269 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DTSYQGK DMDI269 MN Multidrug resistance-associated protein 1 (ABCC1) DMDI269 MT DTP DMDI269 MA Substrate DMDI269 RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DMDI269 RU https://doi.org/10.1007/s11095-012-0935-x DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DTFI42L DMDI269 MN Multidrug resistance-associated protein 2 (ABCC2) DMDI269 MT DTP DMDI269 MA Substrate DMDI269 RN Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36. DMDI269 RU http://www.ncbi.nlm.nih.gov/pubmed/18845662 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DTPS120 DMDI269 MN Multidrug resistance-associated protein 7 (ABCC10) DMDI269 MT DTP DMDI269 MA Substrate DMDI269 RN Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67. DMDI269 RU http://www.ncbi.nlm.nih.gov/pubmed/23087055 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DT3D8F0 DMDI269 MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMDI269 MT DTP DMDI269 MA Substrate DMDI269 RN FDA Drug Development and Drug Interactions DMDI269 RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DT9C1TS DMDI269 MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMDI269 MT DTP DMDI269 MA Substrate DMDI269 RN Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9. DMDI269 RU http://www.ncbi.nlm.nih.gov/pubmed/18082941 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DTUGYRD DMDI269 MN P-glycoprotein 1 (ABCB1) DMDI269 MT DTP DMDI269 MA Substrate DMDI269 RN Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6. DMDI269 RU http://www.ncbi.nlm.nih.gov/pubmed/20628376 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI DT68UV2 DMDI269 MN TAP-like protein (ABCB9) DMDI269 MT DTP DMDI269 MA Substrate DMDI269 RN RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134. DMDI269 RU http://www.ncbi.nlm.nih.gov/pubmed/28825433 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 MI TTML2WA DMDI269 MN Tubulin (TUB) DMDI269 MT DTT DMDI269 MA Inhibitor DMDI269 RN Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31. DMDI269 RU https://pubmed.ncbi.nlm.nih.gov/16296875 DMOHK1E DI DMOHK1E DMOHK1E DN Docosanol DMOHK1E MI TT1JL7D DMOHK1E MN Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1) DMOHK1E MT DTT DMOHK1E MA Modulator DMOHK1E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOHK1E RU https://www.fda.gov/ DMPN1TW DI DMPN1TW DMPN1TW DN Dofetilide DMPN1TW MI DE4LYSA DMPN1TW MN Cytochrome P450 3A4 (CYP3A4) DMPN1TW MT DME DMPN1TW MA Metabolism DMPN1TW RN Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug Metab Dispos. 1996 Apr;24(4):447-55. DMPN1TW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8801060 DMPN1TW DI DMPN1TW DMPN1TW DN Dofetilide DMPN1TW MI DTZGT0P DMPN1TW MN Multidrug and toxin extrusion protein 1 (SLC47A1) DMPN1TW MT DTP DMPN1TW MA Substrate DMPN1TW RN FDA Drug Development and Drug Interactions DMPN1TW RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DMPN1TW DI DMPN1TW DMPN1TW DN Dofetilide DMPN1TW MI DT3TX4H DMPN1TW MN Multidrug and toxin extrusion protein 2 (SLC47A2) DMPN1TW MT DTP DMPN1TW MA Substrate DMPN1TW RN FDA Drug Development and Drug Interactions DMPN1TW RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DMPN1TW DI DMPN1TW DMPN1TW DN Dofetilide DMPN1TW MI DT9IDPW DMPN1TW MN Organic cation transporter 2 (SLC22A2) DMPN1TW MT DTP DMPN1TW MA Substrate DMPN1TW RN FDA Drug Development and Drug Interactions DMPN1TW RU https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm#table3-2 DMPN1TW DI DMPN1TW DMPN1TW DN Dofetilide DMPN1TW MI TT1VOHK DMPN1TW MN Potassium channel unspecific (KC) DMPN1TW MT DTT DMPN1TW MA Modulator DMPN1TW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPN1TW RU https://www.fda.gov/ DMMG26Z DI DMMG26Z DMMG26Z DN Dolasetron DMMG26Z MI TTPC4TU DMMG26Z MN 5-HT 3A receptor (HTR3A) DMMG26Z MT DTT DMMG26Z MA Antagonist DMMG26Z RN Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24. DMMG26Z RU https://pubmed.ncbi.nlm.nih.gov/19135415 DMMG26Z DI DMMG26Z DMMG26Z DN Dolasetron DMMG26Z MI DE5IED8 DMMG26Z MN Cytochrome P450 2C9 (CYP2C9) DMMG26Z MT DME DMMG26Z MA Metabolism DMMG26Z RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMMG26Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMMG26Z DI DMMG26Z DMMG26Z DN Dolasetron DMMG26Z MI DECB0K3 DMMG26Z MN Cytochrome P450 2D6 (CYP2D6) DMMG26Z MT DME DMMG26Z MA Metabolism DMMG26Z RN Reappraisal of the role of dolasetron in prevention and treatment of nausea and vomiting associated with surgery or chemotherapy. Cancer Manag Res. 2012;4:67-73. DMMG26Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22427733 DMMG26Z DI DMMG26Z DMMG26Z DN Dolasetron DMMG26Z MI DE4LYSA DMMG26Z MN Cytochrome P450 3A4 (CYP3A4) DMMG26Z MT DME DMMG26Z MA Metabolism DMMG26Z RN Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9. DMMG26Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8723743 DMCZGRE DI DMCZGRE DMCZGRE DN Dolutegravir DMCZGRE MI DE4LYSA DMCZGRE MN Cytochrome P450 3A4 (CYP3A4) DMCZGRE MT DME DMCZGRE MA Metabolism DMCZGRE RN Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8. DMCZGRE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25858605 DMCZGRE DI DMCZGRE DMCZGRE DN Dolutegravir DMCZGRE MI TT5FH9Y DMCZGRE MN Human immunodeficiency virus Integrase (HIV IN) DMCZGRE MT DTT DMCZGRE MA Modulator DMCZGRE RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMCZGRE RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMCZGRE DI DMCZGRE DMCZGRE DN Dolutegravir DMCZGRE MI DTUGYRD DMCZGRE MN P-glycoprotein 1 (ABCB1) DMCZGRE MT DTP DMCZGRE MA Substrate DMCZGRE RN Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition. DMCZGRE RU https://books.google.com/books?id=0gBRDwAAQBAJ&pg=PP37&lpg=PP37&dq=Methylergonovine+transporter+uptake+efflex&source=bl&ots=cUTe_ppsmZ&sig=ACfU3U3E_YqrDg0CNEuj8K-7lci47HAnrg&hl=zh-CN&sa=X&ved=2ahUKEwjnj-Dk7d7iAhUsK6YKHd5DBDkQ6AEwEnoECAgQAQ#v=onepage&q&f=false DMCZGRE DI DMCZGRE DMCZGRE DN Dolutegravir DMCZGRE MI DEYGVN4 DMCZGRE MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMCZGRE MT DME DMCZGRE MA Metabolism DMCZGRE RN Mechanisms of action, pharmacology and interactions of dolutegravir. Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:2-8. DMCZGRE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25858605 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 MI DEJGDUW DMBDPY0 MN Cytochrome P450 1A2 (CYP1A2) DMBDPY0 MT DME DMBDPY0 MA Metabolism DMBDPY0 RN Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87. DMBDPY0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 MI DEPKLMQ DMBDPY0 MN Cytochrome P450 2B6 (CYP2B6) DMBDPY0 MT DME DMBDPY0 MA Metabolism DMBDPY0 RN Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87. DMBDPY0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 MI DES5XRU DMBDPY0 MN Cytochrome P450 2C8 (CYP2C8) DMBDPY0 MT DME DMBDPY0 MA Metabolism DMBDPY0 RN Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87. DMBDPY0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 MI DECB0K3 DMBDPY0 MN Cytochrome P450 2D6 (CYP2D6) DMBDPY0 MT DME DMBDPY0 MA Metabolism DMBDPY0 RN Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87. DMBDPY0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15327587 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 MI DE4LYSA DMBDPY0 MN Cytochrome P450 3A4 (CYP3A4) DMBDPY0 MT DME DMBDPY0 MA Metabolism DMBDPY0 RN Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole. Drug Metab Lett. 2010 Apr;4(2):95-103. DMBDPY0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21281268 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 MI DEIBDNY DMBDPY0 MN Cytochrome P450 3A5 (CYP3A5) DMBDPY0 MT DME DMBDPY0 MA Metabolism DMBDPY0 RN Drug Interactions Flockhart Table DMBDPY0 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 MI DERD86B DMBDPY0 MN Cytochrome P450 3A7 (CYP3A7) DMBDPY0 MT DME DMBDPY0 MA Metabolism DMBDPY0 RN Drug Interactions Flockhart Table DMBDPY0 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 MI TTEX248 DMBDPY0 MN Dopamine D2 receptor (D2R) DMBDPY0 MT DTT DMBDPY0 MA Antagonist DMBDPY0 RN Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31. DMBDPY0 RU https://pubmed.ncbi.nlm.nih.gov/18970411 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 MI DTUGYRD DMBDPY0 MN P-glycoprotein 1 (ABCB1) DMBDPY0 MT DTP DMBDPY0 MA Substrate DMBDPY0 RN Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. DMBDPY0 RU http://www.ncbi.nlm.nih.gov/pubmed/15285840 DMIYG7Z DI DMIYG7Z DMIYG7Z DN Donepezil DMIYG7Z MI TT1RS9F DMIYG7Z MN Acetylcholinesterase (AChE) DMIYG7Z MT DTT DMIYG7Z MA Modulator DMIYG7Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMIYG7Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMIYG7Z DI DMIYG7Z DMIYG7Z DN Donepezil DMIYG7Z MI DE5IED8 DMIYG7Z MN Cytochrome P450 2C9 (CYP2C9) DMIYG7Z MT DME DMIYG7Z MA Metabolism DMIYG7Z RN Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease. J Pharmacol Sci. 2015 Nov;129(3):188-95. DMIYG7Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26603528 DMIYG7Z DI DMIYG7Z DMIYG7Z DN Donepezil DMIYG7Z MI DECB0K3 DMIYG7Z MN Cytochrome P450 2D6 (CYP2D6) DMIYG7Z MT DME DMIYG7Z MA Metabolism DMIYG7Z RN Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7. DMIYG7Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26952092 DMIYG7Z DI DMIYG7Z DMIYG7Z DN Donepezil DMIYG7Z MI DE4LYSA DMIYG7Z MN Cytochrome P450 3A4 (CYP3A4) DMIYG7Z MT DME DMIYG7Z MA Metabolism DMIYG7Z RN Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease. Eur J Clin Pharmacol. 2016 Jun;72(6):711-7. DMIYG7Z RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26952092 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DEV3T4A DMPGUCF MN Catechol O-methyltransferase (COMT) DMPGUCF MT DME DMPGUCF MA Metabolism DMPGUCF RN Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60. DMPGUCF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21656904 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DEJGDUW DMPGUCF MN Cytochrome P450 1A2 (CYP1A2) DMPGUCF MT DME DMPGUCF MA Metabolism DMPGUCF RN Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics. 1998 Jun;8(3):251-8. DMPGUCF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9682270 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DE5IED8 DMPGUCF MN Cytochrome P450 2C9 (CYP2C9) DMPGUCF MT DME DMPGUCF MA Metabolism DMPGUCF RN Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106. DMPGUCF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DECB0K3 DMPGUCF MN Cytochrome P450 2D6 (CYP2D6) DMPGUCF MT DME DMPGUCF MA Metabolism DMPGUCF RN Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106. DMPGUCF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI TTEX248 DMPGUCF MN Dopamine D2 receptor (D2R) DMPGUCF MT DTT DMPGUCF MA Agonist DMPGUCF RN The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. DMPGUCF RU https://pubmed.ncbi.nlm.nih.gov/17301410 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DEL0D64 DMPGUCF MN Dopamine dehydroxylase (dadH) DMPGUCF MT DME DMPGUCF MA Metabolism DMPGUCF RN Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323. DMPGUCF RU https://pubmed.ncbi.nlm.nih.gov/31196984 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DEGTFWK DMPGUCF MN Mephenytoin 4-hydroxylase (CYP2C19) DMPGUCF MT DME DMPGUCF MA Metabolism DMPGUCF RN Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106. DMPGUCF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10813809 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DET2NXO DMPGUCF MN Monoamine oxidase type B (MAO-B) DMPGUCF MT DME DMPGUCF MA Metabolism DMPGUCF RN Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32. DMPGUCF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20869994 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DTT79CX DMPGUCF MN Organic cation transporter 1 (SLC22A1) DMPGUCF MT DTP DMPGUCF MA Substrate DMPGUCF RN Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53. DMPGUCF RU https://doi.org/10.2133/dmpk.23.243 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DT9IDPW DMPGUCF MN Organic cation transporter 2 (SLC22A2) DMPGUCF MT DTP DMPGUCF MA Substrate DMPGUCF RN Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52. DMPGUCF RU http://www.ncbi.nlm.nih.gov/pubmed/16581093 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DT3BA8L DMPGUCF MN Sodium-dependent dopamine transporter (SLC6A3) DMPGUCF MT DTP DMPGUCF MA Substrate DMPGUCF RN Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236. DMPGUCF RU http://www.ncbi.nlm.nih.gov/pubmed/28055236 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DED5UR3 DMPGUCF MN Sulfotransferase 1B1 (SULT1B1) DMPGUCF MT DME DMPGUCF MA Metabolism DMPGUCF RN Molecular cloning, expression, and functional characterization of novel mouse sulfotransferases. Biochem Biophys Res Commun. 1998 Jun 29;247(3):681-6. DMPGUCF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9647753 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DT7A9GF DMPGUCF MN Synaptic vesicle glycoprotein 2C (SLC22B3) DMPGUCF MT DTP DMPGUCF MA Substrate DMPGUCF RN Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262. DMPGUCF RU http://www.ncbi.nlm.nih.gov/pubmed/28246328 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DTM953D DMPGUCF MN Vesicular amine transporter 1 (SLC18A1) DMPGUCF MT DTP DMPGUCF MA Substrate DMPGUCF RN SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72. DMPGUCF RU http://www.ncbi.nlm.nih.gov/pubmed/23506877 DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF MI DTT7VPB DMPGUCF MN Vesicular amine transporter 2 (SLC18A2) DMPGUCF MT DTP DMPGUCF MA Substrate DMPGUCF RN SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72. DMPGUCF RU http://www.ncbi.nlm.nih.gov/pubmed/23506877 DMSCIKZ DI DMSCIKZ DMSCIKZ DN Dopexamine DMSCIKZ MI TTEX248 DMSCIKZ MN Dopamine D2 receptor (D2R) DMSCIKZ MT DTT DMSCIKZ MA Modulator DMSCIKZ RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMSCIKZ RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM9UCJK DI DM9UCJK DM9UCJK DN Doripenem DM9UCJK MI TT4ILYC DM9UCJK MN Bacterial Dihydropteroate synthetase (Bact folP) DM9UCJK MT DTT DM9UCJK MA Inhibitor DM9UCJK RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM9UCJK RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM9UCJK DI DM9UCJK DM9UCJK DN Doripenem DM9UCJK MI DEC3G7M DM9UCJK MN Beta-lactamase (blaB) DM9UCJK MT DME DM9UCJK MA Metabolism DM9UCJK RN FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972. DM9UCJK RU https://pubmed.ncbi.nlm.nih.gov/30060114 DM9UCJK DI DM9UCJK DM9UCJK DN Doripenem DM9UCJK MI DEAMVR3 DM9UCJK MN Dehydropeptidase-I (DPEP1) DM9UCJK MT DME DM9UCJK MA Metabolism DM9UCJK RN Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother. 2008 Oct;52(10):3478-83. DM9UCJK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18644951 DM3XU74 DI DM3XU74 DM3XU74 DN Dornase Alfa DM3XU74 MI TTUTN1I DM3XU74 MN Human Deoxyribonucleic acid (hDNA) DM3XU74 MT DTT DM3XU74 MA Breaker DM3XU74 RN Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45. DM3XU74 RU https://pubmed.ncbi.nlm.nih.gov/18031106 DMA17D0 DI DMA17D0 DMA17D0 DN Dorzolamide DMA17D0 MI TTANPDJ DMA17D0 MN Carbonic anhydrase II (CA-II) DMA17D0 MT DTT DMA17D0 MA Inhibitor DMA17D0 RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMA17D0 RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMA17D0 DI DMA17D0 DMA17D0 DN Dorzolamide DMA17D0 MI DE5IED8 DMA17D0 MN Cytochrome P450 2C9 (CYP2C9) DMA17D0 MT DME DMA17D0 MA Metabolism DMA17D0 RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMA17D0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMA17D0 DI DMA17D0 DMA17D0 DN Dorzolamide DMA17D0 MI DEVDYN7 DMA17D0 MN Cytochrome P450 2E1 (CYP2E1) DMA17D0 MT DME DMA17D0 MA Metabolism DMA17D0 RN In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Drug Metab Dispos. 1994 Nov-Dec;22(6):916-21. DMA17D0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=7895610 DMA17D0 DI DMA17D0 DMA17D0 DN Dorzolamide DMA17D0 MI DE4LYSA DMA17D0 MN Cytochrome P450 3A4 (CYP3A4) DMA17D0 MT DME DMA17D0 MA Metabolism DMA17D0 RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMA17D0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DM78NWP DI DM78NWP DM78NWP DN Dostarlimab DM78NWP MI TTNBFWK DM78NWP MN Programmed cell death protein 1 (PD-1) DM78NWP MT DTT DM78NWP MA Inhibitor DM78NWP RN Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892. DM78NWP RU https://pubmed.ncbi.nlm.nih.gov/33251877 DMKE7L9 DI DMKE7L9 DMKE7L9 DN Doxacurium DMKE7L9 MI TTS5WZF DMKE7L9 MN Neuronal acetylcholine receptor alpha (NACHRA) DMKE7L9 MT DTT DMKE7L9 MA Antagonist DMKE7L9 RN Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61. DMKE7L9 RU https://pubmed.ncbi.nlm.nih.gov/8572329 DMCYANK DI DMCYANK DMCYANK DN Doxapram DMCYANK MI DE4LYSA DMCYANK MN Cytochrome P450 3A4 (CYP3A4) DMCYANK MT DME DMCYANK MA Metabolism DMCYANK RN Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18. DMCYANK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25248340 DMCYANK DI DMCYANK DMCYANK DN Doxapram DMCYANK MI DEIBDNY DMCYANK MN Cytochrome P450 3A5 (CYP3A5) DMCYANK MT DME DMCYANK MA Metabolism DMCYANK RN Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18. DMCYANK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25248340 DMCYANK DI DMCYANK DMCYANK DN Doxapram DMCYANK MI TT6EYVN DMCYANK MN Peripheral carotid chemoreceptor (PCC) DMCYANK MT DTT DMCYANK MA Stimulator DMCYANK RN Ovalbumin sensitization alters the ventilatory responses to chemical challenges in guinea pigs. J Appl Physiol (1985). 2005 Nov;99(5):1782-8. DMCYANK RU https://pubmed.ncbi.nlm.nih.gov/16024517 DM9PLRH DI DM9PLRH DM9PLRH DN Doxazosin DM9PLRH MI TT34BHT DM9PLRH MN Adrenergic receptor alpha-1D (ADRA1D) DM9PLRH MT DTT DM9PLRH MA Antagonist DM9PLRH RN The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. DM9PLRH RU https://pubmed.ncbi.nlm.nih.gov/19002123 DM9PLRH DI DM9PLRH DM9PLRH DN Doxazosin DM9PLRH MI DE5IED8 DM9PLRH MN Cytochrome P450 2C9 (CYP2C9) DM9PLRH MT DME DM9PLRH MA Metabolism DM9PLRH RN Product monograph: CARDURA (Doxazosin mesylate). DM9PLRH RU https://www.pfizer.ca/sites/g/files/g10050796/f/201710/CARDURA_PM_Eng_201486_4Apr2017.pdf DM9PLRH DI DM9PLRH DM9PLRH DN Doxazosin DM9PLRH MI DECB0K3 DM9PLRH MN Cytochrome P450 2D6 (CYP2D6) DM9PLRH MT DME DM9PLRH MA Metabolism DM9PLRH RN Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8. DM9PLRH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799 DM9PLRH DI DM9PLRH DM9PLRH DN Doxazosin DM9PLRH MI DE4LYSA DM9PLRH MN Cytochrome P450 3A4 (CYP3A4) DM9PLRH MT DME DM9PLRH MA Metabolism DM9PLRH RN Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8. DM9PLRH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799 DM9PLRH DI DM9PLRH DM9PLRH DN Doxazosin DM9PLRH MI DEGTFWK DM9PLRH MN Mephenytoin 4-hydroxylase (CYP2C19) DM9PLRH MT DME DM9PLRH MA Metabolism DM9PLRH RN Priapism induced by boceprevir-CYP3A4 inhibition and alpha-adrenergic blockade: case report. Clin Infect Dis. 2014 Jan;58(1):e35-8. DM9PLRH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24092799 DMPI98T DI DMPI98T DMPI98T DN Doxepin DMPI98T MI DEJGDUW DMPI98T MN Cytochrome P450 1A2 (CYP1A2) DMPI98T MT DME DMPI98T MA Metabolism DMPI98T RN The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. DMPI98T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12180536 DMPI98T DI DMPI98T DMPI98T DN Doxepin DMPI98T MI DE5IED8 DMPI98T MN Cytochrome P450 2C9 (CYP2C9) DMPI98T MT DME DMPI98T MA Metabolism DMPI98T RN Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. DMPI98T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12360109 DMPI98T DI DMPI98T DMPI98T DN Doxepin DMPI98T MI DECB0K3 DMPI98T MN Cytochrome P450 2D6 (CYP2D6) DMPI98T MT DME DMPI98T MA Metabolism DMPI98T RN Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4. DMPI98T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15520506 DMPI98T DI DMPI98T DMPI98T DN Doxepin DMPI98T MI DE4LYSA DMPI98T MN Cytochrome P450 3A4 (CYP3A4) DMPI98T MT DME DMPI98T MA Metabolism DMPI98T RN The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7. DMPI98T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12180536 DMPI98T DI DMPI98T DMPI98T DN Doxepin DMPI98T MI TTTIBOJ DMPI98T MN Histamine H1 receptor (H1R) DMPI98T MT DTT DMPI98T MA Inhibitor DMPI98T RN Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305. DMPI98T RU https://pubmed.ncbi.nlm.nih.gov/17685877 DMPI98T DI DMPI98T DMPI98T DN Doxepin DMPI98T MI DEGTFWK DMPI98T MN Mephenytoin 4-hydroxylase (CYP2C19) DMPI98T MT DME DMPI98T MA Metabolism DMPI98T RN Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. DMPI98T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12360109 DM6FG1P DI DM6FG1P DM6FG1P DN Doxercalciferol DM6FG1P MI DEBS639 DM6FG1P MN Vitamin D(3) 25-hydroxylase (CYP27A1) DM6FG1P MT DME DM6FG1P MA Metabolism DM6FG1P RN Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4. Indian J Nephrol. 2013 Jul;23(4):271-5. DM6FG1P RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23960343 DM6FG1P DI DM6FG1P DM6FG1P DN Doxercalciferol DM6FG1P MI TTK59TV DM6FG1P MN Vitamin D3 receptor (VDR) DM6FG1P MT DTT DM6FG1P MA Antagonist DM6FG1P RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DM6FG1P RU https://pubmed.ncbi.nlm.nih.gov/19249988 DMEDKZH DI DMEDKZH DMEDKZH DN Doxofylline DMEDKZH MI DEJGDUW DMEDKZH MN Cytochrome P450 1A2 (CYP1A2) DMEDKZH MT DME DMEDKZH MA Metabolism DMEDKZH RN PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012 May;22(5):389-95. DMEDKZH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22293536 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DED2FW3 DMVP5YE MN Aldo-keto reductase 1A1 (AKR1A1) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18635746 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DEGQTXO DMVP5YE MN Aldo-keto reductase 1C3 (AKR1C3) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18616992 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DTKVEXO DMVP5YE MN ATP-binding cassette sub-family B member 5 (ABCB5) DMVP5YE MT DTP DMVP5YE MA Substrate DMVP5YE RN ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33. DMVP5YE RU http://www.ncbi.nlm.nih.gov/pubmed/15899824 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DT0KQND DMVP5YE MN ATP-binding cassette sub-family B member 8 (ABCB8) DMVP5YE MT DTP DMVP5YE MA Substrate DMVP5YE RN ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87. DMVP5YE RU http://www.ncbi.nlm.nih.gov/pubmed/19147539 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DTI7UX6 DMVP5YE MN Breast cancer resistance protein (ABCG2) DMVP5YE MT DTP DMVP5YE MA Substrate DMVP5YE RN Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25. DMVP5YE RU http://www.ncbi.nlm.nih.gov/pubmed/17273774 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DECB0K3 DMVP5YE MN Cytochrome P450 2D6 (CYP2D6) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8258200 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DE4LYSA DMVP5YE MN Cytochrome P450 3A4 (CYP3A4) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17279585 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DEIBDNY DMVP5YE MN Cytochrome P450 3A5 (CYP3A5) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18930278 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI TT0IHXV DMVP5YE MN DNA topoisomerase II (TOP2) DMVP5YE MT DTT DMVP5YE MA Modulator DMVP5YE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVP5YE RU https://www.fda.gov/ DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DTPATLS DMVP5YE MN Fly-like putative transporter 2 (SLC22A16) DMVP5YE MT DTP DMVP5YE MA Substrate DMVP5YE RN Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9. DMVP5YE RU http://www.ncbi.nlm.nih.gov/pubmed/20179710 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DE6NIY9 DMVP5YE MN Methionine synthase reductase (MTRR) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12416982 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DEYSOD0 DMVP5YE MN Molybdopterin-dependent enzyme (molD) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76. DMVP5YE RU https://pubmed.ncbi.nlm.nih.gov/29160065 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DE1QMDG DMVP5YE MN Molybdopterin-dependent enzyme (molD) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76. DMVP5YE RU https://pubmed.ncbi.nlm.nih.gov/29160065 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DEME01W DMVP5YE MN Molybdopterin-dependent enzyme (molD) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76. DMVP5YE RU https://pubmed.ncbi.nlm.nih.gov/29160065 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DT342ZG DMVP5YE MN Monocarboxylate transporter 1 (SLC16A1) DMVP5YE MT DTP DMVP5YE MA Substrate DMVP5YE RN Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17. DMVP5YE RU https://doi.org/10.1016/j.addr.2010.05.009 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DTSYQGK DMVP5YE MN Multidrug resistance-associated protein 1 (ABCC1) DMVP5YE MT DTP DMVP5YE MA Substrate DMVP5YE RN The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97. DMVP5YE RU http://www.ncbi.nlm.nih.gov/pubmed/15942634 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DTFI42L DMVP5YE MN Multidrug resistance-associated protein 2 (ABCC2) DMVP5YE MT DTP DMVP5YE MA Substrate DMVP5YE RN Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7. DMVP5YE RU http://www.ncbi.nlm.nih.gov/pubmed/16377671 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DEAMEF2 DMVP5YE MN NADH dehydrogenase (nuoE) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012 Oct 26;19(10):1255-64. DMVP5YE RU https://pubmed.ncbi.nlm.nih.gov/23102220 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DEIW03B DMVP5YE MN NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DE741FI DMVP5YE MN NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DEKX5CD DMVP5YE MN NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DE3N2FM DMVP5YE MN NADPH-cytochrome P450 reductase (CPR) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=6305277 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DEYEK78 DMVP5YE MN Nitric oxide synthase brain (NOS1) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15054088 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DE708H2 DMVP5YE MN Nitric oxide synthase endothelial (NOS3) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15054088 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DE3C1JY DMVP5YE MN Nitric oxide synthase inducible (NOS2) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15054088 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DTUGYRD DMVP5YE MN P-glycoprotein 1 (ABCB1) DMVP5YE MT DTP DMVP5YE MA Substrate DMVP5YE RN MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. DMVP5YE RU http://www.ncbi.nlm.nih.gov/pubmed/19123050 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DENP5RY DMVP5YE MN Quinone reductase 1 (NQO1) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12688675 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DE4G629 DMVP5YE MN Succinic semialdehyde reductase (AKR7A2) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther. 2010 Dec;335(3):533-45. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20837989 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI TTQY2EJ DMVP5YE MN TERT messenger RNA (TERT mRNA) DMVP5YE MT DTT DMVP5YE RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMVP5YE RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE MI DECG04O DMVP5YE MN Xanthine dehydrogenase/oxidase (XDH) DMVP5YE MT DME DMVP5YE MA Metabolism DMVP5YE RN Xanthine oxidoreductase in drug metabolism: beyond a role as a detoxifying enzyme. Curr Med Chem. 2016;23(35):4027-4036. DMVP5YE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27458036 DM7ICNU DI DM7ICNU DM7ICNU DN Doxycycline DM7ICNU MI TTOVFH2 DM7ICNU MN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM7ICNU MT DTT DM7ICNU MA Modulator DM7ICNU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7ICNU RU https://www.fda.gov/ DM7ICNU DI DM7ICNU DM7ICNU DN Doxycycline DM7ICNU MI DE4LYSA DM7ICNU MN Cytochrome P450 3A4 (CYP3A4) DM7ICNU MT DME DM7ICNU MA Metabolism DM7ICNU RN A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):272-8. DM7ICNU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10716067 DM7ICNU DI DM7ICNU DM7ICNU DN Doxycycline DM7ICNU MI DTUGYRD DM7ICNU MN P-glycoprotein 1 (ABCB1) DM7ICNU MT DTP DM7ICNU MA Substrate DM7ICNU RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DM7ICNU RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMKOXFE DI DMKOXFE DMKOXFE DN Doxylamine DMKOXFE MI TTTIBOJ DMKOXFE MN Histamine H1 receptor (H1R) DMKOXFE MT DTT DMKOXFE MA Antagonist DMKOXFE RN First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med. 2007 May;78(5):514-22. DMKOXFE RU https://pubmed.ncbi.nlm.nih.gov/17539447 DMGOXPQ DI DMGOXPQ DMGOXPQ DN DP-VPA DMGOXPQ MI TTNJYV2 DMGOXPQ MN Gamma-aminobutyric acid receptor (GAR) DMGOXPQ MT DTT DMGOXPQ MA Modulator DMGOXPQ RN DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3. DMGOXPQ RU https://pubmed.ncbi.nlm.nih.gov/12137414 DMF2JDG DI DMF2JDG DMF2JDG DN Dromostanolone DMF2JDG MI TTS64P2 DMF2JDG MN Androgen receptor (AR) DMF2JDG MT DTT DMF2JDG MA Binder DMF2JDG RN Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr J. 2004 Aug;51(4):425-34. DMF2JDG RU https://pubmed.ncbi.nlm.nih.gov/15351799 DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 MI DECB0K3 DMA8FS5 MN Cytochrome P450 2D6 (CYP2D6) DMA8FS5 MT DME DMA8FS5 MA Metabolism DMA8FS5 RN Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Eur J Pharm Sci. 2018 Jan 1;111:13-19. DMA8FS5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28942006 DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 MI DE4LYSA DMA8FS5 MN Cytochrome P450 3A4 (CYP3A4) DMA8FS5 MT DME DMA8FS5 MA Metabolism DMA8FS5 RN Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45. DMA8FS5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22971242 DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 MI DEIBDNY DMA8FS5 MN Cytochrome P450 3A5 (CYP3A5) DMA8FS5 MT DME DMA8FS5 MA Metabolism DMA8FS5 RN Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and N-desbutyl dronedarone. Mol Pharmacol. 2016 Jan;89(1):1-13. DMA8FS5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26490246 DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 MI TT1VOHK DMA8FS5 MN Potassium channel unspecific (KC) DMA8FS5 MT DTT DMA8FS5 MA Inhibitor DMA8FS5 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMA8FS5 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 MI TTW0CMT DMA8FS5 MN Voltage-gated potassium channel Kv1.5 (KCNA5) DMA8FS5 MT DTT DMA8FS5 MA Blocker DMA8FS5 RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMA8FS5 RU https://pubmed.ncbi.nlm.nih.gov/15934869 DM0DXA8 DI DM0DXA8 DM0DXA8 DN Droperidol DM0DXA8 MI TTEX248 DM0DXA8 MN Dopamine D2 receptor (D2R) DM0DXA8 MT DTT DM0DXA8 MA Binder DM0DXA8 RN Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102. DM0DXA8 RU https://pubmed.ncbi.nlm.nih.gov/12505540 DM1A9W3 DI DM1A9W3 DM1A9W3 DN Drospirenone DM1A9W3 MI DE4LYSA DM1A9W3 MN Cytochrome P450 3A4 (CYP3A4) DM1A9W3 MT DME DM1A9W3 MA Metabolism DM1A9W3 RN Role of CYP3A in oral contraceptives clearance. Clin Transl Sci. 2018 May;11(3):251-260. DM1A9W3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28986954 DM1A9W3 DI DM1A9W3 DM1A9W3 DN Drospirenone DM1A9W3 MI TT26PHO DM1A9W3 MN Mineralocorticoid receptor (MR) DM1A9W3 MT DTT DM1A9W3 MA Binder DM1A9W3 RN Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78. DM1A9W3 RU https://pubmed.ncbi.nlm.nih.gov/16719803 DM59JCN DI DM59JCN DM59JCN DN Drotrecogin alfa DM59JCN MI TT1O264 DM59JCN MN Coagulation factor Va (F5) DM59JCN MT DTT DM59JCN MA Inhibitor DM59JCN RN Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. DM59JCN RU https://pubmed.ncbi.nlm.nih.gov/19498123 DM59JCN DI DM59JCN DM59JCN DN Drotrecogin alfa DM59JCN MI TT1290U DM59JCN MN Coagulation factor VIII (F8) DM59JCN MT DTT DM59JCN MA Inhibitor DM59JCN RN Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. DM59JCN RU https://pubmed.ncbi.nlm.nih.gov/19498123 DM5YF4M DI DM5YF4M DM5YF4M DN Droxidopa DM5YF4M MI DETK9CN DM5YF4M MN DOPA decarboxylase (DDC) DM5YF4M MT DME DM5YF4M MA Metabolism DM5YF4M RN L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):189-203. DM5YF4M RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17214596 DMXZRW0 DI DMXZRW0 DMXZRW0 DN DTI-015 DMXZRW0 MI DEJGDUW DMXZRW0 MN Cytochrome P450 1A2 (CYP1A2) DMXZRW0 MT DME DMXZRW0 MA Metabolism DMXZRW0 RN Principal drug-metabolizing enzyme systems in L1210 leukemia sensitive or resistant to BCNU in vivo. Leuk Res. 1994 Nov;18(11):829-35. DMXZRW0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=7967709 DMXZRW0 DI DMXZRW0 DMXZRW0 DN DTI-015 DMXZRW0 MI DE4ZHS1 DMXZRW0 MN Glutathione S-transferase alpha-1 (GSTA1) DMXZRW0 MT DME DMXZRW0 MA Metabolism DMXZRW0 RN Expression of glutathione S-transferase T1 (GSTT1) in human brain tumours. Histol Histopathol. 2006 Nov;21(11):1199-207. DMXZRW0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16874663 DMXZRW0 DI DMXZRW0 DMXZRW0 DN DTI-015 DMXZRW0 MI TTUTN1I DMXZRW0 MN Human Deoxyribonucleic acid (hDNA) DMXZRW0 MT DTT DMXZRW0 MA Binder DMXZRW0 RN Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62. DMXZRW0 RU https://pubmed.ncbi.nlm.nih.gov/1664221 DMCIJBH DI DMCIJBH DMCIJBH DN DU-176B DMCIJBH MI TTCIHJA DMCIJBH MN Coagulation factor Xa (F10) DMCIJBH MT DTT DMCIJBH MA Modulator DMCIJBH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359). DMCIJBH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359 DMCIJBH DI DMCIJBH DMCIJBH DN DU-176B DMCIJBH MI DE4LYSA DMCIJBH MN Cytochrome P450 3A4 (CYP3A4) DMCIJBH MT DME DMCIJBH MA Metabolism DMCIJBH RN Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600. DMCIJBH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27530188 DMCIJBH DI DMCIJBH DMCIJBH DN DU-176B DMCIJBH MI DTUGYRD DMCIJBH MN P-glycoprotein 1 (ABCB1) DMCIJBH MT DTP DMCIJBH MA Substrate DMCIJBH RN Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol. 2016 Dec;82(6):1591-1600. DMCIJBH RU http://www.ncbi.nlm.nih.gov/pubmed/27530188 DMYXBV3 DI DMYXBV3 DMYXBV3 DN Dulaglutide DMYXBV3 MI TTVIMDE DMYXBV3 MN Glucagon-like peptide 1 receptor (GLP1R) DMYXBV3 MT DTT DMYXBV3 MA Agonist DMYXBV3 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMYXBV3 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M MI DEJGDUW DM9BI7M MN Cytochrome P450 1A2 (CYP1A2) DM9BI7M MT DME DM9BI7M MA Metabolism DM9BI7M RN Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. DM9BI7M RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359 DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M MI DE5IED8 DM9BI7M MN Cytochrome P450 2C9 (CYP2C9) DM9BI7M MT DME DM9BI7M MA Metabolism DM9BI7M RN Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. DM9BI7M RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359 DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M MI DECB0K3 DM9BI7M MN Cytochrome P450 2D6 (CYP2D6) DM9BI7M MT DME DM9BI7M MA Metabolism DM9BI7M RN Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. DM9BI7M RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359 DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M MI TTAWNKZ DM9BI7M MN Norepinephrine transporter (NET) DM9BI7M MT DTT DM9BI7M MA Inhibitor DM9BI7M RN Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. DM9BI7M RU https://pubmed.ncbi.nlm.nih.gov/17198971 DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M MI TT3ROYC DM9BI7M MN Serotonin transporter (SERT) DM9BI7M MT DTT DM9BI7M MA Inhibitor DM9BI7M RN Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. DM9BI7M RU https://pubmed.ncbi.nlm.nih.gov/17198971 DMOAD2Y DI DMOAD2Y DMOAD2Y DN Dupilumab DMOAD2Y MI TTDWHC3 DMOAD2Y MN Interleukin 4 receptor alpha (IL4R) DMOAD2Y MT DTT DMOAD2Y RN Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. DMOAD2Y RU https://pubmed.ncbi.nlm.nih.gov/23688323 DM4PVDY DI DM4PVDY DM4PVDY DN Durvalumab DM4PVDY MI TT8ZLTI DM4PVDY MN Programmed cell death 1 ligand 1 (PD-L1) DM4PVDY MT DTT DM4PVDY MA Modulator DM4PVDY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PVDY RU https://www.fda.gov/ DMQ4TJK DI DMQ4TJK DMQ4TJK DN Dutasteride DMQ4TJK MI DECB0K3 DMQ4TJK MN Cytochrome P450 2D6 (CYP2D6) DMQ4TJK MT DME DMQ4TJK MA Metabolism DMQ4TJK RN Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011 May;50(5):281-94. DMQ4TJK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21366359 DMQ4TJK DI DMQ4TJK DMQ4TJK DN Dutasteride DMQ4TJK MI DEIBDNY DMQ4TJK MN Cytochrome P450 3A5 (CYP3A5) DMQ4TJK MT DME DMQ4TJK MA Metabolism DMQ4TJK RN Product monograph: Avodart (dutasteride capsules). DMQ4TJK RU https://ca.gsk.com/media/588688/avodart.pdf DMQ4TJK DI DMQ4TJK DMQ4TJK DN Dutasteride DMQ4TJK MI TT2A0DR DMQ4TJK MN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMQ4TJK MT DTT DMQ4TJK MA Inhibitor DMQ4TJK RN The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. DMQ4TJK RU https://pubmed.ncbi.nlm.nih.gov/19543428 DMU6OFP DI DMU6OFP DMU6OFP DN Dyclonine DMU6OFP MI TTZOVE0 DMU6OFP MN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMU6OFP MT DTT DMU6OFP MA Blocker DMU6OFP RN Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. DMU6OFP RU https://pubmed.ncbi.nlm.nih.gov/9476974 DMAKIDV DI DMAKIDV DMAKIDV DN Dydrogesterone DMAKIDV MI DE4LYSA DMAKIDV MN Cytochrome P450 3A4 (CYP3A4) DMAKIDV MT DME DMAKIDV MA Metabolism DMAKIDV RN Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes. Xenobiotica. 2016 Oct;46(10):868-74. DMAKIDV RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26796435 DMAKIDV DI DMAKIDV DMAKIDV DN Dydrogesterone DMAKIDV MI TTUV8G9 DMAKIDV MN Progesterone receptor (PGR) DMAKIDV MT DTT DMAKIDV MA Agonist DMAKIDV RN Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31. DMAKIDV RU https://pubmed.ncbi.nlm.nih.gov/18061638 DM8DZC1 DI DM8DZC1 DM8DZC1 DN Dyphylline DM8DZC1 MI TTZ97H5 DM8DZC1 MN Phosphodiesterase 4A (PDE4A) DM8DZC1 MT DTT DM8DZC1 MA Inhibitor DM8DZC1 RN Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. DM8DZC1 RU https://pubmed.ncbi.nlm.nih.gov/7925603 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ MI DEJGDUW DMJDYNQ MN Cytochrome P450 1A2 (CYP1A2) DMJDYNQ MT DME DMJDYNQ MA Metabolism DMJDYNQ RN Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy. P T. 2016 Nov;41(11):683-698. DMJDYNQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27904300 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ MI DE4LYSA DMJDYNQ MN Cytochrome P450 3A4 (CYP3A4) DMJDYNQ MT DME DMJDYNQ MA Metabolism DMJDYNQ RN The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015 Jan;56(1):12-27. DMJDYNQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25495693 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ MI DEIBDNY DMJDYNQ MN Cytochrome P450 3A5 (CYP3A5) DMJDYNQ MT DME DMJDYNQ MA Metabolism DMJDYNQ RN FDA label of Perampanel. The 2020 official website of the U.S. Food and Drug Administration. DMJDYNQ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202834s011lbl.pdf DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ MI TTAN6JD DMJDYNQ MN Glutamate receptor AMPA (GRIA) DMJDYNQ MT DTT DMJDYNQ MA Modulator DMJDYNQ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ MI TTVPQTF DMJDYNQ MN Glutamate receptor AMPA 1 (GRIA1) DMJDYNQ MT DTT DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ MI TT9HLZ0 DMJDYNQ MN Glutamate receptor AMPA 2 (GRIA2) DMJDYNQ MT DTT DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ MI TT82EZV DMJDYNQ MN Glutamate receptor AMPA 3 (GRIA3) DMJDYNQ MT DTT DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ MI TTPJR0G DMJDYNQ MN Glutamate receptor AMPA 4 (GRIA4) DMJDYNQ MT DTT DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMOF2C6 DI DMOF2C6 DMOF2C6 DN Ecallantide DMOF2C6 MI TT5L2VC DMOF2C6 MN Kallikrein-related peptidase (KLK) DMOF2C6 MT DTT DMOF2C6 MA Inhibitor DMOF2C6 RN Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99. DMOF2C6 RU https://pubmed.ncbi.nlm.nih.gov/18613770 DMOF2C6 DI DMOF2C6 DMOF2C6 DN Ecallantide DMOF2C6 MI TTMF8H9 DMOF2C6 MN Plasma kallikrein (KLKB1) DMOF2C6 MT DTT DMOF2C6 MA Inhibitor DMOF2C6 RN Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99. DMOF2C6 RU https://pubmed.ncbi.nlm.nih.gov/18613770 DMSNVGB DI DMSNVGB DMSNVGB DN Echothiophate Iodide DMSNVGB MI TT1RS9F DMSNVGB MN Acetylcholinesterase (AChE) DMSNVGB MT DTT DMSNVGB MA Modulator DMSNVGB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSNVGB RU https://www.fda.gov/ DMFSWGH DI DMFSWGH DMFSWGH DN Econazole DMFSWGH MI TTTSOUD DMFSWGH MN Candida Cytochrome P450 51 (Candi ERG11) DMFSWGH MT DTT DMFSWGH MA Inhibitor DMFSWGH RN Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603. DMFSWGH RU https://pubmed.ncbi.nlm.nih.gov/18694951 DMCRQHB DI DMCRQHB DMCRQHB DN Edrophonium DMCRQHB MI TT1RS9F DMCRQHB MN Acetylcholinesterase (AChE) DMCRQHB MT DTT DMCRQHB MA Inhibitor DMCRQHB RN Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56. DMCRQHB RU https://pubmed.ncbi.nlm.nih.gov/19472276 DMCKL5V DI DMCKL5V DMCKL5V DN Efalizumab DMCKL5V MI TT48WR6 DMCKL5V MN Integrin alpha-L (ITGAL) DMCKL5V MT DTT DMCKL5V RN [Successful therapy of discoid lupus erythematosus with efalizumab]. Hautarzt. 2010 Mar;61(3):246-9. DMCKL5V RU https://pubmed.ncbi.nlm.nih.gov/19436973 DMC0GSJ DI DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ MI DEJGDUW DMC0GSJ MN Cytochrome P450 1A2 (CYP1A2) DMC0GSJ MT DME DMC0GSJ MA Metabolism DMC0GSJ RN CYP2B6 genotype-dependent inhibition of CYP1A2 and induction of CYP2A6 by the antiretroviral drug efavirenz in healthy volunteers. Clin Transl Sci. 2019 Nov;12(6):657-666. DMC0GSJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31339646 DMC0GSJ DI DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ MI DEPKLMQ DMC0GSJ MN Cytochrome P450 2B6 (CYP2B6) DMC0GSJ MT DME DMC0GSJ MA Metabolism DMC0GSJ RN Evaluation of CYP2B6 induction and prediction of clinical drug-drug interactions: considerations from the IQ consortium induction working group-an industry perspective. Drug Metab Dispos. 2016 Oct;44(10):1720-30. DMC0GSJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27422672 DMC0GSJ DI DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ MI DE4LYSA DMC0GSJ MN Cytochrome P450 3A4 (CYP3A4) DMC0GSJ MT DME DMC0GSJ MA Metabolism DMC0GSJ RN Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol. 2004 Nov;44(11):1273-81. DMC0GSJ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15496645 DMC0GSJ DI DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ MI TT84ETX DMC0GSJ MN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMC0GSJ MT DTT DMC0GSJ MA Modulator DMC0GSJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC0GSJ RU https://www.fda.gov/ DMC0GSJ DI DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ MI DTQ3ZHF DMC0GSJ MN Multidrug resistance-associated protein 3 (ABCC3) DMC0GSJ MT DTP DMC0GSJ MA Substrate DMC0GSJ RN Induction of multiple drug transporters by efavirenz. J Pharmacol Sci. 2009 Feb;109(2):242-50. DMC0GSJ RU https://doi.org/10.1254/jphs.08209FP DMC0GSJ DI DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ MI DTUGYRD DMC0GSJ MN P-glycoprotein 1 (ABCB1) DMC0GSJ MT DTP DMC0GSJ MA Substrate DMC0GSJ RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DMC0GSJ RU https://doi.org/10.1007/s11095-012-0935-x DMFA9MV DI DMFA9MV DMFA9MV DN Efinaconazole DMFA9MV MI TTTSOUD DMFA9MV MN Candida Cytochrome P450 51 (Candi ERG11) DMFA9MV MT DTT DMFA9MV MA Inhibitor DMFA9MV RN Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol. 2015 Apr;52:18-25. DMFA9MV RU https://pubmed.ncbi.nlm.nih.gov/25527861 DMJOQM3 DI DMJOQM3 DMJOQM3 DN Eflornithine DMJOQM3 MI TTUMGNO DMJOQM3 MN Ornithine decarboxylase (ODC1) DMJOQM3 MT DTT DMJOQM3 MA Inhibitor DMJOQM3 RN Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43. DMJOQM3 RU https://pubmed.ncbi.nlm.nih.gov/3115816 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 MI DE5IED8 DMMUCG4 MN Cytochrome P450 2C9 (CYP2C9) DMMUCG4 MT DME DMMUCG4 MA Metabolism DMMUCG4 RN CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):99-108. DMMUCG4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21945326 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 MI DT5G94L DMMUCG4 MN Major facilitator superfamily domain-containing protein 2A (SLC59A1) DMMUCG4 MT DTP DMMUCG4 MA Substrate DMMUCG4 RN Mfsd2a Is a Transporter for the Essential -3 Fatty Acid Docosahexaenoic Acid (DHA) in Eye and Is Important for Photoreceptor Cell Development. J Biol Chem. 2016 May 13;291(20):10501-14. DMMUCG4 RU http://www.ncbi.nlm.nih.gov/pubmed/27008858 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 MI TT8NGED DMMUCG4 MN Prostaglandin G/H synthase 1 (COX-1) DMMUCG4 MT DTT DMMUCG4 MA Inhibitor DMMUCG4 RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMMUCG4 RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 MI DE073H6 DMMUCG4 MN Prostaglandin G/H synthase 1 (COX-1) DMMUCG4 MT DME DMMUCG4 MA Metabolism DMMUCG4 RN Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108. DMMUCG4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 MI TTVKILB DMMUCG4 MN Prostaglandin G/H synthase 2 (COX-2) DMMUCG4 MT DTT DMMUCG4 MA Inhibitor DMMUCG4 RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMMUCG4 RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 MI DE492CE DMMUCG4 MN Prostaglandin G/H synthase 2 (COX-2) DMMUCG4 MT DME DMMUCG4 MA Metabolism DMMUCG4 RN Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108. DMMUCG4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16770009 DMRDUC0 DI DMRDUC0 DMRDUC0 DN Elagolix sodium DMRDUC0 MI TT8R70G DMRDUC0 MN Gonadotropin-releasing hormone receptor (GNRHR) DMRDUC0 MT DTT DMRDUC0 MA Antagonist DMRDUC0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMRDUC0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMS7OU8 DI DMS7OU8 DMS7OU8 DN Elapegademase DMS7OU8 MI TTLP57V DMS7OU8 MN Adenosine deaminase (ADA) DMS7OU8 MT DTT DMS7OU8 MA Modulator DMS7OU8 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMS7OU8 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMJLE18 DI DMJLE18 DMJLE18 DN Elbasvir DMJLE18 MI DE4LYSA DMJLE18 MN Cytochrome P450 3A4 (CYP3A4) DMJLE18 MT DME DMJLE18 MA Metabolism DMJLE18 RN Clinical pharmacokinetics and drug-drug interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):509-531. DMJLE18 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29557529 DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X MI TTK8CXU DMW649X MN 5-HT 1B receptor (HTR1B) DMW649X MT DTT DMW649X MA Modulator DMW649X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW649X RU https://www.fda.gov/ DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X MI TT6MSOK DMW649X MN 5-HT 1D receptor (HTR1D) DMW649X MT DTT DMW649X MA Modulator DMW649X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW649X RU https://www.fda.gov/ DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X MI DE5IED8 DMW649X MN Cytochrome P450 2C9 (CYP2C9) DMW649X MT DME DMW649X MA Metabolism DMW649X RN Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016 Sep;9(5):414-23. DMW649X RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27582896 DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X MI DECB0K3 DMW649X MN Cytochrome P450 2D6 (CYP2D6) DMW649X MT DME DMW649X MA Metabolism DMW649X RN Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9. DMW649X RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12814962 DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X MI DE4LYSA DMW649X MN Cytochrome P450 3A4 (CYP3A4) DMW649X MT DME DMW649X MA Metabolism DMW649X RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMW649X RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X MI DTUGYRD DMW649X MN P-glycoprotein 1 (ABCB1) DMW649X MT DTP DMW649X MA Substrate DMW649X RN Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. DMW649X RU https://doi.org/10.1016/j.addr.2011.12.008 DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X MI DE073H6 DMW649X MN Prostaglandin G/H synthase 1 (COX-1) DMW649X MT DME DMW649X MA Metabolism DMW649X RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMW649X RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMSRZAO DI DMSRZAO DMSRZAO DN Eliglustat tartrate DMSRZAO MI TTPHEX3 DMSRZAO MN Ceramide glucosyltransferase (UGCG) DMSRZAO MT DTT DMSRZAO MA Modulator DMSRZAO RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSRZAO RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSRZAO DI DMSRZAO DMSRZAO DN Eliglustat tartrate DMSRZAO MI DECB0K3 DMSRZAO MN Cytochrome P450 2D6 (CYP2D6) DMSRZAO MT DME DMSRZAO MA Metabolism DMSRZAO RN Eliglustat: first global approval. Drugs. 2014 Oct;74(15):1829-36. DMSRZAO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25239269 DMSRZAO DI DMSRZAO DMSRZAO DN Eliglustat tartrate DMSRZAO MI DE4LYSA DMSRZAO MN Cytochrome P450 3A4 (CYP3A4) DMSRZAO MT DME DMSRZAO MA Metabolism DMSRZAO RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMSRZAO RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMSRZAO DI DMSRZAO DMSRZAO DN Eliglustat tartrate DMSRZAO MI DTUGYRD DMSRZAO MN P-glycoprotein 1 (ABCB1) DMSRZAO MT DTP DMSRZAO MA Substrate DMSRZAO RN KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) DMSRZAO RU https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665 DMZC6GT DI DMZC6GT DMZC6GT DN Elliptinium acetate DMZC6GT MI TTABD5E DMZC6GT MN DNA replication (DNA repli) DMZC6GT MT DTT DMZC6GT MA Modulator DMZC6GT RN Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64. DMZC6GT RU https://pubmed.ncbi.nlm.nih.gov/91123 DMRCX8K DI DMRCX8K DMRCX8K DN Eloctate DMRCX8K MI TT1290U DMRCX8K MN Coagulation factor VIII (F8) DMRCX8K MT DTT DMRCX8K MA Modulator DMRCX8K RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMRCX8K RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMA9REV DI DMA9REV DMA9REV DN Elosulfase alfa DMA9REV MI TTT9YPO DMA9REV MN N-acetylgalactosamine 6 sulfatase (GALNS) DMA9REV MT DTT DMA9REV MA Modulator DMA9REV RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMA9REV RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMEYHG9 DI DMEYHG9 DMEYHG9 DN Elotuzumab DMEYHG9 MI TT7ILZ1 DMEYHG9 MN SLAM family member 7 SLAMF7 (CS1) DMEYHG9 MT DTT DMEYHG9 RN Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228. DMEYHG9 RU https://pubmed.ncbi.nlm.nih.gov/25764988 DMOGFIX DI DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX MI DTI7UX6 DMOGFIX MN Breast cancer resistance protein (ABCG2) DMOGFIX MT DTP DMOGFIX MA Substrate DMOGFIX RN Assessment of the pharmacokinetic interaction between eltrombopag and lopinavir-ritonavir in healthy adult subjects. Antimicrob Agents Chemother. 2012 Jun;56(6):2846-51. DMOGFIX RU https://doi.org/10.1128/AAC.05214-11 DMOGFIX DI DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX MI DEJGDUW DMOGFIX MN Cytochrome P450 1A2 (CYP1A2) DMOGFIX MT DME DMOGFIX MA Metabolism DMOGFIX RN Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018 Feb 27;2(4):454-461. DMOGFIX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29487060 DMOGFIX DI DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX MI DES5XRU DMOGFIX MN Cytochrome P450 2C8 (CYP2C8) DMOGFIX MT DME DMOGFIX MA Metabolism DMOGFIX RN Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther Drug Monit. 2018 Aug;40(4):386-388. DMOGFIX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29683873 DMOGFIX DI DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX MI DTPFTEQ DMOGFIX MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DMOGFIX MT DTP DMOGFIX MA Substrate DMOGFIX RN Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96. DMOGFIX RU http://www.ncbi.nlm.nih.gov/pubmed/21422191 DMOGFIX DI DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX MI TTIHYA4 DMOGFIX MN Thrombopoietin receptor (MPL) DMOGFIX MT DTT DMOGFIX MA Agonist DMOGFIX RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMOGFIX RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMOGFIX DI DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX MI DEYGVN4 DMOGFIX MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMOGFIX MT DME DMOGFIX MA Metabolism DMOGFIX RN Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis. Ther Drug Monit. 2018 Aug;40(4):386-388. DMOGFIX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29683873 DMYZ0P1 DI DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 MI TT27RFC DMYZ0P1 MN Opioid receptor delta (OPRD1) DMYZ0P1 MT DTT DMYZ0P1 MA Modulator DMYZ0P1 RN Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56. DMYZ0P1 RU https://www.ncbi.nlm.nih.gov/pubmed/25261794 DMYZ0P1 DI DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 MI TTKWM86 DMYZ0P1 MN Opioid receptor mu (MOP) DMYZ0P1 MT DTT DMYZ0P1 MA Modulator DMYZ0P1 RN Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56. DMYZ0P1 RU https://www.ncbi.nlm.nih.gov/pubmed/25261794 DMYZ0P1 DI DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 MI DT3D8F0 DMYZ0P1 MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMYZ0P1 MT DTP DMYZ0P1 MA Substrate DMYZ0P1 RN Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline. J Clin Pharmacol. 2015 May;55(5):534-42. DMYZ0P1 RU http://www.ncbi.nlm.nih.gov/pubmed/25491493 DMG9B1U DI DMG9B1U DMG9B1U DN Elvitegravir DMG9B1U MI DE4LYSA DMG9B1U MN Cytochrome P450 3A4 (CYP3A4) DMG9B1U MT DME DMG9B1U MA Metabolism DMG9B1U RN FDA Label of Elvitegravir. The 2020 official website of the U.S. Food and Drug Administration. DMG9B1U RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203100s030lbl.pdf DMG9B1U DI DMG9B1U DMG9B1U DN Elvitegravir DMG9B1U MI TT5FH9Y DMG9B1U MN Human immunodeficiency virus Integrase (HIV IN) DMG9B1U MT DTT DMG9B1U MA Modulator DMG9B1U RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMG9B1U RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMG9B1U DI DMG9B1U DMG9B1U DN Elvitegravir DMG9B1U MI DEYGVN4 DMG9B1U MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMG9B1U MT DME DMG9B1U MA Metabolism DMG9B1U RN Elvitegravir for the treatment of HIV infection. Drugs Today (Barc). 2014 Mar;50(3):209-17. DMG9B1U RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24696866 DMZG5WL DI DMZG5WL DMZG5WL DN Emapalumab DMZG5WL MI TT93WF5 DMZG5WL MN Interferon-gamma (IFNG) DMZG5WL MT DTT DMZG5WL MA Modulator DMZG5WL RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMZG5WL RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM36LAJ DI DM36LAJ DM36LAJ DN Emedastine DM36LAJ MI TTTIBOJ DM36LAJ MN Histamine H1 receptor (H1R) DM36LAJ MT DTT DM36LAJ MA Antagonist DM36LAJ RN Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67. DM36LAJ RU https://pubmed.ncbi.nlm.nih.gov/19558341 DMCOAVT DI DMCOAVT DMCOAVT DN Emepronium DMCOAVT MI TTH18TF DMCOAVT MN Muscarinic acetylcholine receptor M5 (CHRM5) DMCOAVT MT DTT DMCOAVT MA Modulator DMCOAVT RN Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 1995 Jul;274(1):458-68. DMCOAVT RU https://pubmed.ncbi.nlm.nih.gov/7616431 DMCT2YF DI DMCT2YF DMCT2YF DN Emetine DMCT2YF MI DECB0K3 DMCT2YF MN Cytochrome P450 2D6 (CYP2D6) DMCT2YF MT DME DMCT2YF MA Metabolism DMCT2YF RN Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82. DMCT2YF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11411558 DMCT2YF DI DMCT2YF DMCT2YF DN Emetine DMCT2YF MI DE4LYSA DMCT2YF MN Cytochrome P450 3A4 (CYP3A4) DMCT2YF MT DME DMCT2YF MA Metabolism DMCT2YF RN Metabolism of ipecac alkaloids cephaeline and emetine by human hepatic microsomal cytochrome P450s, and their inhibitory effects on P450 enzyme activities. Biol Pharm Bull. 2001 Jun;24(6):678-82. DMCT2YF RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11411558 DMCT2YF DI DMCT2YF DMCT2YF DN Emetine DMCT2YF MI DTUGYRD DMCT2YF MN P-glycoprotein 1 (ABCB1) DMCT2YF MT DTP DMCT2YF MA Substrate DMCT2YF RN Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005 Feb;46(2):224-35. DMCT2YF RU https://doi.org/10.1111/j.0013-9580.2005.31904.x DM0AQ83 DI DM0AQ83 DM0AQ83 DN Emicizumab DM0AQ83 MI TTFEZ5Q DM0AQ83 MN Coagulation factor IX (F9) DM0AQ83 MT DTT DM0AQ83 MA Modulator DM0AQ83 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0AQ83 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0AQ83 DI DM0AQ83 DM0AQ83 DN Emicizumab DM0AQ83 MI TTCIHJA DM0AQ83 MN Coagulation factor Xa (F10) DM0AQ83 MT DTT DM0AQ83 MA Modulator DM0AQ83 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0AQ83 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK MI DTI7UX6 DMRF9YK MN Breast cancer resistance protein (ABCG2) DMRF9YK MT DTP DMRF9YK MA Substrate DMRF9YK RN KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913) DMRF9YK RU https://www.kegg.jp/dbget-bin/www_bget?dg:DG01913 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK MI DTUGYRD DMRF9YK MN P-glycoprotein 1 (ABCB1) DMRF9YK MT DTP DMRF9YK MA Substrate DMRF9YK RN KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) DMRF9YK RU https://www.kegg.jp/dbget-bin/www_bget?dg:DG01665 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK MI TTLWPVF DMRF9YK MN Sodium/glucose cotransporter 2 (SGLT2) DMRF9YK MT DTT DMRF9YK MA Modulator DMRF9YK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMRF9YK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK MI DEF2WXN DMRF9YK MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMRF9YK MT DME DMRF9YK MA Metabolism DMRF9YK RN Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8. DMRF9YK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK MI DE2GB8N DMRF9YK MN UDP-glucuronosyltransferase 1A8 (UGT1A8) DMRF9YK MT DME DMRF9YK MA Metabolism DMRF9YK RN Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8. DMRF9YK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK MI DE85D2P DMRF9YK MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMRF9YK MT DME DMRF9YK MA Metabolism DMRF9YK RN Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8. DMRF9YK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK MI DEB3CV1 DMRF9YK MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMRF9YK MT DME DMRF9YK MA Metabolism DMRF9YK RN Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8. DMRF9YK RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26045645 DMBMUWZ DI DMBMUWZ DMBMUWZ DN Emtricitabine DMBMUWZ MI TT84ETX DMBMUWZ MN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBMUWZ MT DTT DMBMUWZ MA Modulator DMBMUWZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMBMUWZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMBMUWZ DI DMBMUWZ DMBMUWZ DN Emtricitabine DMBMUWZ MI DTZGT0P DMBMUWZ MN Multidrug and toxin extrusion protein 1 (SLC47A1) DMBMUWZ MT DTP DMBMUWZ MA Substrate DMBMUWZ RN Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica. 2017 Jan;47(1):77-85. DMBMUWZ RU http://www.ncbi.nlm.nih.gov/pubmed/27052107 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI TTL69WB DMNFUZR MN Angiotensin-converting enzyme (ACE) DMNFUZR MT DTT DMNFUZR MA Inhibitor DMNFUZR RN Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8. DMNFUZR RU https://pubmed.ncbi.nlm.nih.gov/19557238 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI DEB30C5 DMNFUZR MN Carboxylesterase 1 (CES1) DMNFUZR MT DME DMNFUZR MA Metabolism DMNFUZR RN Absorption and cleavage of enalapril, a carboxyl ester prodrug, in the rat intestine: in vitro, in situ intestinal perfusion and portal vein cannulation models. Biopharm Drug Dispos. 2015 Sep;36(6):385-397. DMNFUZR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25832562 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI DE4LYSA DMNFUZR MN Cytochrome P450 3A4 (CYP3A4) DMNFUZR MT DME DMNFUZR MA Metabolism DMNFUZR RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMNFUZR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI DEQMBHW DMNFUZR MN Dipeptidase (pepV) DMNFUZR MT DME DMNFUZR MA Metabolism DMNFUZR RN Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45. DMNFUZR RU https://pubmed.ncbi.nlm.nih.gov/16962986 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI DTFI42L DMNFUZR MN Multidrug resistance-associated protein 2 (ABCC2) DMNFUZR MT DTP DMNFUZR MA Substrate DMNFUZR RN Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402. DMNFUZR RU http://www.ncbi.nlm.nih.gov/pubmed/16627748 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI DTE2B1D DMNFUZR MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DMNFUZR MT DTP DMNFUZR MA Substrate DMNFUZR RN Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6. DMNFUZR RU http://www.ncbi.nlm.nih.gov/pubmed/10859154 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI DT3D8F0 DMNFUZR MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMNFUZR MT DTP DMNFUZR MA Substrate DMNFUZR RN The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. Hepatology. 1998 Nov;28(5):1341-6. DMNFUZR RU http://www.ncbi.nlm.nih.gov/pubmed/9794920 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI DT9C1TS DMNFUZR MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMNFUZR MT DTP DMNFUZR MA Substrate DMNFUZR RN Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006 Jul;318(1):395-402. DMNFUZR RU http://www.ncbi.nlm.nih.gov/pubmed/16627748 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI DT9G7XN DMNFUZR MN Peptide transporter 1 (SLC15A1) DMNFUZR MT DTP DMNFUZR MA Substrate DMNFUZR RN The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60. DMNFUZR RU https://doi.org/10.1016/S0928-0987(03)00142-8 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR MI DT8QKNP DMNFUZR MN Peptide transporter 2 (SLC15A2) DMNFUZR MT DTP DMNFUZR MA Substrate DMNFUZR RN Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May;32(5):777-84. DMNFUZR RU http://www.ncbi.nlm.nih.gov/pubmed/18336632 DMPRBQV DI DMPRBQV DMPRBQV DN Enalaprilat DMPRBQV MI TTL69WB DMPRBQV MN Angiotensin-converting enzyme (ACE) DMPRBQV MT DTT DMPRBQV MA Inhibitor DMPRBQV RN Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687. DMPRBQV RU https://pubmed.ncbi.nlm.nih.gov/11862223 DMFYAM1 DI DMFYAM1 DMFYAM1 DN Enalaprilat DMFYAM1 MI DEQMBHW DMFYAM1 MN Dipeptidase (pepV) DMFYAM1 MT DME DMFYAM1 MA Metabolism DMFYAM1 RN Characterization and kinetic analysis of enzyme-substrate recognition by three recombinant lactococcal PepVs. Arch Biochem Biophys. 2006 Oct 15;454(2):137-45. DMFYAM1 RU https://pubmed.ncbi.nlm.nih.gov/16962986 DMPRBQV DI DMPRBQV DMPRBQV DN Enalaprilat DMPRBQV MI DT9G7XN DMPRBQV MN Peptide transporter 1 (SLC15A1) DMPRBQV MT DTP DMPRBQV MA Substrate DMPRBQV RN Transporter-mediated Drug Interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74. DMPRBQV RU https://doi.org/10.2133/dmpk.17.253 DM8QXOC DI DM8QXOC DM8QXOC DN Enasidenib DM8QXOC MI DEJGDUW DM8QXOC MN Cytochrome P450 1A2 (CYP1A2) DM8QXOC MT DME DM8QXOC MA Metabolism DM8QXOC RN FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration. DM8QXOC RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf DM8QXOC DI DM8QXOC DM8QXOC DN Enasidenib DM8QXOC MI DEPKLMQ DM8QXOC MN Cytochrome P450 2B6 (CYP2B6) DM8QXOC MT DME DM8QXOC MA Metabolism DM8QXOC RN FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration. DM8QXOC RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf DM8QXOC DI DM8QXOC DM8QXOC DN Enasidenib DM8QXOC MI DES5XRU DM8QXOC MN Cytochrome P450 2C8 (CYP2C8) DM8QXOC MT DME DM8QXOC MA Metabolism DM8QXOC RN FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration. DM8QXOC RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf DM8QXOC DI DM8QXOC DM8QXOC DN Enasidenib DM8QXOC MI DE5IED8 DM8QXOC MN Cytochrome P450 2C9 (CYP2C9) DM8QXOC MT DME DM8QXOC MA Metabolism DM8QXOC RN FDA Label of Enasidenib. The 2020 official website of the U.S. Food and Drug Administration. DM8QXOC RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209606s000lbl.pdf DM8QXOC DI DM8QXOC DM8QXOC DN Enasidenib DM8QXOC MI DEGTFWK DM8QXOC MN Mephenytoin 4-hydroxylase (CYP2C19) DM8QXOC MT DME DM8QXOC MA Metabolism DM8QXOC RN Enasidenib for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018 Aug;11(8):755-760. DM8QXOC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29770715 DMPOU5H DI DMPOU5H DMPOU5H DN ENASIDENIB MESYLATE DMPOU5H MI TTDTWV0 DMPOU5H MN Isocitrate dehydrogenase (IDH) DMPOU5H MT DTT DMPOU5H MA Inhibitor DMPOU5H RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMPOU5H RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM7RNP3 DI DM7RNP3 DM7RNP3 DN Enbrel DM7RNP3 MI TTF8CQI DM7RNP3 MN Tumor necrosis factor (TNF) DM7RNP3 MT DTT DM7RNP3 MA Modulator DM7RNP3 RN Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61. DM7RNP3 RU https://www.ncbi.nlm.nih.gov/pubmed/11451976 DM0YJSB DI DM0YJSB DM0YJSB DN Enflurane DM0YJSB MI DEVDYN7 DM0YJSB MN Cytochrome P450 2E1 (CYP2E1) DM0YJSB MT DME DM0YJSB MA Metabolism DM0YJSB RN Stereoselective metabolism of enflurane by human liver cytochrome P450 2E1. Drug Metab Dispos. 1995 Dec;23(12):1426-30. DM0YJSB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8689955 DM0YJSB DI DM0YJSB DM0YJSB DN Enflurane DM0YJSB MI DED5AT3 DM0YJSB MN Cytochrome P450 2F1 (CYP2F1) DM0YJSB MT DME DM0YJSB MA Metabolism DM0YJSB RN Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther. 1994 Apr;55(4):434-40. DM0YJSB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8162670 DM0YJSB DI DM0YJSB DM0YJSB DN Enflurane DM0YJSB MI TTAN6JD DM0YJSB MN Glutamate receptor AMPA (GRIA) DM0YJSB MT DTT DM0YJSB MA Suppressor DM0YJSB RN Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84. DM0YJSB RU https://pubmed.ncbi.nlm.nih.gov/11020764 DMFS63G DI DMFS63G DMFS63G DN Enfortumab DMFS63G MI TTPO9EG DMFS63G MN Nectin cell adhesion molecule 4 (NECTIN4) DMFS63G MT DTT DMFS63G MA Inhibitor DMFS63G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMFS63G RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf DM7YPM1 DI DM7YPM1 DM7YPM1 DN Enfuvirtide DM7YPM1 MI DEVDYN7 DM7YPM1 MN Cytochrome P450 2E1 (CYP2E1) DM7YPM1 MT DME DM7YPM1 MA Metabolism DM7YPM1 RN Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86. DM7YPM1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15656696 DM7YPM1 DI DM7YPM1 DM7YPM1 DN Enfuvirtide DM7YPM1 MI TTG90S6 DM7YPM1 MN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DM7YPM1 MT DTT DM7YPM1 MA Modulator DM7YPM1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7YPM1 RU https://www.fda.gov/ DM7YPM1 DI DM7YPM1 DM7YPM1 DN Enfuvirtide DM7YPM1 MI DEGTFWK DM7YPM1 MN Mephenytoin 4-hydroxylase (CYP2C19) DM7YPM1 MT DME DM7YPM1 MA Metabolism DM7YPM1 RN Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet. 2005;44(2):175-86. DM7YPM1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15656696 DMYTE6L DI DMYTE6L DMYTE6L DN Enoxacin DMYTE6L MI TT0IHXV DMYTE6L MN DNA topoisomerase II (TOP2) DMYTE6L MT DTT DMYTE6L MA Inhibitor DMYTE6L RN Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. DMYTE6L RU https://pubmed.ncbi.nlm.nih.gov/3282749 DMYTE6L DI DMYTE6L DMYTE6L DN Enoxacin DMYTE6L MI DTZGT0P DMYTE6L MN Multidrug and toxin extrusion protein 1 (SLC47A1) DMYTE6L MT DTP DMYTE6L MA Substrate DMYTE6L RN Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34. DMYTE6L RU http://www.ncbi.nlm.nih.gov/pubmed/19004926 DMYTE6L DI DMYTE6L DMYTE6L DN Enoxacin DMYTE6L MI DTE2B1D DMYTE6L MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DMYTE6L MT DTP DMYTE6L MA Substrate DMYTE6L RN Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94. DMYTE6L RU http://www.ncbi.nlm.nih.gov/pubmed/17274666 DMQVZJD DI DMQVZJD DMQVZJD DN Enoximone DMQVZJD MI TTZCG4L DMQVZJD MN Phosphodiesterase 3 (PDE3) DMQVZJD MT DTT DMQVZJD MA Modulator DMQVZJD RN In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9. DMQVZJD RU https://www.ncbi.nlm.nih.gov/pubmed/12657857 DMQVZJD DI DMQVZJD DMQVZJD DN Enoximone DMQVZJD MI TT06AWU DMQVZJD MN Phosphodiesterase 3A (PDE3A) DMQVZJD MT DTT DMQVZJD MA Inhibitor DMQVZJD RN Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18. DMQVZJD RU https://pubmed.ncbi.nlm.nih.gov/3027339 DMFYZKN DI DMFYZKN DMFYZKN DN Enprofylline DMFYZKN MI TTZ97H5 DMFYZKN MN Phosphodiesterase 4A (PDE4A) DMFYZKN MT DTT DMFYZKN MA Inhibitor DMFYZKN RN Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62. DMFYZKN RU https://pubmed.ncbi.nlm.nih.gov/3034059 DMLBVKQ DI DMLBVKQ DMLBVKQ DN Entacapone DMLBVKQ MI DTI7UX6 DMLBVKQ MN Breast cancer resistance protein (ABCG2) DMLBVKQ MT DTP DMLBVKQ MA Substrate DMLBVKQ RN Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors. Drug Metab Dispos. 2017 Dec;45(12):1282-1291. DMLBVKQ RU http://www.ncbi.nlm.nih.gov/pubmed/28916530 DMLBVKQ DI DMLBVKQ DMLBVKQ DN Entacapone DMLBVKQ MI TTKWFB8 DMLBVKQ MN Catechol-O-methyl-transferase (COMT) DMLBVKQ MT DTT DMLBVKQ MA Inhibitor DMLBVKQ RN Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. DMLBVKQ RU https://pubmed.ncbi.nlm.nih.gov/11440283 DMLBVKQ DI DMLBVKQ DMLBVKQ DN Entacapone DMLBVKQ MI DT3D8F0 DMLBVKQ MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMLBVKQ MT DTP DMLBVKQ MA Substrate DMLBVKQ RN Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. DMLBVKQ RU http://www.ncbi.nlm.nih.gov/pubmed/30135178 DMLBVKQ DI DMLBVKQ DMLBVKQ DN Entacapone DMLBVKQ MI DE85D2P DMLBVKQ MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMLBVKQ MT DME DMLBVKQ MA Metabolism DMLBVKQ RN Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos. 2005 Jul;33(7):1017-26. DMLBVKQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15802387 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI DTI7UX6 DM7VTQO MN Breast cancer resistance protein (ABCG2) DM7VTQO MT DTP DM7VTQO MA Substrate DM7VTQO RN Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278. DM7VTQO RU http://www.ncbi.nlm.nih.gov/pubmed/28062543 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI DT4YL5R DM7VTQO MN Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3) DM7VTQO MT DTP DM7VTQO MA Substrate DM7VTQO RN Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278. DM7VTQO RU http://www.ncbi.nlm.nih.gov/pubmed/28062543 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI DT82KPY DM7VTQO MN Concentrative nucleoside transporter 2 (SLC28A2) DM7VTQO MT DTP DM7VTQO MA Substrate DM7VTQO RN Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278. DM7VTQO RU http://www.ncbi.nlm.nih.gov/pubmed/28062543 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI DTXD1TQ DM7VTQO MN Equilibrative nucleoside transporter 1 (SLC29A1) DM7VTQO MT DTP DM7VTQO MA Substrate DM7VTQO RN Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278. DM7VTQO RU http://www.ncbi.nlm.nih.gov/pubmed/28062543 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI DTW78DQ DM7VTQO MN Equilibrative nucleoside transporter 2 (SLC29A2) DM7VTQO MT DTP DM7VTQO MA Substrate DM7VTQO RN Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278. DM7VTQO RU http://www.ncbi.nlm.nih.gov/pubmed/28062543 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI TTS5K1M DM7VTQO MN Hepatitis B virus Reverse transcriptase (HBV RT) DM7VTQO MT DTT DM7VTQO MA Modulator DM7VTQO RN Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014 Sep 1;210(5):701-7. DM7VTQO RU https://pubmed.ncbi.nlm.nih.gov/24610871 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI DT0OC1Q DM7VTQO MN Organic anion transporter 2 (SLC22A7) DM7VTQO MT DTP DM7VTQO MA Substrate DM7VTQO RN Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119. DM7VTQO RU http://www.ncbi.nlm.nih.gov/pubmed/27916488 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI DT6201N DM7VTQO MN Organic cation transporter 3 (SLC22A3) DM7VTQO MT DTP DM7VTQO MA Substrate DM7VTQO RN Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278. DM7VTQO RU http://www.ncbi.nlm.nih.gov/pubmed/28062543 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI DT3HUVD DM7VTQO MN Organic cation/carnitine transporter 2 (SLC22A5) DM7VTQO MT DTP DM7VTQO MA Substrate DM7VTQO RN Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278. DM7VTQO RU http://www.ncbi.nlm.nih.gov/pubmed/28062543 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO MI DT8QKNP DM7VTQO MN Peptide transporter 2 (SLC15A2) DM7VTQO MT DTP DM7VTQO MA Substrate DM7VTQO RN The oligopeptide transporter 2-mediated reabsorption of entecavir in rat kidney. Eur J Pharm Sci. 2014 Feb 14;52:41-7. DM7VTQO RU http://www.ncbi.nlm.nih.gov/pubmed/24184752 DMK659W DI DMK659W DMK659W DN Enteric-coated mycophenolate sodium DMK659W MI TTCAQMW DMK659W MN Inosine-5'-monophosphate dehydrogenase (IMPDH) DMK659W MT DTT DMK659W MA Inhibitor DMK659W RN Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004 Jul;107(1):63-8. DMK659W RU https://pubmed.ncbi.nlm.nih.gov/14723604 DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH MI TTPMQSO DMMPTLH MN ALK tyrosine kinase receptor (ALK) DMMPTLH MT DTT DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH MI TTKN7QR DMMPTLH MN BDNF/NT-3 growth factors receptor (TrkB) DMMPTLH MT DTT DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH MI DE4LYSA DMMPTLH MN Cytochrome P450 3A4 (CYP3A4) DMMPTLH MT DME DMMPTLH MA Metabolism DMMPTLH RN Entrectinib: first global approval. Drugs. 2019 Sep;79(13):1477-1483. DMMPTLH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31372957 DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH MI TTXABCW DMMPTLH MN NT-3 growth factor receptor (TrkC) DMMPTLH MT DTT DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH MI TTSZ6Y3 DMMPTLH MN Proto-oncogene c-Ros (ROS1) DMMPTLH MT DTT DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH MI TTTDVOJ DMMPTLH MN Tropomyosin-related kinase A (TrkA) DMMPTLH MT DTT DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMGL19D DI DMGL19D DMGL19D DN Enzalutamide DMGL19D MI TTS64P2 DMGL19D MN Androgen receptor (AR) DMGL19D MT DTT DMGL19D MA Modulator DMGL19D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMGL19D RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM5OGK0 DI DM5OGK0 DM5OGK0 DN Epalrestat DM5OGK0 MI TTFBNVI DM5OGK0 MN Aldose reductase (AKR1B1) DM5OGK0 MT DTT DM5OGK0 MA Inhibitor DM5OGK0 RN Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4. DM5OGK0 RU https://pubmed.ncbi.nlm.nih.gov/11522497 DM5OGK0 DI DM5OGK0 DM5OGK0 DN Epalrestat DM5OGK0 MI TTXHYV6 DM5OGK0 MN Voltage-gated L-type calcium channel (L-CaC) DM5OGK0 MT DTT DM5OGK0 MA Blocker DM5OGK0 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DM5OGK0 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMHEAGL DI DMHEAGL DMHEAGL DN Epanova DMHEAGL MI DE87OZS DMHEAGL MN Arachidonate 5-lipoxygenase (ALOX5) DMHEAGL MT DME DMHEAGL MA Metabolism DMHEAGL RN Omega-3 fatty acids and inflammatory processes. Nutrients. 2010 Mar;2(3):355-74. DMHEAGL RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22254027 DMHEAGL DI DMHEAGL DMHEAGL DN Epanova DMHEAGL MI DEIPST6 DMHEAGL MN Cytochrome P450 147G1 (cyp147) DMHEAGL MT DME DMHEAGL MA Metabolism DMHEAGL RN Selective Omega-1 oxidation of fatty acids by CYP147G1 from Mycobacterium marinum. Biochim Biophys Acta Gen Subj. 2019 Feb;1863(2):408-417. DMHEAGL RU https://pubmed.ncbi.nlm.nih.gov/30476524 DMHEAGL DI DMHEAGL DMHEAGL DN Epanova DMHEAGL MI DE492CE DMHEAGL MN Prostaglandin G/H synthase 2 (COX-2) DMHEAGL MT DME DMHEAGL MA Metabolism DMHEAGL RN Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63. DMHEAGL RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20463020 DMMV0KW DI DMMV0KW DMMV0KW DN Ephedrine DMMV0KW MI TTEX248 DMMV0KW MN Dopamine D2 receptor (D2R) DMMV0KW MT DTT DMMV0KW MA Agonist DMMV0KW RN The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility. Cogn Behav Neurol. 2006 Dec;19(4):204-7. DMMV0KW RU https://pubmed.ncbi.nlm.nih.gov/17159617 DMMV0KW DI DMMV0KW DMMV0KW DN Ephedrine DMMV0KW MI DEYWLRK DMMV0KW MN Sulfotransferase 1A1 (SULT1A1) DMMV0KW MT DME DMMV0KW MA Metabolism DMMV0KW RN Benzylic alcohols as stereospecific substrates and inhibitors for aryl sulfotransferase. Chirality. 1991;3(2):104-11. DMMV0KW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=1863522 DMVONE6 DI DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 MI DE1TNRG DMVONE6 MN Carboxypeptidase M (CPM) DMVONE6 MT DME DMVONE6 MA Metabolism DMVONE6 RN Extracellular conversion of epidermal growth factor (EGF) to des-Arg53-EGF by carboxypeptidase M. J Biol Chem. 1995 Jul 21;270(29):17154-8. DMVONE6 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=7615511 DMVONE6 DI DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 MI TTED8JB DMVONE6 MN Epidermal growth factor (EGF) DMVONE6 MT DTT DMVONE6 MA Modulator DMVONE6 RN Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52. DMVONE6 RU http://www.palgrave-journals.com/jcb/journal/v17/n1/full/jcb201028a.html DMVONE6 DI DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 MI TTGKNB4 DMVONE6 MN Epidermal growth factor receptor (EGFR) DMVONE6 MT DTT DMVONE6 MA Modulator DMVONE6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMVONE6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMX0K3Q DI DMX0K3Q DMX0K3Q DN Epinastine DMX0K3Q MI DEPKLMQ DMX0K3Q MN Cytochrome P450 2B6 (CYP2B6) DMX0K3Q MT DME DMX0K3Q MA Metabolism DMX0K3Q RN Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92. DMX0K3Q RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522 DMX0K3Q DI DMX0K3Q DMX0K3Q DN Epinastine DMX0K3Q MI DECB0K3 DMX0K3Q MN Cytochrome P450 2D6 (CYP2D6) DMX0K3Q MT DME DMX0K3Q MA Metabolism DMX0K3Q RN Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92. DMX0K3Q RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522 DMX0K3Q DI DMX0K3Q DMX0K3Q DN Epinastine DMX0K3Q MI DE4LYSA DMX0K3Q MN Cytochrome P450 3A4 (CYP3A4) DMX0K3Q MT DME DMX0K3Q MA Metabolism DMX0K3Q RN Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92. DMX0K3Q RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9485522 DMX0K3Q DI DMX0K3Q DMX0K3Q DN Epinastine DMX0K3Q MI TTTIBOJ DMX0K3Q MN Histamine H1 receptor (H1R) DMX0K3Q MT DTT DMX0K3Q MA Antagonist DMX0K3Q RN Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038. DMX0K3Q RU https://pubmed.ncbi.nlm.nih.gov/19381339 DMX0K3Q DI DMX0K3Q DMX0K3Q DN Epinastine DMX0K3Q MI DTUGYRD DMX0K3Q MN P-glycoprotein 1 (ABCB1) DMX0K3Q MT DTP DMX0K3Q MA Substrate DMX0K3Q RN Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004 May;32(5):519-24. DMX0K3Q RU https://doi.org/10.1124/dmd.32.5.519 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC MI TTR6W5O DM3KJBC MN Adrenergic receptor beta-1 (ADRB1) DM3KJBC MT DTT DM3KJBC MA Agonist DM3KJBC RN Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77. DM3KJBC RU https://pubmed.ncbi.nlm.nih.gov/19460844 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC MI DEV3T4A DM3KJBC MN Catechol O-methyltransferase (COMT) DM3KJBC MT DME DM3KJBC MA Metabolism DM3KJBC RN Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. J Pharmacol Exp Ther. 1994 Mar;268(3):1242-51. DM3KJBC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8138937 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC MI DERE4TU DM3KJBC MN Monoamine oxidase type A (MAO-A) DM3KJBC MT DME DM3KJBC MA Metabolism DM3KJBC RN Role of monoamine-oxidase-A-gene variation in the development of glioblastoma in males: a case control study. J Neurooncol. 2019 Nov;145(2):287-294. DM3KJBC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31556016 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC MI DTT79CX DM3KJBC MN Organic cation transporter 1 (SLC22A1) DM3KJBC MT DTP DM3KJBC MA Substrate DM3KJBC RN Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. DM3KJBC RU https://doi.org/10.1007/s11095-012-0935-x DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC MI DT6201N DM3KJBC MN Organic cation transporter 3 (SLC22A3) DM3KJBC MT DTP DM3KJBC MA Substrate DM3KJBC RN Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52. DM3KJBC RU http://www.ncbi.nlm.nih.gov/pubmed/16581093 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC MI DEYWLRK DM3KJBC MN Sulfotransferase 1A1 (SULT1A1) DM3KJBC MT DME DM3KJBC MA Metabolism DM3KJBC RN Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23. DM3KJBC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16083857 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC MI DEFQ8VO DM3KJBC MN Thiopurine methyltransferase (TPMT) DM3KJBC MT DME DM3KJBC MA Metabolism DM3KJBC RN Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7. DM3KJBC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=6859813 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC MI DEYGVN4 DM3KJBC MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM3KJBC MT DME DM3KJBC MA Metabolism DM3KJBC RN Steroid glucuronides: human circulatory levels and formation by LNCaP cells. J Steroid Biochem Mol Biol. 1991;40(4-6):593-8. DM3KJBC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=1835648 DMPDW6T DI DMPDW6T DMPDW6T DN Epirubicin DMPDW6T MI DTI7UX6 DMPDW6T MN Breast cancer resistance protein (ABCG2) DMPDW6T MT DTP DMPDW6T MA Substrate DMPDW6T RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMPDW6T RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMPDW6T DI DMPDW6T DMPDW6T DN Epirubicin DMPDW6T MI TT0IHXV DMPDW6T MN DNA topoisomerase II (TOP2) DMPDW6T MT DTT DMPDW6T MA Modulator DMPDW6T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPDW6T RU https://www.fda.gov/ DMPDW6T DI DMPDW6T DMPDW6T DN Epirubicin DMPDW6T MI DTSYQGK DMPDW6T MN Multidrug resistance-associated protein 1 (ABCC1) DMPDW6T MT DTP DMPDW6T MA Substrate DMPDW6T RN Sulindac sulfide selectively increases sensitivity of ABCC1 expressing tumor cells to doxorubicin and glutathione depletion. J Biomed Res. 2016 Mar;30(2):120-133. DMPDW6T RU http://www.ncbi.nlm.nih.gov/pubmed/28276667 DMPDW6T DI DMPDW6T DMPDW6T DN Epirubicin DMPDW6T MI DTFI42L DMPDW6T MN Multidrug resistance-associated protein 2 (ABCC2) DMPDW6T MT DTP DMPDW6T MA Substrate DMPDW6T RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMPDW6T RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMPDW6T DI DMPDW6T DMPDW6T DN Epirubicin DMPDW6T MI DTUGYRD DMPDW6T MN P-glycoprotein 1 (ABCB1) DMPDW6T MT DTP DMPDW6T MA Substrate DMPDW6T RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMPDW6T RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMPDW6T DI DMPDW6T DMPDW6T DN Epirubicin DMPDW6T MI DEB3CV1 DMPDW6T MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMPDW6T MT DME DMPDW6T MA Metabolism DMPDW6T RN Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006 Dec;34(12):2097-101. DMPDW6T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16985101 DMF0NQR DI DMF0NQR DMF0NQR DN Eplerenone DMF0NQR MI DE4LYSA DMF0NQR MN Cytochrome P450 3A4 (CYP3A4) DMF0NQR MT DME DMF0NQR MA Metabolism DMF0NQR RN Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure. Heart Dis. 2003 Sep-Oct;5(5):354-63. DMF0NQR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14503934 DMF0NQR DI DMF0NQR DMF0NQR DN Eplerenone DMF0NQR MI DEIBDNY DMF0NQR MN Cytochrome P450 3A5 (CYP3A5) DMF0NQR MT DME DMF0NQR MA Metabolism DMF0NQR RN The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13. DMF0NQR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31408697 DMF0NQR DI DMF0NQR DMF0NQR DN Eplerenone DMF0NQR MI TT26PHO DMF0NQR MN Mineralocorticoid receptor (MR) DMF0NQR MT DTT DMF0NQR MA Modulator DMF0NQR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMF0NQR RU https://www.fda.gov/ DMKWB73 DI DMKWB73 DMKWB73 DN Epoetin alfa DMKWB73 MI TTAUX24 DMKWB73 MN Erythropoietin Receptor (EPOR) DMKWB73 MT DTT DMKWB73 MA Agonist DMKWB73 RN 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12. DMKWB73 RU https://pubmed.ncbi.nlm.nih.gov/19229970 DMUTYR2 DI DMUTYR2 DMUTYR2 DN Epoprostenol DMUTYR2 MI DE5IED8 DMUTYR2 MN Cytochrome P450 2C9 (CYP2C9) DMUTYR2 MT DME DMUTYR2 MA Metabolism DMUTYR2 RN Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):321-6. DMUTYR2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15569819 DMUTYR2 DI DMUTYR2 DMUTYR2 DN Epoprostenol DMUTYR2 MI TTOFYT1 DMUTYR2 MN Prostacyclin receptor (PTGIR) DMUTYR2 MT DTT DMUTYR2 MA Agonist DMUTYR2 RN Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94. DMUTYR2 RU https://pubmed.ncbi.nlm.nih.gov/19302827 DM07K2I DI DM07K2I DM07K2I DN Eprosartan DM07K2I MI TT8DBY3 DM07K2I MN Angiotensin II receptor type-1 (AGTR1) DM07K2I MT DTT DM07K2I MA Antagonist DM07K2I RN Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. DM07K2I RU https://pubmed.ncbi.nlm.nih.gov/18855637 DM07K2I DI DM07K2I DM07K2I DN Eprosartan DM07K2I MI DT9G7XN DM07K2I MN Peptide transporter 1 (SLC15A1) DM07K2I MT DTP DM07K2I MA Substrate DM07K2I RN High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9. DM07K2I RU http://www.ncbi.nlm.nih.gov/pubmed/18824524 DMQXTJS DI DMQXTJS DMQXTJS DN Eptifibatide DMQXTJS MI TT38RM1 DMQXTJS MN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMQXTJS MT DTT DMQXTJS MA Modulator DMQXTJS RN Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62. DMQXTJS RU https://pubmed.ncbi.nlm.nih.gov/2033037 DM5LJCI DI DM5LJCI DM5LJCI DN Eptinezumab DM5LJCI MI TTAFORY DM5LJCI MN Calcitonin gene-related peptide (CALC) DM5LJCI MT DTT DM5LJCI MA Inhibitor DM5LJCI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM5LJCI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf DMI782S DI DMI782S DMI782S DN Erdafitinib DMI782S MI DE5IED8 DMI782S MN Cytochrome P450 2C9 (CYP2C9) DMI782S MT DME DMI782S MA Metabolism DMI782S RN FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration. DMI782S RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf DMI782S DI DMI782S DMI782S DN Erdafitinib DMI782S MI DE4LYSA DMI782S MN Cytochrome P450 3A4 (CYP3A4) DMI782S MT DME DMI782S MA Metabolism DMI782S RN FDA label of Erdafitinib. The 2020 official website of the U.S. Food and Drug Administration. DMI782S RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212018Orig1s000MultidisciplineR.pdf DMI782S DI DMI782S DMI782S DN Erdafitinib DMI782S MI TT0LF7H DMI782S MN Fibroblast growth factor receptor (FGFR) DMI782S MT DTT DMI782S MA Inhibitor DMI782S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMI782S RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf DM6QFSV DI DM6QFSV DM6QFSV DN Erdosteine DM6QFSV MI TT3NKIB DM6QFSV MN Pancreatic elastase 1 (CELA1) DM6QFSV MT DTT DM6QFSV MA Modulator DM6QFSV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM6QFSV RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMWMCN0 DI DMWMCN0 DMWMCN0 DN Erenumab DMWMCN0 MI TTY6O0Q DMWMCN0 MN Calcitonin gene-related peptide receptor (CGRPR) DMWMCN0 MT DTT DMWMCN0 MA Modulator DMWMCN0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMWMCN0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMHO0AR DI DMHO0AR DMHO0AR DN Ergocalciferol DMHO0AR MI DE98XPV DMHO0AR MN Cholesterol desmolase (CYP11A1) DMHO0AR MT DME DMHO0AR MA Metabolism DMHO0AR RN Vitamin D: mechanisms of action and clinical applications. Endocrinol Metab Clin North Am. 2017 Dec;46(4):xvii-xviii. DMHO0AR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29080648 DMHO0AR DI DMHO0AR DMHO0AR DN Ergocalciferol DMHO0AR MI DERSX5P DMHO0AR MN Cytochrome P450 2J2 (CYP2J2) DMHO0AR MT DME DMHO0AR MA Metabolism DMHO0AR RN Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56. DMHO0AR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16842832 DMHO0AR DI DMHO0AR DMHO0AR DN Ergocalciferol DMHO0AR MI DE4LYSA DMHO0AR MN Cytochrome P450 3A4 (CYP3A4) DMHO0AR MT DME DMHO0AR MA Metabolism DMHO0AR RN CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res. 2004 Apr;19(4):680-8. DMHO0AR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15005856 DMHO0AR DI DMHO0AR DMHO0AR DN Ergocalciferol DMHO0AR MI DEBIHM3 DMHO0AR MN Vitamin D 25-hydroxylase (CYP2R1) DMHO0AR MT DME DMHO0AR MA Metabolism DMHO0AR RN CYP2R1 (vitamin D 25-hydroxylase) gene is associated with susceptibility to type 1 diabetes and vitamin D levels in Germans. Diabetes Metab Res Rev. 2007 Nov;23(8):631-6. DMHO0AR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17607662 DMHO0AR DI DMHO0AR DMHO0AR DN Ergocalciferol DMHO0AR MI TTK59TV DMHO0AR MN Vitamin D3 receptor (VDR) DMHO0AR MT DTT DMHO0AR MA Antagonist DMHO0AR RN Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41. DMHO0AR RU https://pubmed.ncbi.nlm.nih.gov/18525006 DMORPBA DI DMORPBA DMORPBA DN Ergoloid mesylate DMORPBA MI TT32XQJ DMORPBA MN Monoamine oxidase (MAO) DMORPBA MT DTT DMORPBA MA Modulator DMORPBA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMORPBA RU https://www.fda.gov/ DM0VEC1 DI DM0VEC1 DM0VEC1 DN Ergonovine DM0VEC1 MI DE4LYSA DM0VEC1 MN Cytochrome P450 3A4 (CYP3A4) DM0VEC1 MT DME DM0VEC1 MA Metabolism DM0VEC1 RN Rational prescription of drugs within similar therapeutic or structural class for gastrointestinal disease treatment: drug metabolism and its related interactions. World J Gastroenterol. 2007 Nov 14;13(42):5618-28. DM0VEC1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17948937 DM0VEC1 DI DM0VEC1 DM0VEC1 DN Ergonovine DM0VEC1 MI TTEX248 DM0VEC1 MN Dopamine D2 receptor (D2R) DM0VEC1 MT DTT DM0VEC1 MA Agonist DM0VEC1 RN Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9. DM0VEC1 RU https://pubmed.ncbi.nlm.nih.gov/2897449 DMKR3C5 DI DMKR3C5 DMKR3C5 DN Ergotamine DMKR3C5 MI TTG28O6 DMKR3C5 MN Adrenergic receptor Alpha-1 (ADRA1) DMKR3C5 MT DTT DMKR3C5 MA Agonist DMKR3C5 RN Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6. DMKR3C5 RU https://pubmed.ncbi.nlm.nih.gov/18763151 DMKR3C5 DI DMKR3C5 DMKR3C5 DN Ergotamine DMKR3C5 MI DEJGDUW DMKR3C5 MN Cytochrome P450 1A2 (CYP1A2) DMKR3C5 MT DME DMKR3C5 MA Metabolism DMKR3C5 RN Frovatriptan: a review of drug-drug interactions. Headache. 2002 Apr;42 Suppl 2:S63-73. DMKR3C5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12028322 DMKR3C5 DI DMKR3C5 DMKR3C5 DN Ergotamine DMKR3C5 MI DE4LYSA DMKR3C5 MN Cytochrome P450 3A4 (CYP3A4) DMKR3C5 MT DME DMKR3C5 MA Metabolism DMKR3C5 RN Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine. Vet Hum Toxicol. 2003 Feb;45(1):6-9. DMKR3C5 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12583687 DMKR3C5 DI DMKR3C5 DMKR3C5 DN Ergotamine DMKR3C5 MI DTUGYRD DMKR3C5 MN P-glycoprotein 1 (ABCB1) DMKR3C5 MT DTP DMKR3C5 MA Substrate DMKR3C5 RN Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. DMKR3C5 RU https://doi.org/10.1016/j.addr.2011.12.008 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DETECWH DM78IME MN Amiloride-sensitive amine oxidase (AOC1) DM78IME MT DME DM78IME MA Metabolism DM78IME RN Human kidney diamine oxidase: heterologous expression, purification, and characterization. J Biol Inorg Chem. 2002 Jun;7(6):565-79. DM78IME RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12072962 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DE5IED8 DM78IME MN Cytochrome P450 2C9 (CYP2C9) DM78IME MT DME DM78IME MA Metabolism DM78IME RN Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. DM78IME RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DE4LYSA DM78IME MN Cytochrome P450 3A4 (CYP3A4) DM78IME MT DME DM78IME MA Metabolism DM78IME RN Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004 Dec;24(12):1732-47. DM78IME RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15585441 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DT3EAQP DM78IME MN Equilibrative nucleoside transporter 4 (SLC29A4) DM78IME MT DTP DM78IME MA Substrate DM78IME RN Histamine uptake mediated by plasma membrane monoamine transporter and organic cation transporters in rat mast cell lines. Eur J Pharmacol. 2019 Apr 15;849:75-83. DM78IME RU http://www.ncbi.nlm.nih.gov/pubmed/30707958 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI TTTIBOJ DM78IME MN Histamine H1 receptor (H1R) DM78IME MT DTT DM78IME MA Agonist DM78IME RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DM78IME RU https://pubmed.ncbi.nlm.nih.gov/11179434 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DE3PZ0I DM78IME MN Histamine N-methyltransferase (HNMT) DM78IME MT DME DM78IME MA Metabolism DM78IME RN Histamine pharmacogenomics. Pharmacogenomics. 2009 May;10(5):867-83. DM78IME RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19450133 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DT9IDPW DM78IME MN Organic cation transporter 2 (SLC22A2) DM78IME MT DTP DM78IME MA Substrate DM78IME RN The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11. DM78IME RU http://www.ncbi.nlm.nih.gov/pubmed/17393420 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DT6201N DM78IME MN Organic cation transporter 3 (SLC22A3) DM78IME MT DTP DM78IME MA Substrate DM78IME RN Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52. DM78IME RU http://www.ncbi.nlm.nih.gov/pubmed/16581093 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DEFQ8VO DM78IME MN Thiopurine methyltransferase (TPMT) DM78IME MT DME DM78IME MA Metabolism DM78IME RN Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8. DM78IME RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19538200 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DTM953D DM78IME MN Vesicular amine transporter 1 (SLC18A1) DM78IME MT DTP DM78IME MA Substrate DM78IME RN Gastrin-producing endocrine cells: a novel source of histamine in the rat stomach. Endocrinology. 1998 Oct;139(10):4404-15. DM78IME RU http://www.ncbi.nlm.nih.gov/pubmed/9751525 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME MI DTT7VPB DM78IME MN Vesicular amine transporter 2 (SLC18A2) DM78IME MT DTP DM78IME MA Substrate DM78IME RN The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int. 2014 Jul;73:89-97. DM78IME RU http://www.ncbi.nlm.nih.gov/pubmed/24398404 DM1DX4Q DI DM1DX4Q DM1DX4Q DN Eribulin DM1DX4Q MI DE4LYSA DM1DX4Q MN Cytochrome P450 3A4 (CYP3A4) DM1DX4Q MT DME DM1DX4Q MA Metabolism DM1DX4Q RN Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16. DM1DX4Q RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18431572 DM1DX4Q DI DM1DX4Q DM1DX4Q DN Eribulin DM1DX4Q MI TTML2WA DM1DX4Q MN Tubulin (TUB) DM1DX4Q MT DTT DM1DX4Q MA Inhibitor DM1DX4Q RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM1DX4Q RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA MI DTI7UX6 DMCMBHA MN Breast cancer resistance protein (ABCG2) DMCMBHA MT DTP DMCMBHA MA Substrate DMCMBHA RN Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 2009 Jan 31;61(1):26-33. DMCMBHA RU https://doi.org/10.1016/j.addr.2008.07.003 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA MI DEJGDUW DMCMBHA MN Cytochrome P450 1A2 (CYP1A2) DMCMBHA MT DME DMCMBHA MA Metabolism DMCMBHA RN Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. DMCMBHA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA MI DECB0K3 DMCMBHA MN Cytochrome P450 2D6 (CYP2D6) DMCMBHA MT DME DMCMBHA MA Metabolism DMCMBHA RN Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. DMCMBHA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA MI DE4LYSA DMCMBHA MN Cytochrome P450 3A4 (CYP3A4) DMCMBHA MT DME DMCMBHA MA Metabolism DMCMBHA RN In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos. 2014 Jul;42(7):1202-9. DMCMBHA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24713129 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA MI DEIBDNY DMCMBHA MN Cytochrome P450 3A5 (CYP3A5) DMCMBHA MT DME DMCMBHA MA Metabolism DMCMBHA RN Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706. DMCMBHA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19733976 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA MI TTGKNB4 DMCMBHA MN Epidermal growth factor receptor (EGFR) DMCMBHA MT DTT DMCMBHA MA Inhibitor DMCMBHA RN Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48. DMCMBHA RU https://pubmed.ncbi.nlm.nih.gov/19627157 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA MI DTUGYRD DMCMBHA MN P-glycoprotein 1 (ABCB1) DMCMBHA MT DTP DMCMBHA MA Substrate DMCMBHA RN Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7. DMCMBHA RU https://doi.org/10.1158/1535-7163.MCT-07-2250 DM4S3O8 DI DM4S3O8 DM4S3O8 DN Ertapenem DM4S3O8 MI TTJP4SM DM4S3O8 MN Bacterial Penicillin binding protein (Bact PBP) DM4S3O8 MT DTT DM4S3O8 MA Binder DM4S3O8 RN Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24. DM4S3O8 RU https://pubmed.ncbi.nlm.nih.gov/15716453 DM4S3O8 DI DM4S3O8 DM4S3O8 DN Ertapenem DM4S3O8 MI DEC3G7M DM4S3O8 MN Beta-lactamase (blaB) DM4S3O8 MT DME DM4S3O8 MA Metabolism DM4S3O8 RN FRI-4 carbapenemase-producing Enterobacter cloacae complex isolated in Tokyo, Japan. J Antimicrob Chemother. 2018 Nov 1;73(11):2969-2972. DM4S3O8 RU https://pubmed.ncbi.nlm.nih.gov/30060114 DM4S3O8 DI DM4S3O8 DM4S3O8 DN Ertapenem DM4S3O8 MI DEMIUB2 DM4S3O8 MN Beta-lactamase (blaB) DM4S3O8 MT DME DM4S3O8 MA Metabolism DM4S3O8 RN War wound treatment complications due to transfer of an IncN plasmid harboring bla(OXA-181) from Morganella morganii to CTX-M-27-producing sequence type 131 Escherichia coli. Antimicrob Agents Chemother. 2015;59(6):3556-62. DM4S3O8 RU https://pubmed.ncbi.nlm.nih.gov/25870058 DM4S3O8 DI DM4S3O8 DM4S3O8 DN Ertapenem DM4S3O8 MI DECWSA9 DM4S3O8 MN Beta-lactamase (blaB) DM4S3O8 MT DME DM4S3O8 MA Metabolism DM4S3O8 RN War wound treatment complications due to transfer of an IncN plasmid harboring bla(OXA-181) from Morganella morganii to CTX-M-27-producing sequence type 131 Escherichia coli. Antimicrob Agents Chemother. 2015;59(6):3556-62. DM4S3O8 RU https://pubmed.ncbi.nlm.nih.gov/25870058 DMFGQ2S DI DMFGQ2S DMFGQ2S DN Erythrityl Tetranitrate DMFGQ2S MI TT6HPVC DMFGQ2S MN Guanylate cyclase (GC) DMFGQ2S MT DTT DMFGQ2S MA Stimulator DMFGQ2S RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMFGQ2S RU https://pubmed.ncbi.nlm.nih.gov/19618122 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI TTUWYEA DM4K7GQ MN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4K7GQ MT DTT DM4K7GQ MA Binder DM4K7GQ RN A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54. DM4K7GQ RU https://pubmed.ncbi.nlm.nih.gov/1945852 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DE7IQ34 DM4K7GQ MN Beta-glucuronidase (uidA) DM4K7GQ MT DME DM4K7GQ MA Metabolism DM4K7GQ RN Identification of Lactobacillus sakei genes induced during meat fermentation and their role in survival and growth. Appl Environ Microbiol. 2007 Apr;73(8):2522-31. DM4K7GQ RU https://pubmed.ncbi.nlm.nih.gov/17308175 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DTI7UX6 DM4K7GQ MN Breast cancer resistance protein (ABCG2) DM4K7GQ MT DTP DM4K7GQ MA Substrate DM4K7GQ RN ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13. DM4K7GQ RU https://doi.org/10.1016/j.addr.2008.11.003 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DE6OQ3W DM4K7GQ MN Cytochrome P450 1A1 (CYP1A1) DM4K7GQ MT DME DM4K7GQ MA Metabolism DM4K7GQ RN Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72. DM4K7GQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9972457 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DEJGDUW DM4K7GQ MN Cytochrome P450 1A2 (CYP1A2) DM4K7GQ MT DME DM4K7GQ MA Metabolism DM4K7GQ RN Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos. 1998 Nov;26(11):1053-7. DM4K7GQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9806945 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DE9QHP6 DM4K7GQ MN Cytochrome P450 1B1 (CYP1B1) DM4K7GQ MT DME DM4K7GQ MA Metabolism DM4K7GQ RN Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72. DM4K7GQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9972457 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DE4LYSA DM4K7GQ MN Cytochrome P450 3A4 (CYP3A4) DM4K7GQ MT DME DM4K7GQ MA Metabolism DM4K7GQ RN Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol. 2003 Jan;55(1):86-93. DM4K7GQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12534644 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DEIBDNY DM4K7GQ MN Cytochrome P450 3A5 (CYP3A5) DM4K7GQ MT DME DM4K7GQ MA Metabolism DM4K7GQ RN Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105. DM4K7GQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28558634 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DERD86B DM4K7GQ MN Cytochrome P450 3A7 (CYP3A7) DM4K7GQ MT DME DM4K7GQ MA Metabolism DM4K7GQ RN Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos. 2007 Mar;35(3):484-92. DM4K7GQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17178770 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DEIZLTN DM4K7GQ MN Docosahexaenoic acid omega-hydroxylase (CYP4F11) DM4K7GQ MT DME DM4K7GQ MA Metabolism DM4K7GQ RN Expression and characterization of human cytochrome P450 4F11: putative role in the metabolism of therapeutic drugs and eicosanoids. Toxicol Appl Pharmacol. 2004 Sep 15;199(3):295-304. DM4K7GQ RU https://pubmed.ncbi.nlm.nih.gov/15364545 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DTFI42L DM4K7GQ MN Multidrug resistance-associated protein 2 (ABCC2) DM4K7GQ MT DTP DM4K7GQ MA Substrate DM4K7GQ RN Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther. 2011 May;89(5):693-701. DM4K7GQ RU http://www.ncbi.nlm.nih.gov/pubmed/21451505 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DT0OC1Q DM4K7GQ MN Organic anion transporter 2 (SLC22A7) DM4K7GQ MT DTP DM4K7GQ MA Substrate DM4K7GQ RN Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22. DM4K7GQ RU http://www.ncbi.nlm.nih.gov/pubmed/15708966 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DT9C1TS DM4K7GQ MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DM4K7GQ MT DTP DM4K7GQ MA Substrate DM4K7GQ RN Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705. DM4K7GQ RU http://www.ncbi.nlm.nih.gov/pubmed/19785645 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ MI DTUGYRD DM4K7GQ MN P-glycoprotein 1 (ABCB1) DM4K7GQ MT DTP DM4K7GQ MA Substrate DM4K7GQ RN Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids. Pharm Res. 2009 May;26(5):1270-82. DM4K7GQ RU http://www.ncbi.nlm.nih.gov/pubmed/18958406 DMFK9HG DI DMFK9HG DMFK9HG DN Escitalopram DMFK9HG MI DECB0K3 DMFK9HG MN Cytochrome P450 2D6 (CYP2D6) DMFK9HG MT DME DMFK9HG MA Metabolism DMFK9HG RN CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig. 2013 Sep;10(3):286-93. DMFK9HG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24302953 DMFK9HG DI DMFK9HG DMFK9HG DN Escitalopram DMFK9HG MI DE4LYSA DMFK9HG MN Cytochrome P450 3A4 (CYP3A4) DMFK9HG MT DME DMFK9HG MA Metabolism DMFK9HG RN PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72. DMFK9HG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21546862 DMFK9HG DI DMFK9HG DMFK9HG DN Escitalopram DMFK9HG MI DEGTFWK DMFK9HG MN Mephenytoin 4-hydroxylase (CYP2C19) DMFK9HG MT DME DMFK9HG MA Metabolism DMFK9HG RN Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015 Nov;25(11):548-54. DMFK9HG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26313485 DMFK9HG DI DMFK9HG DMFK9HG DN Escitalopram DMFK9HG MI TT3ROYC DMFK9HG MN Serotonin transporter (SERT) DMFK9HG MT DTT DMFK9HG MA Inhibitor DMFK9HG RN Antidepressants and sleep: a review. Perspect Psychiatr Care. 2009 Jul;45(3):191-7. DMFK9HG RU https://pubmed.ncbi.nlm.nih.gov/19566691 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ MI TTRK8B9 DMZREFQ MN Sodium channel unspecific (NaC) DMZREFQ MT DTT DMZREFQ MA Blocker DMZREFQ RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/19008076 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ MI DEYGVN4 DMZREFQ MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMZREFQ MT DME DMZREFQ MA Metabolism DMZREFQ RN Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation. Drug Metab Dispos. 2011 Sep;39(9):1486-94. DMZREFQ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21673130 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ MI TTIG65Q DMZREFQ MN Voltage-gated sodium channel (Nav) DMZREFQ MT DTT DMZREFQ MA Inhibitor DMZREFQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ MI TTN9VTF DMZREFQ MN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMZREFQ MT DTT DMZREFQ MA Inhibitor DMZREFQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMREUZV DI DMREUZV DMREUZV DN Eslicarbazepine acetate DMREUZV MI DTUGYRD DMREUZV MN P-glycoprotein 1 (ABCB1) DMREUZV MT DTP DMREUZV MA Substrate DMREUZV RN In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein. Epilepsia. 2011 Oct;52(10):1894-904. DMREUZV RU https://doi.org/10.1111/j.1528-1167.2011.03140.x DM51TYR DI DM51TYR DM51TYR DN Esmolol DM51TYR MI TTR6W5O DM51TYR MN Adrenergic receptor beta-1 (ADRB1) DM51TYR MT DTT DM51TYR MA Antagonist DM51TYR RN Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009 Jan-Feb;38(1):48-55. DM51TYR RU https://pubmed.ncbi.nlm.nih.gov/19150530 DM51TYR DI DM51TYR DM51TYR DN Esmolol DM51TYR MI DECB0K3 DM51TYR MN Cytochrome P450 2D6 (CYP2D6) DM51TYR MT DME DM51TYR MA Metabolism DM51TYR RN Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. DM51TYR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27836712 DM7BN0X DI DM7BN0X DM7BN0X DN Esomeprazole DM7BN0X MI TTLOKXP DM7BN0X MN Gastric H(+)/K(+) ATPase (Proton pump) DM7BN0X MT DTT DM7BN0X MA Modulator DM7BN0X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7BN0X RU https://www.fda.gov/ DM7BN0X DI DM7BN0X DM7BN0X DN Esomeprazole DM7BN0X MI DEGTFWK DM7BN0X MN Mephenytoin 4-hydroxylase (CYP2C19) DM7BN0X MT DME DM7BN0X MA Metabolism DM7BN0X RN Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children. Clin Pharmacol Ther. 2018 Jul;104(1):188-200. DM7BN0X RU https://www.ncbi.nlm.nih.gov/pubmed/?term=29027194 DMZGXUM DI DMZGXUM DMZGXUM DN Estazolam DMZGXUM MI DE4LYSA DMZGXUM MN Cytochrome P450 3A4 (CYP3A4) DMZGXUM MT DME DMZGXUM MA Metabolism DMZGXUM RN Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam. Xenobiotica. 2005 May;35(5):455-65. DMZGXUM RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16012077 DMZGXUM DI DMZGXUM DMZGXUM DN Estazolam DMZGXUM MI TTPTXIN DMZGXUM MN Translocator protein (TSPO) DMZGXUM MT DTT DMZGXUM MA Agonist DMZGXUM RN Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3126-9. DMZGXUM RU https://pubmed.ncbi.nlm.nih.gov/15876530 DM9KZDO DI DM9KZDO DM9KZDO DN Esterified estrogens DM9KZDO MI TTZAYWL DM9KZDO MN Estrogen receptor (ESR) DM9KZDO MT DTT DM9KZDO MA Modulator DM9KZDO RN Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2011 Jan;95(1):366-8. DM9KZDO RU https://pubmed.ncbi.nlm.nih.gov/20850731 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DTI7UX6 DMUNTE3 MN Breast cancer resistance protein (ABCG2) DMUNTE3 MT DTP DMUNTE3 MA Substrate DMUNTE3 RN Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51. DMUNTE3 RU http://www.ncbi.nlm.nih.gov/pubmed/12668685 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DE6OQ3W DMUNTE3 MN Cytochrome P450 1A1 (CYP1A1) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17570247 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DEJGDUW DMUNTE3 MN Cytochrome P450 1A2 (CYP1A2) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15217502 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DE9QHP6 DMUNTE3 MN Cytochrome P450 1B1 (CYP1B1) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17570247 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DES5XRU DMUNTE3 MN Cytochrome P450 2C8 (CYP2C8) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DE5IED8 DMUNTE3 MN Cytochrome P450 2C9 (CYP2C9) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DE4LYSA DMUNTE3 MN Cytochrome P450 3A4 (CYP3A4) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22837389 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DEIBDNY DMUNTE3 MN Cytochrome P450 3A5 (CYP3A5) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Drug Interactions Flockhart Table DMUNTE3 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DERD86B DMUNTE3 MN Cytochrome P450 3A7 (CYP3A7) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Drug Interactions Flockhart Table DMUNTE3 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DEGTB1K DMUNTE3 MN Dehydrogenase/reductase retSDR3 (HSD17B14) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Expression patterns of 17beta-hydroxysteroid dehydrogenase 14 in human tissues. Horm Metab Res. 2012 Dec;44(13):949-56. DMUNTE3 RU https://pubmed.ncbi.nlm.nih.gov/22864907 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI TTZAYWL DMUNTE3 MN Estrogen receptor (ESR) DMUNTE3 MT DTT DMUNTE3 MA Agonist DMUNTE3 RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DMUNTE3 RU https://pubmed.ncbi.nlm.nih.gov/19434891 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DER0XCH DMUNTE3 MN Farnesol dehydrogenase (AKR1B15) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DEHX1DZ DMUNTE3 MN Lactoperoxidase (LPO) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN The metabolism of 17 beta-estradiol by lactoperoxidase: a possible source of oxidative stress in breast cancer. Carcinogenesis. 1994 Nov;15(11):2637-43. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=7955118 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DEGTFWK DMUNTE3 MN Mephenytoin 4-hydroxylase (CYP2C19) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18521743 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DTUGYRD DMUNTE3 MN P-glycoprotein 1 (ABCB1) DMUNTE3 MT DTP DMUNTE3 MA Substrate DMUNTE3 RN Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92. DMUNTE3 RU http://www.ncbi.nlm.nih.gov/pubmed/7914405 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DEYWLRK DMUNTE3 MN Sulfotransferase 1A1 (SULT1A1) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21669803 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DEFQ8VO DMUNTE3 MN Thiopurine methyltransferase (TPMT) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8055052 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DEYGVN4 DMUNTE3 MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8. DMUNTE3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 MI DEB7I4M DMUNTE3 MN UDP-glucuronosyltransferase 2B28 (UGT2B28) DMUNTE3 MT DME DMUNTE3 MA Metabolism DMUNTE3 RN Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry. 2001 Apr 3;40(13):3869-81. DMUNTE3 RU https://pubmed.ncbi.nlm.nih.gov/11300766 DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A MI DEJGDUW DM07U2A MN Cytochrome P450 1A2 (CYP1A2) DM07U2A MT DME DM07U2A MA Metabolism DM07U2A RN Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. DM07U2A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317 DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A MI DES5XRU DM07U2A MN Cytochrome P450 2C8 (CYP2C8) DM07U2A MT DME DM07U2A MA Metabolism DM07U2A RN Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. DM07U2A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26721703 DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A MI DE5IED8 DM07U2A MN Cytochrome P450 2C9 (CYP2C9) DM07U2A MT DME DM07U2A MA Metabolism DM07U2A RN A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7. DM07U2A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066 DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A MI DE4LYSA DM07U2A MN Cytochrome P450 3A4 (CYP3A4) DM07U2A MT DME DM07U2A MA Metabolism DM07U2A RN A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7. DM07U2A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066 DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A MI DEIBDNY DM07U2A MN Cytochrome P450 3A5 (CYP3A5) DM07U2A MT DME DM07U2A MA Metabolism DM07U2A RN Drug Interactions Flockhart Table DM07U2A RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A MI DERD86B DM07U2A MN Cytochrome P450 3A7 (CYP3A7) DM07U2A MT DME DM07U2A MA Metabolism DM07U2A RN Drug Interactions Flockhart Table DM07U2A RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A MI TTZAYWL DM07U2A MN Estrogen receptor (ESR) DM07U2A MT DTT DM07U2A MA Modulator DM07U2A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM07U2A RU https://www.fda.gov/ DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A MI DEGTFWK DM07U2A MN Mephenytoin 4-hydroxylase (CYP2C19) DM07U2A MT DME DM07U2A MA Metabolism DM07U2A RN Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54. DM07U2A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520 DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A MI DEYGVN4 DM07U2A MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM07U2A MT DME DM07U2A MA Metabolism DM07U2A RN Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8. DM07U2A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155 DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T MI DEJGDUW DM27Z5T MN Cytochrome P450 1A2 (CYP1A2) DM27Z5T MT DME DM27Z5T MA Metabolism DM27Z5T RN Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos. 2006 Sep;34(9):1606-14. DM27Z5T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16790556 DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T MI DES5XRU DM27Z5T MN Cytochrome P450 2C8 (CYP2C8) DM27Z5T MT DME DM27Z5T MA Metabolism DM27Z5T RN Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54. DM27Z5T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520 DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T MI DE5IED8 DM27Z5T MN Cytochrome P450 2C9 (CYP2C9) DM27Z5T MT DME DM27Z5T MA Metabolism DM27Z5T RN A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7. DM27Z5T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066 DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T MI DE4LYSA DM27Z5T MN Cytochrome P450 3A4 (CYP3A4) DM27Z5T MT DME DM27Z5T MA Metabolism DM27Z5T RN A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7. DM27Z5T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066 DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T MI DEIBDNY DM27Z5T MN Cytochrome P450 3A5 (CYP3A5) DM27Z5T MT DME DM27Z5T MA Metabolism DM27Z5T RN Drug Interactions Flockhart Table DM27Z5T RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T MI DERD86B DM27Z5T MN Cytochrome P450 3A7 (CYP3A7) DM27Z5T MT DME DM27Z5T MA Metabolism DM27Z5T RN Drug Interactions Flockhart Table DM27Z5T RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T MI TTZAYWL DM27Z5T MN Estrogen receptor (ESR) DM27Z5T MT DTT DM27Z5T MA Modulator DM27Z5T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM27Z5T RU https://www.fda.gov/ DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T MI DEGTFWK DM27Z5T MN Mephenytoin 4-hydroxylase (CYP2C19) DM27Z5T MT DME DM27Z5T MA Metabolism DM27Z5T RN Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54. DM27Z5T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520 DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T MI DEYGVN4 DM27Z5T MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM27Z5T MT DME DM27Z5T MA Metabolism DM27Z5T RN Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8. DM27Z5T RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155 DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O MI DEJGDUW DM8MC6O MN Cytochrome P450 1A2 (CYP1A2) DM8MC6O MT DME DM8MC6O MA Metabolism DM8MC6O RN Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos. 2006 Sep;34(9):1606-14. DM8MC6O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16790556 DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O MI DES5XRU DM8MC6O MN Cytochrome P450 2C8 (CYP2C8) DM8MC6O MT DME DM8MC6O MA Metabolism DM8MC6O RN Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54. DM8MC6O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520 DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O MI DE5IED8 DM8MC6O MN Cytochrome P450 2C9 (CYP2C9) DM8MC6O MT DME DM8MC6O MA Metabolism DM8MC6O RN A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7. DM8MC6O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066 DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O MI DE4LYSA DM8MC6O MN Cytochrome P450 3A4 (CYP3A4) DM8MC6O MT DME DM8MC6O MA Metabolism DM8MC6O RN A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7. DM8MC6O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066 DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O MI DEIBDNY DM8MC6O MN Cytochrome P450 3A5 (CYP3A5) DM8MC6O MT DME DM8MC6O MA Metabolism DM8MC6O RN Drug Interactions Flockhart Table DM8MC6O RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O MI DERD86B DM8MC6O MN Cytochrome P450 3A7 (CYP3A7) DM8MC6O MT DME DM8MC6O MA Metabolism DM8MC6O RN Drug Interactions Flockhart Table DM8MC6O RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O MI TTZAYWL DM8MC6O MN Estrogen receptor (ESR) DM8MC6O MT DTT DM8MC6O MA Modulator DM8MC6O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8MC6O RU https://www.fda.gov/ DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O MI DEGTFWK DM8MC6O MN Mephenytoin 4-hydroxylase (CYP2C19) DM8MC6O MT DME DM8MC6O MA Metabolism DM8MC6O RN Role of cytochrome P450 in estradiol metabolism in vitro. Acta Pharmacol Sin. 2001 Feb;22(2):148-54. DM8MC6O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11741520 DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O MI DEYGVN4 DM8MC6O MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM8MC6O MT DME DM8MC6O MA Metabolism DM8MC6O RN Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8. DM8MC6O RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20620155 DMLNMEA DI DMLNMEA DMLNMEA DN Estradiol valerate/dienogest DMLNMEA MI TTUV8G9 DMLNMEA MN Progesterone receptor (PGR) DMLNMEA MT DTT DMLNMEA MA Modulator DMLNMEA RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMLNMEA RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMWTAOI DI DMWTAOI DMWTAOI DN Estramustine DMWTAOI MI DE4LYSA DMWTAOI MN Cytochrome P450 3A4 (CYP3A4) DMWTAOI MT DME DMWTAOI MA Metabolism DMWTAOI RN Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol. 2003 May;169(5):1729-34. DMWTAOI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12686819 DMWTAOI DI DMWTAOI DMWTAOI DN Estramustine DMWTAOI MI TTSBFYK DMWTAOI MN Estramustine binding protein (EMBP) DMWTAOI MT DTT DMWTAOI MA Binder DMWTAOI RN Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5. DMWTAOI RU https://pubmed.ncbi.nlm.nih.gov/7703721 DMOEM2I DI DMOEM2I DMOEM2I DN Estriol DMOEM2I MI DERD86B DMOEM2I MN Cytochrome P450 3A7 (CYP3A7) DMOEM2I MT DME DMOEM2I MA Metabolism DMOEM2I RN Expression and cyclic variability of CYP3A4 and CYP3A7 isoforms in human endometrium and cervix during the menstrual cycle. Drug Metab Dispos. 2003 Jan;31(1):1-6. DMOEM2I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12485945 DMOEM2I DI DMOEM2I DMOEM2I DN Estriol DMOEM2I MI TTZAYWL DMOEM2I MN Estrogen receptor (ESR) DMOEM2I MT DTT DMOEM2I MA Agonist DMOEM2I RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DMOEM2I RU https://pubmed.ncbi.nlm.nih.gov/19434891 DMOEM2I DI DMOEM2I DMOEM2I DN Estriol DMOEM2I MI DTUGYRD DMOEM2I MN P-glycoprotein 1 (ABCB1) DMOEM2I MT DTP DMOEM2I MA Substrate DMOEM2I RN P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. DMOEM2I RU http://www.ncbi.nlm.nih.gov/pubmed/15290871 DMOEM2I DI DMOEM2I DMOEM2I DN Estriol DMOEM2I MI DEYGVN4 DMOEM2I MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMOEM2I MT DME DMOEM2I MA Metabolism DMOEM2I RN Stimulation of microsomal uridine diphosphate glucuronyltransferase by glucuronic acid derivatives. Biochem J. 1974 Apr;139(1):243-9. DMOEM2I RU https://www.ncbi.nlm.nih.gov/pubmed/?term=4219139 DMGY0UT DI DMGY0UT DMGY0UT DN Estrogen DMGY0UT MI TTZAYWL DMGY0UT MN Estrogen receptor (ESR) DMGY0UT MT DTT DMGY0UT MA Agonist DMGY0UT RN Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002 Mar 28;346(13):967-74. DMGY0UT RU https://pubmed.ncbi.nlm.nih.gov/11919305 DMGY0UT DI DMGY0UT DMGY0UT DN Estrogen DMGY0UT MI TTOM3J0 DMGY0UT MN Estrogen receptor beta (ESR2) DMGY0UT MT DTT DMGY0UT MA Agonist DMGY0UT RN Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6. DMGY0UT RU https://pubmed.ncbi.nlm.nih.gov/10611350 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DE6OQ3W DM5T6US MN Cytochrome P450 1A1 (CYP1A1) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16207128 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DEJGDUW DM5T6US MN Cytochrome P450 1A2 (CYP1A2) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN A transgenic mouse expressing human CYP1A2 in the pancreas. Biochem Pharmacol. 2000 Sep 15;60(6):857-63. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10930541 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DE9QHP6 DM5T6US MN Cytochrome P450 1B1 (CYP1B1) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16207128 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DEPKLMQ DM5T6US MN Cytochrome P450 2B6 (CYP2B6) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DE5IED8 DM5T6US MN Cytochrome P450 2C9 (CYP2C9) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=14703066 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DEVDYN7 DM5T6US MN Cytochrome P450 2E1 (CYP2E1) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10640505 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DE4LYSA DM5T6US MN Cytochrome P450 3A4 (CYP3A4) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN Regioselective hydroxylation of steroid hormones by human cytochromes P450. Drug Metab Rev. 2015 May;47(2):89-110. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25678418 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DEIBDNY DM5T6US MN Cytochrome P450 3A5 (CYP3A5) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9635876 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DEBMFZ8 DM5T6US MN Estradiol 17-beta-dehydrogenase 2 (HSD17B2) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI TTZAYWL DM5T6US MN Estrogen receptor (ESR) DM5T6US MT DTT DM5T6US MA Agonist DM5T6US RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DM5T6US RU https://pubmed.ncbi.nlm.nih.gov/19434891 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DER0XCH DM5T6US MN Farnesol dehydrogenase (AKR1B15) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN Aldo-keto Reductase 1B15 (AKR1B15): a mitochondrial human aldo-keto reductase with activity toward steroids and 3-keto-acyl-CoA conjugates. J Biol Chem. 2015 Mar 6;290(10):6531-45. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25577493 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DE915QP DM5T6US MN Ketoacyl-CoA reductase (HSD17B12) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol Endocrinol. 2006 Feb;20(2):437-43. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16166196 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DEDMWFX DM5T6US MN Keto-steroid reductase (HSD17B7) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DE2XQGW DM5T6US MN Lauric acid omega-hydroxylase (CYP4A11) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12865317 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DEJHG19 DM5T6US MN Peroxisomal multifunctional enzyme 2 (HSD17B4) DM5T6US MT DME DM5T6US MA Metabolism DM5T6US RN Steroid signalling in the ovarian surface epithelium. Trends Endocrinol Metab. 2005 Sep;16(7):327-33. DM5T6US RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16054388 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US MI DTUGYRD DM5T6US MN P-glycoprotein 1 (ABCB1) DM5T6US MT DTP DM5T6US MA Substrate DM5T6US RN P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. DM5T6US RU http://www.ncbi.nlm.nih.gov/pubmed/15290871 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DT9NXMV DMVBIZL MN ATP-binding cassette sub-family A member 8 (ABCA8) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun. 2002 Oct 18;298(1):41-5. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/12379217 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTI7UX6 DMVBIZL MN Breast cancer resistance protein (ABCG2) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/12682043 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTI7UX6 DMVBIZL MN Breast cancer resistance protein (ABCG2) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci. 2012 May;101(5):1888-97. DMVBIZL RU https://doi.org/10.1002/jps.23069 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTZGT0P DMVBIZL MN Multidrug and toxin extrusion protein 1 (SLC47A1) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/17509534 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DT3TX4H DMVBIZL MN Multidrug and toxin extrusion protein 2 (SLC47A2) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/17509534 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTSYQGK DMVBIZL MN Multidrug resistance-associated protein 1 (ABCC1) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/12867490 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTFI42L DMVBIZL MN Multidrug resistance-associated protein 2 (ABCC2) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol Pharmacol. 2005 Oct;68(4):1031-8. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/16046661 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTVP67E DMVBIZL MN Organic anion transporter 3 (SLC22A8) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Involvement of tyrosine kinase and PI3K in the regulation of OAT3-mediated estrone sulfate transport in isolated rabbit renal proximal tubules. Am J Physiol Renal Physiol. 2005 Nov;289(5):F1057-64. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/15956776 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DT06JWZ DMVBIZL MN Organic anion transporter 4 (SLC22A11) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4. J Pharm Pharmacol. 2006 Nov;58(11):1499-505. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/17132213 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTT3IKQ DMVBIZL MN Organic anion transporter 6 (SLC22A20) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20). Am J Physiol Renal Physiol. 2006 Aug;291(2):F314-21. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/16478971 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTE2B1D DMVBIZL MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci. 2011 Jul 17;43(4):297-307. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/21605667 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DT3D8F0 DMVBIZL MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Role of transmembrane domain 10 for the function of organic anion transporting polypeptide 1B1. Protein Sci. 2009 Nov;18(11):2298-306. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/19760661 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DT9C1TS DMVBIZL MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/18321482 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTPFTEQ DMVBIZL MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos. 2007 Aug;35(8):1308-14. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/17470528 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTVNRXW DMVBIZL MN Organic anion transporting polypeptide 3A1 (SLCO3A1) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/10873595 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DT8H2IC DMVBIZL MN Organic anion transporting polypeptide 4A1 (SLCO4A1) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther. 2004 Dec;311(3):1032-7. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/15328376 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTY0QMU DMVBIZL MN Organic anion transporting polypeptide 4C1 (SLCO4C1) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1. Drug Metab Pharmacokinet. 2010;25(3):314-7. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/20610891 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTMEQ32 DMVBIZL MN Organic solute transporter subunit alpha (SLC51A) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/12719432 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DT1V9AJ DMVBIZL MN Organic solute transporter subunit beta (SLC51B) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/12719432 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DT1V9AJ DMVBIZL MN Organic solute transporter subunit beta (SLC51B) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta. J Biol Chem. 2003 Jul 25;278(30):27473-82. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/12719432 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DTUGYRD DMVBIZL MN P-glycoprotein 1 (ABCB1) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. DMVBIZL RU https://doi.org/10.1124/jpet.105.085589 DMVBIZL DI DMVBIZL DMVBIZL DN Estrone sulfate DMVBIZL MI DT56EKP DMVBIZL MN Sodium/taurocholate cotransporting polypeptide (SLC10A1) DMVBIZL MT DTP DMVBIZL MA Substrate DMVBIZL RN Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem. 2004 Feb 20;279(8):7213-22. DMVBIZL RU http://www.ncbi.nlm.nih.gov/pubmed/14660639 DMRMDWA DI DMRMDWA DMRMDWA DN Estropipate DMRMDWA MI DE4LYSA DMRMDWA MN Cytochrome P450 3A4 (CYP3A4) DMRMDWA MT DME DMRMDWA MA Metabolism DMRMDWA RN Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004 Nov;311(2):728-35. DMRMDWA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15282264 DMRMDWA DI DMRMDWA DMRMDWA DN Estropipate DMRMDWA MI TTZAYWL DMRMDWA MN Estrogen receptor (ESR) DMRMDWA MT DTT DMRMDWA MA Modulator DMRMDWA RN US patent application no. 5,004,651, Stabilizing system for solid dosage forms. DMRMDWA RU http://www.google.com/patents/US5004651 DM8RZ9H DI DM8RZ9H DM8RZ9H DN Eszopiclone DM8RZ9H MI DES5XRU DM8RZ9H MN Cytochrome P450 2C8 (CYP2C8) DM8RZ9H MT DME DM8RZ9H MA Metabolism DM8RZ9H RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM8RZ9H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM8RZ9H DI DM8RZ9H DM8RZ9H DN Eszopiclone DM8RZ9H MI DEVDYN7 DM8RZ9H MN Cytochrome P450 2E1 (CYP2E1) DM8RZ9H MT DME DM8RZ9H MA Metabolism DM8RZ9H RN Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther. 2006 Apr;28(4):491-516. DM8RZ9H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16750462 DM8RZ9H DI DM8RZ9H DM8RZ9H DN Eszopiclone DM8RZ9H MI DE4LYSA DM8RZ9H MN Cytochrome P450 3A4 (CYP3A4) DM8RZ9H MT DME DM8RZ9H MA Metabolism DM8RZ9H RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM8RZ9H RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM8RZ9H DI DM8RZ9H DM8RZ9H DN Eszopiclone DM8RZ9H MI TTPTXIN DM8RZ9H MN Translocator protein (TSPO) DM8RZ9H MT DTT DM8RZ9H MA Agonist DM8RZ9H RN New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9. DM8RZ9H RU https://pubmed.ncbi.nlm.nih.gov/18265473 DMCV109 DI DMCV109 DMCV109 DN Etanercept DMCV109 MI TTF8CQI DMCV109 MN Tumor necrosis factor (TNF) DMCV109 MT DTT DMCV109 MA Modulator DMCV109 RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMCV109 RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMHP9BL DI DMHP9BL DMHP9BL DN Etelcalcetide DMHP9BL MI TTBUYHA DMHP9BL MN Extracellular calcium-sensing receptor (CASR) DMHP9BL MT DTT DMHP9BL MA Modulator DMHP9BL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHP9BL RU https://www.fda.gov/ DM2QBHP DI DM2QBHP DM2QBHP DN Eteplirsen DM2QBHP MI TTWLFXU DM2QBHP MN Dystrophin messenger RNA (DMD mRNA) DM2QBHP MT DTT DM2QBHP MA Modulator DM2QBHP RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM2QBHP RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM5M4NT DI DM5M4NT DM5M4NT DN Ethacrynate sodium DM5M4NT MI TTS087L DM5M4NT MN Solute carrier family 12 member 1 (SLC12A1) DM5M4NT MT DTT DM5M4NT MA Modulator DM5M4NT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5M4NT RU https://www.fda.gov/ DM60QMR DI DM60QMR DM60QMR DN Ethacrynic acid DM60QMR MI DE6OQ3W DM60QMR MN Cytochrome P450 1A1 (CYP1A1) DM60QMR MT DME DM60QMR MA Metabolism DM60QMR RN Xenobiotic metabolizing and antioxidant enzymes in normal and neoplastic human breast tissue. Eur J Drug Metab Pharmacokinet. 1998 Oct-Dec;23(4):497-500. DM60QMR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10323333 DM60QMR DI DM60QMR DM60QMR DN Ethacrynic acid DM60QMR MI DE4ZHS1 DM60QMR MN Glutathione S-transferase alpha-1 (GSTA1) DM60QMR MT DME DM60QMR MA Metabolism DM60QMR RN Purification and biochemical properties of glutathione S-transferase from Lactuca sativa. J Biochem Mol Biol. 2005 Mar 31;38(2):232-7. DM60QMR RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15826502 DM60QMR DI DM60QMR DM60QMR DN Ethacrynic acid DM60QMR MI DTSYQGK DM60QMR MN Multidrug resistance-associated protein 1 (ABCC1) DM60QMR MT DTP DM60QMR MA Substrate DM60QMR RN Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol. 2002 Nov;62(5):1160-6. DM60QMR RU http://www.ncbi.nlm.nih.gov/pubmed/12391280 DM60QMR DI DM60QMR DM60QMR DN Ethacrynic acid DM60QMR MI TTS087L DM60QMR MN Solute carrier family 12 member 1 (SLC12A1) DM60QMR MT DTT DM60QMR MA Blocker DM60QMR RN Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74. DM60QMR RU https://pubmed.ncbi.nlm.nih.gov/7733229 DMR87LC DI DMR87LC DMR87LC DN Ethambutol DMR87LC MI TT1Q8GP DMR87LC MN Mycobacterium Arabinosyltransferase C (MycB embC) DMR87LC MT DTT DMR87LC MA Inhibitor DMR87LC RN The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4138-46. DMR87LC RU https://pubmed.ncbi.nlm.nih.gov/19596878 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEG8NJD DMDRQZU MN Alcohol dehydrogenase (ADH) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Functional profiles of coronal and dentin caries in children. J Oral Microbiol. 2018 Jul 16;10(1):1495976. DMDRQZU RU https://pubmed.ncbi.nlm.nih.gov/30034639 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEE5M8O DMDRQZU MN Alcohol dehydrogenase class-I alpha (ADH1A) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21329681 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEEN9RD DMDRQZU MN Alcohol dehydrogenase class-I beta (ADH1B) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21329681 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEM1HNL DMDRQZU MN Alcohol dehydrogenase class-I gamma (ADH1C) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Natural alcohol exposure: is ethanol the main substrate for alcohol dehydrogenases in animals? Chem Biol Interact. 2011 May 30;191(1-3):14-25. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21329681 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEOCWU3 DMDRQZU MN Alcohol dehydrogenase class-II (ADH4) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Oxidation of alcohols and reduction of aldehydes derived from methyl- and dimethylpyrenes by cDNA-expressed human alcohol dehydrogenases. Toxicology. 2008 Mar 12;245(1-2):65-75. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18242813 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEIOH6A DMDRQZU MN Alcohol dehydrogenase class-III (ADH5) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DE017IC DMDRQZU MN Alcohol dehydrogenase class-V (ADH6) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DED2FW3 DMDRQZU MN Aldo-keto reductase 1A1 (AKR1A1) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEJGDUW DMDRQZU MN Cytochrome P450 1A2 (CYP1A2) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEVDYN7 DMDRQZU MN Cytochrome P450 2E1 (CYP2E1) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12707490 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DE4LYSA DMDRQZU MN Cytochrome P450 3A4 (CYP3A4) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI TT1MPAY DMDRQZU MN GABA(A) receptor alpha-1 (GABRA1) DMDRQZU MT DTT DMDRQZU MA Antagonist DMDRQZU RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMDRQZU RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEZMAHX DMDRQZU MN Gastric alcohol dehydrogenase (ADH7) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16792560 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU MI DEYGVN4 DMDRQZU MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMDRQZU MT DME DMDRQZU MA Metabolism DMDRQZU RN Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32. DMDRQZU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=24553666 DM3B654 DI DM3B654 DM3B654 DN Ethanolamine oleate DM3B654 MI DEVDYN7 DM3B654 MN Cytochrome P450 2E1 (CYP2E1) DM3B654 MT DME DM3B654 MA Metabolism DM3B654 RN CYP2E1--biochemical and toxicological aspects and role in alcohol-induced liver injury. Mt Sinai J Med. 2006 Jul;73(4):657-72. DM3B654 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16878272 DM53IP1 DI DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 MI DE4LYSA DM53IP1 MN Cytochrome P450 3A4 (CYP3A4) DM53IP1 MT DME DM53IP1 MA Metabolism DM53IP1 RN Alkylation of the prosthetic heme in cytochrome P-450 during oxidative metabolism of the sedative-hypnotic ethchlorvynol. J Med Chem. 1982 Oct;25(10):1174-9. DM53IP1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=7143353 DM53IP1 DI DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 MI TT1MPAY DM53IP1 MN GABA(A) receptor alpha-1 (GABRA1) DM53IP1 MT DTT DM53IP1 MA Antagonist DM53IP1 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM53IP1 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM53IP1 DI DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 MI TTZA1NY DM53IP1 MN GABA(A) receptor beta-2 (GABRB2) DM53IP1 MT DTT DM53IP1 MA Antagonist DM53IP1 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM53IP1 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMK57GB DI DMK57GB DMK57GB DN Ethinamate DMK57GB MI TTANPDJ DMK57GB MN Carbonic anhydrase II (CA-II) DMK57GB MT DTT DMK57GB MA Inhibitor DMK57GB RN Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50. DMK57GB RU https://pubmed.ncbi.nlm.nih.gov/1460006 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 MI DE6OQ3W DMODJ40 MN Cytochrome P450 1A1 (CYP1A1) DMODJ40 MT DME DMODJ40 MA Metabolism DMODJ40 RN The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12. DMODJ40 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 MI DES5XRU DMODJ40 MN Cytochrome P450 2C8 (CYP2C8) DMODJ40 MT DME DMODJ40 MA Metabolism DMODJ40 RN Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. DMODJ40 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15601807 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 MI DE5IED8 DMODJ40 MN Cytochrome P450 2C9 (CYP2C9) DMODJ40 MT DME DMODJ40 MA Metabolism DMODJ40 RN The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12. DMODJ40 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15304426 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 MI DE4LYSA DMODJ40 MN Cytochrome P450 3A4 (CYP3A4) DMODJ40 MT DME DMODJ40 MA Metabolism DMODJ40 RN Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004 Oct;36(3-4):497-509. DMODJ40 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15554232 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 MI TTZAYWL DMODJ40 MN Estrogen receptor (ESR) DMODJ40 MT DTT DMODJ40 MA Agonist DMODJ40 RN 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8. DMODJ40 RU https://pubmed.ncbi.nlm.nih.gov/19237207 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 MI DEGTFWK DMODJ40 MN Mephenytoin 4-hydroxylase (CYP2C19) DMODJ40 MT DME DMODJ40 MA Metabolism DMODJ40 RN The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol. 2003 Aug;56(2):232-7. DMODJ40 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12895199 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 MI DTUGYRD DMODJ40 MN P-glycoprotein 1 (ABCB1) DMODJ40 MT DTP DMODJ40 MA Substrate DMODJ40 RN P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. DMODJ40 RU http://www.ncbi.nlm.nih.gov/pubmed/15290871 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 MI DEYGVN4 DMODJ40 MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMODJ40 MT DME DMODJ40 MA Metabolism DMODJ40 RN Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. DMODJ40 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429 DM8K3EI DI DM8K3EI DM8K3EI DN Ethionamide DM8K3EI MI TTVTX4N DM8K3EI MN Bacterial Fatty acid synthetase I (Bact inhA) DM8K3EI MT DTT DM8K3EI MA Inhibitor DM8K3EI RN Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8. DM8K3EI RU https://pubmed.ncbi.nlm.nih.gov/17227913 DM8K3EI DI DM8K3EI DM8K3EI DN Ethionamide DM8K3EI MI DEIASEZ DM8K3EI MN Dimethylaniline oxidase 2 (FMO2) DM8K3EI MT DME DM8K3EI MA Metabolism DM8K3EI RN Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181. DM8K3EI RU https://pubmed.ncbi.nlm.nih.gov/27678284 DM8K3EI DI DM8K3EI DM8K3EI DN Ethionamide DM8K3EI MI DEP76YL DM8K3EI MN Dimethylaniline oxidase 3 (FMO3) DM8K3EI MT DME DM8K3EI MA Metabolism DM8K3EI RN Physiologically based pharmacokinetic modeling approach to predict drug-drug interactions with ethionamide involving impact of genetic polymorphism on FMO3. J Clin Pharmacol. 2019 Jun;59(6):880-889. DM8K3EI RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30690726 DM0N3L7 DI DM0N3L7 DM0N3L7 DN Ethopropazine DM0N3L7 MI TTTIBOJ DM0N3L7 MN Histamine H1 receptor (H1R) DM0N3L7 MT DTT DM0N3L7 MA Modulator DM0N3L7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N3L7 RU https://www.fda.gov/ DMDZ9LT DI DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT MI DEVDYN7 DMDZ9LT MN Cytochrome P450 2E1 (CYP2E1) DMDZ9LT MT DME DMDZ9LT MA Metabolism DMDZ9LT RN Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76. DMDZ9LT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244 DMDZ9LT DI DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT MI DE4LYSA DMDZ9LT MN Cytochrome P450 3A4 (CYP3A4) DMDZ9LT MT DME DMDZ9LT MA Metabolism DMDZ9LT RN Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76. DMDZ9LT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244 DMDZ9LT DI DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT MI DEO1IE3 DMDZ9LT MN Cytochrome P450 3A43 (CYP3A43) DMDZ9LT MT DME DMDZ9LT MA Metabolism DMDZ9LT RN Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76. DMDZ9LT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244 DMDZ9LT DI DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT MI DEIBDNY DMDZ9LT MN Cytochrome P450 3A5 (CYP3A5) DMDZ9LT MT DME DMDZ9LT MA Metabolism DMDZ9LT RN Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76. DMDZ9LT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244 DMDZ9LT DI DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT MI DERD86B DMDZ9LT MN Cytochrome P450 3A7 (CYP3A7) DMDZ9LT MT DME DMDZ9LT MA Metabolism DMDZ9LT RN Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76. DMDZ9LT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12637244 DMDZ9LT DI DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT MI TT729IR DMDZ9LT MN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMDZ9LT MT DTT DMDZ9LT MA Blocker DMDZ9LT RN Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. DMDZ9LT RU https://pubmed.ncbi.nlm.nih.gov/19005061 DMXWOCP DI DMXWOCP DMXWOCP DN Ethotoin DMXWOCP MI TTZOVE0 DMXWOCP MN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMXWOCP MT DTT DMXWOCP MA Blocker DMXWOCP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXWOCP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVO4ED DI DMVO4ED DMVO4ED DN Ethoxzolamide DMVO4ED MI TTHQPL7 DMVO4ED MN Carbonic anhydrase I (CA-I) DMVO4ED MT DTT DMVO4ED MA Modulator DMVO4ED RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVO4ED RU https://www.fda.gov/ DMVO4ED DI DMVO4ED DMVO4ED DN Ethoxzolamide DMVO4ED MI TTANPDJ DMVO4ED MN Carbonic anhydrase II (CA-II) DMVO4ED MT DTT DMVO4ED MA Inhibitor DMVO4ED RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVO4ED RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM20VMW DI DM20VMW DM20VMW DN Ethylestrenol DM20VMW MI TTS64P2 DM20VMW MN Androgen receptor (AR) DM20VMW MT DTT DM20VMW MA Modulator DM20VMW RN Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, ... Endocrinology. 1984 Jun;114(6):2100-6. DM20VMW RU https://www.ncbi.nlm.nih.gov/pubmed/6539197 DMZM84R DI DMZM84R DMZM84R DN Ethynodiol diacetate DMZM84R MI DE4LYSA DMZM84R MN Cytochrome P450 3A4 (CYP3A4) DMZM84R MT DME DMZM84R MA Metabolism DMZM84R RN News and information in drug research: Ethynodiol diacetate. DMZM84R RU http://genelabs.com/drugsdb/details/ethynodiol-diacetate/ DMZM84R DI DMZM84R DMZM84R DN Ethynodiol diacetate DMZM84R MI TTUV8G9 DMZM84R MN Progesterone receptor (PGR) DMZM84R MT DTT DMZM84R MA Binder DMZM84R RN Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84. DMZM84R RU https://pubmed.ncbi.nlm.nih.gov/858280 DMBIYNH DI DMBIYNH DMBIYNH DN ETI-204 DMBIYNH MI TTRLPUB DMBIYNH MN Bacillus anthracis Protective antigen (Anthrax PA) DMBIYNH MT DTT DMBIYNH RN Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14. DMBIYNH RU https://pubmed.ncbi.nlm.nih.gov/25645849 DMAWJIN DI DMAWJIN DMAWJIN DN Etidronate Disodium DMAWJIN MI TT8X5NO DMAWJIN MN Calcium (Ca) DMAWJIN MT DTT DMAWJIN MA Modulator DMAWJIN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAWJIN RU https://www.fda.gov/ DMAWJIN DI DMAWJIN DMAWJIN DN Etidronate Disodium DMAWJIN MI TTUDR0C DMAWJIN MN Iron (Fe) DMAWJIN MT DTT DMAWJIN MA Modulator DMAWJIN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAWJIN RU https://www.fda.gov/ DM1XHYJ DI DM1XHYJ DM1XHYJ DN Etidronic acid DM1XHYJ MI TTCWXFA DM1XHYJ MN Protein-tyrosine phosphatase sigma (R-PTP-sigma) DM1XHYJ MT DTT DM1XHYJ MA Inhibitor DM1XHYJ RN Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43. DM1XHYJ RU https://pubmed.ncbi.nlm.nih.gov/8992885 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 MI DE5IED8 DM6WJO9 MN Cytochrome P450 2C9 (CYP2C9) DM6WJO9 MT DME DM6WJO9 MA Metabolism DM6WJO9 RN Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61. DM6WJO9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15370961 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 MI TTVKILB DM6WJO9 MN Prostaglandin G/H synthase 2 (COX-2) DM6WJO9 MT DTT DM6WJO9 MA Inhibitor DM6WJO9 RN Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8. DM6WJO9 RU https://pubmed.ncbi.nlm.nih.gov/17603251 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 MI DEYGVN4 DM6WJO9 MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM6WJO9 MT DME DM6WJO9 MA Metabolism DM6WJO9 RN Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61. DM6WJO9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15370961 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 MI DEL5N6Y DM6WJO9 MN UDP-glucuronosyltransferase 1A10 (UGT1A10) DM6WJO9 MT DME DM6WJO9 MA Metabolism DM6WJO9 RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM6WJO9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 MI DEF2WXN DM6WJO9 MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DM6WJO9 MT DME DM6WJO9 MA Metabolism DM6WJO9 RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM6WJO9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 MI DE85D2P DM6WJO9 MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DM6WJO9 MT DME DM6WJO9 MA Metabolism DM6WJO9 RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM6WJO9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 MI DEB3CV1 DM6WJO9 MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DM6WJO9 MT DME DM6WJO9 MA Metabolism DM6WJO9 RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DM6WJO9 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMZI3WO DI DMZI3WO DMZI3WO DN Etomidate DMZI3WO MI TTEX6LM DMZI3WO MN GABA(A) receptor gamma-3 (GABRG3) DMZI3WO MT DTT DMZI3WO MA Modulator DMZI3WO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZI3WO RU https://www.fda.gov/ DMKA8J4 DI DMKA8J4 DMKA8J4 DN Etonogestrel DMKA8J4 MI DE4LYSA DMKA8J4 MN Cytochrome P450 3A4 (CYP3A4) DMKA8J4 MT DME DMKA8J4 MA Metabolism DMKA8J4 RN The role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrel. Br J Clin Pharmacol. 2005 Jul;60(1):69-75. DMKA8J4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15963096 DMKA8J4 DI DMKA8J4 DMKA8J4 DN Etonogestrel DMKA8J4 MI TTUV8G9 DMKA8J4 MN Progesterone receptor (PGR) DMKA8J4 MT DTT DMKA8J4 MA Binder DMKA8J4 RN Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7. DMKA8J4 RU https://pubmed.ncbi.nlm.nih.gov/19434887 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DTI7UX6 DMNH3PG MN Breast cancer resistance protein (ABCG2) DMNH3PG MT DTP DMNH3PG MA Substrate DMNH3PG RN Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38. DMNH3PG RU http://www.ncbi.nlm.nih.gov/pubmed/25128152 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DEJGDUW DMNH3PG MN Cytochrome P450 1A2 (CYP1A2) DMNH3PG MT DME DMNH3PG MA Metabolism DMNH3PG RN Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17315145 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DEVDYN7 DMNH3PG MN Cytochrome P450 2E1 (CYP2E1) DMNH3PG MT DME DMNH3PG MA Metabolism DMNH3PG RN A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9732391 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DE4LYSA DMNH3PG MN Cytochrome P450 3A4 (CYP3A4) DMNH3PG MT DME DMNH3PG MA Metabolism DMNH3PG RN Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17315145 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DEIBDNY DMNH3PG MN Cytochrome P450 3A5 (CYP3A5) DMNH3PG MT DME DMNH3PG MA Metabolism DMNH3PG RN Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15319341 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI TT0IHXV DMNH3PG MN DNA topoisomerase II (TOP2) DMNH3PG MT DTT DMNH3PG MA Modulator DMNH3PG RN Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/16101488 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DEK6079 DMNH3PG MN Glutathione S-transferase pi (GSTP1) DMNH3PG MT DME DMNH3PG MA Metabolism DMNH3PG RN Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=1315544 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DE3PKUG DMNH3PG MN Glutathione S-transferase theta-1 (GSTT1) DMNH3PG MT DME DMNH3PG MA Metabolism DMNH3PG RN Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=1315544 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DTSYQGK DMNH3PG MN Multidrug resistance-associated protein 1 (ABCC1) DMNH3PG MT DTP DMNH3PG MA Substrate DMNH3PG RN Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205. DMNH3PG RU http://www.ncbi.nlm.nih.gov/pubmed/11504821 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DTFI42L DMNH3PG MN Multidrug resistance-associated protein 2 (ABCC2) DMNH3PG MT DTP DMNH3PG MA Substrate DMNH3PG RN Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63. DMNH3PG RU http://www.ncbi.nlm.nih.gov/pubmed/11901101 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DTQ3ZHF DMNH3PG MN Multidrug resistance-associated protein 3 (ABCC3) DMNH3PG MT DTP DMNH3PG MA Substrate DMNH3PG RN Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30. DMNH3PG RU http://www.ncbi.nlm.nih.gov/pubmed/19334674 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DT3D8F0 DMNH3PG MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMNH3PG MT DTP DMNH3PG MA Substrate DMNH3PG RN Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847. DMNH3PG RU https://doi.org/10.1111/j.1476-5381.2011.01672.x DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DT9C1TS DMNH3PG MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMNH3PG MT DTP DMNH3PG MA Substrate DMNH3PG RN Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65. DMNH3PG RU http://www.ncbi.nlm.nih.gov/pubmed/18321482 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DTPFTEQ DMNH3PG MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DMNH3PG MT DTP DMNH3PG MA Substrate DMNH3PG RN Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847. DMNH3PG RU https://doi.org/10.1111/j.1476-5381.2011.01672.x DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DTUGYRD DMNH3PG MN P-glycoprotein 1 (ABCB1) DMNH3PG MT DTP DMNH3PG MA Substrate DMNH3PG RN Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9. DMNH3PG RU http://www.ncbi.nlm.nih.gov/pubmed/12948018 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DE073H6 DMNH3PG MN Prostaglandin G/H synthase 1 (COX-1) DMNH3PG MT DME DMNH3PG MA Metabolism DMNH3PG RN Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=3006680 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DE492CE DMNH3PG MN Prostaglandin G/H synthase 2 (COX-2) DMNH3PG MT DME DMNH3PG MA Metabolism DMNH3PG RN Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=3006680 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG MI DEYGVN4 DMNH3PG MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMNH3PG MT DME DMNH3PG MA Metabolism DMNH3PG RN UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17151191 DM6A4NW DI DM6A4NW DM6A4NW DN Etoricoxib DM6A4NW MI DEJGDUW DM6A4NW MN Cytochrome P450 1A2 (CYP1A2) DM6A4NW MT DME DM6A4NW MA Metabolism DM6A4NW RN Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20. DM6A4NW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749 DM6A4NW DI DM6A4NW DM6A4NW DN Etoricoxib DM6A4NW MI DE5IED8 DM6A4NW MN Cytochrome P450 2C9 (CYP2C9) DM6A4NW MT DME DM6A4NW MA Metabolism DM6A4NW RN Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20. DM6A4NW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749 DM6A4NW DI DM6A4NW DM6A4NW DN Etoricoxib DM6A4NW MI DE4LYSA DM6A4NW MN Cytochrome P450 3A4 (CYP3A4) DM6A4NW MT DME DM6A4NW MA Metabolism DM6A4NW RN Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos. 2001 Jun;29(6):813-20. DM6A4NW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11353749 DM6A4NW DI DM6A4NW DM6A4NW DN Etoricoxib DM6A4NW MI TTVKILB DM6A4NW MN Prostaglandin G/H synthase 2 (COX-2) DM6A4NW MT DTT DM6A4NW MA Inhibitor DM6A4NW RN The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res. 2009 May 26;4:17. DM6A4NW RU https://pubmed.ncbi.nlm.nih.gov/19470170 DMGV8QU DI DMGV8QU DMGV8QU DN Etravirine DMGV8QU MI DE5IED8 DMGV8QU MN Cytochrome P450 2C9 (CYP2C9) DMGV8QU MT DME DMGV8QU MA Metabolism DMGV8QU RN Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39. DMGV8QU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21142266 DMGV8QU DI DMGV8QU DMGV8QU DN Etravirine DMGV8QU MI DE4LYSA DMGV8QU MN Cytochrome P450 3A4 (CYP3A4) DMGV8QU MT DME DMGV8QU MA Metabolism DMGV8QU RN Pharmacokinetic interactions between etravirine and non-antiretroviral drugs. Clin Pharmacokinet. 2011 Jan;50(1):25-39. DMGV8QU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21142266 DMGV8QU DI DMGV8QU DMGV8QU DN Etravirine DMGV8QU MI TT84ETX DMGV8QU MN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMGV8QU MT DTT DMGV8QU MA Modulator DMGV8QU RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMGV8QU RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMGV8QU DI DMGV8QU DMGV8QU DN Etravirine DMGV8QU MI DEGTFWK DMGV8QU MN Mephenytoin 4-hydroxylase (CYP2C19) DMGV8QU MT DME DMGV8QU MA Metabolism DMGV8QU RN Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab Dispos. 2012 Apr;40(4):803-14. DMGV8QU RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22269145 DMGV8QU DI DMGV8QU DMGV8QU DN Etravirine DMGV8QU MI DTQ3ZHF DMGV8QU MN Multidrug resistance-associated protein 3 (ABCC3) DMGV8QU MT DTP DMGV8QU MA Substrate DMGV8QU RN Interaction potential of etravirine with drug transporters assessed in vitro. Antimicrob Agents Chemother. 2011 Mar;55(3):1282-4. DMGV8QU RU http://www.ncbi.nlm.nih.gov/pubmed/21189339 DM2CZFA DI DM2CZFA DM2CZFA DN Etretinate DM2CZFA MI DEZT8FM DM2CZFA MN Retinoic acid 4-hydroxylase 26B1 (CYP26B1) DM2CZFA MT DME DM2CZFA MA Metabolism DM2CZFA RN Lipopolysaccharide opposes the induction of CYP26A1 and CYP26B1 gene expression by retinoic acid in the rat liver in vivo. Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1029-36. DM2CZFA RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17185629 DM5GT1M DI DM5GT1M DM5GT1M DN EVANS BLUE DM5GT1M MI TTFNGC9 DM5GT1M MN Serum albumin (ALB) DM5GT1M MT DTT DM5GT1M MA Modulator DM5GT1M RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM5GT1M RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM8X2EH DI DM8X2EH DM8X2EH DN Everolimus DM8X2EH MI DE4LYSA DM8X2EH MN Cytochrome P450 3A4 (CYP3A4) DM8X2EH MT DME DM8X2EH MA Metabolism DM8X2EH RN The evolving experience using everolimus in clinical transplantation. Transplant Proc. 2004 Mar;36(2 Suppl):495S-499S. DM8X2EH RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15041395 DM8X2EH DI DM8X2EH DM8X2EH DN Everolimus DM8X2EH MI DTUGYRD DM8X2EH MN P-glycoprotein 1 (ABCB1) DM8X2EH MT DTP DM8X2EH MA Substrate DM8X2EH RN Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations. Ther Drug Monit. 2015 Oct;37(5):675-80. DM8X2EH RU http://www.ncbi.nlm.nih.gov/pubmed/25565673 DM8X2EH DI DM8X2EH DM8X2EH DN Everolimus DM8X2EH MI TTCJG29 DM8X2EH MN Serine/threonine-protein kinase mTOR (mTOR) DM8X2EH MT DTT DM8X2EH MA Inhibitor DM8X2EH RN Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. DM8X2EH RU https://pubmed.ncbi.nlm.nih.gov/19620795 DMBLX7U DI DMBLX7U DMBLX7U DN Evinacumab DMBLX7U MI TTUO98L DMBLX7U MN Angiopoietin-related protein 3 (ANGPTL3) DMBLX7U MT DTT DMBLX7U MA Inhibitor DMBLX7U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMBLX7U RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf DM9HPW3 DI DM9HPW3 DM9HPW3 DN Exemestane DM9HPW3 MI TTSZLWK DM9HPW3 MN Aromatase (CYP19A1) DM9HPW3 MT DTT DM9HPW3 MA Inhibitor DM9HPW3 RN Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51. DM9HPW3 RU https://pubmed.ncbi.nlm.nih.gov/14505258 DM9HPW3 DI DM9HPW3 DM9HPW3 DN Exemestane DM9HPW3 MI DE4LYSA DM9HPW3 MN Cytochrome P450 3A4 (CYP3A4) DM9HPW3 MT DME DM9HPW3 MA Metabolism DM9HPW3 RN In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17beta-dihydroexemestane. Pharmacol Res Perspect. 2017 Apr 27;5(3):e00314. DM9HPW3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=28603633 DMYHBKN DI DMYHBKN DMYHBKN DN Exenatide DMYHBKN MI DEKZQY6 DMYHBKN MN Dipeptidyl peptidase IV (DPP4) DMYHBKN MT DME DMYHBKN MA Metabolism DMYHBKN RN In vitro metabolic stability of exendin-4: pharmacokinetics and identification of cleavage products. PLoS One. 2015 Feb 27;10(2):e0116805. DMYHBKN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25723538 DMYHBKN DI DMYHBKN DMYHBKN DN Exenatide DMYHBKN MI TTVIMDE DMYHBKN MN Glucagon-like peptide 1 receptor (GLP1R) DMYHBKN MT DTT DMYHBKN MA Binder DMYHBKN RN Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9. DMYHBKN RU https://pubmed.ncbi.nlm.nih.gov/19459763 DMHPRWG DI DMHPRWG DMHPRWG DN Exjade DMHPRWG MI TTUDR0C DMHPRWG MN Iron (Fe) DMHPRWG MT DTT DMHPRWG MA Modulator DMHPRWG RN Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30. DMHPRWG RU https://pubmed.ncbi.nlm.nih.gov/17927285 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DTJ0EW4 DM7A8TW MN Bile salt export pump (ABCB11) DM7A8TW MT DTP DM7A8TW MA Substrate DM7A8TW RN Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. DM7A8TW RU http://www.ncbi.nlm.nih.gov/pubmed/24014644 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DTI7UX6 DM7A8TW MN Breast cancer resistance protein (ABCG2) DM7A8TW MT DTP DM7A8TW MA Substrate DM7A8TW RN Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702. DM7A8TW RU http://www.ncbi.nlm.nih.gov/pubmed/19443695 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DE4LYSA DM7A8TW MN Cytochrome P450 3A4 (CYP3A4) DM7A8TW MT DME DM7A8TW MA Metabolism DM7A8TW RN Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94. DM7A8TW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DTFI42L DM7A8TW MN Multidrug resistance-associated protein 2 (ABCC2) DM7A8TW MT DTP DM7A8TW MA Substrate DM7A8TW RN Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther. 2006 Mar;79(3):206-17. DM7A8TW RU http://www.ncbi.nlm.nih.gov/pubmed/16513445 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DTQ3ZHF DM7A8TW MN Multidrug resistance-associated protein 3 (ABCC3) DM7A8TW MT DTP DM7A8TW MA Substrate DM7A8TW RN Complex pharmacokinetic behavior of ezetimibe depends on abcc2, abcc3, and abcg2. Drug Metab Dispos. 2009 Aug;37(8):1698-702. DM7A8TW RU http://www.ncbi.nlm.nih.gov/pubmed/19443695 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI TTPD1CN DM7A8TW MN Niemann-Pick C1-like protein 1 (NPC1L1) DM7A8TW MT DTT DM7A8TW MA Inhibitor DM7A8TW RN Update on patented cholesterol absorption inhibitors. Expert Opin Ther Pat. 2009 Aug;19(8):1083-107. DM7A8TW RU https://pubmed.ncbi.nlm.nih.gov/19552506 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DT3D8F0 DM7A8TW MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DM7A8TW MT DTP DM7A8TW MA Substrate DM7A8TW RN A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 2;830(1):143-50. DM7A8TW RU http://www.ncbi.nlm.nih.gov/pubmed/16280261 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DTUGYRD DM7A8TW MN P-glycoprotein 1 (ABCB1) DM7A8TW MT DTP DM7A8TW MA Substrate DM7A8TW RN Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2010 Jun;87(6):663-7. DM7A8TW RU http://www.ncbi.nlm.nih.gov/pubmed/20220747 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DEYGVN4 DM7A8TW MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DM7A8TW MT DME DM7A8TW MA Metabolism DM7A8TW RN Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94. DM7A8TW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DEF2WXN DM7A8TW MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DM7A8TW MT DME DM7A8TW MA Metabolism DM7A8TW RN Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8. DM7A8TW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21368751 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DENZ6B1 DM7A8TW MN UDP-glucuronosyltransferase 2B15 (UGT2B15) DM7A8TW MT DME DM7A8TW MA Metabolism DM7A8TW RN Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94. DM7A8TW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634 DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW MI DEB3CV1 DM7A8TW MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DM7A8TW MT DME DM7A8TW MA Metabolism DM7A8TW RN Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94. DM7A8TW RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15871634 DMAB6PM DI DMAB6PM DMAB6PM DN Factor 8 DMAB6PM MI TT1290U DMAB6PM MN Coagulation factor VIII (F8) DMAB6PM MT DTT DMAB6PM MA Modulator DMAB6PM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMAB6PM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMZUW6P DI DMZUW6P DMZUW6P DN Factor viia DMZUW6P MI TTF0EGX DMZUW6P MN Coagulation factor VII (F7) DMZUW6P MT DTT DMZUW6P MA Modulator DMZUW6P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMZUW6P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DM3C5GZ DI DM3C5GZ DM3C5GZ DN FADROZOLE DM3C5GZ MI TTSZLWK DM3C5GZ MN Aromatase (CYP19A1) DM3C5GZ MT DTT DM3C5GZ MA Inhibitor DM3C5GZ RN Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9. DM3C5GZ RU https://pubmed.ncbi.nlm.nih.gov/16279787 DM3C5GZ DI DM3C5GZ DM3C5GZ DN FADROZOLE DM3C5GZ MI TTIQUX7 DM3C5GZ MN Steroid 11-beta-hydroxylase (CYP11B1) DM3C5GZ MT DTT DM3C5GZ MA Inhibitor DM3C5GZ RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM3C5GZ RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMBI9ZJ DI DMBI9ZJ DMBI9ZJ DN Falecalcitrol DMBI9ZJ MI TTK59TV DMBI9ZJ MN Vitamin D3 receptor (VDR) DMBI9ZJ MT DTT DMBI9ZJ MA Agonist DMBI9ZJ RN Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66. DMBI9ZJ RU https://pubmed.ncbi.nlm.nih.gov/11003160 DMJHLSD DI DMJHLSD DMJHLSD DN Famciclovir DMJHLSD MI DE4LYSA DMJHLSD MN Cytochrome P450 3A4 (CYP3A4) DMJHLSD MT DME DMJHLSD MA Metabolism DMJHLSD RN Evidence that famciclovir (BRL 42810) and its associated metabolites do not inhibit the 6 beta-hydroxylation of testosterone in human liver microsomes. Drug Metab Dispos. 1993 Jan-Feb;21(1):18-23. DMJHLSD RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8095215 DMJHLSD DI DMJHLSD DMJHLSD DN Famciclovir DMJHLSD MI TTIU7X1 DMJHLSD MN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMJHLSD MT DTT DMJHLSD MA Inhibitor DMJHLSD RN Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8. DMJHLSD RU https://pubmed.ncbi.nlm.nih.gov/15452407 DMJHLSD DI DMJHLSD DMJHLSD DN Famciclovir DMJHLSD MI DTUGYRD DMJHLSD MN P-glycoprotein 1 (ABCB1) DMJHLSD MT DTP DMJHLSD MA Substrate DMJHLSD RN Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. DMJHLSD RU http://www.ncbi.nlm.nih.gov/pubmed/12438524 DMRL3AB DI DMRL3AB DMRL3AB DN Famotidine DMRL3AB MI TTQHJ1K DMRL3AB MN Histamine H2 receptor (H2R) DMRL3AB MT DTT DMRL3AB MA Antagonist DMRL3AB RN Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. DMRL3AB RU https://pubmed.ncbi.nlm.nih.gov/11180002 DMRL3AB DI DMRL3AB DMRL3AB DN Famotidine DMRL3AB MI DEGTFWK DMRL3AB MN Mephenytoin 4-hydroxylase (CYP2C19) DMRL3AB MT DME DMRL3AB MA Metabolism DMRL3AB RN Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther. 2006 Nov;80(5):539-48. DMRL3AB RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17112810 DMRL3AB DI DMRL3AB DMRL3AB DN Famotidine DMRL3AB MI DTQ23VB DMRL3AB MN Organic anion transporter 1 (SLC22A6) DMRL3AB MT DTP DMRL3AB MA Substrate DMRL3AB RN Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30. DMRL3AB RU http://www.ncbi.nlm.nih.gov/pubmed/15496291 DMRL3AB DI DMRL3AB DMRL3AB DN Famotidine DMRL3AB MI DTVP67E DMRL3AB MN Organic anion transporter 3 (SLC22A8) DMRL3AB MT DTP DMRL3AB MA Substrate DMRL3AB RN A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45. DMRL3AB RU http://www.ncbi.nlm.nih.gov/pubmed/16006492 DMRL3AB DI DMRL3AB DMRL3AB DN Famotidine DMRL3AB MI DT9IDPW DMRL3AB MN Organic cation transporter 2 (SLC22A2) DMRL3AB MT DTP DMRL3AB MA Substrate DMRL3AB RN A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45. DMRL3AB RU http://www.ncbi.nlm.nih.gov/pubmed/16006492 DMX7A5V DI DMX7A5V DMX7A5V DN Faropenem DMX7A5V MI TT4ILYC DMX7A5V MN Bacterial Dihydropteroate synthetase (Bact folP) DMX7A5V MT DTT DMX7A5V MA Inhibitor DMX7A5V RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMX7A5V RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMDEXQ0 DI DMDEXQ0 DMDEXQ0 DN Febuxostat DMDEXQ0 MI DEYGVN4 DMDEXQ0 MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMDEXQ0 MT DME DMDEXQ0 MA Metabolism DMDEXQ0 RN In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition. Xenobiotica. 2008 May;38(5):496-510. DMDEXQ0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18421623 DMDEXQ0 DI DMDEXQ0 DMDEXQ0 DN Febuxostat DMDEXQ0 MI TT7RJY8 DMDEXQ0 MN Xanthine dehydrogenase/oxidase (XDH) DMDEXQ0 MT DTT DMDEXQ0 MA Inhibitor DMDEXQ0 RN Clinical pipeline report, company report or official report of Takeda (2009). DMDEXQ0 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM4ZBK6 DI DM4ZBK6 DM4ZBK6 DN Fedratinib DM4ZBK6 MI TTRMX3V DM4ZBK6 MN Janus kinase 2 (JAK-2) DM4ZBK6 MT DTT DM4ZBK6 MA Inhibitor DM4ZBK6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM4ZBK6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf DML2DCR DI DML2DCR DML2DCR DN Fedratinib hydrochloride DML2DCR MI DE4LYSA DML2DCR MN Cytochrome P450 3A4 (CYP3A4) DML2DCR MT DME DML2DCR MA Metabolism DML2DCR RN FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration. DML2DCR RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf DML2DCR DI DML2DCR DML2DCR DN Fedratinib hydrochloride DML2DCR MI DEP76YL DML2DCR MN Dimethylaniline oxidase 3 (FMO3) DML2DCR MT DME DML2DCR MA Metabolism DML2DCR RN FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration. DML2DCR RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf DML2DCR DI DML2DCR DML2DCR DN Fedratinib hydrochloride DML2DCR MI DEGTFWK DML2DCR MN Mephenytoin 4-hydroxylase (CYP2C19) DML2DCR MT DME DML2DCR MA Metabolism DML2DCR RN FDA label of Fedratinib. The 2020 official website of the U.S. Food and Drug Administration. DML2DCR RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf DM1V5ZS DI DM1V5ZS DM1V5ZS DN Felbamate DM1V5ZS MI DEVDYN7 DM1V5ZS MN Cytochrome P450 2E1 (CYP2E1) DM1V5ZS MT DME DM1V5ZS MA Metabolism DM1V5ZS RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DM1V5ZS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DM1V5ZS DI DM1V5ZS DM1V5ZS DN Felbamate DM1V5ZS MI DE4LYSA DM1V5ZS MN Cytochrome P450 3A4 (CYP3A4) DM1V5ZS MT DME DM1V5ZS MA Metabolism DM1V5ZS RN A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63. DM1V5ZS RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9606477 DM1V5ZS DI DM1V5ZS DM1V5ZS DN Felbamate DM1V5ZS MI TT9IK2Z DM1V5ZS MN N-methyl-D-aspartate receptor (NMDAR) DM1V5ZS MT DTT DM1V5ZS MA Antagonist DM1V5ZS RN Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. DM1V5ZS RU https://pubmed.ncbi.nlm.nih.gov/18311896 DMKZEIB DI DMKZEIB DMKZEIB DN Felbinac DMKZEIB MI TTK0943 DMKZEIB MN Prostaglandin G/H synthase (COX) DMKZEIB MT DTT DMKZEIB MA Modulator DMKZEIB RN A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneimittelforschung. 1980;30(4A):702-7. DMKZEIB RU https://pubmed.ncbi.nlm.nih.gov/6254545 DMOSW35 DI DMOSW35 DMOSW35 DN Felodipine DMOSW35 MI TT5HONZ DMOSW35 MN Calcium channel unspecific (CaC) DMOSW35 MT DTT DMOSW35 MA Blocker DMOSW35 RN Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. DMOSW35 RU https://pubmed.ncbi.nlm.nih.gov/18974361 DMOSW35 DI DMOSW35 DMOSW35 DN Felodipine DMOSW35 MI DE4LYSA DMOSW35 MN Cytochrome P450 3A4 (CYP3A4) DMOSW35 MT DME DMOSW35 MA Metabolism DMOSW35 RN Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30. DMOSW35 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10640508 DMOSW35 DI DMOSW35 DMOSW35 DN Felodipine DMOSW35 MI DEIBDNY DMOSW35 MN Cytochrome P450 3A5 (CYP3A5) DMOSW35 MT DME DMOSW35 MA Metabolism DMOSW35 RN Drug Interactions Flockhart Table DMOSW35 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMOSW35 DI DMOSW35 DMOSW35 DN Felodipine DMOSW35 MI DERD86B DMOSW35 MN Cytochrome P450 3A7 (CYP3A7) DMOSW35 MT DME DMOSW35 MA Metabolism DMOSW35 RN Drug Interactions Flockhart Table DMOSW35 RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMOSW35 DI DMOSW35 DMOSW35 DN Felodipine DMOSW35 MI DTUGYRD DMOSW35 MN P-glycoprotein 1 (ABCB1) DMOSW35 MT DTP DMOSW35 MA Substrate DMOSW35 RN The influence of CYP3A5*3 and BCRPC421A genetic polymorphisms on the pharmacokinetics of felodipine in healthy Chinese volunteers. J Clin Pharm Ther. 2017 Jun;42(3):345-349. DMOSW35 RU http://www.ncbi.nlm.nih.gov/pubmed/28244604 DMHLP9C DI DMHLP9C DMHLP9C DN Felypressin DMHLP9C MI TT4TFGN DMHLP9C MN Vasopressin V1a receptor (V1AR) DMHLP9C MT DTT DMHLP9C MA Agonist DMHLP9C RN Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. DMHLP9C RU https://pubmed.ncbi.nlm.nih.gov/18655903 DMXGDFK DI DMXGDFK DMXGDFK DN Fenbufen DMXGDFK MI TT8NGED DMXGDFK MN Prostaglandin G/H synthase 1 (COX-1) DMXGDFK MT DTT DMXGDFK MA Inhibitor DMXGDFK RN Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804. DMXGDFK RU https://pubmed.ncbi.nlm.nih.gov/19457595 DMXGDFK DI DMXGDFK DMXGDFK DN Fenbufen DMXGDFK MI TTVKILB DMXGDFK MN Prostaglandin G/H synthase 2 (COX-2) DMXGDFK MT DTT DMXGDFK MA Inhibitor DMXGDFK RN Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804. DMXGDFK RU https://pubmed.ncbi.nlm.nih.gov/19457595 DM0LRU9 DI DM0LRU9 DM0LRU9 DN Fendrix DM0LRU9 MI TT3J5ZI DM0LRU9 MN Cell mediated immunity response (CMIR) DM0LRU9 MT DTT DM0LRU9 RN Revaccination with Fendrix or HBVaxPro results in better response rates than does revaccination with three doses of Engerix-B in previous non-responders. Vaccine. 2012 Nov 6;30(48):6734-7. DM0LRU9 RU https://pubmed.ncbi.nlm.nih.gov/22981848 DMFKXDY DI DMFKXDY DMFKXDY DN Fenofibrate DMFKXDY MI DE4LYSA DMFKXDY MN Cytochrome P450 3A4 (CYP3A4) DMFKXDY MT DME DMFKXDY MA Metabolism DMFKXDY RN Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62. DMFKXDY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=9515185 DMFKXDY DI DMFKXDY DMFKXDY DN Fenofibrate DMFKXDY MI TTJ584C DMFKXDY MN Peroxisome proliferator-activated receptor alpha (PPARA) DMFKXDY MT DTT DMFKXDY MA Agonist DMFKXDY RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMFKXDY RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMFKXDY DI DMFKXDY DMFKXDY DN Fenofibrate DMFKXDY MI DE85D2P DMFKXDY MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMFKXDY MT DME DMFKXDY MA Metabolism DMFKXDY RN Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8. DMFKXDY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=15304429 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC MI DE7WS3H DMGO2MC MN Aldo-keto reductase 1B1 (AKR1B1) DMGO2MC MT DME DMGO2MC MA Metabolism DMGO2MC RN In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. DMGO2MC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC MI DE7P2FB DMGO2MC MN Aldo-keto reductase 1C1 (AKR1C1) DMGO2MC MT DME DMGO2MC MA Metabolism DMGO2MC RN In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. DMGO2MC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC MI DEOY5ZM DMGO2MC MN Aldo-keto reductase 1C2 (AKR1C2) DMGO2MC MT DME DMGO2MC MA Metabolism DMGO2MC RN In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. DMGO2MC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC MI DEGQTXO DMGO2MC MN Aldo-keto reductase 1C3 (AKR1C3) DMGO2MC MT DME DMGO2MC MA Metabolism DMGO2MC RN In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. DMGO2MC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC MI DT61TWI DMGO2MC MN ATP-binding cassette sub-family A member 1 (ABCA1) DMGO2MC MT DTP DMGO2MC MA Substrate DMGO2MC RN Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1193-7. DMGO2MC RU http://www.ncbi.nlm.nih.gov/pubmed/15790930 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC MI TTIV96N DMGO2MC MN Fatty acid-binding protein 1 (FABP1) DMGO2MC MT DTT DMGO2MC MA Inhibitor DMGO2MC RN Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64. DMGO2MC RU https://pubmed.ncbi.nlm.nih.gov/18533710 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC MI DE9JFMC DMGO2MC MN NADPH-dependent carbonyl reductase 1 (CBR1) DMGO2MC MT DME DMGO2MC MA Metabolism DMGO2MC RN In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8. DMGO2MC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27599626 DMFAOKP DI DMFAOKP DMFAOKP DN Fenoldopam DMFAOKP MI TTZFYLI DMFAOKP MN Dopamine D1 receptor (D1R) DMFAOKP MT DTT DMFAOKP MA Agonist DMFAOKP RN Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9. DMFAOKP RU https://pubmed.ncbi.nlm.nih.gov/18591870 DML5VQ0 DI DML5VQ0 DML5VQ0 DN Fenoprofen DML5VQ0 MI TTK0943 DML5VQ0 MN Prostaglandin G/H synthase (COX) DML5VQ0 MT DTT DML5VQ0 MA Inhibitor DML5VQ0 RN The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62. DML5VQ0 RU https://pubmed.ncbi.nlm.nih.gov/17409433 DMIP3ZV DI DMIP3ZV DMIP3ZV DN Fenoterol DMIP3ZV MI TT2CJVK DMIP3ZV MN Adrenergic receptor beta-2 (ADRB2) DMIP3ZV MT DTT DMIP3ZV MA Agonist DMIP3ZV RN Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75. DMIP3ZV RU https://pubmed.ncbi.nlm.nih.gov/19334040 DMIP3ZV DI DMIP3ZV DMIP3ZV DN Fenoterol DMIP3ZV MI DTT79CX DMIP3ZV MN Organic cation transporter 1 (SLC22A1) DMIP3ZV MT DTP DMIP3ZV MA Substrate DMIP3ZV RN Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42. DMIP3ZV RU http://www.ncbi.nlm.nih.gov/pubmed/23984907 DM8WAHT DI DM8WAHT DM8WAHT DN Fentanyl DM8WAHT MI DE4LYSA DM8WAHT MN Cytochrome P450 3A4 (CYP3A4) DM8WAHT MT DME DM8WAHT MA Metabolism DM8WAHT RN Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33. DM8WAHT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10490933 DM8WAHT DI DM8WAHT DM8WAHT DN Fentanyl DM8WAHT MI DEIBDNY DM8WAHT MN Cytochrome P450 3A5 (CYP3A5) DM8WAHT MT DME DM8WAHT MA Metabolism DM8WAHT RN Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8. DM8WAHT RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16419387 DM8WAHT DI DM8WAHT DM8WAHT DN Fentanyl DM8WAHT MI DERD86B DM8WAHT MN Cytochrome P450 3A7 (CYP3A7) DM8WAHT MT DME DM8WAHT MA Metabolism DM8WAHT RN Drug Interactions Flockhart Table DM8WAHT RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DM8WAHT DI DM8WAHT DM8WAHT DN Fentanyl DM8WAHT MI TTKWM86 DM8WAHT MN Opioid receptor mu (MOP) DM8WAHT MT DTT DM8WAHT MA Modulator DM8WAHT RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM8WAHT RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM8WAHT DI DM8WAHT DM8WAHT DN Fentanyl DM8WAHT MI DTUGYRD DM8WAHT MN P-glycoprotein 1 (ABCB1) DM8WAHT MT DTP DM8WAHT MA Substrate DM8WAHT RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DM8WAHT RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DM13495 DI DM13495 DM13495 DN Fesoterodine fumarate DM13495 MI DECB0K3 DM13495 MN Cytochrome P450 2D6 (CYP2D6) DM13495 MT DME DM13495 MA Metabolism DM13495 RN Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. DM13495 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21545485 DM13495 DI DM13495 DM13495 DN Fesoterodine fumarate DM13495 MI DE4LYSA DM13495 MN Cytochrome P450 3A4 (CYP3A4) DM13495 MT DME DM13495 MA Metabolism DM13495 RN Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. DM13495 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21545485 DM13495 DI DM13495 DM13495 DN Fesoterodine fumarate DM13495 MI TTZ9SOR DM13495 MN Muscarinic acetylcholine receptor M1 (CHRM1) DM13495 MT DTT DM13495 MA Modulator DM13495 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM13495 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM13495 DI DM13495 DM13495 DN Fesoterodine fumarate DM13495 MI DTUGYRD DM13495 MN P-glycoprotein 1 (ABCB1) DM13495 MT DTP DM13495 MA Substrate DM13495 RN Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladder. Drugs Aging. 2012 Apr 1;29(4):259-73. DM13495 RU http://www.ncbi.nlm.nih.gov/pubmed/22390261 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX MI TTTIBOJ DM17ONX MN Histamine H1 receptor (H1R) DM17ONX MT DTT DM17ONX MA Antagonist DM17ONX RN Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8. DM17ONX RU https://pubmed.ncbi.nlm.nih.gov/19210904 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX MI DTQ3ZHF DM17ONX MN Multidrug resistance-associated protein 3 (ABCC3) DM17ONX MT DTP DM17ONX MA Substrate DM17ONX RN Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol. 2008 May;73(5):1474-83. DM17ONX RU http://www.ncbi.nlm.nih.gov/pubmed/18245269 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX MI DTE2B1D DM17ONX MN Organic anion transporting polypeptide 1A2 (SLCO1A2) DM17ONX MT DTP DM17ONX MA Substrate DM17ONX RN Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53. DM17ONX RU http://www.ncbi.nlm.nih.gov/pubmed/20797388 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX MI DT9C1TS DM17ONX MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DM17ONX MT DTP DM17ONX MA Substrate DM17ONX RN Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos. 2005 Oct;33(10):1477-81. DM17ONX RU http://www.ncbi.nlm.nih.gov/pubmed/16014768 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX MI DTPFTEQ DM17ONX MN Organic anion transporting polypeptide 2B1 (SLCO2B1) DM17ONX MT DTP DM17ONX MA Substrate DM17ONX RN The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011 Feb;21(2):84-93. DM17ONX RU http://www.ncbi.nlm.nih.gov/pubmed/21280267 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX MI DTT79CX DM17ONX MN Organic cation transporter 1 (SLC22A1) DM17ONX MT DTP DM17ONX MA Substrate DM17ONX RN Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007 Mar;81(3):362-70. DM17ONX RU https://doi.org/10.1038/sj.clpt.6100056 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX MI DTUGYRD DM17ONX MN P-glycoprotein 1 (ABCB1) DM17ONX MT DTP DM17ONX MA Substrate DM17ONX RN Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 Aug;78(2):191-201. DM17ONX RU http://www.ncbi.nlm.nih.gov/pubmed/16084853 DM9Q8SO DI DM9Q8SO DM9Q8SO DN Fibrinolysin DM9Q8SO MI TTWODQF DM9Q8SO MN Fibrin (FG) DM9Q8SO MT DTT DM9Q8SO MA Modulator DM9Q8SO RN FIBRINOLYSIN, FIBRIN AND HYALINE MEMBRANES. Pediatrics. 1963 Nov;32:940-2. DM9Q8SO RU https://pubmed.ncbi.nlm.nih.gov/14075642 DMFP6MV DI DMFP6MV DMFP6MV DN Fidaxomicin DMFP6MV MI TTIJ5EB DMFP6MV MN Bacterial RNA polymerase switch region (Bact RNAP-SR) DMFP6MV MT DTT DMFP6MV MA Modulator DMFP6MV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMFP6MV RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMZEONG DI DMZEONG DMZEONG DN Finafloxacin DMZEONG MI TTN6J5F DMZEONG MN Bacterial DNA gyrase (Bact gyrase) DMZEONG MT DTT DMZEONG MA Modulator DMZEONG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMZEONG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMZEONG DI DMZEONG DMZEONG DN Finafloxacin DMZEONG MI TTIXTO3 DMZEONG MN Staphylococcus Topoisomerase IV (Stap-coc parC) DMZEONG MT DTT DMZEONG MA Modulator DMZEONG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMZEONG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ MI DE4LYSA DMWV3TZ MN Cytochrome P450 3A4 (CYP3A4) DMWV3TZ MT DME DMWV3TZ MA Metabolism DMWV3TZ RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMWV3TZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ MI DEIBDNY DMWV3TZ MN Cytochrome P450 3A5 (CYP3A5) DMWV3TZ MT DME DMWV3TZ MA Metabolism DMWV3TZ RN Drug Interactions Flockhart Table DMWV3TZ RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ MI DERD86B DMWV3TZ MN Cytochrome P450 3A7 (CYP3A7) DMWV3TZ MT DME DMWV3TZ MA Metabolism DMWV3TZ RN Drug Interactions Flockhart Table DMWV3TZ RU https://drug-interactions.medicine.iu.edu/Main-Table.aspx DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ MI TT2A0DR DMWV3TZ MN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMWV3TZ MT DTT DMWV3TZ MA Inhibitor DMWV3TZ RN The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. DMWV3TZ RU https://pubmed.ncbi.nlm.nih.gov/19543428 DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ MI TTT02K8 DMWV3TZ MN Steroid 5-alpha-reductase 2 (SRD5A2) DMWV3TZ MT DTT DMWV3TZ MA Inhibitor DMWV3TZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWV3TZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5JVAN DI DM5JVAN DM5JVAN DN Fingolimod DM5JVAN MI DED26GV DM5JVAN MN Cytochrome P450 4F12 (CYP4F12) DM5JVAN MT DME DM5JVAN MA Metabolism DM5JVAN RN CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8. DM5JVAN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21045201 DM5JVAN DI DM5JVAN DM5JVAN DN Fingolimod DM5JVAN MI DE3GT9C DM5JVAN MN Cytochrome P450 4F2 (CYP4F2) DM5JVAN MT DME DM5JVAN MA Metabolism DM5JVAN RN CYP4F enzymes are responsible for the elimination of fingolimod (FTY720), a novel treatment of relapsing multiple sclerosis. Drug Metab Dispos. 2011 Feb;39(2):191-8. DM5JVAN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21045201 DM5JVAN DI DM5JVAN DM5JVAN DN Fingolimod DM5JVAN MI TT9JZCK DM5JVAN MN Sphingosine-1-phosphate receptor 1 (S1PR1) DM5JVAN MT DTT DM5JVAN MA Modulator DM5JVAN RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM5JVAN RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMKV4NL DI DMKV4NL DMKV4NL DN Flavoxate DMKV4NL MI TTH18TF DMKV4NL MN Muscarinic acetylcholine receptor M5 (CHRM5) DMKV4NL MT DTT DMKV4NL MA Antagonist DMKV4NL RN Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996 Jul 15;727(1-2):91-8. DMKV4NL RU https://pubmed.ncbi.nlm.nih.gov/8842386 DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE MI DEJGDUW DMSQDLE MN Cytochrome P450 1A2 (CYP1A2) DMSQDLE MT DME DMSQDLE MA Metabolism DMSQDLE RN Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85. DMSQDLE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25717355 DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE MI DECB0K3 DMSQDLE MN Cytochrome P450 2D6 (CYP2D6) DMSQDLE MT DME DMSQDLE MA Metabolism DMSQDLE RN Flecainide: current status and perspectives in arrhythmia management. World J Cardiol. 2015 Feb 26;7(2):76-85. DMSQDLE RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25717355 DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE MI TT05DLS DMSQDLE MN E3 ubiquitin-protein ligase COP1 (RFWD2) DMSQDLE MT DTT DMSQDLE MA Modulator DMSQDLE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSQDLE RU https://www.fda.gov/ DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE MI TTN9VTF DMSQDLE MN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMSQDLE MT DTT DMSQDLE MA Blocker DMSQDLE RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMSQDLE RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMXGQYZ DI DMXGQYZ DMXGQYZ DN Fleroxacin DMXGQYZ MI TT0IHXV DMXGQYZ MN DNA topoisomerase II (TOP2) DMXGQYZ MT DTT DMXGQYZ MA Inhibitor DMXGQYZ RN Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9. DMXGQYZ RU https://pubmed.ncbi.nlm.nih.gov/8861529 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN MI TTSQIFT DM70DTN MN 5-HT 1A receptor (HTR1A) DM70DTN MT DTT DM70DTN MA Modulator DM70DTN RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM70DTN RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN MI TTJQOD7 DM70DTN MN 5-HT 2A receptor (HTR2A) DM70DTN MT DTT DM70DTN MA Modulator DM70DTN RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM70DTN RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN MI DE4LYSA DM70DTN MN Cytochrome P450 3A4 (CYP3A4) DM70DTN MT DME DM70DTN MA Metabolism DM70DTN RN Flibanserin: first global approval. Drugs. 2015 Oct;75(15):1815-22. DM70DTN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=26412054 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN MI DEGTFWK DM70DTN MN Mephenytoin 4-hydroxylase (CYP2C19) DM70DTN MT DME DM70DTN MA Metabolism DM70DTN RN Flibanserin therapy and CYP2C19 genotype. DM70DTN RU https://www.ncbi.nlm.nih.gov/pubmed/?term=31550099 DMJ8A3Z DI DMJ8A3Z DMJ8A3Z DN Florbetapir F-18 DMJ8A3Z MI TTE4KHA DMJ8A3Z MN Amyloid beta A4 protein (APP) DMJ8A3Z MT DTT DMJ8A3Z MA Modulator DMJ8A3Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMJ8A3Z RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM04LR2 DI DM04LR2 DM04LR2 DN Floxuridine DM04LR2 MI TTU6BFZ DM04LR2 MN Candida Thymidylate synthase (Candi TMP1) DM04LR2 MT DTT DM04LR2 MA Inhibitor DM04LR2 RN Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86. DM04LR2 RU https://pubmed.ncbi.nlm.nih.gov/10482907 DM04LR2 DI DM04LR2 DM04LR2 DN Floxuridine DM04LR2 MI DE4HCYL DM04LR2 MN Thymidine phosphorylase (TYMP) DM04LR2 MT DME DM04LR2 MA Metabolism DM04LR2 RN Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008 Sep-Oct;5(5):717-27. DM04LR2 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18652477 DMNUWST DI DMNUWST DMNUWST DN Flucloxacillin DMNUWST MI TTJP4SM DMNUWST MN Bacterial Penicillin binding protein (Bact PBP) DMNUWST MT DTT DMNUWST MA Binder DMNUWST RN Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71. DMNUWST RU https://pubmed.ncbi.nlm.nih.gov/6335600 DMNUWST DI DMNUWST DMNUWST DN Flucloxacillin DMNUWST MI DE4LYSA DMNUWST MN Cytochrome P450 3A4 (CYP3A4) DMNUWST MT DME DMNUWST MA Metabolism DMNUWST RN Characterization of kinetics of human cytochrome P450s involved in bioactivation of flucloxacillin: inhibition of CYP3A-catalysed hydroxylation by sulfaphenazole. Br J Pharmacol. 2019 Feb;176(3):466-477. DMNUWST RU https://www.ncbi.nlm.nih.gov/pubmed/?term=30447161 DMNUWST DI DMNUWST DMNUWST DN Flucloxacillin DMNUWST MI DT9G7XN DMNUWST MN Peptide transporter 1 (SLC15A1) DMNUWST MT DTP DMNUWST MA Substrate DMNUWST RN Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9. DMNUWST RU http://www.ncbi.nlm.nih.gov/pubmed/15974593 DMOWZ6B DI DMOWZ6B DMOWZ6B DN Fluconazole DMOWZ6B MI TTTSOUD DMOWZ6B MN Candida Cytochrome P450 51 (Candi ERG11) DMOWZ6B MT DTT DMOWZ6B MA Modulator DMOWZ6B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOWZ6B RU https://www.fda.gov/ DMOWZ6B DI DMOWZ6B DMOWZ6B DN Fluconazole DMOWZ6B MI DE5IED8 DMOWZ6B MN Cytochrome P450 2C9 (CYP2C9) DMOWZ6B MT DME DMOWZ6B MA Metabolism DMOWZ6B RN Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol. 2000 Jun;56(3):225-9. DMOWZ6B RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10952477 DM13VTW DI DM13VTW DM13VTW DN Flucytosine DM13VTW MI TTU6BFZ DM13VTW MN Candida Thymidylate synthase (Candi TMP1) DM13VTW MT DTT DM13VTW MA Inhibitor DM13VTW RN Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. DM13VTW RU https://pubmed.ncbi.nlm.nih.gov/16964330 DMVRLT7 DI DMVRLT7 DMVRLT7 DN Fludarabine DMVRLT7 MI TTLP57V DMVRLT7 MN Adenosine deaminase (ADA) DMVRLT7 MT DTT DMVRLT7 MA Inhibitor DMVRLT7 RN Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5. DMVRLT7 RU https://pubmed.ncbi.nlm.nih.gov/10887639 DMD2K4I DI DMD2K4I DMD2K4I DN Fludiazepam DMD2K4I MI TTPTXIN DMD2K4I MN Translocator protein (TSPO) DMD2K4I MT DTT DMD2K4I MA Agonist DMD2K4I RN Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. DMD2K4I RU https://pubmed.ncbi.nlm.nih.gov/2857046 DMUDIR8 DI DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 MI TTS64P2 DMUDIR8 MN Androgen receptor (AR) DMUDIR8 MT DTT DMUDIR8 MA Inhibitor DMUDIR8 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUDIR8 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUDIR8 DI DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 MI DE4LYSA DMUDIR8 MN Cytochrome P450 3A4 (CYP3A4) DMUDIR8 MT DME DMUDIR8 MA Metabolism DMUDIR8 RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMUDIR8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMUDIR8 DI DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 MI TT26PHO DMUDIR8 MN Mineralocorticoid receptor (MR) DMUDIR8 MT DTT DMUDIR8 MA Agonist DMUDIR8 RN Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5. DMUDIR8 RU https://pubmed.ncbi.nlm.nih.gov/14570856 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH MI TTS64P2 DMC8VNH MN Androgen receptor (AR) DMC8VNH MT DTT DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH MI TT5ZWB6 DMC8VNH MN Dihydrodiol dehydrogenase type I (AKR1C3) DMC8VNH MT DTT DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH MI TT8NGED DMC8VNH MN Prostaglandin G/H synthase 1 (COX-1) DMC8VNH MT DTT DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH MI TTVKILB DMC8VNH MN Prostaglandin G/H synthase 2 (COX-2) DMC8VNH MT DTT DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L MI TTBMV1G DMPCG2L MN GABA(A) receptor alpha-2 (GABRA2) DMPCG2L MT DTT DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L MI TT37EDJ DMPCG2L MN GABA(A) receptor alpha-3 (GABRA3) DMPCG2L MT DTT DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L MI TTNZPQ1 DMPCG2L MN GABA(A) receptor alpha-5 (GABRA5) DMPCG2L MT DTT DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L MI TTEX6LM DMPCG2L MN GABA(A) receptor gamma-3 (GABRG3) DMPCG2L MT DTT DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L MI TTPTXIN DMPCG2L MN Translocator protein (TSPO) DMPCG2L MT DTT DMPCG2L MA Antagonist DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DMUNG4A DI DMUNG4A DMUNG4A DN Flumethasone DMUNG4A MI DE4LYSA DMUNG4A MN Cytochrome P450 3A4 (CYP3A4) DMUNG4A MT DME DMUNG4A MA Metabolism DMUNG4A RN Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8. DMUNG4A RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097 DMU0YP6 DI DMU0YP6 DMU0YP6 DN Flumethasone Pivalate DMU0YP6 MI TTP3UTW DMU0YP6 MN Steroid hormone receptor ERR (ESRR) DMU0YP6 MT DTT DMU0YP6 MA Modulator DMU0YP6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU0YP6 RU https://www.fda.gov/ DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP MI DE6OQ3W DMZU5JP MN Cytochrome P450 1A1 (CYP1A1) DMZU5JP MT DME DMZU5JP MA Metabolism DMZU5JP RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMZU5JP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP MI DEJGDUW DMZU5JP MN Cytochrome P450 1A2 (CYP1A2) DMZU5JP MT DME DMZU5JP MA Metabolism DMZU5JP RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMZU5JP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP MI DEJVYAZ DMZU5JP MN Cytochrome P450 2A6 (CYP2A6) DMZU5JP MT DME DMZU5JP MA Metabolism DMZU5JP RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMZU5JP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP MI DE5IED8 DMZU5JP MN Cytochrome P450 2C9 (CYP2C9) DMZU5JP MT DME DMZU5JP MA Metabolism DMZU5JP RN Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull. 1996 Nov;19(11):1511-4. DMZU5JP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=8951176 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP MI DECB0K3 DMZU5JP MN Cytochrome P450 2D6 (CYP2D6) DMZU5JP MT DME DMZU5JP MA Metabolism DMZU5JP RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMZU5JP RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP MI TTX4QDJ DMZU5JP MN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DMZU5JP MT DTT DMZU5JP MA Inhibitor DMZU5JP RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZU5JP RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP MI TTZPWGN DMZU5JP MN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMZU5JP MT DTT DMZU5JP MA Blocker DMZU5JP RN Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. DMZU5JP RU https://pubmed.ncbi.nlm.nih.gov/19582593 DMZSWQC DI DMZSWQC DMZSWQC DN Flunisolide DMZSWQC MI DE4LYSA DMZSWQC MN Cytochrome P450 3A4 (CYP3A4) DMZSWQC MT DME DMZSWQC MA Metabolism DMZSWQC RN Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89. DMZSWQC RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891 DMZSWQC DI DMZSWQC DMZSWQC DN Flunisolide DMZSWQC MI TTYRL6O DMZSWQC MN Glucocorticoid receptor (NR3C1) DMZSWQC MT DTT DMZSWQC MA Agonist DMZSWQC RN The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticost... J Allergy Clin Immunol. 2009 Jun;123(6):1376-83.e7. DMZSWQC RU https://pubmed.ncbi.nlm.nih.gov/19254810 DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 MI DEJGDUW DMGR5Z3 MN Cytochrome P450 1A2 (CYP1A2) DMGR5Z3 MT DME DMGR5Z3 MA Metabolism DMGR5Z3 RN Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. DMGR5Z3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11996015 DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 MI DEJVYAZ DMGR5Z3 MN Cytochrome P450 2A6 (CYP2A6) DMGR5Z3 MT DME DMGR5Z3 MA Metabolism DMGR5Z3 RN CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40. DMGR5Z3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802 DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 MI DEPKLMQ DMGR5Z3 MN Cytochrome P450 2B6 (CYP2B6) DMGR5Z3 MT DME DMGR5Z3 MA Metabolism DMGR5Z3 RN CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40. DMGR5Z3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802 DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 MI DE5IED8 DMGR5Z3 MN Cytochrome P450 2C9 (CYP2C9) DMGR5Z3 MT DME DMGR5Z3 MA Metabolism DMGR5Z3 RN CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos. 2001 Feb;29(2):133-40. DMGR5Z3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11159802 DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 MI DE4LYSA DMGR5Z3 MN Cytochrome P450 3A4 (CYP3A4) DMGR5Z3 MT DME DMGR5Z3 MA Metabolism DMGR5Z3 RN Cytochrome P450 3A4 and benzodiazepines. Seishin Shinkeigaku Zasshi. 2003;105(5):631-42. DMGR5Z3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12875231 DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 MI DEGTFWK DMGR5Z3 MN Mephenytoin 4-hydroxylase (CYP2C19) DMGR5Z3 MT DME DMGR5Z3 MA Metabolism DMGR5Z3 RN The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol. 2003 Apr;23(2):169-75. DMGR5Z3 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12640218 DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 MI DE0QLUZ DMGR5Z3 MN Oxygen-insensitive NADPH nitroreductase B (nfsB) DMGR5Z3 MT DME DMGR5Z3 MA Metabolism DMGR5Z3 RN Structure-based development of bacterial nitroreductase against nitrobenzodiazepine-induced hypnosis. Biochem Pharmacol. 2012 Jun 15;83(12):1690-9. DMGR5Z3 RU https://pubmed.ncbi.nlm.nih.gov/22445794 DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 MI TTPTXIN DMGR5Z3 MN Translocator protein (TSPO) DMGR5Z3 MT DTT DMGR5Z3 MA Agonist DMGR5Z3 RN Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. DMGR5Z3 RU https://pubmed.ncbi.nlm.nih.gov/19443999 DMG2KI4 DI DMG2KI4 DMG2KI4 DN Fluocinolone acetonide DMG2KI4 MI DE4LYSA DMG2KI4 MN Cytochrome P450 3A4 (CYP3A4) DMG2KI4 MT DME DMG2KI4 MA Metabolism DMG2KI4 RN Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89. DMG2KI4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891 DMG2KI4 DI DMG2KI4 DMG2KI4 DN Fluocinolone acetonide DMG2KI4 MI TTYRL6O DMG2KI4 MN Glucocorticoid receptor (NR3C1) DMG2KI4 MT DTT DMG2KI4 MA Modulator DMG2KI4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMG2KI4 RU https://www.fda.gov/ DM65KL8 DI DM65KL8 DM65KL8 DN Fluocinonide DM65KL8 MI DE4LYSA DM65KL8 MN Cytochrome P450 3A4 (CYP3A4) DM65KL8 MT DME DM65KL8 MA Metabolism DM65KL8 RN Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89. DM65KL8 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=23143891 DM65KL8 DI DM65KL8 DM65KL8 DN Fluocinonide DM65KL8 MI TTP3UTW DM65KL8 MN Steroid hormone receptor ERR (ESRR) DM65KL8 MT DTT DM65KL8 MA Modulator DM65KL8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM65KL8 RU https://www.fda.gov/ DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO MI TTHQZV7 DMQTFAO MN Mothers against decapentaplegic homolog 3 (SMAD3) DMQTFAO MT DTT DMQTFAO MA Inhibitor DMQTFAO RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMQTFAO RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO MI DTSYQGK DMQTFAO MN Multidrug resistance-associated protein 1 (ABCC1) DMQTFAO MT DTP DMQTFAO MA Substrate DMQTFAO RN Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9. DMQTFAO RU http://www.ncbi.nlm.nih.gov/pubmed/11409873 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO MI DTFI42L DMQTFAO MN Multidrug resistance-associated protein 2 (ABCC2) DMQTFAO MT DTP DMQTFAO MA Substrate DMQTFAO RN Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010 Oct;52(4):1465-76. DMQTFAO RU http://www.ncbi.nlm.nih.gov/pubmed/20815017 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO MI DTYVM24 DMQTFAO MN Multidrug resistance-associated protein 5 (ABCC5) DMQTFAO MT DTP DMQTFAO MA Substrate DMQTFAO RN Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007 Jul 20;282(29):20999-1004. DMQTFAO RU http://www.ncbi.nlm.nih.gov/pubmed/17540771 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO MI DTQ23VB DMQTFAO MN Organic anion transporter 1 (SLC22A6) DMQTFAO MT DTP DMQTFAO MA Substrate DMQTFAO RN Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86. DMQTFAO RU http://www.ncbi.nlm.nih.gov/pubmed/15107594 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO MI DT3D8F0 DMQTFAO MN Organic anion transporting polypeptide 1B1 (SLCO1B1) DMQTFAO MT DTP DMQTFAO MA Substrate DMQTFAO RN Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. DMQTFAO RU http://www.ncbi.nlm.nih.gov/pubmed/30135178 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO MI DT9C1TS DMQTFAO MN Organic anion transporting polypeptide 1B3 (SLCO1B3) DMQTFAO MT DTP DMQTFAO MA Substrate DMQTFAO RN Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics. 2010 Mar 1;4:1-8. DMQTFAO RU http://www.ncbi.nlm.nih.gov/pubmed/20448812 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO MI TTTQR47 DMQTFAO MN Solute carrier family 22 member 8 (SLC22A8) DMQTFAO MT DTT DMQTFAO MA Inhibitor DMQTFAO RN Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53. DMQTFAO RU https://pubmed.ncbi.nlm.nih.gov/17553798 DM2HKC4 DI DM2HKC4 DM2HKC4 DN Fluorometholone DM2HKC4 MI DE4LYSA DM2HKC4 MN Cytochrome P450 3A4 (CYP3A4) DM2HKC4 MT DME DM2HKC4 MA Metabolism DM2HKC4 RN Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. DM2HKC4 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20482443 DM2HKC4 DI DM2HKC4 DM2HKC4 DN Fluorometholone DM2HKC4 MI TTYRL6O DM2HKC4 MN Glucocorticoid receptor (NR3C1) DM2HKC4 MT DTT DM2HKC4 MA Binder DM2HKC4 RN Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20. DM2HKC4 RU https://pubmed.ncbi.nlm.nih.gov/12861354 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DEMJ7R2 DMUM7HZ MN Amidophosphoribosyltransferase (GPAT) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150653776) DMUM7HZ RU https://www.pharmgkb.org/pathway/PA150653776 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DTI7UX6 DMUM7HZ MN Breast cancer resistance protein (ABCG2) DMUM7HZ MT DTP DMUM7HZ MA Substrate DMUM7HZ RN Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10. DMUM7HZ RU http://www.ncbi.nlm.nih.gov/pubmed/18820913 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI TTU6BFZ DMUM7HZ MN Candida Thymidylate synthase (Candi TMP1) DMUM7HZ MT DTT DMUM7HZ MA Inhibitor DMUM7HZ RN The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304. DMUM7HZ RU https://pubmed.ncbi.nlm.nih.gov/14689231 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DEJGDUW DMUM7HZ MN Cytochrome P450 1A2 (CYP1A2) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DEJVYAZ DMUM7HZ MN Cytochrome P450 2A6 (CYP2A6) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DES5XRU DMUM7HZ MN Cytochrome P450 2C8 (CYP2C8) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11095583 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI TTZPS91 DMUM7HZ MN Dihydrothymine dehydrogenase (DPYD) DMUM7HZ MT DTT DMUM7HZ MA Inhibitor DMUM7HZ RN Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7. DMUM7HZ RU https://pubmed.ncbi.nlm.nih.gov/12044515 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DESOEW1 DMUM7HZ MN Dihydrothymine dehydrogenase (DPYD) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep. 2008 Mar-Apr;60(2):238-42. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18443386 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DTXD1TQ DMUM7HZ MN Equilibrative nucleoside transporter 1 (SLC29A1) DMUM7HZ MT DTP DMUM7HZ MA Substrate DMUM7HZ RN Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer. Anticancer Res. 2007 Jul-Aug;27(4B):2241-9. DMUM7HZ RU http://www.ncbi.nlm.nih.gov/pubmed/17695509 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DEOXTPZ DMUM7HZ MN Methylenetetrahydrofolate reductase (MTHFR) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21332317 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DTFI42L DMUM7HZ MN Multidrug resistance-associated protein 2 (ABCC2) DMUM7HZ MT DTP DMUM7HZ MA Substrate DMUM7HZ RN Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114. DMUM7HZ RU http://www.ncbi.nlm.nih.gov/pubmed/27602148 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DTQ3ZHF DMUM7HZ MN Multidrug resistance-associated protein 3 (ABCC3) DMUM7HZ MT DTP DMUM7HZ MA Substrate DMUM7HZ RN ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. DMUM7HZ RU http://www.ncbi.nlm.nih.gov/pubmed/19077464 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DTCSGPB DMUM7HZ MN Multidrug resistance-associated protein 4 (ABCC4) DMUM7HZ MT DTP DMUM7HZ MA Substrate DMUM7HZ RN ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. DMUM7HZ RU http://www.ncbi.nlm.nih.gov/pubmed/19077464 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DTYVM24 DMUM7HZ MN Multidrug resistance-associated protein 5 (ABCC5) DMUM7HZ MT DTP DMUM7HZ MA Substrate DMUM7HZ RN ATP-binding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5-fluorouracil-resistant cells. Pancreatology. 2009;9(1-2):136-44. DMUM7HZ RU http://www.ncbi.nlm.nih.gov/pubmed/19077464 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DT0OC1Q DMUM7HZ MN Organic anion transporter 2 (SLC22A7) DMUM7HZ MT DTP DMUM7HZ MA Substrate DMUM7HZ RN Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8. DMUM7HZ RU http://www.ncbi.nlm.nih.gov/pubmed/15901346 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DTUGYRD DMUM7HZ MN P-glycoprotein 1 (ABCB1) DMUM7HZ MT DTP DMUM7HZ MA Substrate DMUM7HZ RN Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. DMUM7HZ RU http://www.ncbi.nlm.nih.gov/pubmed/26499806 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI TTQY2EJ DMUM7HZ MN TERT messenger RNA (TERT mRNA) DMUM7HZ MT DTT DMUM7HZ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUM7HZ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DE4HCYL DMUM7HZ MN Thymidine phosphorylase (TYMP) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21332317 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DEASG0Q DMUM7HZ MN Thymidylate synthase (TYMS) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=21332317 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI TTP1UKZ DMUM7HZ MN Thymidylate synthase messenger RNA (TYMS mRNA) DMUM7HZ MT DTT DMUM7HZ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUM7HZ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DE20ETR DMUM7HZ MN Uracil phosphoribosyltransferase (UPRT) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of escherichia coli cytosine deaminase gene and Escherichia coli uracil phosphoribosyltransferase gene with 5-fluorocytosine. Cancer Gene Ther. 2000 Jul;7(7):1015-22. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10917204 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DEWJYTE DMUM7HZ MN Uridine 5'-monophosphate synthase (UMPS) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression. Rare Dis. 2016 Apr 5;4(1):e1165909. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=27274438 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DEFZWAX DMUM7HZ MN Uridine phosphorylase 1 (UPP1) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16720348 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ MI DEBQ2WU DMUM7HZ MN Uridine phosphorylase 2 (UPP2) DMUM7HZ MT DME DMUM7HZ MA Metabolism DMUM7HZ RN Uridine phosphorylase in breast cancer: a new prognostic factor? Front Biosci. 2006 Sep 1;11:2759-66. DMUM7HZ RU https://www.ncbi.nlm.nih.gov/pubmed/?term=16720348 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI DEJGDUW DM3PD2C MN Cytochrome P450 1A2 (CYP1A2) DM3PD2C MT DME DM3PD2C MA Metabolism DM3PD2C RN Clinically significant psychotropic drug-drug interactions in the primary care setting. Curr Psychiatry Rep. 2012 Aug;14(4):376-90. DM3PD2C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22707017 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI DEPKLMQ DM3PD2C MN Cytochrome P450 2B6 (CYP2B6) DM3PD2C MT DME DM3PD2C MA Metabolism DM3PD2C RN Molecular characterization of CYP2B6 substrates. Curr Drug Metab. 2008 Jun;9(5):363-73. DM3PD2C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18537573 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI DE5IED8 DM3PD2C MN Cytochrome P450 2C9 (CYP2C9) DM3PD2C MT DME DM3PD2C MA Metabolism DM3PD2C RN Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism. Med Chem. 2009 May;5(3):263-70. DM3PD2C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19442216 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI DECB0K3 DM3PD2C MN Cytochrome P450 2D6 (CYP2D6) DM3PD2C MT DME DM3PD2C MA Metabolism DM3PD2C RN (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. DM3PD2C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10997938 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI DEVDYN7 DM3PD2C MN Cytochrome P450 2E1 (CYP2E1) DM3PD2C MT DME DM3PD2C MA Metabolism DM3PD2C RN Antidepressant drugs in the elderly--role of the cytochrome P450 2D6. World J Biol Psychiatry. 2003 Apr;4(2):74-80. DM3PD2C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=12692778 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI DE4LYSA DM3PD2C MN Cytochrome P450 3A4 (CYP3A4) DM3PD2C MT DME DM3PD2C MA Metabolism DM3PD2C RN O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. J Pharmacol Exp Ther. 2002 Jan;300(1):105-11. DM3PD2C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11752104 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI DEIBDNY DM3PD2C MN Cytochrome P450 3A5 (CYP3A5) DM3PD2C MT DME DM3PD2C MA Metabolism DM3PD2C RN (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91. DM3PD2C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10997938 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI DEGTFWK DM3PD2C MN Mephenytoin 4-hydroxylase (CYP2C19) DM3PD2C MT DME DM3PD2C MA Metabolism DM3PD2C RN Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin. 2001 Jan;22(1):85-90. DM3PD2C RU https://www.ncbi.nlm.nih.gov/pubmed/?term=11730569 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI DTUGYRD DM3PD2C MN P-glycoprotein 1 (ABCB1) DM3PD2C MT DTP DM3PD2C MA Substrate DM3PD2C RN Fluoxetine and reversal of multidrug resistance. Cancer Lett. 2006 Jun 18;237(2):180-7. DM3PD2C RU https://doi.org/10.1016/j.canlet.2005.06.003 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C MI TT3ROYC DM3PD2C MN Serotonin transporter (SERT) DM3PD2C MT DTT DM3PD2C MA Modulator DM3PD2C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3PD2C RU https://www.fda.gov/ DMUHCF1 DI DMUHCF1 DMUHCF1 DN Fluoxymesterone DMUHCF1 MI TTS64P2 DMUHCF1 MN Androgen receptor (AR) DMUHCF1 MT DTT DMUHCF1 MA Agonist DMUHCF1 RN An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. DMUHCF1 RU https://pubmed.ncbi.nlm.nih.gov/17023534 DMUHCF1 DI DMUHCF1 DMUHCF1 DN Fluoxymesterone DMUHCF1 MI DE4LYSA DMUHCF1 MN Cytochrome P450 3A4 (CYP3A4) DMUHCF1 MT DME DMUHCF1 MA Metabolism DMUHCF1 RN Effect of dexamethasone on cytochrome P-450 mediated metabolism of 2-acetylaminofluorene in cultured rat hepatocytes. Biochem Pharmacol. 1987 Jan 15;36(2):237-43. DMUHCF1 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=2880590 DM0DJ9O DI DM0DJ9O DM0DJ9O DN Flupentixol DM0DJ9O MI DTUGYRD DM0DJ9O MN P-glycoprotein 1 (ABCB1) DM0DJ9O MT DTP DM0DJ9O MA Substrate DM0DJ9O RN Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. DM0DJ9O RU http://www.ncbi.nlm.nih.gov/pubmed/15285840 DMIT8LX DI DMIT8LX DMIT8LX DN Fluphenazine DMIT8LX MI TTK8CXU DMIT8LX MN 5-HT 1B receptor (HTR1B) DMIT8LX MT DTT DMIT8LX MA Modulator DMIT8LX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIT8LX RU https://www.fda.gov/ DMIT8LX DI DMIT8LX DMIT8LX DN Fluphenazine DMIT8LX MI DECB0K3 DMIT8LX MN Cytochrome P450 2D6 (CYP2D6) DMIT8LX MT DME DMIT8LX MA Metabolism DMIT8LX RN Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999 Sep;27(9):1078-84. DMIT8LX RU https://www.ncbi.nlm.nih.gov/pubmed/?term=10460810 DMIT8LX DI DMIT8LX DMIT8LX DN Fluphenazine DMIT8LX MI DTUGYRD DMIT8LX MN P-glycoprotein 1 (ABCB1) DMIT8LX MT DTP DMIT8LX MA Substrate DMIT8LX RN Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75. DMIT8LX RU http://www.ncbi.nlm.nih.gov/pubmed/15285840 DMZWBKG DI DMZWBKG DMZWBKG DN Fluprednisolone DMZWBKG MI DE4LYSA DMZWBKG MN Cytochrome P450 3A4 (CYP3A4) DMZWBKG MT DME DMZWBKG MA Metabolism DMZWBKG RN NCIthesaurus: Fluprednisolone DMZWBKG RU https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=18.06d&code=C65730&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null DMHCI9S DI DMHCI9S DMHCI9S DN Flurandrenolide DMHCI9S MI DE4LYSA DMHCI9S MN Cytochrome P450 3A4 (CYP3A4) DMHCI9S MT DME DMHCI9S MA Metabolism DMHCI9S RN Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol. 2010 Jul 16;10:8. DMHCI9S RU https://www.ncbi.nlm.nih.gov/pubmed/?term=20637097 DMHCI9S DI DMHCI9S DMHCI9S DN Flurandrenolide DMHCI9S MI TTP3UTW DMHCI9S MN Steroid hormone receptor ERR (ESRR) DMHCI9S MT DTT DMHCI9S MA Modulator DMHCI9S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHCI9S RU https://www.fda.gov/ DMAL4G0 DI DMAL4G0 DMAL4G0 DN Flurazepam DMAL4G0 MI DEJVYAZ DMAL4G0 MN Cytochrome P450 2A6 (CYP2A6) DMAL4G0 MT DME DMAL4G0 MA Metabolism DMAL4G0 RN Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3. DMAL4G0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18936109 DMAL4G0 DI DMAL4G0 DMAL4G0 DN Flurazepam DMAL4G0 MI DE4LYSA DMAL4G0 MN Cytochrome P450 3A4 (CYP3A4) DMAL4G0 MT DME DMAL4G0 MA Metabolism DMAL4G0 RN Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3. DMAL4G0 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=18936109 DMAL4G0 DI DMAL4G0 DMAL4G0 DN Flurazepam DMAL4G0 MI TTPTXIN DMAL4G0 MN Translocator protein (TSPO) DMAL4G0 MT DTT DMAL4G0 MA Modulator DMAL4G0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAL4G0 RU https://www.fda.gov/ DMGN4BY DI DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY MI DE5IED8 DMGN4BY MN Cytochrome P450 2C9 (CYP2C9) DMGN4BY MT DME DMGN4BY MA Metabolism DMGN4BY RN Effect of CYP2C9 genetic polymorphism on the metabolism of flurbiprofen in vitro. Drug Dev Ind Pharm. 2015;41(8):1363-7. DMGN4BY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=25144335 DMGN4BY DI DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY MI TTVKILB DMGN4BY MN Prostaglandin G/H synthase 2 (COX-2) DMGN4BY MT DTT DMGN4BY MA Modulator DMGN4BY RN Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35. DMGN4BY RU https://www.ncbi.nlm.nih.gov/pubmed/22714712 DMGN4BY DI DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY MI DEYGVN4 DMGN4BY MN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMGN4BY MT DME DMGN4BY MA Metabolism DMGN4BY RN Predominant contribution of UDP-glucuronosyltransferase 2B7 in the glucuronidation of racemic flurbiprofen in the human liver. Drug Metab Dispos. 2007 Jul;35(7):1182-7. DMGN4BY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=17446261 DMGN4BY DI DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY MI DEF2WXN DMGN4BY MN UDP-glucuronosyltransferase 1A3 (UGT1A3) DMGN4BY MT DME DMGN4BY MA Metabolism DMGN4BY RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMGN4BY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMGN4BY DI DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY MI DE85D2P DMGN4BY MN UDP-glucuronosyltransferase 1A9 (UGT1A9) DMGN4BY MT DME DMGN4BY MA Metabolism DMGN4BY RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMGN4BY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMGN4BY DI DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY MI DEB3CV1 DMGN4BY MN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMGN4BY MT DME DMGN4BY MA Metabolism DMGN4BY RN Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. DMGN4BY RU https://www.ncbi.nlm.nih.gov/pubmed/?term=19515014 DMFO843 DI DMFO843 DMFO843 DN Fluspirilene DMFO843 MI DE4LYSA DMFO843 MN Cytochrome P450 3A4 (CYP3A4) DMFO843 MT DME DMFO843 MA Metabolism DMFO843 RN Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. DMFO843 RU https://www.ncbi.nlm.nih.gov/pubmed/?term=22039822 DMFO843 DI DMFO843 DMFO843 DN Fluspirilene DMFO843 MI TTEX248 DMFO843 MN Dopamine D2 receptor (D2R) DMFO843 MT DTT DMFO843 MA Antagonist DMFO843 RN Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. DMFO843 RU https://pubmed.ncbi.nlm.nih.gov/11842444 DMK0O7U DI DMK0O7U DMK0O7U DN Flutam